data_2lxj_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 2lxj _Structure_validation_residue.Date_analyzed 2016-10-07 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 2' ' ' GLU . . . . . 0.916 ' HG3' HH12 ' A' ' 20' ' ' ARG . 0.1 OUTLIER . . . . . 0 C--O 1.235 0.337 0 CA-C-O 121.06 0.457 . . . . 74.420000000000002 111.209 . . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 41.1 mt-30 -96.54 148.52 22.75 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.539 -0.755 . . . . 74.420000000000002 110.123 178.481 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -155.91 153.7 24.95 Favored Glycine 0 N--CA 1.445 -0.726 0 C-N-CA 120.934 -0.651 . . . . 71.329999999999998 111.866 177.114 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 4.7 m -104.57 134.81 47.12 Favored 'General case' 0 C--N 1.319 -0.752 0 N-CA-C 109.812 -0.44 . . . . 74.140000000000001 109.812 178.124 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 61.8 t -68.13 112.18 3.01 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.609 0 CA-C-O 120.745 0.307 . . . . 74.439999999999998 110.41 177.952 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 7' ' ' LYS . . . . . 0.673 ' HD3' ' HB3' ' A' ' 19' ' ' GLU . 12.3 mmmm -71.3 -68.5 0.44 Allowed 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.831 -0.622 . . . . 71.430000000000007 109.822 179.159 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 8' ' ' TRP . . . . . . . . . . . . . 4.6 p-90 -153.06 149.01 27.68 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-N 115.462 -0.79 . . . . 74.329999999999998 109.32 177.774 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . 0.408 ' CE2' ' HA ' ' A' ' 40' ' ' SER . 68.5 t80 -114.59 120.15 39.21 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-O 121.001 0.429 . . . . 74.209999999999994 111.563 -173.227 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 10' ' ' ASN . . . . . 0.439 ' HB3' ' HB2' ' A' ' 13' ' ' LYS . 15.3 m120 -81.92 78.31 8.64 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.669 -0.696 . . . . 74.209999999999994 109.472 176.261 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -61.71 -37.64 84.92 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 115.905 -0.589 . . . . 55.409999999999997 111.303 -177.114 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 32.0 mm-40 -76.8 -11.33 59.81 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.379 -0.373 . . . . 73.340000000000003 111.554 -178.925 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' LYS . . . . . 0.469 ' HB3' ' HD2' ' A' ' 15' ' ' PHE . 70.1 mmtt -99.79 -33.69 10.47 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-O 121.072 0.463 . . . . 73.319999999999993 110.553 176.839 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 89.85 24.28 30.53 Favored Glycine 0 N--CA 1.448 -0.536 0 N-CA-C 111.075 -0.81 . . . . 75.140000000000001 111.075 -174.147 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . 0.469 ' HD2' ' HB3' ' A' ' 13' ' ' LYS . 64.3 m-85 -136.92 173.73 11.38 Favored 'General case' 0 C--N 1.324 -0.519 0 N-CA-C 109.549 -0.538 . . . . 73.319999999999993 109.549 -178.338 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -160.98 167.56 36.02 Favored Glycine 0 N--CA 1.447 -0.6 0 C-N-CA 120.281 -0.962 . . . . 64.409999999999997 112.285 178.543 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 96.2 m-85 -119.67 119.67 34.39 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-O 121.105 0.478 . . . . 73.540000000000006 110.668 179.095 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 56.4 mt -112.76 124.95 69.91 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.657 0 N-CA-C 109.187 -0.671 . . . . 62.130000000000003 109.187 177.72 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' GLU . . . . . 0.673 ' HB3' ' HD3' ' A' ' 7' ' ' LYS . 10.3 pt-20 -71.88 140.38 49.25 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-O 121.342 0.592 . . . . 73.409999999999997 111.468 -173.792 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' ARG . . . . . 0.916 HH12 ' HG3' ' A' ' 2' ' ' GLU . 9.7 tpt180 -90.84 172.98 8.24 Favored 'General case' 0 C--N 1.32 -0.7 0 N-CA-C 107.521 -1.289 . . . . 74.439999999999998 107.521 167.107 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . 0.558 ' OE2' ' HG3' ' A' ' 20' ' ' ARG . 0.0 OUTLIER -59.79 -23.15 63.05 Favored 'General case' 0 N--CA 1.467 0.413 0 CA-C-N 118.383 0.538 . . . . 71.450000000000003 112.327 -172.93 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 91.9 m-20 -101.4 17.79 21.76 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.855 0.36 . . . . 75.319999999999993 111.594 179.005 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 80.15 2.08 88.59 Favored Glycine 0 N--CA 1.452 -0.253 0 C-N-CA 120.943 -0.646 . . . . 51.149999999999999 112.751 176.897 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 28.4 t70 -69.19 97.85 0.96 Allowed 'General case' 0 C--N 1.323 -0.557 0 N-CA-C 109.955 -0.387 . . . . 74.420000000000002 109.955 179.712 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.466 ' OD1' ' HG3' ' A' ' 7' ' ' LYS . 52.5 m-20 -53.66 113.67 1.27 Allowed 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.331 -0.85 . . . . 74.140000000000001 111.119 176.363 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . 0.667 HG12 ' HB1' ' A' ' 60' ' ' ALA . 25.3 t -89.27 135.56 25.66 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.602 0 CA-C-N 115.663 -0.698 . . . . 75.310000000000002 109.457 176.316 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 27' ' ' PHE . . . . . . . . . . . . . 40.4 t80 -90.72 109.65 20.83 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 120.988 0.423 . . . . 75.209999999999994 110.79 -172.894 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.425 ' HA ' ' HB3' ' A' ' 60' ' ' ALA . 7.9 p -97.52 151.45 4.29 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 CA-C-N 116.185 -0.461 . . . . 72.209999999999994 110.508 -179.434 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 29' ' ' HIS . . . . . 0.431 ' HA ' ' HD1' ' A' ' 15' ' ' PHE . 34.0 m80 -115.46 158.53 22.4 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.175 -0.466 . . . . 62.109999999999999 110.969 -175.924 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 34.3 p90 -61.69 -31.34 71.47 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.029 -0.532 . . . . 72.239999999999995 111.774 179.742 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 8.0 t -94.43 12.85 25.72 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 121.433 0.635 . . . . 72.129999999999995 109.977 -179.628 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . 0.592 ' HB2' ' HA ' ' A' ' 61' ' ' ALA . . . -112.68 -28.85 7.65 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 115.701 -0.681 . . . . 74.310000000000002 110.124 178.132 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 55.7 mt -80.33 139.01 18.82 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.53 0 CA-C-N 115.443 -0.799 . . . . 64.230000000000004 109.926 177.126 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 34' ' ' GLN . . . . . 0.41 ' HG3' ' O ' ' A' ' 34' ' ' GLN . 10.5 pt20 . . . . . 0 N--CA 1.45 -0.432 0 CA-C-O 121.395 0.617 . . . . 73.25 109.518 173.436 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 40' ' ' SER . . . . . 0.408 ' HA ' ' CE2' ' A' ' 9' ' ' PHE . 66.4 m . . . . . 0 N--CA 1.453 -0.305 0 N-CA-C 109.939 -0.393 . . . . 74.129999999999995 109.939 . . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 87.6 mt -110.96 126.52 54.85 Favored 'General case' 0 C--N 1.321 -0.642 0 N-CA-C 109.328 -0.619 . . . . 75.329999999999998 109.328 174.301 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 36.0 t70 -69.44 112.91 6.29 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-O 121.001 0.429 . . . . 71.129999999999995 109.95 179.991 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 55.6 mt-10 -65.57 120.46 12.94 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 115.956 -0.565 . . . . 52.329999999999998 110.35 -176.89 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 105.22 -13.07 48.56 Favored Glycine 0 N--CA 1.449 -0.498 0 C-N-CA 121.014 -0.612 . . . . 63.329999999999998 111.903 -175.305 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 6.2 tp-100 -83.64 145.6 28.72 Favored 'General case' 0 C--O 1.235 0.318 0 CA-C-O 120.795 0.331 . . . . 65.310000000000002 110.272 -179.855 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -100.22 135.21 42.0 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 116.161 -0.472 . . . . 74.230000000000004 110.465 178.743 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 8.9 m -141.68 -175.93 0.9 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.493 0 CA-C-N 116.096 -0.502 . . . . 75.319999999999993 110.537 179.444 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 19.8 p -124.54 157.97 34.06 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 115.971 -0.559 . . . . 73.319999999999993 109.693 177.302 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 37.8 p90 -156.48 151.07 25.7 Favored 'General case' 0 C--N 1.321 -0.637 0 C-N-CA 120.56 -0.456 . . . . 73.129999999999995 111.545 -176.748 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . 0.713 ' HB3' ' HB2' ' A' ' 62' ' ' ASN . 26.3 t70 -91.35 94.4 9.49 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 115.834 -0.621 . . . . 75.239999999999995 109.697 174.562 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 7.6 p -73.56 133.63 31.29 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.55 0 CA-C-N 115.871 -0.604 . . . . 64.219999999999999 111.079 -176.399 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 25.7 mt-10 -119.31 171.69 8.14 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 115.847 -0.615 . . . . 74.319999999999993 110.155 179.273 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 10.8 pt-20 -72.08 149.51 44.76 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.834 -0.621 . . . . 72.519999999999996 110.87 179.968 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . 0.486 ' HA3' ' O ' ' A' ' 57' ' ' GLY . . . -155.02 124.98 1.6 Allowed Glycine 0 N--CA 1.445 -0.715 0 CA-C-N 115.87 -0.604 . . . . 73.329999999999998 111.804 178.387 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 35.4 tt0 -61.49 -33.08 73.17 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-O 120.654 0.264 . . . . 71.540000000000006 111.306 -177.535 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 22.2 mmt180 -114.47 25.98 10.6 Favored 'General case' 0 C--N 1.327 -0.375 0 N-CA-C 111.741 0.274 . . . . 72.219999999999999 111.741 -179.515 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . 0.486 ' O ' ' HA3' ' A' ' 54' ' ' GLY . . . 139.86 157.25 7.19 Favored Glycine 0 N--CA 1.448 -0.55 0 C-N-CA 120.319 -0.943 . . . . 61.420000000000002 112.378 176.757 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . 0.531 ' HG2' ' HA ' ' A' ' 26' ' ' VAL . 37.5 Cg_endo -66.47 127.2 16.85 Favored 'Trans proline' 0 C--O 1.234 0.323 0 C-N-CA 122.629 2.219 . . . . 65.319999999999993 111.517 -179.758 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 26.9 tt0 -88.72 107.86 19.17 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 116.039 -0.528 . . . . 71.540000000000006 110.728 -176.841 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . 0.667 ' HB1' HG12 ' A' ' 26' ' ' VAL . . . -79.2 97.75 6.34 Favored 'General case' 0 C--N 1.323 -0.575 0 N-CA-C 109.728 -0.471 . . . . 72.310000000000002 109.728 175.879 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 61' ' ' ALA . . . . . 0.592 ' HA ' ' HB2' ' A' ' 32' ' ' ALA . . . -111.44 165.83 11.64 Favored 'General case' 0 C--N 1.319 -0.74 0 CA-C-N 115.829 -0.623 . . . . 72.129999999999995 110.017 -179.994 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 62' ' ' ASN . . . . . 0.713 ' HB2' ' HB3' ' A' ' 50' ' ' ASP . 56.3 m-20 48.37 65.89 1.21 Allowed 'General case' 0 C--N 1.33 -0.271 0 O-C-N 123.727 0.642 . . . . 75.109999999999999 111.03 174.915 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 58.7 t -77.26 120.64 28.12 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.464 0 CA-C-N 116.086 -0.507 . . . . 72.519999999999996 110.493 -178.603 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 77.2 mm-40 -108.12 133.76 51.94 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-N 115.827 -0.624 . . . . 74.209999999999994 110.058 179.694 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 96.8 mttt -73.92 134.41 43.19 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 116.194 -0.457 . . . . 72.140000000000001 110.503 -179.397 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.246 0.87 0 CA-C-O 118.346 -0.835 . . . . 73.420000000000002 110.326 -179.783 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 11.1 mp0 . . . . . 0 N--CA 1.453 -0.297 0 N-CA-C 110.254 -0.276 . . . . 64.319999999999993 110.254 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 3' ' ' GLN . . . . . 0.477 ' HA ' ' O ' ' A' ' 47' ' ' VAL . 28.6 tt0 -92.65 131.17 37.98 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 116.38 -0.373 . . . . 74.209999999999994 110.065 176.733 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . 0.424 ' HA3' ' HE2' ' A' ' 49' ' ' PHE . . . -146.16 151.62 23.83 Favored Glycine 0 N--CA 1.446 -0.685 0 C-N-CA 120.872 -0.68 . . . . 65.319999999999993 112.292 -179.58 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 5' ' ' THR . . . . . 0.404 ' O ' ' HG2' ' A' ' 19' ' ' GLU . 0.2 OUTLIER -89.0 125.8 35.14 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-O 120.659 0.266 . . . . 73.420000000000002 110.923 -177.287 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.86 ' HA ' HG13 ' A' ' 18' ' ' ILE . 31.2 t -68.55 102.53 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.495 0 N-CA-C 110.098 -0.334 . . . . 71.340000000000003 110.098 176.623 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 8.8 mmmm -72.59 -68.29 0.49 Allowed 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 116.296 -0.411 . . . . 73.140000000000001 110.672 -177.531 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 8' ' ' TRP . . . . . . . . . . . . . 80.7 m95 -135.32 131.69 36.76 Favored 'General case' 0 C--N 1.323 -0.546 0 N-CA-C 109.755 -0.461 . . . . 73.340000000000003 109.755 178.286 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . 0.456 ' HA ' ' HA3' ' A' ' 16' ' ' GLY . 73.3 t80 -134.42 104.35 6.09 Favored 'General case' 0 C--N 1.318 -0.765 0 CA-C-O 120.912 0.387 . . . . 74.530000000000001 110.125 176.939 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 10' ' ' ASN . . . . . 0.617 ' OD1' ' HG2' ' A' ' 13' ' ' LYS . 16.7 t-20 -78.53 86.64 4.53 Favored 'General case' 0 C--N 1.321 -0.639 0 N-CA-C 109.305 -0.628 . . . . 74.010000000000005 109.305 178.897 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -66.31 -15.76 63.49 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 115.243 -0.89 . . . . 63.409999999999997 111.494 -177.17 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 32.7 mt-10 -68.01 -38.46 82.65 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.142 -0.481 . . . . 75.340000000000003 109.983 177.867 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' LYS . . . . . 0.617 ' HG2' ' OD1' ' A' ' 10' ' ' ASN . 28.9 mmtp -98.2 -30.45 12.63 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 116.112 -0.494 . . . . 74.049999999999997 109.946 179.955 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 104.9 20.73 9.61 Favored Glycine 0 N--CA 1.448 -0.555 0 C-N-CA 120.746 -0.74 . . . . 61.229999999999997 113.068 175.857 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 39.7 p90 -147.08 162.59 38.52 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 117.157 0.478 . . . . 73.420000000000002 110.853 -178.857 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.456 ' HA3' ' HA ' ' A' ' 9' ' ' PHE . . . -168.45 -164.15 23.66 Favored Glycine 0 N--CA 1.444 -0.823 0 C-N-CA 120.665 -0.778 . . . . 72.109999999999999 112.064 178.857 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 91.9 m-85 -133.83 124.3 26.28 Favored 'General case' 0 C--N 1.322 -0.61 0 N-CA-C 109.408 -0.59 . . . . 74.129999999999995 109.408 -178.005 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . 0.86 HG13 ' HA ' ' A' ' 6' ' ' VAL . 11.0 tt -116.51 158.22 17.07 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.96 0 N-CA-C 109.095 -0.706 . . . . 71.540000000000006 109.095 -177.712 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' GLU . . . . . 0.404 ' HG2' ' O ' ' A' ' 5' ' ' THR . 19.8 pt-20 -106.49 134.13 50.1 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 121.375 0.607 . . . . 71.329999999999998 111.229 -178.148 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' ARG . . . . . . . . . . . . . 14.3 ttt180 -97.35 157.98 15.7 Favored 'General case' 0 C--N 1.317 -0.83 0 N-CA-C 108.224 -1.028 . . . . 73.519999999999996 108.224 172.026 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 31.7 mt-10 -44.0 -40.65 4.87 Favored 'General case' 0 N--CA 1.467 0.416 0 O-C-N 123.503 0.502 . . . . 74.540000000000006 110.885 -179.499 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 23.1 t-20 -127.59 73.62 1.46 Allowed 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 115.89 -0.595 . . . . 72.510000000000005 109.784 171.498 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 164.61 94.99 0.1 Allowed Glycine 0 C--O 1.227 -0.306 0 C-N-CA 120.41 -0.9 . . . . 71.319999999999993 112.843 175.846 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 13.3 m-20 -78.44 18.16 0.58 Allowed 'General case' 0 N--CA 1.468 0.458 0 N-CA-C 111.877 0.325 . . . . 75.049999999999997 111.877 -178.02 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 36.5 t70 -142.7 85.24 1.88 Allowed 'General case' 0 C--N 1.321 -0.671 0 CA-C-O 120.999 0.428 . . . . 71.439999999999998 110.824 -177.724 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . 0.411 ' HB ' HG23 ' A' ' 18' ' ' ILE . 47.2 t -125.48 124.04 66.08 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.526 0 CA-C-N 115.609 -0.723 . . . . 73.549999999999997 109.185 174.94 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 27' ' ' PHE . . . . . . . . . . . . . 70.6 t80 -83.44 104.36 13.52 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-O 121.321 0.581 . . . . 73.409999999999997 110.834 -175.328 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.404 HG21 HD11 ' A' ' 33' ' ' ILE . 13.5 p -93.77 142.05 13.9 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.664 0 CA-C-N 115.851 -0.613 . . . . 75.230000000000004 109.788 179.089 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 29' ' ' HIS . . . . . 0.515 ' CE1' ' HB3' ' A' ' 32' ' ' ALA . 3.7 p80 -140.53 142.55 35.19 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.761 0.315 . . . . 74.340000000000003 111.017 -175.976 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 17.2 p90 -60.49 -25.14 65.84 Favored 'General case' 0 N--CA 1.469 0.476 0 CA-C-N 115.8 -0.636 . . . . 74.540000000000006 112.706 -170.775 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 11.6 p -77.87 -8.0 57.47 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-O 121.028 0.442 . . . . 75.209999999999994 111.587 -178.11 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . 0.547 ' HB1' ' HA ' ' A' ' 61' ' ' ALA . . . -113.81 -23.53 9.61 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 120.921 0.391 . . . . 63.409999999999997 111.074 179.178 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.418 HD12 ' HB2' ' A' ' 41' ' ' LEU . 56.9 mt -69.07 150.51 10.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 N-CA-C 109.556 -0.535 . . . . 74.530000000000001 109.556 174.104 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 4.8 pp0? . . . . . 0 C--N 1.326 -0.449 0 N-CA-C 109.45 -0.574 . . . . 73.340000000000003 109.45 175.056 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 13.3 p . . . . . 0 N--CA 1.45 -0.425 0 CA-C-O 121.068 0.461 . . . . 73.239999999999995 110.705 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . 0.418 ' HB2' HD12 ' A' ' 33' ' ' ILE . 12.6 tp -92.63 146.81 23.38 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 116.029 -0.532 . . . . 75.230000000000004 109.675 178.699 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 42' ' ' ASP . . . . . 0.834 ' HB2' ' HB2' ' A' ' 45' ' ' GLN . 2.1 m-20 -73.92 124.81 26.88 Favored 'General case' 0 C--N 1.318 -0.787 0 CA-C-N 115.837 -0.62 . . . . 72.349999999999994 110.885 -175.108 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 9.3 pt-20 -69.47 131.34 44.58 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-O 120.845 0.355 . . . . 64.200000000000003 110.164 177.456 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 82.24 4.06 90.34 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.863 -0.684 . . . . 64.420000000000002 112.113 -177.65 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 45' ' ' GLN . . . . . 0.834 ' HB2' ' HB2' ' A' ' 42' ' ' ASP . 24.6 tp60 -80.91 126.32 31.22 Favored 'General case' 0 C--N 1.326 -0.455 0 N-CA-C 110.109 -0.33 . . . . 70.120000000000005 110.109 -179.693 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 0.439 ' O ' ' HB2' ' A' ' 66' ' ' ALA . . . -86.88 83.15 7.59 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-O 121.042 0.449 . . . . 75.010000000000005 110.048 176.006 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . 0.507 HG12 ' HA ' ' A' ' 65' ' ' LYS . 19.1 m -89.85 167.98 1.59 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.578 0 CA-C-N 115.631 -0.713 . . . . 73.310000000000002 111.734 -173.563 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 48' ' ' THR . . . . . 0.487 ' OG1' ' HB3' ' A' ' 64' ' ' GLN . 4.9 p -112.4 107.32 16.08 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 115.959 -0.564 . . . . 74.510000000000005 110.145 177.379 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 49' ' ' PHE . . . . . 0.569 ' HA ' ' O ' ' A' ' 62' ' ' ASN . 38.2 p90 -122.17 160.57 24.85 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 115.838 -0.619 . . . . 74.549999999999997 111.234 -173.063 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 22.6 t70 -107.67 115.59 30.43 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-O 121.07 0.462 . . . . 72.109999999999999 110.563 175.058 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 66.5 t -66.65 132.51 32.02 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.498 0 CA-C-N 115.734 -0.667 . . . . 75.540000000000006 112.12 -174.692 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 52' ' ' GLU . . . . . 1.071 ' HB2' ' HB2' ' A' ' 59' ' ' GLN . 34.4 mt-10 -94.27 159.55 15.08 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.736 -0.666 . . . . 73.219999999999999 109.675 174.309 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 39.1 mt-10 -114.72 110.63 20.03 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-N 116.38 -0.373 . . . . 74.439999999999998 110.353 178.382 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -126.49 170.8 18.26 Favored Glycine 0 N--CA 1.448 -0.515 0 C-N-CA 120.878 -0.677 . . . . 74.120000000000005 112.092 -179.802 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 18.3 mt-30 -92.98 69.3 4.5 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-O 121.365 0.602 . . . . 74.150000000000006 110.034 -177.852 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 15.8 ptp180 178.59 -30.47 0.01 OUTLIER 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 114.741 -1.118 . . . . 72.510000000000005 108.921 -176.154 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 162.71 -179.54 37.92 Favored Glycine 0 N--CA 1.44 -1.098 0 N-CA-C 110.325 -1.11 . . . . 73.409999999999997 110.325 178.486 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 57.5 Cg_endo -76.34 128.12 10.24 Favored 'Trans proline' 0 N--CA 1.454 -0.822 0 C-N-CA 121.884 1.723 . . . . 71.5 111.161 175.228 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . 1.071 ' HB2' ' HB2' ' A' ' 52' ' ' GLU . 9.4 mm100 -93.4 169.73 10.14 Favored 'General case' 0 C--N 1.321 -0.639 0 N-CA-C 109.0 -0.741 . . . . 74.349999999999994 109.0 178.591 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . 0.404 ' HB1' ' HA ' ' A' ' 28' ' ' VAL . . . -124.75 111.33 15.42 Favored 'General case' 0 C--N 1.319 -0.745 0 C-N-CA 120.719 -0.393 . . . . 73.129999999999995 111.327 179.308 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 61' ' ' ALA . . . . . 0.547 ' HA ' ' HB1' ' A' ' 32' ' ' ALA . . . -123.11 159.35 28.71 Favored 'General case' 0 CA--C 1.515 -0.379 0 CA-C-N 115.984 -0.553 . . . . 74.409999999999997 110.161 177.156 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 62' ' ' ASN . . . . . 0.569 ' O ' ' HA ' ' A' ' 49' ' ' PHE . 94.9 m-20 53.65 78.3 0.16 Allowed 'General case' 0 CA--C 1.517 -0.304 0 CA-C-O 121.274 0.559 . . . . 72.409999999999997 109.569 -177.481 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 44.1 t -107.8 101.72 12.93 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.611 0 CA-C-N 115.147 -0.933 . . . . 75.519999999999996 110.572 -175.995 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 64' ' ' GLN . . . . . 0.487 ' HB3' ' OG1' ' A' ' 48' ' ' THR . 8.3 tt0 -85.3 124.13 31.57 Favored 'General case' 0 C--N 1.319 -0.728 0 CA-C-N 115.959 -0.564 . . . . 75.329999999999998 110.066 -179.382 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . 0.507 ' HA ' HG12 ' A' ' 47' ' ' VAL . 42.9 mttm -68.16 127.39 32.72 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.346 -0.388 . . . . 74.209999999999994 110.263 -179.289 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 66' ' ' ALA . . . . . 0.439 ' HB2' ' O ' ' A' ' 46' ' ' ALA . . . . . . . . 0 C--O 1.246 0.898 0 CA-C-O 118.091 -0.956 . . . . 72.340000000000003 110.444 -178.615 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 C--O 1.236 0.383 0 CA-C-O 121.122 0.486 . . . . 63.340000000000003 111.164 . . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 35.1 tt0 -88.35 116.29 26.46 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 115.832 -0.622 . . . . 74.439999999999998 110.237 177.58 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -126.91 -174.33 13.77 Favored Glycine 0 N--CA 1.449 -0.472 0 N-CA-C 110.99 -0.844 . . . . 71.040000000000006 110.99 177.727 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 5' ' ' THR . . . . . 0.526 ' O ' ' HG2' ' A' ' 19' ' ' GLU . 10.1 m -130.09 132.19 46.05 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-N 117.3 0.55 . . . . 71.219999999999999 110.682 179.515 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 60.3 t -76.22 119.83 25.08 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.446 0 CA-C-N 116.495 -0.321 . . . . 73.530000000000001 110.169 -179.286 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 7' ' ' LYS . . . . . 0.955 ' HA ' ' HE3' ' A' ' 7' ' ' LYS . 0.0 OUTLIER -92.97 -68.22 0.81 Allowed 'General case' 0 C--N 1.325 -0.467 0 CA-C-O 120.92 0.391 . . . . 74.25 110.797 179.113 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 8' ' ' TRP . . . . . . . . . . . . . 63.7 m95 -112.79 126.53 55.53 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 116.078 -0.51 . . . . 75.140000000000001 109.73 -177.917 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 54.1 t80 -125.07 91.14 3.37 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-O 121.201 0.525 . . . . 72.329999999999998 110.542 -176.807 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 18.2 m120 -87.47 78.36 8.64 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-O 121.426 0.631 . . . . 63.409999999999997 109.815 -179.945 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -63.71 -32.57 74.1 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 115.136 -0.938 . . . . 63.310000000000002 110.833 -179.292 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 42.9 mt-10 -76.89 -8.86 58.14 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.112 -0.494 . . . . 64.019999999999996 111.026 179.426 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' LYS . . . . . 0.401 ' HB3' ' CE2' ' A' ' 15' ' ' PHE . 75.5 mmtt -107.75 -26.06 10.98 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 120.938 0.399 . . . . 73.209999999999994 110.28 178.948 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 96.61 20.69 23.83 Favored Glycine 0 N--CA 1.449 -0.482 0 C-N-CA 120.942 -0.647 . . . . 71.450000000000003 113.017 175.779 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . 0.401 ' CE2' ' HB3' ' A' ' 13' ' ' LYS . 31.5 p90 -155.09 167.11 31.45 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-O 120.982 0.42 . . . . 74.430000000000007 111.262 179.104 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -157.84 168.49 34.44 Favored Glycine 0 N--CA 1.445 -0.719 0 CA-C-N 115.819 -0.628 . . . . 74.230000000000004 112.021 180.0 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 91.4 m-85 -121.13 118.6 30.11 Favored 'General case' 0 C--N 1.321 -0.63 0 CA-C-O 120.885 0.374 . . . . 74.230000000000004 110.543 -178.459 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 55.2 mt -104.16 124.51 58.65 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 N-CA-C 109.601 -0.518 . . . . 74.150000000000006 109.601 177.711 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' GLU . . . . . 0.526 ' HG2' ' O ' ' A' ' 5' ' ' THR . 14.6 pt-20 -82.8 130.29 35.11 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-O 121.436 0.636 . . . . 73.510000000000005 111.525 -173.12 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' ARG . . . . . 0.407 ' HB3' ' HB3' ' A' ' 24' ' ' ASP . 16.2 ttp180 -113.15 158.82 19.93 Favored 'General case' 0 C--N 1.324 -0.532 0 N-CA-C 108.839 -0.801 . . . . 74.019999999999996 108.839 175.03 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 5.6 mm-40 -49.36 -36.43 21.57 Favored 'General case' 0 N--CA 1.472 0.657 0 N-CA-C 113.961 1.097 . . . . 65.430000000000007 113.961 -168.951 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 61.7 t30 -84.16 12.49 6.4 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 121.189 0.519 . . . . 73.400000000000006 111.321 -175.667 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 76.39 10.2 85.66 Favored Glycine 0 N--CA 1.454 -0.103 0 N-CA-C 110.508 -1.037 . . . . 73.239999999999995 110.508 -173.185 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . 0.407 ' HB3' ' HB3' ' A' ' 20' ' ' ARG . 17.7 t70 -76.75 90.12 3.42 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-N 114.417 -0.892 . . . . 61.229999999999997 109.894 -177.714 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 12.1 p-10 -70.59 114.16 8.41 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-O 121.592 0.71 . . . . 75.430000000000007 110.734 178.845 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 23.8 t -84.53 122.55 38.15 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.683 0 CA-C-N 115.185 -0.916 . . . . 74.420000000000002 109.839 179.721 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 27' ' ' PHE . . . . . . . . . . . . . 70.8 t80 -85.36 109.31 18.31 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 115.855 -0.611 . . . . 74.519999999999996 110.831 -174.997 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.47 ' HB ' ' HB2' ' A' ' 60' ' ' ALA . 11.3 p -96.06 147.14 6.28 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.596 0 N-CA-C 109.867 -0.42 . . . . 54.509999999999998 109.867 178.256 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 29' ' ' HIS . . . . . 0.489 ' O ' HG13 ' A' ' 33' ' ' ILE . 5.7 p80 -128.02 153.53 46.66 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 120.741 0.305 . . . . 72.129999999999995 110.902 -176.911 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 48.0 p90 -57.26 -29.34 63.75 Favored 'General case' 0 N--CA 1.468 0.447 0 N-CA-C 113.489 0.922 . . . . 75.430000000000007 113.489 -170.192 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 21.9 m -76.64 -1.2 26.5 Favored 'General case' 0 C--N 1.326 -0.45 0 C-N-CA 120.93 -0.308 . . . . 72.099999999999994 111.245 -179.998 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . 0.549 ' HB2' ' HA ' ' A' ' 61' ' ' ALA . . . -125.02 -11.36 7.09 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.874 0.369 . . . . 73.010000000000005 110.919 177.631 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.489 HG13 ' O ' ' A' ' 29' ' ' HIS . 85.9 mt -77.49 137.93 21.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.114 -0.494 . . . . 74.120000000000005 110.837 178.372 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 34' ' ' GLN . . . . . 0.4 ' HG3' ' O ' ' A' ' 34' ' ' GLN . 7.6 pt20 . . . . . 0 C--N 1.329 -0.291 0 CA-C-O 120.974 0.416 . . . . 65.450000000000003 109.947 173.527 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 14.7 p . . . . . 0 N--CA 1.452 -0.37 0 CA-C-O 120.925 0.393 . . . . 72.340000000000003 110.71 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 3.7 mm? -110.43 158.17 18.78 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 116.101 -0.499 . . . . 72.209999999999994 109.851 177.202 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 28.3 t70 -118.3 137.77 52.84 Favored 'General case' 0 C--N 1.321 -0.636 0 N-CA-C 109.634 -0.506 . . . . 75.409999999999997 109.634 -177.562 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 8.5 pt-20 -71.14 116.99 12.08 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-O 121.523 0.677 . . . . 63.5 110.072 179.73 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 105.54 6.2 38.6 Favored Glycine 0 N--CA 1.445 -0.723 0 CA-C-N 115.69 -0.687 . . . . 70.129999999999995 111.463 -174.002 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 62.2 tp60 -92.11 132.09 36.86 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 120.743 0.306 . . . . 71.299999999999997 110.877 179.05 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -78.66 132.14 36.94 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 116.01 -0.541 . . . . 72.409999999999997 109.561 173.504 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 25.5 m -137.81 153.66 28.0 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.634 0 CA-C-N 116.064 -0.516 . . . . 74.129999999999995 111.699 -177.191 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 9.4 p -113.1 111.79 22.74 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-N 115.872 -0.604 . . . . 72.329999999999998 109.78 174.754 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 49' ' ' PHE . . . . . 0.405 ' HA ' ' O ' ' A' ' 62' ' ' ASN . 39.5 p90 -120.81 161.93 20.65 Favored 'General case' 0 C--N 1.319 -0.729 0 CA-C-N 115.959 -0.564 . . . . 73.200000000000003 110.569 -172.551 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 33.1 t70 -93.15 118.0 30.72 Favored 'General case' 0 C--N 1.32 -0.711 0 N-CA-C 109.491 -0.559 . . . . 71.329999999999998 109.491 173.978 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 5.1 p -78.23 109.13 12.54 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.65 0 CA-C-O 121.67 0.748 . . . . 73.409999999999997 111.06 -176.539 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 9.7 tp10 -92.75 119.88 32.57 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-N 115.375 -0.83 . . . . 62.210000000000001 108.886 175.583 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 12.9 pt-20 -107.15 124.89 50.36 Favored 'General case' 0 C--N 1.317 -0.821 0 CA-C-O 120.897 0.38 . . . . 63.439999999999998 110.227 -179.923 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -146.78 -142.25 3.69 Favored Glycine 0 N--CA 1.448 -0.525 0 C-N-CA 120.615 -0.802 . . . . 71.540000000000006 112.281 -179.751 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 16.4 mm100 -77.64 -26.36 50.42 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-O 120.982 0.42 . . . . 74.299999999999997 110.451 -178.465 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 24.4 mmm180 -87.35 4.51 42.68 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 116.082 -0.508 . . . . 74.5 110.351 -179.445 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 89.36 -138.39 14.64 Favored Glycine 0 N--CA 1.446 -0.646 0 C-N-CA 120.928 -0.653 . . . . 64.549999999999997 111.618 -178.361 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 89.2 Cg_endo -84.73 104.86 0.96 Allowed 'Trans proline' 0 N--CA 1.455 -0.749 0 C-N-CA 122.701 2.267 . . . . 64.219999999999999 112.329 177.455 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 12.3 pt20 -112.52 135.62 53.01 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-O 121.144 0.497 . . . . 72.5 110.017 177.551 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . 0.47 ' HB2' ' HB ' ' A' ' 28' ' ' VAL . . . -86.34 128.12 34.89 Favored 'General case' 0 C--N 1.319 -0.758 0 CA-C-O 121.149 0.499 . . . . 55.310000000000002 111.708 -172.743 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 61' ' ' ALA . . . . . 0.549 ' HA ' ' HB2' ' A' ' 32' ' ' ALA . . . -130.21 143.63 50.89 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 115.436 -0.802 . . . . 74.120000000000005 109.282 174.016 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 62' ' ' ASN . . . . . 0.405 ' O ' ' HA ' ' A' ' 49' ' ' PHE . 45.0 m-80 59.45 87.23 0.08 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 121.244 0.545 . . . . 71.450000000000003 110.391 -176.965 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 47.8 t -105.39 111.14 33.49 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.591 0 CA-C-N 115.721 -0.672 . . . . 74.040000000000006 110.273 -176.883 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 24.6 mt-30 -107.93 142.53 37.9 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-N 116.149 -0.478 . . . . 74.319999999999993 109.944 -179.73 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 46.0 mttp -77.48 144.22 37.9 Favored 'General case' 0 C--N 1.325 -0.492 0 C-N-CA 120.868 -0.333 . . . . 73.400000000000006 110.422 179.567 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.247 0.958 0 CA-C-O 118.781 -0.628 . . . . 52.310000000000002 110.413 178.077 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 2' ' ' GLU . . . . . 0.635 ' HG2' HG22 ' A' ' 51' ' ' VAL . 4.8 mp0 . . . . . 0 C--O 1.234 0.248 0 CA-C-O 121.125 0.488 . . . . 73.400000000000006 111.318 . . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 3' ' ' GLN . . . . . 0.642 ' HG2' HG22 ' A' ' 48' ' ' THR . 79.7 mt-30 -97.49 122.95 41.13 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.732 -0.667 . . . . 74.310000000000002 109.638 172.209 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -138.14 178.31 19.33 Favored Glycine 0 N--CA 1.445 -0.721 0 N-CA-C 111.136 -0.786 . . . . 70.430000000000007 111.136 179.178 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 5' ' ' THR . . . . . 0.402 ' O ' ' HG2' ' A' ' 19' ' ' GLU . 13.1 m -125.11 130.54 52.42 Favored 'General case' 0 C--N 1.315 -0.919 0 CA-C-N 117.28 0.54 . . . . 75.209999999999994 110.512 178.088 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 61.3 t -72.58 108.57 4.06 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.472 0 CA-C-N 116.376 -0.375 . . . . 71.310000000000002 110.01 178.813 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 7' ' ' LYS . . . . . 0.438 ' HB3' ' CE3' ' A' ' 8' ' ' TRP . 6.5 mmtm -73.62 -48.48 32.23 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 116.26 -0.427 . . . . 75.530000000000001 110.208 177.622 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 8' ' ' TRP . . . . . 0.521 ' HE1' ' HD2' ' A' ' 17' ' ' PHE . 15.6 p90 -164.14 158.92 19.76 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.661 -0.7 . . . . 75.310000000000002 110.075 177.763 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . 0.407 ' HD1' ' HA3' ' A' ' 16' ' ' GLY . 71.4 t80 -134.33 106.48 7.12 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 116.264 -0.426 . . . . 75.109999999999999 110.12 178.622 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 87.8 m-20 -76.71 85.09 3.34 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 116.048 -0.524 . . . . 72.219999999999999 109.821 179.791 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -62.39 -38.11 88.36 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 115.519 -0.764 . . . . 70.040000000000006 111.492 -177.234 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 42.0 mt-10 -72.55 -14.41 61.63 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 116.253 -0.43 . . . . 74.329999999999998 111.056 -179.571 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 32.2 mmmt -101.21 -26.32 13.69 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.88 0.372 . . . . 72.349999999999994 110.225 177.922 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 100.15 7.3 52.61 Favored Glycine 0 N--CA 1.45 -0.427 0 C-N-CA 120.83 -0.7 . . . . 63.229999999999997 113.253 175.423 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 41.0 p90 -151.16 154.96 37.91 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-O 121.125 0.488 . . . . 75.329999999999998 111.602 -176.077 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.407 ' HA3' ' HD1' ' A' ' 9' ' ' PHE . . . -135.95 178.45 18.71 Favored Glycine 0 N--CA 1.444 -0.803 0 N-CA-C 111.055 -0.818 . . . . 71.549999999999997 111.055 178.65 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . 0.521 ' HD2' ' HE1' ' A' ' 8' ' ' TRP . 79.9 m-85 -131.28 123.23 27.92 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-O 121.197 0.522 . . . . 74.420000000000002 111.243 -177.975 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 64.5 mt -106.43 126.48 62.15 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 CA-C-N 115.482 -0.781 . . . . 74.239999999999995 109.144 176.803 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' GLU . . . . . 0.402 ' HG2' ' O ' ' A' ' 5' ' ' THR . 17.2 pt-20 -79.53 139.36 37.58 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-O 121.327 0.584 . . . . 75.310000000000002 112.299 -173.464 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' ARG . . . . . . . . . . . . . 10.0 tpt180 -109.83 166.61 10.79 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.082 -0.963 . . . . 72.319999999999993 108.94 174.846 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 2.3 mp0 -43.95 -48.68 8.62 Favored 'General case' 0 N--CA 1.472 0.635 0 N-CA-C 112.397 0.518 . . . . 75.099999999999994 112.397 179.409 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 74.6 m-20 -71.41 -7.08 44.97 Favored 'General case' 0 N--CA 1.468 0.429 0 CA-C-N 116.295 -0.411 . . . . 74.340000000000003 112.025 -174.9 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 90.01 7.63 67.94 Favored Glycine 0 N--CA 1.45 -0.387 0 N-CA-C 110.084 -1.206 . . . . 75.409999999999997 110.084 -170.145 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 13.0 t70 -70.28 93.2 0.83 Allowed 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 114.486 -0.857 . . . . 73.0 109.953 -179.262 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 13.4 p-10 -65.76 101.92 0.69 Allowed 'General case' 0 C--N 1.321 -0.644 0 CA-C-N 115.549 -0.75 . . . . 75.219999999999999 110.65 176.848 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 40.0 t -71.01 130.41 34.95 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.587 0 CA-C-N 115.444 -0.798 . . . . 74.430000000000007 110.547 -178.487 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 27' ' ' PHE . . . . . . . . . . . . . 63.1 t80 -79.39 108.64 13.07 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 116.079 -0.51 . . . . 72.519999999999996 110.147 -178.294 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 9.3 p -111.16 141.5 26.33 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.598 0 N-CA-C 110.061 -0.348 . . . . 65.150000000000006 110.061 179.242 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 29' ' ' HIS . . . . . 0.548 ' O ' HG13 ' A' ' 33' ' ' ILE . 6.0 p80 -128.94 145.75 51.15 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.795 0.331 . . . . 74.129999999999995 110.863 -177.03 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 37.5 p90 -58.82 -27.69 65.31 Favored 'General case' 0 N--CA 1.467 0.421 0 CA-C-N 115.679 -0.691 . . . . 74.0 112.294 -171.227 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 1.5 p -79.03 6.64 8.91 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-O 120.744 0.307 . . . . 74.230000000000004 111.707 -179.331 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -129.25 -14.74 4.26 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 121.002 0.429 . . . . 72.209999999999994 110.879 175.287 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.762 HD12 HD22 ' A' ' 41' ' ' LEU . 24.9 mt -80.45 161.68 3.86 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.164 -0.471 . . . . 65.519999999999996 110.089 176.263 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 34' ' ' GLN . . . . . 0.673 ' NE2' ' HA ' ' A' ' 64' ' ' GLN . 26.5 pt20 . . . . . 0 C--N 1.327 -0.383 0 N-CA-C 110.107 -0.331 . . . . 64.450000000000003 110.107 177.485 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 37.4 m . . . . . 0 N--CA 1.449 -0.493 0 N-CA-C 109.676 -0.49 . . . . 64.409999999999997 109.676 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . 0.762 HD22 HD12 ' A' ' 33' ' ' ILE . 3.5 mm? -91.22 148.01 22.65 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 116.346 -0.388 . . . . 72.299999999999997 110.758 -176.708 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 4.8 m-20 -91.61 113.35 25.6 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 115.797 -0.638 . . . . 63.350000000000001 109.293 175.452 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 4.5 mp0 -62.97 129.82 42.06 Favored 'General case' 0 C--N 1.321 -0.669 0 CA-C-N 116.061 -0.518 . . . . 62.229999999999997 110.422 -179.305 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 97.89 -7.88 63.09 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 121.042 -0.599 . . . . 63.140000000000001 112.102 -178.263 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 29.6 tp60 -84.15 123.85 30.52 Favored 'General case' 0 C--N 1.324 -0.523 0 N-CA-C 110.173 -0.306 . . . . 63.049999999999997 110.173 179.83 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -68.1 135.28 51.94 Favored 'General case' 0 C--N 1.328 -0.345 0 N-CA-C 109.403 -0.592 . . . . 75.200000000000003 109.403 172.623 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . 0.511 HG13 ' HA ' ' A' ' 65' ' ' LYS . 21.1 m -134.24 154.05 36.9 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.771 0 CA-C-O 121.214 0.53 . . . . 75.319999999999993 111.501 -175.704 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 48' ' ' THR . . . . . 0.642 HG22 ' HG2' ' A' ' 3' ' ' GLN . 33.0 p -113.72 117.13 30.66 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 115.503 -0.771 . . . . 73.430000000000007 109.433 174.68 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 49' ' ' PHE . . . . . 0.409 ' HA ' ' O ' ' A' ' 62' ' ' ASN . 40.8 p90 -129.76 170.37 13.93 Favored 'General case' 0 C--N 1.316 -0.872 0 CA-C-N 115.966 -0.561 . . . . 72.310000000000002 110.913 -173.148 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 38.8 t70 -112.01 143.87 42.3 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-N 115.864 -0.607 . . . . 63.340000000000003 109.813 174.306 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . 0.635 HG22 ' HG2' ' A' ' 2' ' ' GLU . 84.7 t -94.88 121.52 45.54 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.553 0 CA-C-O 121.165 0.507 . . . . 73.319999999999993 110.875 -178.528 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 52' ' ' GLU . . . . . 0.545 ' HB3' ' HG3' ' A' ' 59' ' ' GLN . 0.0 OUTLIER -94.24 141.97 27.94 Favored 'General case' 0 C--N 1.321 -0.648 0 N-CA-C 108.849 -0.797 . . . . 74.239999999999995 108.849 174.288 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 4.9 pt-20 -111.93 106.37 15.05 Favored 'General case' 0 C--N 1.316 -0.855 0 CA-C-O 121.287 0.565 . . . . 73.099999999999994 111.0 -174.557 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -126.76 -169.58 12.76 Favored Glycine 0 N--CA 1.448 -0.538 0 C-N-CA 120.852 -0.69 . . . . 63.340000000000003 112.019 -179.403 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 44.7 mt-30 -76.77 -3.1 36.48 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.952 0.406 . . . . 63.439999999999998 111.109 -178.095 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 56' ' ' ARG . . . . . 0.407 HH11 ' HD2' ' A' ' 56' ' ' ARG . 17.7 mmm180 -100.24 3.82 43.83 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-O 120.95 0.405 . . . . 74.230000000000004 110.496 176.416 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 94.28 -142.43 16.02 Favored Glycine 0 N--CA 1.446 -0.644 0 C-N-CA 120.843 -0.694 . . . . 45.130000000000003 111.872 -178.364 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 74.3 Cg_endo -79.97 106.93 2.0 Favored 'Trans proline' 0 N--CA 1.458 -0.597 0 C-N-CA 122.76 2.306 . . . . 75.019999999999996 112.703 -179.309 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . 0.545 ' HG3' ' HB3' ' A' ' 52' ' ' GLU . 4.1 pt20 -111.7 126.43 55.03 Favored 'General case' 0 C--N 1.322 -0.627 0 CA-C-N 115.778 -0.646 . . . . 75.0 109.655 177.701 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -80.05 130.47 35.28 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-O 121.024 0.44 . . . . 71.430000000000007 111.464 -174.871 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -135.13 145.35 47.75 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 115.452 -0.795 . . . . 53.25 109.321 177.717 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 62' ' ' ASN . . . . . 0.409 ' O ' ' HA ' ' A' ' 49' ' ' PHE . 89.2 m-20 59.59 82.99 0.14 Allowed 'General case' 0 C--N 1.327 -0.398 0 CA-C-O 121.164 0.507 . . . . 75.530000000000001 110.225 -176.621 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 39.2 t -113.06 106.35 20.57 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.511 0 CA-C-N 115.545 -0.752 . . . . 70.120000000000005 110.394 -177.061 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 64' ' ' GLN . . . . . 0.673 ' HA ' ' NE2' ' A' ' 34' ' ' GLN . 53.4 mt-30 -99.73 145.32 27.79 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 116.401 -0.363 . . . . 75.430000000000007 110.395 -179.349 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . 0.511 ' HA ' HG13 ' A' ' 47' ' ' VAL . 28.4 mtmm -82.61 136.4 34.81 Favored 'General case' 0 C--N 1.324 -0.54 0 N-CA-C 110.076 -0.342 . . . . 75.019999999999996 110.076 -179.864 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.247 0.941 0 CA-C-O 118.843 -0.599 . . . . 53.030000000000001 110.485 -179.108 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 2.2 mp0 . . . . . 0 C--O 1.237 0.447 0 CA-C-O 121.215 0.531 . . . . 72.219999999999999 111.676 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 3' ' ' GLN . . . . . 0.449 ' HG2' HG22 ' A' ' 48' ' ' THR . 65.8 mt-30 -91.95 143.6 26.32 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.341 -0.845 . . . . 70.439999999999998 110.248 179.612 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . 0.69 ' HA3' ' HE2' ' A' ' 49' ' ' PHE . . . -159.26 150.86 21.58 Favored Glycine 0 N--CA 1.447 -0.626 0 C-N-CA 120.932 -0.652 . . . . 73.230000000000004 111.917 178.252 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 5' ' ' THR . . . . . 0.525 ' HA ' ' HA ' ' A' ' 46' ' ' ALA . 3.5 m -98.02 133.47 42.44 Favored 'General case' 0 C--N 1.32 -0.703 0 CA-C-O 120.563 0.22 . . . . 73.129999999999995 110.438 -179.029 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 51.2 t -68.16 103.62 0.71 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 N-CA-C 109.541 -0.54 . . . . 73.420000000000002 109.541 175.068 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 7' ' ' LYS . . . . . 0.762 ' HD3' ' HB3' ' A' ' 19' ' ' GLU . 31.0 mmmt -61.56 -60.7 3.3 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 121.342 0.591 . . . . 73.200000000000003 110.543 -176.706 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 8' ' ' TRP . . . . . . . . . . . . . 28.7 p90 -156.42 136.47 12.77 Favored 'General case' 0 C--N 1.319 -0.726 0 CA-C-N 115.349 -0.841 . . . . 74.230000000000004 109.533 176.695 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . 0.485 ' HA ' ' HA3' ' A' ' 16' ' ' GLY . 70.7 t80 -132.41 113.13 12.79 Favored 'General case' 0 C--N 1.317 -0.807 0 CA-C-O 121.09 0.471 . . . . 75.450000000000003 110.287 -177.033 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 2.6 m-20 -78.0 80.26 4.44 Favored 'General case' 0 C--N 1.322 -0.624 0 N-CA-C 108.892 -0.781 . . . . 74.319999999999993 108.892 176.014 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -60.53 -33.26 72.39 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 121.079 0.466 . . . . 73.409999999999997 110.918 -178.386 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' GLU . . . . . 0.433 ' HG3' ' HG2' ' A' ' 13' ' ' LYS . 6.8 pt-20 -67.71 -25.12 65.5 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 115.462 -0.79 . . . . 72.219999999999999 111.555 -179.824 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' LYS . . . . . 0.433 ' HG2' ' HG3' ' A' ' 12' ' ' GLU . 47.5 mmtm -110.06 -15.4 14.04 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-O 120.845 0.355 . . . . 75.5 111.222 -176.881 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 94.06 20.37 30.88 Favored Glycine 0 N--CA 1.449 -0.456 0 C-N-CA 120.995 -0.621 . . . . 73.310000000000002 114.148 170.237 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 43.2 p90 -153.62 156.44 37.94 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 117.67 0.735 . . . . 74.400000000000006 111.384 -179.321 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.485 ' HA3' ' HA ' ' A' ' 9' ' ' PHE . . . -167.73 -169.75 31.65 Favored Glycine 0 N--CA 1.45 -0.398 0 N-CA-C 111.883 -0.487 . . . . 52.119999999999997 111.883 178.389 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 88.1 m-85 -133.09 139.29 47.05 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 121.122 0.487 . . . . 60.240000000000002 111.309 -179.068 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 56.9 mt -119.93 145.33 26.36 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.547 0 N-CA-C 108.908 -0.775 . . . . 73.129999999999995 108.908 176.697 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' GLU . . . . . 0.762 ' HB3' ' HD3' ' A' ' 7' ' ' LYS . 20.9 pt-20 -89.37 158.22 17.86 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-O 121.15 0.5 . . . . 65.049999999999997 111.045 -177.123 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' ARG . . . . . 0.59 ' HD3' ' HB3' ' A' ' 24' ' ' ASP . 70.4 ttt180 -134.15 158.72 42.94 Favored 'General case' 0 C--N 1.32 -0.674 0 N-CA-C 108.523 -0.918 . . . . 75.129999999999995 108.523 179.146 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 44.1 mt-10 -48.2 -50.92 27.41 Favored 'General case' 0 N--CA 1.466 0.336 0 N-CA-C 113.229 0.825 . . . . 74.310000000000002 113.229 -172.316 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 57.8 m-80 -87.5 20.58 2.84 Favored 'General case' 0 C--N 1.327 -0.405 0 N-CA-C 111.878 0.325 . . . . 60.240000000000002 111.878 -173.964 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 76.16 10.55 85.32 Favored Glycine 0 C--N 1.33 0.234 0 C-N-CA 120.605 -0.807 . . . . 70.030000000000001 111.731 -178.897 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . 0.59 ' HB3' ' HD3' ' A' ' 20' ' ' ARG . 38.5 t70 -76.95 84.06 3.49 Favored 'General case' 0 C--N 1.322 -0.622 0 N-CA-C 109.772 -0.455 . . . . 75.239999999999995 109.772 -179.571 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 8.1 p-10 -58.62 127.56 32.76 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 121.361 0.6 . . . . 64.019999999999996 111.123 -176.467 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . 0.523 ' HA ' ' HB2' ' A' ' 58' ' ' PRO . 17.1 t -105.64 124.37 60.62 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.615 0 CA-C-N 115.424 -0.807 . . . . 64.239999999999995 110.216 -176.453 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 27' ' ' PHE . . . . . . . . . . . . . 91.9 t80 -82.57 131.21 35.22 Favored 'General case' 0 C--N 1.326 -0.453 0 N-CA-C 110.063 -0.347 . . . . 73.230000000000004 110.063 179.944 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 9.8 p -123.3 137.41 56.72 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-O 121.278 0.561 . . . . 72.310000000000002 111.006 -179.481 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 22.0 t60 -115.02 151.77 33.62 Favored 'General case' 0 C--N 1.324 -0.504 0 N-CA-C 108.142 -1.059 . . . . 65.439999999999998 108.142 176.844 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 17.3 p90 -60.2 -20.15 57.43 Favored 'General case' 0 N--CA 1.472 0.661 0 N-CA-C 112.555 0.576 . . . . 74.409999999999997 112.555 -172.052 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 23.1 t -90.14 -9.06 49.68 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 120.892 0.377 . . . . 62.439999999999998 110.633 -179.166 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -103.99 -25.46 13.0 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 121.075 0.464 . . . . 75.209999999999994 110.747 -179.129 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.654 HD11 HD21 ' A' ' 41' ' ' LEU . 15.4 tt -77.55 163.75 3.71 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.55 0 N-CA-C 108.863 -0.792 . . . . 72.010000000000005 108.863 175.726 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 34' ' ' GLN . . . . . 0.515 ' HG2' ' O ' ' A' ' 34' ' ' GLN . 18.8 pm0 . . . . . 0 CA--C 1.533 0.321 0 CA-C-O 121.774 0.797 . . . . 75.299999999999997 111.646 -176.121 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 22.0 p . . . . . 0 N--CA 1.45 -0.449 0 CA-C-O 121.062 0.458 . . . . 61.409999999999997 110.229 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . 0.654 HD21 HD11 ' A' ' 33' ' ' ILE . 10.7 mp -83.28 126.06 32.26 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 116.158 -0.474 . . . . 74.319999999999993 110.241 178.786 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 28.5 t70 -75.51 139.58 42.26 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-N 115.595 -0.73 . . . . 75.030000000000001 110.616 -177.342 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 3.0 mp0 -61.22 105.72 0.53 Allowed 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.96 0.41 . . . . 71.349999999999994 110.317 178.142 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 126.49 -10.25 7.24 Favored Glycine 0 N--CA 1.447 -0.587 0 CA-C-N 115.871 -0.604 . . . . 63.240000000000002 111.731 -175.049 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 7.1 tt0 -77.37 127.49 32.65 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.846 0.355 . . . . 74.319999999999993 110.63 178.061 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 0.525 ' HA ' ' HA ' ' A' ' 5' ' ' THR . . . -92.39 130.43 38.07 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 116.201 -0.454 . . . . 74.310000000000002 110.371 177.747 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . 0.423 HG13 ' HA ' ' A' ' 65' ' ' LYS . 15.5 m -137.37 174.39 11.57 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 CA-C-O 120.949 0.405 . . . . 73.329999999999998 111.316 -177.058 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 48' ' ' THR . . . . . 0.449 HG22 ' HG2' ' A' ' 3' ' ' GLN . 23.5 p -111.69 114.06 26.84 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 115.836 -0.62 . . . . 74.340000000000003 109.67 176.425 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 49' ' ' PHE . . . . . 0.69 ' HE2' ' HA3' ' A' ' 4' ' ' GLY . 39.7 p90 -125.17 165.38 18.35 Favored 'General case' 0 C--N 1.317 -0.823 0 CA-C-N 116.094 -0.503 . . . . 74.049999999999997 110.302 -174.322 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 22.0 t0 -108.43 151.1 26.5 Favored 'General case' 0 C--N 1.317 -0.808 0 C-N-CA 119.992 -0.683 . . . . 70.400000000000006 109.883 173.646 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 61.1 t -105.13 109.35 27.42 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.779 0 CA-C-O 121.089 0.471 . . . . 72.219999999999999 110.593 -176.332 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 44.3 tt0 -81.85 96.31 7.59 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-N 115.41 -0.813 . . . . 72.209999999999994 109.062 175.463 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 6.7 pt-20 -74.67 90.62 2.3 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-O 121.519 0.676 . . . . 72.409999999999997 109.576 176.612 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -121.49 -144.58 6.94 Favored Glycine 0 N--CA 1.444 -0.772 0 CA-C-N 115.164 -0.926 . . . . 42.210000000000001 112.282 -177.925 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 55' ' ' GLN . . . . . 0.578 ' O ' ' HG2' ' A' ' 56' ' ' ARG . 6.6 tp-100 -80.86 82.29 6.89 Favored 'General case' 0 C--N 1.323 -0.552 0 N-CA-C 111.59 0.218 . . . . 74.25 111.59 -175.418 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 56' ' ' ARG . . . . . 0.578 ' HG2' ' O ' ' A' ' 55' ' ' GLN . 2.3 mmm180 156.73 -36.35 0.01 OUTLIER 'General case' 0 N--CA 1.478 0.974 0 C-N-CA 125.881 1.672 . . . . 74.049999999999997 108.498 173.109 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . 0.438 ' HA3' ' HD3' ' A' ' 58' ' ' PRO . . . 138.09 -120.05 1.93 Allowed Glycine 0 N--CA 1.445 -0.746 0 CA-C-N 115.186 -0.916 . . . . 73.010000000000005 111.712 -178.581 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . 0.523 ' HB2' ' HA ' ' A' ' 26' ' ' VAL . 2.9 Cg_endo -80.96 100.35 1.19 Allowed 'Trans proline' 0 N--CA 1.458 -0.574 0 C-N-CA 123.179 2.586 . . . . 65.219999999999999 112.721 -178.405 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 22.1 mt-30 -104.76 126.3 51.7 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 115.93 -0.577 . . . . 70.030000000000001 109.631 176.016 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -74.77 115.48 14.4 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-O 120.626 0.25 . . . . 72.219999999999999 110.784 -177.536 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -136.36 142.12 43.77 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 116.195 -0.457 . . . . 73.140000000000001 110.058 178.754 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 42.1 m-80 58.48 85.48 0.09 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 121.38 0.609 . . . . 64.329999999999998 110.492 -179.61 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.536 HG13 ' HB3' ' A' ' 49' ' ' PHE . 17.8 t -112.23 131.68 63.02 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.612 0 CA-C-N 115.737 -0.665 . . . . 73.319999999999993 110.284 -176.999 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 6.5 tp-100 -128.4 147.11 50.63 Favored 'General case' 0 C--N 1.32 -0.677 0 N-CA-C 109.896 -0.409 . . . . 73.450000000000003 109.896 179.063 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . 0.423 ' HA ' HG13 ' A' ' 47' ' ' VAL . 60.2 mttm -65.06 144.99 56.9 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-O 120.671 0.272 . . . . 64.340000000000003 110.359 177.533 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.039 0 CA-C-O 118.723 -0.656 . . . . 65.430000000000007 110.785 -179.06 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 1.3 pm0 . . . . . 0 C--O 1.234 0.265 0 CA-C-O 120.787 0.327 . . . . 73.530000000000001 111.808 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 7.5 tt0 -87.84 116.68 26.16 Favored 'General case' 0 C--N 1.321 -0.652 0 N-CA-C 109.471 -0.566 . . . . 74.209999999999994 109.471 174.657 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -132.39 153.8 20.76 Favored Glycine 0 N--CA 1.445 -0.749 0 C-N-CA 120.314 -0.946 . . . . 63.140000000000001 112.367 -177.768 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 5' ' ' THR . . . . . 0.49 ' O ' ' HG3' ' A' ' 19' ' ' GLU . 2.8 m -98.49 129.69 45.08 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-O 120.72 0.295 . . . . 73.219999999999999 110.273 178.933 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.428 HG22 HG12 ' A' ' 18' ' ' ILE . 61.7 t -79.75 118.4 27.22 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.606 0 O-C-N 122.357 -0.215 . . . . 62.310000000000002 110.462 178.815 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 7' ' ' LYS . . . . . 0.802 ' HZ2' ' HB3' ' A' ' 19' ' ' GLU . 49.3 mttp -74.18 -65.21 0.87 Allowed 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.926 0.393 . . . . 75.209999999999994 110.501 178.053 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 8' ' ' TRP . . . . . . . . . . . . . 90.6 m95 -144.87 160.86 40.61 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 115.821 -0.627 . . . . 75.430000000000007 111.211 -176.768 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 14.1 p90 -120.89 106.38 11.58 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 115.503 -0.771 . . . . 74.049999999999997 110.527 179.16 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 2.3 m-20 -84.95 77.12 10.17 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-N 115.944 -0.571 . . . . 73.019999999999996 109.805 -179.407 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . 0.51 ' HA ' ' HE2' ' A' ' 30' ' ' PHE . . . -63.63 -28.2 69.75 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.589 -0.732 . . . . 61.200000000000003 111.268 -178.804 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 65.6 mm-40 -74.87 -13.59 60.57 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 116.2 -0.455 . . . . 63.340000000000003 111.314 178.8 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' LYS . . . . . 0.496 ' HB3' ' CE2' ' A' ' 15' ' ' PHE . 31.2 mmmt -109.76 -30.09 8.02 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 116.297 -0.411 . . . . 72.420000000000002 111.053 -179.012 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 102.12 17.66 19.72 Favored Glycine 0 N--CA 1.449 -0.476 0 C-N-CA 120.632 -0.794 . . . . 63.420000000000002 112.668 177.389 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . 0.496 ' CE2' ' HB3' ' A' ' 13' ' ' LYS . 26.7 p90 -152.71 172.47 16.62 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 120.629 0.252 . . . . 74.540000000000006 110.736 -179.618 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -140.85 175.04 22.37 Favored Glycine 0 N--CA 1.446 -0.652 0 C-N-CA 121.06 -0.591 . . . . 65.109999999999999 111.77 178.887 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 97.5 m-85 -120.81 116.45 25.23 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-O 120.933 0.397 . . . . 72.340000000000003 111.171 -178.636 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . 0.567 ' O ' ' HA ' ' A' ' 25' ' ' ASP . 36.7 mt -102.57 165.09 3.05 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.581 0 N-CA-C 107.816 -1.179 . . . . 61.219999999999999 107.816 173.202 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' GLU . . . . . 0.802 ' HB3' ' HZ2' ' A' ' 7' ' ' LYS . 0.3 OUTLIER -130.31 163.22 27.29 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-N 118.857 0.753 . . . . 71.5 111.364 179.05 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' ARG . . . . . 0.402 ' HG2' ' H ' ' A' ' 21' ' ' GLU . 15.6 ttp180 -126.17 -163.23 1.2 Allowed 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 115.573 -0.739 . . . . 71.420000000000002 109.464 -178.902 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . 0.402 ' H ' ' HG2' ' A' ' 20' ' ' ARG . 0.0 OUTLIER -64.14 -37.54 87.81 Favored 'General case' 0 C--N 1.329 -0.312 0 N-CA-C 112.277 0.473 . . . . 70.299999999999997 112.277 -172.776 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 87.6 m-20 -93.59 13.43 22.02 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-O 120.713 0.292 . . . . 71.129999999999995 111.113 -177.877 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 74.2 20.44 79.65 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.329 -0.938 . . . . 64.310000000000002 110.764 -173.558 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 14.4 t70 -72.08 93.1 1.38 Allowed 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 115.132 -0.534 . . . . 74.439999999999998 109.823 -179.017 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.567 ' HA ' ' O ' ' A' ' 18' ' ' ILE . 2.3 m-20 -60.46 121.03 11.07 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.642 -0.708 . . . . 72.019999999999996 111.594 178.58 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 36.6 t -96.69 131.48 43.38 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.62 0 CA-C-N 115.013 -0.994 . . . . 75.310000000000002 109.897 179.945 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 27' ' ' PHE . . . . . . . . . . . . . 47.4 t80 -83.49 98.7 9.68 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 116.144 -0.48 . . . . 70.519999999999996 110.525 -175.817 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.524 ' HB ' ' HB2' ' A' ' 60' ' ' ALA . 13.2 p -98.82 138.66 22.67 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 CA-C-O 121.069 0.461 . . . . 74.030000000000001 111.072 -177.782 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 6.9 m80 -99.29 139.19 35.31 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 116.064 -0.517 . . . . 74.010000000000005 110.112 176.81 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 30' ' ' PHE . . . . . 0.612 ' HD1' HD11 ' A' ' 33' ' ' ILE . 20.4 m-85 -65.74 -26.2 67.62 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.643 0.258 . . . . 75.340000000000003 110.819 179.008 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 38.3 t -72.36 -16.97 61.87 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-O 121.111 0.481 . . . . 72.120000000000005 110.48 175.805 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . 0.501 ' HB3' ' HA ' ' A' ' 61' ' ' ALA . . . -94.61 -20.01 19.96 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 121.085 0.469 . . . . 75.310000000000002 110.049 177.033 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.676 HG12 HG22 ' A' ' 63' ' ' VAL . 54.6 mt -82.02 135.32 25.2 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.465 0 CA-C-N 115.807 -0.633 . . . . 72.439999999999998 110.078 175.443 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 12.7 pt20 . . . . . 0 C--N 1.324 -0.534 0 CA-C-O 121.259 0.552 . . . . 71.400000000000006 110.563 176.377 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 42.0 m . . . . . 0 N--CA 1.455 -0.18 0 N-CA-C 110.368 -0.234 . . . . 73.540000000000006 110.368 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 3.5 mm? -107.52 162.23 14.13 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.29 -0.413 . . . . 72.209999999999994 110.136 178.568 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 42' ' ' ASP . . . . . 0.48 ' HB2' ' HB2' ' A' ' 45' ' ' GLN . 5.9 m-20 -69.62 157.23 37.61 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 116.017 -0.538 . . . . 73.310000000000002 111.1 179.967 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -77.18 105.74 8.46 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-O 121.521 0.677 . . . . 70.450000000000003 110.039 176.018 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 108.96 5.48 30.84 Favored Glycine 0 N--CA 1.446 -0.657 0 CA-C-N 115.678 -0.692 . . . . 55.240000000000002 111.656 -174.014 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 45' ' ' GLN . . . . . 0.48 ' HB2' ' HB2' ' A' ' 42' ' ' ASP . 8.6 tp-100 -80.78 130.68 35.2 Favored 'General case' 0 C--N 1.326 -0.424 0 N-CA-C 109.993 -0.373 . . . . 75.430000000000007 109.993 178.944 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -102.46 127.71 49.39 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-O 120.778 0.323 . . . . 74.099999999999994 110.721 179.764 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 17.5 m -136.02 172.59 15.28 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.562 0 CA-C-N 115.961 -0.563 . . . . 63.43 110.528 -179.109 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 20.4 p -116.66 115.01 24.86 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 116.177 -0.465 . . . . 75.239999999999995 110.328 179.476 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 33.1 p90 -117.42 163.36 16.49 Favored 'General case' 0 C--N 1.319 -0.752 0 CA-C-O 121.157 0.503 . . . . 73.329999999999998 111.925 -174.137 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 25.8 t70 -86.07 136.72 33.12 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 115.861 -0.609 . . . . 70.340000000000003 109.585 172.908 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 3.7 p -81.83 114.46 22.78 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.499 0 CA-C-O 121.913 0.863 . . . . 75.239999999999995 112.06 -174.632 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 9.6 tp10 -108.93 162.0 14.62 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 114.763 -1.108 . . . . 64.420000000000002 108.374 175.693 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 39.1 mt-10 -122.59 169.18 11.29 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-O 121.159 0.504 . . . . 52.420000000000002 111.517 -179.999 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -162.48 158.25 30.33 Favored Glycine 0 N--CA 1.443 -0.897 0 N-CA-C 110.736 -0.946 . . . . 62.200000000000003 110.736 179.046 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 20.6 pt20 -75.73 9.32 2.37 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 117.093 0.447 . . . . 74.430000000000007 111.929 -177.088 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 69.3 mtm180 -130.19 15.32 5.65 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 121.005 0.431 . . . . 72.230000000000004 110.285 174.654 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 129.21 -179.68 16.54 Favored Glycine 0 N--CA 1.45 -0.427 0 C-N-CA 120.651 -0.785 . . . . 64.299999999999997 112.083 179.871 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo -74.6 146.27 34.23 Favored 'Trans proline' 0 N--CA 1.461 -0.428 0 C-N-CA 122.508 2.138 . . . . 74.549999999999997 112.427 -179.055 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 42.3 mt-30 -118.5 162.22 18.71 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 115.952 -0.567 . . . . 75.219999999999999 110.013 178.335 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . 0.524 ' HB2' ' HB ' ' A' ' 28' ' ' VAL . . . -118.35 125.29 49.73 Favored 'General case' 0 C--N 1.318 -0.794 0 CA-C-O 121.047 0.451 . . . . 73.200000000000003 111.039 -179.672 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 61' ' ' ALA . . . . . 0.501 ' HA ' ' HB3' ' A' ' 32' ' ' ALA . . . -127.81 164.59 21.86 Favored 'General case' 0 C--N 1.321 -0.673 0 N-CA-C 108.763 -0.829 . . . . 75.040000000000006 108.763 175.871 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 39.7 m-80 48.25 76.87 0.11 Allowed 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 121.032 0.444 . . . . 74.049999999999997 110.989 -177.843 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.676 HG22 HG12 ' A' ' 33' ' ' ILE . 46.6 t -89.21 92.08 3.86 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.67 0 CA-C-N 116.042 -0.526 . . . . 72.329999999999998 110.142 -178.751 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -80.38 125.82 30.39 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 115.434 -0.803 . . . . 73.340000000000003 109.368 -177.868 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 52.9 mttp -64.25 137.54 57.98 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.301 -0.409 . . . . 72.140000000000001 110.381 -177.403 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.251 1.135 0 CA-C-O 118.439 -0.791 . . . . 74.219999999999999 109.927 179.496 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 2.8 mp0 . . . . . 0 C--O 1.235 0.313 0 CA-C-O 121.04 0.448 . . . . 72.540000000000006 110.619 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 84.0 mt-30 -95.15 126.83 40.75 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 115.357 -0.838 . . . . 75.239999999999995 109.482 176.813 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . 0.684 ' HA3' ' HE2' ' A' ' 49' ' ' PHE . . . -140.83 151.11 22.22 Favored Glycine 0 N--CA 1.445 -0.756 0 C-N-CA 120.291 -0.956 . . . . 72.109999999999999 112.533 -177.985 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 5' ' ' THR . . . . . 0.436 ' O ' ' HG2' ' A' ' 19' ' ' GLU . 7.4 m -107.15 125.82 51.58 Favored 'General case' 0 C--N 1.319 -0.75 0 N-CA-C 110.21 -0.293 . . . . 72.340000000000003 110.21 -179.718 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 48.3 t -68.01 117.39 9.76 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 N-CA-C 110.168 -0.308 . . . . 73.120000000000005 110.168 179.705 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 7' ' ' LYS . . . . . 0.646 ' HD3' ' HB3' ' A' ' 19' ' ' GLU . 30.1 mmmt -75.55 -56.37 4.76 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 121.405 0.622 . . . . 74.450000000000003 109.329 179.422 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 8' ' ' TRP . . . . . 0.785 ' HZ3' ' HB2' ' A' ' 10' ' ' ASN . 63.5 p-90 -164.71 157.95 17.21 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-N 114.849 -1.069 . . . . 72.019999999999996 108.921 175.927 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 11.3 p90 -129.04 115.1 17.24 Favored 'General case' 0 C--N 1.317 -0.816 0 CA-C-O 121.596 0.713 . . . . 73.340000000000003 110.805 -176.593 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 10' ' ' ASN . . . . . 0.785 ' HB2' ' HZ3' ' A' ' 8' ' ' TRP . 34.1 t30 -86.72 71.86 10.28 Favored 'General case' 0 C--N 1.319 -0.729 0 N-CA-C 108.527 -0.916 . . . . 72.540000000000006 108.527 179.008 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -62.83 -32.15 73.3 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 114.709 -1.132 . . . . 74.109999999999999 112.536 -171.284 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 33.1 mt-10 -75.53 -9.76 58.86 Favored 'General case' 0 C--N 1.326 -0.429 0 C-N-CA 120.905 -0.318 . . . . 74.209999999999994 111.252 -177.458 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 30.7 mmmt -110.92 -11.75 14.31 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 121.174 0.511 . . . . 75.109999999999999 110.124 174.253 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 95.21 15.83 43.08 Favored Glycine 0 N--CA 1.447 -0.596 0 C-N-CA 120.805 -0.712 . . . . 65.409999999999997 114.414 169.91 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 54.6 p90 -145.8 155.3 42.84 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 117.941 0.871 . . . . 75.239999999999995 111.601 -179.254 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -140.64 166.82 25.76 Favored Glycine 0 N--CA 1.445 -0.728 0 N-CA-C 111.078 -0.809 . . . . 71.219999999999999 111.078 177.422 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 79.0 m-85 -120.89 121.92 39.12 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-O 121.201 0.524 . . . . 74.430000000000007 111.201 -178.323 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 56.4 mt -111.25 139.59 34.55 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.615 0 CA-C-N 115.331 -0.85 . . . . 74.019999999999996 109.459 178.166 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' GLU . . . . . 0.646 ' HB3' ' HD3' ' A' ' 7' ' ' LYS . 9.1 pt-20 -88.6 134.36 33.9 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 120.896 0.379 . . . . 73.510000000000005 110.523 179.008 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' ARG . . . . . . . . . . . . . 27.8 ttp180 -121.84 152.01 40.02 Favored 'General case' 0 C--N 1.322 -0.63 0 N-CA-C 108.996 -0.742 . . . . 74.030000000000001 108.996 174.13 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -50.71 -40.81 55.12 Favored 'General case' 0 N--CA 1.463 0.189 0 O-C-N 123.279 0.362 . . . . 73.140000000000001 111.795 -177.83 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -109.44 65.75 0.62 Allowed 'General case' 0 C--N 1.322 -0.63 0 CA-C-O 121.004 0.431 . . . . 72.310000000000002 110.339 171.62 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . 0.433 ' C ' ' H ' ' A' ' 25' ' ' ASP . . . 132.85 94.88 0.57 Allowed Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.816 -0.707 . . . . 74.310000000000002 112.227 174.257 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . 0.523 ' HA ' ' HA ' ' A' ' 19' ' ' GLU . 3.9 p30 -71.0 6.41 1.58 Allowed 'General case' 0 N--CA 1.468 0.432 0 CA-C-O 120.962 0.41 . . . . 72.409999999999997 111.48 -178.108 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.433 ' H ' ' C ' ' A' ' 23' ' ' GLY . 7.2 p-10 -122.6 88.59 2.96 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-O 121.708 0.766 . . . . 72.019999999999996 110.916 -177.266 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . 0.432 HG13 ' HB1' ' A' ' 60' ' ' ALA . 55.9 t -112.34 118.59 58.17 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.621 0 CA-C-N 115.431 -0.804 . . . . 71.310000000000002 109.565 173.769 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 27' ' ' PHE . . . . . 0.438 ' O ' ' HA ' ' A' ' 59' ' ' GLN . 63.1 t80 -82.08 105.09 12.9 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 115.773 -0.648 . . . . 74.310000000000002 110.484 -176.183 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 12.2 p -100.03 133.95 41.24 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.603 0 CA-C-O 121.207 0.527 . . . . 74.129999999999995 110.531 179.122 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 85.8 t60 -91.87 133.05 36.01 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 115.843 -0.617 . . . . 64.409999999999997 109.855 -178.226 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 14.0 p90 -56.39 -36.39 68.82 Favored 'General case' 0 N--CA 1.467 0.399 0 N-CA-C 111.938 0.347 . . . . 74.310000000000002 111.938 -174.015 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 6.9 t -87.31 6.44 33.47 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 121.293 0.568 . . . . 70.299999999999997 110.644 -177.763 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -105.67 -19.7 13.68 Favored 'General case' 0 C--N 1.326 -0.447 0 N-CA-C 109.144 -0.687 . . . . 72.120000000000005 109.144 173.216 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 69.2 mt -74.72 105.45 3.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 114.998 -1.001 . . . . 75.310000000000002 110.271 175.329 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 C--N 1.325 -0.494 0 CA-C-O 121.854 0.835 . . . . 75.340000000000003 109.943 175.478 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 22.8 p . . . . . 0 N--CA 1.451 -0.381 0 N-CA-C 110.114 -0.328 . . . . 74.209999999999994 110.114 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 95.1 mt -132.39 130.48 40.72 Favored 'General case' 0 C--N 1.325 -0.483 0 N-CA-C 109.277 -0.638 . . . . 74.409999999999997 109.277 176.318 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 3.4 m-20 -55.88 125.05 19.73 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 121.205 0.526 . . . . 75.430000000000007 111.557 -179.36 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 7.6 pt-20 -66.95 123.27 19.72 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-N 115.834 -0.621 . . . . 71.519999999999996 109.831 175.895 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 101.81 5.76 50.4 Favored Glycine 0 N--CA 1.448 -0.502 0 C-N-CA 121.032 -0.604 . . . . 75.439999999999998 111.648 -173.229 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 7.5 tp60 -102.84 138.03 40.26 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.652 0.263 . . . . 74.209999999999994 110.521 178.603 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -92.16 131.91 37.03 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 116.293 -0.412 . . . . 73.049999999999997 110.427 176.329 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 24.0 m -134.77 173.84 13.89 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 CA-C-N 116.121 -0.49 . . . . 74.019999999999996 110.308 -179.793 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 19.3 p -117.34 115.69 25.74 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-O 121.185 0.517 . . . . 75.209999999999994 110.805 179.431 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 49' ' ' PHE . . . . . 0.684 ' HE2' ' HA3' ' A' ' 4' ' ' GLY . 38.0 p90 -120.63 152.72 37.8 Favored 'General case' 0 C--N 1.319 -0.76 0 CA-C-N 115.74 -0.664 . . . . 73.230000000000004 110.325 -177.523 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 22.7 t70 -97.64 116.76 30.47 Favored 'General case' 0 C--N 1.322 -0.596 0 N-CA-C 109.224 -0.658 . . . . 71.519999999999996 109.224 174.883 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 9.9 p -77.86 140.71 16.57 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.497 0 CA-C-O 121.52 0.676 . . . . 61.439999999999998 111.637 -170.553 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 52' ' ' GLU . . . . . 0.432 ' HB3' ' HG3' ' A' ' 59' ' ' GLN . 32.6 tt0 -137.38 156.91 47.66 Favored 'General case' 0 C--N 1.32 -0.688 0 N-CA-C 108.163 -1.051 . . . . 75.209999999999994 108.163 175.173 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . 0.407 ' HA ' ' O ' ' A' ' 57' ' ' GLY . 0.0 OUTLIER -149.49 -177.78 6.05 Favored 'General case' 0 C--N 1.32 -0.708 0 O-C-N 122.092 -0.38 . . . . 73.540000000000006 110.794 -178.487 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 143.94 -101.78 0.26 Allowed Glycine 0 N--CA 1.442 -0.933 0 C-N-CA 120.62 -0.8 . . . . 65.140000000000001 113.132 177.669 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 35.3 tt0 -80.14 -23.88 40.82 Favored 'General case' 0 C--N 1.326 -0.443 0 N-CA-C 112.361 0.504 . . . . 71.209999999999994 112.361 -168.925 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 2.0 ptp180 -137.95 43.39 2.23 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-O 121.07 0.462 . . . . 75.230000000000004 111.733 -178.591 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . 0.407 ' O ' ' HA ' ' A' ' 53' ' ' GLU . . . 76.07 -157.38 48.42 Favored Glycine 0 N--CA 1.449 -0.454 0 C-N-CA 120.842 -0.694 . . . . 72.019999999999996 113.127 174.667 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 1.7 Cg_endo -81.43 110.39 2.21 Favored 'Trans proline' 0 N--CA 1.455 -0.776 0 C-N-CA 123.242 2.628 . . . . 74.239999999999995 112.053 -178.999 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . 0.438 ' HA ' ' O ' ' A' ' 27' ' ' PHE . 16.8 pt20 -105.45 139.11 40.57 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 115.892 -0.595 . . . . 71.310000000000002 109.97 179.091 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . 0.432 ' HB1' HG13 ' A' ' 26' ' ' VAL . . . -89.8 109.35 20.35 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 116.178 -0.465 . . . . 74.430000000000007 110.997 -179.344 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -111.41 149.9 30.56 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-N 115.825 -0.625 . . . . 74.510000000000005 109.519 176.315 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 94.9 m-20 51.49 80.17 0.09 Allowed 'General case' 0 C--O 1.235 0.321 0 CA-C-O 121.286 0.565 . . . . 73.450000000000003 110.841 -176.76 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 38.9 t -102.88 103.97 15.88 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.589 0 CA-C-N 115.732 -0.667 . . . . 75.530000000000001 110.245 -179.355 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 54.4 mt-30 -94.9 160.54 14.54 Favored 'General case' 0 C--N 1.319 -0.735 0 CA-C-N 115.918 -0.583 . . . . 74.530000000000001 110.52 -179.647 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -82.77 171.35 14.05 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 115.717 -0.674 . . . . 72.329999999999998 110.894 -176.773 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.097 0 CA-C-O 118.413 -0.803 . . . . 73.340000000000003 109.544 177.172 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 56.9 mp0 . . . . . 0 N--CA 1.451 -0.424 0 CA-C-O 121.268 0.556 . . . . 65.340000000000003 111.871 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -96.79 112.78 24.39 Favored 'General case' 0 C--N 1.323 -0.545 0 N-CA-C 108.095 -1.076 . . . . 73.519999999999996 108.095 172.956 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . 0.479 ' HA3' ' HE2' ' A' ' 49' ' ' PHE . . . -137.61 168.53 24.43 Favored Glycine 0 N--CA 1.447 -0.608 0 C-N-CA 120.392 -0.908 . . . . 75.019999999999996 112.558 -175.864 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 26.9 m -108.24 134.26 51.33 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-O 120.634 0.254 . . . . 74.219999999999999 110.457 -179.024 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 47.8 t -68.75 112.7 3.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 CA-C-O 120.772 0.32 . . . . 72.329999999999998 110.378 178.494 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 48.3 mtpt -71.76 -70.86 0.3 Allowed 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 115.808 -0.633 . . . . 74.200000000000003 110.21 179.887 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 8' ' ' TRP . . . . . . . . . . . . . 92.1 m95 -139.4 132.61 29.81 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 115.094 -0.957 . . . . 72.329999999999998 108.819 178.117 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . 0.494 ' HD1' ' HA3' ' A' ' 16' ' ' GLY . 59.4 t80 -132.22 102.1 5.64 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-O 121.272 0.558 . . . . 72.439999999999998 110.822 179.15 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 19.0 m120 -80.99 84.8 6.38 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 115.583 -0.735 . . . . 74.530000000000001 109.534 176.444 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -61.66 -33.25 73.63 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 115.393 -0.821 . . . . 54.439999999999998 111.074 179.055 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 44.3 mt-10 -69.6 -25.9 64.19 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.015 -0.538 . . . . 73.129999999999995 110.73 179.532 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 75.7 mmtt -92.24 -35.53 13.74 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.219 -0.446 . . . . 63.200000000000003 110.187 -179.948 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 110.12 14.11 14.14 Favored Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 120.965 -0.636 . . . . 44.310000000000002 113.35 175.574 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 50.0 p90 -152.73 162.08 41.73 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 117.157 0.479 . . . . 74.540000000000006 111.451 -177.546 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.494 ' HA3' ' HD1' ' A' ' 9' ' ' PHE . . . -163.38 178.25 39.04 Favored Glycine 0 N--CA 1.446 -0.692 0 C-N-CA 120.885 -0.674 . . . . 74.219999999999999 112.197 179.071 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 90.8 m-85 -126.28 127.76 46.1 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-O 120.7 0.286 . . . . 74.310000000000002 110.507 -178.967 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 46.3 mt -112.93 129.91 67.72 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.497 0 N-CA-C 109.151 -0.685 . . . . 74.340000000000003 109.151 175.787 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 11.1 pt-20 -73.7 139.88 45.65 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 121.502 0.668 . . . . 73.030000000000001 111.559 -171.851 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' ARG . . . . . . . . . . . . . 43.5 ttt180 -112.48 141.2 46.51 Favored 'General case' 0 C--N 1.319 -0.733 0 N-CA-C 107.434 -1.321 . . . . 62.420000000000002 107.434 175.035 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 16.1 pt-20 -55.67 -26.57 45.47 Favored 'General case' 0 C--N 1.327 -0.406 0 N-CA-C 112.85 0.685 . . . . 70.219999999999999 112.85 -170.116 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 28.6 t-20 -79.69 -19.58 48.62 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-O 120.845 0.355 . . . . 74.420000000000002 111.434 -178.813 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 106.48 -9.33 41.49 Favored Glycine 0 CA--C 1.511 -0.157 0 N-CA-C 111.229 -0.748 . . . . 74.510000000000005 111.229 -174.514 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 36.5 t70 -80.32 72.24 7.16 Favored 'General case' 0 C--N 1.322 -0.615 0 N-CA-C 109.279 -0.638 . . . . 71.400000000000006 109.279 176.294 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 10.1 p-10 -70.28 138.07 51.26 Favored 'General case' 0 C--N 1.333 -0.14 0 CA-C-O 121.52 0.676 . . . . 62.520000000000003 110.811 -172.899 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . 0.526 HG12 ' HB2' ' A' ' 58' ' ' PRO . 4.3 t -94.57 138.98 19.4 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.55 0 CA-C-N 115.187 -0.915 . . . . 74.099999999999994 111.4 -167.734 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 27' ' ' PHE . . . . . . . . . . . . . 50.4 t80 -92.27 111.72 23.39 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.769 -0.65 . . . . 74.019999999999996 110.461 -177.449 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.522 ' HB ' ' HB2' ' A' ' 60' ' ' ALA . 14.8 p -95.86 148.49 5.22 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.381 0 CA-C-O 120.905 0.383 . . . . 75.450000000000003 111.325 -175.462 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 28.0 m170 -114.31 145.72 41.42 Favored 'General case' 0 C--O 1.236 0.343 0 CA-C-N 116.151 -0.477 . . . . 71.109999999999999 109.889 177.623 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 20.5 p90 -62.19 -26.24 68.24 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 121.11 0.481 . . . . 73.530000000000001 110.46 177.659 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 4.2 m -81.56 -14.36 56.93 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 115.77 -0.65 . . . . 73.109999999999999 110.875 179.277 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . 0.482 ' HB1' ' HA ' ' A' ' 61' ' ' ALA . . . -94.51 -21.3 18.97 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 121.044 0.449 . . . . 64.140000000000001 110.819 -176.709 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 44.9 mt -71.04 155.8 7.39 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-N 115.777 -0.647 . . . . 74.349999999999994 110.188 174.534 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 14.5 pt20 . . . . . 0 C--N 1.328 -0.368 0 CA-C-O 121.226 0.536 . . . . 72.219999999999999 110.458 175.755 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 22.9 t . . . . . 0 C--O 1.235 0.298 0 CA-C-O 121.022 0.439 . . . . 75.420000000000002 111.181 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 81.7 mt -95.94 119.04 33.72 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 116.013 -0.54 . . . . 73.319999999999993 109.892 177.385 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 42' ' ' ASP . . . . . 0.609 ' HB3' ' HB2' ' A' ' 45' ' ' GLN . 30.7 t70 -82.43 139.93 33.72 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-N 115.942 -0.572 . . . . 65.150000000000006 111.048 -175.988 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 6.8 pt-20 -66.11 116.72 7.5 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 115.84 -0.618 . . . . 72.209999999999994 110.846 178.383 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 87.3 18.9 56.55 Favored Glycine 0 N--CA 1.448 -0.508 0 C-N-CA 120.642 -0.79 . . . . 53.549999999999997 112.182 -177.77 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 45' ' ' GLN . . . . . 0.609 ' HB2' ' HB3' ' A' ' 42' ' ' ASP . 35.6 tt0 -99.22 135.5 40.54 Favored 'General case' 0 C--N 1.326 -0.451 0 N-CA-C 110.208 -0.293 . . . . 71.239999999999995 110.208 178.497 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -85.52 129.01 34.92 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 116.36 -0.382 . . . . 64.349999999999994 110.271 177.807 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 16.6 m -138.36 153.62 26.61 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.518 0 CA-C-O 120.988 0.423 . . . . 74.109999999999999 111.01 -177.927 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 48' ' ' THR . . . . . 0.513 ' HG1' ' HB3' ' A' ' 64' ' ' GLN . 20.7 p -102.51 104.87 15.33 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 115.994 -0.548 . . . . 73.510000000000005 109.814 175.988 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 49' ' ' PHE . . . . . 0.479 ' HE2' ' HA3' ' A' ' 4' ' ' GLY . 41.8 p90 -110.74 158.51 18.57 Favored 'General case' 0 C--N 1.316 -0.852 0 CA-C-N 115.449 -0.796 . . . . 74.510000000000005 110.174 -174.994 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 19.7 t0 -104.61 151.77 23.24 Favored 'General case' 0 C--N 1.317 -0.842 0 C-N-CA 120.074 -0.65 . . . . 71.030000000000001 109.958 173.552 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 4.9 p -103.17 112.41 36.52 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.599 0 CA-C-O 121.405 0.621 . . . . 74.129999999999995 111.194 -173.57 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 49.8 mm-40 -109.85 112.88 25.19 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-N 115.586 -0.733 . . . . 72.239999999999995 109.689 177.613 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . 0.532 ' HA ' ' O ' ' A' ' 57' ' ' GLY . 8.1 pt-20 -76.81 115.47 16.62 Favored 'General case' 0 C--N 1.325 -0.498 0 C-N-CA 120.211 -0.595 . . . . 75.439999999999998 109.941 177.202 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . 0.508 ' HA3' ' NE2' ' A' ' 59' ' ' GLN . . . -122.57 -121.2 2.68 Favored Glycine 0 N--CA 1.445 -0.736 0 C-N-CA 120.354 -0.927 . . . . 45.130000000000003 113.365 -174.658 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -84.77 1.68 45.6 Favored 'General case' 0 C--N 1.329 -0.311 0 N-CA-C 112.157 0.429 . . . . 74.439999999999998 112.157 -169.632 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 10.2 ptp180 -158.87 28.39 0.22 Allowed 'General case' 0 C--N 1.325 -0.457 0 CA-C-O 120.748 0.308 . . . . 75.420000000000002 111.237 177.678 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . 0.532 ' O ' ' HA ' ' A' ' 53' ' ' GLU . . . 93.29 -132.81 11.4 Favored Glycine 0 N--CA 1.444 -0.784 0 C-N-CA 120.44 -0.886 . . . . 74.420000000000002 112.18 -179.054 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . 0.526 ' HB2' HG12 ' A' ' 26' ' ' VAL . 33.0 Cg_endo -64.32 106.66 0.72 Allowed 'Trans proline' 0 CA--C 1.529 0.239 0 C-N-CA 122.837 2.358 . . . . 64.400000000000006 113.323 -174.806 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . 0.508 ' NE2' ' HA3' ' A' ' 54' ' ' GLY . 22.2 mt-30 -112.53 128.41 56.34 Favored 'General case' 0 C--N 1.323 -0.567 0 N-CA-C 109.011 -0.737 . . . . 74.340000000000003 109.011 173.615 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . 0.522 ' HB2' ' HB ' ' A' ' 28' ' ' VAL . . . -82.13 115.1 21.09 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-O 120.984 0.421 . . . . 64.530000000000001 110.955 -176.127 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 61' ' ' ALA . . . . . 0.482 ' HA ' ' HB1' ' A' ' 32' ' ' ALA . . . -130.89 154.14 48.4 Favored 'General case' 0 C--N 1.319 -0.75 0 N-CA-C 108.845 -0.798 . . . . 75.099999999999994 108.845 176.818 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 90.2 m-20 57.84 73.93 0.45 Allowed 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 121.492 0.663 . . . . 74.019999999999996 109.967 -176.125 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 45.3 t -100.21 103.71 15.16 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.664 0 CA-C-N 115.357 -0.838 . . . . 64.530000000000001 109.813 179.857 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 64' ' ' GLN . . . . . 0.513 ' HB3' ' HG1' ' A' ' 48' ' ' THR . 6.3 tp-100 -91.63 143.19 26.82 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-N 116.027 -0.533 . . . . 74.120000000000005 110.673 -176.941 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 66.8 mmtt -72.72 130.22 40.01 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 115.684 -0.689 . . . . 73.239999999999995 109.992 177.817 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.251 1.167 0 CA-C-O 118.432 -0.794 . . . . 75.010000000000005 110.53 -178.164 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 1.7 pm0 . . . . . 0 N--CA 1.448 -0.531 0 N-CA-C 110.275 -0.269 . . . . 75.420000000000002 110.275 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -100.24 128.74 46.25 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-O 121.215 0.531 . . . . 74.420000000000002 110.616 179.31 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -131.14 164.7 23.29 Favored Glycine 0 N--CA 1.444 -0.774 0 CA-C-N 115.803 -0.635 . . . . 63.310000000000002 111.751 -179.17 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 21.3 m -105.38 122.87 46.86 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-O 120.542 0.21 . . . . 74.510000000000005 110.707 -178.775 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 58.7 t -64.37 114.36 2.21 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.227 0 CA-C-N 116.392 -0.367 . . . . 73.129999999999995 110.547 -179.331 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 4.5 mmmm -95.28 -53.16 3.88 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 115.859 -0.609 . . . . 75.340000000000003 110.255 -178.832 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 8' ' ' TRP . . . . . 0.472 ' HB2' ' HB2' ' A' ' 17' ' ' PHE . 76.5 m95 -118.11 130.63 56.24 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 115.687 -0.688 . . . . 74.349999999999994 110.082 179.793 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . 0.423 ' CE2' ' HB1' ' A' ' 11' ' ' ALA . 62.6 t80 -128.66 84.37 2.23 Favored 'General case' 0 C--N 1.318 -0.781 0 CA-C-O 121.282 0.563 . . . . 74.5 109.692 178.862 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 10' ' ' ASN . . . . . 0.786 ' HB3' ' HB2' ' A' ' 13' ' ' LYS . 44.0 m-80 -87.53 74.35 9.31 Favored 'General case' 0 C--N 1.321 -0.663 0 CA-C-N 115.909 -0.587 . . . . 73.349999999999994 110.021 -177.61 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . 0.671 ' HA ' ' CZ ' ' A' ' 30' ' ' PHE . . . -61.07 -39.61 90.53 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.277 -0.874 . . . . 74.150000000000006 111.409 -177.296 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 47.0 mt-10 -84.22 -11.4 56.56 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 116.085 -0.507 . . . . 71.530000000000001 111.173 -177.947 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' LYS . . . . . 0.786 ' HB2' ' HB3' ' A' ' 10' ' ' ASN . 5.2 mmtp -98.6 -28.41 13.57 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 116.274 -0.421 . . . . 74.430000000000007 110.586 -177.02 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 102.2 22.65 9.69 Favored Glycine 0 N--CA 1.448 -0.526 0 C-N-CA 120.652 -0.785 . . . . 73.030000000000001 113.396 174.287 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . 0.452 ' O ' ' HB2' ' A' ' 10' ' ' ASN . 52.5 p90 -163.38 171.49 15.96 Favored 'General case' 0 N--CA 1.463 0.222 0 CA-C-N 117.451 0.625 . . . . 73.319999999999993 111.067 179.649 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -153.98 172.14 32.65 Favored Glycine 0 N--CA 1.445 -0.701 0 C-N-CA 120.827 -0.701 . . . . 61.530000000000001 112.119 179.976 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . 0.794 ' HB3' ' HB3' ' A' ' 25' ' ' ASP . 92.6 m-85 -134.63 122.82 22.82 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 120.802 0.334 . . . . 73.430000000000007 110.269 179.472 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 35.3 mt -122.41 117.44 52.09 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.593 0 CA-C-N 116.103 -0.499 . . . . 74.409999999999997 109.734 179.164 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' GLU . . . . . 0.4 ' HA ' ' HA ' ' A' ' 25' ' ' ASP . 22.8 pt-20 -79.41 148.31 32.01 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-O 121.257 0.551 . . . . 62.310000000000002 112.17 -170.976 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' ARG . . . . . 0.413 ' HG2' ' HG2' ' A' ' 21' ' ' GLU . 14.4 ttm180 -118.61 123.51 45.17 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 115.42 -0.809 . . . . 75.140000000000001 109.684 170.681 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . 0.413 ' HG2' ' HG2' ' A' ' 20' ' ' ARG . 43.1 mm-40 50.78 -90.02 0.02 OUTLIER 'General case' 0 N--CA 1.474 0.738 0 N-CA-C 113.407 0.891 . . . . 73.340000000000003 113.407 173.094 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 1.6 m-20 -58.31 -19.11 32.22 Favored 'General case' 0 N--CA 1.467 0.408 0 C-N-CA 123.847 0.859 . . . . 72.209999999999994 111.79 -175.215 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 104.35 19.92 10.9 Favored Glycine 0 N--CA 1.442 -0.951 0 N-CA-C 110.015 -1.234 . . . . 75.530000000000001 110.015 -170.604 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 5.3 t70 -71.69 90.01 1.04 Allowed 'General case' 0 N--CA 1.45 -0.434 0 N-CA-C 109.0 -0.741 . . . . 73.239999999999995 109.0 178.089 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.794 ' HB3' ' HB3' ' A' ' 17' ' ' PHE . 62.0 m-20 -63.37 104.32 0.6 Allowed 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 115.756 -0.656 . . . . 52.420000000000002 110.613 -179.553 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 59.3 t -74.48 132.36 33.49 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.598 0 CA-C-N 115.602 -0.726 . . . . 64.109999999999999 110.0 179.009 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 27' ' ' PHE . . . . . 0.48 ' O ' ' HA ' ' A' ' 59' ' ' GLN . 78.5 t80 -82.73 127.61 33.58 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 116.089 -0.505 . . . . 73.219999999999999 110.441 -177.261 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.5 ' HB ' ' HB3' ' A' ' 60' ' ' ALA . 14.2 p -131.35 147.64 32.8 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 CA-C-O 121.02 0.438 . . . . 63.32 111.647 -177.416 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 21.9 m170 -108.64 159.57 16.62 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.991 -0.549 . . . . 72.519999999999996 109.684 174.759 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 30' ' ' PHE . . . . . 0.671 ' CZ ' ' HA ' ' A' ' 11' ' ' ALA . 52.4 m-85 -71.95 -14.28 61.87 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-O 120.702 0.287 . . . . 73.409999999999997 111.309 -179.723 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 13.8 t -71.35 -22.13 61.94 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-O 121.337 0.589 . . . . 52.210000000000001 110.07 174.725 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -100.83 -22.53 14.81 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 115.846 -0.615 . . . . 73.319999999999993 110.487 179.387 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 70.6 mt -76.93 145.77 9.7 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 CA-C-N 115.883 -0.599 . . . . 75.310000000000002 109.452 174.521 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 34' ' ' GLN . . . . . 0.419 ' NE2' ' HG3' ' A' ' 65' ' ' LYS . 23.3 pt20 . . . . . 0 C--N 1.327 -0.412 0 CA-C-O 121.455 0.645 . . . . 72.239999999999995 110.626 177.373 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 42.1 m . . . . . 0 N--CA 1.454 -0.234 0 CA-C-O 120.887 0.375 . . . . 74.019999999999996 110.986 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 3.2 mm? -90.62 139.01 31.11 Favored 'General case' 0 C--N 1.324 -0.534 0 N-CA-C 109.228 -0.656 . . . . 73.430000000000007 109.228 175.021 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 30.9 t70 -90.23 146.76 24.0 Favored 'General case' 0 C--N 1.319 -0.729 0 C-N-CA 120.87 -0.332 . . . . 74.109999999999999 110.334 -178.792 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 37.4 mt-10 -70.97 102.01 2.31 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 116.319 -0.401 . . . . 73.109999999999999 109.932 178.293 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 123.03 1.19 9.59 Favored Glycine 0 N--CA 1.45 -0.433 0 CA-C-N 115.784 -0.644 . . . . 74.540000000000006 111.672 -173.272 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 52.1 tp60 -87.49 139.81 30.16 Favored 'General case' 0 N--CA 1.464 0.247 0 C-N-CA 122.247 0.219 . . . . 70.239999999999995 110.873 -179.734 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -90.54 131.68 36.13 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 121.084 0.469 . . . . 73.049999999999997 110.732 176.696 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 21.6 m -132.06 167.06 27.3 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 CA-C-N 116.062 -0.517 . . . . 73.319999999999993 110.782 -178.871 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 3.4 p -120.97 114.95 22.27 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-O 121.185 0.517 . . . . 62.240000000000002 110.211 179.312 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 38.8 p90 -134.78 166.1 23.74 Favored 'General case' 0 C--N 1.319 -0.76 0 CA-C-N 115.949 -0.568 . . . . 74.120000000000005 110.348 -173.802 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 39.1 t0 -106.84 121.62 44.77 Favored 'General case' 0 C--N 1.324 -0.538 0 C-N-CA 120.4 -0.52 . . . . 75.519999999999996 110.447 175.253 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 86.5 t -77.83 117.16 22.54 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.55 0 CA-C-O 120.986 0.422 . . . . 74.549999999999997 111.294 -178.842 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 52' ' ' GLU . . . . . 0.653 ' HB3' ' HG3' ' A' ' 59' ' ' GLN . 8.9 tp10 -94.12 116.79 29.25 Favored 'General case' 0 C--N 1.321 -0.652 0 N-CA-C 108.904 -0.776 . . . . 74.349999999999994 108.904 174.022 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 47.5 mt-10 -92.78 95.73 9.72 Favored 'General case' 0 C--N 1.319 -0.721 0 CA-C-O 121.128 0.49 . . . . 72.310000000000002 110.107 179.837 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -103.61 -143.49 12.76 Favored Glycine 0 N--CA 1.445 -0.701 0 CA-C-N 115.597 -0.729 . . . . 62.140000000000001 112.68 -176.629 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -86.42 -40.41 15.4 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 121.008 0.432 . . . . 64.329999999999998 110.723 -175.381 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 77.2 mtm180 -108.23 81.94 1.56 Allowed 'General case' 0 C--N 1.322 -0.614 0 CA-C-N 116.273 -0.421 . . . . 75.219999999999999 111.305 -176.262 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 68.9 -171.29 38.92 Favored Glycine 0 N--CA 1.448 -0.507 0 CA-C-N 115.619 -0.719 . . . . 63.530000000000001 112.93 178.22 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 87.3 Cg_endo -86.94 123.62 2.05 Favored 'Trans proline' 0 N--CA 1.453 -0.857 0 C-N-CA 122.829 2.353 . . . . 75.439999999999998 111.764 175.752 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . 0.653 ' HG3' ' HB3' ' A' ' 52' ' ' GLU . 3.6 pt20 -109.3 126.91 53.86 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-N 116.212 -0.449 . . . . 65.030000000000001 109.852 178.181 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . 0.5 ' HB3' ' HB ' ' A' ' 28' ' ' VAL . . . -79.42 117.58 20.52 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-O 120.837 0.351 . . . . 64.409999999999997 110.802 -178.771 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -110.87 128.62 55.86 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 116.013 -0.54 . . . . 63.140000000000001 109.816 178.524 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 49.4 m-80 63.78 96.38 0.04 OUTLIER 'General case' 0 C--O 1.235 0.312 0 O-C-N 123.577 0.548 . . . . 73.510000000000005 110.674 -176.521 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.462 HG23 HG23 ' A' ' 28' ' ' VAL . 48.8 t -110.66 107.15 22.21 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.474 0 CA-C-N 115.661 -0.699 . . . . 73.299999999999997 110.746 179.718 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 34.4 tt0 -102.09 168.35 9.44 Favored 'General case' 0 C--N 1.324 -0.542 0 N-CA-C 108.816 -0.809 . . . . 75.120000000000005 108.816 177.556 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . 0.419 ' HG3' ' NE2' ' A' ' 34' ' ' GLN . 55.3 mtmt -103.78 155.29 18.72 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-O 120.801 0.334 . . . . 75.430000000000007 110.658 -179.125 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.251 1.135 0 CA-C-O 118.656 -0.688 . . . . 74.239999999999995 109.79 177.691 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 2' ' ' GLU . . . . . 0.406 ' H ' ' CD ' ' A' ' 2' ' ' GLU . 1.8 pm0 . . . . . 0 C--O 1.239 0.514 0 CA-C-O 121.457 0.646 . . . . 63.039999999999999 110.822 . . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -119.13 162.73 18.14 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 115.002 -0.999 . . . . 74.239999999999995 110.073 -179.297 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -160.65 165.24 34.99 Favored Glycine 0 N--CA 1.442 -0.95 0 C-N-CA 120.889 -0.672 . . . . 72.349999999999994 111.72 178.072 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 5' ' ' THR . . . . . 0.46 ' O ' ' HG2' ' A' ' 19' ' ' GLU . 28.2 m -100.48 137.87 38.3 Favored 'General case' 0 C--N 1.319 -0.726 0 N-CA-C 110.06 -0.348 . . . . 74.400000000000006 110.06 178.451 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 48.1 t -68.62 108.36 1.55 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 N-CA-C 109.793 -0.447 . . . . 64.049999999999997 109.793 175.783 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 7' ' ' LYS . . . . . 0.616 ' HA ' ' HE3' ' A' ' 7' ' ' LYS . 0.0 OUTLIER -75.2 -56.15 5.01 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-O 120.93 0.395 . . . . 73.349999999999994 110.426 178.313 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 8' ' ' TRP . . . . . . . . . . . . . 4.1 p90 -156.98 136.98 12.6 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 115.749 -0.66 . . . . 75.030000000000001 110.205 179.162 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 17.5 p90 -124.35 108.55 12.32 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-O 121.807 0.813 . . . . 74.409999999999997 110.157 178.515 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 41.2 t-20 -85.93 86.83 7.35 Favored 'General case' 0 C--N 1.318 -0.761 0 CA-C-O 121.477 0.656 . . . . 74.200000000000003 109.401 -178.778 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -57.77 -32.46 67.52 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 114.914 -1.039 . . . . 73.209999999999994 111.623 179.182 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 74.2 mm-40 -64.08 -31.25 72.38 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 120.857 0.36 . . . . 70.450000000000003 111.132 178.848 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' LYS . . . . . 0.452 ' HB3' ' CE2' ' A' ' 15' ' ' PHE . 0.1 OUTLIER -92.28 -17.77 24.3 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.894 -0.594 . . . . 73.409999999999997 110.746 179.047 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 86.77 19.24 56.75 Favored Glycine 0 N--CA 1.447 -0.585 0 C-N-CA 120.82 -0.705 . . . . 75.319999999999993 112.898 177.635 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . 0.452 ' CE2' ' HB3' ' A' ' 13' ' ' LYS . 31.0 p90 -157.78 156.66 31.94 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 121.133 0.492 . . . . 64.0 111.443 179.587 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -134.87 -179.24 16.31 Favored Glycine 0 N--CA 1.442 -0.906 0 N-CA-C 111.291 -0.724 . . . . 73.519999999999996 111.291 178.671 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . 0.409 ' HA ' ' O ' ' A' ' 26' ' ' VAL . 97.2 m-85 -132.35 127.65 35.98 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-O 121.305 0.574 . . . . 75.239999999999995 111.266 -179.538 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 63.4 mt -101.32 138.86 24.11 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.569 0 CA-C-N 115.209 -0.905 . . . . 73.510000000000005 109.344 177.864 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' GLU . . . . . 0.46 ' HG2' ' O ' ' A' ' 5' ' ' THR . 11.7 pt-20 -82.86 134.84 35.08 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-O 121.196 0.522 . . . . 73.340000000000003 111.303 -177.022 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' ARG . . . . . 0.737 ' HD2' ' H ' ' A' ' 21' ' ' GLU . 0.1 OUTLIER -113.22 -177.96 3.26 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 115.904 -0.589 . . . . 75.239999999999995 109.775 178.506 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . 0.737 ' H ' ' HD2' ' A' ' 20' ' ' ARG . 10.0 pt-20 -59.51 -37.18 77.64 Favored 'General case' 0 C--N 1.327 -0.387 0 N-CA-C 112.93 0.715 . . . . 72.450000000000003 112.93 -173.205 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 22' ' ' ASN . . . . . 0.407 ' ND2' ' HG3' ' A' ' 21' ' ' GLU . 29.3 m-80 -94.21 5.67 51.03 Favored 'General case' 0 C--N 1.328 -0.346 0 O-C-N 122.096 -0.377 . . . . 72.409999999999997 110.805 -178.306 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 84.97 20.02 58.39 Favored Glycine 0 N--CA 1.447 -0.584 0 N-CA-C 110.236 -1.145 . . . . 61.409999999999997 110.236 -170.509 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . 0.459 ' HB2' ' CB ' ' A' ' 20' ' ' ARG . 3.8 m-20 -67.15 95.02 0.38 Allowed 'General case' 0 N--CA 1.45 -0.448 0 CA-C-N 114.879 -0.66 . . . . 73.400000000000006 109.463 179.59 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 11.1 p-10 -63.65 100.81 0.3 Allowed 'General case' 0 C--N 1.32 -0.676 0 CA-C-O 121.833 0.825 . . . . 71.030000000000001 110.309 175.97 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . 0.409 ' O ' ' HA ' ' A' ' 17' ' ' PHE . 44.9 t -78.38 120.76 29.91 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 CA-C-N 115.15 -0.932 . . . . 72.319999999999993 110.756 -177.273 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 27' ' ' PHE . . . . . . . . . . . . . 68.9 t80 -73.34 113.16 10.11 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 115.65 -0.705 . . . . 54.130000000000003 110.433 -179.092 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.416 ' HB ' ' HB1' ' A' ' 60' ' ' ALA . 10.4 p -117.26 126.59 74.64 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.575 0 CA-C-O 121.083 0.468 . . . . 73.129999999999995 110.24 176.068 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 29' ' ' HIS . . . . . 0.425 ' O ' HG13 ' A' ' 33' ' ' ILE . 41.2 t60 -103.46 149.74 24.54 Favored 'General case' 0 C--N 1.324 -0.529 0 N-CA-C 109.452 -0.573 . . . . 74.239999999999995 109.452 -176.754 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 30' ' ' PHE . . . . . 0.414 ' HA ' HD11 ' A' ' 33' ' ' ILE . 42.2 p90 -58.44 -27.29 64.22 Favored 'General case' 0 N--CA 1.467 0.403 0 CA-C-O 120.819 0.342 . . . . 74.319999999999993 111.607 -175.657 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 6.7 m -72.98 -14.13 61.38 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 116.409 -0.36 . . . . 75.420000000000002 111.283 179.005 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -106.88 -17.65 14.14 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.921 0.391 . . . . 73.120000000000005 111.058 -178.466 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.425 HG13 ' O ' ' A' ' 29' ' ' HIS . 66.5 mt -71.22 144.82 13.06 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 CA-C-N 116.032 -0.531 . . . . 73.450000000000003 110.49 177.989 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 34' ' ' GLN . . . . . 0.468 ' HG3' ' O ' ' A' ' 34' ' ' GLN . 21.6 pt20 . . . . . 0 C--N 1.33 -0.263 0 N-CA-C 109.581 -0.526 . . . . 72.329999999999998 109.581 172.909 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 51.4 p . . . . . 0 N--CA 1.453 -0.319 0 N-CA-C 112.206 0.446 . . . . 74.420000000000002 112.206 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -88.77 103.64 16.16 Favored 'General case' 0 C--N 1.326 -0.439 0 N-CA-C 108.376 -0.972 . . . . 74.510000000000005 108.376 168.968 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 20.5 t70 -76.72 150.85 36.24 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 116.058 -0.519 . . . . 73.019999999999996 111.527 -169.718 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 83.6 mt-10 -61.59 112.82 2.38 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 115.629 -0.714 . . . . 72.239999999999995 110.552 -179.593 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 124.29 -12.87 7.96 Favored Glycine 0 N--CA 1.445 -0.758 0 C-N-CA 120.796 -0.716 . . . . 61.420000000000002 111.547 -177.203 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 6.5 tp-100 -80.06 143.15 34.25 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-O 120.857 0.36 . . . . 74.299999999999997 110.312 178.678 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -99.5 118.75 36.77 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 116.023 -0.535 . . . . 62.32 110.188 179.515 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 27.4 m -123.57 163.01 23.48 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.696 0 CA-C-N 116.227 -0.442 . . . . 70.25 111.11 -176.754 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 1.6 p -117.25 139.86 50.27 Favored 'General case' 0 C--N 1.321 -0.64 0 N-CA-C 108.91 -0.774 . . . . 74.310000000000002 108.91 176.548 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 33.5 p90 -141.24 159.18 42.76 Favored 'General case' 0 C--N 1.317 -0.823 0 C-N-CA 120.3 -0.56 . . . . 72.239999999999995 111.616 -175.26 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 4.9 t70 -88.14 103.16 15.49 Favored 'General case' 0 C--N 1.321 -0.657 0 N-CA-C 108.645 -0.872 . . . . 75.209999999999994 108.645 174.975 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 7.7 p -63.79 123.13 15.99 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 CA-C-O 121.295 0.569 . . . . 71.349999999999994 111.846 -173.09 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 52' ' ' GLU . . . . . 0.536 ' HB3' ' HG2' ' A' ' 59' ' ' GLN . 7.8 tp10 -117.52 139.86 50.38 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 115.648 -0.705 . . . . 64.420000000000002 110.067 178.997 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 10.8 tp10 -101.31 146.32 27.71 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-N 115.956 -0.565 . . . . 73.450000000000003 109.626 -179.701 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -144.83 -175.79 18.29 Favored Glycine 0 N--CA 1.45 -0.417 0 C-N-CA 120.709 -0.757 . . . . 62.420000000000002 112.527 -177.88 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 50.2 mt-30 -75.11 -34.15 61.67 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 120.755 0.312 . . . . 73.230000000000004 110.85 179.757 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 35.0 mtp-105 -77.1 -33.31 56.93 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-O 121.022 0.439 . . . . 74.209999999999994 110.436 174.39 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 146.87 -155.8 26.71 Favored Glycine 0 N--CA 1.448 -0.504 0 CA-C-N 115.904 -0.589 . . . . 43.219999999999999 111.798 -178.223 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 59.7 Cg_endo -74.26 137.13 23.07 Favored 'Trans proline' 0 C--O 1.234 0.298 0 C-N-CA 122.582 2.188 . . . . 74.099999999999994 112.775 -177.752 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . 0.536 ' HG2' ' HB3' ' A' ' 52' ' ' GLU . 0.0 OUTLIER -131.35 154.75 48.26 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 116.101 -0.499 . . . . 72.239999999999995 109.835 175.142 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . 0.416 ' HB1' ' HB ' ' A' ' 28' ' ' VAL . . . -101.77 106.53 17.54 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 116.294 -0.412 . . . . 55.039999999999999 110.993 -177.132 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -111.28 149.1 31.54 Favored 'General case' 0 C--N 1.321 -0.655 0 N-CA-C 109.263 -0.643 . . . . 65.340000000000003 109.263 175.082 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 86.5 m-20 57.06 82.79 0.11 Allowed 'General case' 0 N--CA 1.466 0.354 0 CA-C-O 121.304 0.573 . . . . 72.510000000000005 110.499 -178.459 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 46.4 t -103.54 134.48 44.61 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.588 0 CA-C-N 115.871 -0.604 . . . . 73.329999999999998 111.327 -174.985 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 28.0 mt-30 -130.71 178.2 6.82 Favored 'General case' 0 C--N 1.325 -0.484 0 N-CA-C 109.189 -0.671 . . . . 73.510000000000005 109.189 175.381 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 50.7 mtmt -96.81 144.18 27.02 Favored 'General case' 0 C--N 1.323 -0.554 0 N-CA-C 110.028 -0.36 . . . . 75.340000000000003 110.028 178.074 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 0.98 0 CA-C-O 118.519 -0.753 . . . . 73.019999999999996 110.274 -179.922 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 N--CA 1.452 -0.335 0 N-CA-C 109.994 -0.373 . . . . 71.010000000000005 109.994 . . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 3' ' ' GLN . . . . . 0.424 ' HG2' HG22 ' A' ' 48' ' ' THR . 50.3 mt-30 -105.85 130.67 53.77 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-N 116.029 -0.532 . . . . 71.200000000000003 109.8 174.491 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -150.49 172.9 30.21 Favored Glycine 0 N--CA 1.443 -0.844 0 C-N-CA 120.794 -0.717 . . . . 61.219999999999999 111.683 178.571 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 5' ' ' THR . . . . . 0.521 ' O ' ' HG2' ' A' ' 19' ' ' GLU . 24.3 m -122.65 135.76 54.69 Favored 'General case' 0 C--N 1.317 -0.829 0 N-CA-C 110.167 -0.309 . . . . 74.439999999999998 110.167 179.067 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 46.4 t -72.41 119.06 18.4 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.633 0 CA-C-N 116.741 -0.209 . . . . 72.129999999999995 110.524 -179.114 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 7' ' ' LYS . . . . . 0.557 ' CE ' ' HB3' ' A' ' 19' ' ' GLU . 97.7 mttt -66.01 -62.59 1.41 Allowed 'General case' 0 CA--C 1.52 -0.193 0 CA-C-O 121.7 0.762 . . . . 73.420000000000002 109.223 175.896 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 8' ' ' TRP . . . . . . . . . . . . . 55.1 p-90 -160.45 156.06 25.42 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-N 114.393 -1.276 . . . . 75.299999999999997 108.053 177.571 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 2.1 p90 -136.03 138.52 42.28 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-O 121.603 0.716 . . . . 75.109999999999999 111.858 -174.113 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 10' ' ' ASN . . . . . 0.537 ' HB3' ' HG2' ' A' ' 13' ' ' LYS . 16.6 m120 -84.12 77.52 9.93 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 115.115 -0.948 . . . . 73.430000000000007 109.115 177.009 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -54.12 -38.43 65.43 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.212 -0.904 . . . . 72.329999999999998 112.367 -175.07 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -90.75 -14.28 32.35 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 116.492 -0.322 . . . . 70.340000000000003 111.697 -175.288 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 13' ' ' LYS . . . . . 0.537 ' HG2' ' HB3' ' A' ' 10' ' ' ASN . 59.6 mmtt -90.55 -36.39 14.5 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 121.191 0.52 . . . . 73.040000000000006 109.649 177.017 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 99.59 32.88 5.54 Favored Glycine 0 N--CA 1.447 -0.619 0 CA-C-N 115.698 -0.683 . . . . 62.009999999999998 111.636 -177.676 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 74.0 m-85 -140.19 168.82 18.91 Favored 'General case' 0 C--N 1.329 -0.312 0 N-CA-C 110.152 -0.314 . . . . 72.340000000000003 110.152 -177.941 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -171.12 161.34 33.96 Favored Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.542 -0.837 . . . . 65.209999999999994 112.437 177.764 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 97.4 m-85 -123.93 120.21 31.86 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-O 121.033 0.444 . . . . 75.049999999999997 110.908 -179.847 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . 0.42 HG22 ' CE2' ' A' ' 49' ' ' PHE . 54.0 mt -105.12 135.95 41.0 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.616 0 CA-C-N 115.869 -0.605 . . . . 74.519999999999996 109.74 178.981 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 19' ' ' GLU . . . . . 0.557 ' HB3' ' CE ' ' A' ' 7' ' ' LYS . 11.6 pt-20 -94.81 128.64 41.69 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 121.404 0.621 . . . . 73.439999999999998 111.654 -177.461 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 20' ' ' ARG . . . . . 0.45 ' HB3' ' HB3' ' A' ' 24' ' ' ASP . 18.6 ttt180 -89.67 177.13 6.61 Favored 'General case' 0 C--N 1.323 -0.548 0 N-CA-C 108.289 -1.004 . . . . 74.530000000000001 108.289 171.697 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 44.6 mt-10 -61.04 -12.05 10.41 Favored 'General case' 0 N--CA 1.467 0.409 0 N-CA-C 112.098 0.407 . . . . 73.329999999999998 112.098 -178.787 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 82.6 m-20 -98.05 -4.22 36.46 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.89 0.376 . . . . 73.430000000000007 111.239 177.826 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 82.42 3.17 90.64 Favored Glycine 0 N--CA 1.449 -0.461 0 N-CA-C 110.337 -1.105 . . . . 65.439999999999998 110.337 -168.657 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . 0.45 ' HB3' ' HB3' ' A' ' 20' ' ' ARG . 33.6 t70 -56.3 98.73 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 114.61 -0.795 . . . . 74.049999999999997 110.721 -179.062 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.483 ' CG ' ' HZ3' ' A' ' 7' ' ' LYS . 12.4 m-20 -56.5 100.44 0.04 OUTLIER 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 114.964 -1.016 . . . . 73.200000000000003 111.698 174.999 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . 0.499 HG12 ' HB1' ' A' ' 60' ' ' ALA . 21.4 t -83.1 116.6 27.55 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.743 0 N-CA-C 108.761 -0.829 . . . . 72.549999999999997 108.761 172.883 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 27' ' ' PHE . . . . . . . . . . . . . 81.1 t80 -83.22 116.15 22.26 Favored 'General case' 0 C--N 1.32 -0.682 0 CA-C-N 115.894 -0.594 . . . . 75.299999999999997 111.021 -173.414 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 9.0 p -105.73 148.91 9.61 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.581 0 N-CA-C 109.534 -0.543 . . . . 71.140000000000001 109.534 175.901 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 29' ' ' HIS . . . . . 0.443 ' O ' HG13 ' A' ' 33' ' ' ILE . 2.7 p80 -140.19 163.88 31.56 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 116.277 -0.419 . . . . 72.329999999999998 110.58 -174.173 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 31.3 p90 -53.18 -33.0 50.79 Favored 'General case' 0 N--CA 1.47 0.536 0 N-CA-C 112.871 0.693 . . . . 74.010000000000005 112.871 -174.001 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 27.5 m -84.92 34.23 0.54 Allowed 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 121.174 0.511 . . . . 73.209999999999994 110.906 176.866 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -160.57 -33.56 0.05 Allowed 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 115.826 -0.625 . . . . 75.150000000000006 110.729 -179.364 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.443 HG13 ' O ' ' A' ' 29' ' ' HIS . 71.7 mt -63.7 143.37 15.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.065 -0.516 . . . . 75.439999999999998 110.461 176.195 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 88.4 mt-30 . . . . . 0 C--N 1.329 -0.293 0 N-CA-C 109.792 -0.448 . . . . 75.319999999999993 109.792 172.117 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 15.2 m . . . . . 0 N--CA 1.454 -0.243 0 CA-C-O 120.947 0.403 . . . . 73.530000000000001 111.619 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 92.2 mt -82.16 74.35 9.15 Favored 'General case' 0 C--N 1.324 -0.51 0 N-CA-C 108.797 -0.816 . . . . 75.409999999999997 108.797 171.415 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 27.6 t70 -55.38 139.88 41.64 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 115.18 -0.918 . . . . 75.319999999999993 112.051 -172.467 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 7.8 pt-20 -64.66 129.72 40.87 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-N 115.428 -0.806 . . . . 73.439999999999998 110.582 179.121 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 97.15 -10.22 65.54 Favored Glycine 0 N--CA 1.45 -0.403 0 C-N-CA 120.871 -0.68 . . . . 74.340000000000003 112.036 -177.202 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 54.0 tp60 -81.78 135.35 35.47 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-O 120.767 0.318 . . . . 72.049999999999997 110.558 178.769 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -85.35 138.54 32.22 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 116.117 -0.492 . . . . 74.450000000000003 110.097 176.043 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 16.6 m -136.98 144.84 31.08 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.605 0 CA-C-N 116.348 -0.387 . . . . 73.140000000000001 111.25 -177.415 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 48' ' ' THR . . . . . 0.424 HG22 ' HG2' ' A' ' 3' ' ' GLN . 24.7 p -104.58 122.74 46.23 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-N 115.753 -0.658 . . . . 74.030000000000001 109.571 173.633 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 49' ' ' PHE . . . . . 0.468 ' HA ' ' O ' ' A' ' 62' ' ' ASN . 38.8 p90 -141.09 157.3 45.49 Favored 'General case' 0 C--N 1.32 -0.701 0 CA-C-O 120.701 0.286 . . . . 73.349999999999994 111.206 -172.403 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 30.2 m-20 -90.48 149.49 22.19 Favored 'General case' 0 C--N 1.321 -0.674 0 N-CA-C 109.684 -0.488 . . . . 71.439999999999998 109.684 172.357 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 5.4 p -110.44 117.14 54.16 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.628 0 CA-C-O 121.428 0.633 . . . . 74.430000000000007 111.549 -175.28 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 52' ' ' GLU . . . . . 0.624 ' HB2' ' HB2' ' A' ' 59' ' ' GLN . 6.9 mm-40 -94.76 133.43 38.46 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 115.432 -0.804 . . . . 73.540000000000006 109.476 174.456 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 8.5 pt-20 -82.04 97.82 8.33 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-O 121.354 0.597 . . . . 75.049999999999997 110.86 -179.33 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -90.02 151.84 21.89 Favored Glycine 0 N--CA 1.446 -0.685 0 C-N-CA 120.736 -0.745 . . . . 74.409999999999997 111.671 179.041 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 49.8 mt-30 -58.38 -25.96 62.65 Favored 'General case' 0 C--N 1.327 -0.375 0 N-CA-C 112.377 0.51 . . . . 74.5 112.377 -177.182 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 81.4 mtt180 -130.49 26.86 5.06 Favored 'General case' 0 C--N 1.327 -0.41 0 N-CA-C 111.716 0.265 . . . . 73.129999999999995 111.716 -177.217 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 150.22 153.32 6.06 Favored Glycine 0 N--CA 1.449 -0.441 0 C-N-CA 120.128 -1.034 . . . . 74.150000000000006 113.074 177.319 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 7.2 Cg_exo -72.59 124.42 9.8 Favored 'Trans proline' 0 N--CA 1.46 -0.478 0 C-N-CA 122.834 2.356 . . . . 74.0 111.475 177.449 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . 0.624 ' HB2' ' HB2' ' A' ' 52' ' ' GLU . 26.0 mt-30 -94.53 123.44 37.96 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-N 116.243 -0.435 . . . . 75.239999999999995 110.664 -179.029 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . 0.499 ' HB1' HG12 ' A' ' 26' ' ' VAL . . . -78.99 106.59 11.14 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 116.308 -0.405 . . . . 72.409999999999997 109.946 176.244 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -116.86 139.48 50.57 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 116.311 -0.404 . . . . 63.43 110.033 -179.928 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 62' ' ' ASN . . . . . 0.468 ' O ' ' HA ' ' A' ' 49' ' ' PHE . 76.8 m-20 60.31 92.26 0.05 OUTLIER 'General case' 0 C--O 1.236 0.358 0 O-C-N 123.595 0.56 . . . . 74.310000000000002 110.008 -176.116 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 40.7 t -114.3 136.59 50.35 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.547 0 CA-C-N 115.469 -0.787 . . . . 74.010000000000005 110.55 -175.16 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 64' ' ' GLN . . . . . 0.421 ' HB3' ' OG1' ' A' ' 48' ' ' THR . 31.0 tt0 -121.5 149.14 43.51 Favored 'General case' 0 C--N 1.319 -0.737 0 N-CA-C 109.624 -0.51 . . . . 64.299999999999997 109.624 176.403 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 48.4 mttp -91.49 123.83 35.2 Favored 'General case' 0 C--N 1.324 -0.502 0 N-CA-C 110.112 -0.329 . . . . 73.430000000000007 110.112 178.491 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.246 0.886 0 CA-C-O 118.602 -0.713 . . . . 75.120000000000005 110.647 -179.942 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 60.7 mm-40 . . . . . 0 C--O 1.238 0.471 0 CA-C-O 121.388 0.613 . . . . 75.209999999999994 111.837 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 35.3 tt0 -120.91 136.28 54.99 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-N 115.34 -0.845 . . . . 74.549999999999997 109.478 174.756 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -151.9 164.49 30.4 Favored Glycine 0 N--CA 1.444 -0.788 0 N-CA-C 111.368 -0.693 . . . . 64.310000000000002 111.368 179.027 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 5' ' ' THR . . . . . 0.541 HG22 ' HE3' ' A' ' 7' ' ' LYS . 5.4 m -103.38 125.32 49.92 Favored 'General case' 0 C--N 1.318 -0.802 0 CA-C-N 116.984 0.392 . . . . 74.209999999999994 110.825 -178.623 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.484 HG22 HG12 ' A' ' 18' ' ' ILE . 46.1 t -81.52 90.47 1.94 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 N-CA-C 109.099 -0.704 . . . . 73.439999999999998 109.099 175.473 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 7' ' ' LYS . . . . . 0.541 ' HE3' HG22 ' A' ' 5' ' ' THR . 27.9 mmtp -78.02 -51.9 9.62 Favored 'General case' 0 C--N 1.323 -0.587 0 CA-C-N 115.818 -0.628 . . . . 74.209999999999994 111.584 -176.155 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 8' ' ' TRP . . . . . . . . . . . . . 8.8 p90 -133.12 122.25 23.81 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-O 121.41 0.624 . . . . 72.530000000000001 110.992 178.113 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 22.2 p90 -111.6 123.43 50.21 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-N 115.343 -0.844 . . . . 72.209999999999994 109.544 178.434 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 16.7 t-20 -88.39 76.18 8.34 Favored 'General case' 0 C--N 1.317 -0.806 0 CA-C-O 121.503 0.668 . . . . 61.439999999999998 109.893 -176.737 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -67.75 -7.93 31.39 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.241 -0.89 . . . . 73.530000000000001 110.442 178.438 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 27.3 mt-10 -70.45 -33.41 71.26 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 115.306 -0.861 . . . . 74.400000000000006 110.595 179.081 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 13' ' ' LYS . . . . . 0.409 ' HB2' ' CE1' ' A' ' 15' ' ' PHE . 74.3 mmtt -116.25 -29.66 6.18 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.235 -0.439 . . . . 72.439999999999998 111.296 -178.47 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . 0.608 ' HA2' ' CE2' ' A' ' 30' ' ' PHE . . . 117.52 24.83 3.33 Favored Glycine 0 N--CA 1.452 -0.265 0 C-N-CA 120.178 -1.011 . . . . 70.299999999999997 113.773 175.842 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . 0.409 ' CE1' ' HB2' ' A' ' 13' ' ' LYS . 54.9 p90 -142.1 -174.11 4.01 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 116.921 0.361 . . . . 75.519999999999996 110.124 179.334 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -169.65 170.39 42.68 Favored Glycine 0 N--CA 1.449 -0.454 0 C-N-CA 120.358 -0.925 . . . . 53.030000000000001 112.147 177.713 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 98.2 m-85 -120.17 126.59 51.04 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 121.054 0.454 . . . . 75.530000000000001 110.81 -179.728 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . 0.484 HG12 HG22 ' A' ' 6' ' ' VAL . 62.9 mt -110.81 129.21 66.42 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.572 0 CA-C-N 115.777 -0.647 . . . . 70.530000000000001 110.179 179.724 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 7.0 pt-20 -79.71 113.26 17.73 Favored 'General case' 0 C--N 1.326 -0.436 0 N-CA-C 109.665 -0.494 . . . . 63.100000000000001 109.665 175.673 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 20' ' ' ARG . . . . . 0.413 ' HD3' ' OD2' ' A' ' 24' ' ' ASP . 73.0 ttt-85 -113.02 111.15 21.68 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 116.06 -0.518 . . . . 74.340000000000003 111.332 -175.604 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 10.7 mm-40 47.3 -89.6 0.01 OUTLIER 'General case' 0 N--CA 1.47 0.537 0 N-CA-C 114.158 1.17 . . . . 74.25 114.158 169.725 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 23.6 t-20 -70.51 -31.38 68.44 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 121.12 0.486 . . . . 71.319999999999993 111.27 -174.018 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 130.51 -1.67 5.66 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.728 -0.748 . . . . 62.439999999999998 111.255 -176.405 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . 0.413 ' OD2' ' HD3' ' A' ' 20' ' ' ARG . 2.6 p-10 -67.92 94.35 0.47 Allowed 'General case' 0 C--N 1.323 -0.565 0 CA-C-O 121.355 0.597 . . . . 61.340000000000003 110.185 175.937 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 5.7 p-10 -57.02 123.58 15.68 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 114.989 -1.005 . . . . 75.200000000000003 110.751 176.938 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 46.4 t -97.22 135.05 32.77 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.658 0 CA-C-N 115.614 -0.721 . . . . 72.219999999999999 110.326 -179.764 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 27' ' ' PHE . . . . . . . . . . . . . 32.5 t80 -80.77 105.58 12.12 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 116.142 -0.481 . . . . 75.099999999999994 110.161 -179.188 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 9.9 p -99.74 158.87 3.7 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.516 0 N-CA-C 110.011 -0.366 . . . . 70.239999999999995 110.011 179.522 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 1.1 p80 -147.89 159.49 43.8 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.534 -0.303 . . . . 71.519999999999996 110.29 -178.414 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 30' ' ' PHE . . . . . 0.608 ' CE2' ' HA2' ' A' ' 14' ' ' GLY . 23.0 m-85 -56.82 -37.14 70.8 Favored 'General case' 0 N--CA 1.468 0.443 0 N-CA-C 112.76 0.652 . . . . 72.400000000000006 112.76 -173.767 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 12.7 t -70.97 -3.31 18.75 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 120.893 0.377 . . . . 42.450000000000003 111.269 -178.157 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -107.08 -34.13 7.25 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.75 0.31 . . . . 74.519999999999996 110.668 177.015 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.492 ' HA ' ' HB ' ' A' ' 63' ' ' VAL . 61.2 mt -65.17 140.27 20.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.109 -0.496 . . . . 74.109999999999999 110.708 179.041 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 11.3 pt20 . . . . . 0 CA--C 1.537 0.443 0 N-CA-C 112.359 0.503 . . . . 55.119999999999997 112.359 -177.488 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 18.6 m . . . . . 0 N--CA 1.451 -0.409 0 CA-C-O 120.682 0.277 . . . . 74.219999999999999 110.457 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . 0.401 HD21 ' HA ' ' A' ' 41' ' ' LEU . 1.9 tm? -62.85 125.87 25.42 Favored 'General case' 0 C--N 1.326 -0.433 0 N-CA-C 109.078 -0.712 . . . . 75.230000000000004 109.078 178.374 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 18.1 m-20 -60.16 119.76 8.47 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 116.245 -0.434 . . . . 74.200000000000003 110.974 -176.627 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 8.2 pt-20 -67.18 119.5 12.2 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-O 121.34 0.59 . . . . 64.540000000000006 110.145 177.616 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 112.49 -4.61 26.43 Favored Glycine 0 N--CA 1.445 -0.713 0 N-CA-C 111.179 -0.768 . . . . 64.329999999999998 111.179 -174.532 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 5.8 tp-100 -72.67 132.91 44.31 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 120.874 0.369 . . . . 75.25 110.946 179.73 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -86.08 115.07 23.44 Favored 'General case' 0 C--N 1.325 -0.465 0 N-CA-C 108.89 -0.781 . . . . 73.129999999999995 108.89 173.073 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . 0.51 ' HA ' ' HA ' ' A' ' 65' ' ' LYS . 29.3 m -110.27 155.29 11.6 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.811 0 CA-C-O 121.316 0.579 . . . . 74.010000000000005 111.51 -174.945 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 48' ' ' THR . . . . . 0.534 HG23 ' HB3' ' A' ' 66' ' ' ALA . 45.4 p -121.15 112.31 18.52 Favored 'General case' 0 C--N 1.318 -0.773 0 CA-C-N 115.322 -0.854 . . . . 73.150000000000006 108.832 175.376 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 49' ' ' PHE . . . . . 0.402 ' HA ' ' O ' ' A' ' 62' ' ' ASN . 35.4 p90 -127.07 171.98 10.9 Favored 'General case' 0 C--N 1.319 -0.748 0 CA-C-N 115.95 -0.568 . . . . 71.150000000000006 111.323 -170.969 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 62.9 m-20 -96.12 138.43 33.75 Favored 'General case' 0 C--N 1.322 -0.598 0 N-CA-C 109.065 -0.717 . . . . 75.299999999999997 109.065 169.935 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 12.5 p -102.31 134.67 42.39 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.721 0 CA-C-O 121.008 0.432 . . . . 71.219999999999999 111.27 -174.767 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 40.1 mt-10 -122.35 148.81 44.6 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 116.066 -0.515 . . . . 73.439999999999998 110.24 175.889 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 36.5 mt-10 -106.07 123.41 47.96 Favored 'General case' 0 C--N 1.319 -0.736 0 N-CA-C 109.61 -0.515 . . . . 71.430000000000007 109.61 177.401 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -118.46 -178.99 17.06 Favored Glycine 0 N--CA 1.445 -0.74 0 C-N-CA 120.669 -0.777 . . . . 74.540000000000006 112.287 -178.512 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -67.64 -29.45 68.76 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 120.772 0.32 . . . . 75.209999999999994 111.548 -179.755 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 22.0 ttt180 -85.03 -27.62 26.27 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.184 -0.462 . . . . 73.030000000000001 110.448 179.455 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 148.73 -164.87 29.16 Favored Glycine 0 N--CA 1.446 -0.645 0 C-N-CA 120.893 -0.67 . . . . 71.140000000000001 111.864 -179.282 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 56.4 Cg_endo -72.41 126.85 11.97 Favored 'Trans proline' 0 N--CA 1.463 -0.288 0 C-N-CA 122.702 2.268 . . . . 62.030000000000001 112.388 179.595 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 11.5 pt20 -123.72 154.33 39.61 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-N 115.851 -0.613 . . . . 74.030000000000001 110.152 -179.974 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -99.57 135.25 41.27 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 116.383 -0.371 . . . . 55.240000000000002 111.168 -177.958 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -131.97 149.63 52.38 Favored 'General case' 0 C--N 1.324 -0.529 0 N-CA-C 108.829 -0.804 . . . . 74.540000000000006 108.829 174.461 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 62' ' ' ASN . . . . . 0.402 ' O ' ' HA ' ' A' ' 49' ' ' PHE . 55.5 m-20 53.57 75.57 0.26 Allowed 'General case' 0 C--O 1.239 0.504 0 N-CA-C 110.028 -0.36 . . . . 73.120000000000005 110.028 -174.999 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.492 ' HB ' ' HA ' ' A' ' 33' ' ' ILE . 59.4 t -101.9 101.99 12.89 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.517 0 CA-C-O 121.171 0.51 . . . . 75.109999999999999 110.947 -176.191 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 50.8 mt-30 -107.48 170.27 8.07 Favored 'General case' 0 C--N 1.32 -0.707 0 N-CA-C 108.593 -0.892 . . . . 74.329999999999998 108.593 175.791 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . 0.51 ' HA ' ' HA ' ' A' ' 47' ' ' VAL . 21.9 pttp -93.58 169.1 10.59 Favored 'General case' 0 C--N 1.321 -0.66 0 C-N-CA 120.477 -0.489 . . . . 74.329999999999998 110.277 179.658 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 66' ' ' ALA . . . . . 0.534 ' HB3' HG23 ' A' ' 48' ' ' THR . . . . . . . . 0 C--O 1.246 0.907 0 CA-C-O 118.275 -0.869 . . . . 52.450000000000003 109.96 176.241 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 6.9 mp0 . . . . . 0 N--CA 1.451 -0.382 0 CA-C-O 120.656 0.265 . . . . 65.409999999999997 110.572 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 27.0 tt0 -90.34 98.94 12.07 Favored 'General case' 0 C--N 1.322 -0.614 0 N-CA-C 109.085 -0.709 . . . . 73.5 109.085 174.567 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -120.91 163.42 14.41 Favored Glycine 0 N--CA 1.446 -0.667 0 C-N-CA 120.575 -0.821 . . . . 75.400000000000006 112.668 -174.591 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 5' ' ' THR . . . . . 0.457 ' O ' ' HG2' ' A' ' 19' ' ' GLU . 0.2 OUTLIER -105.23 129.53 53.58 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-O 121.028 0.442 . . . . 74.099999999999994 110.969 179.826 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.539 HG22 HG12 ' A' ' 18' ' ' ILE . 17.0 t -71.06 121.66 21.44 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.582 0 CA-C-N 116.08 -0.509 . . . . 63.100000000000001 110.451 179.684 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 50.5 mttp -74.33 -49.48 22.7 Favored 'General case' 0 C--N 1.329 -0.302 0 C-N-CA 120.719 -0.392 . . . . 74.129999999999995 110.433 177.677 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 8' ' ' TRP . . . . . . . . . . . . . 14.9 p-90 -161.99 163.74 28.74 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.91 -0.586 . . . . 74.510000000000005 109.671 179.469 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 10.9 p90 -145.02 121.1 10.75 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-O 121.31 0.576 . . . . 74.120000000000005 111.098 -178.131 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 52.2 t-20 -82.73 86.43 6.88 Favored 'General case' 0 C--N 1.321 -0.631 0 N-CA-C 109.267 -0.642 . . . . 73.530000000000001 109.267 177.226 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -72.84 -5.33 37.47 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.303 -0.862 . . . . 73.450000000000003 111.748 -179.644 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 9.8 mm-40 -86.25 -19.4 30.01 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-O 120.977 0.418 . . . . 70.140000000000001 110.253 177.355 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 43.4 mmtm -108.76 -48.04 3.37 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 115.945 -0.571 . . . . 70.430000000000007 110.047 176.71 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 115.76 43.83 0.67 Allowed Glycine 0 N--CA 1.442 -0.929 0 C-N-CA 120.765 -0.731 . . . . 63.130000000000003 112.174 -179.134 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 43.8 p90 -152.03 161.29 42.87 Favored 'General case' 0 C--N 1.328 -0.349 0 N-CA-C 110.183 -0.302 . . . . 74.409999999999997 110.183 176.926 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -154.02 171.1 32.66 Favored Glycine 0 N--CA 1.448 -0.548 0 C-N-CA 120.877 -0.678 . . . . 74.109999999999999 112.166 179.88 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 80.9 m-85 -124.04 116.78 23.36 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-O 121.049 0.452 . . . . 75.109999999999999 110.75 179.591 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . 0.539 HG12 HG22 ' A' ' 6' ' ' VAL . 11.3 mt -109.94 123.02 65.48 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.524 0 N-CA-C 108.715 -0.846 . . . . 75.519999999999996 108.715 178.63 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 19' ' ' GLU . . . . . 0.479 ' HA ' ' HA ' ' A' ' 25' ' ' ASP . 16.7 pt-20 -76.15 138.43 40.71 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-O 121.404 0.621 . . . . 73.329999999999998 112.092 -170.549 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 20' ' ' ARG . . . . . 0.589 ' HB3' ' HB3' ' A' ' 24' ' ' ASP . 78.1 ttt180 -91.73 161.33 14.93 Favored 'General case' 0 C--N 1.321 -0.659 0 N-CA-C 108.51 -0.922 . . . . 73.219999999999999 108.51 171.126 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . 0.49 ' OE1' ' HG2' ' A' ' 20' ' ' ARG . 0.0 OUTLIER -71.1 6.45 1.62 Allowed 'General case' 0 CA--C 1.537 0.455 0 N-CA-C 112.745 0.646 . . . . 71.030000000000001 112.745 -173.559 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 9.4 m-80 -108.63 5.29 24.82 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-O 120.792 0.33 . . . . 73.409999999999997 110.895 175.31 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 84.88 0.86 89.07 Favored Glycine 0 N--CA 1.453 -0.227 0 N-CA-C 110.572 -1.011 . . . . 71.209999999999994 110.572 -172.89 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . 0.589 ' HB3' ' HB3' ' A' ' 20' ' ' ARG . 31.5 t70 -76.07 87.49 2.97 Favored 'General case' 0 C--N 1.321 -0.669 0 CA-C-N 114.631 -0.784 . . . . 74.5 109.946 -178.859 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.479 ' HA ' ' HA ' ' A' ' 19' ' ' GLU . 55.9 m-20 -64.5 110.69 2.39 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 116.02 -0.537 . . . . 75.129999999999995 110.647 179.121 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . 0.455 HG12 ' HB2' ' A' ' 58' ' ' PRO . 28.2 t -85.2 130.01 36.88 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.492 0 CA-C-N 115.639 -0.709 . . . . 73.150000000000006 110.977 -175.281 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 27' ' ' PHE . . . . . . . . . . . . . 85.3 t80 -84.87 122.84 29.75 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.745 -0.661 . . . . 74.200000000000003 110.816 -178.48 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.528 ' HB ' ' HB2' ' A' ' 60' ' ' ALA . 12.3 p -120.47 145.62 26.58 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.574 0 CA-C-N 116.591 -0.277 . . . . 73.140000000000001 110.276 178.249 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 29' ' ' HIS . . . . . 0.466 ' O ' HG13 ' A' ' 33' ' ' ILE . 2.0 t-160 -111.7 157.44 20.48 Favored 'General case' 0 C--N 1.327 -0.381 0 N-CA-C 109.432 -0.581 . . . . 75.0 109.432 -179.706 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 33.6 p90 -51.57 -40.18 59.28 Favored 'General case' 0 N--CA 1.471 0.582 0 N-CA-C 113.367 0.877 . . . . 73.319999999999993 113.367 -170.471 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 29.5 t -83.6 -6.95 59.58 Favored 'General case' 0 C--N 1.33 -0.282 0 C-N-CA 120.691 -0.404 . . . . 74.409999999999997 111.262 -176.056 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -93.67 -20.22 20.37 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-O 121.43 0.634 . . . . 72.150000000000006 109.457 174.791 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.466 HG13 ' O ' ' A' ' 29' ' ' HIS . 52.0 mt -75.53 154.28 6.2 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.408 0 CA-C-N 114.979 -1.01 . . . . 74.329999999999998 109.335 174.782 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 34' ' ' GLN . . . . . 0.4 ' HB3' ' O ' ' A' ' 63' ' ' VAL . 3.8 pt20 . . . . . 0 C--N 1.321 -0.633 0 CA-C-O 121.052 0.453 . . . . 63.439999999999998 110.728 179.299 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 18.4 p . . . . . 0 N--CA 1.448 -0.561 0 N-CA-C 109.961 -0.385 . . . . 73.439999999999998 109.961 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 3.8 mm? -81.02 126.83 31.89 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 116.289 -0.414 . . . . 75.310000000000002 110.365 -179.503 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 42' ' ' ASP . . . . . 0.79 ' HB2' ' HB2' ' A' ' 45' ' ' GLN . 5.4 m-20 -65.11 143.93 57.57 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.801 -0.636 . . . . 75.010000000000005 110.18 178.98 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -80.01 90.69 5.4 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-O 122.528 1.156 . . . . 70.129999999999995 109.332 174.737 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 130.65 0.5 5.29 Favored Glycine 0 N--CA 1.445 -0.713 0 CA-C-N 114.007 -1.451 . . . . 63.119999999999997 110.539 -169.148 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 45' ' ' GLN . . . . . 0.79 ' HB2' ' HB2' ' A' ' 42' ' ' ASP . 6.7 tp-100 -78.07 140.78 39.11 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.381 -0.41 . . . . 75.530000000000001 110.291 177.828 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -101.98 120.56 40.61 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 116.207 -0.451 . . . . 74.540000000000006 110.533 179.442 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 17.8 m -132.94 158.78 43.37 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.564 0 CA-C-N 116.181 -0.463 . . . . 74.239999999999995 110.72 -179.134 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 48' ' ' THR . . . . . 0.591 HG23 ' HB3' ' A' ' 66' ' ' ALA . 37.1 p -103.16 99.64 9.52 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 121.33 0.586 . . . . 74.420000000000002 110.876 -178.681 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 49' ' ' PHE . . . . . 0.411 ' HA ' ' O ' ' A' ' 62' ' ' ASN . 42.0 p90 -105.62 167.6 9.65 Favored 'General case' 0 C--N 1.315 -0.911 0 CA-C-N 115.635 -0.711 . . . . 74.219999999999999 109.732 -179.796 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 4.6 t70 -117.34 111.8 19.86 Favored 'General case' 0 C--N 1.319 -0.731 0 C-N-CA 120.197 -0.601 . . . . 74.510000000000005 110.351 172.703 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 9.1 p -69.15 125.67 27.58 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-O 121.707 0.765 . . . . 75.510000000000005 112.275 -176.407 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 6.4 mm-40 -102.69 134.14 46.56 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-N 115.314 -0.857 . . . . 63.520000000000003 108.995 172.467 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 15.4 pt-20 -87.77 127.03 35.32 Favored 'General case' 0 C--N 1.32 -0.709 0 C-N-CA 120.447 -0.501 . . . . 73.439999999999998 110.047 177.499 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -153.53 -158.39 8.56 Favored Glycine 0 N--CA 1.447 -0.625 0 C-N-CA 120.224 -0.989 . . . . 63.149999999999999 113.007 -178.42 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 39.8 mt-30 -66.28 -24.53 66.58 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.865 0.364 . . . . 75.340000000000003 111.276 -175.85 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -93.89 9.36 37.67 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 116.283 -0.417 . . . . 61.520000000000003 110.46 179.158 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 81.34 -115.92 4.11 Favored Glycine 0 N--CA 1.444 -0.791 0 N-CA-C 110.754 -0.939 . . . . 63.25 110.754 -174.504 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . 0.455 ' HB2' HG12 ' A' ' 26' ' ' VAL . 89.3 Cg_endo -81.53 109.01 2.0 Favored 'Trans proline' 0 N--CA 1.455 -0.749 0 C-N-CA 122.482 2.121 . . . . 74.340000000000003 112.005 175.217 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 51.1 tt0 -115.51 118.17 32.42 Favored 'General case' 0 C--N 1.322 -0.594 0 N-CA-C 109.455 -0.572 . . . . 75.019999999999996 109.455 176.947 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . 0.528 ' HB2' ' HB ' ' A' ' 28' ' ' VAL . . . -78.67 123.94 27.67 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-O 121.004 0.431 . . . . 64.420000000000002 111.818 -173.029 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -124.75 145.7 49.58 Favored 'General case' 0 C--N 1.321 -0.667 0 N-CA-C 109.14 -0.689 . . . . 74.439999999999998 109.14 173.325 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 62' ' ' ASN . . . . . 0.411 ' O ' ' HA ' ' A' ' 49' ' ' PHE . 47.3 m-80 60.61 87.83 0.09 Allowed 'General case' 0 C--O 1.236 0.394 0 CA-C-O 121.321 0.581 . . . . 73.510000000000005 110.704 -175.57 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.4 ' O ' ' HB3' ' A' ' 34' ' ' GLN . 58.0 t -100.29 106.72 19.7 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.547 0 CA-C-N 115.443 -0.799 . . . . 74.200000000000003 109.407 176.132 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 48.7 mt-30 -103.98 160.38 14.87 Favored 'General case' 0 C--N 1.319 -0.741 0 CA-C-N 116.086 -0.507 . . . . 75.129999999999995 110.665 -177.191 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . 0.645 ' HB3' ' HZ1' ' A' ' 65' ' ' LYS . 9.7 mtpm? -77.07 136.43 38.66 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 115.928 -0.578 . . . . 75.319999999999993 109.731 176.481 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 66' ' ' ALA . . . . . 0.591 ' HB3' HG23 ' A' ' 48' ' ' THR . . . . . . . . 0 C--O 1.248 1.006 0 CA-C-O 118.666 -0.683 . . . . 63.009999999999998 110.19 -179.505 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 4.5 mm-40 . . . . . 0 C--O 1.236 0.38 0 CA-C-O 121.484 0.659 . . . . 74.129999999999995 111.299 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 24.1 tt0 -86.57 125.16 33.6 Favored 'General case' 0 N--CA 1.448 -0.528 0 CA-C-N 115.077 -0.965 . . . . 74.310000000000002 110.067 177.633 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -136.52 150.4 20.49 Favored Glycine 0 N--CA 1.442 -0.936 0 N-CA-C 111.311 -0.716 . . . . 74.120000000000005 111.311 176.435 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 5' ' ' THR . . . . . 0.415 ' O ' ' HG2' ' A' ' 19' ' ' GLU . 0.7 OUTLIER -98.13 130.39 44.9 Favored 'General case' 0 C--N 1.319 -0.758 0 CA-C-O 120.672 0.272 . . . . 71.099999999999994 110.672 177.763 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 47.3 t -65.54 122.23 16.09 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.491 0 N-CA-C 109.857 -0.423 . . . . 73.329999999999998 109.857 176.547 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 27.6 mtpp -78.33 -60.81 2.22 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 121.209 0.528 . . . . 74.299999999999997 109.604 179.788 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 8' ' ' TRP . . . . . . . . . . . . . 19.0 p90 -152.07 156.4 39.84 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 115.465 -0.789 . . . . 73.219999999999999 109.214 175.79 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 17.9 p90 -127.09 112.57 15.34 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-O 121.607 0.718 . . . . 75.049999999999997 111.055 -174.931 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 77.8 m-20 -86.67 73.5 10.02 Favored 'General case' 0 C--N 1.32 -0.696 0 CA-C-N 115.682 -0.69 . . . . 71.530000000000001 109.608 179.537 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -61.58 -25.52 67.38 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 115.553 -0.749 . . . . 72.319999999999993 111.118 -177.981 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 26.6 mt-10 -58.82 -36.87 75.23 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.531 -0.758 . . . . 74.420000000000002 110.864 179.287 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 28.2 mmtp -104.92 -18.33 14.23 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 116.024 -0.534 . . . . 74.420000000000002 111.007 -177.967 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 95.87 28.76 9.13 Favored Glycine 0 N--CA 1.449 -0.5 0 C-N-CA 120.748 -0.739 . . . . 73.120000000000005 113.491 174.399 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 50.2 p90 -150.69 156.4 41.25 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 117.155 0.478 . . . . 65.319999999999993 110.65 177.451 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -137.43 176.86 20.29 Favored Glycine 0 N--CA 1.447 -0.615 0 C-N-CA 121.075 -0.583 . . . . 54.109999999999999 111.736 178.64 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 75.8 m-85 -126.26 127.5 45.72 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 121.273 0.559 . . . . 75.519999999999996 110.948 179.54 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 64.3 mt -110.18 143.68 19.74 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.618 0 CA-C-N 115.408 -0.815 . . . . 73.530000000000001 109.845 179.191 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 19' ' ' GLU . . . . . 0.415 ' HG2' ' O ' ' A' ' 5' ' ' THR . 7.6 pt-20 -96.63 108.8 21.47 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 121.573 0.701 . . . . 75.439999999999998 110.649 177.213 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 20' ' ' ARG . . . . . 0.412 ' HG2' ' N ' ' A' ' 21' ' ' GLU . 61.3 ttt180 -97.0 162.87 13.2 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 114.954 -1.021 . . . . 75.109999999999999 110.123 -176.749 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . 0.412 ' N ' ' HG2' ' A' ' 20' ' ' ARG . 19.2 mm-40 -51.88 -41.65 62.07 Favored 'General case' 0 CA--C 1.531 0.241 0 CA-C-O 121.156 0.503 . . . . 74.129999999999995 111.002 176.618 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 15.3 m120 -111.09 26.34 10.8 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.983 -0.553 . . . . 62.549999999999997 111.761 -175.257 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 179.14 111.81 0.32 Allowed Glycine 0 C--O 1.225 -0.415 0 C-N-CA 119.86 -1.162 . . . . 44.450000000000003 113.084 -179.888 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 31.8 t70 -74.53 6.4 3.82 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-O 121.472 0.653 . . . . 61.340000000000003 111.05 -176.294 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 10.4 p-10 -152.04 93.21 1.8 Allowed 'General case' 0 C--N 1.324 -0.539 0 CA-C-O 121.882 0.849 . . . . 72.540000000000006 111.096 -178.768 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 89.0 t -102.59 121.18 53.38 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 CA-C-N 115.042 -0.981 . . . . 71.219999999999999 109.784 175.216 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 27' ' ' PHE . . . . . 0.453 ' O ' ' HA ' ' A' ' 59' ' ' GLN . 78.1 t80 -78.6 120.37 23.19 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 116.024 -0.534 . . . . 73.010000000000005 110.535 -178.558 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.459 ' HB ' ' HB3' ' A' ' 60' ' ' ALA . 8.7 p -128.7 136.05 60.82 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.728 0 CA-C-O 120.964 0.412 . . . . 74.409999999999997 111.277 179.516 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 29' ' ' HIS . . . . . 0.474 ' O ' HG13 ' A' ' 33' ' ' ILE . 3.2 m-70 -96.99 142.92 28.36 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 116.14 -0.482 . . . . 74.120000000000005 110.024 175.307 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 30' ' ' PHE . . . . . 0.424 ' HE2' ' HB3' ' A' ' 40' ' ' SER . 17.7 m-85 -62.28 -28.59 69.83 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-O 120.704 0.287 . . . . 73.409999999999997 111.216 -179.545 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 16.5 t -74.92 -12.44 60.35 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 121.0 0.429 . . . . 73.109999999999999 110.877 177.897 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . 0.434 ' HB3' ' HA ' ' A' ' 61' ' ' ALA . . . -97.67 -24.26 15.58 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 121.095 0.474 . . . . 52.43 110.464 178.858 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.474 HG13 ' O ' ' A' ' 29' ' ' HIS . 31.8 mt -68.61 163.48 3.15 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.4 0 CA-C-N 115.86 -0.609 . . . . 75.549999999999997 109.936 176.233 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 34' ' ' GLN . . . . . 0.471 ' N ' HG23 ' A' ' 33' ' ' ILE . 24.9 pt20 . . . . . 0 N--CA 1.466 0.358 0 CA-C-O 120.73 0.3 . . . . 75.420000000000002 111.703 179.426 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 40' ' ' SER . . . . . 0.424 ' HB3' ' HE2' ' A' ' 30' ' ' PHE . 13.8 p . . . . . 0 C--O 1.234 0.282 0 CA-C-O 121.036 0.446 . . . . 74.409999999999997 111.751 . . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . 0.512 HD11 ' HG2' ' A' ' 45' ' ' GLN . 4.4 mm? -103.33 145.28 30.21 Favored 'General case' 0 C--N 1.325 -0.488 0 N-CA-C 109.397 -0.594 . . . . 73.349999999999994 109.397 174.858 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 6.5 m-20 -76.08 156.87 33.5 Favored 'General case' 0 C--N 1.32 -0.691 0 CA-C-N 116.112 -0.495 . . . . 74.409999999999997 111.29 -174.752 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 6.3 pt-20 -68.01 133.21 48.66 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-N 116.051 -0.522 . . . . 71.120000000000005 109.962 175.648 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 87.02 0.23 85.65 Favored Glycine 0 N--CA 1.446 -0.676 0 C-N-CA 120.558 -0.83 . . . . 73.310000000000002 112.146 -177.246 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 45' ' ' GLN . . . . . 0.512 ' HG2' HD11 ' A' ' 41' ' ' LEU . 24.3 tp60 -74.72 115.96 14.89 Favored 'General case' 0 C--N 1.328 -0.368 0 N-CA-C 109.637 -0.505 . . . . 73.439999999999998 109.637 176.9 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -74.84 116.07 15.14 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 116.049 -0.523 . . . . 72.329999999999998 110.125 177.14 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . 0.482 HG13 ' HA ' ' A' ' 65' ' ' LYS . 27.5 m -122.13 150.15 25.58 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.737 0 CA-C-N 116.068 -0.515 . . . . 74.019999999999996 110.751 -179.44 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 59.0 p -106.9 119.01 38.19 Favored 'General case' 0 C--N 1.318 -0.777 0 N-CA-C 108.928 -0.767 . . . . 73.420000000000002 108.928 175.062 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 29.8 p90 -127.99 151.34 49.25 Favored 'General case' 0 C--N 1.319 -0.74 0 CA-C-O 120.932 0.396 . . . . 73.340000000000003 111.745 -172.135 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 17.8 t70 -82.66 120.4 25.52 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.809 -0.632 . . . . 71.519999999999996 109.306 174.397 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 49.6 t -83.33 115.94 26.56 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.63 0 CA-C-N 116.063 -0.517 . . . . 72.310000000000002 111.622 -174.044 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 34.6 tt0 -108.82 104.74 14.07 Favored 'General case' 0 C--N 1.323 -0.585 0 N-CA-C 109.471 -0.566 . . . . 75.439999999999998 109.471 174.417 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 5.9 pt-20 -90.98 108.19 19.69 Favored 'General case' 0 C--N 1.318 -0.785 0 CA-C-O 121.363 0.602 . . . . 74.25 110.639 -179.42 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -118.85 -171.4 15.03 Favored Glycine 0 N--CA 1.445 -0.72 0 CA-C-N 115.428 -0.805 . . . . 70.030000000000001 111.888 -178.856 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 10.7 mm100 -78.62 77.9 5.09 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 121.33 0.586 . . . . 62.009999999999998 110.621 -177.573 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 4.6 ptp85 170.75 -26.49 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 114.534 -1.212 . . . . 74.319999999999993 108.973 -178.954 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 139.32 -170.23 24.21 Favored Glycine 0 N--CA 1.443 -0.857 0 N-CA-C 110.812 -0.915 . . . . 71.230000000000004 110.812 -179.673 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 72.3 Cg_endo -78.56 111.44 3.0 Favored 'Trans proline' 0 N--CA 1.455 -0.742 0 C-N-CA 122.077 1.851 . . . . 74.140000000000001 111.77 177.264 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . 0.453 ' HA ' ' O ' ' A' ' 27' ' ' PHE . 15.0 pt20 -104.34 135.77 45.17 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-O 121.137 0.494 . . . . 74.400000000000006 109.881 176.009 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . 0.459 ' HB3' ' HB ' ' A' ' 28' ' ' VAL . . . -90.09 123.5 34.0 Favored 'General case' 0 C--N 1.321 -0.669 0 CA-C-N 115.879 -0.6 . . . . 63.520000000000003 111.457 -173.995 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 61' ' ' ALA . . . . . 0.434 ' HA ' ' HB3' ' A' ' 32' ' ' ALA . . . -124.09 150.5 44.95 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-N 115.463 -0.79 . . . . 64.010000000000005 108.878 175.373 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 30.8 m-80 56.45 74.06 0.41 Allowed 'General case' 0 C--N 1.329 -0.301 0 N-CA-C 109.313 -0.625 . . . . 74.109999999999999 109.313 -176.155 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.464 ' HB ' HG22 ' A' ' 33' ' ' ILE . 40.5 t -105.37 103.5 15.46 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.599 0 CA-C-N 115.786 -0.643 . . . . 71.430000000000007 110.858 -175.304 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 23.1 mt-30 -111.64 129.96 55.92 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 116.193 -0.458 . . . . 72.299999999999997 109.774 179.29 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . 0.482 ' HA ' HG13 ' A' ' 47' ' ' VAL . 18.2 pttp -62.75 153.51 32.5 Favored 'General case' 0 C--N 1.327 -0.386 0 N-CA-C 110.294 -0.261 . . . . 73.230000000000004 110.294 -178.495 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 0.992 0 CA-C-O 118.193 -0.908 . . . . 72.340000000000003 109.802 176.261 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 2' ' ' GLU . . . . . 0.521 ' HB2' ' O ' ' A' ' 49' ' ' PHE . 1.7 mp0 . . . . . 0 C--O 1.234 0.247 0 CA-C-O 121.325 0.583 . . . . 75.120000000000005 111.114 . . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 3' ' ' GLN . . . . . 0.653 ' HG2' HG22 ' A' ' 48' ' ' THR . 47.8 mt-30 -106.82 120.1 41.12 Favored 'General case' 0 C--N 1.32 -0.711 0 CA-C-N 115.702 -0.681 . . . . 73.129999999999995 109.619 178.086 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -143.81 -164.26 10.29 Favored Glycine 0 N--CA 1.447 -0.57 0 C-N-CA 120.611 -0.804 . . . . 62.219999999999999 112.303 -176.706 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 5' ' ' THR . . . . . 0.492 ' O ' ' HG2' ' A' ' 19' ' ' GLU . 42.7 m -139.76 134.64 32.13 Favored 'General case' 0 C--N 1.319 -0.746 0 CA-C-O 120.674 0.273 . . . . 65.230000000000004 110.589 -178.879 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 47.4 t -68.58 135.63 28.03 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.487 0 CA-C-O 120.773 0.32 . . . . 71.219999999999999 110.343 -179.774 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 7' ' ' LYS . . . . . 0.472 ' HA ' ' HE3' ' A' ' 7' ' ' LYS . 0.0 OUTLIER -108.13 -72.69 0.71 Allowed 'General case' 0 C--N 1.324 -0.518 0 CA-C-O 120.966 0.412 . . . . 71.400000000000006 110.723 177.632 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 8' ' ' TRP . . . . . . . . . . . . . 46.0 m95 -127.43 125.99 41.58 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 116.082 -0.508 . . . . 75.030000000000001 110.134 -176.499 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 4.6 p90 -112.92 93.95 4.67 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-O 121.67 0.748 . . . . 74.329999999999998 110.861 179.866 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 2.0 t-20 -92.93 59.33 3.15 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-O 121.892 0.853 . . . . 72.140000000000001 109.11 -179.738 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -68.83 -15.12 63.41 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 114.751 -1.113 . . . . 62.020000000000003 112.115 -173.067 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 20.5 mt-10 -74.32 -26.79 60.37 Favored 'General case' 0 C--N 1.326 -0.44 0 C-N-CA 120.713 -0.395 . . . . 74.120000000000005 110.693 178.205 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 13' ' ' LYS . . . . . 0.522 ' HB3' ' HZ1' ' A' ' 13' ' ' LYS . 3.8 mmmp? -97.03 -26.48 14.99 Favored 'General case' 0 C--N 1.328 -0.352 0 N-CA-C 109.68 -0.489 . . . . 73.349999999999994 109.68 175.064 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 115.82 23.79 4.2 Favored Glycine 0 N--CA 1.449 -0.488 0 C-N-CA 120.306 -0.95 . . . . 61.5 114.265 169.937 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 55.9 p90 -151.08 162.63 40.48 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 117.576 0.688 . . . . 73.340000000000003 111.455 179.897 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -153.93 171.18 32.6 Favored Glycine 0 N--CA 1.444 -0.788 0 C-N-CA 120.998 -0.62 . . . . 74.329999999999998 111.771 178.299 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 94.9 m-85 -125.69 121.71 34.25 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-O 120.914 0.388 . . . . 74.200000000000003 110.965 -178.604 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 59.6 mt -114.7 127.63 72.13 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.574 0 N-CA-C 108.752 -0.832 . . . . 70.25 108.752 174.484 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 19' ' ' GLU . . . . . 0.492 ' HG2' ' O ' ' A' ' 5' ' ' THR . 17.1 pt-20 -86.66 137.19 32.67 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-O 121.517 0.675 . . . . 72.129999999999995 112.294 -171.074 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 20' ' ' ARG . . . . . 0.79 ' HB3' ' HB2' ' A' ' 24' ' ' ASP . 10.3 tpt180 -100.41 169.31 9.19 Favored 'General case' 0 C--N 1.325 -0.485 0 N-CA-C 108.215 -1.031 . . . . 75.510000000000005 108.215 169.769 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . 0.407 ' H ' ' HG3' ' A' ' 20' ' ' ARG . 44.2 mt-10 -58.44 -22.81 55.7 Favored 'General case' 0 CA--C 1.538 0.506 0 N-CA-C 114.029 1.122 . . . . 73.400000000000006 114.029 -171.54 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 7.3 m-80 -94.81 3.09 55.42 Favored 'General case' 0 N--CA 1.467 0.421 0 CA-C-O 120.964 0.411 . . . . 73.420000000000002 110.43 -179.333 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 92.97 8.61 61.61 Favored Glycine 0 N--CA 1.45 -0.414 0 N-CA-C 111.131 -0.788 . . . . 71.25 111.131 -174.242 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . 0.79 ' HB2' ' HB3' ' A' ' 20' ' ' ARG . 1.6 m-20 -61.06 97.45 0.06 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.193 -0.503 . . . . 74.450000000000003 110.168 -178.84 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 40.3 m-20 -67.55 98.53 0.68 Allowed 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 116.264 -0.425 . . . . 74.219999999999999 110.0 173.669 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 26.4 t -79.19 128.16 38.68 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.665 0 CA-C-N 116.069 -0.514 . . . . 74.329999999999998 109.69 178.595 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 27' ' ' PHE . . . . . . . . . . . . . 17.7 t80 -84.48 108.24 17.16 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 115.957 -0.565 . . . . 75.349999999999994 110.437 -173.062 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.479 ' HB ' ' HB2' ' A' ' 60' ' ' ALA . 12.2 p -101.62 151.34 5.64 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.487 0 CA-C-O 121.141 0.496 . . . . 72.349999999999994 110.828 -178.545 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 29' ' ' HIS . . . . . 0.467 ' O ' HG13 ' A' ' 33' ' ' ILE . 17.8 m170 -118.09 149.53 40.86 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.798 -0.637 . . . . 74.120000000000005 109.422 176.697 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 30' ' ' PHE . . . . . 0.473 ' HA ' HD12 ' A' ' 33' ' ' ILE . 49.3 p90 -68.58 -23.31 64.47 Favored 'General case' 0 N--CA 1.463 0.22 0 CA-C-O 120.955 0.407 . . . . 75.140000000000001 110.471 -177.363 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 23.0 t -71.86 -25.14 61.83 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 115.864 -0.607 . . . . 75.25 110.063 176.682 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . 0.434 ' HB3' ' HA ' ' A' ' 61' ' ' ALA . . . -92.13 -19.99 21.71 Favored 'General case' 0 C--O 1.235 0.302 0 CA-C-N 115.964 -0.562 . . . . 64.409999999999997 110.863 -179.656 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.473 HD12 ' HA ' ' A' ' 30' ' ' PHE . 77.3 mt -65.42 116.4 4.61 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 CA-C-N 116.156 -0.474 . . . . 75.310000000000002 110.114 176.567 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 4.7 pp0? . . . . . 0 C--N 1.328 -0.366 0 CA-C-N 116.184 -0.462 . . . . 72.530000000000001 111.246 -176.531 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 47.3 m . . . . . 0 N--CA 1.453 -0.286 0 CA-C-O 120.804 0.335 . . . . 72.329999999999998 110.608 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 94.7 mt -124.2 121.24 34.56 Favored 'General case' 0 C--N 1.325 -0.468 0 N-CA-C 108.908 -0.775 . . . . 64.109999999999999 108.908 175.825 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 12.1 m-20 -64.19 127.39 31.23 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-O 121.351 0.596 . . . . 64.219999999999999 111.495 -175.924 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 6.2 pt-20 -63.04 119.57 9.74 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 115.226 -0.897 . . . . 75.549999999999997 111.12 179.98 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 100.66 -5.49 56.87 Favored Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.705 -0.76 . . . . 63.299999999999997 112.667 179.167 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 59.2 tp60 -80.98 133.9 35.59 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 120.615 0.245 . . . . 74.519999999999996 110.489 -178.778 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -77.15 130.81 37.82 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.352 -0.386 . . . . 71.239999999999995 110.022 175.221 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . 0.415 HG13 ' HA ' ' A' ' 65' ' ' LYS . 17.5 m -135.19 153.56 34.28 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.492 0 CA-C-O 121.025 0.441 . . . . 75.299999999999997 111.289 -176.05 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 48' ' ' THR . . . . . 0.653 HG22 ' HG2' ' A' ' 3' ' ' GLN . 46.3 p -114.18 107.75 16.04 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-N 115.582 -0.735 . . . . 72.120000000000005 109.223 175.719 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 49' ' ' PHE . . . . . 0.545 ' HA ' ' O ' ' A' ' 62' ' ' ASN . 37.0 p90 -119.53 167.38 12.03 Favored 'General case' 0 C--N 1.315 -0.899 0 CA-C-N 115.847 -0.615 . . . . 74.129999999999995 110.412 -173.515 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 38.7 t70 -107.04 129.21 54.84 Favored 'General case' 0 C--N 1.316 -0.85 0 C-N-CA 120.777 -0.369 . . . . 75.230000000000004 110.305 176.016 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . 0.431 ' HB ' ' HG2' ' A' ' 2' ' ' GLU . 7.3 p -77.26 120.8 28.4 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 CA-C-O 121.533 0.682 . . . . 71.120000000000005 111.388 -176.976 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -110.37 157.89 19.04 Favored 'General case' 0 C--N 1.323 -0.581 0 N-CA-C 108.721 -0.844 . . . . 73.409999999999997 108.721 179.541 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 1.3 mm-40 -95.78 110.32 22.49 Favored 'General case' 0 C--N 1.319 -0.725 0 CA-C-O 121.03 0.443 . . . . 62.310000000000002 110.835 -178.319 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -99.56 157.16 19.85 Favored Glycine 0 N--CA 1.443 -0.892 0 N-CA-C 111.139 -0.785 . . . . 63.539999999999999 111.139 177.033 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 78.5 mt-30 -77.7 7.07 6.19 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 117.014 0.407 . . . . 75.530000000000001 111.69 -178.276 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 99.1 mtt180 -127.79 10.28 6.52 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 120.922 0.392 . . . . 75.209999999999994 110.023 175.313 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 129.29 176.89 14.61 Favored Glycine 0 N--CA 1.446 -0.634 0 C-N-CA 120.854 -0.688 . . . . 74.140000000000001 111.713 -177.412 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 18.3 Cg_endo -60.1 124.45 15.27 Favored 'Trans proline' 0 C--O 1.235 0.349 0 C-N-CA 122.827 2.351 . . . . 74.209999999999994 112.067 179.471 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 6.8 tt0 -104.45 144.35 31.78 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 115.682 -0.69 . . . . 72.510000000000005 110.101 -177.003 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . 0.479 ' HB2' ' HB ' ' A' ' 28' ' ' VAL . . . -91.43 106.81 18.76 Favored 'General case' 0 C--N 1.32 -0.696 0 CA-C-O 120.89 0.376 . . . . 72.439999999999998 110.81 178.585 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 61' ' ' ALA . . . . . 0.434 ' HA ' ' HB3' ' A' ' 32' ' ' ALA . . . -117.18 164.38 14.86 Favored 'General case' 0 C--N 1.32 -0.687 0 N-CA-C 108.769 -0.826 . . . . 74.239999999999995 108.769 176.31 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 62' ' ' ASN . . . . . 0.545 ' O ' ' HA ' ' A' ' 49' ' ' PHE . 85.0 m-20 47.89 66.41 1.05 Allowed 'General case' 0 N--CA 1.465 0.289 0 CA-C-O 120.83 0.347 . . . . 75.450000000000003 110.304 -177.766 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 29.4 t -93.93 89.3 2.56 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 CA-C-N 116.09 -0.505 . . . . 74.129999999999995 110.636 -176.66 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 64' ' ' GLN . . . . . 0.436 ' HB2' ' HG1' ' A' ' 48' ' ' THR . 5.5 mt-30 -82.35 129.66 34.92 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 115.866 -0.606 . . . . 64.420000000000002 110.479 -179.47 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . 0.415 ' HA ' HG13 ' A' ' 47' ' ' VAL . 50.7 mtmt -81.83 137.84 35.2 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 116.532 -0.303 . . . . 75.450000000000003 110.262 178.989 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.251 1.133 0 CA-C-O 118.289 -0.862 . . . . 72.129999999999995 110.157 178.325 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 40.6 mt-10 . . . . . 0 N--CA 1.452 -0.361 0 CA-C-O 120.735 0.302 . . . . 74.400000000000006 110.266 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 35.1 tt0 -91.57 123.77 35.23 Favored 'General case' 0 C--N 1.322 -0.595 0 N-CA-C 109.48 -0.563 . . . . 74.329999999999998 109.48 177.759 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . 0.55 ' HA3' ' HE2' ' A' ' 49' ' ' PHE . . . -138.88 152.65 22.29 Favored Glycine 0 N--CA 1.444 -0.788 0 C-N-CA 120.818 -0.706 . . . . 74.540000000000006 111.829 -178.903 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 5' ' ' THR . . . . . 0.407 ' HA ' ' HA ' ' A' ' 46' ' ' ALA . 9.6 m -85.57 131.05 34.43 Favored 'General case' 0 C--N 1.318 -0.761 0 CA-C-O 120.635 0.255 . . . . 74.239999999999995 110.908 -177.855 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 60.6 t -65.78 115.86 4.37 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 N-CA-C 109.507 -0.553 . . . . 70.209999999999994 109.507 174.761 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 9.3 mmmm -86.12 -62.08 1.6 Allowed 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 115.943 -0.571 . . . . 75.140000000000001 109.976 -178.493 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 8' ' ' TRP . . . . . . . . . . . . . 94.4 m95 -141.78 135.08 29.34 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 116.012 -0.54 . . . . 73.349999999999994 110.08 -179.638 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 62.7 t80 -118.93 98.4 6.17 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-O 121.217 0.532 . . . . 74.129999999999995 109.707 178.12 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 43.4 t30 -82.12 81.84 7.9 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-O 121.556 0.693 . . . . 73.409999999999997 110.262 -177.635 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -70.89 -10.4 59.56 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.103 -0.953 . . . . 72.439999999999998 111.143 179.732 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 31.2 mm-40 -69.77 -16.39 63.29 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.086 -0.507 . . . . 74.430000000000007 110.266 177.447 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 13' ' ' LYS . . . . . 0.594 ' HE3' ' HA ' ' A' ' 13' ' ' LYS . 0.0 OUTLIER -130.01 -35.17 1.63 Allowed 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.132 -0.486 . . . . 73.150000000000006 111.263 179.564 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 111.25 28.51 3.79 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.648 -0.787 . . . . 75.519999999999996 112.907 178.206 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 31.3 p90 -148.03 176.23 10.35 Favored 'General case' 0 C--N 1.323 -0.561 0 O-C-N 122.493 -0.416 . . . . 74.400000000000006 109.965 177.641 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -174.79 -168.43 35.46 Favored Glycine 0 N--CA 1.445 -0.733 0 C-N-CA 120.292 -0.956 . . . . 73.219999999999999 112.27 -179.974 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . 0.49 ' HB3' ' HB3' ' A' ' 25' ' ' ASP . 88.0 m-85 -127.47 124.42 38.32 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-O 120.949 0.404 . . . . 64.420000000000002 110.504 -178.166 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 40.2 mt -121.72 117.81 53.71 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.663 0 N-CA-C 108.38 -0.97 . . . . 73.450000000000003 108.38 175.063 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 19' ' ' GLU . . . . . 0.615 ' HA ' ' HA ' ' A' ' 25' ' ' ASP . 6.7 pt-20 -78.11 137.67 38.33 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-O 121.64 0.733 . . . . 60.210000000000001 112.449 -168.543 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 20' ' ' ARG . . . . . 0.567 ' HB3' ' HB3' ' A' ' 24' ' ' ASP . 62.7 ttt180 -80.3 164.02 23.5 Favored 'General case' 0 C--N 1.32 -0.688 0 N-CA-C 107.691 -1.226 . . . . 73.109999999999999 107.691 168.129 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 43.4 mt-10 -63.53 -12.51 32.92 Favored 'General case' 0 N--CA 1.468 0.466 0 N-CA-C 112.53 0.567 . . . . 72.230000000000004 112.53 -173.718 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 10.4 m120 -87.29 3.64 45.95 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-O 120.901 0.382 . . . . 72.040000000000006 110.774 178.637 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 85.46 2.39 87.35 Favored Glycine 0 N--CA 1.452 -0.271 0 N-CA-C 110.752 -0.939 . . . . 75.319999999999993 110.752 -173.164 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . 0.567 ' HB3' ' HB3' ' A' ' 20' ' ' ARG . 38.3 t70 -75.32 90.51 2.64 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 114.551 -0.825 . . . . 74.319999999999993 110.463 -176.909 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.615 ' HA ' ' HA ' ' A' ' 19' ' ' GLU . 42.8 m-20 -60.82 104.16 0.33 Allowed 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.107 -0.497 . . . . 75.349999999999994 110.248 176.28 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . 0.456 HG11 ' HB2' ' A' ' 58' ' ' PRO . 22.1 t -81.01 132.52 31.39 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 CA-C-N 116.016 -0.538 . . . . 64.230000000000004 110.229 -177.851 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 27' ' ' PHE . . . . . . . . . . . . . 85.7 t80 -76.64 104.28 7.06 Favored 'General case' 0 C--O 1.238 0.452 0 CA-C-O 121.134 0.492 . . . . 72.049999999999997 110.881 -177.189 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.524 ' HA ' ' HB3' ' A' ' 60' ' ' ALA . 9.6 p -88.3 145.71 7.12 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.638 0 N-CA-C 109.392 -0.595 . . . . 75.019999999999996 109.392 177.464 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 29' ' ' HIS . . . . . 0.67 ' HE1' ' HB3' ' A' ' 59' ' ' GLN . 23.8 p-80 -142.05 143.73 33.25 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 116.563 -0.29 . . . . 73.420000000000002 110.997 -173.64 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 52.1 p90 -58.14 -23.37 54.89 Favored 'General case' 0 N--CA 1.469 0.488 0 N-CA-C 113.03 0.752 . . . . 74.099999999999994 113.03 -172.838 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 31' ' ' SER . . . . . 0.414 ' OG ' ' HD2' ' A' ' 29' ' ' HIS . 2.7 p -77.57 -0.05 24.86 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-O 121.0 0.429 . . . . 61.229999999999997 111.576 -179.355 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -126.26 -24.9 3.6 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.149 -0.478 . . . . 75.340000000000003 110.689 175.337 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.493 HG13 ' O ' ' A' ' 29' ' ' HIS . 64.1 mt -68.95 118.47 13.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.293 -0.412 . . . . 74.439999999999998 110.872 179.686 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 2.5 pp0? . . . . . 0 C--N 1.324 -0.503 0 CA-C-O 121.58 0.705 . . . . 75.439999999999998 109.508 172.798 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 39.6 m . . . . . 0 N--CA 1.45 -0.458 0 CA-C-O 120.924 0.392 . . . . 75.010000000000005 111.122 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 9.9 mp -94.02 131.76 39.19 Favored 'General case' 0 C--N 1.324 -0.532 0 N-CA-C 108.891 -0.781 . . . . 62.119999999999997 108.891 174.39 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 21.3 m-20 -96.82 128.1 43.44 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-O 120.775 0.321 . . . . 73.140000000000001 110.388 -173.858 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 2.0 pp20? -61.92 143.19 56.82 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 116.063 -0.517 . . . . 72.349999999999994 110.737 -179.047 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 99.11 -22.72 39.51 Favored Glycine 0 N--CA 1.447 -0.568 0 C-N-CA 120.74 -0.743 . . . . 72.519999999999996 111.847 -175.525 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 45' ' ' GLN . . . . . 0.442 ' HA ' ' OE1' ' A' ' 45' ' ' GLN . 6.1 tp60 -87.95 140.36 29.58 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.713 0.292 . . . . 74.400000000000006 110.315 178.334 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 0.407 ' HA ' ' HA ' ' A' ' 5' ' ' THR . . . -102.93 125.44 49.69 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-N 116.476 -0.329 . . . . 73.019999999999996 110.818 -179.869 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 30.7 m -118.2 171.51 6.43 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.561 0 CA-C-N 116.315 -0.402 . . . . 75.109999999999999 110.467 178.64 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 21.6 p -107.39 112.79 25.76 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-O 121.218 0.532 . . . . 74.109999999999999 110.954 -179.899 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 49' ' ' PHE . . . . . 0.55 ' HE2' ' HA3' ' A' ' 4' ' ' GLY . 41.5 p90 -121.89 161.16 23.29 Favored 'General case' 0 C--N 1.317 -0.833 0 CA-C-N 115.619 -0.719 . . . . 74.340000000000003 109.851 -178.219 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 19.7 t70 -109.06 128.29 54.85 Favored 'General case' 0 C--N 1.316 -0.875 0 CA-C-O 120.99 0.424 . . . . 63.130000000000003 110.311 174.128 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 98.9 t -77.22 104.8 5.46 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 CA-C-O 121.108 0.48 . . . . 71.340000000000003 110.878 -177.873 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -87.15 145.89 26.24 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 115.409 -0.814 . . . . 73.400000000000006 109.19 179.523 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 70.9 mm-40 -84.25 98.2 9.84 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-N 116.153 -0.476 . . . . 75.530000000000001 111.368 -175.641 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -81.39 164.77 45.88 Favored Glycine 0 N--CA 1.446 -0.69 0 C-N-CA 120.837 -0.697 . . . . 75.010000000000005 111.546 176.65 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 26.8 pt20 -69.32 -23.63 63.82 Favored 'General case' 0 C--N 1.324 -0.508 0 N-CA-C 112.207 0.447 . . . . 74.209999999999994 112.207 -175.664 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 9.5 ptm180 -132.1 16.57 4.61 Favored 'General case' 0 C--N 1.328 -0.346 0 C-N-CA 120.326 -0.55 . . . . 73.409999999999997 112.033 -179.26 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 157.69 -178.18 34.13 Favored Glycine 0 N--CA 1.449 -0.444 0 C-N-CA 120.018 -1.087 . . . . 63.240000000000002 112.702 179.282 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . 0.456 ' HB2' HG11 ' A' ' 26' ' ' VAL . 73.4 Cg_endo -75.56 128.59 11.17 Favored 'Trans proline' 0 C--O 1.235 0.341 0 C-N-CA 122.834 2.356 . . . . 72.510000000000005 112.89 -177.738 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . 0.67 ' HB3' ' HE1' ' A' ' 29' ' ' HIS . 90.5 mt-30 -112.61 135.32 53.47 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 115.965 -0.561 . . . . 72.219999999999999 109.92 176.665 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . 0.524 ' HB3' ' HA ' ' A' ' 28' ' ' VAL . . . -85.21 105.19 15.72 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-O 120.899 0.381 . . . . 75.439999999999998 111.037 -178.931 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -115.29 168.78 9.66 Favored 'General case' 0 C--N 1.319 -0.722 0 N-CA-C 108.615 -0.883 . . . . 71.430000000000007 108.615 174.931 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 62' ' ' ASN . . . . . 0.499 ' O ' ' HA ' ' A' ' 49' ' ' PHE . 87.1 m-20 51.03 75.5 0.19 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.981 0.42 . . . . 55.229999999999997 109.958 -175.714 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 22.0 t -98.83 93.25 3.06 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 CA-C-N 115.969 -0.559 . . . . 75.120000000000005 109.526 -177.285 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 40.4 mt-30 -98.12 148.78 23.2 Favored 'General case' 0 C--N 1.32 -0.705 0 CA-C-N 115.923 -0.581 . . . . 75.010000000000005 110.567 -175.96 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 94.9 mttt -76.86 129.12 35.78 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 115.871 -0.604 . . . . 73.200000000000003 110.439 -179.795 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.077 0 CA-C-O 118.366 -0.826 . . . . 75.409999999999997 109.457 175.856 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 4.4 mp0 . . . . . 0 C--O 1.233 0.211 0 CA-C-O 121.029 0.442 . . . . 73.510000000000005 111.151 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 3' ' ' GLN . . . . . 0.543 ' HG2' HG21 ' A' ' 48' ' ' THR . 66.6 mt-30 -98.47 111.43 23.79 Favored 'General case' 0 C--N 1.326 -0.445 0 N-CA-C 109.037 -0.727 . . . . 73.109999999999999 109.037 173.422 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . 0.71 ' HA3' ' HE2' ' A' ' 49' ' ' PHE . . . -122.1 162.3 15.93 Favored Glycine 0 N--CA 1.447 -0.613 0 C-N-CA 120.101 -1.047 . . . . 71.109999999999999 112.984 -174.217 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 8.3 m -98.45 131.03 45.04 Favored 'General case' 0 C--N 1.321 -0.635 0 N-CA-C 110.033 -0.358 . . . . 74.329999999999998 110.033 177.948 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 59.7 t -70.17 118.48 14.71 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.436 0 CA-C-N 116.602 -0.272 . . . . 72.140000000000001 110.619 179.365 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 7' ' ' LYS . . . . . 1.034 ' HE2' ' HB3' ' A' ' 19' ' ' GLU . 70.7 mmtt -70.77 -72.58 0.2 Allowed 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 121.238 0.542 . . . . 73.450000000000003 109.803 176.62 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 8' ' ' TRP . . . . . 0.531 ' HA ' ' HG3' ' A' ' 43' ' ' GLU . 24.5 m-90 -143.85 127.23 16.81 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 114.939 -1.028 . . . . 74.439999999999998 109.005 178.558 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 54.3 t80 -105.82 103.08 12.51 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-O 121.243 0.544 . . . . 71.109999999999999 110.359 179.547 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 39.2 m-80 -83.9 78.46 9.72 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 115.785 -0.643 . . . . 75.450000000000003 110.104 -179.666 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -59.61 -30.86 68.99 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.025 -0.534 . . . . 75.409999999999997 110.59 178.029 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 24.7 mt-10 -64.61 -38.91 92.64 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.401 -0.818 . . . . 75.549999999999997 110.616 178.158 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 48.7 mmtm -90.6 -24.44 20.55 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.683 -0.69 . . . . 73.510000000000005 110.691 -174.201 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 96.15 18.62 30.87 Favored Glycine 0 N--CA 1.445 -0.738 0 C-N-CA 120.806 -0.711 . . . . 73.450000000000003 112.845 177.608 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 46.7 p90 -156.83 163.72 38.88 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 117.074 0.437 . . . . 74.319999999999993 110.803 179.855 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -148.95 177.12 27.4 Favored Glycine 0 N--CA 1.445 -0.703 0 C-N-CA 120.813 -0.708 . . . . 74.099999999999994 111.983 179.289 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 96.8 m-85 -123.98 131.15 53.52 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 120.76 0.314 . . . . 75.540000000000006 110.307 177.949 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . 0.411 HD12 HG21 ' A' ' 47' ' ' VAL . 33.0 mt -122.88 146.61 27.9 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.695 0 N-CA-C 109.115 -0.698 . . . . 72.219999999999999 109.115 178.149 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 19' ' ' GLU . . . . . 1.034 ' HB3' ' HE2' ' A' ' 7' ' ' LYS . 12.9 pt-20 -99.79 129.23 45.88 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-O 121.351 0.596 . . . . 75.319999999999993 111.785 -178.52 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 20' ' ' ARG . . . . . 0.429 ' HG2' ' N ' ' A' ' 21' ' ' GLU . 27.9 ttm180 -98.3 153.81 18.26 Favored 'General case' 0 C--N 1.322 -0.609 0 N-CA-C 108.381 -0.97 . . . . 70.319999999999993 108.381 170.727 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . 0.429 ' N ' ' HG2' ' A' ' 20' ' ' ARG . 43.9 mt-10 -52.02 -34.44 42.96 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 121.047 0.451 . . . . 64.109999999999999 110.491 177.61 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 8.5 t-20 -123.9 58.58 1.16 Allowed 'General case' 0 N--CA 1.453 -0.311 0 CA-C-N 115.85 -0.613 . . . . 75.230000000000004 109.41 175.358 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 164.65 78.88 0.04 OUTLIER Glycine 0 N--CA 1.45 -0.369 0 N-CA-C 111.217 -0.753 . . . . 54.409999999999997 111.217 179.543 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 30.6 t70 -65.71 -2.84 3.97 Favored 'General case' 0 C--N 1.326 -0.445 0 N-CA-C 112.606 0.595 . . . . 64.140000000000001 112.606 -169.51 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 10.2 p-10 -144.73 93.67 2.44 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-O 121.813 0.816 . . . . 71.010000000000005 111.854 -178.575 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 38.9 t -104.12 128.74 57.26 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.492 0 CA-C-N 115.525 -0.761 . . . . 73.230000000000004 109.628 174.579 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 27' ' ' PHE . . . . . . . . . . . . . 42.7 t80 -83.61 106.52 15.4 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-O 120.716 0.293 . . . . 70.329999999999998 110.326 -177.28 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.561 HG21 HG22 ' A' ' 63' ' ' VAL . 12.5 p -99.38 143.9 12.81 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 CA-C-O 121.149 0.5 . . . . 74.140000000000001 111.354 -176.248 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 54.2 m80 -97.27 133.78 41.43 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.543 -0.753 . . . . 75.0 109.996 177.871 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 6.1 p90 -63.95 -26.46 68.6 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.803 0.335 . . . . 75.319999999999993 111.105 -176.837 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 28.2 t -89.57 -14.35 35.26 Favored 'General case' 0 CA--C 1.533 0.291 0 CA-C-N 116.355 -0.384 . . . . 73.129999999999995 110.436 179.689 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -83.22 -23.09 32.94 Favored 'General case' 0 C--O 1.233 0.224 0 CA-C-O 121.383 0.611 . . . . 72.510000000000005 109.9 178.117 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.518 ' HA ' ' HB ' ' A' ' 63' ' ' VAL . 53.1 mt -76.31 138.37 20.83 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.497 0 CA-C-N 115.542 -0.754 . . . . 72.349999999999994 109.51 172.113 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--N 1.329 -0.287 0 CA-C-O 121.397 0.618 . . . . 73.420000000000002 111.554 176.946 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 13.0 m . . . . . 0 N--CA 1.451 -0.397 0 CA-C-O 120.819 0.343 . . . . 71.129999999999995 110.368 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . 0.467 HD23 HG23 ' A' ' 33' ' ' ILE . 3.7 mm? -74.96 107.69 7.2 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 116.298 -0.41 . . . . 73.200000000000003 110.215 178.606 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 32.5 t70 -58.98 135.08 57.5 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.76 -0.655 . . . . 73.230000000000004 111.267 -177.549 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . 0.531 ' HG3' ' HA ' ' A' ' 8' ' ' TRP . 17.9 mp0 -53.93 124.72 16.27 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 115.957 -0.565 . . . . 74.400000000000006 110.619 177.809 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 99.35 -0.68 57.11 Favored Glycine 0 N--CA 1.449 -0.481 0 C-N-CA 120.627 -0.796 . . . . 54.32 112.804 -179.908 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 58.7 tp60 -83.43 149.97 26.34 Favored 'General case' 0 C--N 1.325 -0.495 0 N-CA-C 109.918 -0.401 . . . . 75.329999999999998 109.918 178.423 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -90.8 140.49 29.74 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-N 116.554 -0.294 . . . . 75.310000000000002 110.246 177.21 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . 0.411 HG21 HD12 ' A' ' 18' ' ' ILE . 16.0 m -139.0 153.59 25.01 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 CA-C-O 120.913 0.387 . . . . 75.010000000000005 110.396 177.579 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 48' ' ' THR . . . . . 0.653 HG23 ' HB3' ' A' ' 66' ' ' ALA . 34.4 p -106.47 101.88 11.31 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-O 121.323 0.582 . . . . 75.120000000000005 110.121 178.275 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 49' ' ' PHE . . . . . 0.71 ' HE2' ' HA3' ' A' ' 4' ' ' GLY . 42.1 p90 -111.55 147.47 35.33 Favored 'General case' 0 C--N 1.317 -0.821 0 CA-C-N 115.609 -0.723 . . . . 74.129999999999995 110.666 -174.455 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 36.2 t0 -101.92 160.96 14.04 Favored 'General case' 0 C--N 1.316 -0.855 0 C-N-CA 120.357 -0.537 . . . . 73.5 109.706 172.279 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 67.4 t -109.66 119.37 58.77 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.701 0 CA-C-O 120.922 0.392 . . . . 71.209999999999994 111.459 -172.822 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 27.6 tt0 -111.11 111.31 22.3 Favored 'General case' 0 C--N 1.321 -0.642 0 N-CA-C 109.094 -0.706 . . . . 73.209999999999994 109.094 173.338 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 26.9 mt-10 -69.59 137.08 52.02 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-O 121.203 0.525 . . . . 72.129999999999995 112.091 -177.709 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -118.9 -158.04 10.6 Favored Glycine 0 N--CA 1.441 -1.026 0 N-CA-C 110.001 -1.239 . . . . 74.420000000000002 110.001 170.844 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 50.0 tt0 -99.43 -25.6 14.41 Favored 'General case' 0 C--N 1.319 -0.752 0 CA-C-N 117.162 0.481 . . . . 74.230000000000004 110.498 179.728 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 10.9 mmm180 -97.64 -5.23 35.86 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 116.292 -0.413 . . . . 70.450000000000003 111.191 178.561 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 151.39 -179.61 27.89 Favored Glycine 0 N--CA 1.444 -0.795 0 C-N-CA 120.62 -0.8 . . . . 63.340000000000003 112.311 178.527 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 8.9 Cg_endo -87.41 119.02 1.37 Allowed 'Trans proline' 0 N--CA 1.45 -1.057 0 C-N-CA 123.235 2.623 . . . . 74.099999999999994 112.18 178.931 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 15.8 pt20 -95.39 133.91 38.8 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-N 116.098 -0.501 . . . . 75.409999999999997 109.852 177.654 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . 0.517 ' HB2' ' HA ' ' A' ' 28' ' ' VAL . . . -76.27 112.13 12.43 Favored 'General case' 0 C--N 1.321 -0.645 0 CA-C-N 116.128 -0.487 . . . . 75.340000000000003 110.76 -178.885 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -112.91 153.3 28.18 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 115.493 -0.776 . . . . 65.409999999999997 109.011 176.583 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 95.1 m-20 52.48 77.3 0.16 Allowed 'General case' 0 C--O 1.235 0.341 0 CA-C-O 121.279 0.561 . . . . 72.120000000000005 110.337 -175.426 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.561 HG22 HG21 ' A' ' 28' ' ' VAL . 36.9 t -109.59 107.16 22.19 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 CA-C-N 115.686 -0.688 . . . . 73.420000000000002 110.174 -179.67 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 64' ' ' GLN . . . . . 0.504 ' HB2' ' OG1' ' A' ' 48' ' ' THR . 1.5 mt-30 -99.41 178.54 4.85 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 115.434 -0.803 . . . . 75.109999999999999 110.163 -177.154 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 56.0 mttp -89.05 149.47 23.21 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-O 120.733 0.301 . . . . 73.109999999999999 110.588 -178.494 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 66' ' ' ALA . . . . . 0.653 ' HB3' HG23 ' A' ' 48' ' ' THR . . . . . . . . 0 C--O 1.251 1.165 0 CA-C-O 117.974 -1.012 . . . . 73.530000000000001 109.615 177.304 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 2' ' ' GLU . . . . . 0.433 ' H ' ' CD ' ' A' ' 2' ' ' GLU . 1.4 mp0 . . . . . 0 C--O 1.235 0.336 0 CA-C-O 121.051 0.453 . . . . 73.430000000000007 111.235 . . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 3' ' ' GLN . . . . . 0.51 ' HB3' HG21 ' A' ' 48' ' ' THR . 0.9 OUTLIER -93.54 127.34 39.16 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 115.725 -0.671 . . . . 64.099999999999994 109.83 173.485 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -136.74 160.3 24.8 Favored Glycine 0 N--CA 1.445 -0.709 0 C-N-CA 120.887 -0.673 . . . . 55.32 111.566 -179.853 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -96.48 133.35 41.04 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-O 121.266 0.555 . . . . 75.430000000000007 111.421 -179.336 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 45.6 t -68.81 116.06 8.54 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.556 0 CA-C-N 115.824 -0.625 . . . . 75.140000000000001 110.034 177.759 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 7' ' ' LYS . . . . . 0.831 ' HA ' ' HE3' ' A' ' 7' ' ' LYS . 0.1 OUTLIER -83.04 -62.59 1.55 Allowed 'General case' 0 C--N 1.324 -0.507 0 CA-C-O 121.24 0.543 . . . . 74.310000000000002 109.705 -178.827 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 8' ' ' TRP . . . . . . . . . . . . . 99.5 m95 -126.72 146.94 50.03 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 115.365 -0.834 . . . . 70.140000000000001 109.727 -179.963 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . 0.506 ' CE2' ' HA ' ' A' ' 40' ' ' SER . 68.1 t80 -140.21 98.05 3.36 Favored 'General case' 0 C--N 1.318 -0.773 0 CA-C-O 121.093 0.473 . . . . 75.200000000000003 110.432 176.356 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 91.4 m-20 -82.2 82.57 7.69 Favored 'General case' 0 C--N 1.323 -0.57 0 N-CA-C 109.285 -0.635 . . . . 74.519999999999996 109.285 178.813 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -59.08 -33.74 71.16 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.574 -0.739 . . . . 71.310000000000002 111.297 -178.476 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 36.7 mt-10 -70.1 -26.22 63.87 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 116.066 -0.515 . . . . 72.200000000000003 110.892 -178.733 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 47.9 mmtm -91.44 -29.72 16.88 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.188 -0.46 . . . . 73.310000000000002 110.179 175.999 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 90.99 17.4 51.5 Favored Glycine 0 N--CA 1.447 -0.623 0 CA-C-N 115.853 -0.612 . . . . 72.319999999999993 111.655 -178.895 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 74.3 m-85 -138.15 144.46 40.77 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-O 120.864 0.364 . . . . 73.450000000000003 110.489 -176.568 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -131.16 168.64 21.98 Favored Glycine 0 N--CA 1.444 -0.787 0 C-N-CA 120.438 -0.887 . . . . 73.349999999999994 112.109 -178.621 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . 0.445 ' HA ' ' O ' ' A' ' 26' ' ' VAL . 76.6 m-85 -127.47 118.9 24.92 Favored 'General case' 0 C--N 1.322 -0.603 0 N-CA-C 109.757 -0.46 . . . . 75.439999999999998 109.757 -179.972 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . 0.418 HG21 ' CE2' ' A' ' 49' ' ' PHE . 63.5 mt -109.05 141.82 23.28 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.659 0 CA-C-N 115.992 -0.549 . . . . 73.420000000000002 110.402 -177.526 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 19' ' ' GLU . . . . . 0.614 ' OE1' ' HG2' ' A' ' 7' ' ' LYS . 7.9 pt-20 -92.87 101.42 13.79 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 121.377 0.608 . . . . 72.340000000000003 110.476 178.372 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 20' ' ' ARG . . . . . 0.61 ' HG2' ' OE1' ' A' ' 21' ' ' GLU . 12.4 ttp180 -96.41 158.48 15.42 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 115.854 -0.612 . . . . 75.109999999999999 109.544 -179.503 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . 0.61 ' OE1' ' HG2' ' A' ' 20' ' ' ARG . 0.0 OUTLIER -57.29 -38.02 73.33 Favored 'General case' 0 N--CA 1.466 0.326 0 N-CA-C 112.155 0.428 . . . . 73.319999999999993 112.155 -177.931 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 41.3 m-80 -115.3 36.6 3.85 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-O 120.991 0.424 . . . . 72.340000000000003 110.181 174.949 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -170.38 82.19 0.09 OUTLIER Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.624 -0.798 . . . . 75.150000000000006 112.444 179.846 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 37.4 t70 -63.71 -2.98 1.97 Allowed 'General case' 0 N--CA 1.469 0.48 0 CA-C-O 121.09 0.471 . . . . 72.439999999999998 111.916 -177.039 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 17.5 t70 -152.97 88.55 1.33 Allowed 'General case' 0 C--N 1.325 -0.485 0 CA-C-O 121.105 0.479 . . . . 64.209999999999994 109.829 -179.328 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . 0.445 ' O ' ' HA ' ' A' ' 17' ' ' PHE . 58.8 t -102.97 123.72 56.55 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 CA-C-N 116.005 -0.543 . . . . 74.519999999999996 110.43 179.374 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 27' ' ' PHE . . . . . 0.454 ' O ' ' HA ' ' A' ' 59' ' ' GLN . 62.7 t80 -85.45 102.46 13.48 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 115.612 -0.722 . . . . 73.430000000000007 110.277 -177.025 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.487 HG21 ' HB1' ' A' ' 60' ' ' ALA . 10.2 p -95.77 146.74 6.66 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.505 0 CA-C-O 120.94 0.4 . . . . 74.219999999999999 110.796 -177.453 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 17.3 m-70 -103.83 141.01 36.86 Favored 'General case' 0 C--O 1.234 0.24 0 CA-C-N 115.982 -0.554 . . . . 74.5 111.341 -175.841 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 41.2 p90 -55.91 -36.38 67.63 Favored 'General case' 0 N--CA 1.467 0.412 0 CA-C-N 115.838 -0.619 . . . . 75.129999999999995 112.177 -179.941 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 33.0 t -82.07 -10.52 59.18 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 116.707 -0.224 . . . . 63.140000000000001 111.17 -177.075 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . 0.521 ' HB3' ' HA ' ' A' ' 61' ' ' ALA . . . -92.81 -22.84 19.09 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 121.248 0.547 . . . . 71.409999999999997 109.99 178.829 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.525 ' HA ' ' HB ' ' A' ' 63' ' ' VAL . 67.3 mt -87.68 126.63 41.26 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.468 0 CA-C-N 115.503 -0.771 . . . . 74.230000000000004 110.318 177.012 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 2.3 pp0? . . . . . 0 C--N 1.323 -0.586 0 CA-C-O 121.502 0.668 . . . . 74.510000000000005 109.457 172.639 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 40' ' ' SER . . . . . 0.506 ' HA ' ' CE2' ' A' ' 9' ' ' PHE . 23.5 p . . . . . 0 N--CA 1.448 -0.551 0 N-CA-C 109.981 -0.378 . . . . 71.540000000000006 109.981 . . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 52.0 mt -70.64 137.29 49.78 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-O 120.996 0.427 . . . . 70.5 110.648 179.196 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 42' ' ' ASP . . . . . 0.42 ' HB3' ' HB2' ' A' ' 45' ' ' GLN . 22.7 t70 -74.64 136.93 41.94 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 115.573 -0.74 . . . . 71.040000000000006 110.638 -176.322 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 8.4 pt-20 -65.81 115.25 5.74 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-O 121.25 0.548 . . . . 75.010000000000005 110.71 178.361 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 100.86 -1.54 55.35 Favored Glycine 0 N--CA 1.446 -0.635 0 C-N-CA 120.47 -0.871 . . . . 72.030000000000001 112.109 -178.218 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 45' ' ' GLN . . . . . 0.42 ' HB2' ' HB3' ' A' ' 42' ' ' ASP . 6.0 tp-100 -74.26 133.85 42.64 Favored 'General case' 0 C--N 1.327 -0.398 0 N-CA-C 109.974 -0.38 . . . . 74.319999999999993 109.974 175.802 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -90.23 123.66 34.21 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 116.186 -0.461 . . . . 33.200000000000003 110.454 179.784 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . 0.483 HG22 ' HD2' ' A' ' 49' ' ' PHE . 21.1 m -127.62 153.56 37.02 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.596 0 CA-C-N 116.008 -0.542 . . . . 73.310000000000002 110.339 178.748 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 48' ' ' THR . . . . . 0.51 HG21 ' HB3' ' A' ' 3' ' ' GLN . 63.7 p -106.96 111.23 23.63 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-O 121.261 0.553 . . . . 75.150000000000006 109.733 179.609 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 49' ' ' PHE . . . . . 0.483 ' HD2' HG22 ' A' ' 47' ' ' VAL . 29.5 p90 -128.61 160.53 32.14 Favored 'General case' 0 C--N 1.318 -0.771 0 CA-C-N 116.138 -0.483 . . . . 74.329999999999998 111.171 -172.543 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 71.0 m-20 -105.02 115.09 29.69 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 116.157 -0.474 . . . . 73.430000000000007 110.435 175.536 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . 0.457 HG21 ' HD3' ' A' ' 20' ' ' ARG . 65.3 t -77.43 120.71 28.48 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.599 0 CA-C-O 121.052 0.454 . . . . 73.230000000000004 110.936 -177.459 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 9.2 tp10 -99.44 125.69 45.21 Favored 'General case' 0 N--CA 1.444 -0.769 0 N-CA-C 108.984 -0.747 . . . . 72.530000000000001 108.984 175.43 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 10.0 pt-20 -88.11 141.11 28.83 Favored 'General case' 0 C--N 1.317 -0.806 0 CA-C-N 116.16 -0.473 . . . . 72.230000000000004 110.806 -175.797 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -162.64 -171.46 28.87 Favored Glycine 0 N--CA 1.446 -0.669 0 C-N-CA 120.851 -0.69 . . . . 64.549999999999997 112.081 178.706 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 34.9 tt0 -58.35 -38.57 77.48 Favored 'General case' 0 C--N 1.326 -0.444 0 C-N-CA 122.488 0.315 . . . . 72.420000000000002 111.218 179.557 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 18.0 mmm180 -75.98 4.36 8.46 Favored 'General case' 0 C--N 1.328 -0.337 0 N-CA-C 111.708 0.262 . . . . 74.340000000000003 111.708 179.999 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 93.51 -136.82 13.28 Favored Glycine 0 N--CA 1.444 -0.818 0 C-N-CA 120.942 -0.647 . . . . 75.439999999999998 112.034 178.928 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 1.8 Cg_endo -83.05 108.94 1.63 Allowed 'Trans proline' 0 N--CA 1.454 -0.832 0 C-N-CA 123.132 2.554 . . . . 75.400000000000006 112.015 -179.69 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . 0.454 ' HA ' ' O ' ' A' ' 27' ' ' PHE . 47.6 mt-30 -110.17 117.27 33.25 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-O 120.906 0.384 . . . . 71.420000000000002 110.081 177.827 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . 0.487 ' HB1' HG21 ' A' ' 28' ' ' VAL . . . -77.72 119.05 20.7 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-O 121.078 0.466 . . . . 74.030000000000001 111.308 -175.852 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 61' ' ' ALA . . . . . 0.521 ' HA ' ' HB3' ' A' ' 32' ' ' ALA . . . -120.77 167.91 12.0 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 115.425 -0.807 . . . . 74.120000000000005 109.001 175.362 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 62' ' ' ASN . . . . . 0.477 ' O ' ' HA ' ' A' ' 49' ' ' PHE . 37.4 m-20 47.28 74.46 0.16 Allowed 'General case' 0 C--O 1.236 0.393 0 O-C-N 123.265 0.353 . . . . 73.549999999999997 110.314 -176.885 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.525 ' HB ' ' HA ' ' A' ' 33' ' ' ILE . 57.9 t -96.63 104.13 15.49 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.511 0 CA-C-N 116.337 -0.392 . . . . 74.099999999999994 110.817 -177.19 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 6.6 tp-100 -104.65 165.31 11.15 Favored 'General case' 0 C--N 1.321 -0.649 0 N-CA-C 109.127 -0.694 . . . . 75.540000000000006 109.127 178.093 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 86.0 mttt -80.78 176.57 9.69 Favored 'General case' 0 C--N 1.321 -0.635 0 N-CA-C 110.09 -0.337 . . . . 75.219999999999999 110.09 178.103 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 66' ' ' ALA . . . . . 0.484 ' HB1' HG23 ' A' ' 48' ' ' THR . . . . . . . . 0 C--O 1.249 1.052 0 CA-C-O 118.612 -0.709 . . . . 60.530000000000001 109.876 175.603 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 34.3 mm-40 . . . . . 0 C--O 1.233 0.192 0 CA-C-O 120.811 0.339 . . . . 64.420000000000002 110.307 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 3' ' ' GLN . . . . . 0.947 ' HG2' HG22 ' A' ' 48' ' ' THR . 88.3 mt-30 -124.72 111.78 15.97 Favored 'General case' 0 C--N 1.321 -0.648 0 N-CA-C 109.418 -0.586 . . . . 74.109999999999999 109.418 176.308 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -137.87 163.47 25.57 Favored Glycine 0 N--CA 1.446 -0.653 0 C-N-CA 120.363 -0.922 . . . . 44.409999999999997 112.143 -176.029 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 5' ' ' THR . . . . . 0.543 ' HA ' ' HA ' ' A' ' 46' ' ' ALA . 22.0 m -106.67 130.44 54.4 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-O 120.516 0.198 . . . . 73.439999999999998 110.734 -178.431 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.521 HG23 HG12 ' A' ' 18' ' ' ILE . 42.7 t -70.65 120.67 18.95 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 N-CA-C 109.964 -0.384 . . . . 70.129999999999995 109.964 178.009 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 7' ' ' LYS . . . . . 0.689 ' HD2' ' HB3' ' A' ' 19' ' ' GLU . 27.2 mtpp -98.81 -34.05 10.65 Favored 'General case' 0 C--N 1.327 -0.393 0 C-N-CA 120.91 -0.316 . . . . 74.530000000000001 110.682 -179.305 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 8' ' ' TRP . . . . . . . . . . . . . 10.5 m-90 -140.0 110.82 6.83 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.067 -0.515 . . . . 72.439999999999998 110.361 179.791 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 65.2 t80 -101.88 91.99 4.61 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-O 121.194 0.521 . . . . 75.049999999999997 109.848 177.546 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 90.3 m-20 -79.15 84.97 5.07 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-O 121.238 0.542 . . . . 74.239999999999995 109.976 -178.037 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -60.41 -40.67 91.84 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.065 -0.97 . . . . 75.430000000000007 112.021 -175.761 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 42.7 mt-10 -81.81 0.45 39.25 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 121.134 0.492 . . . . 73.310000000000002 111.181 -176.786 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 70.5 mmtt -103.95 -28.07 11.78 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 115.782 -0.644 . . . . 74.439999999999998 109.38 170.695 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 82.08 19.26 65.38 Favored Glycine 0 N--CA 1.448 -0.554 0 N-CA-C 111.156 -0.778 . . . . 73.120000000000005 111.156 -175.854 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 48.8 m-85 -135.81 154.86 51.07 Favored 'General case' 0 C--N 1.325 -0.483 0 N-CA-C 110.2 -0.296 . . . . 73.150000000000006 110.2 -176.127 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -140.07 146.56 18.08 Favored Glycine 0 N--CA 1.447 -0.59 0 C-N-CA 120.524 -0.846 . . . . 73.140000000000001 112.14 -179.599 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 97.6 m-85 -104.47 111.88 24.71 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 121.051 0.453 . . . . 71.239999999999995 110.486 178.771 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . 0.521 HG12 HG23 ' A' ' 6' ' ' VAL . 55.2 mt -104.48 135.36 42.67 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.589 0 CA-C-N 115.579 -0.737 . . . . 74.25 109.829 -179.493 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 19' ' ' GLU . . . . . 0.689 ' HB3' ' HD2' ' A' ' 7' ' ' LYS . 14.0 pt-20 -83.29 162.18 21.22 Favored 'General case' 0 C--N 1.327 -0.377 0 C-N-CA 120.265 -0.574 . . . . 72.409999999999997 110.686 -178.837 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 20' ' ' ARG . . . . . . . . . . . . . 39.0 ttt180 -144.64 175.9 9.81 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 115.969 -0.56 . . . . 72.519999999999996 109.755 -173.255 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . 0.428 ' HG3' ' N ' ' A' ' 22' ' ' ASN . 7.8 pt-20 -45.71 -49.45 14.65 Favored 'General case' 0 N--CA 1.469 0.507 0 N-CA-C 113.046 0.758 . . . . 72.140000000000001 113.046 -177.488 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 22' ' ' ASN . . . . . 0.428 ' N ' ' HG3' ' A' ' 21' ' ' GLU . 14.9 t-20 -97.9 12.43 34.1 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-O 121.361 0.601 . . . . 63.420000000000002 110.761 -174.646 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 79.28 9.92 86.53 Favored Glycine 0 N--CA 1.452 -0.243 0 C-N-CA 120.528 -0.844 . . . . 72.129999999999995 111.124 -173.923 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 25.2 t70 -67.14 90.93 0.21 Allowed 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 114.8 -0.7 . . . . 53.409999999999997 110.062 179.871 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 4.8 p-10 -60.84 119.15 7.66 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 121.631 0.729 . . . . 74.230000000000004 111.451 -178.819 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . 0.524 HG13 ' HB3' ' A' ' 60' ' ' ALA . 31.3 t -89.88 127.98 42.13 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.58 0 CA-C-N 115.049 -0.978 . . . . 63.109999999999999 110.179 -179.864 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 27' ' ' PHE . . . . . . . . . . . . . 43.4 t80 -92.67 100.18 12.73 Favored 'General case' 0 C--N 1.321 -0.674 0 CA-C-N 115.582 -0.735 . . . . 71.400000000000006 110.333 -175.854 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.513 ' HA ' ' HB2' ' A' ' 60' ' ' ALA . 11.8 p -89.06 142.52 12.76 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 CA-C-O 120.708 0.289 . . . . 73.340000000000003 110.345 178.812 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 29' ' ' HIS . . . . . 0.405 ' O ' HG13 ' A' ' 33' ' ' ILE . 7.9 p80 -118.87 142.12 48.03 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.389 -0.369 . . . . 72.519999999999996 110.832 -178.484 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 30' ' ' PHE . . . . . 0.518 ' HA ' HD12 ' A' ' 33' ' ' ILE . 43.9 p90 -52.43 -32.54 39.83 Favored 'General case' 0 N--CA 1.468 0.443 0 CA-C-N 115.501 -0.772 . . . . 64.019999999999996 112.934 -173.648 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 1.9 p -71.06 -9.19 57.61 Favored 'General case' 0 C--N 1.323 -0.585 0 N-CA-C 111.911 0.337 . . . . 74.430000000000007 111.911 -179.046 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -122.07 -7.05 8.9 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-O 120.916 0.389 . . . . 61.539999999999999 110.941 177.905 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.518 HD12 ' HA ' ' A' ' 30' ' ' PHE . 68.3 mt -67.77 136.5 26.46 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.386 0 CA-C-N 116.21 -0.45 . . . . 73.400000000000006 110.115 175.78 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 24.0 pt20 . . . . . 0 C--N 1.327 -0.395 0 CA-C-O 121.434 0.635 . . . . 71.099999999999994 110.967 177.541 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 3.7 p . . . . . 0 N--CA 1.447 -0.583 0 CA-C-O 121.104 0.478 . . . . 63.409999999999997 111.844 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 93.2 mt -85.62 81.47 8.64 Favored 'General case' 0 C--N 1.327 -0.394 0 N-CA-C 108.726 -0.842 . . . . 73.299999999999997 108.726 172.884 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 69.3 m-20 -73.97 172.21 12.04 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-O 122.038 0.923 . . . . 73.430000000000007 112.911 -169.677 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . 0.452 ' CD ' ' H ' ' A' ' 43' ' ' GLU . 22.2 mp0 -60.64 132.96 55.55 Favored 'General case' 0 N--CA 1.448 -0.554 0 CA-C-N 114.139 -1.391 . . . . 72.349999999999994 110.163 -178.44 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 98.99 -5.94 59.77 Favored Glycine 0 N--CA 1.446 -0.686 0 C-N-CA 120.711 -0.757 . . . . 65.010000000000005 112.713 178.102 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 3.4 tm0? -92.16 126.08 37.1 Favored 'General case' 0 C--N 1.328 -0.354 0 N-CA-C 109.566 -0.531 . . . . 75.230000000000004 109.566 176.751 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 0.543 ' HA ' ' HA ' ' A' ' 5' ' ' THR . . . -97.95 113.09 24.83 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-O 120.944 0.402 . . . . 75.129999999999995 110.675 178.795 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 23.2 m -106.26 160.95 5.74 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 CA-C-N 115.952 -0.567 . . . . 74.349999999999994 111.087 -178.44 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 48' ' ' THR . . . . . 0.947 HG22 ' HG2' ' A' ' 3' ' ' GLN . 53.8 p -106.79 126.13 51.89 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 115.748 -0.66 . . . . 74.219999999999999 109.411 175.743 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 49' ' ' PHE . . . . . 0.459 ' HA ' ' O ' ' A' ' 62' ' ' ASN . 33.4 p90 -142.0 167.49 22.01 Favored 'General case' 0 C--N 1.317 -0.813 0 CA-C-O 120.954 0.407 . . . . 74.230000000000004 111.33 -173.435 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 33.1 t70 -106.55 148.64 28.01 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.747 -0.66 . . . . 74.25 109.947 175.841 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 62.6 t -82.22 105.76 12.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-O 120.953 0.406 . . . . 73.109999999999999 111.137 -178.782 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 52' ' ' GLU . . . . . 0.404 ' HB2' ' HB2' ' A' ' 61' ' ' ALA . 40.6 tt0 -82.49 123.76 29.46 Favored 'General case' 0 C--N 1.319 -0.721 0 N-CA-C 108.881 -0.785 . . . . 54.439999999999998 108.881 174.459 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 43.5 mt-10 -87.94 109.55 19.88 Favored 'General case' 0 C--N 1.319 -0.731 0 CA-C-N 115.974 -0.557 . . . . 71.329999999999998 110.804 -174.901 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -138.16 166.8 25.12 Favored Glycine 0 N--CA 1.446 -0.663 0 CA-C-N 115.454 -0.793 . . . . 71.340000000000003 111.577 -179.579 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 72.6 mt-30 -79.97 82.95 5.95 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 121.343 0.592 . . . . 72.439999999999998 111.245 -175.843 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 56' ' ' ARG . . . . . 0.426 HH11 ' HD3' ' A' ' 56' ' ' ARG . 9.1 ptp180 -179.77 -32.01 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 114.764 -1.107 . . . . 74.120000000000005 109.326 177.893 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 144.95 -152.11 24.19 Favored Glycine 0 N--CA 1.448 -0.553 0 N-CA-C 110.737 -0.945 . . . . 74.239999999999995 110.737 -178.183 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 55.5 Cg_endo -70.98 105.2 1.64 Allowed 'Trans proline' 0 N--CA 1.46 -0.472 0 C-N-CA 122.158 1.906 . . . . 73.219999999999999 111.537 176.871 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 20.3 tt0 -97.8 139.04 34.26 Favored 'General case' 0 C--N 1.322 -0.596 0 N-CA-C 108.63 -0.878 . . . . 73.540000000000006 108.63 179.071 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . 0.524 ' HB3' HG13 ' A' ' 26' ' ' VAL . . . -96.11 120.42 36.37 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-O 121.255 0.55 . . . . 75.329999999999998 112.105 -174.835 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 61' ' ' ALA . . . . . 0.404 ' HB2' ' HB2' ' A' ' 52' ' ' GLU . . . -135.57 163.1 30.89 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 115.05 -0.977 . . . . 74.329999999999998 108.62 173.777 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 62' ' ' ASN . . . . . 0.459 ' O ' ' HA ' ' A' ' 49' ' ' PHE . 88.5 m-20 54.65 77.34 0.21 Allowed 'General case' 0 C--O 1.236 0.348 0 CA-C-O 121.067 0.46 . . . . 74.409999999999997 109.855 -174.494 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 45.9 t -112.67 121.38 64.87 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 CA-C-N 115.643 -0.708 . . . . 73.340000000000003 110.787 -175.998 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 5.1 tp60 -115.61 146.58 41.66 Favored 'General case' 0 C--N 1.323 -0.566 0 N-CA-C 109.29 -0.633 . . . . 62.229999999999997 109.29 177.642 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 19.4 ttpp -84.01 137.8 33.43 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 120.931 0.396 . . . . 73.209999999999994 111.481 -176.867 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 0.987 0 CA-C-O 118.202 -0.904 . . . . 72.150000000000006 108.882 171.109 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 2' ' ' GLU . . . . . 0.466 ' O ' ' HA ' ' A' ' 48' ' ' THR . 5.0 mp0 . . . . . 0 N--CA 1.453 -0.28 0 N-CA-C 109.283 -0.636 . . . . 73.219999999999999 109.283 . . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 17.9 mp0 -63.96 136.32 57.24 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.033 -0.985 . . . . 74.400000000000006 112.606 -173.968 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -153.09 163.38 30.52 Favored Glycine 0 N--CA 1.441 -1.003 0 N-CA-C 109.419 -1.473 . . . . 73.510000000000005 109.419 172.657 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 13.9 m -122.46 127.53 49.72 Favored 'General case' 0 C--N 1.316 -0.861 0 CA-C-N 118.04 0.92 . . . . 64.299999999999997 110.886 -178.174 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 61.5 t -64.93 120.7 12.44 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.462 0 CA-C-N 116.22 -0.445 . . . . 75.239999999999995 111.115 -178.026 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 7' ' ' LYS . . . . . 1.048 ' HE2' ' HB3' ' A' ' 19' ' ' GLU . 66.3 mmtt -74.93 -70.49 0.41 Allowed 'General case' 0 C--N 1.328 -0.344 0 N-CA-C 109.219 -0.66 . . . . 74.340000000000003 109.219 175.309 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 8' ' ' TRP . . . . . . . . . . . . . 15.6 m95 -140.36 128.35 22.08 Favored 'General case' 0 C--O 1.235 0.317 0 CA-C-N 115.059 -0.973 . . . . 72.230000000000004 108.786 -179.537 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 22.8 p90 -99.52 103.69 15.45 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-O 121.702 0.763 . . . . 74.329999999999998 109.706 177.377 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 10' ' ' ASN . . . . . 0.856 ' HB3' ' HG3' ' A' ' 13' ' ' LYS . 37.8 m-80 -91.45 63.79 4.91 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 115.775 -0.648 . . . . 63.210000000000001 110.557 -176.958 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -64.07 -26.29 68.48 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 115.609 -0.723 . . . . 65.430000000000007 110.435 178.732 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 4.1 mm-40 -71.64 -13.27 61.7 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 115.726 -0.67 . . . . 72.230000000000004 110.509 178.684 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 13' ' ' LYS . . . . . 0.856 ' HG3' ' HB3' ' A' ' 10' ' ' ASN . 1.7 mmpt? -112.97 -37.85 4.68 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.895 -0.593 . . . . 75.329999999999998 110.395 -176.99 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . 0.407 ' O ' ' HD1' ' A' ' 30' ' ' PHE . . . 116.85 15.61 6.7 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.956 -0.64 . . . . 73.420000000000002 112.835 178.474 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 45.3 p90 -151.49 -176.36 5.56 Favored 'General case' 0 C--N 1.324 -0.543 0 O-C-N 122.543 -0.386 . . . . 73.340000000000003 110.667 179.96 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -164.55 169.99 39.51 Favored Glycine 0 N--CA 1.445 -0.743 0 C-N-CA 120.915 -0.66 . . . . 73.140000000000001 111.795 177.581 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 96.6 m-85 -123.76 130.12 52.13 Favored 'General case' 0 C--N 1.323 -0.585 0 N-CA-C 109.979 -0.378 . . . . 73.150000000000006 109.979 178.695 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 61.0 mt -127.57 135.35 63.45 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.768 0 N-CA-C 109.701 -0.481 . . . . 71.329999999999998 109.701 178.308 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 19' ' ' GLU . . . . . 1.048 ' HB3' ' HE2' ' A' ' 7' ' ' LYS . 8.5 pt-20 -91.5 135.61 33.72 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-O 121.212 0.529 . . . . 65.140000000000001 110.811 179.451 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 20' ' ' ARG . . . . . 0.648 ' HB2' ' HZ ' ' A' ' 49' ' ' PHE . 45.5 ttt180 -133.93 161.75 33.94 Favored 'General case' 0 C--N 1.315 -0.928 0 N-CA-C 108.576 -0.898 . . . . 73.299999999999997 108.576 174.78 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 7.1 mm-40 -35.87 -57.47 0.67 Allowed 'General case' 0 N--CA 1.468 0.444 0 O-C-N 124.038 0.836 . . . . 73.409999999999997 110.806 178.025 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 34.9 t30 -110.06 76.92 1.02 Allowed 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 115.704 -0.68 . . . . 71.400000000000006 109.749 172.409 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . 0.569 ' O ' HG21 ' A' ' 26' ' ' VAL . . . 152.24 72.44 0.01 OUTLIER Glycine 0 N--CA 1.446 -0.674 0 C-N-CA 120.541 -0.838 . . . . 74.099999999999994 112.213 174.032 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 25.2 t70 -68.17 -1.79 6.76 Favored 'General case' 0 C--N 1.321 -0.663 0 CA-C-O 121.183 0.516 . . . . 73.219999999999999 111.062 -176.278 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 7.0 p-10 -142.65 31.49 1.47 Allowed 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 116.246 -0.434 . . . . 74.109999999999999 110.929 -174.988 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . 0.569 HG21 ' O ' ' A' ' 23' ' ' GLY . 79.2 t -53.28 121.83 2.73 Favored 'Isoleucine or valine' 0 C--O 1.234 0.269 0 CA-C-O 121.109 0.48 . . . . 72.430000000000007 110.743 179.588 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 27' ' ' PHE . . . . . . . . . . . . . 42.6 t80 -84.21 116.74 23.1 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 115.583 -0.735 . . . . 74.120000000000005 110.603 -174.413 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.486 HG21 HG22 ' A' ' 63' ' ' VAL . 9.0 p -110.68 156.1 11.86 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.59 0 CA-C-N 116.339 -0.392 . . . . 75.319999999999993 110.281 179.853 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 92.7 m-70 -108.82 157.27 18.74 Favored 'General case' 0 C--O 1.239 0.513 0 N-CA-C 110.011 -0.366 . . . . 65.530000000000001 110.011 -179.674 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 30' ' ' PHE . . . . . 0.407 ' HD1' ' O ' ' A' ' 14' ' ' GLY . 50.8 p90 -61.65 -34.48 75.78 Favored 'General case' 0 N--CA 1.464 0.234 0 CA-C-N 116.54 -0.3 . . . . 75.239999999999995 111.605 -175.847 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 26.8 t -92.43 2.68 56.52 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 121.053 0.454 . . . . 74.319999999999993 110.589 -179.045 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -93.38 -29.9 15.37 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 121.168 0.509 . . . . 73.319999999999993 110.151 177.127 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.56 ' HA ' ' HB ' ' A' ' 63' ' ' VAL . 59.1 mt -72.66 137.89 22.56 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.386 0 CA-C-N 115.608 -0.724 . . . . 73.310000000000002 109.992 174.277 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 5.1 pp0? . . . . . 0 C--N 1.329 -0.318 0 N-CA-C 110.061 -0.348 . . . . 73.409999999999997 110.061 178.236 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 20.0 m . . . . . 0 N--CA 1.45 -0.472 0 N-CA-C 110.034 -0.358 . . . . 75.310000000000002 110.034 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 98.4 mt -66.35 143.13 57.35 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 116.013 -0.539 . . . . 64.209999999999994 110.93 -177.882 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 35.4 t70 -68.07 149.38 49.73 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-N 115.462 -0.79 . . . . 71.319999999999993 112.176 -172.808 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 7.6 pt-20 -65.25 135.63 55.62 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 115.751 -0.658 . . . . 73.040000000000006 110.518 179.312 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 89.74 -1.23 80.89 Favored Glycine 0 N--CA 1.447 -0.583 0 C-N-CA 120.66 -0.781 . . . . 74.230000000000004 112.233 -177.18 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 6.5 tp-100 -82.92 141.49 32.14 Favored 'General case' 0 C--O 1.237 0.439 0 CA-C-O 120.732 0.301 . . . . 74.230000000000004 110.36 176.984 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -82.38 117.41 22.42 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 115.824 -0.626 . . . . 65.310000000000002 110.257 178.244 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 29.5 m -117.01 166.93 10.83 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.711 0 CA-C-N 115.727 -0.67 . . . . 74.230000000000004 110.884 -178.071 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 48' ' ' THR . . . . . 0.721 HG23 ' HB3' ' A' ' 66' ' ' ALA . 9.6 p -132.91 103.15 5.92 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-O 121.296 0.569 . . . . 63.409999999999997 110.106 178.461 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 49' ' ' PHE . . . . . 0.648 ' HZ ' ' HB2' ' A' ' 20' ' ' ARG . 36.5 p90 -117.16 166.82 11.79 Favored 'General case' 0 C--N 1.318 -0.792 0 CA-C-O 121.072 0.463 . . . . 74.030000000000001 111.751 -172.399 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 35.5 t70 -96.91 128.06 43.5 Favored 'General case' 0 C--N 1.32 -0.68 0 N-CA-C 109.016 -0.735 . . . . 73.140000000000001 109.016 174.169 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 7.4 p -80.62 118.0 27.56 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.564 0 CA-C-O 121.538 0.685 . . . . 73.420000000000002 111.254 -174.746 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 44.0 tt0 -89.14 113.16 24.3 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-N 115.419 -0.81 . . . . 75.049999999999997 109.109 176.942 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 13.9 mm-40 -73.62 86.13 1.62 Allowed 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 115.983 -0.553 . . . . 75.019999999999996 109.875 178.248 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -88.64 160.8 30.48 Favored Glycine 0 N--CA 1.443 -0.858 0 C-N-CA 120.88 -0.676 . . . . 61.109999999999999 112.331 -177.523 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 36.7 tt0 -84.77 0.34 50.99 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-O 121.392 0.615 . . . . 73.209999999999994 109.854 -179.295 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 90.8 mtm180 -119.84 15.64 12.6 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.597 -0.729 . . . . 75.200000000000003 110.855 179.184 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 121.68 169.17 13.56 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.884 -0.674 . . . . 72.310000000000002 112.182 -179.769 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 37.7 Cg_endo -68.03 118.41 5.6 Favored 'Trans proline' 0 C--N 1.344 0.291 0 C-N-CA 122.532 2.155 . . . . 72.340000000000003 111.768 177.249 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 49.9 mt-30 -119.45 164.31 15.96 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 116.325 -0.398 . . . . 73.109999999999999 110.429 -177.791 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -111.65 125.15 53.65 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-O 121.255 0.55 . . . . 75.299999999999997 111.943 -174.048 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -128.57 142.97 50.89 Favored 'General case' 0 C--N 1.321 -0.63 0 CA-C-N 115.3 -0.863 . . . . 65.510000000000005 109.005 174.426 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 39.4 m-80 56.53 78.57 0.21 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 121.216 0.532 . . . . 72.450000000000003 110.448 -175.899 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.56 ' HB ' ' HA ' ' A' ' 33' ' ' ILE . 51.8 t -101.42 109.59 26.14 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.519 0 CA-C-N 115.892 -0.594 . . . . 70.5 110.803 -177.965 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 86.7 mt-30 -94.06 -172.24 2.77 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 116.192 -0.458 . . . . 74.099999999999994 110.105 177.983 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 61.9 tttm -116.45 139.64 50.23 Favored 'General case' 0 C--N 1.321 -0.641 0 N-CA-C 109.303 -0.629 . . . . 73.409999999999997 109.303 178.508 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 66' ' ' ALA . . . . . 0.721 ' HB3' HG23 ' A' ' 48' ' ' THR . . . . . . . . 0 C--O 1.248 1.006 0 CA-C-O 118.795 -0.621 . . . . 75.010000000000005 110.557 -178.614 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 21.9 ttt . . . . . 0 N--CA 1.479 1.019 0 N-CA-C 109.423 -0.584 . . . . 71.549999999999997 109.423 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . 0.916 ' HG3' HH12 ' A' ' 20' ' ' ARG . 0.1 OUTLIER -90.06 83.28 6.07 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 115.842 -0.617 . . . . 74.420000000000002 111.209 -172.919 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 41.1 mt-30 -96.54 148.52 22.75 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.539 -0.755 . . . . 74.420000000000002 110.123 178.481 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -155.91 153.7 24.95 Favored Glycine 0 N--CA 1.445 -0.726 0 C-N-CA 120.934 -0.651 . . . . 71.329999999999998 111.866 177.114 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 4.7 m -104.57 134.81 47.12 Favored 'General case' 0 C--N 1.319 -0.752 0 N-CA-C 109.812 -0.44 . . . . 74.140000000000001 109.812 178.124 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 61.8 t -68.13 112.18 3.01 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.609 0 CA-C-O 120.745 0.307 . . . . 74.439999999999998 110.41 177.952 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . 0.673 ' HD3' ' HB3' ' A' ' 19' ' ' GLU . 12.3 mmmm -71.3 -68.5 0.44 Allowed 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.831 -0.622 . . . . 71.430000000000007 109.822 179.159 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' TRP . . . . . . . . . . . . . 4.6 p-90 -153.06 149.01 27.68 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-N 115.462 -0.79 . . . . 74.329999999999998 109.32 177.774 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . 0.408 ' CE2' ' HA ' ' A' ' 40' ' ' SER . 68.5 t80 -114.59 120.15 39.21 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-O 121.001 0.429 . . . . 74.209999999999994 111.563 -173.227 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' ASN . . . . . 0.439 ' HB3' ' HB2' ' A' ' 13' ' ' LYS . 15.3 m120 -81.92 78.31 8.64 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.669 -0.696 . . . . 74.209999999999994 109.472 176.261 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -61.71 -37.64 84.92 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 115.905 -0.589 . . . . 55.409999999999997 111.303 -177.114 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 32.0 mm-40 -76.8 -11.33 59.81 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.379 -0.373 . . . . 73.340000000000003 111.554 -178.925 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . 0.469 ' HB3' ' HD2' ' A' ' 15' ' ' PHE . 70.1 mmtt -99.79 -33.69 10.47 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-O 121.072 0.463 . . . . 73.319999999999993 110.553 176.839 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 89.85 24.28 30.53 Favored Glycine 0 N--CA 1.448 -0.536 0 N-CA-C 111.075 -0.81 . . . . 75.140000000000001 111.075 -174.147 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . 0.469 ' HD2' ' HB3' ' A' ' 13' ' ' LYS . 64.3 m-85 -136.92 173.73 11.38 Favored 'General case' 0 C--N 1.324 -0.519 0 N-CA-C 109.549 -0.538 . . . . 73.319999999999993 109.549 -178.338 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -160.98 167.56 36.02 Favored Glycine 0 N--CA 1.447 -0.6 0 C-N-CA 120.281 -0.962 . . . . 64.409999999999997 112.285 178.543 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 96.2 m-85 -119.67 119.67 34.39 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-O 121.105 0.478 . . . . 73.540000000000006 110.668 179.095 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 56.4 mt -112.76 124.95 69.91 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.657 0 N-CA-C 109.187 -0.671 . . . . 62.130000000000003 109.187 177.72 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' GLU . . . . . 0.673 ' HB3' ' HD3' ' A' ' 7' ' ' LYS . 10.3 pt-20 -71.88 140.38 49.25 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-O 121.342 0.592 . . . . 73.409999999999997 111.468 -173.792 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' ARG . . . . . 0.916 HH12 ' HG3' ' A' ' 2' ' ' GLU . 9.7 tpt180 -90.84 172.98 8.24 Favored 'General case' 0 C--N 1.32 -0.7 0 N-CA-C 107.521 -1.289 . . . . 74.439999999999998 107.521 167.107 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . 0.558 ' OE2' ' HG3' ' A' ' 20' ' ' ARG . 0.0 OUTLIER -59.79 -23.15 63.05 Favored 'General case' 0 N--CA 1.467 0.413 0 CA-C-N 118.383 0.538 . . . . 71.450000000000003 112.327 -172.93 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 91.9 m-20 -101.4 17.79 21.76 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.855 0.36 . . . . 75.319999999999993 111.594 179.005 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 80.15 2.08 88.59 Favored Glycine 0 N--CA 1.452 -0.253 0 C-N-CA 120.943 -0.646 . . . . 51.149999999999999 112.751 176.897 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 28.4 t70 -69.19 97.85 0.96 Allowed 'General case' 0 C--N 1.323 -0.557 0 N-CA-C 109.955 -0.387 . . . . 74.420000000000002 109.955 179.712 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.466 ' OD1' ' HG3' ' A' ' 7' ' ' LYS . 52.5 m-20 -53.66 113.67 1.27 Allowed 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.331 -0.85 . . . . 74.140000000000001 111.119 176.363 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.667 HG12 ' HB1' ' A' ' 60' ' ' ALA . 25.3 t -89.27 135.56 25.66 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.602 0 CA-C-N 115.663 -0.698 . . . . 75.310000000000002 109.457 176.316 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' PHE . . . . . . . . . . . . . 40.4 t80 -90.72 109.65 20.83 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 120.988 0.423 . . . . 75.209999999999994 110.79 -172.894 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.425 ' HA ' ' HB3' ' A' ' 60' ' ' ALA . 7.9 p -97.52 151.45 4.29 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 CA-C-N 116.185 -0.461 . . . . 72.209999999999994 110.508 -179.434 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' HIS . . . . . 0.431 ' HA ' ' HD1' ' A' ' 15' ' ' PHE . 34.0 m80 -115.46 158.53 22.4 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.175 -0.466 . . . . 62.109999999999999 110.969 -175.924 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 34.3 p90 -61.69 -31.34 71.47 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.029 -0.532 . . . . 72.239999999999995 111.774 179.742 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 8.0 t -94.43 12.85 25.72 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 121.433 0.635 . . . . 72.129999999999995 109.977 -179.628 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . 0.592 ' HB2' ' HA ' ' A' ' 61' ' ' ALA . . . -112.68 -28.85 7.65 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 115.701 -0.681 . . . . 74.310000000000002 110.124 178.132 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 55.7 mt -80.33 139.01 18.82 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.53 0 CA-C-N 115.443 -0.799 . . . . 64.230000000000004 109.926 177.126 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' GLN . . . . . 0.41 ' O ' ' HG3' ' A' ' 34' ' ' GLN . 10.5 pt20 -75.7 90.31 2.84 Favored 'General case' 0 N--CA 1.45 -0.432 0 CA-C-O 121.395 0.617 . . . . 73.25 109.518 173.436 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.4 ' O ' ' HE2' ' A' ' 39' ' ' LYS . . . -74.34 61.61 2.29 Favored Glycine 0 N--CA 1.449 -0.451 0 CA-C-N 115.534 -0.757 . . . . 52.340000000000003 112.086 -179.115 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 18.1 t70 -92.61 110.33 21.76 Favored 'General case' 0 C--N 1.318 -0.764 0 N-CA-C 109.434 -0.58 . . . . 71.340000000000003 109.434 179.064 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 94.01 -57.94 2.11 Favored Glycine 0 N--CA 1.447 -0.573 0 C-N-CA 120.932 -0.652 . . . . 34.530000000000001 111.763 -176.98 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 29.7 p90 -146.14 149.61 34.33 Favored 'General case' 0 C--N 1.325 -0.479 0 N-CA-C 110.237 -0.283 . . . . 72.319999999999993 110.237 178.743 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' LYS . . . . . 0.431 ' N ' ' HD2' ' A' ' 39' ' ' LYS . 0.5 OUTLIER -102.43 75.55 1.47 Allowed 'General case' 0 C--N 1.324 -0.534 0 CA-C-O 121.196 0.522 . . . . 74.209999999999994 110.102 179.791 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' SER . . . . . 0.408 ' HA ' ' CE2' ' A' ' 9' ' ' PHE . 66.4 m -157.43 154.83 29.43 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 115.781 -0.645 . . . . 74.129999999999995 109.939 178.908 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 87.6 mt -110.96 126.52 54.85 Favored 'General case' 0 C--N 1.321 -0.642 0 N-CA-C 109.328 -0.619 . . . . 75.329999999999998 109.328 174.301 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 36.0 t70 -69.44 112.91 6.29 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-O 121.001 0.429 . . . . 71.129999999999995 109.95 179.991 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 55.6 mt-10 -65.57 120.46 12.94 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 115.956 -0.565 . . . . 52.329999999999998 110.35 -176.89 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 105.22 -13.07 48.56 Favored Glycine 0 N--CA 1.449 -0.498 0 C-N-CA 121.014 -0.612 . . . . 63.329999999999998 111.903 -175.305 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 6.2 tp-100 -83.64 145.6 28.72 Favored 'General case' 0 C--O 1.235 0.318 0 CA-C-O 120.795 0.331 . . . . 65.310000000000002 110.272 -179.855 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -100.22 135.21 42.0 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 116.161 -0.472 . . . . 74.230000000000004 110.465 178.743 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 8.9 m -141.68 -175.93 0.9 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.493 0 CA-C-N 116.096 -0.502 . . . . 75.319999999999993 110.537 179.444 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 19.8 p -124.54 157.97 34.06 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 115.971 -0.559 . . . . 73.319999999999993 109.693 177.302 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 37.8 p90 -156.48 151.07 25.7 Favored 'General case' 0 C--N 1.321 -0.637 0 C-N-CA 120.56 -0.456 . . . . 73.129999999999995 111.545 -176.748 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . 0.713 ' HB3' ' HB2' ' A' ' 62' ' ' ASN . 26.3 t70 -91.35 94.4 9.49 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 115.834 -0.621 . . . . 75.239999999999995 109.697 174.562 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 7.6 p -73.56 133.63 31.29 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.55 0 CA-C-N 115.871 -0.604 . . . . 64.219999999999999 111.079 -176.399 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 25.7 mt-10 -119.31 171.69 8.14 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 115.847 -0.615 . . . . 74.319999999999993 110.155 179.273 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 10.8 pt-20 -72.08 149.51 44.76 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.834 -0.621 . . . . 72.519999999999996 110.87 179.968 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . 0.486 ' HA3' ' O ' ' A' ' 57' ' ' GLY . . . -155.02 124.98 1.6 Allowed Glycine 0 N--CA 1.445 -0.715 0 CA-C-N 115.87 -0.604 . . . . 73.329999999999998 111.804 178.387 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 35.4 tt0 -61.49 -33.08 73.17 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-O 120.654 0.264 . . . . 71.540000000000006 111.306 -177.535 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 22.2 mmt180 -114.47 25.98 10.6 Favored 'General case' 0 C--N 1.327 -0.375 0 N-CA-C 111.741 0.274 . . . . 72.219999999999999 111.741 -179.515 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . 0.486 ' O ' ' HA3' ' A' ' 54' ' ' GLY . . . 139.86 157.25 7.19 Favored Glycine 0 N--CA 1.448 -0.55 0 C-N-CA 120.319 -0.943 . . . . 61.420000000000002 112.378 176.757 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . 0.531 ' HG2' ' HA ' ' A' ' 26' ' ' VAL . 37.5 Cg_endo -66.47 127.2 16.85 Favored 'Trans proline' 0 C--O 1.234 0.323 0 C-N-CA 122.629 2.219 . . . . 65.319999999999993 111.517 -179.758 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 26.9 tt0 -88.72 107.86 19.17 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 116.039 -0.528 . . . . 71.540000000000006 110.728 -176.841 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . 0.667 ' HB1' HG12 ' A' ' 26' ' ' VAL . . . -79.2 97.75 6.34 Favored 'General case' 0 C--N 1.323 -0.575 0 N-CA-C 109.728 -0.471 . . . . 72.310000000000002 109.728 175.879 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . 0.592 ' HA ' ' HB2' ' A' ' 32' ' ' ALA . . . -111.44 165.83 11.64 Favored 'General case' 0 C--N 1.319 -0.74 0 CA-C-N 115.829 -0.623 . . . . 72.129999999999995 110.017 -179.994 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 62' ' ' ASN . . . . . 0.713 ' HB2' ' HB3' ' A' ' 50' ' ' ASP . 56.3 m-20 48.37 65.89 1.21 Allowed 'General case' 0 C--N 1.33 -0.271 0 O-C-N 123.727 0.642 . . . . 75.109999999999999 111.03 174.915 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 58.7 t -77.26 120.64 28.12 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.464 0 CA-C-N 116.086 -0.507 . . . . 72.519999999999996 110.493 -178.603 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 77.2 mm-40 -108.12 133.76 51.94 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-N 115.827 -0.624 . . . . 74.209999999999994 110.058 179.694 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 96.8 mttt -73.92 134.41 43.19 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 116.194 -0.457 . . . . 72.140000000000001 110.503 -179.397 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.246 0.87 0 CA-C-O 118.346 -0.835 . . . . 73.420000000000002 110.326 -179.783 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' MET . . . . . 0.499 ' H2 ' ' HA ' ' A' ' 50' ' ' ASP . 23.6 mmt . . . . . 0 N--CA 1.484 1.23 0 CA-C-O 120.994 0.426 . . . . 72.239999999999995 110.387 . . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 11.1 mp0 -112.0 157.39 20.78 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 116.284 -0.416 . . . . 64.319999999999993 110.254 -172.702 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' GLN . . . . . 0.477 ' HA ' ' O ' ' A' ' 47' ' ' VAL . 28.6 tt0 -92.65 131.17 37.98 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 116.38 -0.373 . . . . 74.209999999999994 110.065 176.733 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . 0.424 ' HA3' ' HE2' ' A' ' 49' ' ' PHE . . . -146.16 151.62 23.83 Favored Glycine 0 N--CA 1.446 -0.685 0 C-N-CA 120.872 -0.68 . . . . 65.319999999999993 112.292 -179.58 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' THR . . . . . 0.404 ' O ' ' HG2' ' A' ' 19' ' ' GLU . 0.2 OUTLIER -89.0 125.8 35.14 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-O 120.659 0.266 . . . . 73.420000000000002 110.923 -177.287 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.86 ' HA ' HG13 ' A' ' 18' ' ' ILE . 31.2 t -68.55 102.53 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.495 0 N-CA-C 110.098 -0.334 . . . . 71.340000000000003 110.098 176.623 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 8.8 mmmm -72.59 -68.29 0.49 Allowed 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 116.296 -0.411 . . . . 73.140000000000001 110.672 -177.531 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' TRP . . . . . . . . . . . . . 80.7 m95 -135.32 131.69 36.76 Favored 'General case' 0 C--N 1.323 -0.546 0 N-CA-C 109.755 -0.461 . . . . 73.340000000000003 109.755 178.286 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . 0.456 ' HA ' ' HA3' ' A' ' 16' ' ' GLY . 73.3 t80 -134.42 104.35 6.09 Favored 'General case' 0 C--N 1.318 -0.765 0 CA-C-O 120.912 0.387 . . . . 74.530000000000001 110.125 176.939 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' ASN . . . . . 0.617 ' OD1' ' HG2' ' A' ' 13' ' ' LYS . 16.7 t-20 -78.53 86.64 4.53 Favored 'General case' 0 C--N 1.321 -0.639 0 N-CA-C 109.305 -0.628 . . . . 74.010000000000005 109.305 178.897 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -66.31 -15.76 63.49 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 115.243 -0.89 . . . . 63.409999999999997 111.494 -177.17 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 32.7 mt-10 -68.01 -38.46 82.65 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.142 -0.481 . . . . 75.340000000000003 109.983 177.867 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . 0.617 ' HG2' ' OD1' ' A' ' 10' ' ' ASN . 28.9 mmtp -98.2 -30.45 12.63 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 116.112 -0.494 . . . . 74.049999999999997 109.946 179.955 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 104.9 20.73 9.61 Favored Glycine 0 N--CA 1.448 -0.555 0 C-N-CA 120.746 -0.74 . . . . 61.229999999999997 113.068 175.857 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 39.7 p90 -147.08 162.59 38.52 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 117.157 0.478 . . . . 73.420000000000002 110.853 -178.857 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.456 ' HA3' ' HA ' ' A' ' 9' ' ' PHE . . . -168.45 -164.15 23.66 Favored Glycine 0 N--CA 1.444 -0.823 0 C-N-CA 120.665 -0.778 . . . . 72.109999999999999 112.064 178.857 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 91.9 m-85 -133.83 124.3 26.28 Favored 'General case' 0 C--N 1.322 -0.61 0 N-CA-C 109.408 -0.59 . . . . 74.129999999999995 109.408 -178.005 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.86 HG13 ' HA ' ' A' ' 6' ' ' VAL . 11.0 tt -116.51 158.22 17.07 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.96 0 N-CA-C 109.095 -0.706 . . . . 71.540000000000006 109.095 -177.712 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' GLU . . . . . 0.404 ' HG2' ' O ' ' A' ' 5' ' ' THR . 19.8 pt-20 -106.49 134.13 50.1 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 121.375 0.607 . . . . 71.329999999999998 111.229 -178.148 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' ARG . . . . . . . . . . . . . 14.3 ttt180 -97.35 157.98 15.7 Favored 'General case' 0 C--N 1.317 -0.83 0 N-CA-C 108.224 -1.028 . . . . 73.519999999999996 108.224 172.026 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 31.7 mt-10 -44.0 -40.65 4.87 Favored 'General case' 0 N--CA 1.467 0.416 0 O-C-N 123.503 0.502 . . . . 74.540000000000006 110.885 -179.499 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 23.1 t-20 -127.59 73.62 1.46 Allowed 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 115.89 -0.595 . . . . 72.510000000000005 109.784 171.498 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 164.61 94.99 0.1 Allowed Glycine 0 C--O 1.227 -0.306 0 C-N-CA 120.41 -0.9 . . . . 71.319999999999993 112.843 175.846 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 13.3 m-20 -78.44 18.16 0.58 Allowed 'General case' 0 N--CA 1.468 0.458 0 N-CA-C 111.877 0.325 . . . . 75.049999999999997 111.877 -178.02 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 36.5 t70 -142.7 85.24 1.88 Allowed 'General case' 0 C--N 1.321 -0.671 0 CA-C-O 120.999 0.428 . . . . 71.439999999999998 110.824 -177.724 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.411 ' HB ' HG23 ' A' ' 18' ' ' ILE . 47.2 t -125.48 124.04 66.08 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.526 0 CA-C-N 115.609 -0.723 . . . . 73.549999999999997 109.185 174.94 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' PHE . . . . . . . . . . . . . 70.6 t80 -83.44 104.36 13.52 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-O 121.321 0.581 . . . . 73.409999999999997 110.834 -175.328 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.404 HG21 HD11 ' A' ' 33' ' ' ILE . 13.5 p -93.77 142.05 13.9 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.664 0 CA-C-N 115.851 -0.613 . . . . 75.230000000000004 109.788 179.089 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' HIS . . . . . 0.515 ' CE1' ' HB3' ' A' ' 32' ' ' ALA . 3.7 p80 -140.53 142.55 35.19 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.761 0.315 . . . . 74.340000000000003 111.017 -175.976 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 17.2 p90 -60.49 -25.14 65.84 Favored 'General case' 0 N--CA 1.469 0.476 0 CA-C-N 115.8 -0.636 . . . . 74.540000000000006 112.706 -170.775 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 11.6 p -77.87 -8.0 57.47 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-O 121.028 0.442 . . . . 75.209999999999994 111.587 -178.11 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . 0.547 ' HB1' ' HA ' ' A' ' 61' ' ' ALA . . . -113.81 -23.53 9.61 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 120.921 0.391 . . . . 63.409999999999997 111.074 179.178 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.418 HD12 ' HB2' ' A' ' 41' ' ' LEU . 56.9 mt -69.07 150.51 10.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 N-CA-C 109.556 -0.535 . . . . 74.530000000000001 109.556 174.104 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 4.8 pp0? -112.42 139.14 48.23 Favored 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 109.45 -0.574 . . . . 73.340000000000003 109.45 175.056 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -162.66 158.63 30.86 Favored Glycine 0 N--CA 1.446 -0.674 0 C-N-CA 120.753 -0.737 . . . . 63.100000000000001 111.779 -178.289 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 33.9 t70 -101.41 99.46 9.8 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-O 120.952 0.405 . . . . 62.32 110.391 -178.09 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 94.81 -55.84 1.9 Allowed Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 121.045 -0.598 . . . . 72.230000000000004 112.404 -179.358 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 72.1 m-85 -115.05 145.44 42.3 Favored 'General case' 0 C--N 1.323 -0.577 0 N-CA-C 109.889 -0.411 . . . . 73.120000000000005 109.889 179.593 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 13.9 mmmm -101.91 5.54 40.94 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-O 120.993 0.425 . . . . 75.439999999999998 110.815 -177.899 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 13.3 p -68.98 127.22 32.34 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 115.832 -0.622 . . . . 73.239999999999995 110.705 179.088 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . 0.418 ' HB2' HD12 ' A' ' 33' ' ' ILE . 12.6 tp -92.63 146.81 23.38 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 116.029 -0.532 . . . . 75.230000000000004 109.675 178.699 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . 0.834 ' HB2' ' HB2' ' A' ' 45' ' ' GLN . 2.1 m-20 -73.92 124.81 26.88 Favored 'General case' 0 C--N 1.318 -0.787 0 CA-C-N 115.837 -0.62 . . . . 72.349999999999994 110.885 -175.108 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 9.3 pt-20 -69.47 131.34 44.58 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-O 120.845 0.355 . . . . 64.200000000000003 110.164 177.456 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 82.24 4.06 90.34 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.863 -0.684 . . . . 64.420000000000002 112.113 -177.65 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 45' ' ' GLN . . . . . 0.834 ' HB2' ' HB2' ' A' ' 42' ' ' ASP . 24.6 tp60 -80.91 126.32 31.22 Favored 'General case' 0 C--N 1.326 -0.455 0 N-CA-C 110.109 -0.33 . . . . 70.120000000000005 110.109 -179.693 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 0.439 ' O ' ' HB2' ' A' ' 66' ' ' ALA . . . -86.88 83.15 7.59 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-O 121.042 0.449 . . . . 75.010000000000005 110.048 176.006 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . 0.507 HG12 ' HA ' ' A' ' 65' ' ' LYS . 19.1 m -89.85 167.98 1.59 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.578 0 CA-C-N 115.631 -0.713 . . . . 73.310000000000002 111.734 -173.563 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 48' ' ' THR . . . . . 0.487 ' OG1' ' HB3' ' A' ' 64' ' ' GLN . 4.9 p -112.4 107.32 16.08 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 115.959 -0.564 . . . . 74.510000000000005 110.145 177.379 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 49' ' ' PHE . . . . . 0.569 ' HA ' ' O ' ' A' ' 62' ' ' ASN . 38.2 p90 -122.17 160.57 24.85 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 115.838 -0.619 . . . . 74.549999999999997 111.234 -173.063 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . 0.499 ' HA ' ' H2 ' ' A' ' 1' ' ' MET . 22.6 t70 -107.67 115.59 30.43 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-O 121.07 0.462 . . . . 72.109999999999999 110.563 175.058 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 66.5 t -66.65 132.51 32.02 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.498 0 CA-C-N 115.734 -0.667 . . . . 75.540000000000006 112.12 -174.692 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . 1.071 ' HB2' ' HB2' ' A' ' 59' ' ' GLN . 34.4 mt-10 -94.27 159.55 15.08 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.736 -0.666 . . . . 73.219999999999999 109.675 174.309 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 39.1 mt-10 -114.72 110.63 20.03 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-N 116.38 -0.373 . . . . 74.439999999999998 110.353 178.382 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -126.49 170.8 18.26 Favored Glycine 0 N--CA 1.448 -0.515 0 C-N-CA 120.878 -0.677 . . . . 74.120000000000005 112.092 -179.802 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 18.3 mt-30 -92.98 69.3 4.5 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-O 121.365 0.602 . . . . 74.150000000000006 110.034 -177.852 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 15.8 ptp180 178.59 -30.47 0.01 OUTLIER 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 114.741 -1.118 . . . . 72.510000000000005 108.921 -176.154 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 162.71 -179.54 37.92 Favored Glycine 0 N--CA 1.44 -1.098 0 N-CA-C 110.325 -1.11 . . . . 73.409999999999997 110.325 178.486 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 57.5 Cg_endo -76.34 128.12 10.24 Favored 'Trans proline' 0 N--CA 1.454 -0.822 0 C-N-CA 121.884 1.723 . . . . 71.5 111.161 175.228 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . 1.071 ' HB2' ' HB2' ' A' ' 52' ' ' GLU . 9.4 mm100 -93.4 169.73 10.14 Favored 'General case' 0 C--N 1.321 -0.639 0 N-CA-C 109.0 -0.741 . . . . 74.349999999999994 109.0 178.591 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . 0.404 ' HB1' ' HA ' ' A' ' 28' ' ' VAL . . . -124.75 111.33 15.42 Favored 'General case' 0 C--N 1.319 -0.745 0 C-N-CA 120.719 -0.393 . . . . 73.129999999999995 111.327 179.308 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . 0.547 ' HA ' ' HB1' ' A' ' 32' ' ' ALA . . . -123.11 159.35 28.71 Favored 'General case' 0 CA--C 1.515 -0.379 0 CA-C-N 115.984 -0.553 . . . . 74.409999999999997 110.161 177.156 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 62' ' ' ASN . . . . . 0.569 ' O ' ' HA ' ' A' ' 49' ' ' PHE . 94.9 m-20 53.65 78.3 0.16 Allowed 'General case' 0 CA--C 1.517 -0.304 0 CA-C-O 121.274 0.559 . . . . 72.409999999999997 109.569 -177.481 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 44.1 t -107.8 101.72 12.93 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.611 0 CA-C-N 115.147 -0.933 . . . . 75.519999999999996 110.572 -175.995 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 64' ' ' GLN . . . . . 0.487 ' HB3' ' OG1' ' A' ' 48' ' ' THR . 8.3 tt0 -85.3 124.13 31.57 Favored 'General case' 0 C--N 1.319 -0.728 0 CA-C-N 115.959 -0.564 . . . . 75.329999999999998 110.066 -179.382 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . 0.507 ' HA ' HG12 ' A' ' 47' ' ' VAL . 42.9 mttm -68.16 127.39 32.72 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.346 -0.388 . . . . 74.209999999999994 110.263 -179.289 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 66' ' ' ALA . . . . . 0.439 ' HB2' ' O ' ' A' ' 46' ' ' ALA . . . . . . . . 0 C--O 1.246 0.898 0 CA-C-O 118.091 -0.956 . . . . 72.340000000000003 110.444 -178.615 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 24.6 mmt . . . . . 0 N--CA 1.483 1.178 0 N-CA-C 109.618 -0.512 . . . . 75.120000000000005 109.618 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -152.43 31.31 0.53 Allowed 'General case' 0 C--N 1.323 -0.554 0 CA-C-O 121.122 0.486 . . . . 63.340000000000003 111.164 -170.457 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 35.1 tt0 -88.35 116.29 26.46 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 115.832 -0.622 . . . . 74.439999999999998 110.237 177.58 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -126.91 -174.33 13.77 Favored Glycine 0 N--CA 1.449 -0.472 0 N-CA-C 110.99 -0.844 . . . . 71.040000000000006 110.99 177.727 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' THR . . . . . 0.526 ' O ' ' HG2' ' A' ' 19' ' ' GLU . 10.1 m -130.09 132.19 46.05 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-N 117.3 0.55 . . . . 71.219999999999999 110.682 179.515 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 60.3 t -76.22 119.83 25.08 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.446 0 CA-C-N 116.495 -0.321 . . . . 73.530000000000001 110.169 -179.286 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . 0.955 ' HA ' ' HE3' ' A' ' 7' ' ' LYS . 0.0 OUTLIER -92.97 -68.22 0.81 Allowed 'General case' 0 C--N 1.325 -0.467 0 CA-C-O 120.92 0.391 . . . . 74.25 110.797 179.113 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' TRP . . . . . . . . . . . . . 63.7 m95 -112.79 126.53 55.53 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 116.078 -0.51 . . . . 75.140000000000001 109.73 -177.917 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 54.1 t80 -125.07 91.14 3.37 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-O 121.201 0.525 . . . . 72.329999999999998 110.542 -176.807 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 18.2 m120 -87.47 78.36 8.64 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-O 121.426 0.631 . . . . 63.409999999999997 109.815 -179.945 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -63.71 -32.57 74.1 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 115.136 -0.938 . . . . 63.310000000000002 110.833 -179.292 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 42.9 mt-10 -76.89 -8.86 58.14 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.112 -0.494 . . . . 64.019999999999996 111.026 179.426 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . 0.401 ' HB3' ' CE2' ' A' ' 15' ' ' PHE . 75.5 mmtt -107.75 -26.06 10.98 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 120.938 0.399 . . . . 73.209999999999994 110.28 178.948 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 96.61 20.69 23.83 Favored Glycine 0 N--CA 1.449 -0.482 0 C-N-CA 120.942 -0.647 . . . . 71.450000000000003 113.017 175.779 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . 0.401 ' CE2' ' HB3' ' A' ' 13' ' ' LYS . 31.5 p90 -155.09 167.11 31.45 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-O 120.982 0.42 . . . . 74.430000000000007 111.262 179.104 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -157.84 168.49 34.44 Favored Glycine 0 N--CA 1.445 -0.719 0 CA-C-N 115.819 -0.628 . . . . 74.230000000000004 112.021 180.0 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 91.4 m-85 -121.13 118.6 30.11 Favored 'General case' 0 C--N 1.321 -0.63 0 CA-C-O 120.885 0.374 . . . . 74.230000000000004 110.543 -178.459 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 55.2 mt -104.16 124.51 58.65 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 N-CA-C 109.601 -0.518 . . . . 74.150000000000006 109.601 177.711 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' GLU . . . . . 0.526 ' HG2' ' O ' ' A' ' 5' ' ' THR . 14.6 pt-20 -82.8 130.29 35.11 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-O 121.436 0.636 . . . . 73.510000000000005 111.525 -173.12 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' ARG . . . . . 0.407 ' HB3' ' HB3' ' A' ' 24' ' ' ASP . 16.2 ttp180 -113.15 158.82 19.93 Favored 'General case' 0 C--N 1.324 -0.532 0 N-CA-C 108.839 -0.801 . . . . 74.019999999999996 108.839 175.03 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 5.6 mm-40 -49.36 -36.43 21.57 Favored 'General case' 0 N--CA 1.472 0.657 0 N-CA-C 113.961 1.097 . . . . 65.430000000000007 113.961 -168.951 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 61.7 t30 -84.16 12.49 6.4 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 121.189 0.519 . . . . 73.400000000000006 111.321 -175.667 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 76.39 10.2 85.66 Favored Glycine 0 N--CA 1.454 -0.103 0 N-CA-C 110.508 -1.037 . . . . 73.239999999999995 110.508 -173.185 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . 0.407 ' HB3' ' HB3' ' A' ' 20' ' ' ARG . 17.7 t70 -76.75 90.12 3.42 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-N 114.417 -0.892 . . . . 61.229999999999997 109.894 -177.714 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 12.1 p-10 -70.59 114.16 8.41 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-O 121.592 0.71 . . . . 75.430000000000007 110.734 178.845 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 23.8 t -84.53 122.55 38.15 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.683 0 CA-C-N 115.185 -0.916 . . . . 74.420000000000002 109.839 179.721 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' PHE . . . . . . . . . . . . . 70.8 t80 -85.36 109.31 18.31 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 115.855 -0.611 . . . . 74.519999999999996 110.831 -174.997 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.47 ' HB ' ' HB2' ' A' ' 60' ' ' ALA . 11.3 p -96.06 147.14 6.28 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.596 0 N-CA-C 109.867 -0.42 . . . . 54.509999999999998 109.867 178.256 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' HIS . . . . . 0.489 ' O ' HG13 ' A' ' 33' ' ' ILE . 5.7 p80 -128.02 153.53 46.66 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 120.741 0.305 . . . . 72.129999999999995 110.902 -176.911 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 48.0 p90 -57.26 -29.34 63.75 Favored 'General case' 0 N--CA 1.468 0.447 0 N-CA-C 113.489 0.922 . . . . 75.430000000000007 113.489 -170.192 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 21.9 m -76.64 -1.2 26.5 Favored 'General case' 0 C--N 1.326 -0.45 0 C-N-CA 120.93 -0.308 . . . . 72.099999999999994 111.245 -179.998 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . 0.549 ' HB2' ' HA ' ' A' ' 61' ' ' ALA . . . -125.02 -11.36 7.09 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.874 0.369 . . . . 73.010000000000005 110.919 177.631 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.489 HG13 ' O ' ' A' ' 29' ' ' HIS . 85.9 mt -77.49 137.93 21.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.114 -0.494 . . . . 74.120000000000005 110.837 178.372 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 34' ' ' GLN . . . . . 0.4 ' HG3' ' O ' ' A' ' 34' ' ' GLN . 7.6 pt20 -69.27 110.56 4.68 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.974 0.416 . . . . 65.450000000000003 109.947 173.527 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -148.25 54.61 0.51 Allowed Glycine 0 N--CA 1.448 -0.516 0 C-N-CA 120.303 -0.951 . . . . 73.109999999999999 112.915 -177.889 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . 0.714 ' HB2' ' HD3' ' A' ' 39' ' ' LYS . 5.4 m-20 -76.7 71.72 3.3 Favored 'General case' 0 C--N 1.329 -0.288 0 N-CA-C 109.718 -0.475 . . . . 74.430000000000007 109.718 177.096 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 75.58 -77.22 1.26 Allowed Glycine 0 N--CA 1.445 -0.706 0 C-N-CA 120.787 -0.721 . . . . 73.540000000000006 112.309 -178.935 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 41.4 p90 -105.61 17.4 23.87 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 120.928 0.394 . . . . 64.5 112.036 -174.343 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 39' ' ' LYS . . . . . 0.714 ' HD3' ' HB2' ' A' ' 36' ' ' ASP . 1.9 mptm? -94.17 134.55 36.5 Favored 'General case' 0 C--N 1.321 -0.631 0 N-CA-C 109.616 -0.513 . . . . 73.109999999999999 109.616 174.882 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 14.7 p -159.8 170.18 22.03 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-O 120.925 0.393 . . . . 72.340000000000003 110.71 -179.159 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 3.7 mm? -110.43 158.17 18.78 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 116.101 -0.499 . . . . 72.209999999999994 109.851 177.202 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 28.3 t70 -118.3 137.77 52.84 Favored 'General case' 0 C--N 1.321 -0.636 0 N-CA-C 109.634 -0.506 . . . . 75.409999999999997 109.634 -177.562 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 8.5 pt-20 -71.14 116.99 12.08 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-O 121.523 0.677 . . . . 63.5 110.072 179.73 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 105.54 6.2 38.6 Favored Glycine 0 N--CA 1.445 -0.723 0 CA-C-N 115.69 -0.687 . . . . 70.129999999999995 111.463 -174.002 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 62.2 tp60 -92.11 132.09 36.86 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 120.743 0.306 . . . . 71.299999999999997 110.877 179.05 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -78.66 132.14 36.94 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 116.01 -0.541 . . . . 72.409999999999997 109.561 173.504 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 25.5 m -137.81 153.66 28.0 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.634 0 CA-C-N 116.064 -0.516 . . . . 74.129999999999995 111.699 -177.191 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 9.4 p -113.1 111.79 22.74 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-N 115.872 -0.604 . . . . 72.329999999999998 109.78 174.754 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 49' ' ' PHE . . . . . 0.405 ' HA ' ' O ' ' A' ' 62' ' ' ASN . 39.5 p90 -120.81 161.93 20.65 Favored 'General case' 0 C--N 1.319 -0.729 0 CA-C-N 115.959 -0.564 . . . . 73.200000000000003 110.569 -172.551 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 33.1 t70 -93.15 118.0 30.72 Favored 'General case' 0 C--N 1.32 -0.711 0 N-CA-C 109.491 -0.559 . . . . 71.329999999999998 109.491 173.978 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 5.1 p -78.23 109.13 12.54 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.65 0 CA-C-O 121.67 0.748 . . . . 73.409999999999997 111.06 -176.539 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 9.7 tp10 -92.75 119.88 32.57 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-N 115.375 -0.83 . . . . 62.210000000000001 108.886 175.583 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 12.9 pt-20 -107.15 124.89 50.36 Favored 'General case' 0 C--N 1.317 -0.821 0 CA-C-O 120.897 0.38 . . . . 63.439999999999998 110.227 -179.923 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -146.78 -142.25 3.69 Favored Glycine 0 N--CA 1.448 -0.525 0 C-N-CA 120.615 -0.802 . . . . 71.540000000000006 112.281 -179.751 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 16.4 mm100 -77.64 -26.36 50.42 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-O 120.982 0.42 . . . . 74.299999999999997 110.451 -178.465 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 24.4 mmm180 -87.35 4.51 42.68 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 116.082 -0.508 . . . . 74.5 110.351 -179.445 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 89.36 -138.39 14.64 Favored Glycine 0 N--CA 1.446 -0.646 0 C-N-CA 120.928 -0.653 . . . . 64.549999999999997 111.618 -178.361 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 89.2 Cg_endo -84.73 104.86 0.96 Allowed 'Trans proline' 0 N--CA 1.455 -0.749 0 C-N-CA 122.701 2.267 . . . . 64.219999999999999 112.329 177.455 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 12.3 pt20 -112.52 135.62 53.01 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-O 121.144 0.497 . . . . 72.5 110.017 177.551 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . 0.47 ' HB2' ' HB ' ' A' ' 28' ' ' VAL . . . -86.34 128.12 34.89 Favored 'General case' 0 C--N 1.319 -0.758 0 CA-C-O 121.149 0.499 . . . . 55.310000000000002 111.708 -172.743 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . 0.549 ' HA ' ' HB2' ' A' ' 32' ' ' ALA . . . -130.21 143.63 50.89 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 115.436 -0.802 . . . . 74.120000000000005 109.282 174.016 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 62' ' ' ASN . . . . . 0.405 ' O ' ' HA ' ' A' ' 49' ' ' PHE . 45.0 m-80 59.45 87.23 0.08 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 121.244 0.545 . . . . 71.450000000000003 110.391 -176.965 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 47.8 t -105.39 111.14 33.49 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.591 0 CA-C-N 115.721 -0.672 . . . . 74.040000000000006 110.273 -176.883 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 24.6 mt-30 -107.93 142.53 37.9 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-N 116.149 -0.478 . . . . 74.319999999999993 109.944 -179.73 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 46.0 mttp -77.48 144.22 37.9 Favored 'General case' 0 C--N 1.325 -0.492 0 C-N-CA 120.868 -0.333 . . . . 73.400000000000006 110.422 179.567 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.247 0.958 0 CA-C-O 118.781 -0.628 . . . . 52.310000000000002 110.413 178.077 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 54.2 tpp . . . . . 0 N--CA 1.483 1.19 0 CA-C-O 120.707 0.289 . . . . 72.310000000000002 111.025 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . 0.635 ' HG2' HG22 ' A' ' 51' ' ' VAL . 4.8 mp0 -85.6 101.07 12.39 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 121.125 0.488 . . . . 73.400000000000006 111.318 -178.178 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' GLN . . . . . 0.642 ' HG2' HG22 ' A' ' 48' ' ' THR . 79.7 mt-30 -97.49 122.95 41.13 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.732 -0.667 . . . . 74.310000000000002 109.638 172.209 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -138.14 178.31 19.33 Favored Glycine 0 N--CA 1.445 -0.721 0 N-CA-C 111.136 -0.786 . . . . 70.430000000000007 111.136 179.178 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' THR . . . . . 0.402 ' O ' ' HG2' ' A' ' 19' ' ' GLU . 13.1 m -125.11 130.54 52.42 Favored 'General case' 0 C--N 1.315 -0.919 0 CA-C-N 117.28 0.54 . . . . 75.209999999999994 110.512 178.088 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 61.3 t -72.58 108.57 4.06 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.472 0 CA-C-N 116.376 -0.375 . . . . 71.310000000000002 110.01 178.813 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . 0.438 ' HB3' ' CE3' ' A' ' 8' ' ' TRP . 6.5 mmtm -73.62 -48.48 32.23 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 116.26 -0.427 . . . . 75.530000000000001 110.208 177.622 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' TRP . . . . . 0.521 ' HE1' ' HD2' ' A' ' 17' ' ' PHE . 15.6 p90 -164.14 158.92 19.76 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.661 -0.7 . . . . 75.310000000000002 110.075 177.763 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . 0.407 ' HD1' ' HA3' ' A' ' 16' ' ' GLY . 71.4 t80 -134.33 106.48 7.12 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 116.264 -0.426 . . . . 75.109999999999999 110.12 178.622 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 87.8 m-20 -76.71 85.09 3.34 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 116.048 -0.524 . . . . 72.219999999999999 109.821 179.791 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -62.39 -38.11 88.36 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 115.519 -0.764 . . . . 70.040000000000006 111.492 -177.234 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 42.0 mt-10 -72.55 -14.41 61.63 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 116.253 -0.43 . . . . 74.329999999999998 111.056 -179.571 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 32.2 mmmt -101.21 -26.32 13.69 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.88 0.372 . . . . 72.349999999999994 110.225 177.922 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 100.15 7.3 52.61 Favored Glycine 0 N--CA 1.45 -0.427 0 C-N-CA 120.83 -0.7 . . . . 63.229999999999997 113.253 175.423 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 41.0 p90 -151.16 154.96 37.91 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-O 121.125 0.488 . . . . 75.329999999999998 111.602 -176.077 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.407 ' HA3' ' HD1' ' A' ' 9' ' ' PHE . . . -135.95 178.45 18.71 Favored Glycine 0 N--CA 1.444 -0.803 0 N-CA-C 111.055 -0.818 . . . . 71.549999999999997 111.055 178.65 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . 0.521 ' HD2' ' HE1' ' A' ' 8' ' ' TRP . 79.9 m-85 -131.28 123.23 27.92 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-O 121.197 0.522 . . . . 74.420000000000002 111.243 -177.975 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 64.5 mt -106.43 126.48 62.15 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 CA-C-N 115.482 -0.781 . . . . 74.239999999999995 109.144 176.803 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' GLU . . . . . 0.402 ' HG2' ' O ' ' A' ' 5' ' ' THR . 17.2 pt-20 -79.53 139.36 37.58 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-O 121.327 0.584 . . . . 75.310000000000002 112.299 -173.464 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' ARG . . . . . . . . . . . . . 10.0 tpt180 -109.83 166.61 10.79 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.082 -0.963 . . . . 72.319999999999993 108.94 174.846 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 2.3 mp0 -43.95 -48.68 8.62 Favored 'General case' 0 N--CA 1.472 0.635 0 N-CA-C 112.397 0.518 . . . . 75.099999999999994 112.397 179.409 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 74.6 m-20 -71.41 -7.08 44.97 Favored 'General case' 0 N--CA 1.468 0.429 0 CA-C-N 116.295 -0.411 . . . . 74.340000000000003 112.025 -174.9 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 90.01 7.63 67.94 Favored Glycine 0 N--CA 1.45 -0.387 0 N-CA-C 110.084 -1.206 . . . . 75.409999999999997 110.084 -170.145 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 13.0 t70 -70.28 93.2 0.83 Allowed 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 114.486 -0.857 . . . . 73.0 109.953 -179.262 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 13.4 p-10 -65.76 101.92 0.69 Allowed 'General case' 0 C--N 1.321 -0.644 0 CA-C-N 115.549 -0.75 . . . . 75.219999999999999 110.65 176.848 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 40.0 t -71.01 130.41 34.95 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.587 0 CA-C-N 115.444 -0.798 . . . . 74.430000000000007 110.547 -178.487 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' PHE . . . . . . . . . . . . . 63.1 t80 -79.39 108.64 13.07 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 116.079 -0.51 . . . . 72.519999999999996 110.147 -178.294 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 9.3 p -111.16 141.5 26.33 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.598 0 N-CA-C 110.061 -0.348 . . . . 65.150000000000006 110.061 179.242 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' HIS . . . . . 0.548 ' O ' HG13 ' A' ' 33' ' ' ILE . 6.0 p80 -128.94 145.75 51.15 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.795 0.331 . . . . 74.129999999999995 110.863 -177.03 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 37.5 p90 -58.82 -27.69 65.31 Favored 'General case' 0 N--CA 1.467 0.421 0 CA-C-N 115.679 -0.691 . . . . 74.0 112.294 -171.227 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 1.5 p -79.03 6.64 8.91 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-O 120.744 0.307 . . . . 74.230000000000004 111.707 -179.331 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -129.25 -14.74 4.26 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 121.002 0.429 . . . . 72.209999999999994 110.879 175.287 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.762 HD12 HD22 ' A' ' 41' ' ' LEU . 24.9 mt -80.45 161.68 3.86 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.164 -0.471 . . . . 65.519999999999996 110.089 176.263 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 34' ' ' GLN . . . . . 0.673 ' NE2' ' HA ' ' A' ' 64' ' ' GLN . 26.5 pt20 -87.14 -173.75 4.57 Favored 'General case' 0 C--N 1.327 -0.383 0 N-CA-C 110.107 -0.331 . . . . 64.450000000000003 110.107 177.485 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -143.29 62.61 0.5 Allowed Glycine 0 N--CA 1.449 -0.471 0 C-N-CA 120.72 -0.752 . . . . 62.140000000000001 112.276 178.086 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 13.9 p-10 -94.98 118.01 31.1 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-O 121.434 0.635 . . . . 75.129999999999995 110.445 -179.55 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 81.75 -61.42 4.65 Favored Glycine 0 N--CA 1.45 -0.367 0 N-CA-C 111.41 -0.676 . . . . 43.439999999999998 111.41 -175.054 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 65.5 m-85 -137.58 165.93 25.13 Favored 'General case' 0 C--N 1.325 -0.481 0 N-CA-C 109.292 -0.633 . . . . 71.140000000000001 109.292 175.618 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -99.84 28.54 4.7 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-O 121.71 0.767 . . . . 71.420000000000002 109.613 176.048 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 37.4 m -132.74 151.2 52.04 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 115.168 -0.924 . . . . 64.409999999999997 109.676 178.123 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . 0.762 HD22 HD12 ' A' ' 33' ' ' ILE . 3.5 mm? -91.22 148.01 22.65 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 116.346 -0.388 . . . . 72.299999999999997 110.758 -176.708 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 4.8 m-20 -91.61 113.35 25.6 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 115.797 -0.638 . . . . 63.350000000000001 109.293 175.452 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 4.5 mp0 -62.97 129.82 42.06 Favored 'General case' 0 C--N 1.321 -0.669 0 CA-C-N 116.061 -0.518 . . . . 62.229999999999997 110.422 -179.305 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 97.89 -7.88 63.09 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 121.042 -0.599 . . . . 63.140000000000001 112.102 -178.263 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 29.6 tp60 -84.15 123.85 30.52 Favored 'General case' 0 C--N 1.324 -0.523 0 N-CA-C 110.173 -0.306 . . . . 63.049999999999997 110.173 179.83 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -68.1 135.28 51.94 Favored 'General case' 0 C--N 1.328 -0.345 0 N-CA-C 109.403 -0.592 . . . . 75.200000000000003 109.403 172.623 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . 0.511 HG13 ' HA ' ' A' ' 65' ' ' LYS . 21.1 m -134.24 154.05 36.9 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.771 0 CA-C-O 121.214 0.53 . . . . 75.319999999999993 111.501 -175.704 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 48' ' ' THR . . . . . 0.642 HG22 ' HG2' ' A' ' 3' ' ' GLN . 33.0 p -113.72 117.13 30.66 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 115.503 -0.771 . . . . 73.430000000000007 109.433 174.68 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 49' ' ' PHE . . . . . 0.409 ' HA ' ' O ' ' A' ' 62' ' ' ASN . 40.8 p90 -129.76 170.37 13.93 Favored 'General case' 0 C--N 1.316 -0.872 0 CA-C-N 115.966 -0.561 . . . . 72.310000000000002 110.913 -173.148 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 38.8 t70 -112.01 143.87 42.3 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-N 115.864 -0.607 . . . . 63.340000000000003 109.813 174.306 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . 0.635 HG22 ' HG2' ' A' ' 2' ' ' GLU . 84.7 t -94.88 121.52 45.54 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.553 0 CA-C-O 121.165 0.507 . . . . 73.319999999999993 110.875 -178.528 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . 0.545 ' HB3' ' HG3' ' A' ' 59' ' ' GLN . 0.0 OUTLIER -94.24 141.97 27.94 Favored 'General case' 0 C--N 1.321 -0.648 0 N-CA-C 108.849 -0.797 . . . . 74.239999999999995 108.849 174.288 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 4.9 pt-20 -111.93 106.37 15.05 Favored 'General case' 0 C--N 1.316 -0.855 0 CA-C-O 121.287 0.565 . . . . 73.099999999999994 111.0 -174.557 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -126.76 -169.58 12.76 Favored Glycine 0 N--CA 1.448 -0.538 0 C-N-CA 120.852 -0.69 . . . . 63.340000000000003 112.019 -179.403 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 44.7 mt-30 -76.77 -3.1 36.48 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.952 0.406 . . . . 63.439999999999998 111.109 -178.095 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 56' ' ' ARG . . . . . 0.407 HH11 ' HD2' ' A' ' 56' ' ' ARG . 17.7 mmm180 -100.24 3.82 43.83 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-O 120.95 0.405 . . . . 74.230000000000004 110.496 176.416 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 94.28 -142.43 16.02 Favored Glycine 0 N--CA 1.446 -0.644 0 C-N-CA 120.843 -0.694 . . . . 45.130000000000003 111.872 -178.364 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 74.3 Cg_endo -79.97 106.93 2.0 Favored 'Trans proline' 0 N--CA 1.458 -0.597 0 C-N-CA 122.76 2.306 . . . . 75.019999999999996 112.703 -179.309 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . 0.545 ' HG3' ' HB3' ' A' ' 52' ' ' GLU . 4.1 pt20 -111.7 126.43 55.03 Favored 'General case' 0 C--N 1.322 -0.627 0 CA-C-N 115.778 -0.646 . . . . 75.0 109.655 177.701 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -80.05 130.47 35.28 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-O 121.024 0.44 . . . . 71.430000000000007 111.464 -174.871 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -135.13 145.35 47.75 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 115.452 -0.795 . . . . 53.25 109.321 177.717 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 62' ' ' ASN . . . . . 0.409 ' O ' ' HA ' ' A' ' 49' ' ' PHE . 89.2 m-20 59.59 82.99 0.14 Allowed 'General case' 0 C--N 1.327 -0.398 0 CA-C-O 121.164 0.507 . . . . 75.530000000000001 110.225 -176.621 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 39.2 t -113.06 106.35 20.57 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.511 0 CA-C-N 115.545 -0.752 . . . . 70.120000000000005 110.394 -177.061 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 64' ' ' GLN . . . . . 0.673 ' HA ' ' NE2' ' A' ' 34' ' ' GLN . 53.4 mt-30 -99.73 145.32 27.79 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 116.401 -0.363 . . . . 75.430000000000007 110.395 -179.349 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . 0.511 ' HA ' HG13 ' A' ' 47' ' ' VAL . 28.4 mtmm -82.61 136.4 34.81 Favored 'General case' 0 C--N 1.324 -0.54 0 N-CA-C 110.076 -0.342 . . . . 75.019999999999996 110.076 -179.864 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.247 0.941 0 CA-C-O 118.843 -0.599 . . . . 53.030000000000001 110.485 -179.108 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' MET . . . . . 0.514 ' H3 ' ' HA ' ' A' ' 50' ' ' ASP . 92.9 mtp . . . . . 0 N--CA 1.483 1.194 0 CA-C-O 120.54 0.209 . . . . 73.530000000000001 111.046 . . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 2.2 mp0 -96.52 178.74 5.24 Favored 'General case' 0 C--O 1.237 0.447 0 CA-C-O 121.215 0.531 . . . . 72.219999999999999 111.676 -172.608 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' GLN . . . . . 0.449 ' HG2' HG22 ' A' ' 48' ' ' THR . 65.8 mt-30 -91.95 143.6 26.32 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.341 -0.845 . . . . 70.439999999999998 110.248 179.612 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . 0.69 ' HA3' ' HE2' ' A' ' 49' ' ' PHE . . . -159.26 150.86 21.58 Favored Glycine 0 N--CA 1.447 -0.626 0 C-N-CA 120.932 -0.652 . . . . 73.230000000000004 111.917 178.252 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' THR . . . . . 0.525 ' HA ' ' HA ' ' A' ' 46' ' ' ALA . 3.5 m -98.02 133.47 42.44 Favored 'General case' 0 C--N 1.32 -0.703 0 CA-C-O 120.563 0.22 . . . . 73.129999999999995 110.438 -179.029 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 51.2 t -68.16 103.62 0.71 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 N-CA-C 109.541 -0.54 . . . . 73.420000000000002 109.541 175.068 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . 0.762 ' HD3' ' HB3' ' A' ' 19' ' ' GLU . 31.0 mmmt -61.56 -60.7 3.3 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 121.342 0.591 . . . . 73.200000000000003 110.543 -176.706 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' TRP . . . . . . . . . . . . . 28.7 p90 -156.42 136.47 12.77 Favored 'General case' 0 C--N 1.319 -0.726 0 CA-C-N 115.349 -0.841 . . . . 74.230000000000004 109.533 176.695 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . 0.485 ' HA ' ' HA3' ' A' ' 16' ' ' GLY . 70.7 t80 -132.41 113.13 12.79 Favored 'General case' 0 C--N 1.317 -0.807 0 CA-C-O 121.09 0.471 . . . . 75.450000000000003 110.287 -177.033 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 2.6 m-20 -78.0 80.26 4.44 Favored 'General case' 0 C--N 1.322 -0.624 0 N-CA-C 108.892 -0.781 . . . . 74.319999999999993 108.892 176.014 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -60.53 -33.26 72.39 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 121.079 0.466 . . . . 73.409999999999997 110.918 -178.386 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . 0.433 ' HG3' ' HG2' ' A' ' 13' ' ' LYS . 6.8 pt-20 -67.71 -25.12 65.5 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 115.462 -0.79 . . . . 72.219999999999999 111.555 -179.824 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . 0.433 ' HG2' ' HG3' ' A' ' 12' ' ' GLU . 47.5 mmtm -110.06 -15.4 14.04 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-O 120.845 0.355 . . . . 75.5 111.222 -176.881 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 94.06 20.37 30.88 Favored Glycine 0 N--CA 1.449 -0.456 0 C-N-CA 120.995 -0.621 . . . . 73.310000000000002 114.148 170.237 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 43.2 p90 -153.62 156.44 37.94 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 117.67 0.735 . . . . 74.400000000000006 111.384 -179.321 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.485 ' HA3' ' HA ' ' A' ' 9' ' ' PHE . . . -167.73 -169.75 31.65 Favored Glycine 0 N--CA 1.45 -0.398 0 N-CA-C 111.883 -0.487 . . . . 52.119999999999997 111.883 178.389 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 88.1 m-85 -133.09 139.29 47.05 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 121.122 0.487 . . . . 60.240000000000002 111.309 -179.068 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 56.9 mt -119.93 145.33 26.36 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.547 0 N-CA-C 108.908 -0.775 . . . . 73.129999999999995 108.908 176.697 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' GLU . . . . . 0.762 ' HB3' ' HD3' ' A' ' 7' ' ' LYS . 20.9 pt-20 -89.37 158.22 17.86 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-O 121.15 0.5 . . . . 65.049999999999997 111.045 -177.123 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' ARG . . . . . 0.59 ' HD3' ' HB3' ' A' ' 24' ' ' ASP . 70.4 ttt180 -134.15 158.72 42.94 Favored 'General case' 0 C--N 1.32 -0.674 0 N-CA-C 108.523 -0.918 . . . . 75.129999999999995 108.523 179.146 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 44.1 mt-10 -48.2 -50.92 27.41 Favored 'General case' 0 N--CA 1.466 0.336 0 N-CA-C 113.229 0.825 . . . . 74.310000000000002 113.229 -172.316 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 57.8 m-80 -87.5 20.58 2.84 Favored 'General case' 0 C--N 1.327 -0.405 0 N-CA-C 111.878 0.325 . . . . 60.240000000000002 111.878 -173.964 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 76.16 10.55 85.32 Favored Glycine 0 C--N 1.33 0.234 0 C-N-CA 120.605 -0.807 . . . . 70.030000000000001 111.731 -178.897 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . 0.59 ' HB3' ' HD3' ' A' ' 20' ' ' ARG . 38.5 t70 -76.95 84.06 3.49 Favored 'General case' 0 C--N 1.322 -0.622 0 N-CA-C 109.772 -0.455 . . . . 75.239999999999995 109.772 -179.571 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 8.1 p-10 -58.62 127.56 32.76 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 121.361 0.6 . . . . 64.019999999999996 111.123 -176.467 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.523 ' HA ' ' HB2' ' A' ' 58' ' ' PRO . 17.1 t -105.64 124.37 60.62 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.615 0 CA-C-N 115.424 -0.807 . . . . 64.239999999999995 110.216 -176.453 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' PHE . . . . . . . . . . . . . 91.9 t80 -82.57 131.21 35.22 Favored 'General case' 0 C--N 1.326 -0.453 0 N-CA-C 110.063 -0.347 . . . . 73.230000000000004 110.063 179.944 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 9.8 p -123.3 137.41 56.72 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-O 121.278 0.561 . . . . 72.310000000000002 111.006 -179.481 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 22.0 t60 -115.02 151.77 33.62 Favored 'General case' 0 C--N 1.324 -0.504 0 N-CA-C 108.142 -1.059 . . . . 65.439999999999998 108.142 176.844 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 17.3 p90 -60.2 -20.15 57.43 Favored 'General case' 0 N--CA 1.472 0.661 0 N-CA-C 112.555 0.576 . . . . 74.409999999999997 112.555 -172.052 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 23.1 t -90.14 -9.06 49.68 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 120.892 0.377 . . . . 62.439999999999998 110.633 -179.166 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -103.99 -25.46 13.0 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 121.075 0.464 . . . . 75.209999999999994 110.747 -179.129 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.654 HD11 HD21 ' A' ' 41' ' ' LEU . 15.4 tt -77.55 163.75 3.71 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.55 0 N-CA-C 108.863 -0.792 . . . . 72.010000000000005 108.863 175.726 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 34' ' ' GLN . . . . . 0.515 ' HG2' ' O ' ' A' ' 34' ' ' GLN . 18.8 pm0 -76.55 66.82 2.61 Favored 'General case' 0 CA--C 1.533 0.321 0 CA-C-O 121.774 0.797 . . . . 75.299999999999997 111.646 -176.121 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -78.46 66.23 3.28 Favored Glycine 0 N--CA 1.448 -0.512 0 N-CA-C 110.906 -0.878 . . . . 74.299999999999997 110.906 174.769 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . 0.733 ' HB3' ' HD3' ' A' ' 39' ' ' LYS . 14.1 t70 -74.37 83.81 1.94 Allowed 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 120.991 0.424 . . . . 74.400000000000006 110.459 -177.379 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 75.85 -72.48 1.8 Allowed Glycine 0 N--CA 1.45 -0.4 0 N-CA-C 111.459 -0.656 . . . . 71.310000000000002 111.459 -176.958 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 72.7 m-85 -146.31 83.05 1.61 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.925 0.393 . . . . 73.310000000000002 110.15 176.93 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 39' ' ' LYS . . . . . 0.733 ' HD3' ' HB3' ' A' ' 36' ' ' ASP . 10.6 mptt -132.65 105.58 7.28 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 116.157 -0.474 . . . . 64.400000000000006 110.567 176.468 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 22.0 p -105.37 122.62 46.35 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-O 121.062 0.458 . . . . 61.409999999999997 110.229 175.705 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . 0.654 HD21 HD11 ' A' ' 33' ' ' ILE . 10.7 mp -83.28 126.06 32.26 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 116.158 -0.474 . . . . 74.319999999999993 110.241 178.786 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 28.5 t70 -75.51 139.58 42.26 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-N 115.595 -0.73 . . . . 75.030000000000001 110.616 -177.342 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 3.0 mp0 -61.22 105.72 0.53 Allowed 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.96 0.41 . . . . 71.349999999999994 110.317 178.142 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 126.49 -10.25 7.24 Favored Glycine 0 N--CA 1.447 -0.587 0 CA-C-N 115.871 -0.604 . . . . 63.240000000000002 111.731 -175.049 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 7.1 tt0 -77.37 127.49 32.65 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.846 0.355 . . . . 74.319999999999993 110.63 178.061 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 0.525 ' HA ' ' HA ' ' A' ' 5' ' ' THR . . . -92.39 130.43 38.07 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 116.201 -0.454 . . . . 74.310000000000002 110.371 177.747 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . 0.423 HG13 ' HA ' ' A' ' 65' ' ' LYS . 15.5 m -137.37 174.39 11.57 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 CA-C-O 120.949 0.405 . . . . 73.329999999999998 111.316 -177.058 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 48' ' ' THR . . . . . 0.449 HG22 ' HG2' ' A' ' 3' ' ' GLN . 23.5 p -111.69 114.06 26.84 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 115.836 -0.62 . . . . 74.340000000000003 109.67 176.425 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 49' ' ' PHE . . . . . 0.69 ' HE2' ' HA3' ' A' ' 4' ' ' GLY . 39.7 p90 -125.17 165.38 18.35 Favored 'General case' 0 C--N 1.317 -0.823 0 CA-C-N 116.094 -0.503 . . . . 74.049999999999997 110.302 -174.322 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . 0.514 ' HA ' ' H3 ' ' A' ' 1' ' ' MET . 22.0 t0 -108.43 151.1 26.5 Favored 'General case' 0 C--N 1.317 -0.808 0 C-N-CA 119.992 -0.683 . . . . 70.400000000000006 109.883 173.646 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 61.1 t -105.13 109.35 27.42 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.779 0 CA-C-O 121.089 0.471 . . . . 72.219999999999999 110.593 -176.332 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 44.3 tt0 -81.85 96.31 7.59 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-N 115.41 -0.813 . . . . 72.209999999999994 109.062 175.463 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 6.7 pt-20 -74.67 90.62 2.3 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-O 121.519 0.676 . . . . 72.409999999999997 109.576 176.612 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -121.49 -144.58 6.94 Favored Glycine 0 N--CA 1.444 -0.772 0 CA-C-N 115.164 -0.926 . . . . 42.210000000000001 112.282 -177.925 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 55' ' ' GLN . . . . . 0.578 ' O ' ' HG2' ' A' ' 56' ' ' ARG . 6.6 tp-100 -80.86 82.29 6.89 Favored 'General case' 0 C--N 1.323 -0.552 0 N-CA-C 111.59 0.218 . . . . 74.25 111.59 -175.418 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 56' ' ' ARG . . . . . 0.578 ' HG2' ' O ' ' A' ' 55' ' ' GLN . 2.3 mmm180 156.73 -36.35 0.01 OUTLIER 'General case' 0 N--CA 1.478 0.974 0 C-N-CA 125.881 1.672 . . . . 74.049999999999997 108.498 173.109 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . 0.438 ' HA3' ' HD3' ' A' ' 58' ' ' PRO . . . 138.09 -120.05 1.93 Allowed Glycine 0 N--CA 1.445 -0.746 0 CA-C-N 115.186 -0.916 . . . . 73.010000000000005 111.712 -178.581 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . 0.523 ' HB2' ' HA ' ' A' ' 26' ' ' VAL . 2.9 Cg_endo -80.96 100.35 1.19 Allowed 'Trans proline' 0 N--CA 1.458 -0.574 0 C-N-CA 123.179 2.586 . . . . 65.219999999999999 112.721 -178.405 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 22.1 mt-30 -104.76 126.3 51.7 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 115.93 -0.577 . . . . 70.030000000000001 109.631 176.016 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -74.77 115.48 14.4 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-O 120.626 0.25 . . . . 72.219999999999999 110.784 -177.536 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -136.36 142.12 43.77 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 116.195 -0.457 . . . . 73.140000000000001 110.058 178.754 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 42.1 m-80 58.48 85.48 0.09 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 121.38 0.609 . . . . 64.329999999999998 110.492 -179.61 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.536 HG13 ' HB3' ' A' ' 49' ' ' PHE . 17.8 t -112.23 131.68 63.02 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.612 0 CA-C-N 115.737 -0.665 . . . . 73.319999999999993 110.284 -176.999 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 6.5 tp-100 -128.4 147.11 50.63 Favored 'General case' 0 C--N 1.32 -0.677 0 N-CA-C 109.896 -0.409 . . . . 73.450000000000003 109.896 179.063 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . 0.423 ' HA ' HG13 ' A' ' 47' ' ' VAL . 60.2 mttm -65.06 144.99 56.9 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-O 120.671 0.272 . . . . 64.340000000000003 110.359 177.533 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.039 0 CA-C-O 118.723 -0.656 . . . . 65.430000000000007 110.785 -179.06 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 66.5 mtt . . . . . 0 N--CA 1.477 0.898 0 CA-C-O 121.188 0.518 . . . . 73.230000000000004 109.789 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 1.3 pm0 -110.59 18.14 20.01 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 115.569 -0.742 . . . . 73.530000000000001 111.808 -172.622 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 7.5 tt0 -87.84 116.68 26.16 Favored 'General case' 0 C--N 1.321 -0.652 0 N-CA-C 109.471 -0.566 . . . . 74.209999999999994 109.471 174.657 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -132.39 153.8 20.76 Favored Glycine 0 N--CA 1.445 -0.749 0 C-N-CA 120.314 -0.946 . . . . 63.140000000000001 112.367 -177.768 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' THR . . . . . 0.49 ' O ' ' HG3' ' A' ' 19' ' ' GLU . 2.8 m -98.49 129.69 45.08 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-O 120.72 0.295 . . . . 73.219999999999999 110.273 178.933 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.428 HG22 HG12 ' A' ' 18' ' ' ILE . 61.7 t -79.75 118.4 27.22 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.606 0 O-C-N 122.357 -0.215 . . . . 62.310000000000002 110.462 178.815 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . 0.802 ' HZ2' ' HB3' ' A' ' 19' ' ' GLU . 49.3 mttp -74.18 -65.21 0.87 Allowed 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.926 0.393 . . . . 75.209999999999994 110.501 178.053 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' TRP . . . . . . . . . . . . . 90.6 m95 -144.87 160.86 40.61 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 115.821 -0.627 . . . . 75.430000000000007 111.211 -176.768 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 14.1 p90 -120.89 106.38 11.58 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 115.503 -0.771 . . . . 74.049999999999997 110.527 179.16 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 2.3 m-20 -84.95 77.12 10.17 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-N 115.944 -0.571 . . . . 73.019999999999996 109.805 -179.407 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . 0.51 ' HA ' ' HE2' ' A' ' 30' ' ' PHE . . . -63.63 -28.2 69.75 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.589 -0.732 . . . . 61.200000000000003 111.268 -178.804 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 65.6 mm-40 -74.87 -13.59 60.57 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 116.2 -0.455 . . . . 63.340000000000003 111.314 178.8 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . 0.496 ' HB3' ' CE2' ' A' ' 15' ' ' PHE . 31.2 mmmt -109.76 -30.09 8.02 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 116.297 -0.411 . . . . 72.420000000000002 111.053 -179.012 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 102.12 17.66 19.72 Favored Glycine 0 N--CA 1.449 -0.476 0 C-N-CA 120.632 -0.794 . . . . 63.420000000000002 112.668 177.389 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . 0.496 ' CE2' ' HB3' ' A' ' 13' ' ' LYS . 26.7 p90 -152.71 172.47 16.62 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 120.629 0.252 . . . . 74.540000000000006 110.736 -179.618 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -140.85 175.04 22.37 Favored Glycine 0 N--CA 1.446 -0.652 0 C-N-CA 121.06 -0.591 . . . . 65.109999999999999 111.77 178.887 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 97.5 m-85 -120.81 116.45 25.23 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-O 120.933 0.397 . . . . 72.340000000000003 111.171 -178.636 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.567 ' O ' ' HA ' ' A' ' 25' ' ' ASP . 36.7 mt -102.57 165.09 3.05 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.581 0 N-CA-C 107.816 -1.179 . . . . 61.219999999999999 107.816 173.202 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' GLU . . . . . 0.802 ' HB3' ' HZ2' ' A' ' 7' ' ' LYS . 0.3 OUTLIER -130.31 163.22 27.29 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-N 118.857 0.753 . . . . 71.5 111.364 179.05 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' ARG . . . . . 0.402 ' HG2' ' H ' ' A' ' 21' ' ' GLU . 15.6 ttp180 -126.17 -163.23 1.2 Allowed 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 115.573 -0.739 . . . . 71.420000000000002 109.464 -178.902 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . 0.402 ' H ' ' HG2' ' A' ' 20' ' ' ARG . 0.0 OUTLIER -64.14 -37.54 87.81 Favored 'General case' 0 C--N 1.329 -0.312 0 N-CA-C 112.277 0.473 . . . . 70.299999999999997 112.277 -172.776 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 87.6 m-20 -93.59 13.43 22.02 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-O 120.713 0.292 . . . . 71.129999999999995 111.113 -177.877 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 74.2 20.44 79.65 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.329 -0.938 . . . . 64.310000000000002 110.764 -173.558 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 14.4 t70 -72.08 93.1 1.38 Allowed 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 115.132 -0.534 . . . . 74.439999999999998 109.823 -179.017 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.567 ' HA ' ' O ' ' A' ' 18' ' ' ILE . 2.3 m-20 -60.46 121.03 11.07 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.642 -0.708 . . . . 72.019999999999996 111.594 178.58 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 36.6 t -96.69 131.48 43.38 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.62 0 CA-C-N 115.013 -0.994 . . . . 75.310000000000002 109.897 179.945 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' PHE . . . . . . . . . . . . . 47.4 t80 -83.49 98.7 9.68 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 116.144 -0.48 . . . . 70.519999999999996 110.525 -175.817 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.524 ' HB ' ' HB2' ' A' ' 60' ' ' ALA . 13.2 p -98.82 138.66 22.67 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 CA-C-O 121.069 0.461 . . . . 74.030000000000001 111.072 -177.782 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 6.9 m80 -99.29 139.19 35.31 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 116.064 -0.517 . . . . 74.010000000000005 110.112 176.81 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' PHE . . . . . 0.612 ' HD1' HD11 ' A' ' 33' ' ' ILE . 20.4 m-85 -65.74 -26.2 67.62 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.643 0.258 . . . . 75.340000000000003 110.819 179.008 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 38.3 t -72.36 -16.97 61.87 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-O 121.111 0.481 . . . . 72.120000000000005 110.48 175.805 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . 0.501 ' HB3' ' HA ' ' A' ' 61' ' ' ALA . . . -94.61 -20.01 19.96 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 121.085 0.469 . . . . 75.310000000000002 110.049 177.033 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.676 HG12 HG22 ' A' ' 63' ' ' VAL . 54.6 mt -82.02 135.32 25.2 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.465 0 CA-C-N 115.807 -0.633 . . . . 72.439999999999998 110.078 175.443 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 12.7 pt20 -70.98 89.47 0.79 Allowed 'General case' 0 C--N 1.324 -0.534 0 CA-C-O 121.259 0.552 . . . . 71.400000000000006 110.563 176.377 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.456 ' HA2' ' O ' ' A' ' 38' ' ' PHE . . . -84.07 59.95 4.89 Favored Glycine 0 N--CA 1.449 -0.465 0 C-N-CA 121.121 -0.561 . . . . 54.340000000000003 112.693 -178.492 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -65.54 -68.53 0.36 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.517 0.199 . . . . 74.310000000000002 110.968 179.119 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -108.28 -20.92 7.95 Favored Glycine 0 N--CA 1.447 -0.574 0 C-N-CA 120.763 -0.732 . . . . 72.420000000000002 111.786 176.152 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . 0.456 ' O ' ' HA2' ' A' ' 35' ' ' GLY . 95.7 m-85 -128.2 127.24 42.53 Favored 'General case' 0 C--N 1.326 -0.437 0 N-CA-C 110.25 -0.278 . . . . 75.329999999999998 110.25 -179.805 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 13.5 mptt -87.84 -0.01 56.4 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 116.274 -0.421 . . . . 75.340000000000003 111.253 -179.798 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 42.0 m -155.26 162.51 40.88 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 116.496 -0.32 . . . . 73.540000000000006 110.368 -177.465 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 3.5 mm? -107.52 162.23 14.13 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.29 -0.413 . . . . 72.209999999999994 110.136 178.568 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . 0.48 ' HB2' ' HB2' ' A' ' 45' ' ' GLN . 5.9 m-20 -69.62 157.23 37.61 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 116.017 -0.538 . . . . 73.310000000000002 111.1 179.967 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -77.18 105.74 8.46 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-O 121.521 0.677 . . . . 70.450000000000003 110.039 176.018 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 108.96 5.48 30.84 Favored Glycine 0 N--CA 1.446 -0.657 0 CA-C-N 115.678 -0.692 . . . . 55.240000000000002 111.656 -174.014 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 45' ' ' GLN . . . . . 0.48 ' HB2' ' HB2' ' A' ' 42' ' ' ASP . 8.6 tp-100 -80.78 130.68 35.2 Favored 'General case' 0 C--N 1.326 -0.424 0 N-CA-C 109.993 -0.373 . . . . 75.430000000000007 109.993 178.944 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -102.46 127.71 49.39 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-O 120.778 0.323 . . . . 74.099999999999994 110.721 179.764 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 17.5 m -136.02 172.59 15.28 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.562 0 CA-C-N 115.961 -0.563 . . . . 63.43 110.528 -179.109 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 20.4 p -116.66 115.01 24.86 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 116.177 -0.465 . . . . 75.239999999999995 110.328 179.476 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 33.1 p90 -117.42 163.36 16.49 Favored 'General case' 0 C--N 1.319 -0.752 0 CA-C-O 121.157 0.503 . . . . 73.329999999999998 111.925 -174.137 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 25.8 t70 -86.07 136.72 33.12 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 115.861 -0.609 . . . . 70.340000000000003 109.585 172.908 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 3.7 p -81.83 114.46 22.78 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.499 0 CA-C-O 121.913 0.863 . . . . 75.239999999999995 112.06 -174.632 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 9.6 tp10 -108.93 162.0 14.62 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 114.763 -1.108 . . . . 64.420000000000002 108.374 175.693 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 39.1 mt-10 -122.59 169.18 11.29 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-O 121.159 0.504 . . . . 52.420000000000002 111.517 -179.999 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -162.48 158.25 30.33 Favored Glycine 0 N--CA 1.443 -0.897 0 N-CA-C 110.736 -0.946 . . . . 62.200000000000003 110.736 179.046 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 20.6 pt20 -75.73 9.32 2.37 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 117.093 0.447 . . . . 74.430000000000007 111.929 -177.088 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 69.3 mtm180 -130.19 15.32 5.65 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 121.005 0.431 . . . . 72.230000000000004 110.285 174.654 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 129.21 -179.68 16.54 Favored Glycine 0 N--CA 1.45 -0.427 0 C-N-CA 120.651 -0.785 . . . . 64.299999999999997 112.083 179.871 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo -74.6 146.27 34.23 Favored 'Trans proline' 0 N--CA 1.461 -0.428 0 C-N-CA 122.508 2.138 . . . . 74.549999999999997 112.427 -179.055 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 42.3 mt-30 -118.5 162.22 18.71 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 115.952 -0.567 . . . . 75.219999999999999 110.013 178.335 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . 0.524 ' HB2' ' HB ' ' A' ' 28' ' ' VAL . . . -118.35 125.29 49.73 Favored 'General case' 0 C--N 1.318 -0.794 0 CA-C-O 121.047 0.451 . . . . 73.200000000000003 111.039 -179.672 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . 0.501 ' HA ' ' HB3' ' A' ' 32' ' ' ALA . . . -127.81 164.59 21.86 Favored 'General case' 0 C--N 1.321 -0.673 0 N-CA-C 108.763 -0.829 . . . . 75.040000000000006 108.763 175.871 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 39.7 m-80 48.25 76.87 0.11 Allowed 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 121.032 0.444 . . . . 74.049999999999997 110.989 -177.843 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.676 HG22 HG12 ' A' ' 33' ' ' ILE . 46.6 t -89.21 92.08 3.86 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.67 0 CA-C-N 116.042 -0.526 . . . . 72.329999999999998 110.142 -178.751 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -80.38 125.82 30.39 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 115.434 -0.803 . . . . 73.340000000000003 109.368 -177.868 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 52.9 mttp -64.25 137.54 57.98 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.301 -0.409 . . . . 72.140000000000001 110.381 -177.403 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.251 1.135 0 CA-C-O 118.439 -0.791 . . . . 74.219999999999999 109.927 179.496 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' MET . . . . . 0.544 ' HA ' ' O ' ' A' ' 49' ' ' PHE . 64.7 mtt . . . . . 0 N--CA 1.479 1.009 0 CA-C-O 120.697 0.284 . . . . 74.340000000000003 110.676 . . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 2.8 mp0 -117.16 170.74 8.44 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 121.04 0.448 . . . . 72.540000000000006 110.619 176.82 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 84.0 mt-30 -95.15 126.83 40.75 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 115.357 -0.838 . . . . 75.239999999999995 109.482 176.813 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . 0.684 ' HA3' ' HE2' ' A' ' 49' ' ' PHE . . . -140.83 151.11 22.22 Favored Glycine 0 N--CA 1.445 -0.756 0 C-N-CA 120.291 -0.956 . . . . 72.109999999999999 112.533 -177.985 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' THR . . . . . 0.436 ' O ' ' HG2' ' A' ' 19' ' ' GLU . 7.4 m -107.15 125.82 51.58 Favored 'General case' 0 C--N 1.319 -0.75 0 N-CA-C 110.21 -0.293 . . . . 72.340000000000003 110.21 -179.718 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 48.3 t -68.01 117.39 9.76 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 N-CA-C 110.168 -0.308 . . . . 73.120000000000005 110.168 179.705 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . 0.646 ' HD3' ' HB3' ' A' ' 19' ' ' GLU . 30.1 mmmt -75.55 -56.37 4.76 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 121.405 0.622 . . . . 74.450000000000003 109.329 179.422 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' TRP . . . . . 0.785 ' HZ3' ' HB2' ' A' ' 10' ' ' ASN . 63.5 p-90 -164.71 157.95 17.21 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-N 114.849 -1.069 . . . . 72.019999999999996 108.921 175.927 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 11.3 p90 -129.04 115.1 17.24 Favored 'General case' 0 C--N 1.317 -0.816 0 CA-C-O 121.596 0.713 . . . . 73.340000000000003 110.805 -176.593 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' ASN . . . . . 0.785 ' HB2' ' HZ3' ' A' ' 8' ' ' TRP . 34.1 t30 -86.72 71.86 10.28 Favored 'General case' 0 C--N 1.319 -0.729 0 N-CA-C 108.527 -0.916 . . . . 72.540000000000006 108.527 179.008 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -62.83 -32.15 73.3 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 114.709 -1.132 . . . . 74.109999999999999 112.536 -171.284 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 33.1 mt-10 -75.53 -9.76 58.86 Favored 'General case' 0 C--N 1.326 -0.429 0 C-N-CA 120.905 -0.318 . . . . 74.209999999999994 111.252 -177.458 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 30.7 mmmt -110.92 -11.75 14.31 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 121.174 0.511 . . . . 75.109999999999999 110.124 174.253 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 95.21 15.83 43.08 Favored Glycine 0 N--CA 1.447 -0.596 0 C-N-CA 120.805 -0.712 . . . . 65.409999999999997 114.414 169.91 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 54.6 p90 -145.8 155.3 42.84 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 117.941 0.871 . . . . 75.239999999999995 111.601 -179.254 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -140.64 166.82 25.76 Favored Glycine 0 N--CA 1.445 -0.728 0 N-CA-C 111.078 -0.809 . . . . 71.219999999999999 111.078 177.422 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 79.0 m-85 -120.89 121.92 39.12 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-O 121.201 0.524 . . . . 74.430000000000007 111.201 -178.323 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 56.4 mt -111.25 139.59 34.55 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.615 0 CA-C-N 115.331 -0.85 . . . . 74.019999999999996 109.459 178.166 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' GLU . . . . . 0.646 ' HB3' ' HD3' ' A' ' 7' ' ' LYS . 9.1 pt-20 -88.6 134.36 33.9 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 120.896 0.379 . . . . 73.510000000000005 110.523 179.008 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' ARG . . . . . . . . . . . . . 27.8 ttp180 -121.84 152.01 40.02 Favored 'General case' 0 C--N 1.322 -0.63 0 N-CA-C 108.996 -0.742 . . . . 74.030000000000001 108.996 174.13 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -50.71 -40.81 55.12 Favored 'General case' 0 N--CA 1.463 0.189 0 O-C-N 123.279 0.362 . . . . 73.140000000000001 111.795 -177.83 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -109.44 65.75 0.62 Allowed 'General case' 0 C--N 1.322 -0.63 0 CA-C-O 121.004 0.431 . . . . 72.310000000000002 110.339 171.62 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . 0.433 ' C ' ' H ' ' A' ' 25' ' ' ASP . . . 132.85 94.88 0.57 Allowed Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.816 -0.707 . . . . 74.310000000000002 112.227 174.257 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . 0.523 ' HA ' ' HA ' ' A' ' 19' ' ' GLU . 3.9 p30 -71.0 6.41 1.58 Allowed 'General case' 0 N--CA 1.468 0.432 0 CA-C-O 120.962 0.41 . . . . 72.409999999999997 111.48 -178.108 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.433 ' H ' ' C ' ' A' ' 23' ' ' GLY . 7.2 p-10 -122.6 88.59 2.96 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-O 121.708 0.766 . . . . 72.019999999999996 110.916 -177.266 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.432 HG13 ' HB1' ' A' ' 60' ' ' ALA . 55.9 t -112.34 118.59 58.17 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.621 0 CA-C-N 115.431 -0.804 . . . . 71.310000000000002 109.565 173.769 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' PHE . . . . . 0.438 ' O ' ' HA ' ' A' ' 59' ' ' GLN . 63.1 t80 -82.08 105.09 12.9 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 115.773 -0.648 . . . . 74.310000000000002 110.484 -176.183 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 12.2 p -100.03 133.95 41.24 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.603 0 CA-C-O 121.207 0.527 . . . . 74.129999999999995 110.531 179.122 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 85.8 t60 -91.87 133.05 36.01 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 115.843 -0.617 . . . . 64.409999999999997 109.855 -178.226 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 14.0 p90 -56.39 -36.39 68.82 Favored 'General case' 0 N--CA 1.467 0.399 0 N-CA-C 111.938 0.347 . . . . 74.310000000000002 111.938 -174.015 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 6.9 t -87.31 6.44 33.47 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 121.293 0.568 . . . . 70.299999999999997 110.644 -177.763 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -105.67 -19.7 13.68 Favored 'General case' 0 C--N 1.326 -0.447 0 N-CA-C 109.144 -0.687 . . . . 72.120000000000005 109.144 173.216 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 69.2 mt -74.72 105.45 3.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 114.998 -1.001 . . . . 75.310000000000002 110.271 175.329 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -79.75 71.26 6.39 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 121.854 0.835 . . . . 75.340000000000003 109.943 175.478 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -74.13 163.26 54.52 Favored Glycine 0 N--CA 1.448 -0.519 0 CA-C-N 115.104 -0.953 . . . . 73.030000000000001 112.469 -178.597 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 21.7 t70 -93.89 105.13 17.16 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-O 120.795 0.331 . . . . 62.229999999999997 110.124 -178.94 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 92.28 -53.51 2.81 Favored Glycine 0 N--CA 1.449 -0.438 0 N-CA-C 111.64 -0.584 . . . . 54.020000000000003 111.64 -179.554 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 97.8 m-85 -133.82 147.19 51.19 Favored 'General case' 0 C--N 1.325 -0.497 0 N-CA-C 109.519 -0.549 . . . . 75.5 109.519 177.157 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 13.9 mptt -73.55 91.69 1.85 Allowed 'General case' 0 C--N 1.323 -0.575 0 CA-C-O 121.054 0.454 . . . . 75.450000000000003 110.408 179.22 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 22.8 p -165.85 154.91 11.71 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 115.561 -0.745 . . . . 74.209999999999994 110.114 -179.954 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 95.1 mt -132.39 130.48 40.72 Favored 'General case' 0 C--N 1.325 -0.483 0 N-CA-C 109.277 -0.638 . . . . 74.409999999999997 109.277 176.318 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 3.4 m-20 -55.88 125.05 19.73 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 121.205 0.526 . . . . 75.430000000000007 111.557 -179.36 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 7.6 pt-20 -66.95 123.27 19.72 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-N 115.834 -0.621 . . . . 71.519999999999996 109.831 175.895 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 101.81 5.76 50.4 Favored Glycine 0 N--CA 1.448 -0.502 0 C-N-CA 121.032 -0.604 . . . . 75.439999999999998 111.648 -173.229 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 7.5 tp60 -102.84 138.03 40.26 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.652 0.263 . . . . 74.209999999999994 110.521 178.603 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -92.16 131.91 37.03 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 116.293 -0.412 . . . . 73.049999999999997 110.427 176.329 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 24.0 m -134.77 173.84 13.89 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 CA-C-N 116.121 -0.49 . . . . 74.019999999999996 110.308 -179.793 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 19.3 p -117.34 115.69 25.74 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-O 121.185 0.517 . . . . 75.209999999999994 110.805 179.431 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 49' ' ' PHE . . . . . 0.684 ' HE2' ' HA3' ' A' ' 4' ' ' GLY . 38.0 p90 -120.63 152.72 37.8 Favored 'General case' 0 C--N 1.319 -0.76 0 CA-C-N 115.74 -0.664 . . . . 73.230000000000004 110.325 -177.523 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . 0.425 ' HA ' ' HA ' ' A' ' 1' ' ' MET . 22.7 t70 -97.64 116.76 30.47 Favored 'General case' 0 C--N 1.322 -0.596 0 N-CA-C 109.224 -0.658 . . . . 71.519999999999996 109.224 174.883 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 9.9 p -77.86 140.71 16.57 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.497 0 CA-C-O 121.52 0.676 . . . . 61.439999999999998 111.637 -170.553 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . 0.432 ' HB3' ' HG3' ' A' ' 59' ' ' GLN . 32.6 tt0 -137.38 156.91 47.66 Favored 'General case' 0 C--N 1.32 -0.688 0 N-CA-C 108.163 -1.051 . . . . 75.209999999999994 108.163 175.173 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . 0.407 ' HA ' ' O ' ' A' ' 57' ' ' GLY . 0.0 OUTLIER -149.49 -177.78 6.05 Favored 'General case' 0 C--N 1.32 -0.708 0 O-C-N 122.092 -0.38 . . . . 73.540000000000006 110.794 -178.487 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 143.94 -101.78 0.26 Allowed Glycine 0 N--CA 1.442 -0.933 0 C-N-CA 120.62 -0.8 . . . . 65.140000000000001 113.132 177.669 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 35.3 tt0 -80.14 -23.88 40.82 Favored 'General case' 0 C--N 1.326 -0.443 0 N-CA-C 112.361 0.504 . . . . 71.209999999999994 112.361 -168.925 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 2.0 ptp180 -137.95 43.39 2.23 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-O 121.07 0.462 . . . . 75.230000000000004 111.733 -178.591 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . 0.407 ' O ' ' HA ' ' A' ' 53' ' ' GLU . . . 76.07 -157.38 48.42 Favored Glycine 0 N--CA 1.449 -0.454 0 C-N-CA 120.842 -0.694 . . . . 72.019999999999996 113.127 174.667 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 1.7 Cg_endo -81.43 110.39 2.21 Favored 'Trans proline' 0 N--CA 1.455 -0.776 0 C-N-CA 123.242 2.628 . . . . 74.239999999999995 112.053 -178.999 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . 0.438 ' HA ' ' O ' ' A' ' 27' ' ' PHE . 16.8 pt20 -105.45 139.11 40.57 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 115.892 -0.595 . . . . 71.310000000000002 109.97 179.091 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . 0.432 ' HB1' HG13 ' A' ' 26' ' ' VAL . . . -89.8 109.35 20.35 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 116.178 -0.465 . . . . 74.430000000000007 110.997 -179.344 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -111.41 149.9 30.56 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-N 115.825 -0.625 . . . . 74.510000000000005 109.519 176.315 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 94.9 m-20 51.49 80.17 0.09 Allowed 'General case' 0 C--O 1.235 0.321 0 CA-C-O 121.286 0.565 . . . . 73.450000000000003 110.841 -176.76 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 38.9 t -102.88 103.97 15.88 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.589 0 CA-C-N 115.732 -0.667 . . . . 75.530000000000001 110.245 -179.355 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 54.4 mt-30 -94.9 160.54 14.54 Favored 'General case' 0 C--N 1.319 -0.735 0 CA-C-N 115.918 -0.583 . . . . 74.530000000000001 110.52 -179.647 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -82.77 171.35 14.05 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 115.717 -0.674 . . . . 72.329999999999998 110.894 -176.773 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.097 0 CA-C-O 118.413 -0.803 . . . . 73.340000000000003 109.544 177.172 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' MET . . . . . 0.598 ' H2 ' ' HA ' ' A' ' 50' ' ' ASP . 65.8 mtt . . . . . 0 N--CA 1.484 1.249 0 CA-C-O 121.005 0.431 . . . . 62.450000000000003 110.683 . . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 56.9 mp0 -84.28 151.08 25.0 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-O 121.268 0.556 . . . . 65.340000000000003 111.871 -174.877 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -96.79 112.78 24.39 Favored 'General case' 0 C--N 1.323 -0.545 0 N-CA-C 108.095 -1.076 . . . . 73.519999999999996 108.095 172.956 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . 0.479 ' HA3' ' HE2' ' A' ' 49' ' ' PHE . . . -137.61 168.53 24.43 Favored Glycine 0 N--CA 1.447 -0.608 0 C-N-CA 120.392 -0.908 . . . . 75.019999999999996 112.558 -175.864 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 26.9 m -108.24 134.26 51.33 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-O 120.634 0.254 . . . . 74.219999999999999 110.457 -179.024 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 47.8 t -68.75 112.7 3.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 CA-C-O 120.772 0.32 . . . . 72.329999999999998 110.378 178.494 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 48.3 mtpt -71.76 -70.86 0.3 Allowed 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 115.808 -0.633 . . . . 74.200000000000003 110.21 179.887 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' TRP . . . . . . . . . . . . . 92.1 m95 -139.4 132.61 29.81 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 115.094 -0.957 . . . . 72.329999999999998 108.819 178.117 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . 0.494 ' HD1' ' HA3' ' A' ' 16' ' ' GLY . 59.4 t80 -132.22 102.1 5.64 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-O 121.272 0.558 . . . . 72.439999999999998 110.822 179.15 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 19.0 m120 -80.99 84.8 6.38 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 115.583 -0.735 . . . . 74.530000000000001 109.534 176.444 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -61.66 -33.25 73.63 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 115.393 -0.821 . . . . 54.439999999999998 111.074 179.055 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 44.3 mt-10 -69.6 -25.9 64.19 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.015 -0.538 . . . . 73.129999999999995 110.73 179.532 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 75.7 mmtt -92.24 -35.53 13.74 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.219 -0.446 . . . . 63.200000000000003 110.187 -179.948 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 110.12 14.11 14.14 Favored Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 120.965 -0.636 . . . . 44.310000000000002 113.35 175.574 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 50.0 p90 -152.73 162.08 41.73 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 117.157 0.479 . . . . 74.540000000000006 111.451 -177.546 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.494 ' HA3' ' HD1' ' A' ' 9' ' ' PHE . . . -163.38 178.25 39.04 Favored Glycine 0 N--CA 1.446 -0.692 0 C-N-CA 120.885 -0.674 . . . . 74.219999999999999 112.197 179.071 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 90.8 m-85 -126.28 127.76 46.1 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-O 120.7 0.286 . . . . 74.310000000000002 110.507 -178.967 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 46.3 mt -112.93 129.91 67.72 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.497 0 N-CA-C 109.151 -0.685 . . . . 74.340000000000003 109.151 175.787 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 11.1 pt-20 -73.7 139.88 45.65 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 121.502 0.668 . . . . 73.030000000000001 111.559 -171.851 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' ARG . . . . . . . . . . . . . 43.5 ttt180 -112.48 141.2 46.51 Favored 'General case' 0 C--N 1.319 -0.733 0 N-CA-C 107.434 -1.321 . . . . 62.420000000000002 107.434 175.035 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 16.1 pt-20 -55.67 -26.57 45.47 Favored 'General case' 0 C--N 1.327 -0.406 0 N-CA-C 112.85 0.685 . . . . 70.219999999999999 112.85 -170.116 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 28.6 t-20 -79.69 -19.58 48.62 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-O 120.845 0.355 . . . . 74.420000000000002 111.434 -178.813 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 106.48 -9.33 41.49 Favored Glycine 0 CA--C 1.511 -0.157 0 N-CA-C 111.229 -0.748 . . . . 74.510000000000005 111.229 -174.514 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 36.5 t70 -80.32 72.24 7.16 Favored 'General case' 0 C--N 1.322 -0.615 0 N-CA-C 109.279 -0.638 . . . . 71.400000000000006 109.279 176.294 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 10.1 p-10 -70.28 138.07 51.26 Favored 'General case' 0 C--N 1.333 -0.14 0 CA-C-O 121.52 0.676 . . . . 62.520000000000003 110.811 -172.899 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.526 HG12 ' HB2' ' A' ' 58' ' ' PRO . 4.3 t -94.57 138.98 19.4 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.55 0 CA-C-N 115.187 -0.915 . . . . 74.099999999999994 111.4 -167.734 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' PHE . . . . . . . . . . . . . 50.4 t80 -92.27 111.72 23.39 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.769 -0.65 . . . . 74.019999999999996 110.461 -177.449 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.522 ' HB ' ' HB2' ' A' ' 60' ' ' ALA . 14.8 p -95.86 148.49 5.22 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.381 0 CA-C-O 120.905 0.383 . . . . 75.450000000000003 111.325 -175.462 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 28.0 m170 -114.31 145.72 41.42 Favored 'General case' 0 C--O 1.236 0.343 0 CA-C-N 116.151 -0.477 . . . . 71.109999999999999 109.889 177.623 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 20.5 p90 -62.19 -26.24 68.24 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 121.11 0.481 . . . . 73.530000000000001 110.46 177.659 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 4.2 m -81.56 -14.36 56.93 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 115.77 -0.65 . . . . 73.109999999999999 110.875 179.277 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . 0.482 ' HB1' ' HA ' ' A' ' 61' ' ' ALA . . . -94.51 -21.3 18.97 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 121.044 0.449 . . . . 64.140000000000001 110.819 -176.709 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 44.9 mt -71.04 155.8 7.39 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-N 115.777 -0.647 . . . . 74.349999999999994 110.188 174.534 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 14.5 pt20 -70.51 102.97 2.35 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 121.226 0.536 . . . . 72.219999999999999 110.458 175.755 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -79.03 77.1 1.85 Allowed Glycine 0 N--CA 1.447 -0.573 0 CA-C-N 115.752 -0.658 . . . . 71.519999999999996 112.92 -175.815 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 34.7 t70 -121.61 98.15 5.83 Favored 'General case' 0 C--N 1.323 -0.556 0 N-CA-C 109.639 -0.504 . . . . 74.409999999999997 109.639 174.21 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 72.79 -150.32 44.42 Favored Glycine 0 N--CA 1.446 -0.636 0 C-N-CA 120.749 -0.739 . . . . 61.119999999999997 111.435 -174.983 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 88.6 m-85 -110.92 65.38 0.62 Allowed 'General case' 0 C--N 1.321 -0.664 0 CA-C-O 121.468 0.651 . . . . 74.299999999999997 110.597 178.028 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 91.7 mttt -101.67 86.69 2.98 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 115.333 -0.849 . . . . 70.150000000000006 109.611 178.196 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 22.9 t -84.32 178.9 7.59 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 115.479 -0.782 . . . . 75.420000000000002 111.181 -172.829 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 81.7 mt -95.94 119.04 33.72 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 116.013 -0.54 . . . . 73.319999999999993 109.892 177.385 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . 0.609 ' HB3' ' HB2' ' A' ' 45' ' ' GLN . 30.7 t70 -82.43 139.93 33.72 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-N 115.942 -0.572 . . . . 65.150000000000006 111.048 -175.988 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 6.8 pt-20 -66.11 116.72 7.5 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 115.84 -0.618 . . . . 72.209999999999994 110.846 178.383 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 87.3 18.9 56.55 Favored Glycine 0 N--CA 1.448 -0.508 0 C-N-CA 120.642 -0.79 . . . . 53.549999999999997 112.182 -177.77 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 45' ' ' GLN . . . . . 0.609 ' HB2' ' HB3' ' A' ' 42' ' ' ASP . 35.6 tt0 -99.22 135.5 40.54 Favored 'General case' 0 C--N 1.326 -0.451 0 N-CA-C 110.208 -0.293 . . . . 71.239999999999995 110.208 178.497 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -85.52 129.01 34.92 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 116.36 -0.382 . . . . 64.349999999999994 110.271 177.807 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 16.6 m -138.36 153.62 26.61 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.518 0 CA-C-O 120.988 0.423 . . . . 74.109999999999999 111.01 -177.927 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 48' ' ' THR . . . . . 0.513 ' HG1' ' HB3' ' A' ' 64' ' ' GLN . 20.7 p -102.51 104.87 15.33 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 115.994 -0.548 . . . . 73.510000000000005 109.814 175.988 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 49' ' ' PHE . . . . . 0.479 ' HE2' ' HA3' ' A' ' 4' ' ' GLY . 41.8 p90 -110.74 158.51 18.57 Favored 'General case' 0 C--N 1.316 -0.852 0 CA-C-N 115.449 -0.796 . . . . 74.510000000000005 110.174 -174.994 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . 0.598 ' HA ' ' H2 ' ' A' ' 1' ' ' MET . 19.7 t0 -104.61 151.77 23.24 Favored 'General case' 0 C--N 1.317 -0.842 0 C-N-CA 120.074 -0.65 . . . . 71.030000000000001 109.958 173.552 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 4.9 p -103.17 112.41 36.52 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.599 0 CA-C-O 121.405 0.621 . . . . 74.129999999999995 111.194 -173.57 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 49.8 mm-40 -109.85 112.88 25.19 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-N 115.586 -0.733 . . . . 72.239999999999995 109.689 177.613 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . 0.532 ' HA ' ' O ' ' A' ' 57' ' ' GLY . 8.1 pt-20 -76.81 115.47 16.62 Favored 'General case' 0 C--N 1.325 -0.498 0 C-N-CA 120.211 -0.595 . . . . 75.439999999999998 109.941 177.202 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . 0.508 ' HA3' ' NE2' ' A' ' 59' ' ' GLN . . . -122.57 -121.2 2.68 Favored Glycine 0 N--CA 1.445 -0.736 0 C-N-CA 120.354 -0.927 . . . . 45.130000000000003 113.365 -174.658 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -84.77 1.68 45.6 Favored 'General case' 0 C--N 1.329 -0.311 0 N-CA-C 112.157 0.429 . . . . 74.439999999999998 112.157 -169.632 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 10.2 ptp180 -158.87 28.39 0.22 Allowed 'General case' 0 C--N 1.325 -0.457 0 CA-C-O 120.748 0.308 . . . . 75.420000000000002 111.237 177.678 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . 0.532 ' O ' ' HA ' ' A' ' 53' ' ' GLU . . . 93.29 -132.81 11.4 Favored Glycine 0 N--CA 1.444 -0.784 0 C-N-CA 120.44 -0.886 . . . . 74.420000000000002 112.18 -179.054 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . 0.526 ' HB2' HG12 ' A' ' 26' ' ' VAL . 33.0 Cg_endo -64.32 106.66 0.72 Allowed 'Trans proline' 0 CA--C 1.529 0.239 0 C-N-CA 122.837 2.358 . . . . 64.400000000000006 113.323 -174.806 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . 0.508 ' NE2' ' HA3' ' A' ' 54' ' ' GLY . 22.2 mt-30 -112.53 128.41 56.34 Favored 'General case' 0 C--N 1.323 -0.567 0 N-CA-C 109.011 -0.737 . . . . 74.340000000000003 109.011 173.615 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . 0.522 ' HB2' ' HB ' ' A' ' 28' ' ' VAL . . . -82.13 115.1 21.09 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-O 120.984 0.421 . . . . 64.530000000000001 110.955 -176.127 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . 0.482 ' HA ' ' HB1' ' A' ' 32' ' ' ALA . . . -130.89 154.14 48.4 Favored 'General case' 0 C--N 1.319 -0.75 0 N-CA-C 108.845 -0.798 . . . . 75.099999999999994 108.845 176.818 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 90.2 m-20 57.84 73.93 0.45 Allowed 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 121.492 0.663 . . . . 74.019999999999996 109.967 -176.125 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 45.3 t -100.21 103.71 15.16 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.664 0 CA-C-N 115.357 -0.838 . . . . 64.530000000000001 109.813 179.857 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 64' ' ' GLN . . . . . 0.513 ' HB3' ' HG1' ' A' ' 48' ' ' THR . 6.3 tp-100 -91.63 143.19 26.82 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-N 116.027 -0.533 . . . . 74.120000000000005 110.673 -176.941 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 66.8 mmtt -72.72 130.22 40.01 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 115.684 -0.689 . . . . 73.239999999999995 109.992 177.817 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.251 1.167 0 CA-C-O 118.432 -0.794 . . . . 75.010000000000005 110.53 -178.164 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' MET . . . . . 0.582 ' HA ' ' HA ' ' A' ' 50' ' ' ASP . 27.9 ttt . . . . . 0 N--CA 1.475 0.783 0 CA-C-O 121.364 0.602 . . . . 51.310000000000002 109.602 . . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 1.7 pm0 -143.72 175.33 10.06 Favored 'General case' 0 C--N 1.319 -0.722 0 CA-C-N 115.437 -0.801 . . . . 75.420000000000002 110.275 -175.348 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -100.24 128.74 46.25 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-O 121.215 0.531 . . . . 74.420000000000002 110.616 179.31 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -131.14 164.7 23.29 Favored Glycine 0 N--CA 1.444 -0.774 0 CA-C-N 115.803 -0.635 . . . . 63.310000000000002 111.751 -179.17 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 21.3 m -105.38 122.87 46.86 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-O 120.542 0.21 . . . . 74.510000000000005 110.707 -178.775 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 58.7 t -64.37 114.36 2.21 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.227 0 CA-C-N 116.392 -0.367 . . . . 73.129999999999995 110.547 -179.331 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 4.5 mmmm -95.28 -53.16 3.88 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 115.859 -0.609 . . . . 75.340000000000003 110.255 -178.832 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' TRP . . . . . 0.472 ' HB2' ' HB2' ' A' ' 17' ' ' PHE . 76.5 m95 -118.11 130.63 56.24 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 115.687 -0.688 . . . . 74.349999999999994 110.082 179.793 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . 0.423 ' CE2' ' HB1' ' A' ' 11' ' ' ALA . 62.6 t80 -128.66 84.37 2.23 Favored 'General case' 0 C--N 1.318 -0.781 0 CA-C-O 121.282 0.563 . . . . 74.5 109.692 178.862 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' ASN . . . . . 0.786 ' HB3' ' HB2' ' A' ' 13' ' ' LYS . 44.0 m-80 -87.53 74.35 9.31 Favored 'General case' 0 C--N 1.321 -0.663 0 CA-C-N 115.909 -0.587 . . . . 73.349999999999994 110.021 -177.61 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . 0.671 ' HA ' ' CZ ' ' A' ' 30' ' ' PHE . . . -61.07 -39.61 90.53 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.277 -0.874 . . . . 74.150000000000006 111.409 -177.296 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 47.0 mt-10 -84.22 -11.4 56.56 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 116.085 -0.507 . . . . 71.530000000000001 111.173 -177.947 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . 0.786 ' HB2' ' HB3' ' A' ' 10' ' ' ASN . 5.2 mmtp -98.6 -28.41 13.57 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 116.274 -0.421 . . . . 74.430000000000007 110.586 -177.02 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 102.2 22.65 9.69 Favored Glycine 0 N--CA 1.448 -0.526 0 C-N-CA 120.652 -0.785 . . . . 73.030000000000001 113.396 174.287 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . 0.452 ' O ' ' HB2' ' A' ' 10' ' ' ASN . 52.5 p90 -163.38 171.49 15.96 Favored 'General case' 0 N--CA 1.463 0.222 0 CA-C-N 117.451 0.625 . . . . 73.319999999999993 111.067 179.649 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -153.98 172.14 32.65 Favored Glycine 0 N--CA 1.445 -0.701 0 C-N-CA 120.827 -0.701 . . . . 61.530000000000001 112.119 179.976 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . 0.794 ' HB3' ' HB3' ' A' ' 25' ' ' ASP . 92.6 m-85 -134.63 122.82 22.82 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 120.802 0.334 . . . . 73.430000000000007 110.269 179.472 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 35.3 mt -122.41 117.44 52.09 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.593 0 CA-C-N 116.103 -0.499 . . . . 74.409999999999997 109.734 179.164 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' GLU . . . . . 0.4 ' HA ' ' HA ' ' A' ' 25' ' ' ASP . 22.8 pt-20 -79.41 148.31 32.01 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-O 121.257 0.551 . . . . 62.310000000000002 112.17 -170.976 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' ARG . . . . . 0.413 ' HG2' ' HG2' ' A' ' 21' ' ' GLU . 14.4 ttm180 -118.61 123.51 45.17 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 115.42 -0.809 . . . . 75.140000000000001 109.684 170.681 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . 0.413 ' HG2' ' HG2' ' A' ' 20' ' ' ARG . 43.1 mm-40 50.78 -90.02 0.02 OUTLIER 'General case' 0 N--CA 1.474 0.738 0 N-CA-C 113.407 0.891 . . . . 73.340000000000003 113.407 173.094 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 1.6 m-20 -58.31 -19.11 32.22 Favored 'General case' 0 N--CA 1.467 0.408 0 C-N-CA 123.847 0.859 . . . . 72.209999999999994 111.79 -175.215 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 104.35 19.92 10.9 Favored Glycine 0 N--CA 1.442 -0.951 0 N-CA-C 110.015 -1.234 . . . . 75.530000000000001 110.015 -170.604 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 5.3 t70 -71.69 90.01 1.04 Allowed 'General case' 0 N--CA 1.45 -0.434 0 N-CA-C 109.0 -0.741 . . . . 73.239999999999995 109.0 178.089 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.794 ' HB3' ' HB3' ' A' ' 17' ' ' PHE . 62.0 m-20 -63.37 104.32 0.6 Allowed 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 115.756 -0.656 . . . . 52.420000000000002 110.613 -179.553 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 59.3 t -74.48 132.36 33.49 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.598 0 CA-C-N 115.602 -0.726 . . . . 64.109999999999999 110.0 179.009 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' PHE . . . . . 0.48 ' O ' ' HA ' ' A' ' 59' ' ' GLN . 78.5 t80 -82.73 127.61 33.58 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 116.089 -0.505 . . . . 73.219999999999999 110.441 -177.261 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.5 ' HB ' ' HB3' ' A' ' 60' ' ' ALA . 14.2 p -131.35 147.64 32.8 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 CA-C-O 121.02 0.438 . . . . 63.32 111.647 -177.416 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 21.9 m170 -108.64 159.57 16.62 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.991 -0.549 . . . . 72.519999999999996 109.684 174.759 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' PHE . . . . . 0.671 ' CZ ' ' HA ' ' A' ' 11' ' ' ALA . 52.4 m-85 -71.95 -14.28 61.87 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-O 120.702 0.287 . . . . 73.409999999999997 111.309 -179.723 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 13.8 t -71.35 -22.13 61.94 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-O 121.337 0.589 . . . . 52.210000000000001 110.07 174.725 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -100.83 -22.53 14.81 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 115.846 -0.615 . . . . 73.319999999999993 110.487 179.387 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 70.6 mt -76.93 145.77 9.7 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 CA-C-N 115.883 -0.599 . . . . 75.310000000000002 109.452 174.521 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 34' ' ' GLN . . . . . 0.419 ' NE2' ' HG3' ' A' ' 65' ' ' LYS . 23.3 pt20 -68.92 100.4 1.19 Allowed 'General case' 0 C--N 1.327 -0.412 0 CA-C-O 121.455 0.645 . . . . 72.239999999999995 110.626 177.373 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -100.1 68.34 0.52 Allowed Glycine 0 N--CA 1.445 -0.708 0 C-N-CA 120.937 -0.649 . . . . 63.140000000000001 111.978 -178.914 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 6.2 m-20 -78.1 79.21 4.57 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-O 120.765 0.316 . . . . 71.450000000000003 110.41 177.316 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 71.82 -99.56 0.85 Allowed Glycine 0 N--CA 1.447 -0.606 0 C-N-CA 120.75 -0.738 . . . . 71.310000000000002 111.601 -178.004 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 93.8 m-85 -118.65 101.41 8.09 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-O 121.089 0.471 . . . . 71.340000000000003 110.567 178.954 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 75.2 mmtt -126.18 152.06 46.5 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 115.733 -0.667 . . . . 74.319999999999993 109.227 176.755 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 42.1 m -149.17 125.62 10.93 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-O 120.887 0.375 . . . . 74.019999999999996 110.986 -179.889 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 3.2 mm? -90.62 139.01 31.11 Favored 'General case' 0 C--N 1.324 -0.534 0 N-CA-C 109.228 -0.656 . . . . 73.430000000000007 109.228 175.021 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 30.9 t70 -90.23 146.76 24.0 Favored 'General case' 0 C--N 1.319 -0.729 0 C-N-CA 120.87 -0.332 . . . . 74.109999999999999 110.334 -178.792 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 37.4 mt-10 -70.97 102.01 2.31 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 116.319 -0.401 . . . . 73.109999999999999 109.932 178.293 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 123.03 1.19 9.59 Favored Glycine 0 N--CA 1.45 -0.433 0 CA-C-N 115.784 -0.644 . . . . 74.540000000000006 111.672 -173.272 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 52.1 tp60 -87.49 139.81 30.16 Favored 'General case' 0 N--CA 1.464 0.247 0 C-N-CA 122.247 0.219 . . . . 70.239999999999995 110.873 -179.734 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -90.54 131.68 36.13 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 121.084 0.469 . . . . 73.049999999999997 110.732 176.696 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 21.6 m -132.06 167.06 27.3 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 CA-C-N 116.062 -0.517 . . . . 73.319999999999993 110.782 -178.871 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 3.4 p -120.97 114.95 22.27 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-O 121.185 0.517 . . . . 62.240000000000002 110.211 179.312 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 49' ' ' PHE . . . . . 0.495 ' O ' ' HA ' ' A' ' 1' ' ' MET . 38.8 p90 -134.78 166.1 23.74 Favored 'General case' 0 C--N 1.319 -0.76 0 CA-C-N 115.949 -0.568 . . . . 74.120000000000005 110.348 -173.802 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . 0.582 ' HA ' ' HA ' ' A' ' 1' ' ' MET . 39.1 t0 -106.84 121.62 44.77 Favored 'General case' 0 C--N 1.324 -0.538 0 C-N-CA 120.4 -0.52 . . . . 75.519999999999996 110.447 175.253 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 86.5 t -77.83 117.16 22.54 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.55 0 CA-C-O 120.986 0.422 . . . . 74.549999999999997 111.294 -178.842 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . 0.653 ' HB3' ' HG3' ' A' ' 59' ' ' GLN . 8.9 tp10 -94.12 116.79 29.25 Favored 'General case' 0 C--N 1.321 -0.652 0 N-CA-C 108.904 -0.776 . . . . 74.349999999999994 108.904 174.022 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 47.5 mt-10 -92.78 95.73 9.72 Favored 'General case' 0 C--N 1.319 -0.721 0 CA-C-O 121.128 0.49 . . . . 72.310000000000002 110.107 179.837 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -103.61 -143.49 12.76 Favored Glycine 0 N--CA 1.445 -0.701 0 CA-C-N 115.597 -0.729 . . . . 62.140000000000001 112.68 -176.629 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -86.42 -40.41 15.4 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 121.008 0.432 . . . . 64.329999999999998 110.723 -175.381 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 77.2 mtm180 -108.23 81.94 1.56 Allowed 'General case' 0 C--N 1.322 -0.614 0 CA-C-N 116.273 -0.421 . . . . 75.219999999999999 111.305 -176.262 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 68.9 -171.29 38.92 Favored Glycine 0 N--CA 1.448 -0.507 0 CA-C-N 115.619 -0.719 . . . . 63.530000000000001 112.93 178.22 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 87.3 Cg_endo -86.94 123.62 2.05 Favored 'Trans proline' 0 N--CA 1.453 -0.857 0 C-N-CA 122.829 2.353 . . . . 75.439999999999998 111.764 175.752 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . 0.653 ' HG3' ' HB3' ' A' ' 52' ' ' GLU . 3.6 pt20 -109.3 126.91 53.86 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-N 116.212 -0.449 . . . . 65.030000000000001 109.852 178.181 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . 0.5 ' HB3' ' HB ' ' A' ' 28' ' ' VAL . . . -79.42 117.58 20.52 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-O 120.837 0.351 . . . . 64.409999999999997 110.802 -178.771 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -110.87 128.62 55.86 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 116.013 -0.54 . . . . 63.140000000000001 109.816 178.524 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 49.4 m-80 63.78 96.38 0.04 OUTLIER 'General case' 0 C--O 1.235 0.312 0 O-C-N 123.577 0.548 . . . . 73.510000000000005 110.674 -176.521 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.462 HG23 HG23 ' A' ' 28' ' ' VAL . 48.8 t -110.66 107.15 22.21 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.474 0 CA-C-N 115.661 -0.699 . . . . 73.299999999999997 110.746 179.718 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 34.4 tt0 -102.09 168.35 9.44 Favored 'General case' 0 C--N 1.324 -0.542 0 N-CA-C 108.816 -0.809 . . . . 75.120000000000005 108.816 177.556 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . 0.419 ' HG3' ' NE2' ' A' ' 34' ' ' GLN . 55.3 mtmt -103.78 155.29 18.72 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-O 120.801 0.334 . . . . 75.430000000000007 110.658 -179.125 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.251 1.135 0 CA-C-O 118.656 -0.688 . . . . 74.239999999999995 109.79 177.691 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 27.0 ptt? . . . . . 0 N--CA 1.483 1.177 0 CA-C-O 120.847 0.356 . . . . 75.439999999999998 110.842 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . 0.406 ' H ' ' CD ' ' A' ' 2' ' ' GLU . 1.8 pm0 -88.36 114.16 24.7 Favored 'General case' 0 C--O 1.239 0.514 0 CA-C-O 121.457 0.646 . . . . 63.039999999999999 110.822 -179.732 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -119.13 162.73 18.14 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 115.002 -0.999 . . . . 74.239999999999995 110.073 -179.297 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -160.65 165.24 34.99 Favored Glycine 0 N--CA 1.442 -0.95 0 C-N-CA 120.889 -0.672 . . . . 72.349999999999994 111.72 178.072 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' THR . . . . . 0.46 ' O ' ' HG2' ' A' ' 19' ' ' GLU . 28.2 m -100.48 137.87 38.3 Favored 'General case' 0 C--N 1.319 -0.726 0 N-CA-C 110.06 -0.348 . . . . 74.400000000000006 110.06 178.451 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 48.1 t -68.62 108.36 1.55 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 N-CA-C 109.793 -0.447 . . . . 64.049999999999997 109.793 175.783 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . 0.616 ' HA ' ' HE3' ' A' ' 7' ' ' LYS . 0.0 OUTLIER -75.2 -56.15 5.01 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-O 120.93 0.395 . . . . 73.349999999999994 110.426 178.313 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' TRP . . . . . . . . . . . . . 4.1 p90 -156.98 136.98 12.6 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 115.749 -0.66 . . . . 75.030000000000001 110.205 179.162 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 17.5 p90 -124.35 108.55 12.32 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-O 121.807 0.813 . . . . 74.409999999999997 110.157 178.515 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 41.2 t-20 -85.93 86.83 7.35 Favored 'General case' 0 C--N 1.318 -0.761 0 CA-C-O 121.477 0.656 . . . . 74.200000000000003 109.401 -178.778 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -57.77 -32.46 67.52 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 114.914 -1.039 . . . . 73.209999999999994 111.623 179.182 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 74.2 mm-40 -64.08 -31.25 72.38 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 120.857 0.36 . . . . 70.450000000000003 111.132 178.848 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . 0.452 ' HB3' ' CE2' ' A' ' 15' ' ' PHE . 0.1 OUTLIER -92.28 -17.77 24.3 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.894 -0.594 . . . . 73.409999999999997 110.746 179.047 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 86.77 19.24 56.75 Favored Glycine 0 N--CA 1.447 -0.585 0 C-N-CA 120.82 -0.705 . . . . 75.319999999999993 112.898 177.635 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . 0.452 ' CE2' ' HB3' ' A' ' 13' ' ' LYS . 31.0 p90 -157.78 156.66 31.94 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 121.133 0.492 . . . . 64.0 111.443 179.587 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -134.87 -179.24 16.31 Favored Glycine 0 N--CA 1.442 -0.906 0 N-CA-C 111.291 -0.724 . . . . 73.519999999999996 111.291 178.671 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . 0.409 ' HA ' ' O ' ' A' ' 26' ' ' VAL . 97.2 m-85 -132.35 127.65 35.98 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-O 121.305 0.574 . . . . 75.239999999999995 111.266 -179.538 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 63.4 mt -101.32 138.86 24.11 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.569 0 CA-C-N 115.209 -0.905 . . . . 73.510000000000005 109.344 177.864 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' GLU . . . . . 0.46 ' HG2' ' O ' ' A' ' 5' ' ' THR . 11.7 pt-20 -82.86 134.84 35.08 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-O 121.196 0.522 . . . . 73.340000000000003 111.303 -177.022 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' ARG . . . . . 0.737 ' HD2' ' H ' ' A' ' 21' ' ' GLU . 0.1 OUTLIER -113.22 -177.96 3.26 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 115.904 -0.589 . . . . 75.239999999999995 109.775 178.506 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . 0.737 ' H ' ' HD2' ' A' ' 20' ' ' ARG . 10.0 pt-20 -59.51 -37.18 77.64 Favored 'General case' 0 C--N 1.327 -0.387 0 N-CA-C 112.93 0.715 . . . . 72.450000000000003 112.93 -173.205 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' ASN . . . . . 0.407 ' ND2' ' HG3' ' A' ' 21' ' ' GLU . 29.3 m-80 -94.21 5.67 51.03 Favored 'General case' 0 C--N 1.328 -0.346 0 O-C-N 122.096 -0.377 . . . . 72.409999999999997 110.805 -178.306 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 84.97 20.02 58.39 Favored Glycine 0 N--CA 1.447 -0.584 0 N-CA-C 110.236 -1.145 . . . . 61.409999999999997 110.236 -170.509 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . 0.459 ' HB2' ' CB ' ' A' ' 20' ' ' ARG . 3.8 m-20 -67.15 95.02 0.38 Allowed 'General case' 0 N--CA 1.45 -0.448 0 CA-C-N 114.879 -0.66 . . . . 73.400000000000006 109.463 179.59 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 11.1 p-10 -63.65 100.81 0.3 Allowed 'General case' 0 C--N 1.32 -0.676 0 CA-C-O 121.833 0.825 . . . . 71.030000000000001 110.309 175.97 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.409 ' O ' ' HA ' ' A' ' 17' ' ' PHE . 44.9 t -78.38 120.76 29.91 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 CA-C-N 115.15 -0.932 . . . . 72.319999999999993 110.756 -177.273 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' PHE . . . . . . . . . . . . . 68.9 t80 -73.34 113.16 10.11 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 115.65 -0.705 . . . . 54.130000000000003 110.433 -179.092 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.416 ' HB ' ' HB1' ' A' ' 60' ' ' ALA . 10.4 p -117.26 126.59 74.64 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.575 0 CA-C-O 121.083 0.468 . . . . 73.129999999999995 110.24 176.068 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' HIS . . . . . 0.425 ' O ' HG13 ' A' ' 33' ' ' ILE . 41.2 t60 -103.46 149.74 24.54 Favored 'General case' 0 C--N 1.324 -0.529 0 N-CA-C 109.452 -0.573 . . . . 74.239999999999995 109.452 -176.754 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' PHE . . . . . 0.414 ' HA ' HD11 ' A' ' 33' ' ' ILE . 42.2 p90 -58.44 -27.29 64.22 Favored 'General case' 0 N--CA 1.467 0.403 0 CA-C-O 120.819 0.342 . . . . 74.319999999999993 111.607 -175.657 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 6.7 m -72.98 -14.13 61.38 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 116.409 -0.36 . . . . 75.420000000000002 111.283 179.005 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -106.88 -17.65 14.14 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.921 0.391 . . . . 73.120000000000005 111.058 -178.466 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.425 HG13 ' O ' ' A' ' 29' ' ' HIS . 66.5 mt -71.22 144.82 13.06 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 CA-C-N 116.032 -0.531 . . . . 73.450000000000003 110.49 177.989 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 34' ' ' GLN . . . . . 0.468 ' HG3' ' O ' ' A' ' 34' ' ' GLN . 21.6 pt20 -66.47 103.96 1.15 Allowed 'General case' 0 C--N 1.33 -0.263 0 N-CA-C 109.581 -0.526 . . . . 72.329999999999998 109.581 172.909 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.508 ' HA2' ' CG ' ' A' ' 39' ' ' LYS . . . -145.52 130.39 3.79 Favored Glycine 0 N--CA 1.442 -0.912 0 C-N-CA 119.633 -1.27 . . . . 74.030000000000001 114.054 -174.474 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 6.5 m-20 -83.03 80.56 9.01 Favored 'General case' 0 C--N 1.324 -0.543 0 N-CA-C 107.761 -1.2 . . . . 70.439999999999998 107.761 167.434 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 80.7 -73.32 2.56 Favored Glycine 0 N--CA 1.443 -0.895 0 N-CA-C 109.979 -1.248 . . . . 71.450000000000003 109.979 -167.137 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 68.2 m-85 -146.72 130.0 16.62 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-O 120.792 0.33 . . . . 73.430000000000007 110.27 173.403 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 39' ' ' LYS . . . . . 0.508 ' CG ' ' HA2' ' A' ' 35' ' ' GLY . 12.1 mmmm -125.69 128.16 47.37 Favored 'General case' 0 C--N 1.326 -0.456 0 N-CA-C 109.16 -0.681 . . . . 74.319999999999993 109.16 174.867 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 51.4 p -87.06 104.0 15.91 Favored 'General case' 0 C--N 1.32 -0.685 0 N-CA-C 112.206 0.446 . . . . 74.420000000000002 112.206 -173.725 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -88.77 103.64 16.16 Favored 'General case' 0 C--N 1.326 -0.439 0 N-CA-C 108.376 -0.972 . . . . 74.510000000000005 108.376 168.968 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 20.5 t70 -76.72 150.85 36.24 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 116.058 -0.519 . . . . 73.019999999999996 111.527 -169.718 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 83.6 mt-10 -61.59 112.82 2.38 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 115.629 -0.714 . . . . 72.239999999999995 110.552 -179.593 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 124.29 -12.87 7.96 Favored Glycine 0 N--CA 1.445 -0.758 0 C-N-CA 120.796 -0.716 . . . . 61.420000000000002 111.547 -177.203 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 6.5 tp-100 -80.06 143.15 34.25 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-O 120.857 0.36 . . . . 74.299999999999997 110.312 178.678 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -99.5 118.75 36.77 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 116.023 -0.535 . . . . 62.32 110.188 179.515 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 27.4 m -123.57 163.01 23.48 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.696 0 CA-C-N 116.227 -0.442 . . . . 70.25 111.11 -176.754 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 1.6 p -117.25 139.86 50.27 Favored 'General case' 0 C--N 1.321 -0.64 0 N-CA-C 108.91 -0.774 . . . . 74.310000000000002 108.91 176.548 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 33.5 p90 -141.24 159.18 42.76 Favored 'General case' 0 C--N 1.317 -0.823 0 C-N-CA 120.3 -0.56 . . . . 72.239999999999995 111.616 -175.26 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 4.9 t70 -88.14 103.16 15.49 Favored 'General case' 0 C--N 1.321 -0.657 0 N-CA-C 108.645 -0.872 . . . . 75.209999999999994 108.645 174.975 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 7.7 p -63.79 123.13 15.99 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 CA-C-O 121.295 0.569 . . . . 71.349999999999994 111.846 -173.09 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . 0.536 ' HB3' ' HG2' ' A' ' 59' ' ' GLN . 7.8 tp10 -117.52 139.86 50.38 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 115.648 -0.705 . . . . 64.420000000000002 110.067 178.997 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 10.8 tp10 -101.31 146.32 27.71 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-N 115.956 -0.565 . . . . 73.450000000000003 109.626 -179.701 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -144.83 -175.79 18.29 Favored Glycine 0 N--CA 1.45 -0.417 0 C-N-CA 120.709 -0.757 . . . . 62.420000000000002 112.527 -177.88 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 50.2 mt-30 -75.11 -34.15 61.67 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 120.755 0.312 . . . . 73.230000000000004 110.85 179.757 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 35.0 mtp-105 -77.1 -33.31 56.93 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-O 121.022 0.439 . . . . 74.209999999999994 110.436 174.39 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 146.87 -155.8 26.71 Favored Glycine 0 N--CA 1.448 -0.504 0 CA-C-N 115.904 -0.589 . . . . 43.219999999999999 111.798 -178.223 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 59.7 Cg_endo -74.26 137.13 23.07 Favored 'Trans proline' 0 C--O 1.234 0.298 0 C-N-CA 122.582 2.188 . . . . 74.099999999999994 112.775 -177.752 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . 0.536 ' HG2' ' HB3' ' A' ' 52' ' ' GLU . 0.0 OUTLIER -131.35 154.75 48.26 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 116.101 -0.499 . . . . 72.239999999999995 109.835 175.142 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . 0.416 ' HB1' ' HB ' ' A' ' 28' ' ' VAL . . . -101.77 106.53 17.54 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 116.294 -0.412 . . . . 55.039999999999999 110.993 -177.132 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -111.28 149.1 31.54 Favored 'General case' 0 C--N 1.321 -0.655 0 N-CA-C 109.263 -0.643 . . . . 65.340000000000003 109.263 175.082 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 86.5 m-20 57.06 82.79 0.11 Allowed 'General case' 0 N--CA 1.466 0.354 0 CA-C-O 121.304 0.573 . . . . 72.510000000000005 110.499 -178.459 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 46.4 t -103.54 134.48 44.61 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.588 0 CA-C-N 115.871 -0.604 . . . . 73.329999999999998 111.327 -174.985 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 28.0 mt-30 -130.71 178.2 6.82 Favored 'General case' 0 C--N 1.325 -0.484 0 N-CA-C 109.189 -0.671 . . . . 73.510000000000005 109.189 175.381 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 50.7 mtmt -96.81 144.18 27.02 Favored 'General case' 0 C--N 1.323 -0.554 0 N-CA-C 110.028 -0.36 . . . . 75.340000000000003 110.028 178.074 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 0.98 0 CA-C-O 118.519 -0.753 . . . . 73.019999999999996 110.274 -179.922 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' MET . . . . . 0.465 ' H2 ' ' HA ' ' A' ' 50' ' ' ASP . 21.1 ptp . . . . . 0 N--CA 1.478 0.935 0 CA-C-O 121.153 0.501 . . . . 74.25 109.926 . . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -91.37 157.7 16.95 Favored 'General case' 0 N--CA 1.452 -0.335 0 CA-C-N 115.653 -0.703 . . . . 71.010000000000005 109.994 -174.105 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' GLN . . . . . 0.424 ' HG2' HG22 ' A' ' 48' ' ' THR . 50.3 mt-30 -105.85 130.67 53.77 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-N 116.029 -0.532 . . . . 71.200000000000003 109.8 174.491 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -150.49 172.9 30.21 Favored Glycine 0 N--CA 1.443 -0.844 0 C-N-CA 120.794 -0.717 . . . . 61.219999999999999 111.683 178.571 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' THR . . . . . 0.521 ' O ' ' HG2' ' A' ' 19' ' ' GLU . 24.3 m -122.65 135.76 54.69 Favored 'General case' 0 C--N 1.317 -0.829 0 N-CA-C 110.167 -0.309 . . . . 74.439999999999998 110.167 179.067 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 46.4 t -72.41 119.06 18.4 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.633 0 CA-C-N 116.741 -0.209 . . . . 72.129999999999995 110.524 -179.114 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . 0.557 ' CE ' ' HB3' ' A' ' 19' ' ' GLU . 97.7 mttt -66.01 -62.59 1.41 Allowed 'General case' 0 CA--C 1.52 -0.193 0 CA-C-O 121.7 0.762 . . . . 73.420000000000002 109.223 175.896 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' TRP . . . . . . . . . . . . . 55.1 p-90 -160.45 156.06 25.42 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-N 114.393 -1.276 . . . . 75.299999999999997 108.053 177.571 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 2.1 p90 -136.03 138.52 42.28 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-O 121.603 0.716 . . . . 75.109999999999999 111.858 -174.113 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' ASN . . . . . 0.537 ' HB3' ' HG2' ' A' ' 13' ' ' LYS . 16.6 m120 -84.12 77.52 9.93 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 115.115 -0.948 . . . . 73.430000000000007 109.115 177.009 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -54.12 -38.43 65.43 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.212 -0.904 . . . . 72.329999999999998 112.367 -175.07 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -90.75 -14.28 32.35 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 116.492 -0.322 . . . . 70.340000000000003 111.697 -175.288 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . 0.537 ' HG2' ' HB3' ' A' ' 10' ' ' ASN . 59.6 mmtt -90.55 -36.39 14.5 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 121.191 0.52 . . . . 73.040000000000006 109.649 177.017 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 99.59 32.88 5.54 Favored Glycine 0 N--CA 1.447 -0.619 0 CA-C-N 115.698 -0.683 . . . . 62.009999999999998 111.636 -177.676 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 74.0 m-85 -140.19 168.82 18.91 Favored 'General case' 0 C--N 1.329 -0.312 0 N-CA-C 110.152 -0.314 . . . . 72.340000000000003 110.152 -177.941 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -171.12 161.34 33.96 Favored Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.542 -0.837 . . . . 65.209999999999994 112.437 177.764 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 97.4 m-85 -123.93 120.21 31.86 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-O 121.033 0.444 . . . . 75.049999999999997 110.908 -179.847 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.42 HG22 ' CE2' ' A' ' 49' ' ' PHE . 54.0 mt -105.12 135.95 41.0 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.616 0 CA-C-N 115.869 -0.605 . . . . 74.519999999999996 109.74 178.981 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' GLU . . . . . 0.557 ' HB3' ' CE ' ' A' ' 7' ' ' LYS . 11.6 pt-20 -94.81 128.64 41.69 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 121.404 0.621 . . . . 73.439999999999998 111.654 -177.461 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 20' ' ' ARG . . . . . 0.45 ' HB3' ' HB3' ' A' ' 24' ' ' ASP . 18.6 ttt180 -89.67 177.13 6.61 Favored 'General case' 0 C--N 1.323 -0.548 0 N-CA-C 108.289 -1.004 . . . . 74.530000000000001 108.289 171.697 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 44.6 mt-10 -61.04 -12.05 10.41 Favored 'General case' 0 N--CA 1.467 0.409 0 N-CA-C 112.098 0.407 . . . . 73.329999999999998 112.098 -178.787 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 82.6 m-20 -98.05 -4.22 36.46 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.89 0.376 . . . . 73.430000000000007 111.239 177.826 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 82.42 3.17 90.64 Favored Glycine 0 N--CA 1.449 -0.461 0 N-CA-C 110.337 -1.105 . . . . 65.439999999999998 110.337 -168.657 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . 0.45 ' HB3' ' HB3' ' A' ' 20' ' ' ARG . 33.6 t70 -56.3 98.73 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 114.61 -0.795 . . . . 74.049999999999997 110.721 -179.062 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.483 ' CG ' ' HZ3' ' A' ' 7' ' ' LYS . 12.4 m-20 -56.5 100.44 0.04 OUTLIER 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 114.964 -1.016 . . . . 73.200000000000003 111.698 174.999 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.499 HG12 ' HB1' ' A' ' 60' ' ' ALA . 21.4 t -83.1 116.6 27.55 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.743 0 N-CA-C 108.761 -0.829 . . . . 72.549999999999997 108.761 172.883 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 27' ' ' PHE . . . . . . . . . . . . . 81.1 t80 -83.22 116.15 22.26 Favored 'General case' 0 C--N 1.32 -0.682 0 CA-C-N 115.894 -0.594 . . . . 75.299999999999997 111.021 -173.414 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 9.0 p -105.73 148.91 9.61 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.581 0 N-CA-C 109.534 -0.543 . . . . 71.140000000000001 109.534 175.901 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 29' ' ' HIS . . . . . 0.443 ' O ' HG13 ' A' ' 33' ' ' ILE . 2.7 p80 -140.19 163.88 31.56 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 116.277 -0.419 . . . . 72.329999999999998 110.58 -174.173 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 31.3 p90 -53.18 -33.0 50.79 Favored 'General case' 0 N--CA 1.47 0.536 0 N-CA-C 112.871 0.693 . . . . 74.010000000000005 112.871 -174.001 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 27.5 m -84.92 34.23 0.54 Allowed 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 121.174 0.511 . . . . 73.209999999999994 110.906 176.866 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -160.57 -33.56 0.05 Allowed 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 115.826 -0.625 . . . . 75.150000000000006 110.729 -179.364 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.443 HG13 ' O ' ' A' ' 29' ' ' HIS . 71.7 mt -63.7 143.37 15.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.065 -0.516 . . . . 75.439999999999998 110.461 176.195 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 34' ' ' GLN . . . . . 0.502 ' O ' ' HA ' ' A' ' 39' ' ' LYS . 88.4 mt-30 -53.69 113.33 1.15 Allowed 'General case' 0 C--N 1.329 -0.293 0 N-CA-C 109.792 -0.448 . . . . 75.319999999999993 109.792 172.117 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -101.54 -31.32 5.55 Favored Glycine 0 N--CA 1.45 -0.431 0 C-N-CA 120.321 -0.943 . . . . 52.340000000000003 112.266 -178.839 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 9.7 m-20 -106.38 115.4 30.15 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-O 120.882 0.372 . . . . 75.099999999999994 110.099 -178.797 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 116.06 -123.3 5.83 Favored Glycine 0 N--CA 1.446 -0.667 0 N-CA-C 111.126 -0.79 . . . . 74.230000000000004 111.126 -175.407 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 72.9 m-85 -96.46 93.51 6.86 Favored 'General case' 0 C--N 1.325 -0.499 0 N-CA-C 109.628 -0.508 . . . . 75.310000000000002 109.628 175.899 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 39' ' ' LYS . . . . . 0.502 ' HA ' ' O ' ' A' ' 34' ' ' GLN . 0.0 OUTLIER -74.98 -29.34 60.87 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 116.098 -0.501 . . . . 75.209999999999994 111.901 -173.182 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 15.2 m -67.88 108.12 2.89 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-O 120.947 0.403 . . . . 73.530000000000001 111.619 -174.01 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 92.2 mt -82.16 74.35 9.15 Favored 'General case' 0 C--N 1.324 -0.51 0 N-CA-C 108.797 -0.816 . . . . 75.409999999999997 108.797 171.415 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 27.6 t70 -55.38 139.88 41.64 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 115.18 -0.918 . . . . 75.319999999999993 112.051 -172.467 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 7.8 pt-20 -64.66 129.72 40.87 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-N 115.428 -0.806 . . . . 73.439999999999998 110.582 179.121 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 97.15 -10.22 65.54 Favored Glycine 0 N--CA 1.45 -0.403 0 C-N-CA 120.871 -0.68 . . . . 74.340000000000003 112.036 -177.202 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 54.0 tp60 -81.78 135.35 35.47 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-O 120.767 0.318 . . . . 72.049999999999997 110.558 178.769 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -85.35 138.54 32.22 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 116.117 -0.492 . . . . 74.450000000000003 110.097 176.043 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 16.6 m -136.98 144.84 31.08 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.605 0 CA-C-N 116.348 -0.387 . . . . 73.140000000000001 111.25 -177.415 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 48' ' ' THR . . . . . 0.424 HG22 ' HG2' ' A' ' 3' ' ' GLN . 24.7 p -104.58 122.74 46.23 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-N 115.753 -0.658 . . . . 74.030000000000001 109.571 173.633 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 49' ' ' PHE . . . . . 0.468 ' HA ' ' O ' ' A' ' 62' ' ' ASN . 38.8 p90 -141.09 157.3 45.49 Favored 'General case' 0 C--N 1.32 -0.701 0 CA-C-O 120.701 0.286 . . . . 73.349999999999994 111.206 -172.403 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . 0.465 ' HA ' ' H2 ' ' A' ' 1' ' ' MET . 30.2 m-20 -90.48 149.49 22.19 Favored 'General case' 0 C--N 1.321 -0.674 0 N-CA-C 109.684 -0.488 . . . . 71.439999999999998 109.684 172.357 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 5.4 p -110.44 117.14 54.16 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.628 0 CA-C-O 121.428 0.633 . . . . 74.430000000000007 111.549 -175.28 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . 0.624 ' HB2' ' HB2' ' A' ' 59' ' ' GLN . 6.9 mm-40 -94.76 133.43 38.46 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 115.432 -0.804 . . . . 73.540000000000006 109.476 174.456 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 8.5 pt-20 -82.04 97.82 8.33 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-O 121.354 0.597 . . . . 75.049999999999997 110.86 -179.33 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -90.02 151.84 21.89 Favored Glycine 0 N--CA 1.446 -0.685 0 C-N-CA 120.736 -0.745 . . . . 74.409999999999997 111.671 179.041 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 49.8 mt-30 -58.38 -25.96 62.65 Favored 'General case' 0 C--N 1.327 -0.375 0 N-CA-C 112.377 0.51 . . . . 74.5 112.377 -177.182 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 81.4 mtt180 -130.49 26.86 5.06 Favored 'General case' 0 C--N 1.327 -0.41 0 N-CA-C 111.716 0.265 . . . . 73.129999999999995 111.716 -177.217 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 150.22 153.32 6.06 Favored Glycine 0 N--CA 1.449 -0.441 0 C-N-CA 120.128 -1.034 . . . . 74.150000000000006 113.074 177.319 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 7.2 Cg_exo -72.59 124.42 9.8 Favored 'Trans proline' 0 N--CA 1.46 -0.478 0 C-N-CA 122.834 2.356 . . . . 74.0 111.475 177.449 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . 0.624 ' HB2' ' HB2' ' A' ' 52' ' ' GLU . 26.0 mt-30 -94.53 123.44 37.96 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-N 116.243 -0.435 . . . . 75.239999999999995 110.664 -179.029 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . 0.499 ' HB1' HG12 ' A' ' 26' ' ' VAL . . . -78.99 106.59 11.14 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 116.308 -0.405 . . . . 72.409999999999997 109.946 176.244 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -116.86 139.48 50.57 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 116.311 -0.404 . . . . 63.43 110.033 -179.928 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 62' ' ' ASN . . . . . 0.468 ' O ' ' HA ' ' A' ' 49' ' ' PHE . 76.8 m-20 60.31 92.26 0.05 OUTLIER 'General case' 0 C--O 1.236 0.358 0 O-C-N 123.595 0.56 . . . . 74.310000000000002 110.008 -176.116 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 40.7 t -114.3 136.59 50.35 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.547 0 CA-C-N 115.469 -0.787 . . . . 74.010000000000005 110.55 -175.16 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 64' ' ' GLN . . . . . 0.421 ' HB3' ' OG1' ' A' ' 48' ' ' THR . 31.0 tt0 -121.5 149.14 43.51 Favored 'General case' 0 C--N 1.319 -0.737 0 N-CA-C 109.624 -0.51 . . . . 64.299999999999997 109.624 176.403 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 48.4 mttp -91.49 123.83 35.2 Favored 'General case' 0 C--N 1.324 -0.502 0 N-CA-C 110.112 -0.329 . . . . 73.430000000000007 110.112 178.491 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.246 0.886 0 CA-C-O 118.602 -0.713 . . . . 75.120000000000005 110.647 -179.942 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 27.2 ttt . . . . . 0 N--CA 1.483 1.178 0 CA-C-O 120.931 0.396 . . . . 74.349999999999994 110.852 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 60.7 mm-40 -81.48 69.7 8.18 Favored 'General case' 0 C--O 1.238 0.471 0 CA-C-O 121.388 0.613 . . . . 75.209999999999994 111.837 -178.979 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 35.3 tt0 -120.91 136.28 54.99 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-N 115.34 -0.845 . . . . 74.549999999999997 109.478 174.756 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -151.9 164.49 30.4 Favored Glycine 0 N--CA 1.444 -0.788 0 N-CA-C 111.368 -0.693 . . . . 64.310000000000002 111.368 179.027 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' THR . . . . . 0.541 HG22 ' HE3' ' A' ' 7' ' ' LYS . 5.4 m -103.38 125.32 49.92 Favored 'General case' 0 C--N 1.318 -0.802 0 CA-C-N 116.984 0.392 . . . . 74.209999999999994 110.825 -178.623 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.484 HG22 HG12 ' A' ' 18' ' ' ILE . 46.1 t -81.52 90.47 1.94 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 N-CA-C 109.099 -0.704 . . . . 73.439999999999998 109.099 175.473 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . 0.541 ' HE3' HG22 ' A' ' 5' ' ' THR . 27.9 mmtp -78.02 -51.9 9.62 Favored 'General case' 0 C--N 1.323 -0.587 0 CA-C-N 115.818 -0.628 . . . . 74.209999999999994 111.584 -176.155 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' TRP . . . . . . . . . . . . . 8.8 p90 -133.12 122.25 23.81 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-O 121.41 0.624 . . . . 72.530000000000001 110.992 178.113 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 22.2 p90 -111.6 123.43 50.21 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-N 115.343 -0.844 . . . . 72.209999999999994 109.544 178.434 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 16.7 t-20 -88.39 76.18 8.34 Favored 'General case' 0 C--N 1.317 -0.806 0 CA-C-O 121.503 0.668 . . . . 61.439999999999998 109.893 -176.737 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -67.75 -7.93 31.39 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.241 -0.89 . . . . 73.530000000000001 110.442 178.438 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 27.3 mt-10 -70.45 -33.41 71.26 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 115.306 -0.861 . . . . 74.400000000000006 110.595 179.081 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . 0.409 ' HB2' ' CE1' ' A' ' 15' ' ' PHE . 74.3 mmtt -116.25 -29.66 6.18 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.235 -0.439 . . . . 72.439999999999998 111.296 -178.47 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . 0.608 ' HA2' ' CE2' ' A' ' 30' ' ' PHE . . . 117.52 24.83 3.33 Favored Glycine 0 N--CA 1.452 -0.265 0 C-N-CA 120.178 -1.011 . . . . 70.299999999999997 113.773 175.842 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . 0.409 ' CE1' ' HB2' ' A' ' 13' ' ' LYS . 54.9 p90 -142.1 -174.11 4.01 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 116.921 0.361 . . . . 75.519999999999996 110.124 179.334 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -169.65 170.39 42.68 Favored Glycine 0 N--CA 1.449 -0.454 0 C-N-CA 120.358 -0.925 . . . . 53.030000000000001 112.147 177.713 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 98.2 m-85 -120.17 126.59 51.04 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 121.054 0.454 . . . . 75.530000000000001 110.81 -179.728 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.484 HG12 HG22 ' A' ' 6' ' ' VAL . 62.9 mt -110.81 129.21 66.42 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.572 0 CA-C-N 115.777 -0.647 . . . . 70.530000000000001 110.179 179.724 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 7.0 pt-20 -79.71 113.26 17.73 Favored 'General case' 0 C--N 1.326 -0.436 0 N-CA-C 109.665 -0.494 . . . . 63.100000000000001 109.665 175.673 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 20' ' ' ARG . . . . . 0.413 ' HD3' ' OD2' ' A' ' 24' ' ' ASP . 73.0 ttt-85 -113.02 111.15 21.68 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 116.06 -0.518 . . . . 74.340000000000003 111.332 -175.604 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 10.7 mm-40 47.3 -89.6 0.01 OUTLIER 'General case' 0 N--CA 1.47 0.537 0 N-CA-C 114.158 1.17 . . . . 74.25 114.158 169.725 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 23.6 t-20 -70.51 -31.38 68.44 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 121.12 0.486 . . . . 71.319999999999993 111.27 -174.018 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 130.51 -1.67 5.66 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.728 -0.748 . . . . 62.439999999999998 111.255 -176.405 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . 0.413 ' OD2' ' HD3' ' A' ' 20' ' ' ARG . 2.6 p-10 -67.92 94.35 0.47 Allowed 'General case' 0 C--N 1.323 -0.565 0 CA-C-O 121.355 0.597 . . . . 61.340000000000003 110.185 175.937 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 5.7 p-10 -57.02 123.58 15.68 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 114.989 -1.005 . . . . 75.200000000000003 110.751 176.938 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 46.4 t -97.22 135.05 32.77 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.658 0 CA-C-N 115.614 -0.721 . . . . 72.219999999999999 110.326 -179.764 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 27' ' ' PHE . . . . . . . . . . . . . 32.5 t80 -80.77 105.58 12.12 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 116.142 -0.481 . . . . 75.099999999999994 110.161 -179.188 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 9.9 p -99.74 158.87 3.7 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.516 0 N-CA-C 110.011 -0.366 . . . . 70.239999999999995 110.011 179.522 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 1.1 p80 -147.89 159.49 43.8 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.534 -0.303 . . . . 71.519999999999996 110.29 -178.414 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 30' ' ' PHE . . . . . 0.608 ' CE2' ' HA2' ' A' ' 14' ' ' GLY . 23.0 m-85 -56.82 -37.14 70.8 Favored 'General case' 0 N--CA 1.468 0.443 0 N-CA-C 112.76 0.652 . . . . 72.400000000000006 112.76 -173.767 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 12.7 t -70.97 -3.31 18.75 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 120.893 0.377 . . . . 42.450000000000003 111.269 -178.157 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -107.08 -34.13 7.25 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.75 0.31 . . . . 74.519999999999996 110.668 177.015 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.492 ' HA ' ' HB ' ' A' ' 63' ' ' VAL . 61.2 mt -65.17 140.27 20.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.109 -0.496 . . . . 74.109999999999999 110.708 179.041 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 11.3 pt20 -74.36 23.35 0.09 Allowed 'General case' 0 CA--C 1.537 0.443 0 N-CA-C 112.359 0.503 . . . . 55.119999999999997 112.359 -177.488 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.406 ' H ' ' C ' ' A' ' 33' ' ' ILE . . . -83.16 116.62 4.25 Favored Glycine 0 N--CA 1.449 -0.498 0 C-N-CA 120.617 -0.801 . . . . 74.540000000000006 112.003 -179.689 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 14.7 t70 -81.98 111.26 17.99 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.741 0.305 . . . . 74.450000000000003 110.512 178.825 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 75.41 -118.9 5.66 Favored Glycine 0 N--CA 1.446 -0.665 0 C-N-CA 120.969 -0.634 . . . . 64.400000000000006 112.076 179.915 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 97.5 m-85 -106.06 90.25 3.31 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-O 120.946 0.403 . . . . 75.019999999999996 110.515 -179.189 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 32.1 mmmt -130.57 146.58 52.11 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.785 -0.643 . . . . 64.430000000000007 109.66 177.367 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 18.6 m -109.05 113.69 26.78 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-O 120.682 0.277 . . . . 74.219999999999999 110.457 -179.691 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . 0.401 HD21 ' HA ' ' A' ' 41' ' ' LEU . 1.9 tm? -62.85 125.87 25.42 Favored 'General case' 0 C--N 1.326 -0.433 0 N-CA-C 109.078 -0.712 . . . . 75.230000000000004 109.078 178.374 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 18.1 m-20 -60.16 119.76 8.47 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 116.245 -0.434 . . . . 74.200000000000003 110.974 -176.627 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 8.2 pt-20 -67.18 119.5 12.2 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-O 121.34 0.59 . . . . 64.540000000000006 110.145 177.616 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 112.49 -4.61 26.43 Favored Glycine 0 N--CA 1.445 -0.713 0 N-CA-C 111.179 -0.768 . . . . 64.329999999999998 111.179 -174.532 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 5.8 tp-100 -72.67 132.91 44.31 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 120.874 0.369 . . . . 75.25 110.946 179.73 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -86.08 115.07 23.44 Favored 'General case' 0 C--N 1.325 -0.465 0 N-CA-C 108.89 -0.781 . . . . 73.129999999999995 108.89 173.073 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . 0.51 ' HA ' ' HA ' ' A' ' 65' ' ' LYS . 29.3 m -110.27 155.29 11.6 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.811 0 CA-C-O 121.316 0.579 . . . . 74.010000000000005 111.51 -174.945 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 48' ' ' THR . . . . . 0.534 HG23 ' HB3' ' A' ' 66' ' ' ALA . 45.4 p -121.15 112.31 18.52 Favored 'General case' 0 C--N 1.318 -0.773 0 CA-C-N 115.322 -0.854 . . . . 73.150000000000006 108.832 175.376 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 49' ' ' PHE . . . . . 0.402 ' HA ' ' O ' ' A' ' 62' ' ' ASN . 35.4 p90 -127.07 171.98 10.9 Favored 'General case' 0 C--N 1.319 -0.748 0 CA-C-N 115.95 -0.568 . . . . 71.150000000000006 111.323 -170.969 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 62.9 m-20 -96.12 138.43 33.75 Favored 'General case' 0 C--N 1.322 -0.598 0 N-CA-C 109.065 -0.717 . . . . 75.299999999999997 109.065 169.935 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 12.5 p -102.31 134.67 42.39 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.721 0 CA-C-O 121.008 0.432 . . . . 71.219999999999999 111.27 -174.767 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 40.1 mt-10 -122.35 148.81 44.6 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 116.066 -0.515 . . . . 73.439999999999998 110.24 175.889 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 36.5 mt-10 -106.07 123.41 47.96 Favored 'General case' 0 C--N 1.319 -0.736 0 N-CA-C 109.61 -0.515 . . . . 71.430000000000007 109.61 177.401 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -118.46 -178.99 17.06 Favored Glycine 0 N--CA 1.445 -0.74 0 C-N-CA 120.669 -0.777 . . . . 74.540000000000006 112.287 -178.512 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -67.64 -29.45 68.76 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 120.772 0.32 . . . . 75.209999999999994 111.548 -179.755 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 22.0 ttt180 -85.03 -27.62 26.27 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.184 -0.462 . . . . 73.030000000000001 110.448 179.455 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 148.73 -164.87 29.16 Favored Glycine 0 N--CA 1.446 -0.645 0 C-N-CA 120.893 -0.67 . . . . 71.140000000000001 111.864 -179.282 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 56.4 Cg_endo -72.41 126.85 11.97 Favored 'Trans proline' 0 N--CA 1.463 -0.288 0 C-N-CA 122.702 2.268 . . . . 62.030000000000001 112.388 179.595 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 11.5 pt20 -123.72 154.33 39.61 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-N 115.851 -0.613 . . . . 74.030000000000001 110.152 -179.974 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -99.57 135.25 41.27 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 116.383 -0.371 . . . . 55.240000000000002 111.168 -177.958 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -131.97 149.63 52.38 Favored 'General case' 0 C--N 1.324 -0.529 0 N-CA-C 108.829 -0.804 . . . . 74.540000000000006 108.829 174.461 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 62' ' ' ASN . . . . . 0.402 ' O ' ' HA ' ' A' ' 49' ' ' PHE . 55.5 m-20 53.57 75.57 0.26 Allowed 'General case' 0 C--O 1.239 0.504 0 N-CA-C 110.028 -0.36 . . . . 73.120000000000005 110.028 -174.999 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.492 ' HB ' ' HA ' ' A' ' 33' ' ' ILE . 59.4 t -101.9 101.99 12.89 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.517 0 CA-C-O 121.171 0.51 . . . . 75.109999999999999 110.947 -176.191 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 50.8 mt-30 -107.48 170.27 8.07 Favored 'General case' 0 C--N 1.32 -0.707 0 N-CA-C 108.593 -0.892 . . . . 74.329999999999998 108.593 175.791 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . 0.51 ' HA ' ' HA ' ' A' ' 47' ' ' VAL . 21.9 pttp -93.58 169.1 10.59 Favored 'General case' 0 C--N 1.321 -0.66 0 C-N-CA 120.477 -0.489 . . . . 74.329999999999998 110.277 179.658 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 66' ' ' ALA . . . . . 0.534 ' HB3' HG23 ' A' ' 48' ' ' THR . . . . . . . . 0 C--O 1.246 0.907 0 CA-C-O 118.275 -0.869 . . . . 52.450000000000003 109.96 176.241 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' MET . . . . . 0.418 ' HG2' ' OE2' ' A' ' 2' ' ' GLU . 22.3 ptp . . . . . 0 N--CA 1.486 1.326 0 CA-C-O 121.113 0.483 . . . . 75.140000000000001 110.075 . . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . 0.418 ' OE2' ' HG2' ' A' ' 1' ' ' MET . 6.9 mp0 -94.05 128.35 40.36 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 115.982 -0.554 . . . . 65.409999999999997 110.572 -169.887 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 27.0 tt0 -90.34 98.94 12.07 Favored 'General case' 0 C--N 1.322 -0.614 0 N-CA-C 109.085 -0.709 . . . . 73.5 109.085 174.567 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -120.91 163.42 14.41 Favored Glycine 0 N--CA 1.446 -0.667 0 C-N-CA 120.575 -0.821 . . . . 75.400000000000006 112.668 -174.591 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' THR . . . . . 0.457 ' O ' ' HG2' ' A' ' 19' ' ' GLU . 0.2 OUTLIER -105.23 129.53 53.58 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-O 121.028 0.442 . . . . 74.099999999999994 110.969 179.826 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.539 HG22 HG12 ' A' ' 18' ' ' ILE . 17.0 t -71.06 121.66 21.44 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.582 0 CA-C-N 116.08 -0.509 . . . . 63.100000000000001 110.451 179.684 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 50.5 mttp -74.33 -49.48 22.7 Favored 'General case' 0 C--N 1.329 -0.302 0 C-N-CA 120.719 -0.392 . . . . 74.129999999999995 110.433 177.677 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' TRP . . . . . . . . . . . . . 14.9 p-90 -161.99 163.74 28.74 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.91 -0.586 . . . . 74.510000000000005 109.671 179.469 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 10.9 p90 -145.02 121.1 10.75 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-O 121.31 0.576 . . . . 74.120000000000005 111.098 -178.131 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 52.2 t-20 -82.73 86.43 6.88 Favored 'General case' 0 C--N 1.321 -0.631 0 N-CA-C 109.267 -0.642 . . . . 73.530000000000001 109.267 177.226 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -72.84 -5.33 37.47 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.303 -0.862 . . . . 73.450000000000003 111.748 -179.644 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 9.8 mm-40 -86.25 -19.4 30.01 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-O 120.977 0.418 . . . . 70.140000000000001 110.253 177.355 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 43.4 mmtm -108.76 -48.04 3.37 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 115.945 -0.571 . . . . 70.430000000000007 110.047 176.71 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 115.76 43.83 0.67 Allowed Glycine 0 N--CA 1.442 -0.929 0 C-N-CA 120.765 -0.731 . . . . 63.130000000000003 112.174 -179.134 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 43.8 p90 -152.03 161.29 42.87 Favored 'General case' 0 C--N 1.328 -0.349 0 N-CA-C 110.183 -0.302 . . . . 74.409999999999997 110.183 176.926 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -154.02 171.1 32.66 Favored Glycine 0 N--CA 1.448 -0.548 0 C-N-CA 120.877 -0.678 . . . . 74.109999999999999 112.166 179.88 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 80.9 m-85 -124.04 116.78 23.36 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-O 121.049 0.452 . . . . 75.109999999999999 110.75 179.591 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.539 HG12 HG22 ' A' ' 6' ' ' VAL . 11.3 mt -109.94 123.02 65.48 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.524 0 N-CA-C 108.715 -0.846 . . . . 75.519999999999996 108.715 178.63 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' GLU . . . . . 0.479 ' HA ' ' HA ' ' A' ' 25' ' ' ASP . 16.7 pt-20 -76.15 138.43 40.71 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-O 121.404 0.621 . . . . 73.329999999999998 112.092 -170.549 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 20' ' ' ARG . . . . . 0.589 ' HB3' ' HB3' ' A' ' 24' ' ' ASP . 78.1 ttt180 -91.73 161.33 14.93 Favored 'General case' 0 C--N 1.321 -0.659 0 N-CA-C 108.51 -0.922 . . . . 73.219999999999999 108.51 171.126 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . 0.49 ' OE1' ' HG2' ' A' ' 20' ' ' ARG . 0.0 OUTLIER -71.1 6.45 1.62 Allowed 'General case' 0 CA--C 1.537 0.455 0 N-CA-C 112.745 0.646 . . . . 71.030000000000001 112.745 -173.559 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 9.4 m-80 -108.63 5.29 24.82 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-O 120.792 0.33 . . . . 73.409999999999997 110.895 175.31 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 84.88 0.86 89.07 Favored Glycine 0 N--CA 1.453 -0.227 0 N-CA-C 110.572 -1.011 . . . . 71.209999999999994 110.572 -172.89 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . 0.589 ' HB3' ' HB3' ' A' ' 20' ' ' ARG . 31.5 t70 -76.07 87.49 2.97 Favored 'General case' 0 C--N 1.321 -0.669 0 CA-C-N 114.631 -0.784 . . . . 74.5 109.946 -178.859 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.479 ' HA ' ' HA ' ' A' ' 19' ' ' GLU . 55.9 m-20 -64.5 110.69 2.39 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 116.02 -0.537 . . . . 75.129999999999995 110.647 179.121 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.455 HG12 ' HB2' ' A' ' 58' ' ' PRO . 28.2 t -85.2 130.01 36.88 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.492 0 CA-C-N 115.639 -0.709 . . . . 73.150000000000006 110.977 -175.281 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 27' ' ' PHE . . . . . . . . . . . . . 85.3 t80 -84.87 122.84 29.75 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.745 -0.661 . . . . 74.200000000000003 110.816 -178.48 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.528 ' HB ' ' HB2' ' A' ' 60' ' ' ALA . 12.3 p -120.47 145.62 26.58 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.574 0 CA-C-N 116.591 -0.277 . . . . 73.140000000000001 110.276 178.249 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 29' ' ' HIS . . . . . 0.466 ' O ' HG13 ' A' ' 33' ' ' ILE . 2.0 t-160 -111.7 157.44 20.48 Favored 'General case' 0 C--N 1.327 -0.381 0 N-CA-C 109.432 -0.581 . . . . 75.0 109.432 -179.706 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 33.6 p90 -51.57 -40.18 59.28 Favored 'General case' 0 N--CA 1.471 0.582 0 N-CA-C 113.367 0.877 . . . . 73.319999999999993 113.367 -170.471 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 29.5 t -83.6 -6.95 59.58 Favored 'General case' 0 C--N 1.33 -0.282 0 C-N-CA 120.691 -0.404 . . . . 74.409999999999997 111.262 -176.056 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -93.67 -20.22 20.37 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-O 121.43 0.634 . . . . 72.150000000000006 109.457 174.791 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.466 HG13 ' O ' ' A' ' 29' ' ' HIS . 52.0 mt -75.53 154.28 6.2 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.408 0 CA-C-N 114.979 -1.01 . . . . 74.329999999999998 109.335 174.782 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 34' ' ' GLN . . . . . 0.4 ' HB3' ' O ' ' A' ' 63' ' ' VAL . 3.8 pt20 -69.43 128.0 35.01 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-O 121.052 0.453 . . . . 63.439999999999998 110.728 179.299 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -85.27 -9.53 79.52 Favored Glycine 0 N--CA 1.45 -0.429 0 C-N-CA 120.438 -0.887 . . . . 72.439999999999998 111.36 176.566 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 5.7 m-20 -124.61 146.57 49.0 Favored 'General case' 0 C--N 1.324 -0.537 0 N-CA-C 109.222 -0.658 . . . . 63.409999999999997 109.222 179.849 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 104.99 -88.68 0.6 Allowed Glycine 0 N--CA 1.448 -0.507 0 N-CA-C 111.164 -0.774 . . . . 74.450000000000003 111.164 -175.419 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 77.3 m-85 -112.96 109.57 19.08 Favored 'General case' 0 C--N 1.323 -0.565 0 N-CA-C 109.773 -0.455 . . . . 75.420000000000002 109.773 174.903 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -72.37 -15.43 61.86 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 121.262 0.553 . . . . 64.439999999999998 110.076 179.005 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 18.4 p -142.2 115.25 8.78 Favored 'General case' 0 N--CA 1.448 -0.561 0 CA-C-N 115.608 -0.724 . . . . 73.439999999999998 109.961 176.093 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 3.8 mm? -81.02 126.83 31.89 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 116.289 -0.414 . . . . 75.310000000000002 110.365 -179.503 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . 0.79 ' HB2' ' HB2' ' A' ' 45' ' ' GLN . 5.4 m-20 -65.11 143.93 57.57 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.801 -0.636 . . . . 75.010000000000005 110.18 178.98 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -80.01 90.69 5.4 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-O 122.528 1.156 . . . . 70.129999999999995 109.332 174.737 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 130.65 0.5 5.29 Favored Glycine 0 N--CA 1.445 -0.713 0 CA-C-N 114.007 -1.451 . . . . 63.119999999999997 110.539 -169.148 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 45' ' ' GLN . . . . . 0.79 ' HB2' ' HB2' ' A' ' 42' ' ' ASP . 6.7 tp-100 -78.07 140.78 39.11 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.381 -0.41 . . . . 75.530000000000001 110.291 177.828 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -101.98 120.56 40.61 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 116.207 -0.451 . . . . 74.540000000000006 110.533 179.442 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 17.8 m -132.94 158.78 43.37 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.564 0 CA-C-N 116.181 -0.463 . . . . 74.239999999999995 110.72 -179.134 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 48' ' ' THR . . . . . 0.591 HG23 ' HB3' ' A' ' 66' ' ' ALA . 37.1 p -103.16 99.64 9.52 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 121.33 0.586 . . . . 74.420000000000002 110.876 -178.681 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 49' ' ' PHE . . . . . 0.411 ' HA ' ' O ' ' A' ' 62' ' ' ASN . 42.0 p90 -105.62 167.6 9.65 Favored 'General case' 0 C--N 1.315 -0.911 0 CA-C-N 115.635 -0.711 . . . . 74.219999999999999 109.732 -179.796 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 4.6 t70 -117.34 111.8 19.86 Favored 'General case' 0 C--N 1.319 -0.731 0 C-N-CA 120.197 -0.601 . . . . 74.510000000000005 110.351 172.703 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 9.1 p -69.15 125.67 27.58 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-O 121.707 0.765 . . . . 75.510000000000005 112.275 -176.407 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 6.4 mm-40 -102.69 134.14 46.56 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-N 115.314 -0.857 . . . . 63.520000000000003 108.995 172.467 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 15.4 pt-20 -87.77 127.03 35.32 Favored 'General case' 0 C--N 1.32 -0.709 0 C-N-CA 120.447 -0.501 . . . . 73.439999999999998 110.047 177.499 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -153.53 -158.39 8.56 Favored Glycine 0 N--CA 1.447 -0.625 0 C-N-CA 120.224 -0.989 . . . . 63.149999999999999 113.007 -178.42 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 39.8 mt-30 -66.28 -24.53 66.58 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.865 0.364 . . . . 75.340000000000003 111.276 -175.85 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -93.89 9.36 37.67 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 116.283 -0.417 . . . . 61.520000000000003 110.46 179.158 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 81.34 -115.92 4.11 Favored Glycine 0 N--CA 1.444 -0.791 0 N-CA-C 110.754 -0.939 . . . . 63.25 110.754 -174.504 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . 0.455 ' HB2' HG12 ' A' ' 26' ' ' VAL . 89.3 Cg_endo -81.53 109.01 2.0 Favored 'Trans proline' 0 N--CA 1.455 -0.749 0 C-N-CA 122.482 2.121 . . . . 74.340000000000003 112.005 175.217 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 51.1 tt0 -115.51 118.17 32.42 Favored 'General case' 0 C--N 1.322 -0.594 0 N-CA-C 109.455 -0.572 . . . . 75.019999999999996 109.455 176.947 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . 0.528 ' HB2' ' HB ' ' A' ' 28' ' ' VAL . . . -78.67 123.94 27.67 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-O 121.004 0.431 . . . . 64.420000000000002 111.818 -173.029 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -124.75 145.7 49.58 Favored 'General case' 0 C--N 1.321 -0.667 0 N-CA-C 109.14 -0.689 . . . . 74.439999999999998 109.14 173.325 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 62' ' ' ASN . . . . . 0.411 ' O ' ' HA ' ' A' ' 49' ' ' PHE . 47.3 m-80 60.61 87.83 0.09 Allowed 'General case' 0 C--O 1.236 0.394 0 CA-C-O 121.321 0.581 . . . . 73.510000000000005 110.704 -175.57 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.4 ' O ' ' HB3' ' A' ' 34' ' ' GLN . 58.0 t -100.29 106.72 19.7 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.547 0 CA-C-N 115.443 -0.799 . . . . 74.200000000000003 109.407 176.132 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 48.7 mt-30 -103.98 160.38 14.87 Favored 'General case' 0 C--N 1.319 -0.741 0 CA-C-N 116.086 -0.507 . . . . 75.129999999999995 110.665 -177.191 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . 0.645 ' HB3' ' HZ1' ' A' ' 65' ' ' LYS . 9.7 mtpm? -77.07 136.43 38.66 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 115.928 -0.578 . . . . 75.319999999999993 109.731 176.481 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 66' ' ' ALA . . . . . 0.591 ' HB3' HG23 ' A' ' 48' ' ' THR . . . . . . . . 0 C--O 1.248 1.006 0 CA-C-O 118.666 -0.683 . . . . 63.009999999999998 110.19 -179.505 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.479 1.003 0 N-CA-C 110.12 -0.326 . . . . 70.450000000000003 110.12 . . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 4.5 mm-40 53.21 61.47 3.14 Favored 'General case' 0 C--O 1.236 0.38 0 O-C-N 123.783 0.677 . . . . 74.129999999999995 111.299 175.729 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 24.1 tt0 -86.57 125.16 33.6 Favored 'General case' 0 N--CA 1.448 -0.528 0 CA-C-N 115.077 -0.965 . . . . 74.310000000000002 110.067 177.633 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -136.52 150.4 20.49 Favored Glycine 0 N--CA 1.442 -0.936 0 N-CA-C 111.311 -0.716 . . . . 74.120000000000005 111.311 176.435 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' THR . . . . . 0.415 ' O ' ' HG2' ' A' ' 19' ' ' GLU . 0.7 OUTLIER -98.13 130.39 44.9 Favored 'General case' 0 C--N 1.319 -0.758 0 CA-C-O 120.672 0.272 . . . . 71.099999999999994 110.672 177.763 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 47.3 t -65.54 122.23 16.09 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.491 0 N-CA-C 109.857 -0.423 . . . . 73.329999999999998 109.857 176.547 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 27.6 mtpp -78.33 -60.81 2.22 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 121.209 0.528 . . . . 74.299999999999997 109.604 179.788 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' TRP . . . . . . . . . . . . . 19.0 p90 -152.07 156.4 39.84 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 115.465 -0.789 . . . . 73.219999999999999 109.214 175.79 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 17.9 p90 -127.09 112.57 15.34 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-O 121.607 0.718 . . . . 75.049999999999997 111.055 -174.931 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 77.8 m-20 -86.67 73.5 10.02 Favored 'General case' 0 C--N 1.32 -0.696 0 CA-C-N 115.682 -0.69 . . . . 71.530000000000001 109.608 179.537 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -61.58 -25.52 67.38 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 115.553 -0.749 . . . . 72.319999999999993 111.118 -177.981 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 26.6 mt-10 -58.82 -36.87 75.23 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.531 -0.758 . . . . 74.420000000000002 110.864 179.287 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 28.2 mmtp -104.92 -18.33 14.23 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 116.024 -0.534 . . . . 74.420000000000002 111.007 -177.967 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 95.87 28.76 9.13 Favored Glycine 0 N--CA 1.449 -0.5 0 C-N-CA 120.748 -0.739 . . . . 73.120000000000005 113.491 174.399 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 50.2 p90 -150.69 156.4 41.25 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 117.155 0.478 . . . . 65.319999999999993 110.65 177.451 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -137.43 176.86 20.29 Favored Glycine 0 N--CA 1.447 -0.615 0 C-N-CA 121.075 -0.583 . . . . 54.109999999999999 111.736 178.64 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 75.8 m-85 -126.26 127.5 45.72 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 121.273 0.559 . . . . 75.519999999999996 110.948 179.54 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 64.3 mt -110.18 143.68 19.74 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.618 0 CA-C-N 115.408 -0.815 . . . . 73.530000000000001 109.845 179.191 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' GLU . . . . . 0.415 ' HG2' ' O ' ' A' ' 5' ' ' THR . 7.6 pt-20 -96.63 108.8 21.47 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 121.573 0.701 . . . . 75.439999999999998 110.649 177.213 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 20' ' ' ARG . . . . . 0.412 ' HG2' ' N ' ' A' ' 21' ' ' GLU . 61.3 ttt180 -97.0 162.87 13.2 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 114.954 -1.021 . . . . 75.109999999999999 110.123 -176.749 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . 0.412 ' N ' ' HG2' ' A' ' 20' ' ' ARG . 19.2 mm-40 -51.88 -41.65 62.07 Favored 'General case' 0 CA--C 1.531 0.241 0 CA-C-O 121.156 0.503 . . . . 74.129999999999995 111.002 176.618 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 15.3 m120 -111.09 26.34 10.8 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.983 -0.553 . . . . 62.549999999999997 111.761 -175.257 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 179.14 111.81 0.32 Allowed Glycine 0 C--O 1.225 -0.415 0 C-N-CA 119.86 -1.162 . . . . 44.450000000000003 113.084 -179.888 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 31.8 t70 -74.53 6.4 3.82 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-O 121.472 0.653 . . . . 61.340000000000003 111.05 -176.294 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 10.4 p-10 -152.04 93.21 1.8 Allowed 'General case' 0 C--N 1.324 -0.539 0 CA-C-O 121.882 0.849 . . . . 72.540000000000006 111.096 -178.768 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 89.0 t -102.59 121.18 53.38 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 CA-C-N 115.042 -0.981 . . . . 71.219999999999999 109.784 175.216 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 27' ' ' PHE . . . . . 0.453 ' O ' ' HA ' ' A' ' 59' ' ' GLN . 78.1 t80 -78.6 120.37 23.19 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 116.024 -0.534 . . . . 73.010000000000005 110.535 -178.558 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.459 ' HB ' ' HB3' ' A' ' 60' ' ' ALA . 8.7 p -128.7 136.05 60.82 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.728 0 CA-C-O 120.964 0.412 . . . . 74.409999999999997 111.277 179.516 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 29' ' ' HIS . . . . . 0.474 ' O ' HG13 ' A' ' 33' ' ' ILE . 3.2 m-70 -96.99 142.92 28.36 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 116.14 -0.482 . . . . 74.120000000000005 110.024 175.307 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 30' ' ' PHE . . . . . 0.424 ' HE2' ' HB3' ' A' ' 40' ' ' SER . 17.7 m-85 -62.28 -28.59 69.83 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-O 120.704 0.287 . . . . 73.409999999999997 111.216 -179.545 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 16.5 t -74.92 -12.44 60.35 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 121.0 0.429 . . . . 73.109999999999999 110.877 177.897 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . 0.434 ' HB3' ' HA ' ' A' ' 61' ' ' ALA . . . -97.67 -24.26 15.58 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 121.095 0.474 . . . . 52.43 110.464 178.858 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.474 HG13 ' O ' ' A' ' 29' ' ' HIS . 31.8 mt -68.61 163.48 3.15 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.4 0 CA-C-N 115.86 -0.609 . . . . 75.549999999999997 109.936 176.233 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 34' ' ' GLN . . . . . 0.471 ' N ' HG23 ' A' ' 33' ' ' ILE . 24.9 pt20 -72.19 10.62 0.72 Allowed 'General case' 0 N--CA 1.466 0.358 0 CA-C-O 120.73 0.3 . . . . 75.420000000000002 111.703 179.426 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.445 ' H ' ' C ' ' A' ' 33' ' ' ILE . . . -65.21 114.96 7.19 Favored Glycine 0 N--CA 1.446 -0.634 0 C-N-CA 121.092 -0.575 . . . . 71.109999999999999 112.402 -175.599 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 22.6 t70 -62.05 112.28 2.28 Favored 'General case' 0 C--N 1.327 -0.403 0 N-CA-C 109.235 -0.654 . . . . 62.240000000000002 109.235 176.062 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 76.83 -99.45 1.38 Allowed Glycine 0 N--CA 1.447 -0.568 0 N-CA-C 110.49 -1.044 . . . . 61.520000000000003 110.49 -170.6 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 53.4 m-85 -146.58 100.66 3.37 Favored 'General case' 0 C--N 1.325 -0.477 0 N-CA-C 109.765 -0.458 . . . . 73.299999999999997 109.765 173.583 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 54.7 mtpt -125.22 135.01 52.14 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.163 -0.472 . . . . 74.340000000000003 110.205 -177.355 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 40' ' ' SER . . . . . 0.424 ' HB3' ' HE2' ' A' ' 30' ' ' PHE . 13.8 p -91.95 149.56 21.48 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-O 121.036 0.446 . . . . 74.409999999999997 111.751 -175.862 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . 0.512 HD11 ' HG2' ' A' ' 45' ' ' GLN . 4.4 mm? -103.33 145.28 30.21 Favored 'General case' 0 C--N 1.325 -0.488 0 N-CA-C 109.397 -0.594 . . . . 73.349999999999994 109.397 174.858 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 6.5 m-20 -76.08 156.87 33.5 Favored 'General case' 0 C--N 1.32 -0.691 0 CA-C-N 116.112 -0.495 . . . . 74.409999999999997 111.29 -174.752 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 6.3 pt-20 -68.01 133.21 48.66 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-N 116.051 -0.522 . . . . 71.120000000000005 109.962 175.648 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 87.02 0.23 85.65 Favored Glycine 0 N--CA 1.446 -0.676 0 C-N-CA 120.558 -0.83 . . . . 73.310000000000002 112.146 -177.246 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 45' ' ' GLN . . . . . 0.512 ' HG2' HD11 ' A' ' 41' ' ' LEU . 24.3 tp60 -74.72 115.96 14.89 Favored 'General case' 0 C--N 1.328 -0.368 0 N-CA-C 109.637 -0.505 . . . . 73.439999999999998 109.637 176.9 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -74.84 116.07 15.14 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 116.049 -0.523 . . . . 72.329999999999998 110.125 177.14 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . 0.482 HG13 ' HA ' ' A' ' 65' ' ' LYS . 27.5 m -122.13 150.15 25.58 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.737 0 CA-C-N 116.068 -0.515 . . . . 74.019999999999996 110.751 -179.44 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 59.0 p -106.9 119.01 38.19 Favored 'General case' 0 C--N 1.318 -0.777 0 N-CA-C 108.928 -0.767 . . . . 73.420000000000002 108.928 175.062 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 29.8 p90 -127.99 151.34 49.25 Favored 'General case' 0 C--N 1.319 -0.74 0 CA-C-O 120.932 0.396 . . . . 73.340000000000003 111.745 -172.135 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 17.8 t70 -82.66 120.4 25.52 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.809 -0.632 . . . . 71.519999999999996 109.306 174.397 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 49.6 t -83.33 115.94 26.56 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.63 0 CA-C-N 116.063 -0.517 . . . . 72.310000000000002 111.622 -174.044 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 34.6 tt0 -108.82 104.74 14.07 Favored 'General case' 0 C--N 1.323 -0.585 0 N-CA-C 109.471 -0.566 . . . . 75.439999999999998 109.471 174.417 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 5.9 pt-20 -90.98 108.19 19.69 Favored 'General case' 0 C--N 1.318 -0.785 0 CA-C-O 121.363 0.602 . . . . 74.25 110.639 -179.42 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -118.85 -171.4 15.03 Favored Glycine 0 N--CA 1.445 -0.72 0 CA-C-N 115.428 -0.805 . . . . 70.030000000000001 111.888 -178.856 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 10.7 mm100 -78.62 77.9 5.09 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 121.33 0.586 . . . . 62.009999999999998 110.621 -177.573 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 4.6 ptp85 170.75 -26.49 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 114.534 -1.212 . . . . 74.319999999999993 108.973 -178.954 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 139.32 -170.23 24.21 Favored Glycine 0 N--CA 1.443 -0.857 0 N-CA-C 110.812 -0.915 . . . . 71.230000000000004 110.812 -179.673 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 72.3 Cg_endo -78.56 111.44 3.0 Favored 'Trans proline' 0 N--CA 1.455 -0.742 0 C-N-CA 122.077 1.851 . . . . 74.140000000000001 111.77 177.264 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . 0.453 ' HA ' ' O ' ' A' ' 27' ' ' PHE . 15.0 pt20 -104.34 135.77 45.17 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-O 121.137 0.494 . . . . 74.400000000000006 109.881 176.009 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . 0.459 ' HB3' ' HB ' ' A' ' 28' ' ' VAL . . . -90.09 123.5 34.0 Favored 'General case' 0 C--N 1.321 -0.669 0 CA-C-N 115.879 -0.6 . . . . 63.520000000000003 111.457 -173.995 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . 0.434 ' HA ' ' HB3' ' A' ' 32' ' ' ALA . . . -124.09 150.5 44.95 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-N 115.463 -0.79 . . . . 64.010000000000005 108.878 175.373 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 30.8 m-80 56.45 74.06 0.41 Allowed 'General case' 0 C--N 1.329 -0.301 0 N-CA-C 109.313 -0.625 . . . . 74.109999999999999 109.313 -176.155 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.464 ' HB ' HG22 ' A' ' 33' ' ' ILE . 40.5 t -105.37 103.5 15.46 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.599 0 CA-C-N 115.786 -0.643 . . . . 71.430000000000007 110.858 -175.304 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 23.1 mt-30 -111.64 129.96 55.92 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 116.193 -0.458 . . . . 72.299999999999997 109.774 179.29 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . 0.482 ' HA ' HG13 ' A' ' 47' ' ' VAL . 18.2 pttp -62.75 153.51 32.5 Favored 'General case' 0 C--N 1.327 -0.386 0 N-CA-C 110.294 -0.261 . . . . 73.230000000000004 110.294 -178.495 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 0.992 0 CA-C-O 118.193 -0.908 . . . . 72.340000000000003 109.802 176.261 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 15.1 tpt . . . . . 0 N--CA 1.481 1.104 0 CA-C-O 120.773 0.321 . . . . 74.129999999999995 110.986 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . 0.521 ' HB2' ' O ' ' A' ' 49' ' ' PHE . 1.7 mp0 -81.01 101.98 9.89 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 121.325 0.583 . . . . 75.120000000000005 111.114 -178.854 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' GLN . . . . . 0.653 ' HG2' HG22 ' A' ' 48' ' ' THR . 47.8 mt-30 -106.82 120.1 41.12 Favored 'General case' 0 C--N 1.32 -0.711 0 CA-C-N 115.702 -0.681 . . . . 73.129999999999995 109.619 178.086 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -143.81 -164.26 10.29 Favored Glycine 0 N--CA 1.447 -0.57 0 C-N-CA 120.611 -0.804 . . . . 62.219999999999999 112.303 -176.706 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' THR . . . . . 0.492 ' O ' ' HG2' ' A' ' 19' ' ' GLU . 42.7 m -139.76 134.64 32.13 Favored 'General case' 0 C--N 1.319 -0.746 0 CA-C-O 120.674 0.273 . . . . 65.230000000000004 110.589 -178.879 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 47.4 t -68.58 135.63 28.03 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.487 0 CA-C-O 120.773 0.32 . . . . 71.219999999999999 110.343 -179.774 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . 0.472 ' HA ' ' HE3' ' A' ' 7' ' ' LYS . 0.0 OUTLIER -108.13 -72.69 0.71 Allowed 'General case' 0 C--N 1.324 -0.518 0 CA-C-O 120.966 0.412 . . . . 71.400000000000006 110.723 177.632 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' TRP . . . . . . . . . . . . . 46.0 m95 -127.43 125.99 41.58 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 116.082 -0.508 . . . . 75.030000000000001 110.134 -176.499 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 4.6 p90 -112.92 93.95 4.67 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-O 121.67 0.748 . . . . 74.329999999999998 110.861 179.866 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 2.0 t-20 -92.93 59.33 3.15 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-O 121.892 0.853 . . . . 72.140000000000001 109.11 -179.738 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -68.83 -15.12 63.41 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 114.751 -1.113 . . . . 62.020000000000003 112.115 -173.067 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 20.5 mt-10 -74.32 -26.79 60.37 Favored 'General case' 0 C--N 1.326 -0.44 0 C-N-CA 120.713 -0.395 . . . . 74.120000000000005 110.693 178.205 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . 0.522 ' HB3' ' HZ1' ' A' ' 13' ' ' LYS . 3.8 mmmp? -97.03 -26.48 14.99 Favored 'General case' 0 C--N 1.328 -0.352 0 N-CA-C 109.68 -0.489 . . . . 73.349999999999994 109.68 175.064 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 115.82 23.79 4.2 Favored Glycine 0 N--CA 1.449 -0.488 0 C-N-CA 120.306 -0.95 . . . . 61.5 114.265 169.937 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 55.9 p90 -151.08 162.63 40.48 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 117.576 0.688 . . . . 73.340000000000003 111.455 179.897 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -153.93 171.18 32.6 Favored Glycine 0 N--CA 1.444 -0.788 0 C-N-CA 120.998 -0.62 . . . . 74.329999999999998 111.771 178.299 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 94.9 m-85 -125.69 121.71 34.25 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-O 120.914 0.388 . . . . 74.200000000000003 110.965 -178.604 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 59.6 mt -114.7 127.63 72.13 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.574 0 N-CA-C 108.752 -0.832 . . . . 70.25 108.752 174.484 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' GLU . . . . . 0.492 ' HG2' ' O ' ' A' ' 5' ' ' THR . 17.1 pt-20 -86.66 137.19 32.67 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-O 121.517 0.675 . . . . 72.129999999999995 112.294 -171.074 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 20' ' ' ARG . . . . . 0.79 ' HB3' ' HB2' ' A' ' 24' ' ' ASP . 10.3 tpt180 -100.41 169.31 9.19 Favored 'General case' 0 C--N 1.325 -0.485 0 N-CA-C 108.215 -1.031 . . . . 75.510000000000005 108.215 169.769 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . 0.407 ' H ' ' HG3' ' A' ' 20' ' ' ARG . 44.2 mt-10 -58.44 -22.81 55.7 Favored 'General case' 0 CA--C 1.538 0.506 0 N-CA-C 114.029 1.122 . . . . 73.400000000000006 114.029 -171.54 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 7.3 m-80 -94.81 3.09 55.42 Favored 'General case' 0 N--CA 1.467 0.421 0 CA-C-O 120.964 0.411 . . . . 73.420000000000002 110.43 -179.333 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 92.97 8.61 61.61 Favored Glycine 0 N--CA 1.45 -0.414 0 N-CA-C 111.131 -0.788 . . . . 71.25 111.131 -174.242 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . 0.79 ' HB2' ' HB3' ' A' ' 20' ' ' ARG . 1.6 m-20 -61.06 97.45 0.06 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.193 -0.503 . . . . 74.450000000000003 110.168 -178.84 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 40.3 m-20 -67.55 98.53 0.68 Allowed 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 116.264 -0.425 . . . . 74.219999999999999 110.0 173.669 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 26.4 t -79.19 128.16 38.68 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.665 0 CA-C-N 116.069 -0.514 . . . . 74.329999999999998 109.69 178.595 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 27' ' ' PHE . . . . . . . . . . . . . 17.7 t80 -84.48 108.24 17.16 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 115.957 -0.565 . . . . 75.349999999999994 110.437 -173.062 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.479 ' HB ' ' HB2' ' A' ' 60' ' ' ALA . 12.2 p -101.62 151.34 5.64 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.487 0 CA-C-O 121.141 0.496 . . . . 72.349999999999994 110.828 -178.545 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 29' ' ' HIS . . . . . 0.467 ' O ' HG13 ' A' ' 33' ' ' ILE . 17.8 m170 -118.09 149.53 40.86 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.798 -0.637 . . . . 74.120000000000005 109.422 176.697 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 30' ' ' PHE . . . . . 0.473 ' HA ' HD12 ' A' ' 33' ' ' ILE . 49.3 p90 -68.58 -23.31 64.47 Favored 'General case' 0 N--CA 1.463 0.22 0 CA-C-O 120.955 0.407 . . . . 75.140000000000001 110.471 -177.363 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 23.0 t -71.86 -25.14 61.83 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 115.864 -0.607 . . . . 75.25 110.063 176.682 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . 0.434 ' HB3' ' HA ' ' A' ' 61' ' ' ALA . . . -92.13 -19.99 21.71 Favored 'General case' 0 C--O 1.235 0.302 0 CA-C-N 115.964 -0.562 . . . . 64.409999999999997 110.863 -179.656 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.545 HG22 ' H ' ' A' ' 35' ' ' GLY . 77.3 mt -65.42 116.4 4.61 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 CA-C-N 116.156 -0.474 . . . . 75.310000000000002 110.114 176.567 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 4.7 pp0? -87.95 14.32 9.16 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.184 -0.462 . . . . 72.530000000000001 111.246 -176.531 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.545 ' H ' HG22 ' A' ' 33' ' ' ILE . . . -53.95 121.81 20.38 Favored Glycine 0 N--CA 1.453 -0.187 0 CA-C-N 115.846 -0.615 . . . . 72.010000000000005 112.156 -178.952 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 11.4 p-10 -77.73 129.45 35.52 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-O 121.278 0.561 . . . . 74.109999999999999 111.065 -176.844 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 98.43 -53.48 1.15 Allowed Glycine 0 N--CA 1.448 -0.533 0 C-N-CA 120.841 -0.695 . . . . 74.209999999999994 112.379 179.57 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 39.7 p90 -146.61 150.54 35.68 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-O 120.69 0.281 . . . . 73.510000000000005 110.6 -177.917 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 73.5 mmtt -86.94 86.54 7.33 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.911 0.386 . . . . 73.219999999999999 110.615 -179.799 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 47.3 m -153.42 147.05 25.09 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 116.384 -0.371 . . . . 72.329999999999998 110.608 177.812 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 94.7 mt -124.2 121.24 34.56 Favored 'General case' 0 C--N 1.325 -0.468 0 N-CA-C 108.908 -0.775 . . . . 64.109999999999999 108.908 175.825 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 12.1 m-20 -64.19 127.39 31.23 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-O 121.351 0.596 . . . . 64.219999999999999 111.495 -175.924 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 6.2 pt-20 -63.04 119.57 9.74 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 115.226 -0.897 . . . . 75.549999999999997 111.12 179.98 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 100.66 -5.49 56.87 Favored Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.705 -0.76 . . . . 63.299999999999997 112.667 179.167 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 59.2 tp60 -80.98 133.9 35.59 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 120.615 0.245 . . . . 74.519999999999996 110.489 -178.778 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -77.15 130.81 37.82 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.352 -0.386 . . . . 71.239999999999995 110.022 175.221 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . 0.415 HG13 ' HA ' ' A' ' 65' ' ' LYS . 17.5 m -135.19 153.56 34.28 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.492 0 CA-C-O 121.025 0.441 . . . . 75.299999999999997 111.289 -176.05 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 48' ' ' THR . . . . . 0.653 HG22 ' HG2' ' A' ' 3' ' ' GLN . 46.3 p -114.18 107.75 16.04 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-N 115.582 -0.735 . . . . 72.120000000000005 109.223 175.719 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 49' ' ' PHE . . . . . 0.545 ' HA ' ' O ' ' A' ' 62' ' ' ASN . 37.0 p90 -119.53 167.38 12.03 Favored 'General case' 0 C--N 1.315 -0.899 0 CA-C-N 115.847 -0.615 . . . . 74.129999999999995 110.412 -173.515 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 38.7 t70 -107.04 129.21 54.84 Favored 'General case' 0 C--N 1.316 -0.85 0 C-N-CA 120.777 -0.369 . . . . 75.230000000000004 110.305 176.016 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . 0.431 ' HB ' ' HG2' ' A' ' 2' ' ' GLU . 7.3 p -77.26 120.8 28.4 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 CA-C-O 121.533 0.682 . . . . 71.120000000000005 111.388 -176.976 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -110.37 157.89 19.04 Favored 'General case' 0 C--N 1.323 -0.581 0 N-CA-C 108.721 -0.844 . . . . 73.409999999999997 108.721 179.541 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 1.3 mm-40 -95.78 110.32 22.49 Favored 'General case' 0 C--N 1.319 -0.725 0 CA-C-O 121.03 0.443 . . . . 62.310000000000002 110.835 -178.319 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -99.56 157.16 19.85 Favored Glycine 0 N--CA 1.443 -0.892 0 N-CA-C 111.139 -0.785 . . . . 63.539999999999999 111.139 177.033 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 78.5 mt-30 -77.7 7.07 6.19 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 117.014 0.407 . . . . 75.530000000000001 111.69 -178.276 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 99.1 mtt180 -127.79 10.28 6.52 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 120.922 0.392 . . . . 75.209999999999994 110.023 175.313 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 129.29 176.89 14.61 Favored Glycine 0 N--CA 1.446 -0.634 0 C-N-CA 120.854 -0.688 . . . . 74.140000000000001 111.713 -177.412 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 18.3 Cg_endo -60.1 124.45 15.27 Favored 'Trans proline' 0 C--O 1.235 0.349 0 C-N-CA 122.827 2.351 . . . . 74.209999999999994 112.067 179.471 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 6.8 tt0 -104.45 144.35 31.78 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 115.682 -0.69 . . . . 72.510000000000005 110.101 -177.003 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . 0.479 ' HB2' ' HB ' ' A' ' 28' ' ' VAL . . . -91.43 106.81 18.76 Favored 'General case' 0 C--N 1.32 -0.696 0 CA-C-O 120.89 0.376 . . . . 72.439999999999998 110.81 178.585 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . 0.434 ' HA ' ' HB3' ' A' ' 32' ' ' ALA . . . -117.18 164.38 14.86 Favored 'General case' 0 C--N 1.32 -0.687 0 N-CA-C 108.769 -0.826 . . . . 74.239999999999995 108.769 176.31 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 62' ' ' ASN . . . . . 0.545 ' O ' ' HA ' ' A' ' 49' ' ' PHE . 85.0 m-20 47.89 66.41 1.05 Allowed 'General case' 0 N--CA 1.465 0.289 0 CA-C-O 120.83 0.347 . . . . 75.450000000000003 110.304 -177.766 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 29.4 t -93.93 89.3 2.56 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 CA-C-N 116.09 -0.505 . . . . 74.129999999999995 110.636 -176.66 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 64' ' ' GLN . . . . . 0.436 ' HB2' ' HG1' ' A' ' 48' ' ' THR . 5.5 mt-30 -82.35 129.66 34.92 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 115.866 -0.606 . . . . 64.420000000000002 110.479 -179.47 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . 0.415 ' HA ' HG13 ' A' ' 47' ' ' VAL . 50.7 mtmt -81.83 137.84 35.2 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 116.532 -0.303 . . . . 75.450000000000003 110.262 178.989 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.251 1.133 0 CA-C-O 118.289 -0.862 . . . . 72.129999999999995 110.157 178.325 . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 60.8 mtt . . . . . 0 N--CA 1.481 1.112 0 CA-C-O 120.765 0.317 . . . . 73.450000000000003 110.358 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 40.6 mt-10 -133.34 150.76 51.84 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 116.187 -0.461 . . . . 74.400000000000006 110.266 -179.366 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 35.1 tt0 -91.57 123.77 35.23 Favored 'General case' 0 C--N 1.322 -0.595 0 N-CA-C 109.48 -0.563 . . . . 74.329999999999998 109.48 177.759 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . 0.55 ' HA3' ' HE2' ' A' ' 49' ' ' PHE . . . -138.88 152.65 22.29 Favored Glycine 0 N--CA 1.444 -0.788 0 C-N-CA 120.818 -0.706 . . . . 74.540000000000006 111.829 -178.903 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 5' ' ' THR . . . . . 0.407 ' HA ' ' HA ' ' A' ' 46' ' ' ALA . 9.6 m -85.57 131.05 34.43 Favored 'General case' 0 C--N 1.318 -0.761 0 CA-C-O 120.635 0.255 . . . . 74.239999999999995 110.908 -177.855 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 60.6 t -65.78 115.86 4.37 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 N-CA-C 109.507 -0.553 . . . . 70.209999999999994 109.507 174.761 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 9.3 mmmm -86.12 -62.08 1.6 Allowed 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 115.943 -0.571 . . . . 75.140000000000001 109.976 -178.493 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 8' ' ' TRP . . . . . . . . . . . . . 94.4 m95 -141.78 135.08 29.34 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 116.012 -0.54 . . . . 73.349999999999994 110.08 -179.638 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 62.7 t80 -118.93 98.4 6.17 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-O 121.217 0.532 . . . . 74.129999999999995 109.707 178.12 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 43.4 t30 -82.12 81.84 7.9 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-O 121.556 0.693 . . . . 73.409999999999997 110.262 -177.635 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -70.89 -10.4 59.56 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.103 -0.953 . . . . 72.439999999999998 111.143 179.732 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 31.2 mm-40 -69.77 -16.39 63.29 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.086 -0.507 . . . . 74.430000000000007 110.266 177.447 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . 0.594 ' HE3' ' HA ' ' A' ' 13' ' ' LYS . 0.0 OUTLIER -130.01 -35.17 1.63 Allowed 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.132 -0.486 . . . . 73.150000000000006 111.263 179.564 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 111.25 28.51 3.79 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.648 -0.787 . . . . 75.519999999999996 112.907 178.206 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 31.3 p90 -148.03 176.23 10.35 Favored 'General case' 0 C--N 1.323 -0.561 0 O-C-N 122.493 -0.416 . . . . 74.400000000000006 109.965 177.641 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -174.79 -168.43 35.46 Favored Glycine 0 N--CA 1.445 -0.733 0 C-N-CA 120.292 -0.956 . . . . 73.219999999999999 112.27 -179.974 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . 0.49 ' HB3' ' HB3' ' A' ' 25' ' ' ASP . 88.0 m-85 -127.47 124.42 38.32 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-O 120.949 0.404 . . . . 64.420000000000002 110.504 -178.166 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 40.2 mt -121.72 117.81 53.71 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.663 0 N-CA-C 108.38 -0.97 . . . . 73.450000000000003 108.38 175.063 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 19' ' ' GLU . . . . . 0.615 ' HA ' ' HA ' ' A' ' 25' ' ' ASP . 6.7 pt-20 -78.11 137.67 38.33 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-O 121.64 0.733 . . . . 60.210000000000001 112.449 -168.543 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 20' ' ' ARG . . . . . 0.567 ' HB3' ' HB3' ' A' ' 24' ' ' ASP . 62.7 ttt180 -80.3 164.02 23.5 Favored 'General case' 0 C--N 1.32 -0.688 0 N-CA-C 107.691 -1.226 . . . . 73.109999999999999 107.691 168.129 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 43.4 mt-10 -63.53 -12.51 32.92 Favored 'General case' 0 N--CA 1.468 0.466 0 N-CA-C 112.53 0.567 . . . . 72.230000000000004 112.53 -173.718 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 10.4 m120 -87.29 3.64 45.95 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-O 120.901 0.382 . . . . 72.040000000000006 110.774 178.637 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 85.46 2.39 87.35 Favored Glycine 0 N--CA 1.452 -0.271 0 N-CA-C 110.752 -0.939 . . . . 75.319999999999993 110.752 -173.164 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . 0.567 ' HB3' ' HB3' ' A' ' 20' ' ' ARG . 38.3 t70 -75.32 90.51 2.64 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 114.551 -0.825 . . . . 74.319999999999993 110.463 -176.909 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.615 ' HA ' ' HA ' ' A' ' 19' ' ' GLU . 42.8 m-20 -60.82 104.16 0.33 Allowed 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.107 -0.497 . . . . 75.349999999999994 110.248 176.28 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.456 HG11 ' HB2' ' A' ' 58' ' ' PRO . 22.1 t -81.01 132.52 31.39 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 CA-C-N 116.016 -0.538 . . . . 64.230000000000004 110.229 -177.851 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 27' ' ' PHE . . . . . . . . . . . . . 85.7 t80 -76.64 104.28 7.06 Favored 'General case' 0 C--O 1.238 0.452 0 CA-C-O 121.134 0.492 . . . . 72.049999999999997 110.881 -177.189 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.524 ' HA ' ' HB3' ' A' ' 60' ' ' ALA . 9.6 p -88.3 145.71 7.12 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.638 0 N-CA-C 109.392 -0.595 . . . . 75.019999999999996 109.392 177.464 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 29' ' ' HIS . . . . . 0.67 ' HE1' ' HB3' ' A' ' 59' ' ' GLN . 23.8 p-80 -142.05 143.73 33.25 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 116.563 -0.29 . . . . 73.420000000000002 110.997 -173.64 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 52.1 p90 -58.14 -23.37 54.89 Favored 'General case' 0 N--CA 1.469 0.488 0 N-CA-C 113.03 0.752 . . . . 74.099999999999994 113.03 -172.838 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 31' ' ' SER . . . . . 0.414 ' OG ' ' HD2' ' A' ' 29' ' ' HIS . 2.7 p -77.57 -0.05 24.86 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-O 121.0 0.429 . . . . 61.229999999999997 111.576 -179.355 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -126.26 -24.9 3.6 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.149 -0.478 . . . . 75.340000000000003 110.689 175.337 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.493 HG13 ' O ' ' A' ' 29' ' ' HIS . 64.1 mt -68.95 118.47 13.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.293 -0.412 . . . . 74.439999999999998 110.872 179.686 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 2.5 pp0? -83.03 102.76 11.98 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-O 121.58 0.705 . . . . 75.439999999999998 109.508 172.798 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -82.82 56.54 5.05 Favored Glycine 0 N--CA 1.449 -0.45 0 CA-C-N 115.612 -0.722 . . . . 72.129999999999995 112.216 -175.76 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 27.4 t70 -78.74 102.96 8.37 Favored 'General case' 0 C--N 1.319 -0.737 0 CA-C-O 120.835 0.35 . . . . 65.209999999999994 110.479 -179.376 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 110.69 -91.33 0.61 Allowed Glycine 0 N--CA 1.448 -0.53 0 C-N-CA 121.101 -0.571 . . . . 72.329999999999998 111.722 -178.656 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 84.6 m-85 -122.37 135.8 54.77 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-O 120.859 0.361 . . . . 75.239999999999995 110.179 177.932 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 13.8 mptt -86.65 53.55 2.86 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-N 116.146 -0.479 . . . . 73.349999999999994 110.03 -178.902 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 39.6 m -149.86 110.68 4.31 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 116.154 -0.475 . . . . 75.010000000000005 111.122 -177.79 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 9.9 mp -94.02 131.76 39.19 Favored 'General case' 0 C--N 1.324 -0.532 0 N-CA-C 108.891 -0.781 . . . . 62.119999999999997 108.891 174.39 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 21.3 m-20 -96.82 128.1 43.44 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-O 120.775 0.321 . . . . 73.140000000000001 110.388 -173.858 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 2.0 pp20? -61.92 143.19 56.82 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 116.063 -0.517 . . . . 72.349999999999994 110.737 -179.047 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 99.11 -22.72 39.51 Favored Glycine 0 N--CA 1.447 -0.568 0 C-N-CA 120.74 -0.743 . . . . 72.519999999999996 111.847 -175.525 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 45' ' ' GLN . . . . . 0.442 ' HA ' ' OE1' ' A' ' 45' ' ' GLN . 6.1 tp60 -87.95 140.36 29.58 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.713 0.292 . . . . 74.400000000000006 110.315 178.334 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 0.407 ' HA ' ' HA ' ' A' ' 5' ' ' THR . . . -102.93 125.44 49.69 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-N 116.476 -0.329 . . . . 73.019999999999996 110.818 -179.869 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 30.7 m -118.2 171.51 6.43 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.561 0 CA-C-N 116.315 -0.402 . . . . 75.109999999999999 110.467 178.64 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 21.6 p -107.39 112.79 25.76 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-O 121.218 0.532 . . . . 74.109999999999999 110.954 -179.899 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 49' ' ' PHE . . . . . 0.55 ' HE2' ' HA3' ' A' ' 4' ' ' GLY . 41.5 p90 -121.89 161.16 23.29 Favored 'General case' 0 C--N 1.317 -0.833 0 CA-C-N 115.619 -0.719 . . . . 74.340000000000003 109.851 -178.219 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 19.7 t70 -109.06 128.29 54.85 Favored 'General case' 0 C--N 1.316 -0.875 0 CA-C-O 120.99 0.424 . . . . 63.130000000000003 110.311 174.128 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 98.9 t -77.22 104.8 5.46 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 CA-C-O 121.108 0.48 . . . . 71.340000000000003 110.878 -177.873 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -87.15 145.89 26.24 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 115.409 -0.814 . . . . 73.400000000000006 109.19 179.523 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 70.9 mm-40 -84.25 98.2 9.84 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-N 116.153 -0.476 . . . . 75.530000000000001 111.368 -175.641 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -81.39 164.77 45.88 Favored Glycine 0 N--CA 1.446 -0.69 0 C-N-CA 120.837 -0.697 . . . . 75.010000000000005 111.546 176.65 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 26.8 pt20 -69.32 -23.63 63.82 Favored 'General case' 0 C--N 1.324 -0.508 0 N-CA-C 112.207 0.447 . . . . 74.209999999999994 112.207 -175.664 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 9.5 ptm180 -132.1 16.57 4.61 Favored 'General case' 0 C--N 1.328 -0.346 0 C-N-CA 120.326 -0.55 . . . . 73.409999999999997 112.033 -179.26 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 157.69 -178.18 34.13 Favored Glycine 0 N--CA 1.449 -0.444 0 C-N-CA 120.018 -1.087 . . . . 63.240000000000002 112.702 179.282 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . 0.456 ' HB2' HG11 ' A' ' 26' ' ' VAL . 73.4 Cg_endo -75.56 128.59 11.17 Favored 'Trans proline' 0 C--O 1.235 0.341 0 C-N-CA 122.834 2.356 . . . . 72.510000000000005 112.89 -177.738 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . 0.67 ' HB3' ' HE1' ' A' ' 29' ' ' HIS . 90.5 mt-30 -112.61 135.32 53.47 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 115.965 -0.561 . . . . 72.219999999999999 109.92 176.665 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . 0.524 ' HB3' ' HA ' ' A' ' 28' ' ' VAL . . . -85.21 105.19 15.72 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-O 120.899 0.381 . . . . 75.439999999999998 111.037 -178.931 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -115.29 168.78 9.66 Favored 'General case' 0 C--N 1.319 -0.722 0 N-CA-C 108.615 -0.883 . . . . 71.430000000000007 108.615 174.931 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 62' ' ' ASN . . . . . 0.499 ' O ' ' HA ' ' A' ' 49' ' ' PHE . 87.1 m-20 51.03 75.5 0.19 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.981 0.42 . . . . 55.229999999999997 109.958 -175.714 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 22.0 t -98.83 93.25 3.06 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 CA-C-N 115.969 -0.559 . . . . 75.120000000000005 109.526 -177.285 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 40.4 mt-30 -98.12 148.78 23.2 Favored 'General case' 0 C--N 1.32 -0.705 0 CA-C-N 115.923 -0.581 . . . . 75.010000000000005 110.567 -175.96 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 94.9 mttt -76.86 129.12 35.78 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 115.871 -0.604 . . . . 73.200000000000003 110.439 -179.795 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.077 0 CA-C-O 118.366 -0.826 . . . . 75.409999999999997 109.457 175.856 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 1' ' ' MET . . . . . 0.641 ' N ' ' HA ' ' A' ' 50' ' ' ASP . 26.0 ptm . . . . . 0 N--CA 1.482 1.16 0 CA-C-O 120.718 0.294 . . . . 71.040000000000006 111.268 . . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 4.4 mp0 -105.55 165.7 10.96 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 121.029 0.442 . . . . 73.510000000000005 111.151 -175.351 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 3' ' ' GLN . . . . . 0.543 ' HG2' HG21 ' A' ' 48' ' ' THR . 66.6 mt-30 -98.47 111.43 23.79 Favored 'General case' 0 C--N 1.326 -0.445 0 N-CA-C 109.037 -0.727 . . . . 73.109999999999999 109.037 173.422 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . 0.71 ' HA3' ' HE2' ' A' ' 49' ' ' PHE . . . -122.1 162.3 15.93 Favored Glycine 0 N--CA 1.447 -0.613 0 C-N-CA 120.101 -1.047 . . . . 71.109999999999999 112.984 -174.217 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 8.3 m -98.45 131.03 45.04 Favored 'General case' 0 C--N 1.321 -0.635 0 N-CA-C 110.033 -0.358 . . . . 74.329999999999998 110.033 177.948 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 59.7 t -70.17 118.48 14.71 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.436 0 CA-C-N 116.602 -0.272 . . . . 72.140000000000001 110.619 179.365 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . 1.034 ' HE2' ' HB3' ' A' ' 19' ' ' GLU . 70.7 mmtt -70.77 -72.58 0.2 Allowed 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 121.238 0.542 . . . . 73.450000000000003 109.803 176.62 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 8' ' ' TRP . . . . . 0.531 ' HA ' ' HG3' ' A' ' 43' ' ' GLU . 24.5 m-90 -143.85 127.23 16.81 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 114.939 -1.028 . . . . 74.439999999999998 109.005 178.558 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 54.3 t80 -105.82 103.08 12.51 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-O 121.243 0.544 . . . . 71.109999999999999 110.359 179.547 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 39.2 m-80 -83.9 78.46 9.72 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 115.785 -0.643 . . . . 75.450000000000003 110.104 -179.666 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -59.61 -30.86 68.99 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.025 -0.534 . . . . 75.409999999999997 110.59 178.029 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 24.7 mt-10 -64.61 -38.91 92.64 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.401 -0.818 . . . . 75.549999999999997 110.616 178.158 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 48.7 mmtm -90.6 -24.44 20.55 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.683 -0.69 . . . . 73.510000000000005 110.691 -174.201 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 96.15 18.62 30.87 Favored Glycine 0 N--CA 1.445 -0.738 0 C-N-CA 120.806 -0.711 . . . . 73.450000000000003 112.845 177.608 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 46.7 p90 -156.83 163.72 38.88 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 117.074 0.437 . . . . 74.319999999999993 110.803 179.855 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -148.95 177.12 27.4 Favored Glycine 0 N--CA 1.445 -0.703 0 C-N-CA 120.813 -0.708 . . . . 74.099999999999994 111.983 179.289 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 96.8 m-85 -123.98 131.15 53.52 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 120.76 0.314 . . . . 75.540000000000006 110.307 177.949 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.411 HD12 HG21 ' A' ' 47' ' ' VAL . 33.0 mt -122.88 146.61 27.9 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.695 0 N-CA-C 109.115 -0.698 . . . . 72.219999999999999 109.115 178.149 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 19' ' ' GLU . . . . . 1.034 ' HB3' ' HE2' ' A' ' 7' ' ' LYS . 12.9 pt-20 -99.79 129.23 45.88 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-O 121.351 0.596 . . . . 75.319999999999993 111.785 -178.52 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 20' ' ' ARG . . . . . 0.429 ' HG2' ' N ' ' A' ' 21' ' ' GLU . 27.9 ttm180 -98.3 153.81 18.26 Favored 'General case' 0 C--N 1.322 -0.609 0 N-CA-C 108.381 -0.97 . . . . 70.319999999999993 108.381 170.727 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . 0.429 ' N ' ' HG2' ' A' ' 20' ' ' ARG . 43.9 mt-10 -52.02 -34.44 42.96 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 121.047 0.451 . . . . 64.109999999999999 110.491 177.61 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 8.5 t-20 -123.9 58.58 1.16 Allowed 'General case' 0 N--CA 1.453 -0.311 0 CA-C-N 115.85 -0.613 . . . . 75.230000000000004 109.41 175.358 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 164.65 78.88 0.04 OUTLIER Glycine 0 N--CA 1.45 -0.369 0 N-CA-C 111.217 -0.753 . . . . 54.409999999999997 111.217 179.543 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 30.6 t70 -65.71 -2.84 3.97 Favored 'General case' 0 C--N 1.326 -0.445 0 N-CA-C 112.606 0.595 . . . . 64.140000000000001 112.606 -169.51 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 10.2 p-10 -144.73 93.67 2.44 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-O 121.813 0.816 . . . . 71.010000000000005 111.854 -178.575 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 38.9 t -104.12 128.74 57.26 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.492 0 CA-C-N 115.525 -0.761 . . . . 73.230000000000004 109.628 174.579 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 27' ' ' PHE . . . . . . . . . . . . . 42.7 t80 -83.61 106.52 15.4 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-O 120.716 0.293 . . . . 70.329999999999998 110.326 -177.28 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.561 HG21 HG22 ' A' ' 63' ' ' VAL . 12.5 p -99.38 143.9 12.81 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 CA-C-O 121.149 0.5 . . . . 74.140000000000001 111.354 -176.248 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 54.2 m80 -97.27 133.78 41.43 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.543 -0.753 . . . . 75.0 109.996 177.871 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 6.1 p90 -63.95 -26.46 68.6 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.803 0.335 . . . . 75.319999999999993 111.105 -176.837 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 28.2 t -89.57 -14.35 35.26 Favored 'General case' 0 CA--C 1.533 0.291 0 CA-C-N 116.355 -0.384 . . . . 73.129999999999995 110.436 179.689 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -83.22 -23.09 32.94 Favored 'General case' 0 C--O 1.233 0.224 0 CA-C-O 121.383 0.611 . . . . 72.510000000000005 109.9 178.117 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.518 ' HA ' ' HB ' ' A' ' 63' ' ' VAL . 53.1 mt -76.31 138.37 20.83 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.497 0 CA-C-N 115.542 -0.754 . . . . 72.349999999999994 109.51 172.113 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -75.93 59.84 1.31 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 121.397 0.618 . . . . 73.420000000000002 111.554 176.946 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -69.05 141.14 35.43 Favored Glycine 0 N--CA 1.446 -0.646 0 CA-C-N 115.841 -0.618 . . . . 41.299999999999997 112.376 -179.373 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -77.98 84.11 4.27 Favored 'General case' 0 C--N 1.324 -0.532 0 N-CA-C 109.95 -0.389 . . . . 71.049999999999997 109.95 177.332 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 75.16 -68.77 1.99 Allowed Glycine 0 N--CA 1.451 -0.346 0 N-CA-C 111.491 -0.644 . . . . 72.129999999999995 111.491 -176.125 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 44.1 t80 -152.26 93.81 1.85 Allowed 'General case' 0 C--N 1.321 -0.664 0 N-CA-C 108.505 -0.924 . . . . 74.439999999999998 108.505 174.965 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 41.1 tptt -114.15 115.87 28.19 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 116.241 -0.436 . . . . 73.129999999999995 110.569 -173.239 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 13.0 m -85.27 115.35 22.99 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-N 116.044 -0.525 . . . . 71.129999999999995 110.368 179.138 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . 0.467 HD23 HG23 ' A' ' 33' ' ' ILE . 3.7 mm? -74.96 107.69 7.2 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 116.298 -0.41 . . . . 73.200000000000003 110.215 178.606 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 32.5 t70 -58.98 135.08 57.5 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.76 -0.655 . . . . 73.230000000000004 111.267 -177.549 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . 0.531 ' HG3' ' HA ' ' A' ' 8' ' ' TRP . 17.9 mp0 -53.93 124.72 16.27 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 115.957 -0.565 . . . . 74.400000000000006 110.619 177.809 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 99.35 -0.68 57.11 Favored Glycine 0 N--CA 1.449 -0.481 0 C-N-CA 120.627 -0.796 . . . . 54.32 112.804 -179.908 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 58.7 tp60 -83.43 149.97 26.34 Favored 'General case' 0 C--N 1.325 -0.495 0 N-CA-C 109.918 -0.401 . . . . 75.329999999999998 109.918 178.423 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -90.8 140.49 29.74 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-N 116.554 -0.294 . . . . 75.310000000000002 110.246 177.21 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . 0.411 HG21 HD12 ' A' ' 18' ' ' ILE . 16.0 m -139.0 153.59 25.01 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 CA-C-O 120.913 0.387 . . . . 75.010000000000005 110.396 177.579 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 48' ' ' THR . . . . . 0.653 HG23 ' HB3' ' A' ' 66' ' ' ALA . 34.4 p -106.47 101.88 11.31 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-O 121.323 0.582 . . . . 75.120000000000005 110.121 178.275 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 49' ' ' PHE . . . . . 0.71 ' HE2' ' HA3' ' A' ' 4' ' ' GLY . 42.1 p90 -111.55 147.47 35.33 Favored 'General case' 0 C--N 1.317 -0.821 0 CA-C-N 115.609 -0.723 . . . . 74.129999999999995 110.666 -174.455 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . 0.641 ' HA ' ' N ' ' A' ' 1' ' ' MET . 36.2 t0 -101.92 160.96 14.04 Favored 'General case' 0 C--N 1.316 -0.855 0 C-N-CA 120.357 -0.537 . . . . 73.5 109.706 172.279 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 67.4 t -109.66 119.37 58.77 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.701 0 CA-C-O 120.922 0.392 . . . . 71.209999999999994 111.459 -172.822 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 27.6 tt0 -111.11 111.31 22.3 Favored 'General case' 0 C--N 1.321 -0.642 0 N-CA-C 109.094 -0.706 . . . . 73.209999999999994 109.094 173.338 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 26.9 mt-10 -69.59 137.08 52.02 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-O 121.203 0.525 . . . . 72.129999999999995 112.091 -177.709 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -118.9 -158.04 10.6 Favored Glycine 0 N--CA 1.441 -1.026 0 N-CA-C 110.001 -1.239 . . . . 74.420000000000002 110.001 170.844 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 50.0 tt0 -99.43 -25.6 14.41 Favored 'General case' 0 C--N 1.319 -0.752 0 CA-C-N 117.162 0.481 . . . . 74.230000000000004 110.498 179.728 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 10.9 mmm180 -97.64 -5.23 35.86 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 116.292 -0.413 . . . . 70.450000000000003 111.191 178.561 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 151.39 -179.61 27.89 Favored Glycine 0 N--CA 1.444 -0.795 0 C-N-CA 120.62 -0.8 . . . . 63.340000000000003 112.311 178.527 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 8.9 Cg_endo -87.41 119.02 1.37 Allowed 'Trans proline' 0 N--CA 1.45 -1.057 0 C-N-CA 123.235 2.623 . . . . 74.099999999999994 112.18 178.931 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 15.8 pt20 -95.39 133.91 38.8 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-N 116.098 -0.501 . . . . 75.409999999999997 109.852 177.654 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . 0.517 ' HB2' ' HA ' ' A' ' 28' ' ' VAL . . . -76.27 112.13 12.43 Favored 'General case' 0 C--N 1.321 -0.645 0 CA-C-N 116.128 -0.487 . . . . 75.340000000000003 110.76 -178.885 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -112.91 153.3 28.18 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 115.493 -0.776 . . . . 65.409999999999997 109.011 176.583 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 95.1 m-20 52.48 77.3 0.16 Allowed 'General case' 0 C--O 1.235 0.341 0 CA-C-O 121.279 0.561 . . . . 72.120000000000005 110.337 -175.426 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.561 HG22 HG21 ' A' ' 28' ' ' VAL . 36.9 t -109.59 107.16 22.19 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 CA-C-N 115.686 -0.688 . . . . 73.420000000000002 110.174 -179.67 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 64' ' ' GLN . . . . . 0.504 ' HB2' ' OG1' ' A' ' 48' ' ' THR . 1.5 mt-30 -99.41 178.54 4.85 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 115.434 -0.803 . . . . 75.109999999999999 110.163 -177.154 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 56.0 mttp -89.05 149.47 23.21 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-O 120.733 0.301 . . . . 73.109999999999999 110.588 -178.494 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 66' ' ' ALA . . . . . 0.653 ' HB3' HG23 ' A' ' 48' ' ' THR . . . . . . . . 0 C--O 1.251 1.165 0 CA-C-O 117.974 -1.012 . . . . 73.530000000000001 109.615 177.304 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 1.9 mpt? . . . . . 0 N--CA 1.482 1.174 0 CA-C-O 120.826 0.346 . . . . 75.219999999999999 110.156 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . 0.433 ' H ' ' CD ' ' A' ' 2' ' ' GLU . 1.4 mp0 -61.94 143.35 56.6 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 115.68 -0.691 . . . . 73.430000000000007 111.235 -176.113 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 3' ' ' GLN . . . . . 0.51 ' HB3' HG21 ' A' ' 48' ' ' THR . 0.9 OUTLIER -93.54 127.34 39.16 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 115.725 -0.671 . . . . 64.099999999999994 109.83 173.485 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -136.74 160.3 24.8 Favored Glycine 0 N--CA 1.445 -0.709 0 C-N-CA 120.887 -0.673 . . . . 55.32 111.566 -179.853 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -96.48 133.35 41.04 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-O 121.266 0.555 . . . . 75.430000000000007 111.421 -179.336 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 45.6 t -68.81 116.06 8.54 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.556 0 CA-C-N 115.824 -0.625 . . . . 75.140000000000001 110.034 177.759 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . 0.831 ' HA ' ' HE3' ' A' ' 7' ' ' LYS . 0.1 OUTLIER -83.04 -62.59 1.55 Allowed 'General case' 0 C--N 1.324 -0.507 0 CA-C-O 121.24 0.543 . . . . 74.310000000000002 109.705 -178.827 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 8' ' ' TRP . . . . . . . . . . . . . 99.5 m95 -126.72 146.94 50.03 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 115.365 -0.834 . . . . 70.140000000000001 109.727 -179.963 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . 0.506 ' CE2' ' HA ' ' A' ' 40' ' ' SER . 68.1 t80 -140.21 98.05 3.36 Favored 'General case' 0 C--N 1.318 -0.773 0 CA-C-O 121.093 0.473 . . . . 75.200000000000003 110.432 176.356 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 91.4 m-20 -82.2 82.57 7.69 Favored 'General case' 0 C--N 1.323 -0.57 0 N-CA-C 109.285 -0.635 . . . . 74.519999999999996 109.285 178.813 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -59.08 -33.74 71.16 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.574 -0.739 . . . . 71.310000000000002 111.297 -178.476 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 36.7 mt-10 -70.1 -26.22 63.87 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 116.066 -0.515 . . . . 72.200000000000003 110.892 -178.733 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 47.9 mmtm -91.44 -29.72 16.88 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.188 -0.46 . . . . 73.310000000000002 110.179 175.999 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 90.99 17.4 51.5 Favored Glycine 0 N--CA 1.447 -0.623 0 CA-C-N 115.853 -0.612 . . . . 72.319999999999993 111.655 -178.895 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 74.3 m-85 -138.15 144.46 40.77 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-O 120.864 0.364 . . . . 73.450000000000003 110.489 -176.568 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -131.16 168.64 21.98 Favored Glycine 0 N--CA 1.444 -0.787 0 C-N-CA 120.438 -0.887 . . . . 73.349999999999994 112.109 -178.621 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . 0.445 ' HA ' ' O ' ' A' ' 26' ' ' VAL . 76.6 m-85 -127.47 118.9 24.92 Favored 'General case' 0 C--N 1.322 -0.603 0 N-CA-C 109.757 -0.46 . . . . 75.439999999999998 109.757 -179.972 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.418 HG21 ' CE2' ' A' ' 49' ' ' PHE . 63.5 mt -109.05 141.82 23.28 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.659 0 CA-C-N 115.992 -0.549 . . . . 73.420000000000002 110.402 -177.526 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 19' ' ' GLU . . . . . 0.614 ' OE1' ' HG2' ' A' ' 7' ' ' LYS . 7.9 pt-20 -92.87 101.42 13.79 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 121.377 0.608 . . . . 72.340000000000003 110.476 178.372 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 20' ' ' ARG . . . . . 0.61 ' HG2' ' OE1' ' A' ' 21' ' ' GLU . 12.4 ttp180 -96.41 158.48 15.42 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 115.854 -0.612 . . . . 75.109999999999999 109.544 -179.503 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . 0.61 ' OE1' ' HG2' ' A' ' 20' ' ' ARG . 0.0 OUTLIER -57.29 -38.02 73.33 Favored 'General case' 0 N--CA 1.466 0.326 0 N-CA-C 112.155 0.428 . . . . 73.319999999999993 112.155 -177.931 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 41.3 m-80 -115.3 36.6 3.85 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-O 120.991 0.424 . . . . 72.340000000000003 110.181 174.949 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -170.38 82.19 0.09 OUTLIER Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.624 -0.798 . . . . 75.150000000000006 112.444 179.846 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 37.4 t70 -63.71 -2.98 1.97 Allowed 'General case' 0 N--CA 1.469 0.48 0 CA-C-O 121.09 0.471 . . . . 72.439999999999998 111.916 -177.039 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 17.5 t70 -152.97 88.55 1.33 Allowed 'General case' 0 C--N 1.325 -0.485 0 CA-C-O 121.105 0.479 . . . . 64.209999999999994 109.829 -179.328 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.445 ' O ' ' HA ' ' A' ' 17' ' ' PHE . 58.8 t -102.97 123.72 56.55 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 CA-C-N 116.005 -0.543 . . . . 74.519999999999996 110.43 179.374 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 27' ' ' PHE . . . . . 0.454 ' O ' ' HA ' ' A' ' 59' ' ' GLN . 62.7 t80 -85.45 102.46 13.48 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 115.612 -0.722 . . . . 73.430000000000007 110.277 -177.025 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.487 HG21 ' HB1' ' A' ' 60' ' ' ALA . 10.2 p -95.77 146.74 6.66 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.505 0 CA-C-O 120.94 0.4 . . . . 74.219999999999999 110.796 -177.453 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 17.3 m-70 -103.83 141.01 36.86 Favored 'General case' 0 C--O 1.234 0.24 0 CA-C-N 115.982 -0.554 . . . . 74.5 111.341 -175.841 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 41.2 p90 -55.91 -36.38 67.63 Favored 'General case' 0 N--CA 1.467 0.412 0 CA-C-N 115.838 -0.619 . . . . 75.129999999999995 112.177 -179.941 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 33.0 t -82.07 -10.52 59.18 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 116.707 -0.224 . . . . 63.140000000000001 111.17 -177.075 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . 0.521 ' HB3' ' HA ' ' A' ' 61' ' ' ALA . . . -92.81 -22.84 19.09 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 121.248 0.547 . . . . 71.409999999999997 109.99 178.829 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.525 ' HA ' ' HB ' ' A' ' 63' ' ' VAL . 67.3 mt -87.68 126.63 41.26 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.468 0 CA-C-N 115.503 -0.771 . . . . 74.230000000000004 110.318 177.012 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 2.3 pp0? -86.64 109.46 19.18 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-O 121.502 0.668 . . . . 74.510000000000005 109.457 172.639 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -81.89 62.2 4.56 Favored Glycine 0 N--CA 1.449 -0.459 0 CA-C-N 115.751 -0.659 . . . . 74.439999999999998 112.709 -175.485 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 31.0 t70 -74.98 109.69 8.65 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-O 120.772 0.32 . . . . 75.120000000000005 110.493 179.254 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 80.77 -53.95 4.61 Favored Glycine 0 N--CA 1.45 -0.407 0 CA-C-N 115.957 -0.565 . . . . 70.099999999999994 112.059 -178.957 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 84.1 m-85 -117.59 120.41 37.97 Favored 'General case' 0 C--N 1.324 -0.529 0 N-CA-C 109.901 -0.407 . . . . 74.430000000000007 109.901 179.111 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 4.4 mptp? -82.38 -30.93 29.97 Favored 'General case' 0 C--N 1.324 -0.528 0 N-CA-C 109.325 -0.62 . . . . 74.099999999999994 109.325 176.842 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 40' ' ' SER . . . . . 0.506 ' HA ' ' CE2' ' A' ' 9' ' ' PHE . 23.5 p -93.46 116.23 28.76 Favored 'General case' 0 N--CA 1.448 -0.551 0 CA-C-N 115.467 -0.788 . . . . 71.540000000000006 109.981 173.803 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 52.0 mt -70.64 137.29 49.78 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-O 120.996 0.427 . . . . 70.5 110.648 179.196 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . 0.42 ' HB3' ' HB2' ' A' ' 45' ' ' GLN . 22.7 t70 -74.64 136.93 41.94 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 115.573 -0.74 . . . . 71.040000000000006 110.638 -176.322 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 8.4 pt-20 -65.81 115.25 5.74 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-O 121.25 0.548 . . . . 75.010000000000005 110.71 178.361 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 100.86 -1.54 55.35 Favored Glycine 0 N--CA 1.446 -0.635 0 C-N-CA 120.47 -0.871 . . . . 72.030000000000001 112.109 -178.218 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 45' ' ' GLN . . . . . 0.42 ' HB2' ' HB3' ' A' ' 42' ' ' ASP . 6.0 tp-100 -74.26 133.85 42.64 Favored 'General case' 0 C--N 1.327 -0.398 0 N-CA-C 109.974 -0.38 . . . . 74.319999999999993 109.974 175.802 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -90.23 123.66 34.21 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 116.186 -0.461 . . . . 33.200000000000003 110.454 179.784 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . 0.483 HG22 ' HD2' ' A' ' 49' ' ' PHE . 21.1 m -127.62 153.56 37.02 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.596 0 CA-C-N 116.008 -0.542 . . . . 73.310000000000002 110.339 178.748 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 48' ' ' THR . . . . . 0.51 HG21 ' HB3' ' A' ' 3' ' ' GLN . 63.7 p -106.96 111.23 23.63 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-O 121.261 0.553 . . . . 75.150000000000006 109.733 179.609 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 49' ' ' PHE . . . . . 0.483 ' HD2' HG22 ' A' ' 47' ' ' VAL . 29.5 p90 -128.61 160.53 32.14 Favored 'General case' 0 C--N 1.318 -0.771 0 CA-C-N 116.138 -0.483 . . . . 74.329999999999998 111.171 -172.543 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 71.0 m-20 -105.02 115.09 29.69 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 116.157 -0.474 . . . . 73.430000000000007 110.435 175.536 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . 0.457 HG21 ' HD3' ' A' ' 20' ' ' ARG . 65.3 t -77.43 120.71 28.48 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.599 0 CA-C-O 121.052 0.454 . . . . 73.230000000000004 110.936 -177.459 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 9.2 tp10 -99.44 125.69 45.21 Favored 'General case' 0 N--CA 1.444 -0.769 0 N-CA-C 108.984 -0.747 . . . . 72.530000000000001 108.984 175.43 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 10.0 pt-20 -88.11 141.11 28.83 Favored 'General case' 0 C--N 1.317 -0.806 0 CA-C-N 116.16 -0.473 . . . . 72.230000000000004 110.806 -175.797 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -162.64 -171.46 28.87 Favored Glycine 0 N--CA 1.446 -0.669 0 C-N-CA 120.851 -0.69 . . . . 64.549999999999997 112.081 178.706 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 34.9 tt0 -58.35 -38.57 77.48 Favored 'General case' 0 C--N 1.326 -0.444 0 C-N-CA 122.488 0.315 . . . . 72.420000000000002 111.218 179.557 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 18.0 mmm180 -75.98 4.36 8.46 Favored 'General case' 0 C--N 1.328 -0.337 0 N-CA-C 111.708 0.262 . . . . 74.340000000000003 111.708 179.999 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 93.51 -136.82 13.28 Favored Glycine 0 N--CA 1.444 -0.818 0 C-N-CA 120.942 -0.647 . . . . 75.439999999999998 112.034 178.928 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 1.8 Cg_endo -83.05 108.94 1.63 Allowed 'Trans proline' 0 N--CA 1.454 -0.832 0 C-N-CA 123.132 2.554 . . . . 75.400000000000006 112.015 -179.69 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . 0.454 ' HA ' ' O ' ' A' ' 27' ' ' PHE . 47.6 mt-30 -110.17 117.27 33.25 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-O 120.906 0.384 . . . . 71.420000000000002 110.081 177.827 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . 0.487 ' HB1' HG21 ' A' ' 28' ' ' VAL . . . -77.72 119.05 20.7 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-O 121.078 0.466 . . . . 74.030000000000001 111.308 -175.852 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . 0.521 ' HA ' ' HB3' ' A' ' 32' ' ' ALA . . . -120.77 167.91 12.0 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 115.425 -0.807 . . . . 74.120000000000005 109.001 175.362 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 62' ' ' ASN . . . . . 0.477 ' O ' ' HA ' ' A' ' 49' ' ' PHE . 37.4 m-20 47.28 74.46 0.16 Allowed 'General case' 0 C--O 1.236 0.393 0 O-C-N 123.265 0.353 . . . . 73.549999999999997 110.314 -176.885 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.525 ' HB ' ' HA ' ' A' ' 33' ' ' ILE . 57.9 t -96.63 104.13 15.49 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.511 0 CA-C-N 116.337 -0.392 . . . . 74.099999999999994 110.817 -177.19 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 6.6 tp-100 -104.65 165.31 11.15 Favored 'General case' 0 C--N 1.321 -0.649 0 N-CA-C 109.127 -0.694 . . . . 75.540000000000006 109.127 178.093 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 86.0 mttt -80.78 176.57 9.69 Favored 'General case' 0 C--N 1.321 -0.635 0 N-CA-C 110.09 -0.337 . . . . 75.219999999999999 110.09 178.103 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 66' ' ' ALA . . . . . 0.484 ' HB1' HG23 ' A' ' 48' ' ' THR . . . . . . . . 0 C--O 1.249 1.052 0 CA-C-O 118.612 -0.709 . . . . 60.530000000000001 109.876 175.603 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 56.8 ttp . . . . . 0 N--CA 1.482 1.15 0 N-CA-C 110.289 -0.263 . . . . 75.439999999999998 110.289 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 34.3 mm-40 -100.35 145.17 28.48 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-O 120.811 0.339 . . . . 64.420000000000002 110.307 -179.32 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 3' ' ' GLN . . . . . 0.947 ' HG2' HG22 ' A' ' 48' ' ' THR . 88.3 mt-30 -124.72 111.78 15.97 Favored 'General case' 0 C--N 1.321 -0.648 0 N-CA-C 109.418 -0.586 . . . . 74.109999999999999 109.418 176.308 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -137.87 163.47 25.57 Favored Glycine 0 N--CA 1.446 -0.653 0 C-N-CA 120.363 -0.922 . . . . 44.409999999999997 112.143 -176.029 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 5' ' ' THR . . . . . 0.543 ' HA ' ' HA ' ' A' ' 46' ' ' ALA . 22.0 m -106.67 130.44 54.4 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-O 120.516 0.198 . . . . 73.439999999999998 110.734 -178.431 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.521 HG23 HG12 ' A' ' 18' ' ' ILE . 42.7 t -70.65 120.67 18.95 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 N-CA-C 109.964 -0.384 . . . . 70.129999999999995 109.964 178.009 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . 0.689 ' HD2' ' HB3' ' A' ' 19' ' ' GLU . 27.2 mtpp -98.81 -34.05 10.65 Favored 'General case' 0 C--N 1.327 -0.393 0 C-N-CA 120.91 -0.316 . . . . 74.530000000000001 110.682 -179.305 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 8' ' ' TRP . . . . . . . . . . . . . 10.5 m-90 -140.0 110.82 6.83 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.067 -0.515 . . . . 72.439999999999998 110.361 179.791 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 65.2 t80 -101.88 91.99 4.61 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-O 121.194 0.521 . . . . 75.049999999999997 109.848 177.546 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 90.3 m-20 -79.15 84.97 5.07 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-O 121.238 0.542 . . . . 74.239999999999995 109.976 -178.037 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -60.41 -40.67 91.84 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.065 -0.97 . . . . 75.430000000000007 112.021 -175.761 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 42.7 mt-10 -81.81 0.45 39.25 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 121.134 0.492 . . . . 73.310000000000002 111.181 -176.786 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 70.5 mmtt -103.95 -28.07 11.78 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 115.782 -0.644 . . . . 74.439999999999998 109.38 170.695 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 82.08 19.26 65.38 Favored Glycine 0 N--CA 1.448 -0.554 0 N-CA-C 111.156 -0.778 . . . . 73.120000000000005 111.156 -175.854 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 48.8 m-85 -135.81 154.86 51.07 Favored 'General case' 0 C--N 1.325 -0.483 0 N-CA-C 110.2 -0.296 . . . . 73.150000000000006 110.2 -176.127 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -140.07 146.56 18.08 Favored Glycine 0 N--CA 1.447 -0.59 0 C-N-CA 120.524 -0.846 . . . . 73.140000000000001 112.14 -179.599 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 97.6 m-85 -104.47 111.88 24.71 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 121.051 0.453 . . . . 71.239999999999995 110.486 178.771 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.521 HG12 HG23 ' A' ' 6' ' ' VAL . 55.2 mt -104.48 135.36 42.67 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.589 0 CA-C-N 115.579 -0.737 . . . . 74.25 109.829 -179.493 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 19' ' ' GLU . . . . . 0.689 ' HB3' ' HD2' ' A' ' 7' ' ' LYS . 14.0 pt-20 -83.29 162.18 21.22 Favored 'General case' 0 C--N 1.327 -0.377 0 C-N-CA 120.265 -0.574 . . . . 72.409999999999997 110.686 -178.837 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 20' ' ' ARG . . . . . . . . . . . . . 39.0 ttt180 -144.64 175.9 9.81 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 115.969 -0.56 . . . . 72.519999999999996 109.755 -173.255 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . 0.428 ' HG3' ' N ' ' A' ' 22' ' ' ASN . 7.8 pt-20 -45.71 -49.45 14.65 Favored 'General case' 0 N--CA 1.469 0.507 0 N-CA-C 113.046 0.758 . . . . 72.140000000000001 113.046 -177.488 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 22' ' ' ASN . . . . . 0.428 ' N ' ' HG3' ' A' ' 21' ' ' GLU . 14.9 t-20 -97.9 12.43 34.1 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-O 121.361 0.601 . . . . 63.420000000000002 110.761 -174.646 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 79.28 9.92 86.53 Favored Glycine 0 N--CA 1.452 -0.243 0 C-N-CA 120.528 -0.844 . . . . 72.129999999999995 111.124 -173.923 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 25.2 t70 -67.14 90.93 0.21 Allowed 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 114.8 -0.7 . . . . 53.409999999999997 110.062 179.871 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 4.8 p-10 -60.84 119.15 7.66 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 121.631 0.729 . . . . 74.230000000000004 111.451 -178.819 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.524 HG13 ' HB3' ' A' ' 60' ' ' ALA . 31.3 t -89.88 127.98 42.13 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.58 0 CA-C-N 115.049 -0.978 . . . . 63.109999999999999 110.179 -179.864 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 27' ' ' PHE . . . . . . . . . . . . . 43.4 t80 -92.67 100.18 12.73 Favored 'General case' 0 C--N 1.321 -0.674 0 CA-C-N 115.582 -0.735 . . . . 71.400000000000006 110.333 -175.854 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.513 ' HA ' ' HB2' ' A' ' 60' ' ' ALA . 11.8 p -89.06 142.52 12.76 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 CA-C-O 120.708 0.289 . . . . 73.340000000000003 110.345 178.812 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 29' ' ' HIS . . . . . 0.405 ' O ' HG13 ' A' ' 33' ' ' ILE . 7.9 p80 -118.87 142.12 48.03 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.389 -0.369 . . . . 72.519999999999996 110.832 -178.484 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 30' ' ' PHE . . . . . 0.518 ' HA ' HD12 ' A' ' 33' ' ' ILE . 43.9 p90 -52.43 -32.54 39.83 Favored 'General case' 0 N--CA 1.468 0.443 0 CA-C-N 115.501 -0.772 . . . . 64.019999999999996 112.934 -173.648 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 1.9 p -71.06 -9.19 57.61 Favored 'General case' 0 C--N 1.323 -0.585 0 N-CA-C 111.911 0.337 . . . . 74.430000000000007 111.911 -179.046 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -122.07 -7.05 8.9 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-O 120.916 0.389 . . . . 61.539999999999999 110.941 177.905 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.518 HD12 ' HA ' ' A' ' 30' ' ' PHE . 68.3 mt -67.77 136.5 26.46 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.386 0 CA-C-N 116.21 -0.45 . . . . 73.400000000000006 110.115 175.78 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 24.0 pt20 -64.75 102.11 0.55 Allowed 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 121.434 0.635 . . . . 71.099999999999994 110.967 177.541 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -91.36 17.89 54.16 Favored Glycine 0 N--CA 1.45 -0.413 0 C-N-CA 120.847 -0.692 . . . . 71.340000000000003 111.967 179.143 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 22.4 t70 -90.5 105.81 18.07 Favored 'General case' 0 C--N 1.325 -0.491 0 N-CA-C 109.902 -0.407 . . . . 73.319999999999993 109.902 -179.711 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 93.66 -102.63 2.93 Favored Glycine 0 N--CA 1.446 -0.674 0 C-N-CA 120.757 -0.735 . . . . 71.239999999999995 112.001 -177.855 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 99.1 m-85 -90.57 117.46 29.26 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 120.814 0.34 . . . . 74.239999999999995 110.392 178.767 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -83.09 -8.92 59.46 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-O 121.118 0.485 . . . . 74.340000000000003 110.357 179.494 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 3.7 p -103.37 92.66 4.59 Favored 'General case' 0 N--CA 1.447 -0.583 0 CA-C-N 115.974 -0.557 . . . . 63.409999999999997 111.844 -176.1 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 93.2 mt -85.62 81.47 8.64 Favored 'General case' 0 C--N 1.327 -0.394 0 N-CA-C 108.726 -0.842 . . . . 73.299999999999997 108.726 172.884 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 69.3 m-20 -73.97 172.21 12.04 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-O 122.038 0.923 . . . . 73.430000000000007 112.911 -169.677 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . 0.452 ' CD ' ' H ' ' A' ' 43' ' ' GLU . 22.2 mp0 -60.64 132.96 55.55 Favored 'General case' 0 N--CA 1.448 -0.554 0 CA-C-N 114.139 -1.391 . . . . 72.349999999999994 110.163 -178.44 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 98.99 -5.94 59.77 Favored Glycine 0 N--CA 1.446 -0.686 0 C-N-CA 120.711 -0.757 . . . . 65.010000000000005 112.713 178.102 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 3.4 tm0? -92.16 126.08 37.1 Favored 'General case' 0 C--N 1.328 -0.354 0 N-CA-C 109.566 -0.531 . . . . 75.230000000000004 109.566 176.751 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 0.543 ' HA ' ' HA ' ' A' ' 5' ' ' THR . . . -97.95 113.09 24.83 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-O 120.944 0.402 . . . . 75.129999999999995 110.675 178.795 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 23.2 m -106.26 160.95 5.74 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 CA-C-N 115.952 -0.567 . . . . 74.349999999999994 111.087 -178.44 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 48' ' ' THR . . . . . 0.947 HG22 ' HG2' ' A' ' 3' ' ' GLN . 53.8 p -106.79 126.13 51.89 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 115.748 -0.66 . . . . 74.219999999999999 109.411 175.743 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 49' ' ' PHE . . . . . 0.459 ' HA ' ' O ' ' A' ' 62' ' ' ASN . 33.4 p90 -142.0 167.49 22.01 Favored 'General case' 0 C--N 1.317 -0.813 0 CA-C-O 120.954 0.407 . . . . 74.230000000000004 111.33 -173.435 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 33.1 t70 -106.55 148.64 28.01 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.747 -0.66 . . . . 74.25 109.947 175.841 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 62.6 t -82.22 105.76 12.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-O 120.953 0.406 . . . . 73.109999999999999 111.137 -178.782 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . 0.404 ' HB2' ' HB2' ' A' ' 61' ' ' ALA . 40.6 tt0 -82.49 123.76 29.46 Favored 'General case' 0 C--N 1.319 -0.721 0 N-CA-C 108.881 -0.785 . . . . 54.439999999999998 108.881 174.459 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 43.5 mt-10 -87.94 109.55 19.88 Favored 'General case' 0 C--N 1.319 -0.731 0 CA-C-N 115.974 -0.557 . . . . 71.329999999999998 110.804 -174.901 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -138.16 166.8 25.12 Favored Glycine 0 N--CA 1.446 -0.663 0 CA-C-N 115.454 -0.793 . . . . 71.340000000000003 111.577 -179.579 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 72.6 mt-30 -79.97 82.95 5.95 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 121.343 0.592 . . . . 72.439999999999998 111.245 -175.843 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 56' ' ' ARG . . . . . 0.426 HH11 ' HD3' ' A' ' 56' ' ' ARG . 9.1 ptp180 -179.77 -32.01 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 114.764 -1.107 . . . . 74.120000000000005 109.326 177.893 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 144.95 -152.11 24.19 Favored Glycine 0 N--CA 1.448 -0.553 0 N-CA-C 110.737 -0.945 . . . . 74.239999999999995 110.737 -178.183 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 55.5 Cg_endo -70.98 105.2 1.64 Allowed 'Trans proline' 0 N--CA 1.46 -0.472 0 C-N-CA 122.158 1.906 . . . . 73.219999999999999 111.537 176.871 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 20.3 tt0 -97.8 139.04 34.26 Favored 'General case' 0 C--N 1.322 -0.596 0 N-CA-C 108.63 -0.878 . . . . 73.540000000000006 108.63 179.071 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . 0.524 ' HB3' HG13 ' A' ' 26' ' ' VAL . . . -96.11 120.42 36.37 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-O 121.255 0.55 . . . . 75.329999999999998 112.105 -174.835 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . 0.404 ' HB2' ' HB2' ' A' ' 52' ' ' GLU . . . -135.57 163.1 30.89 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 115.05 -0.977 . . . . 74.329999999999998 108.62 173.777 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 62' ' ' ASN . . . . . 0.459 ' O ' ' HA ' ' A' ' 49' ' ' PHE . 88.5 m-20 54.65 77.34 0.21 Allowed 'General case' 0 C--O 1.236 0.348 0 CA-C-O 121.067 0.46 . . . . 74.409999999999997 109.855 -174.494 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 45.9 t -112.67 121.38 64.87 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 CA-C-N 115.643 -0.708 . . . . 73.340000000000003 110.787 -175.998 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 5.1 tp60 -115.61 146.58 41.66 Favored 'General case' 0 C--N 1.323 -0.566 0 N-CA-C 109.29 -0.633 . . . . 62.229999999999997 109.29 177.642 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 19.4 ttpp -84.01 137.8 33.43 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 120.931 0.396 . . . . 73.209999999999994 111.481 -176.867 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 0.987 0 CA-C-O 118.202 -0.904 . . . . 72.150000000000006 108.882 171.109 . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 1.4 mpt? . . . . . 0 N--CA 1.481 1.087 0 CA-C-O 121.177 0.513 . . . . 73.239999999999995 110.133 . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . 0.466 ' O ' ' HA ' ' A' ' 48' ' ' THR . 5.0 mp0 -114.24 14.99 18.21 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-N 115.752 -0.658 . . . . 73.219999999999999 109.283 -179.453 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 17.9 mp0 -63.96 136.32 57.24 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.033 -0.985 . . . . 74.400000000000006 112.606 -173.968 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -153.09 163.38 30.52 Favored Glycine 0 N--CA 1.441 -1.003 0 N-CA-C 109.419 -1.473 . . . . 73.510000000000005 109.419 172.657 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 13.9 m -122.46 127.53 49.72 Favored 'General case' 0 C--N 1.316 -0.861 0 CA-C-N 118.04 0.92 . . . . 64.299999999999997 110.886 -178.174 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 61.5 t -64.93 120.7 12.44 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.462 0 CA-C-N 116.22 -0.445 . . . . 75.239999999999995 111.115 -178.026 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . 1.048 ' HE2' ' HB3' ' A' ' 19' ' ' GLU . 66.3 mmtt -74.93 -70.49 0.41 Allowed 'General case' 0 C--N 1.328 -0.344 0 N-CA-C 109.219 -0.66 . . . . 74.340000000000003 109.219 175.309 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 8' ' ' TRP . . . . . . . . . . . . . 15.6 m95 -140.36 128.35 22.08 Favored 'General case' 0 C--O 1.235 0.317 0 CA-C-N 115.059 -0.973 . . . . 72.230000000000004 108.786 -179.537 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 22.8 p90 -99.52 103.69 15.45 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-O 121.702 0.763 . . . . 74.329999999999998 109.706 177.377 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 10' ' ' ASN . . . . . 0.856 ' HB3' ' HG3' ' A' ' 13' ' ' LYS . 37.8 m-80 -91.45 63.79 4.91 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 115.775 -0.648 . . . . 63.210000000000001 110.557 -176.958 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -64.07 -26.29 68.48 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 115.609 -0.723 . . . . 65.430000000000007 110.435 178.732 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 4.1 mm-40 -71.64 -13.27 61.7 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 115.726 -0.67 . . . . 72.230000000000004 110.509 178.684 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . 0.856 ' HG3' ' HB3' ' A' ' 10' ' ' ASN . 1.7 mmpt? -112.97 -37.85 4.68 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.895 -0.593 . . . . 75.329999999999998 110.395 -176.99 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . 0.407 ' O ' ' HD1' ' A' ' 30' ' ' PHE . . . 116.85 15.61 6.7 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.956 -0.64 . . . . 73.420000000000002 112.835 178.474 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 45.3 p90 -151.49 -176.36 5.56 Favored 'General case' 0 C--N 1.324 -0.543 0 O-C-N 122.543 -0.386 . . . . 73.340000000000003 110.667 179.96 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -164.55 169.99 39.51 Favored Glycine 0 N--CA 1.445 -0.743 0 C-N-CA 120.915 -0.66 . . . . 73.140000000000001 111.795 177.581 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 96.6 m-85 -123.76 130.12 52.13 Favored 'General case' 0 C--N 1.323 -0.585 0 N-CA-C 109.979 -0.378 . . . . 73.150000000000006 109.979 178.695 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 61.0 mt -127.57 135.35 63.45 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.768 0 N-CA-C 109.701 -0.481 . . . . 71.329999999999998 109.701 178.308 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 19' ' ' GLU . . . . . 1.048 ' HB3' ' HE2' ' A' ' 7' ' ' LYS . 8.5 pt-20 -91.5 135.61 33.72 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-O 121.212 0.529 . . . . 65.140000000000001 110.811 179.451 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 20' ' ' ARG . . . . . 0.648 ' HB2' ' HZ ' ' A' ' 49' ' ' PHE . 45.5 ttt180 -133.93 161.75 33.94 Favored 'General case' 0 C--N 1.315 -0.928 0 N-CA-C 108.576 -0.898 . . . . 73.299999999999997 108.576 174.78 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 7.1 mm-40 -35.87 -57.47 0.67 Allowed 'General case' 0 N--CA 1.468 0.444 0 O-C-N 124.038 0.836 . . . . 73.409999999999997 110.806 178.025 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 34.9 t30 -110.06 76.92 1.02 Allowed 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 115.704 -0.68 . . . . 71.400000000000006 109.749 172.409 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . 0.569 ' O ' HG21 ' A' ' 26' ' ' VAL . . . 152.24 72.44 0.01 OUTLIER Glycine 0 N--CA 1.446 -0.674 0 C-N-CA 120.541 -0.838 . . . . 74.099999999999994 112.213 174.032 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 25.2 t70 -68.17 -1.79 6.76 Favored 'General case' 0 C--N 1.321 -0.663 0 CA-C-O 121.183 0.516 . . . . 73.219999999999999 111.062 -176.278 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 7.0 p-10 -142.65 31.49 1.47 Allowed 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 116.246 -0.434 . . . . 74.109999999999999 110.929 -174.988 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.569 HG21 ' O ' ' A' ' 23' ' ' GLY . 79.2 t -53.28 121.83 2.73 Favored 'Isoleucine or valine' 0 C--O 1.234 0.269 0 CA-C-O 121.109 0.48 . . . . 72.430000000000007 110.743 179.588 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 27' ' ' PHE . . . . . . . . . . . . . 42.6 t80 -84.21 116.74 23.1 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 115.583 -0.735 . . . . 74.120000000000005 110.603 -174.413 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.486 HG21 HG22 ' A' ' 63' ' ' VAL . 9.0 p -110.68 156.1 11.86 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.59 0 CA-C-N 116.339 -0.392 . . . . 75.319999999999993 110.281 179.853 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 92.7 m-70 -108.82 157.27 18.74 Favored 'General case' 0 C--O 1.239 0.513 0 N-CA-C 110.011 -0.366 . . . . 65.530000000000001 110.011 -179.674 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 30' ' ' PHE . . . . . 0.407 ' HD1' ' O ' ' A' ' 14' ' ' GLY . 50.8 p90 -61.65 -34.48 75.78 Favored 'General case' 0 N--CA 1.464 0.234 0 CA-C-N 116.54 -0.3 . . . . 75.239999999999995 111.605 -175.847 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 26.8 t -92.43 2.68 56.52 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 121.053 0.454 . . . . 74.319999999999993 110.589 -179.045 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -93.38 -29.9 15.37 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 121.168 0.509 . . . . 73.319999999999993 110.151 177.127 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.56 ' HA ' ' HB ' ' A' ' 63' ' ' VAL . 59.1 mt -72.66 137.89 22.56 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.386 0 CA-C-N 115.608 -0.724 . . . . 73.310000000000002 109.992 174.277 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 5.1 pp0? -71.66 146.51 48.23 Favored 'General case' 0 C--N 1.329 -0.318 0 N-CA-C 110.061 -0.348 . . . . 73.409999999999997 110.061 178.236 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 164.41 133.12 1.44 Allowed Glycine 0 N--CA 1.442 -0.955 0 C-N-CA 120.749 -0.739 . . . . 51.350000000000001 111.947 179.299 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 9.2 m-20 -65.26 106.42 1.34 Allowed 'General case' 0 C--N 1.326 -0.428 0 N-CA-C 109.735 -0.469 . . . . 72.450000000000003 109.735 178.307 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 78.4 -95.36 1.32 Allowed Glycine 0 N--CA 1.446 -0.636 0 N-CA-C 111.077 -0.809 . . . . 50.140000000000001 111.077 -173.737 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . 0.414 ' O ' ' HD2' ' A' ' 39' ' ' LYS . 74.1 m-85 -138.04 94.5 2.89 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 120.873 0.368 . . . . 71.019999999999996 110.406 176.379 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 39' ' ' LYS . . . . . 0.414 ' HD2' ' O ' ' A' ' 38' ' ' PHE . 13.1 mptt -125.95 88.41 2.85 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 116.159 -0.473 . . . . 72.109999999999999 110.497 177.509 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 20.0 m -76.21 121.82 23.46 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-N 115.902 -0.59 . . . . 75.310000000000002 110.034 177.594 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 98.4 mt -66.35 143.13 57.35 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 116.013 -0.539 . . . . 64.209999999999994 110.93 -177.882 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 35.4 t70 -68.07 149.38 49.73 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-N 115.462 -0.79 . . . . 71.319999999999993 112.176 -172.808 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 7.6 pt-20 -65.25 135.63 55.62 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 115.751 -0.658 . . . . 73.040000000000006 110.518 179.312 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 89.74 -1.23 80.89 Favored Glycine 0 N--CA 1.447 -0.583 0 C-N-CA 120.66 -0.781 . . . . 74.230000000000004 112.233 -177.18 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 6.5 tp-100 -82.92 141.49 32.14 Favored 'General case' 0 C--O 1.237 0.439 0 CA-C-O 120.732 0.301 . . . . 74.230000000000004 110.36 176.984 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -82.38 117.41 22.42 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 115.824 -0.626 . . . . 65.310000000000002 110.257 178.244 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 29.5 m -117.01 166.93 10.83 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.711 0 CA-C-N 115.727 -0.67 . . . . 74.230000000000004 110.884 -178.071 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 48' ' ' THR . . . . . 0.721 HG23 ' HB3' ' A' ' 66' ' ' ALA . 9.6 p -132.91 103.15 5.92 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-O 121.296 0.569 . . . . 63.409999999999997 110.106 178.461 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 49' ' ' PHE . . . . . 0.648 ' HZ ' ' HB2' ' A' ' 20' ' ' ARG . 36.5 p90 -117.16 166.82 11.79 Favored 'General case' 0 C--N 1.318 -0.792 0 CA-C-O 121.072 0.463 . . . . 74.030000000000001 111.751 -172.399 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 35.5 t70 -96.91 128.06 43.5 Favored 'General case' 0 C--N 1.32 -0.68 0 N-CA-C 109.016 -0.735 . . . . 73.140000000000001 109.016 174.169 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 7.4 p -80.62 118.0 27.56 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.564 0 CA-C-O 121.538 0.685 . . . . 73.420000000000002 111.254 -174.746 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 44.0 tt0 -89.14 113.16 24.3 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-N 115.419 -0.81 . . . . 75.049999999999997 109.109 176.942 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 13.9 mm-40 -73.62 86.13 1.62 Allowed 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 115.983 -0.553 . . . . 75.019999999999996 109.875 178.248 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -88.64 160.8 30.48 Favored Glycine 0 N--CA 1.443 -0.858 0 C-N-CA 120.88 -0.676 . . . . 61.109999999999999 112.331 -177.523 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 36.7 tt0 -84.77 0.34 50.99 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-O 121.392 0.615 . . . . 73.209999999999994 109.854 -179.295 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 90.8 mtm180 -119.84 15.64 12.6 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.597 -0.729 . . . . 75.200000000000003 110.855 179.184 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 121.68 169.17 13.56 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.884 -0.674 . . . . 72.310000000000002 112.182 -179.769 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 37.7 Cg_endo -68.03 118.41 5.6 Favored 'Trans proline' 0 C--N 1.344 0.291 0 C-N-CA 122.532 2.155 . . . . 72.340000000000003 111.768 177.249 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 49.9 mt-30 -119.45 164.31 15.96 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 116.325 -0.398 . . . . 73.109999999999999 110.429 -177.791 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -111.65 125.15 53.65 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-O 121.255 0.55 . . . . 75.299999999999997 111.943 -174.048 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -128.57 142.97 50.89 Favored 'General case' 0 C--N 1.321 -0.63 0 CA-C-N 115.3 -0.863 . . . . 65.510000000000005 109.005 174.426 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 39.4 m-80 56.53 78.57 0.21 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 121.216 0.532 . . . . 72.450000000000003 110.448 -175.899 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.56 ' HB ' ' HA ' ' A' ' 33' ' ' ILE . 51.8 t -101.42 109.59 26.14 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.519 0 CA-C-N 115.892 -0.594 . . . . 70.5 110.803 -177.965 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 86.7 mt-30 -94.06 -172.24 2.77 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 116.192 -0.458 . . . . 74.099999999999994 110.105 177.983 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 61.9 tttm -116.45 139.64 50.23 Favored 'General case' 0 C--N 1.321 -0.641 0 N-CA-C 109.303 -0.629 . . . . 73.409999999999997 109.303 178.508 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 66' ' ' ALA . . . . . 0.721 ' HB3' HG23 ' A' ' 48' ' ' THR . . . . . . . . 0 C--O 1.248 1.006 0 CA-C-O 118.795 -0.621 . . . . 75.010000000000005 110.557 -178.614 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 2' ' ' GLU . . . . . 0.943 ' HG3' HH12 ' A' ' 20' ' ' ARG . 0.1 OUTLIER . . . . . 0 C--O 1.235 0.337 0 CA-C-O 121.06 0.457 . . . . 74.42 111.209 . . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 41.1 mt-30 -96.54 148.52 22.75 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.539 -0.755 . . . . 51.42 110.123 178.481 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -155.91 153.7 24.95 Favored Glycine 0 N--CA 1.445 -0.726 0 C-N-CA 120.934 -0.651 . . . . 71.33 111.866 177.114 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 4.7 m -104.57 134.81 47.12 Favored 'General case' 0 C--N 1.319 -0.752 0 N-CA-C 109.812 -0.44 . . . . 73.12 109.812 178.124 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 61.8 t -68.13 112.18 3.01 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.609 0 CA-C-O 120.745 0.307 . . . . 63.52 110.41 177.952 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 7' ' ' LYS . . . . . 0.683 ' HD3' ' HB3' ' A' ' 19' ' ' GLU . 12.3 mmmm -71.3 -68.5 0.44 Allowed 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.831 -0.622 . . . . 62.45 109.822 179.159 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 8' ' ' TRP . . . . . . . . . . . . . 4.6 p-90 -153.06 149.01 27.68 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-N 115.462 -0.79 . . . . 74.33 109.32 177.774 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 9' ' ' PHE . . . . . 0.419 ' CE2' ' HA ' ' A' ' 40' ' ' SER . 68.5 t80 -114.59 120.15 39.21 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-O 121.001 0.429 . . . . 74.21 111.563 -173.227 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 10' ' ' ASN . . . . . 0.454 ' HB3' ' HB2' ' A' ' 13' ' ' LYS . 15.3 m120 -81.92 78.31 8.64 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.669 -0.696 . . . . 74.21 109.472 176.261 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -61.71 -37.64 84.92 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 115.905 -0.589 . . . . 14.0 111.303 -177.114 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 32.0 mm-40 -76.8 -11.33 59.81 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.379 -0.373 . . . . 73.34 111.554 -178.925 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 13' ' ' LYS . . . . . 0.487 ' HB3' ' HD2' ' A' ' 15' ' ' PHE . 70.1 mmtt -99.79 -33.69 10.47 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-O 121.072 0.463 . . . . 73.32 110.553 176.839 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 89.85 24.28 30.53 Favored Glycine 0 N--CA 1.448 -0.536 0 N-CA-C 111.075 -0.81 . . . . 75.14 111.075 -174.147 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 15' ' ' PHE . . . . . 0.487 ' HD2' ' HB3' ' A' ' 13' ' ' LYS . 64.3 m-85 -136.92 173.73 11.38 Favored 'General case' 0 C--N 1.324 -0.519 0 N-CA-C 109.549 -0.538 . . . . 73.32 109.549 -178.338 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -160.98 167.56 36.02 Favored Glycine 0 N--CA 1.447 -0.6 0 C-N-CA 120.281 -0.962 . . . . 64.41 112.285 178.543 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 96.2 m-85 -119.67 119.67 34.39 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-O 121.105 0.478 . . . . 73.54 110.668 179.095 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 56.4 mt -112.76 124.95 69.91 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.657 0 N-CA-C 109.187 -0.671 . . . . 62.13 109.187 177.72 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 19' ' ' GLU . . . . . 0.683 ' HB3' ' HD3' ' A' ' 7' ' ' LYS . 10.3 pt-20 -71.88 140.38 49.25 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-O 121.342 0.592 . . . . 73.41 111.468 -173.792 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 20' ' ' ARG . . . . . 0.943 HH12 ' HG3' ' A' ' 2' ' ' GLU . 9.7 tpt180 -90.84 172.98 8.24 Favored 'General case' 0 C--N 1.32 -0.7 0 N-CA-C 107.521 -1.289 . . . . 35.3 107.521 167.107 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 21' ' ' GLU . . . . . 0.575 ' OE2' ' HG3' ' A' ' 20' ' ' ARG . 0.0 OUTLIER -59.79 -23.15 63.05 Favored 'General case' 0 N--CA 1.467 0.413 0 CA-C-N 118.383 0.538 . . . . 61.32 112.327 -172.93 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 91.9 m-20 -101.4 17.79 21.76 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.855 0.36 . . . . 42.51 111.594 179.005 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 80.15 2.08 88.59 Favored Glycine 0 N--CA 1.452 -0.253 0 C-N-CA 120.943 -0.646 . . . . 40.52 112.751 176.897 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 28.4 t70 -69.19 97.85 0.96 Allowed 'General case' 0 C--N 1.323 -0.557 0 N-CA-C 109.955 -0.387 . . . . 63.51 109.955 179.712 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.47 ' OD1' ' HG3' ' A' ' 7' ' ' LYS . 52.5 m-20 -53.66 113.67 1.27 Allowed 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.331 -0.85 . . . . 74.14 111.119 176.363 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.608 HG12 ' HB2' ' A' ' 60' ' ' ALA . 25.3 t -89.27 135.56 25.66 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.602 0 CA-C-N 115.663 -0.698 . . . . 73.23 109.457 176.316 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 27' ' ' PHE . . . . . . . . . . . . . 40.4 t80 -90.72 109.65 20.83 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 120.988 0.423 . . . . 74.34 110.79 -172.894 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.436 ' HA ' ' HB3' ' A' ' 60' ' ' ALA . 7.9 p -97.52 151.45 4.29 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 CA-C-N 116.185 -0.461 . . . . 44.32 110.508 -179.434 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 29' ' ' HIS . . . . . 0.44 ' HA ' ' HD1' ' A' ' 15' ' ' PHE . 86.9 m-70 -115.46 158.53 22.4 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.175 -0.466 . . . . 62.11 110.969 -175.924 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 34.3 p90 -61.69 -31.34 71.47 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.029 -0.532 . . . . 72.24 111.774 179.742 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 8.0 t -94.43 12.85 25.72 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 121.433 0.635 . . . . 62.53 109.977 -179.628 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 32' ' ' ALA . . . . . 0.72 ' HB1' ' HA ' ' A' ' 61' ' ' ALA . . . -112.68 -28.85 7.65 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 115.701 -0.681 . . . . 60.31 110.124 178.132 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 55.7 mt -80.33 139.01 18.82 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.53 0 CA-C-N 115.443 -0.799 . . . . 51.32 109.926 177.126 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 34' ' ' GLN . . . . . 0.415 ' HG3' ' O ' ' A' ' 34' ' ' GLN . 10.5 pt20 . . . . . 0 N--CA 1.45 -0.432 0 CA-C-O 121.395 0.617 . . . . 63.31 109.518 173.436 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 40' ' ' SER . . . . . 0.419 ' HA ' ' CE2' ' A' ' 9' ' ' PHE . 66.4 m . . . . . 0 N--CA 1.453 -0.305 0 N-CA-C 109.939 -0.393 . . . . 51.21 109.939 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 87.6 mt -110.96 126.52 54.85 Favored 'General case' 0 C--N 1.321 -0.642 0 N-CA-C 109.328 -0.619 . . . . 75.33 109.328 174.301 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 36.0 t70 -69.44 112.91 6.29 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-O 121.001 0.429 . . . . 71.13 109.95 179.991 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 55.6 mt-10 -65.57 120.46 12.94 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 115.956 -0.565 . . . . 52.33 110.35 -176.89 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 105.22 -13.07 48.56 Favored Glycine 0 N--CA 1.449 -0.498 0 C-N-CA 121.014 -0.612 . . . . 32.41 111.903 -175.305 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 6.2 tp-100 -83.64 145.6 28.72 Favored 'General case' 0 C--O 1.235 0.318 0 CA-C-O 120.795 0.331 . . . . 64.21 110.272 -179.855 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -100.22 135.21 42.0 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 116.161 -0.472 . . . . 74.23 110.465 178.743 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 8.9 m -141.68 -175.93 0.9 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.493 0 CA-C-N 116.096 -0.502 . . . . 54.34 110.537 179.444 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 19.8 p -124.54 157.97 34.06 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 115.971 -0.559 . . . . 60.43 109.693 177.302 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 37.8 p90 -156.48 151.07 25.7 Favored 'General case' 0 C--N 1.321 -0.637 0 C-N-CA 120.56 -0.456 . . . . 73.13 111.545 -176.748 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 50' ' ' ASP . . . . . 0.736 ' HB3' ' HB2' ' A' ' 62' ' ' ASN . 26.3 t70 -91.35 94.4 9.49 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 115.834 -0.621 . . . . 75.24 109.697 174.562 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 7.6 p -73.56 133.63 31.29 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.55 0 CA-C-N 115.871 -0.604 . . . . 64.22 111.079 -176.399 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 25.7 mt-10 -119.31 171.69 8.14 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 115.847 -0.615 . . . . 74.32 110.155 179.273 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 10.8 pt-20 -72.08 149.51 44.76 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.834 -0.621 . . . . 72.52 110.87 179.968 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 54' ' ' GLY . . . . . 0.48 ' HA3' ' O ' ' A' ' 57' ' ' GLY . . . -155.02 124.98 1.6 Allowed Glycine 0 N--CA 1.445 -0.715 0 CA-C-N 115.87 -0.604 . . . . 32.53 111.804 178.387 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 35.4 tt0 -61.49 -33.08 73.17 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-O 120.654 0.264 . . . . 64.21 111.306 -177.535 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 22.2 mmt180 -114.47 25.98 10.6 Favored 'General case' 0 C--N 1.327 -0.375 0 N-CA-C 111.741 0.274 . . . . 72.22 111.741 -179.515 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 57' ' ' GLY . . . . . 0.48 ' O ' ' HA3' ' A' ' 54' ' ' GLY . . . 139.86 157.25 7.19 Favored Glycine 0 N--CA 1.448 -0.55 0 C-N-CA 120.319 -0.943 . . . . 60.23 112.378 176.757 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 58' ' ' PRO . . . . . 0.567 ' HG2' ' HA ' ' A' ' 26' ' ' VAL . 37.5 Cg_endo -66.47 127.2 16.85 Favored 'Trans proline' 0 C--O 1.234 0.323 0 C-N-CA 122.629 2.219 . . . . 63.23 111.517 -179.758 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 26.9 tt0 -88.72 107.86 19.17 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 116.039 -0.528 . . . . 52.23 110.728 -176.841 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 60' ' ' ALA . . . . . 0.608 ' HB2' HG12 ' A' ' 26' ' ' VAL . . . -79.2 97.75 6.34 Favored 'General case' 0 C--N 1.323 -0.575 0 N-CA-C 109.728 -0.471 . . . . 71.23 109.728 175.879 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 61' ' ' ALA . . . . . 0.72 ' HA ' ' HB1' ' A' ' 32' ' ' ALA . . . -111.44 165.83 11.64 Favored 'General case' 0 C--N 1.319 -0.74 0 CA-C-N 115.829 -0.623 . . . . 61.51 110.017 -179.994 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 62' ' ' ASN . . . . . 0.736 ' HB2' ' HB3' ' A' ' 50' ' ' ASP . 56.3 m-20 48.37 65.89 1.21 Allowed 'General case' 0 C--N 1.33 -0.271 0 O-C-N 123.727 0.642 . . . . 72.41 111.03 174.915 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 58.7 t -77.26 120.64 28.12 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.464 0 CA-C-N 116.086 -0.507 . . . . 72.52 110.493 -178.603 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 77.2 mm-40 -108.12 133.76 51.94 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-N 115.827 -0.624 . . . . 74.21 110.058 179.694 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 96.8 mttt -73.92 134.41 43.19 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 116.194 -0.457 . . . . 61.31 110.503 -179.397 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.246 0.87 0 CA-C-O 118.346 -0.835 . . . . 60.41 110.326 -179.783 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 11.1 mp0 . . . . . 0 N--CA 1.453 -0.297 0 N-CA-C 110.254 -0.276 . . . . 64.32 110.254 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 3' ' ' GLN . . . . . 0.49 ' HA ' ' O ' ' A' ' 47' ' ' VAL . 28.6 tt0 -92.65 131.17 37.98 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 116.38 -0.373 . . . . 53.22 110.065 176.733 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 4' ' ' GLY . . . . . 0.412 ' HA3' ' HE2' ' A' ' 49' ' ' PHE . . . -146.16 151.62 23.83 Favored Glycine 0 N--CA 1.446 -0.685 0 C-N-CA 120.872 -0.68 . . . . 65.32 112.292 -179.58 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 5' ' ' THR . . . . . 0.42 ' O ' ' HG2' ' A' ' 19' ' ' GLU . 0.2 OUTLIER -89.0 125.8 35.14 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-O 120.659 0.266 . . . . 73.42 110.923 -177.287 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.863 ' HA ' HG13 ' A' ' 18' ' ' ILE . 31.2 t -68.55 102.53 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.495 0 N-CA-C 110.098 -0.334 . . . . 60.01 110.098 176.623 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 8.8 mmmm -72.59 -68.29 0.49 Allowed 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 116.296 -0.411 . . . . 60.13 110.672 -177.531 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 8' ' ' TRP . . . . . . . . . . . . . 80.7 m95 -135.32 131.69 36.76 Favored 'General case' 0 C--N 1.323 -0.546 0 N-CA-C 109.755 -0.461 . . . . 70.44 109.755 178.286 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 9' ' ' PHE . . . . . 0.487 ' HA ' ' HA3' ' A' ' 16' ' ' GLY . 73.3 t80 -134.42 104.35 6.09 Favored 'General case' 0 C--N 1.318 -0.765 0 CA-C-O 120.912 0.387 . . . . 73.43 110.125 176.939 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 10' ' ' ASN . . . . . 0.628 ' OD1' ' HG2' ' A' ' 13' ' ' LYS . 16.7 t-20 -78.53 86.64 4.53 Favored 'General case' 0 C--N 1.321 -0.639 0 N-CA-C 109.305 -0.628 . . . . 64.52 109.305 178.897 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -66.31 -15.76 63.49 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 115.243 -0.89 . . . . 63.41 111.494 -177.17 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 32.7 mt-10 -68.01 -38.46 82.65 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.142 -0.481 . . . . 62.24 109.983 177.867 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 13' ' ' LYS . . . . . 0.628 ' HG2' ' OD1' ' A' ' 10' ' ' ASN . 28.9 mmtp -98.2 -30.45 12.63 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 116.112 -0.494 . . . . 74.05 109.946 179.955 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 104.9 20.73 9.61 Favored Glycine 0 N--CA 1.448 -0.555 0 C-N-CA 120.746 -0.74 . . . . 61.23 113.068 175.857 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 39.7 p90 -147.08 162.59 38.52 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 117.157 0.478 . . . . 73.42 110.853 -178.857 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.487 ' HA3' ' HA ' ' A' ' 9' ' ' PHE . . . -168.45 -164.15 23.66 Favored Glycine 0 N--CA 1.444 -0.823 0 C-N-CA 120.665 -0.778 . . . . 72.11 112.064 178.857 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 91.9 m-85 -133.83 124.3 26.28 Favored 'General case' 0 C--N 1.322 -0.61 0 N-CA-C 109.408 -0.59 . . . . 74.02 109.408 -178.005 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.863 HG13 ' HA ' ' A' ' 6' ' ' VAL . 11.0 tt -116.51 158.22 17.07 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.96 0 N-CA-C 109.095 -0.706 . . . . 51.45 109.095 -177.712 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 19' ' ' GLU . . . . . 0.42 ' HG2' ' O ' ' A' ' 5' ' ' THR . 19.8 pt-20 -106.49 134.13 50.1 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 121.375 0.607 . . . . 71.12 111.229 -178.148 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 20' ' ' ARG . . . . . . . . . . . . . 14.3 ttt180 -97.35 157.98 15.7 Favored 'General case' 0 C--N 1.317 -0.83 0 N-CA-C 108.224 -1.028 . . . . 63.32 108.224 172.026 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 31.7 mt-10 -44.0 -40.65 4.87 Favored 'General case' 0 N--CA 1.467 0.416 0 O-C-N 123.503 0.502 . . . . 74.54 110.885 -179.499 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 23.1 t-20 -127.59 73.62 1.46 Allowed 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 115.89 -0.595 . . . . 72.51 109.784 171.498 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 164.61 94.99 0.1 Allowed Glycine 0 C--O 1.227 -0.306 0 C-N-CA 120.41 -0.9 . . . . 71.32 112.843 175.846 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 13.3 m-20 -78.44 18.16 0.58 Allowed 'General case' 0 N--CA 1.468 0.458 0 N-CA-C 111.877 0.325 . . . . 75.05 111.877 -178.02 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 36.5 t70 -142.7 85.24 1.88 Allowed 'General case' 0 C--N 1.321 -0.671 0 CA-C-O 120.999 0.428 . . . . 71.44 110.824 -177.724 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.457 ' HB ' HG22 ' A' ' 18' ' ' ILE . 47.2 t -125.48 124.04 66.08 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.526 0 CA-C-N 115.609 -0.723 . . . . 61.3 109.185 174.94 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 27' ' ' PHE . . . . . . . . . . . . . 70.6 t80 -83.44 104.36 13.52 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-O 121.321 0.581 . . . . 52.14 110.834 -175.328 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.439 ' HA ' ' HB3' ' A' ' 60' ' ' ALA . 13.5 p -93.77 142.05 13.9 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.664 0 CA-C-N 115.851 -0.613 . . . . 75.23 109.788 179.089 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 29' ' ' HIS . . . . . 0.437 ' CE1' ' HB2' ' A' ' 32' ' ' ALA . 3.7 p80 -140.53 142.55 35.19 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.761 0.315 . . . . 74.34 111.017 -175.976 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 17.2 p90 -60.49 -25.14 65.84 Favored 'General case' 0 N--CA 1.469 0.476 0 CA-C-N 115.8 -0.636 . . . . 65.1 112.706 -170.775 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 11.6 p -77.87 -8.0 57.47 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-O 121.028 0.442 . . . . 43.21 111.587 -178.11 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 32' ' ' ALA . . . . . 0.688 ' HB1' ' HA ' ' A' ' 61' ' ' ALA . . . -113.81 -23.53 9.61 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 120.921 0.391 . . . . 63.3 111.074 179.178 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.437 HD13 ' HB2' ' A' ' 41' ' ' LEU . 56.9 mt -69.07 150.51 10.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 N-CA-C 109.556 -0.535 . . . . 74.53 109.556 174.104 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 34' ' ' GLN . . . . . 0.415 HE21 ' HA ' ' A' ' 64' ' ' GLN . 4.8 pp0? . . . . . 0 C--N 1.326 -0.449 0 N-CA-C 109.45 -0.574 . . . . 64.23 109.45 175.056 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 13.3 p . . . . . 0 N--CA 1.45 -0.425 0 CA-C-O 121.068 0.461 . . . . 73.24 110.705 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 41' ' ' LEU . . . . . 0.437 ' HB2' HD13 ' A' ' 33' ' ' ILE . 12.6 tp -92.63 146.81 23.38 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 116.029 -0.532 . . . . 74.14 109.675 178.699 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 42' ' ' ASP . . . . . 0.856 ' HB2' ' HB2' ' A' ' 45' ' ' GLN . 2.1 m-20 -73.92 124.81 26.88 Favored 'General case' 0 C--N 1.318 -0.787 0 CA-C-N 115.837 -0.62 . . . . 72.35 110.885 -175.108 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 9.3 pt-20 -69.47 131.34 44.58 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-O 120.845 0.355 . . . . 64.2 110.164 177.456 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 82.24 4.06 90.34 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.863 -0.684 . . . . 64.42 112.113 -177.65 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 45' ' ' GLN . . . . . 0.856 ' HB2' ' HB2' ' A' ' 42' ' ' ASP . 24.6 tp60 -80.91 126.32 31.22 Favored 'General case' 0 C--N 1.326 -0.455 0 N-CA-C 110.109 -0.33 . . . . 70.12 110.109 -179.693 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 0.438 ' O ' ' HB3' ' A' ' 66' ' ' ALA . . . -86.88 83.15 7.59 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-O 121.042 0.449 . . . . 42.12 110.048 176.006 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 0.507 HG12 ' HA ' ' A' ' 65' ' ' LYS . 19.1 m -89.85 167.98 1.59 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.578 0 CA-C-N 115.631 -0.713 . . . . 70.12 111.734 -173.563 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 48' ' ' THR . . . . . 0.497 ' OG1' ' HB3' ' A' ' 64' ' ' GLN . 4.9 p -112.4 107.32 16.08 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 115.959 -0.564 . . . . 74.51 110.145 177.379 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 49' ' ' PHE . . . . . 0.582 ' HA ' ' O ' ' A' ' 62' ' ' ASN . 38.2 p90 -122.17 160.57 24.85 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 115.838 -0.619 . . . . 73.53 111.234 -173.063 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 22.6 t70 -107.67 115.59 30.43 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-O 121.07 0.462 . . . . 72.11 110.563 175.058 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 66.5 t -66.65 132.51 32.02 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.498 0 CA-C-N 115.734 -0.667 . . . . 63.52 112.12 -174.692 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 52' ' ' GLU . . . . . 1.044 ' HB2' ' HB2' ' A' ' 59' ' ' GLN . 34.4 mt-10 -94.27 159.55 15.08 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.736 -0.666 . . . . 73.22 109.675 174.309 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 39.1 mt-10 -114.72 110.63 20.03 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-N 116.38 -0.373 . . . . 74.43 110.353 178.382 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -126.49 170.8 18.26 Favored Glycine 0 N--CA 1.448 -0.515 0 C-N-CA 120.878 -0.677 . . . . 34.21 112.092 -179.802 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 67.8 mt-30 -92.98 69.3 4.5 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-O 121.365 0.602 . . . . 74.15 110.034 -177.852 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 15.8 ptp180 178.59 -30.47 0.01 OUTLIER 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 114.741 -1.118 . . . . 72.51 108.921 -176.154 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 162.71 -179.54 37.92 Favored Glycine 0 N--CA 1.44 -1.098 0 N-CA-C 110.325 -1.11 . . . . 65.52 110.325 178.486 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 57.5 Cg_endo -76.34 128.12 10.24 Favored 'Trans proline' 0 N--CA 1.454 -0.822 0 C-N-CA 121.884 1.723 . . . . 60.15 111.161 175.228 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 59' ' ' GLN . . . . . 1.044 ' HB2' ' HB2' ' A' ' 52' ' ' GLU . 9.4 mm100 -93.4 169.73 10.14 Favored 'General case' 0 C--N 1.321 -0.639 0 N-CA-C 109.0 -0.741 . . . . 71.13 109.0 178.591 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 60' ' ' ALA . . . . . 0.439 ' HB3' ' HA ' ' A' ' 28' ' ' VAL . . . -124.75 111.33 15.42 Favored 'General case' 0 C--N 1.319 -0.745 0 C-N-CA 120.719 -0.393 . . . . 73.13 111.327 179.308 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 61' ' ' ALA . . . . . 0.688 ' HA ' ' HB1' ' A' ' 32' ' ' ALA . . . -123.11 159.35 28.71 Favored 'General case' 0 CA--C 1.515 -0.379 0 CA-C-N 115.984 -0.553 . . . . 74.41 110.161 177.156 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 62' ' ' ASN . . . . . 0.582 ' O ' ' HA ' ' A' ' 49' ' ' PHE . 94.9 m-20 53.65 78.3 0.16 Allowed 'General case' 0 CA--C 1.517 -0.304 0 CA-C-O 121.274 0.559 . . . . 63.45 109.569 -177.481 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.404 HG11 HD21 ' A' ' 41' ' ' LEU . 44.1 t -107.8 101.72 12.93 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.611 0 CA-C-N 115.147 -0.933 . . . . 60.24 110.572 -175.995 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 64' ' ' GLN . . . . . 0.497 ' HB3' ' OG1' ' A' ' 48' ' ' THR . 8.3 tt0 -85.3 124.13 31.57 Favored 'General case' 0 C--N 1.319 -0.728 0 CA-C-N 115.959 -0.564 . . . . 64.13 110.066 -179.382 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 65' ' ' LYS . . . . . 0.507 ' HA ' HG12 ' A' ' 47' ' ' VAL . 42.9 mttm -68.16 127.39 32.72 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.346 -0.388 . . . . 74.21 110.263 -179.289 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 66' ' ' ALA . . . . . 0.438 ' HB3' ' O ' ' A' ' 46' ' ' ALA . . . . . . . . 0 C--O 1.246 0.898 0 CA-C-O 118.091 -0.956 . . . . 52.13 110.444 -178.615 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 C--O 1.236 0.383 0 CA-C-O 121.122 0.486 . . . . 63.34 111.164 . . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 35.1 tt0 -88.35 116.29 26.46 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 115.832 -0.622 . . . . 74.44 110.237 177.58 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -126.91 -174.33 13.77 Favored Glycine 0 N--CA 1.449 -0.472 0 N-CA-C 110.99 -0.844 . . . . 63.54 110.99 177.727 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 5' ' ' THR . . . . . 0.538 ' O ' ' HG2' ' A' ' 19' ' ' GLU . 10.1 m -130.09 132.19 46.05 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-N 117.3 0.55 . . . . 71.22 110.682 179.515 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 60.3 t -76.22 119.83 25.08 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.446 0 CA-C-N 116.495 -0.321 . . . . 73.53 110.169 -179.286 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 7' ' ' LYS . . . . . 0.964 ' HE3' ' HA ' ' A' ' 7' ' ' LYS . 0.0 OUTLIER -92.97 -68.22 0.81 Allowed 'General case' 0 C--N 1.325 -0.467 0 CA-C-O 120.92 0.391 . . . . 74.25 110.797 179.113 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 8' ' ' TRP . . . . . . . . . . . . . 63.7 m95 -112.79 126.53 55.53 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 116.078 -0.51 . . . . 75.14 109.73 -177.917 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 9' ' ' PHE . . . . . 0.407 ' CE2' ' HB2' ' A' ' 11' ' ' ALA . 54.1 t80 -125.07 91.14 3.37 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-O 121.201 0.525 . . . . 72.33 110.542 -176.807 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 18.2 m120 -87.47 78.36 8.64 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-O 121.426 0.631 . . . . 63.41 109.815 -179.945 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 11' ' ' ALA . . . . . 0.407 ' HB2' ' CE2' ' A' ' 9' ' ' PHE . . . -63.71 -32.57 74.1 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 115.136 -0.938 . . . . 63.31 110.833 -179.292 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 42.9 mt-10 -76.89 -8.86 58.14 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.112 -0.494 . . . . 64.02 111.026 179.426 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 13' ' ' LYS . . . . . 0.419 ' HB3' ' CE2' ' A' ' 15' ' ' PHE . 75.5 mmtt -107.75 -26.06 10.98 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 120.938 0.399 . . . . 73.02 110.28 178.948 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 96.61 20.69 23.83 Favored Glycine 0 N--CA 1.449 -0.482 0 C-N-CA 120.942 -0.647 . . . . 71.45 113.017 175.779 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 15' ' ' PHE . . . . . 0.419 ' CE2' ' HB3' ' A' ' 13' ' ' LYS . 31.5 p90 -155.09 167.11 31.45 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-O 120.982 0.42 . . . . 71.11 111.262 179.104 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -157.84 168.49 34.44 Favored Glycine 0 N--CA 1.445 -0.719 0 CA-C-N 115.819 -0.628 . . . . 74.23 112.021 180.0 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 91.4 m-85 -121.13 118.6 30.11 Favored 'General case' 0 C--N 1.321 -0.63 0 CA-C-O 120.885 0.374 . . . . 74.23 110.543 -178.459 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 55.2 mt -104.16 124.51 58.65 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 N-CA-C 109.601 -0.518 . . . . 70.34 109.601 177.711 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 19' ' ' GLU . . . . . 0.538 ' HG2' ' O ' ' A' ' 5' ' ' THR . 14.6 pt-20 -82.8 130.29 35.11 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-O 121.436 0.636 . . . . 73.51 111.525 -173.12 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 20' ' ' ARG . . . . . 0.413 ' HB3' ' HB3' ' A' ' 24' ' ' ASP . 16.2 ttp180 -113.15 158.82 19.93 Favored 'General case' 0 C--N 1.324 -0.532 0 N-CA-C 108.839 -0.801 . . . . 63.33 108.839 175.03 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 5.6 mm-40 -49.36 -36.43 21.57 Favored 'General case' 0 N--CA 1.472 0.657 0 N-CA-C 113.961 1.097 . . . . 62.33 113.961 -168.951 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 61.7 t30 -84.16 12.49 6.4 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 121.189 0.519 . . . . 72.0 111.321 -175.667 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 76.39 10.2 85.66 Favored Glycine 0 N--CA 1.454 -0.103 0 N-CA-C 110.508 -1.037 . . . . 73.24 110.508 -173.185 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 24' ' ' ASP . . . . . 0.413 ' HB3' ' HB3' ' A' ' 20' ' ' ARG . 17.7 t70 -76.75 90.12 3.42 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-N 114.417 -0.892 . . . . 43.5 109.894 -177.714 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 12.1 p-10 -70.59 114.16 8.41 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-O 121.592 0.71 . . . . 75.43 110.734 178.845 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 23.8 t -84.53 122.55 38.15 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.683 0 CA-C-N 115.185 -0.916 . . . . 74.42 109.839 179.721 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 27' ' ' PHE . . . . . . . . . . . . . 70.8 t80 -85.36 109.31 18.31 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 115.855 -0.611 . . . . 72.0 110.831 -174.997 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.485 ' HB ' ' HB3' ' A' ' 60' ' ' ALA . 11.3 p -96.06 147.14 6.28 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.596 0 N-CA-C 109.867 -0.42 . . . . 54.51 109.867 178.256 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 29' ' ' HIS . . . . . 0.494 ' O ' HG13 ' A' ' 33' ' ' ILE . 5.7 p80 -128.02 153.53 46.66 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 120.741 0.305 . . . . 72.13 110.902 -176.911 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 48.0 p90 -57.26 -29.34 63.75 Favored 'General case' 0 N--CA 1.468 0.447 0 N-CA-C 113.489 0.922 . . . . 74.52 113.489 -170.192 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 21.9 m -76.64 -1.2 26.5 Favored 'General case' 0 C--N 1.326 -0.45 0 C-N-CA 120.93 -0.308 . . . . 71.22 111.245 -179.998 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 32' ' ' ALA . . . . . 0.597 ' HB1' ' HA ' ' A' ' 61' ' ' ALA . . . -125.02 -11.36 7.09 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.874 0.369 . . . . 73.01 110.919 177.631 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.494 HG13 ' O ' ' A' ' 29' ' ' HIS . 85.9 mt -77.49 137.93 21.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.114 -0.494 . . . . 74.12 110.837 178.372 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 7.6 pt20 . . . . . 0 C--N 1.329 -0.291 0 CA-C-O 120.974 0.416 . . . . 65.45 109.947 173.527 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 14.7 p . . . . . 0 N--CA 1.452 -0.37 0 CA-C-O 120.925 0.393 . . . . 72.03 110.71 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 3.7 mm? -110.43 158.17 18.78 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 116.101 -0.499 . . . . 64.32 109.851 177.202 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 28.3 t70 -118.3 137.77 52.84 Favored 'General case' 0 C--N 1.321 -0.636 0 N-CA-C 109.634 -0.506 . . . . 75.41 109.634 -177.562 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 8.5 pt-20 -71.14 116.99 12.08 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-O 121.523 0.677 . . . . 63.5 110.072 179.73 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 105.54 6.2 38.6 Favored Glycine 0 N--CA 1.445 -0.723 0 CA-C-N 115.69 -0.687 . . . . 70.13 111.463 -174.002 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 62.2 tp60 -92.11 132.09 36.86 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 120.743 0.306 . . . . 71.3 110.877 179.05 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -78.66 132.14 36.94 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 116.01 -0.541 . . . . 72.41 109.561 173.504 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 25.5 m -137.81 153.66 28.0 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.634 0 CA-C-N 116.064 -0.516 . . . . 60.51 111.699 -177.191 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 9.4 p -113.1 111.79 22.74 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-N 115.872 -0.604 . . . . 72.33 109.78 174.754 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 49' ' ' PHE . . . . . 0.421 ' HA ' ' O ' ' A' ' 62' ' ' ASN . 39.5 p90 -120.81 161.93 20.65 Favored 'General case' 0 C--N 1.319 -0.729 0 CA-C-N 115.959 -0.564 . . . . 73.2 110.569 -172.551 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 33.1 t70 -93.15 118.0 30.72 Favored 'General case' 0 C--N 1.32 -0.711 0 N-CA-C 109.491 -0.559 . . . . 71.33 109.491 173.978 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 5.1 p -78.23 109.13 12.54 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.65 0 CA-C-O 121.67 0.748 . . . . 73.41 111.06 -176.539 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 9.7 tp10 -92.75 119.88 32.57 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-N 115.375 -0.83 . . . . 62.21 108.886 175.583 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 12.9 pt-20 -107.15 124.89 50.36 Favored 'General case' 0 C--N 1.317 -0.821 0 CA-C-O 120.897 0.38 . . . . 63.44 110.227 -179.923 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -146.78 -142.25 3.69 Favored Glycine 0 N--CA 1.448 -0.525 0 C-N-CA 120.615 -0.802 . . . . 71.54 112.281 -179.751 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 16.4 mm100 -77.64 -26.36 50.42 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-O 120.982 0.42 . . . . 73.43 110.451 -178.465 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 24.4 mmm180 -87.35 4.51 42.68 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 116.082 -0.508 . . . . 74.5 110.351 -179.445 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 89.36 -138.39 14.64 Favored Glycine 0 N--CA 1.446 -0.646 0 C-N-CA 120.928 -0.653 . . . . 64.55 111.618 -178.361 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 89.2 Cg_endo -84.73 104.86 0.96 Allowed 'Trans proline' 0 N--CA 1.455 -0.749 0 C-N-CA 122.701 2.267 . . . . 64.14 112.329 177.455 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 12.3 pt20 -112.52 135.62 53.01 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-O 121.144 0.497 . . . . 72.5 110.017 177.551 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 60' ' ' ALA . . . . . 0.485 ' HB3' ' HB ' ' A' ' 28' ' ' VAL . . . -86.34 128.12 34.89 Favored 'General case' 0 C--N 1.319 -0.758 0 CA-C-O 121.149 0.499 . . . . 55.31 111.708 -172.743 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 61' ' ' ALA . . . . . 0.597 ' HA ' ' HB1' ' A' ' 32' ' ' ALA . . . -130.21 143.63 50.89 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 115.436 -0.802 . . . . 74.12 109.282 174.016 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 62' ' ' ASN . . . . . 0.421 ' O ' ' HA ' ' A' ' 49' ' ' PHE . 45.0 m-80 59.45 87.23 0.08 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 121.244 0.545 . . . . 71.45 110.391 -176.965 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 47.8 t -105.39 111.14 33.49 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.591 0 CA-C-N 115.721 -0.672 . . . . 71.13 110.273 -176.883 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 71.9 mt-30 -107.93 142.53 37.9 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-N 116.149 -0.478 . . . . 74.32 109.944 -179.73 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 46.0 mttp -77.48 144.22 37.9 Favored 'General case' 0 C--N 1.325 -0.492 0 C-N-CA 120.868 -0.333 . . . . 73.4 110.422 179.567 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.247 0.958 0 CA-C-O 118.781 -0.628 . . . . 52.31 110.413 178.077 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 2' ' ' GLU . . . . . 0.607 ' HG2' HG23 ' A' ' 51' ' ' VAL . 4.8 mp0 . . . . . 0 C--O 1.234 0.248 0 CA-C-O 121.125 0.488 . . . . 73.4 111.318 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 3' ' ' GLN . . . . . 0.663 ' HG2' HG22 ' A' ' 48' ' ' THR . 79.7 mt-30 -97.49 122.95 41.13 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.732 -0.667 . . . . 74.31 109.638 172.209 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -138.14 178.31 19.33 Favored Glycine 0 N--CA 1.445 -0.721 0 N-CA-C 111.136 -0.786 . . . . 62.24 111.136 179.178 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 5' ' ' THR . . . . . 0.422 ' O ' ' HG2' ' A' ' 19' ' ' GLU . 13.1 m -125.11 130.54 52.42 Favored 'General case' 0 C--N 1.315 -0.919 0 CA-C-N 117.28 0.54 . . . . 74.55 110.512 178.088 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 61.3 t -72.58 108.57 4.06 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.472 0 CA-C-N 116.376 -0.375 . . . . 64.2 110.01 178.813 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 7' ' ' LYS . . . . . 0.444 ' HB3' ' CE3' ' A' ' 8' ' ' TRP . 6.5 mmtm -73.62 -48.48 32.23 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 116.26 -0.427 . . . . 75.53 110.208 177.622 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 8' ' ' TRP . . . . . 0.542 ' HE1' ' HD2' ' A' ' 17' ' ' PHE . 15.6 p90 -164.14 158.92 19.76 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.661 -0.7 . . . . 75.31 110.075 177.763 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 9' ' ' PHE . . . . . 0.415 ' HD1' ' HA3' ' A' ' 16' ' ' GLY . 71.4 t80 -134.33 106.48 7.12 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 116.264 -0.426 . . . . 74.44 110.12 178.622 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 87.8 m-20 -76.71 85.09 3.34 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 116.048 -0.524 . . . . 54.44 109.821 179.791 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -62.39 -38.11 88.36 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 115.519 -0.764 . . . . 62.24 111.492 -177.234 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 42.0 mt-10 -72.55 -14.41 61.63 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 116.253 -0.43 . . . . 72.23 111.056 -179.571 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 32.2 mmmt -101.21 -26.32 13.69 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.88 0.372 . . . . 65.44 110.225 177.922 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 100.15 7.3 52.61 Favored Glycine 0 N--CA 1.45 -0.427 0 C-N-CA 120.83 -0.7 . . . . 63.23 113.253 175.423 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 41.0 p90 -151.16 154.96 37.91 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-O 121.125 0.488 . . . . 75.33 111.602 -176.077 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.415 ' HA3' ' HD1' ' A' ' 9' ' ' PHE . . . -135.95 178.45 18.71 Favored Glycine 0 N--CA 1.444 -0.803 0 N-CA-C 111.055 -0.818 . . . . 62.34 111.055 178.65 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 17' ' ' PHE . . . . . 0.542 ' HD2' ' HE1' ' A' ' 8' ' ' TRP . 79.9 m-85 -131.28 123.23 27.92 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-O 121.197 0.522 . . . . 55.23 111.243 -177.975 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 64.5 mt -106.43 126.48 62.15 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 CA-C-N 115.482 -0.781 . . . . 54.24 109.144 176.803 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 19' ' ' GLU . . . . . 0.422 ' HG2' ' O ' ' A' ' 5' ' ' THR . 17.2 pt-20 -79.53 139.36 37.58 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-O 121.327 0.584 . . . . 75.31 112.299 -173.464 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 20' ' ' ARG . . . . . . . . . . . . . 10.0 tpt180 -109.83 166.61 10.79 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.082 -0.963 . . . . 64.1 108.94 174.846 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 21' ' ' GLU . . . . . 0.453 ' CD ' ' H ' ' A' ' 21' ' ' GLU . 2.3 mp0 -43.95 -48.68 8.62 Favored 'General case' 0 N--CA 1.472 0.635 0 N-CA-C 112.397 0.518 . . . . 75.1 112.397 179.409 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 74.6 m-20 -71.41 -7.08 44.97 Favored 'General case' 0 N--CA 1.468 0.429 0 CA-C-N 116.295 -0.411 . . . . 74.34 112.025 -174.9 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 90.01 7.63 67.94 Favored Glycine 0 N--CA 1.45 -0.387 0 N-CA-C 110.084 -1.206 . . . . 52.13 110.084 -170.145 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 13.0 t70 -70.28 93.2 0.83 Allowed 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 114.486 -0.857 . . . . 73.0 109.953 -179.262 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.405 ' HB2' ' HB3' ' A' ' 17' ' ' PHE . 13.4 p-10 -65.76 101.92 0.69 Allowed 'General case' 0 C--N 1.321 -0.644 0 CA-C-N 115.549 -0.75 . . . . 54.11 110.65 176.848 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 40.0 t -71.01 130.41 34.95 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.587 0 CA-C-N 115.444 -0.798 . . . . 71.24 110.547 -178.487 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 27' ' ' PHE . . . . . . . . . . . . . 63.1 t80 -79.39 108.64 13.07 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 116.079 -0.51 . . . . 65.25 110.147 -178.294 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 9.3 p -111.16 141.5 26.33 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.598 0 N-CA-C 110.061 -0.348 . . . . 65.15 110.061 179.242 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 29' ' ' HIS . . . . . 0.555 ' O ' HG13 ' A' ' 33' ' ' ILE . 6.0 p80 -128.94 145.75 51.15 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.795 0.331 . . . . 52.13 110.863 -177.03 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 37.5 p90 -58.82 -27.69 65.31 Favored 'General case' 0 N--CA 1.467 0.421 0 CA-C-N 115.679 -0.691 . . . . 73.42 112.294 -171.227 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 1.5 p -79.03 6.64 8.91 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-O 120.744 0.307 . . . . 74.23 111.707 -179.331 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -129.25 -14.74 4.26 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 121.002 0.429 . . . . 72.21 110.879 175.287 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.755 HD13 HD21 ' A' ' 41' ' ' LEU . 24.9 mt -80.45 161.68 3.86 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.164 -0.471 . . . . 65.52 110.089 176.263 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 34' ' ' GLN . . . . . 0.682 ' NE2' ' HA ' ' A' ' 64' ' ' GLN . 26.5 pt20 . . . . . 0 C--N 1.327 -0.383 0 N-CA-C 110.107 -0.331 . . . . 43.23 110.107 177.485 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 37.4 m . . . . . 0 N--CA 1.449 -0.493 0 N-CA-C 109.676 -0.49 . . . . 64.41 109.676 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 41' ' ' LEU . . . . . 0.755 HD21 HD13 ' A' ' 33' ' ' ILE . 3.5 mm? -91.22 148.01 22.65 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 116.346 -0.388 . . . . 72.3 110.758 -176.708 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 4.8 m-20 -91.61 113.35 25.6 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 115.797 -0.638 . . . . 63.35 109.293 175.452 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 4.5 mp0 -62.97 129.82 42.06 Favored 'General case' 0 C--N 1.321 -0.669 0 CA-C-N 116.061 -0.518 . . . . 62.23 110.422 -179.305 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 97.89 -7.88 63.09 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 121.042 -0.599 . . . . 63.14 112.102 -178.263 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 7.8 tp-100 -84.15 123.85 30.52 Favored 'General case' 0 C--N 1.324 -0.523 0 N-CA-C 110.173 -0.306 . . . . 60.34 110.173 179.83 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -68.1 135.28 51.94 Favored 'General case' 0 C--N 1.328 -0.345 0 N-CA-C 109.403 -0.592 . . . . 75.2 109.403 172.623 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 0.546 HG12 ' HA ' ' A' ' 65' ' ' LYS . 21.1 m -134.24 154.05 36.9 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.771 0 CA-C-O 121.214 0.53 . . . . 75.32 111.501 -175.704 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 48' ' ' THR . . . . . 0.663 HG22 ' HG2' ' A' ' 3' ' ' GLN . 33.0 p -113.72 117.13 30.66 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 115.503 -0.771 . . . . 73.43 109.433 174.68 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 49' ' ' PHE . . . . . 0.424 ' HA ' ' O ' ' A' ' 62' ' ' ASN . 40.8 p90 -129.76 170.37 13.93 Favored 'General case' 0 C--N 1.316 -0.872 0 CA-C-N 115.966 -0.561 . . . . 72.31 110.913 -173.148 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 38.8 t70 -112.01 143.87 42.3 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-N 115.864 -0.607 . . . . 63.34 109.813 174.306 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 51' ' ' VAL . . . . . 0.607 HG23 ' HG2' ' A' ' 2' ' ' GLU . 84.7 t -94.88 121.52 45.54 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.553 0 CA-C-O 121.165 0.507 . . . . 73.32 110.875 -178.528 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 52' ' ' GLU . . . . . 0.582 ' HB3' ' HG3' ' A' ' 59' ' ' GLN . 0.0 OUTLIER -94.24 141.97 27.94 Favored 'General case' 0 C--N 1.321 -0.648 0 N-CA-C 108.849 -0.797 . . . . 64.45 108.849 174.288 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 4.9 pt-20 -111.93 106.37 15.05 Favored 'General case' 0 C--N 1.316 -0.855 0 CA-C-O 121.287 0.565 . . . . 73.1 111.0 -174.557 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -126.76 -169.58 12.76 Favored Glycine 0 N--CA 1.448 -0.538 0 C-N-CA 120.852 -0.69 . . . . 44.13 112.019 -179.403 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 44.7 mt-30 -76.77 -3.1 36.48 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.952 0.406 . . . . 63.2 111.109 -178.095 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 56' ' ' ARG . . . . . 0.423 HH11 ' HD2' ' A' ' 56' ' ' ARG . 17.7 mmm180 -100.24 3.82 43.83 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-O 120.95 0.405 . . . . 72.33 110.496 176.416 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 94.28 -142.43 16.02 Favored Glycine 0 N--CA 1.446 -0.644 0 C-N-CA 120.843 -0.694 . . . . 33.21 111.872 -178.364 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 74.3 Cg_endo -79.97 106.93 2.0 Favored 'Trans proline' 0 N--CA 1.458 -0.597 0 C-N-CA 122.76 2.306 . . . . 75.02 112.703 -179.309 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 59' ' ' GLN . . . . . 0.582 ' HG3' ' HB3' ' A' ' 52' ' ' GLU . 4.1 pt20 -111.7 126.43 55.03 Favored 'General case' 0 C--N 1.322 -0.627 0 CA-C-N 115.778 -0.646 . . . . 74.21 109.655 177.701 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -80.05 130.47 35.28 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-O 121.024 0.44 . . . . 20.05 111.464 -174.871 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -135.13 145.35 47.75 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 115.452 -0.795 . . . . 33.1 109.321 177.717 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 62' ' ' ASN . . . . . 0.424 ' O ' ' HA ' ' A' ' 49' ' ' PHE . 89.2 m-20 59.59 82.99 0.14 Allowed 'General case' 0 C--N 1.327 -0.398 0 CA-C-O 121.164 0.507 . . . . 75.53 110.225 -176.621 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.407 HG13 ' HB3' ' A' ' 49' ' ' PHE . 39.2 t -113.06 106.35 20.57 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.511 0 CA-C-N 115.545 -0.752 . . . . 63.31 110.394 -177.061 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 64' ' ' GLN . . . . . 0.682 ' HA ' ' NE2' ' A' ' 34' ' ' GLN . 53.4 mt-30 -99.73 145.32 27.79 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 116.401 -0.363 . . . . 75.43 110.395 -179.349 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 65' ' ' LYS . . . . . 0.546 ' HA ' HG12 ' A' ' 47' ' ' VAL . 28.4 mtmm -82.61 136.4 34.81 Favored 'General case' 0 C--N 1.324 -0.54 0 N-CA-C 110.076 -0.342 . . . . 75.02 110.076 -179.864 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.247 0.941 0 CA-C-O 118.843 -0.599 . . . . 53.03 110.485 -179.108 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 2.2 mp0 . . . . . 0 C--O 1.237 0.447 0 CA-C-O 121.215 0.531 . . . . 72.22 111.676 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 3' ' ' GLN . . . . . 0.472 ' HG2' HG22 ' A' ' 48' ' ' THR . 65.8 mt-30 -91.95 143.6 26.32 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.341 -0.845 . . . . 60.52 110.248 179.612 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 4' ' ' GLY . . . . . 0.68 ' HA3' ' HE2' ' A' ' 49' ' ' PHE . . . -159.26 150.86 21.58 Favored Glycine 0 N--CA 1.447 -0.626 0 C-N-CA 120.932 -0.652 . . . . 70.11 111.917 178.252 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 5' ' ' THR . . . . . 0.543 ' HA ' ' HA ' ' A' ' 46' ' ' ALA . 3.5 m -98.02 133.47 42.44 Favored 'General case' 0 C--N 1.32 -0.703 0 CA-C-O 120.563 0.22 . . . . 43.42 110.438 -179.029 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 51.2 t -68.16 103.62 0.71 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 N-CA-C 109.541 -0.54 . . . . 73.42 109.541 175.068 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 7' ' ' LYS . . . . . 0.764 ' HD3' ' HB3' ' A' ' 19' ' ' GLU . 31.0 mmmt -61.56 -60.7 3.3 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 121.342 0.591 . . . . 71.1 110.543 -176.706 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 8' ' ' TRP . . . . . . . . . . . . . 28.7 p90 -156.42 136.47 12.77 Favored 'General case' 0 C--N 1.319 -0.726 0 CA-C-N 115.349 -0.841 . . . . 74.23 109.533 176.695 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 9' ' ' PHE . . . . . 0.514 ' HA ' ' HA3' ' A' ' 16' ' ' GLY . 70.7 t80 -132.41 113.13 12.79 Favored 'General case' 0 C--N 1.317 -0.807 0 CA-C-O 121.09 0.471 . . . . 65.1 110.287 -177.033 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 2.6 m-20 -78.0 80.26 4.44 Favored 'General case' 0 C--N 1.322 -0.624 0 N-CA-C 108.892 -0.781 . . . . 74.32 108.892 176.014 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -60.53 -33.26 72.39 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 121.079 0.466 . . . . 73.31 110.918 -178.386 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 12' ' ' GLU . . . . . 0.434 ' HG3' ' HG2' ' A' ' 13' ' ' LYS . 6.8 pt-20 -67.71 -25.12 65.5 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 115.462 -0.79 . . . . 64.22 111.555 -179.824 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 13' ' ' LYS . . . . . 0.434 ' HG2' ' HG3' ' A' ' 12' ' ' GLU . 47.5 mmtm -110.06 -15.4 14.04 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-O 120.845 0.355 . . . . 73.01 111.222 -176.881 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 94.06 20.37 30.88 Favored Glycine 0 N--CA 1.449 -0.456 0 C-N-CA 120.995 -0.621 . . . . 73.31 114.148 170.237 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 43.2 p90 -153.62 156.44 37.94 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 117.67 0.735 . . . . 74.4 111.384 -179.321 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.514 ' HA3' ' HA ' ' A' ' 9' ' ' PHE . . . -167.73 -169.75 31.65 Favored Glycine 0 N--CA 1.45 -0.398 0 N-CA-C 111.883 -0.487 . . . . 52.12 111.883 178.389 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 88.1 m-85 -133.09 139.29 47.05 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 121.122 0.487 . . . . 60.24 111.309 -179.068 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 56.9 mt -119.93 145.33 26.36 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.547 0 N-CA-C 108.908 -0.775 . . . . 73.13 108.908 176.697 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 19' ' ' GLU . . . . . 0.764 ' HB3' ' HD3' ' A' ' 7' ' ' LYS . 20.9 pt-20 -89.37 158.22 17.86 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-O 121.15 0.5 . . . . 65.05 111.045 -177.123 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 20' ' ' ARG . . . . . 0.6 ' HD3' ' HB3' ' A' ' 24' ' ' ASP . 70.4 ttt180 -134.15 158.72 42.94 Favored 'General case' 0 C--N 1.32 -0.674 0 N-CA-C 108.523 -0.918 . . . . 75.13 108.523 179.146 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 44.1 mt-10 -48.2 -50.92 27.41 Favored 'General case' 0 N--CA 1.466 0.336 0 N-CA-C 113.229 0.825 . . . . 74.31 113.229 -172.316 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 57.8 m-80 -87.5 20.58 2.84 Favored 'General case' 0 C--N 1.327 -0.405 0 N-CA-C 111.878 0.325 . . . . 60.24 111.878 -173.964 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 76.16 10.55 85.32 Favored Glycine 0 C--N 1.33 0.234 0 C-N-CA 120.605 -0.807 . . . . 70.03 111.731 -178.897 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 24' ' ' ASP . . . . . 0.6 ' HB3' ' HD3' ' A' ' 20' ' ' ARG . 38.5 t70 -76.95 84.06 3.49 Favored 'General case' 0 C--N 1.322 -0.622 0 N-CA-C 109.772 -0.455 . . . . 75.24 109.772 -179.571 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 8.1 p-10 -58.62 127.56 32.76 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 121.361 0.6 . . . . 64.02 111.123 -176.467 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.545 ' HA ' ' HB2' ' A' ' 58' ' ' PRO . 17.1 t -105.64 124.37 60.62 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.615 0 CA-C-N 115.424 -0.807 . . . . 64.24 110.216 -176.453 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 27' ' ' PHE . . . . . . . . . . . . . 91.9 t80 -82.57 131.21 35.22 Favored 'General case' 0 C--N 1.326 -0.453 0 N-CA-C 110.063 -0.347 . . . . 73.23 110.063 179.944 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 9.8 p -123.3 137.41 56.72 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-O 121.278 0.561 . . . . 72.31 111.006 -179.481 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 22.0 t60 -115.02 151.77 33.62 Favored 'General case' 0 C--N 1.324 -0.504 0 N-CA-C 108.142 -1.059 . . . . 64.1 108.142 176.844 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 17.3 p90 -60.2 -20.15 57.43 Favored 'General case' 0 N--CA 1.472 0.661 0 N-CA-C 112.555 0.576 . . . . 74.41 112.555 -172.052 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 23.1 t -90.14 -9.06 49.68 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 120.892 0.377 . . . . 62.44 110.633 -179.166 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -103.99 -25.46 13.0 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 121.075 0.464 . . . . 72.11 110.747 -179.129 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.661 HD11 HD22 ' A' ' 41' ' ' LEU . 15.4 tt -77.55 163.75 3.71 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.55 0 N-CA-C 108.863 -0.792 . . . . 72.01 108.863 175.726 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 34' ' ' GLN . . . . . 0.518 ' O ' ' HG2' ' A' ' 34' ' ' GLN . 18.8 pm0 . . . . . 0 CA--C 1.533 0.321 0 CA-C-O 121.774 0.797 . . . . 75.3 111.646 -176.121 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 22.0 p . . . . . 0 N--CA 1.45 -0.449 0 CA-C-O 121.062 0.458 . . . . 61.41 110.229 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 41' ' ' LEU . . . . . 0.661 HD22 HD11 ' A' ' 33' ' ' ILE . 10.7 mp -83.28 126.06 32.26 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 116.158 -0.474 . . . . 74.32 110.241 178.786 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 28.5 t70 -75.51 139.58 42.26 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-N 115.595 -0.73 . . . . 71.35 110.616 -177.342 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 3.0 mp0 -61.22 105.72 0.53 Allowed 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.96 0.41 . . . . 70.42 110.317 178.142 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 126.49 -10.25 7.24 Favored Glycine 0 N--CA 1.447 -0.587 0 CA-C-N 115.871 -0.604 . . . . 63.24 111.731 -175.049 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 7.1 tt0 -77.37 127.49 32.65 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.846 0.355 . . . . 74.32 110.63 178.061 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 0.543 ' HA ' ' HA ' ' A' ' 5' ' ' THR . . . -92.39 130.43 38.07 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 116.201 -0.454 . . . . 61.01 110.371 177.747 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 0.414 HG12 ' HA ' ' A' ' 65' ' ' LYS . 15.5 m -137.37 174.39 11.57 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 CA-C-O 120.949 0.405 . . . . 62.42 111.316 -177.058 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 48' ' ' THR . . . . . 0.472 HG22 ' HG2' ' A' ' 3' ' ' GLN . 23.5 p -111.69 114.06 26.84 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 115.836 -0.62 . . . . 74.34 109.67 176.425 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 49' ' ' PHE . . . . . 0.68 ' HE2' ' HA3' ' A' ' 4' ' ' GLY . 39.7 p90 -125.17 165.38 18.35 Favored 'General case' 0 C--N 1.317 -0.823 0 CA-C-N 116.094 -0.503 . . . . 74.05 110.302 -174.322 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 22.0 t0 -108.43 151.1 26.5 Favored 'General case' 0 C--N 1.317 -0.808 0 C-N-CA 119.992 -0.683 . . . . 54.43 109.883 173.646 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 51' ' ' VAL . . . . . 0.407 HG21 ' CZ ' ' A' ' 20' ' ' ARG . 61.1 t -105.13 109.35 27.42 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.779 0 CA-C-O 121.089 0.471 . . . . 72.22 110.593 -176.332 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 44.3 tt0 -81.85 96.31 7.59 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-N 115.41 -0.813 . . . . 63.33 109.062 175.463 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 6.7 pt-20 -74.67 90.62 2.3 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-O 121.519 0.676 . . . . 72.41 109.576 176.612 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -121.49 -144.58 6.94 Favored Glycine 0 N--CA 1.444 -0.772 0 CA-C-N 115.164 -0.926 . . . . 32.42 112.282 -177.925 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 55' ' ' GLN . . . . . 0.571 ' O ' ' HG2' ' A' ' 56' ' ' ARG . 6.6 tp-100 -80.86 82.29 6.89 Favored 'General case' 0 C--N 1.323 -0.552 0 N-CA-C 111.59 0.218 . . . . 74.25 111.59 -175.418 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 56' ' ' ARG . . . . . 0.571 ' HG2' ' O ' ' A' ' 55' ' ' GLN . 2.3 mmm180 156.73 -36.35 0.01 OUTLIER 'General case' 0 N--CA 1.478 0.974 0 C-N-CA 125.881 1.672 . . . . 72.51 108.498 173.109 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 57' ' ' GLY . . . . . 0.443 ' HA3' ' HD3' ' A' ' 58' ' ' PRO . . . 138.09 -120.05 1.93 Allowed Glycine 0 N--CA 1.445 -0.746 0 CA-C-N 115.186 -0.916 . . . . 72.15 111.712 -178.581 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 58' ' ' PRO . . . . . 0.545 ' HB2' ' HA ' ' A' ' 26' ' ' VAL . 2.9 Cg_endo -80.96 100.35 1.19 Allowed 'Trans proline' 0 N--CA 1.458 -0.574 0 C-N-CA 123.179 2.586 . . . . 64.32 112.721 -178.405 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 64.1 mt-30 -104.76 126.3 51.7 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 115.93 -0.577 . . . . 62.42 109.631 176.016 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -74.77 115.48 14.4 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-O 120.626 0.25 . . . . 72.22 110.784 -177.536 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -136.36 142.12 43.77 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 116.195 -0.457 . . . . 73.14 110.058 178.754 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 42.1 m-80 58.48 85.48 0.09 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 121.38 0.609 . . . . 52.44 110.492 -179.61 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.586 HG13 ' HB3' ' A' ' 49' ' ' PHE . 17.8 t -112.23 131.68 63.02 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.612 0 CA-C-N 115.737 -0.665 . . . . 61.41 110.284 -176.999 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 6.5 tp-100 -128.4 147.11 50.63 Favored 'General case' 0 C--N 1.32 -0.677 0 N-CA-C 109.896 -0.409 . . . . 73.25 109.896 179.063 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 65' ' ' LYS . . . . . 0.414 ' HA ' HG12 ' A' ' 47' ' ' VAL . 60.2 mttm -65.06 144.99 56.9 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-O 120.671 0.272 . . . . 63.43 110.359 177.533 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.039 0 CA-C-O 118.723 -0.656 . . . . 64.4 110.785 -179.06 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 1.3 pm0 . . . . . 0 C--O 1.234 0.265 0 CA-C-O 120.787 0.327 . . . . 73.53 111.808 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 46.6 tt0 -87.84 116.68 26.16 Favored 'General case' 0 C--N 1.321 -0.652 0 N-CA-C 109.471 -0.566 . . . . 64.34 109.471 174.657 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -132.39 153.8 20.76 Favored Glycine 0 N--CA 1.445 -0.749 0 C-N-CA 120.314 -0.946 . . . . 63.14 112.367 -177.768 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 5' ' ' THR . . . . . 0.508 ' O ' ' HG3' ' A' ' 19' ' ' GLU . 2.8 m -98.49 129.69 45.08 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-O 120.72 0.295 . . . . 73.22 110.273 178.933 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.435 HG22 HG12 ' A' ' 18' ' ' ILE . 61.7 t -79.75 118.4 27.22 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.606 0 O-C-N 122.357 -0.215 . . . . 62.15 110.462 178.815 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 7' ' ' LYS . . . . . 0.516 ' NZ ' ' HB3' ' A' ' 19' ' ' GLU . 49.3 mttp -74.18 -65.21 0.87 Allowed 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.926 0.393 . . . . 75.21 110.501 178.053 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 8' ' ' TRP . . . . . . . . . . . . . 90.6 m95 -144.87 160.86 40.61 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 115.821 -0.627 . . . . 75.42 111.211 -176.768 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 14.1 p90 -120.89 106.38 11.58 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 115.503 -0.771 . . . . 64.41 110.527 179.16 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 2.3 m-20 -84.95 77.12 10.17 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-N 115.944 -0.571 . . . . 71.34 109.805 -179.407 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 11' ' ' ALA . . . . . 0.517 ' HA ' ' HE2' ' A' ' 30' ' ' PHE . . . -63.63 -28.2 69.75 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.589 -0.732 . . . . 61.2 111.268 -178.804 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 65.6 mm-40 -74.87 -13.59 60.57 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 116.2 -0.455 . . . . 63.34 111.314 178.8 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 13' ' ' LYS . . . . . 0.516 ' HB3' ' CE2' ' A' ' 15' ' ' PHE . 31.2 mmmt -109.76 -30.09 8.02 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 116.297 -0.411 . . . . 71.44 111.053 -179.012 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 102.12 17.66 19.72 Favored Glycine 0 N--CA 1.449 -0.476 0 C-N-CA 120.632 -0.794 . . . . 63.42 112.668 177.389 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 15' ' ' PHE . . . . . 0.516 ' CE2' ' HB3' ' A' ' 13' ' ' LYS . 26.7 p90 -152.71 172.47 16.62 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 120.629 0.252 . . . . 73.0 110.736 -179.618 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -140.85 175.04 22.37 Favored Glycine 0 N--CA 1.446 -0.652 0 C-N-CA 121.06 -0.591 . . . . 65.11 111.77 178.887 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 97.5 m-85 -120.81 116.45 25.23 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-O 120.933 0.397 . . . . 65.1 111.171 -178.636 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.573 ' O ' ' HA ' ' A' ' 25' ' ' ASP . 36.7 mt -102.57 165.09 3.05 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.581 0 N-CA-C 107.816 -1.179 . . . . 61.22 107.816 173.202 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 19' ' ' GLU . . . . . 0.516 ' HB3' ' NZ ' ' A' ' 7' ' ' LYS . 0.3 OUTLIER -130.31 163.22 27.29 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-N 118.857 0.753 . . . . 71.5 111.364 179.05 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 20' ' ' ARG . . . . . . . . . . . . . 15.6 ttp180 -126.17 -163.23 1.2 Allowed 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 115.573 -0.739 . . . . 70.14 109.464 -178.902 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -64.14 -37.54 87.81 Favored 'General case' 0 C--N 1.329 -0.312 0 N-CA-C 112.277 0.473 . . . . 70.3 112.277 -172.776 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 87.6 m-20 -93.59 13.43 22.02 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-O 120.713 0.292 . . . . 71.13 111.113 -177.877 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 74.2 20.44 79.65 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.329 -0.938 . . . . 64.31 110.764 -173.558 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 14.4 t70 -72.08 93.1 1.38 Allowed 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 115.132 -0.534 . . . . 74.3 109.823 -179.017 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.573 ' HA ' ' O ' ' A' ' 18' ' ' ILE . 2.3 m-20 -60.46 121.03 11.07 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.642 -0.708 . . . . 72.02 111.594 178.58 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 36.6 t -96.69 131.48 43.38 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.62 0 CA-C-N 115.013 -0.994 . . . . 73.25 109.897 179.945 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 27' ' ' PHE . . . . . . . . . . . . . 47.4 t80 -83.49 98.7 9.68 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 116.144 -0.48 . . . . 61.11 110.525 -175.817 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.537 ' HB ' ' HB3' ' A' ' 60' ' ' ALA . 13.2 p -98.82 138.66 22.67 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 CA-C-O 121.069 0.461 . . . . 74.03 111.072 -177.782 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 21.1 m-70 -99.29 139.19 35.31 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 116.064 -0.517 . . . . 74.01 110.112 176.81 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 30' ' ' PHE . . . . . 0.628 ' HD1' HD12 ' A' ' 33' ' ' ILE . 20.4 m-85 -65.74 -26.2 67.62 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.643 0.258 . . . . 75.34 110.819 179.008 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 38.3 t -72.36 -16.97 61.87 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-O 121.111 0.481 . . . . 72.12 110.48 175.805 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 32' ' ' ALA . . . . . 0.546 ' HB1' ' HA ' ' A' ' 61' ' ' ALA . . . -94.61 -20.01 19.96 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 121.085 0.469 . . . . 65.11 110.049 177.033 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.706 HG12 HG21 ' A' ' 63' ' ' VAL . 54.6 mt -82.02 135.32 25.2 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.465 0 CA-C-N 115.807 -0.633 . . . . 72.44 110.078 175.443 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 12.7 pt20 . . . . . 0 C--N 1.324 -0.534 0 CA-C-O 121.259 0.552 . . . . 54.32 110.563 176.377 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 42.0 m . . . . . 0 N--CA 1.455 -0.18 0 N-CA-C 110.368 -0.234 . . . . 72.31 110.368 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 3.5 mm? -107.52 162.23 14.13 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.29 -0.413 . . . . 72.21 110.136 178.568 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 42' ' ' ASP . . . . . 0.493 ' HB2' ' HB2' ' A' ' 45' ' ' GLN . 5.9 m-20 -69.62 157.23 37.61 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 116.017 -0.538 . . . . 73.31 111.1 179.967 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -77.18 105.74 8.46 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-O 121.521 0.677 . . . . 70.45 110.039 176.018 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 108.96 5.48 30.84 Favored Glycine 0 N--CA 1.446 -0.657 0 CA-C-N 115.678 -0.692 . . . . 24.05 111.656 -174.014 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 45' ' ' GLN . . . . . 0.493 ' HB2' ' HB2' ' A' ' 42' ' ' ASP . 58.4 tp60 -80.78 130.68 35.2 Favored 'General case' 0 C--N 1.326 -0.424 0 N-CA-C 109.993 -0.373 . . . . 75.43 109.993 178.944 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -102.46 127.71 49.39 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-O 120.778 0.323 . . . . 64.42 110.721 179.764 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 17.5 m -136.02 172.59 15.28 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.562 0 CA-C-N 115.961 -0.563 . . . . 51.24 110.528 -179.109 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 20.4 p -116.66 115.01 24.86 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 116.177 -0.465 . . . . 64.32 110.328 179.476 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 33.1 p90 -117.42 163.36 16.49 Favored 'General case' 0 C--N 1.319 -0.752 0 CA-C-O 121.157 0.503 . . . . 73.33 111.925 -174.137 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 25.8 t70 -86.07 136.72 33.12 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 115.861 -0.609 . . . . 70.34 109.585 172.908 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 3.7 p -81.83 114.46 22.78 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.499 0 CA-C-O 121.913 0.863 . . . . 74.44 112.06 -174.632 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 9.6 tp10 -108.93 162.0 14.62 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 114.763 -1.108 . . . . 62.13 108.374 175.693 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 39.1 mt-10 -122.59 169.18 11.29 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-O 121.159 0.504 . . . . 52.42 111.517 -179.999 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -162.48 158.25 30.33 Favored Glycine 0 N--CA 1.443 -0.897 0 N-CA-C 110.736 -0.946 . . . . 62.2 110.736 179.046 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 20.6 pt20 -75.73 9.32 2.37 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 117.093 0.447 . . . . 74.43 111.929 -177.088 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 69.3 mtm180 -130.19 15.32 5.65 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 121.005 0.431 . . . . 72.23 110.285 174.654 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 129.21 -179.68 16.54 Favored Glycine 0 N--CA 1.45 -0.427 0 C-N-CA 120.651 -0.785 . . . . 54.22 112.083 179.871 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo -74.6 146.27 34.23 Favored 'Trans proline' 0 N--CA 1.461 -0.428 0 C-N-CA 122.508 2.138 . . . . 71.1 112.427 -179.055 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 42.3 mt-30 -118.5 162.22 18.71 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 115.952 -0.567 . . . . 75.22 110.013 178.335 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 60' ' ' ALA . . . . . 0.537 ' HB3' ' HB ' ' A' ' 28' ' ' VAL . . . -118.35 125.29 49.73 Favored 'General case' 0 C--N 1.318 -0.794 0 CA-C-O 121.047 0.451 . . . . 73.2 111.039 -179.672 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 61' ' ' ALA . . . . . 0.546 ' HA ' ' HB1' ' A' ' 32' ' ' ALA . . . -127.81 164.59 21.86 Favored 'General case' 0 C--N 1.321 -0.673 0 N-CA-C 108.763 -0.829 . . . . 75.04 108.763 175.871 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 39.7 m-80 48.25 76.87 0.11 Allowed 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 121.032 0.444 . . . . 74.05 110.989 -177.843 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.706 HG21 HG12 ' A' ' 33' ' ' ILE . 46.6 t -89.21 92.08 3.86 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.67 0 CA-C-N 116.042 -0.526 . . . . 72.33 110.142 -178.751 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -80.38 125.82 30.39 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 115.434 -0.803 . . . . 73.05 109.368 -177.868 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 52.9 mttp -64.25 137.54 57.98 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.301 -0.409 . . . . 62.44 110.381 -177.403 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.251 1.135 0 CA-C-O 118.439 -0.791 . . . . 74.22 109.927 179.496 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 2.8 mp0 . . . . . 0 C--O 1.235 0.313 0 CA-C-O 121.04 0.448 . . . . 71.1 110.619 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 84.0 mt-30 -95.15 126.83 40.75 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 115.357 -0.838 . . . . 75.24 109.482 176.813 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 4' ' ' GLY . . . . . 0.681 ' HA3' ' HE2' ' A' ' 49' ' ' PHE . . . -140.83 151.11 22.22 Favored Glycine 0 N--CA 1.445 -0.756 0 C-N-CA 120.291 -0.956 . . . . 72.11 112.533 -177.985 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 5' ' ' THR . . . . . 0.452 ' O ' ' HG2' ' A' ' 19' ' ' GLU . 7.4 m -107.15 125.82 51.58 Favored 'General case' 0 C--N 1.319 -0.75 0 N-CA-C 110.21 -0.293 . . . . 72.34 110.21 -179.718 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 48.3 t -68.01 117.39 9.76 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 N-CA-C 110.168 -0.308 . . . . 72.03 110.168 179.705 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 7' ' ' LYS . . . . . 0.632 ' HD3' ' HB3' ' A' ' 19' ' ' GLU . 30.1 mmmt -75.55 -56.37 4.76 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 121.405 0.622 . . . . 61.44 109.329 179.422 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 8' ' ' TRP . . . . . 0.789 ' HZ3' ' HB2' ' A' ' 10' ' ' ASN . 63.5 p-90 -164.71 157.95 17.21 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-N 114.849 -1.069 . . . . 45.12 108.921 175.927 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 11.3 p90 -129.04 115.1 17.24 Favored 'General case' 0 C--N 1.317 -0.816 0 CA-C-O 121.596 0.713 . . . . 73.21 110.805 -176.593 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 10' ' ' ASN . . . . . 0.789 ' HB2' ' HZ3' ' A' ' 8' ' ' TRP . 34.1 t30 -86.72 71.86 10.28 Favored 'General case' 0 C--N 1.319 -0.729 0 N-CA-C 108.527 -0.916 . . . . 72.54 108.527 179.008 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -62.83 -32.15 73.3 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 114.709 -1.132 . . . . 72.13 112.536 -171.284 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 33.1 mt-10 -75.53 -9.76 58.86 Favored 'General case' 0 C--N 1.326 -0.429 0 C-N-CA 120.905 -0.318 . . . . 73.23 111.252 -177.458 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 30.7 mmmt -110.92 -11.75 14.31 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 121.174 0.511 . . . . 52.4 110.124 174.253 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 95.21 15.83 43.08 Favored Glycine 0 N--CA 1.447 -0.596 0 C-N-CA 120.805 -0.712 . . . . 65.41 114.414 169.91 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 54.6 p90 -145.8 155.3 42.84 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 117.941 0.871 . . . . 75.24 111.601 -179.254 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -140.64 166.82 25.76 Favored Glycine 0 N--CA 1.445 -0.728 0 N-CA-C 111.078 -0.809 . . . . 71.22 111.078 177.422 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 79.0 m-85 -120.89 121.92 39.12 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-O 121.201 0.524 . . . . 74.43 111.201 -178.323 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 56.4 mt -111.25 139.59 34.55 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.615 0 CA-C-N 115.331 -0.85 . . . . 71.12 109.459 178.166 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 19' ' ' GLU . . . . . 0.632 ' HB3' ' HD3' ' A' ' 7' ' ' LYS . 9.1 pt-20 -88.6 134.36 33.9 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 120.896 0.379 . . . . 71.25 110.523 179.008 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 20' ' ' ARG . . . . . . . . . . . . . 27.8 ttp180 -121.84 152.01 40.02 Favored 'General case' 0 C--N 1.322 -0.63 0 N-CA-C 108.996 -0.742 . . . . 74.03 108.996 174.13 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 21' ' ' GLU . . . . . 0.435 ' HG3' ' H ' ' A' ' 21' ' ' GLU . 0.0 OUTLIER -50.71 -40.81 55.12 Favored 'General case' 0 N--CA 1.463 0.189 0 O-C-N 123.279 0.362 . . . . 73.14 111.795 -177.83 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 6.2 m-20 -109.44 65.75 0.62 Allowed 'General case' 0 C--N 1.322 -0.63 0 CA-C-O 121.004 0.431 . . . . 72.31 110.339 171.62 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 132.85 94.88 0.57 Allowed Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.816 -0.707 . . . . 61.04 112.227 174.257 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 24' ' ' ASP . . . . . 0.527 ' HA ' ' HA ' ' A' ' 19' ' ' GLU . 3.9 p30 -71.0 6.41 1.58 Allowed 'General case' 0 N--CA 1.468 0.432 0 CA-C-O 120.962 0.41 . . . . 71.41 111.48 -178.108 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 7.2 p-10 -122.6 88.59 2.96 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-O 121.708 0.766 . . . . 70.25 110.916 -177.266 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.434 HG12 ' HB2' ' A' ' 60' ' ' ALA . 55.9 t -112.34 118.59 58.17 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.621 0 CA-C-N 115.431 -0.804 . . . . 71.31 109.565 173.769 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 27' ' ' PHE . . . . . 0.458 ' O ' ' HA ' ' A' ' 59' ' ' GLN . 63.1 t80 -82.08 105.09 12.9 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 115.773 -0.648 . . . . 73.44 110.484 -176.183 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 12.2 p -100.03 133.95 41.24 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.603 0 CA-C-O 121.207 0.527 . . . . 73.25 110.531 179.122 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 85.8 t60 -91.87 133.05 36.01 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 115.843 -0.617 . . . . 62.33 109.855 -178.226 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 14.0 p90 -56.39 -36.39 68.82 Favored 'General case' 0 N--CA 1.467 0.399 0 N-CA-C 111.938 0.347 . . . . 74.21 111.938 -174.015 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 6.9 t -87.31 6.44 33.47 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 121.293 0.568 . . . . 43.12 110.644 -177.763 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -105.67 -19.7 13.68 Favored 'General case' 0 C--N 1.326 -0.447 0 N-CA-C 109.144 -0.687 . . . . 34.22 109.144 173.216 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 69.2 mt -74.72 105.45 3.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 114.998 -1.001 . . . . 75.31 110.271 175.329 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 34' ' ' GLN . . . . . 0.405 ' O ' ' HE3' ' A' ' 65' ' ' LYS . 0.9 OUTLIER . . . . . 0 C--N 1.325 -0.494 0 CA-C-O 121.854 0.835 . . . . 62.54 109.943 175.478 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 22.8 p . . . . . 0 N--CA 1.451 -0.381 0 N-CA-C 110.114 -0.328 . . . . 52.4 110.114 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 95.1 mt -132.39 130.48 40.72 Favored 'General case' 0 C--N 1.325 -0.483 0 N-CA-C 109.277 -0.638 . . . . 74.41 109.277 176.318 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 3.4 m-20 -55.88 125.05 19.73 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 121.205 0.526 . . . . 75.43 111.557 -179.36 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 7.6 pt-20 -66.95 123.27 19.72 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-N 115.834 -0.621 . . . . 71.52 109.831 175.895 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 101.81 5.76 50.4 Favored Glycine 0 N--CA 1.448 -0.502 0 C-N-CA 121.032 -0.604 . . . . 32.03 111.648 -173.229 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 7.5 tp60 -102.84 138.03 40.26 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.652 0.263 . . . . 74.21 110.521 178.603 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -92.16 131.91 37.03 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 116.293 -0.412 . . . . 43.12 110.427 176.329 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 24.0 m -134.77 173.84 13.89 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 CA-C-N 116.121 -0.49 . . . . 72.21 110.308 -179.793 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 19.3 p -117.34 115.69 25.74 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-O 121.185 0.517 . . . . 54.41 110.805 179.431 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 49' ' ' PHE . . . . . 0.681 ' HE2' ' HA3' ' A' ' 4' ' ' GLY . 38.0 p90 -120.63 152.72 37.8 Favored 'General case' 0 C--N 1.319 -0.76 0 CA-C-N 115.74 -0.664 . . . . 72.11 110.325 -177.523 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 22.7 t70 -97.64 116.76 30.47 Favored 'General case' 0 C--N 1.322 -0.596 0 N-CA-C 109.224 -0.658 . . . . 54.4 109.224 174.883 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 9.9 p -77.86 140.71 16.57 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.497 0 CA-C-O 121.52 0.676 . . . . 61.44 111.637 -170.553 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 52' ' ' GLU . . . . . 0.457 ' HB3' ' HG3' ' A' ' 59' ' ' GLN . 32.6 tt0 -137.38 156.91 47.66 Favored 'General case' 0 C--N 1.32 -0.688 0 N-CA-C 108.163 -1.051 . . . . 75.21 108.163 175.173 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 53' ' ' GLU . . . . . 0.42 ' HA ' ' O ' ' A' ' 57' ' ' GLY . 0.0 OUTLIER -149.49 -177.78 6.05 Favored 'General case' 0 C--N 1.32 -0.708 0 O-C-N 122.092 -0.38 . . . . 73.54 110.794 -178.487 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 143.94 -101.78 0.26 Allowed Glycine 0 N--CA 1.442 -0.933 0 C-N-CA 120.62 -0.8 . . . . 65.14 113.132 177.669 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 35.3 tt0 -80.14 -23.88 40.82 Favored 'General case' 0 C--N 1.326 -0.443 0 N-CA-C 112.361 0.504 . . . . 71.21 112.361 -168.925 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 2.0 ptp180 -137.95 43.39 2.23 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-O 121.07 0.462 . . . . 75.23 111.733 -178.591 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 57' ' ' GLY . . . . . 0.42 ' O ' ' HA ' ' A' ' 53' ' ' GLU . . . 76.07 -157.38 48.42 Favored Glycine 0 N--CA 1.449 -0.454 0 C-N-CA 120.842 -0.694 . . . . 72.02 113.127 174.667 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 1.7 Cg_endo -81.43 110.39 2.21 Favored 'Trans proline' 0 N--CA 1.455 -0.776 0 C-N-CA 123.242 2.628 . . . . 63.21 112.053 -178.999 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 59' ' ' GLN . . . . . 0.458 ' HA ' ' O ' ' A' ' 27' ' ' PHE . 16.8 pt20 -105.45 139.11 40.57 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 115.892 -0.595 . . . . 71.31 109.97 179.091 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 60' ' ' ALA . . . . . 0.434 ' HB2' HG12 ' A' ' 26' ' ' VAL . . . -89.8 109.35 20.35 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 116.178 -0.465 . . . . 74.43 110.997 -179.344 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -111.41 149.9 30.56 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-N 115.825 -0.625 . . . . 74.51 109.519 176.315 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 94.9 m-20 51.49 80.17 0.09 Allowed 'General case' 0 C--O 1.235 0.321 0 CA-C-O 121.286 0.565 . . . . 71.11 110.841 -176.76 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 38.9 t -102.88 103.97 15.88 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.589 0 CA-C-N 115.732 -0.667 . . . . 74.42 110.245 -179.355 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 54.4 mt-30 -94.9 160.54 14.54 Favored 'General case' 0 C--N 1.319 -0.735 0 CA-C-N 115.918 -0.583 . . . . 71.15 110.52 -179.647 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 65' ' ' LYS . . . . . 0.405 ' HE3' ' O ' ' A' ' 34' ' ' GLN . 0.7 OUTLIER -82.77 171.35 14.05 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 115.717 -0.674 . . . . 52.45 110.894 -176.773 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.097 0 CA-C-O 118.413 -0.803 . . . . 51.33 109.544 177.172 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 56.9 mp0 . . . . . 0 N--CA 1.451 -0.424 0 CA-C-O 121.268 0.556 . . . . 63.44 111.871 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -96.79 112.78 24.39 Favored 'General case' 0 C--N 1.323 -0.545 0 N-CA-C 108.095 -1.076 . . . . 72.03 108.095 172.956 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 4' ' ' GLY . . . . . 0.474 ' HA3' ' HE2' ' A' ' 49' ' ' PHE . . . -137.61 168.53 24.43 Favored Glycine 0 N--CA 1.447 -0.608 0 C-N-CA 120.392 -0.908 . . . . 63.12 112.558 -175.864 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 5' ' ' THR . . . . . 0.408 ' O ' ' HG2' ' A' ' 19' ' ' GLU . 26.9 m -108.24 134.26 51.33 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-O 120.634 0.254 . . . . 74.22 110.457 -179.024 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 47.8 t -68.75 112.7 3.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 CA-C-O 120.772 0.32 . . . . 55.33 110.378 178.494 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 48.3 mtpt -71.76 -70.86 0.3 Allowed 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 115.808 -0.633 . . . . 74.2 110.21 179.887 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 8' ' ' TRP . . . . . . . . . . . . . 92.1 m95 -139.4 132.61 29.81 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 115.094 -0.957 . . . . 72.33 108.819 178.117 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 9' ' ' PHE . . . . . 0.499 ' HD1' ' HA3' ' A' ' 16' ' ' GLY . 59.4 t80 -132.22 102.1 5.64 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-O 121.272 0.558 . . . . 72.43 110.822 179.15 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 19.0 m120 -80.99 84.8 6.38 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 115.583 -0.735 . . . . 74.53 109.534 176.444 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -61.66 -33.25 73.63 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 115.393 -0.821 . . . . 54.44 111.074 179.055 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 44.3 mt-10 -69.6 -25.9 64.19 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.015 -0.538 . . . . 73.13 110.73 179.532 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 75.7 mmtt -92.24 -35.53 13.74 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.219 -0.446 . . . . 63.2 110.187 -179.948 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 110.12 14.11 14.14 Favored Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 120.965 -0.636 . . . . 44.31 113.35 175.574 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 50.0 p90 -152.73 162.08 41.73 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 117.157 0.479 . . . . 74.54 111.451 -177.546 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.499 ' HA3' ' HD1' ' A' ' 9' ' ' PHE . . . -163.38 178.25 39.04 Favored Glycine 0 N--CA 1.446 -0.692 0 C-N-CA 120.885 -0.674 . . . . 31.12 112.197 179.071 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 90.8 m-85 -126.28 127.76 46.1 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-O 120.7 0.286 . . . . 74.31 110.507 -178.967 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 46.3 mt -112.93 129.91 67.72 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.497 0 N-CA-C 109.151 -0.685 . . . . 74.34 109.151 175.787 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 19' ' ' GLU . . . . . 0.408 ' HG2' ' O ' ' A' ' 5' ' ' THR . 11.1 pt-20 -73.7 139.88 45.65 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 121.502 0.668 . . . . 73.03 111.559 -171.851 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 20' ' ' ARG . . . . . . . . . . . . . 43.5 ttt180 -112.48 141.2 46.51 Favored 'General case' 0 C--N 1.319 -0.733 0 N-CA-C 107.434 -1.321 . . . . 60.44 107.434 175.035 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 16.1 pt-20 -55.67 -26.57 45.47 Favored 'General case' 0 C--N 1.327 -0.406 0 N-CA-C 112.85 0.685 . . . . 64.44 112.85 -170.116 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 28.6 t-20 -79.69 -19.58 48.62 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-O 120.845 0.355 . . . . 73.42 111.434 -178.813 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 106.48 -9.33 41.49 Favored Glycine 0 CA--C 1.511 -0.157 0 N-CA-C 111.229 -0.748 . . . . 74.51 111.229 -174.514 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 36.5 t70 -80.32 72.24 7.16 Favored 'General case' 0 C--N 1.322 -0.615 0 N-CA-C 109.279 -0.638 . . . . 71.4 109.279 176.294 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 10.1 p-10 -70.28 138.07 51.26 Favored 'General case' 0 C--N 1.333 -0.14 0 CA-C-O 121.52 0.676 . . . . 62.52 110.811 -172.899 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.529 HG13 ' HB2' ' A' ' 58' ' ' PRO . 4.3 t -94.57 138.98 19.4 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.55 0 CA-C-N 115.187 -0.915 . . . . 65.21 111.4 -167.734 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 27' ' ' PHE . . . . . . . . . . . . . 50.4 t80 -92.27 111.72 23.39 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.769 -0.65 . . . . 74.02 110.461 -177.449 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.539 ' HB ' ' HB3' ' A' ' 60' ' ' ALA . 14.8 p -95.86 148.49 5.22 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.381 0 CA-C-O 120.905 0.383 . . . . 74.05 111.325 -175.462 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 28.0 m170 -114.31 145.72 41.42 Favored 'General case' 0 C--O 1.236 0.343 0 CA-C-N 116.151 -0.477 . . . . 62.41 109.889 177.623 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 20.5 p90 -62.19 -26.24 68.24 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 121.11 0.481 . . . . 73.53 110.46 177.659 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 4.2 m -81.56 -14.36 56.93 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 115.77 -0.65 . . . . 65.43 110.875 179.277 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 32' ' ' ALA . . . . . 0.559 ' HB1' ' HA ' ' A' ' 61' ' ' ALA . . . -94.51 -21.3 18.97 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 121.044 0.449 . . . . 64.14 110.819 -176.709 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 44.9 mt -71.04 155.8 7.39 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-N 115.777 -0.647 . . . . 74.23 110.188 174.534 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 14.5 pt20 . . . . . 0 C--N 1.328 -0.368 0 CA-C-O 121.226 0.536 . . . . 72.22 110.458 175.755 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 22.9 t . . . . . 0 C--O 1.235 0.298 0 CA-C-O 121.022 0.439 . . . . 75.42 111.181 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 81.7 mt -95.94 119.04 33.72 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 116.013 -0.54 . . . . 64.02 109.892 177.385 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 42' ' ' ASP . . . . . 0.626 ' HB3' ' HB2' ' A' ' 45' ' ' GLN . 30.7 t70 -82.43 139.93 33.72 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-N 115.942 -0.572 . . . . 65.15 111.048 -175.988 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 6.8 pt-20 -66.11 116.72 7.5 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 115.84 -0.618 . . . . 71.05 110.846 178.383 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 87.3 18.9 56.55 Favored Glycine 0 N--CA 1.448 -0.508 0 C-N-CA 120.642 -0.79 . . . . 53.55 112.182 -177.77 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 45' ' ' GLN . . . . . 0.626 ' HB2' ' HB3' ' A' ' 42' ' ' ASP . 35.6 tt0 -99.22 135.5 40.54 Favored 'General case' 0 C--N 1.326 -0.451 0 N-CA-C 110.208 -0.293 . . . . 71.24 110.208 178.497 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -85.52 129.01 34.92 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 116.36 -0.382 . . . . 62.12 110.271 177.807 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 16.6 m -138.36 153.62 26.61 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.518 0 CA-C-O 120.988 0.423 . . . . 74.11 111.01 -177.927 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 20.7 p -102.51 104.87 15.33 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 115.994 -0.548 . . . . 73.51 109.814 175.988 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 49' ' ' PHE . . . . . 0.474 ' HE2' ' HA3' ' A' ' 4' ' ' GLY . 41.8 p90 -110.74 158.51 18.57 Favored 'General case' 0 C--N 1.316 -0.852 0 CA-C-N 115.449 -0.796 . . . . 74.13 110.174 -174.994 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 19.7 t0 -104.61 151.77 23.24 Favored 'General case' 0 C--N 1.317 -0.842 0 C-N-CA 120.074 -0.65 . . . . 71.03 109.958 173.552 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 4.9 p -103.17 112.41 36.52 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.599 0 CA-C-O 121.405 0.621 . . . . 44.14 111.194 -173.57 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 49.8 mm-40 -109.85 112.88 25.19 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-N 115.586 -0.733 . . . . 72.24 109.689 177.613 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 53' ' ' GLU . . . . . 0.536 ' HA ' ' O ' ' A' ' 57' ' ' GLY . 8.1 pt-20 -76.81 115.47 16.62 Favored 'General case' 0 C--N 1.325 -0.498 0 C-N-CA 120.211 -0.595 . . . . 75.44 109.941 177.202 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 54' ' ' GLY . . . . . 0.514 ' HA3' ' NE2' ' A' ' 59' ' ' GLN . . . -122.57 -121.2 2.68 Favored Glycine 0 N--CA 1.445 -0.736 0 C-N-CA 120.354 -0.927 . . . . 45.13 113.365 -174.658 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -84.77 1.68 45.6 Favored 'General case' 0 C--N 1.329 -0.311 0 N-CA-C 112.157 0.429 . . . . 71.1 112.157 -169.632 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 10.2 ptp180 -158.87 28.39 0.22 Allowed 'General case' 0 C--N 1.325 -0.457 0 CA-C-O 120.748 0.308 . . . . 75.42 111.237 177.678 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 57' ' ' GLY . . . . . 0.536 ' O ' ' HA ' ' A' ' 53' ' ' GLU . . . 93.29 -132.81 11.4 Favored Glycine 0 N--CA 1.444 -0.784 0 C-N-CA 120.44 -0.886 . . . . 74.42 112.18 -179.054 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 58' ' ' PRO . . . . . 0.529 ' HB2' HG13 ' A' ' 26' ' ' VAL . 33.0 Cg_endo -64.32 106.66 0.72 Allowed 'Trans proline' 0 CA--C 1.529 0.239 0 C-N-CA 122.837 2.358 . . . . 64.4 113.323 -174.806 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 59' ' ' GLN . . . . . 0.514 ' NE2' ' HA3' ' A' ' 54' ' ' GLY . 22.2 mt-30 -112.53 128.41 56.34 Favored 'General case' 0 C--N 1.323 -0.567 0 N-CA-C 109.011 -0.737 . . . . 74.34 109.011 173.615 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 60' ' ' ALA . . . . . 0.539 ' HB3' ' HB ' ' A' ' 28' ' ' VAL . . . -82.13 115.1 21.09 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-O 120.984 0.421 . . . . 33.04 110.955 -176.127 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 61' ' ' ALA . . . . . 0.559 ' HA ' ' HB1' ' A' ' 32' ' ' ALA . . . -130.89 154.14 48.4 Favored 'General case' 0 C--N 1.319 -0.75 0 N-CA-C 108.845 -0.798 . . . . 75.1 108.845 176.818 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 90.2 m-20 57.84 73.93 0.45 Allowed 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 121.492 0.663 . . . . 70.24 109.967 -176.125 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 45.3 t -100.21 103.71 15.16 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.664 0 CA-C-N 115.357 -0.838 . . . . 33.11 109.813 179.857 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 6.3 tp-100 -91.63 143.19 26.82 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-N 116.027 -0.533 . . . . 74.12 110.673 -176.941 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 66.8 mmtt -72.72 130.22 40.01 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 115.684 -0.689 . . . . 73.24 109.992 177.817 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.251 1.167 0 CA-C-O 118.432 -0.794 . . . . 75.01 110.53 -178.164 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 1.7 pm0 . . . . . 0 N--CA 1.448 -0.531 0 N-CA-C 110.275 -0.269 . . . . 70.44 110.275 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -100.24 128.74 46.25 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-O 121.215 0.531 . . . . 74.42 110.616 179.31 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -131.14 164.7 23.29 Favored Glycine 0 N--CA 1.444 -0.774 0 CA-C-N 115.803 -0.635 . . . . 63.31 111.751 -179.17 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 21.3 m -105.38 122.87 46.86 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-O 120.542 0.21 . . . . 72.41 110.707 -178.775 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 58.7 t -64.37 114.36 2.21 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.227 0 CA-C-N 116.392 -0.367 . . . . 72.5 110.547 -179.331 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 4.5 mmmm -95.28 -53.16 3.88 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 115.859 -0.609 . . . . 75.2 110.255 -178.832 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 8' ' ' TRP . . . . . 0.464 ' HB2' ' HB2' ' A' ' 17' ' ' PHE . 76.5 m95 -118.11 130.63 56.24 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 115.687 -0.688 . . . . 74.32 110.082 179.793 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 9' ' ' PHE . . . . . 0.439 ' CE2' ' HB2' ' A' ' 11' ' ' ALA . 62.6 t80 -128.66 84.37 2.23 Favored 'General case' 0 C--N 1.318 -0.781 0 CA-C-O 121.282 0.563 . . . . 74.31 109.692 178.862 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 10' ' ' ASN . . . . . 0.797 ' HB3' ' HB2' ' A' ' 13' ' ' LYS . 44.0 m-80 -87.53 74.35 9.31 Favored 'General case' 0 C--N 1.321 -0.663 0 CA-C-N 115.909 -0.587 . . . . 73.35 110.021 -177.61 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 11' ' ' ALA . . . . . 0.676 ' HA ' ' CZ ' ' A' ' 30' ' ' PHE . . . -61.07 -39.61 90.53 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.277 -0.874 . . . . 74.15 111.409 -177.296 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 47.0 mt-10 -84.22 -11.4 56.56 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 116.085 -0.507 . . . . 64.02 111.173 -177.947 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 13' ' ' LYS . . . . . 0.797 ' HB2' ' HB3' ' A' ' 10' ' ' ASN . 5.2 mmtp -98.6 -28.41 13.57 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 116.274 -0.421 . . . . 74.43 110.586 -177.02 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 102.2 22.65 9.69 Favored Glycine 0 N--CA 1.448 -0.526 0 C-N-CA 120.652 -0.785 . . . . 64.3 113.396 174.287 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 15' ' ' PHE . . . . . 0.454 ' O ' ' HB2' ' A' ' 10' ' ' ASN . 52.5 p90 -163.38 171.49 15.96 Favored 'General case' 0 N--CA 1.463 0.222 0 CA-C-N 117.451 0.625 . . . . 72.33 111.067 179.649 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -153.98 172.14 32.65 Favored Glycine 0 N--CA 1.445 -0.701 0 C-N-CA 120.827 -0.701 . . . . 61.53 112.119 179.976 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 17' ' ' PHE . . . . . 0.792 ' HB3' ' HB3' ' A' ' 25' ' ' ASP . 92.6 m-85 -134.63 122.82 22.82 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 120.802 0.334 . . . . 73.43 110.269 179.472 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 35.3 mt -122.41 117.44 52.09 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.593 0 CA-C-N 116.103 -0.499 . . . . 72.4 109.734 179.164 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 19' ' ' GLU . . . . . 0.417 ' HA ' ' HA ' ' A' ' 25' ' ' ASP . 22.8 pt-20 -79.41 148.31 32.01 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-O 121.257 0.551 . . . . 61.23 112.17 -170.976 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 20' ' ' ARG . . . . . 0.423 ' HG2' ' HG2' ' A' ' 21' ' ' GLU . 14.4 ttm180 -118.61 123.51 45.17 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 115.42 -0.809 . . . . 75.14 109.684 170.681 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 21' ' ' GLU . . . . . 0.423 ' HG2' ' HG2' ' A' ' 20' ' ' ARG . 43.1 mm-40 50.78 -90.02 0.02 OUTLIER 'General case' 0 N--CA 1.474 0.738 0 N-CA-C 113.407 0.891 . . . . 73.34 113.407 173.094 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 1.6 m-20 -58.31 -19.11 32.22 Favored 'General case' 0 N--CA 1.467 0.408 0 C-N-CA 123.847 0.859 . . . . 62.01 111.79 -175.215 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 104.35 19.92 10.9 Favored Glycine 0 N--CA 1.442 -0.951 0 N-CA-C 110.015 -1.234 . . . . 42.33 110.015 -170.604 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 5.3 t70 -71.69 90.01 1.04 Allowed 'General case' 0 N--CA 1.45 -0.434 0 N-CA-C 109.0 -0.741 . . . . 73.24 109.0 178.089 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.792 ' HB3' ' HB3' ' A' ' 17' ' ' PHE . 62.0 m-20 -63.37 104.32 0.6 Allowed 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 115.756 -0.656 . . . . 52.42 110.613 -179.553 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 59.3 t -74.48 132.36 33.49 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.598 0 CA-C-N 115.602 -0.726 . . . . 64.11 110.0 179.009 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 27' ' ' PHE . . . . . 0.493 ' O ' ' HA ' ' A' ' 59' ' ' GLN . 78.5 t80 -82.73 127.61 33.58 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 116.089 -0.505 . . . . 64.02 110.441 -177.261 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.545 ' HB ' ' HB3' ' A' ' 60' ' ' ALA . 14.2 p -131.35 147.64 32.8 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 CA-C-O 121.02 0.438 . . . . 63.32 111.647 -177.416 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 21.9 m170 -108.64 159.57 16.62 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.991 -0.549 . . . . 72.52 109.684 174.759 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 30' ' ' PHE . . . . . 0.676 ' CZ ' ' HA ' ' A' ' 11' ' ' ALA . 52.4 m-85 -71.95 -14.28 61.87 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-O 120.702 0.287 . . . . 62.15 111.309 -179.723 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 13.8 t -71.35 -22.13 61.94 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-O 121.337 0.589 . . . . 51.42 110.07 174.725 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -100.83 -22.53 14.81 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 115.846 -0.615 . . . . 73.32 110.487 179.387 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 70.6 mt -76.93 145.77 9.7 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 CA-C-N 115.883 -0.599 . . . . 75.31 109.452 174.521 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 4.1 pt20 . . . . . 0 C--N 1.327 -0.412 0 CA-C-O 121.455 0.645 . . . . 62.15 110.626 177.373 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 42.1 m . . . . . 0 N--CA 1.454 -0.234 0 CA-C-O 120.887 0.375 . . . . 44.25 110.986 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 3.2 mm? -90.62 139.01 31.11 Favored 'General case' 0 C--N 1.324 -0.534 0 N-CA-C 109.228 -0.656 . . . . 73.43 109.228 175.021 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 30.9 t70 -90.23 146.76 24.0 Favored 'General case' 0 C--N 1.319 -0.729 0 C-N-CA 120.87 -0.332 . . . . 74.11 110.334 -178.792 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 37.4 mt-10 -70.97 102.01 2.31 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 116.319 -0.401 . . . . 63.13 109.932 178.293 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 123.03 1.19 9.59 Favored Glycine 0 N--CA 1.45 -0.433 0 CA-C-N 115.784 -0.644 . . . . 74.54 111.672 -173.272 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 52.1 tp60 -87.49 139.81 30.16 Favored 'General case' 0 N--CA 1.464 0.247 0 C-N-CA 122.247 0.219 . . . . 70.24 110.873 -179.734 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -90.54 131.68 36.13 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 121.084 0.469 . . . . 53.35 110.732 176.696 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 21.6 m -132.06 167.06 27.3 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 CA-C-N 116.062 -0.517 . . . . 72.13 110.782 -178.871 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 3.4 p -120.97 114.95 22.27 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-O 121.185 0.517 . . . . 62.24 110.211 179.312 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 38.8 p90 -134.78 166.1 23.74 Favored 'General case' 0 C--N 1.319 -0.76 0 CA-C-N 115.949 -0.568 . . . . 73.45 110.348 -173.802 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 39.1 t0 -106.84 121.62 44.77 Favored 'General case' 0 C--N 1.324 -0.538 0 C-N-CA 120.4 -0.52 . . . . 71.32 110.447 175.253 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 86.5 t -77.83 117.16 22.54 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.55 0 CA-C-O 120.986 0.422 . . . . 74.55 111.294 -178.842 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 52' ' ' GLU . . . . . 0.66 ' HB3' ' HG3' ' A' ' 59' ' ' GLN . 8.9 tp10 -94.12 116.79 29.25 Favored 'General case' 0 C--N 1.321 -0.652 0 N-CA-C 108.904 -0.776 . . . . 74.35 108.904 174.022 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 47.5 mt-10 -92.78 95.73 9.72 Favored 'General case' 0 C--N 1.319 -0.721 0 CA-C-O 121.128 0.49 . . . . 71.34 110.107 179.837 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -103.61 -143.49 12.76 Favored Glycine 0 N--CA 1.445 -0.701 0 CA-C-N 115.597 -0.729 . . . . 52.42 112.68 -176.629 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -86.42 -40.41 15.4 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 121.008 0.432 . . . . 62.35 110.723 -175.381 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 77.2 mtm180 -108.23 81.94 1.56 Allowed 'General case' 0 C--N 1.322 -0.614 0 CA-C-N 116.273 -0.421 . . . . 62.34 111.305 -176.262 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 68.9 -171.29 38.92 Favored Glycine 0 N--CA 1.448 -0.507 0 CA-C-N 115.619 -0.719 . . . . 63.53 112.93 178.22 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 87.3 Cg_endo -86.94 123.62 2.05 Favored 'Trans proline' 0 N--CA 1.453 -0.857 0 C-N-CA 122.829 2.353 . . . . 75.44 111.764 175.752 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 59' ' ' GLN . . . . . 0.66 ' HG3' ' HB3' ' A' ' 52' ' ' GLU . 18.9 pt20 -109.3 126.91 53.86 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-N 116.212 -0.449 . . . . 51.44 109.852 178.181 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 60' ' ' ALA . . . . . 0.545 ' HB3' ' HB ' ' A' ' 28' ' ' VAL . . . -79.42 117.58 20.52 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-O 120.837 0.351 . . . . 64.41 110.802 -178.771 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -110.87 128.62 55.86 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 116.013 -0.54 . . . . 63.13 109.816 178.524 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 49.4 m-80 63.78 96.38 0.04 OUTLIER 'General case' 0 C--O 1.235 0.312 0 O-C-N 123.577 0.548 . . . . 71.43 110.674 -176.521 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.472 HG21 HG21 ' A' ' 28' ' ' VAL . 48.8 t -110.66 107.15 22.21 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.474 0 CA-C-N 115.661 -0.699 . . . . 65.11 110.746 179.718 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 64' ' ' GLN . . . . . 0.404 ' HG2' ' N ' ' A' ' 65' ' ' LYS . 34.4 tt0 -102.09 168.35 9.44 Favored 'General case' 0 C--N 1.324 -0.542 0 N-CA-C 108.816 -0.809 . . . . 75.12 108.816 177.556 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 65' ' ' LYS . . . . . 0.404 ' N ' ' HG2' ' A' ' 64' ' ' GLN . 55.3 mtmt -103.78 155.29 18.72 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-O 120.801 0.334 . . . . 74.44 110.658 -179.125 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.251 1.135 0 CA-C-O 118.656 -0.688 . . . . 71.3 109.79 177.691 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 1.8 pm0 . . . . . 0 C--O 1.239 0.514 0 CA-C-O 121.457 0.646 . . . . 51.4 110.822 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -119.13 162.73 18.14 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 115.002 -0.999 . . . . 72.31 110.073 -179.297 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -160.65 165.24 34.99 Favored Glycine 0 N--CA 1.442 -0.95 0 C-N-CA 120.889 -0.672 . . . . 72.35 111.72 178.072 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 5' ' ' THR . . . . . 0.465 ' O ' ' HG2' ' A' ' 19' ' ' GLU . 28.2 m -100.48 137.87 38.3 Favored 'General case' 0 C--N 1.319 -0.726 0 N-CA-C 110.06 -0.348 . . . . 74.4 110.06 178.451 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 48.1 t -68.62 108.36 1.55 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 N-CA-C 109.793 -0.447 . . . . 64.02 109.793 175.783 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 7' ' ' LYS . . . . . 0.614 ' HE3' ' HA ' ' A' ' 7' ' ' LYS . 0.0 OUTLIER -75.2 -56.15 5.01 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-O 120.93 0.395 . . . . 73.35 110.426 178.313 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 8' ' ' TRP . . . . . . . . . . . . . 4.1 p90 -156.98 136.98 12.6 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 115.749 -0.66 . . . . 75.03 110.205 179.162 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 17.5 p90 -124.35 108.55 12.32 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-O 121.807 0.813 . . . . 74.41 110.157 178.515 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 41.2 t-20 -85.93 86.83 7.35 Favored 'General case' 0 C--N 1.318 -0.761 0 CA-C-O 121.477 0.656 . . . . 74.2 109.401 -178.778 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -57.77 -32.46 67.52 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 114.914 -1.039 . . . . 73.21 111.623 179.182 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 74.2 mm-40 -64.08 -31.25 72.38 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 120.857 0.36 . . . . 70.45 111.132 178.848 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 13' ' ' LYS . . . . . 0.458 ' HB3' ' CE2' ' A' ' 15' ' ' PHE . 0.1 OUTLIER -92.28 -17.77 24.3 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.894 -0.594 . . . . 73.41 110.746 179.047 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 86.77 19.24 56.75 Favored Glycine 0 N--CA 1.447 -0.585 0 C-N-CA 120.82 -0.705 . . . . 75.32 112.898 177.635 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 15' ' ' PHE . . . . . 0.458 ' CE2' ' HB3' ' A' ' 13' ' ' LYS . 31.0 p90 -157.78 156.66 31.94 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 121.133 0.492 . . . . 54.45 111.443 179.587 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -134.87 -179.24 16.31 Favored Glycine 0 N--CA 1.442 -0.906 0 N-CA-C 111.291 -0.724 . . . . 73.52 111.291 178.671 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 17' ' ' PHE . . . . . 0.421 ' HA ' ' O ' ' A' ' 26' ' ' VAL . 97.2 m-85 -132.35 127.65 35.98 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-O 121.305 0.574 . . . . 75.24 111.266 -179.538 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 63.4 mt -101.32 138.86 24.11 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.569 0 CA-C-N 115.209 -0.905 . . . . 73.51 109.344 177.864 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 19' ' ' GLU . . . . . 0.495 ' HB3' ' HG3' ' A' ' 7' ' ' LYS . 11.7 pt-20 -82.86 134.84 35.08 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-O 121.196 0.522 . . . . 73.34 111.303 -177.022 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 20' ' ' ARG . . . . . 0.754 ' HD2' ' H ' ' A' ' 21' ' ' GLU . 0.1 OUTLIER -113.22 -177.96 3.26 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 115.904 -0.589 . . . . 72.14 109.775 178.506 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 21' ' ' GLU . . . . . 0.754 ' H ' ' HD2' ' A' ' 20' ' ' ARG . 10.0 pt-20 -59.51 -37.18 77.64 Favored 'General case' 0 C--N 1.327 -0.387 0 N-CA-C 112.93 0.715 . . . . 72.45 112.93 -173.205 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 22' ' ' ASN . . . . . 0.422 ' ND2' ' HG3' ' A' ' 21' ' ' GLU . 29.3 m-80 -94.21 5.67 51.03 Favored 'General case' 0 C--N 1.328 -0.346 0 O-C-N 122.096 -0.377 . . . . 72.41 110.805 -178.306 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 84.97 20.02 58.39 Favored Glycine 0 N--CA 1.447 -0.584 0 N-CA-C 110.236 -1.145 . . . . 31.11 110.236 -170.509 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 24' ' ' ASP . . . . . 0.457 ' HB2' ' CB ' ' A' ' 20' ' ' ARG . 3.8 m-20 -67.15 95.02 0.38 Allowed 'General case' 0 N--CA 1.45 -0.448 0 CA-C-N 114.879 -0.66 . . . . 73.4 109.463 179.59 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 11.1 p-10 -63.65 100.81 0.3 Allowed 'General case' 0 C--N 1.32 -0.676 0 CA-C-O 121.833 0.825 . . . . 60.43 110.309 175.97 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.421 ' O ' ' HA ' ' A' ' 17' ' ' PHE . 44.9 t -78.38 120.76 29.91 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 CA-C-N 115.15 -0.932 . . . . 72.12 110.756 -177.273 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 27' ' ' PHE . . . . . . . . . . . . . 68.9 t80 -73.34 113.16 10.11 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 115.65 -0.705 . . . . 54.13 110.433 -179.092 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.434 ' HB ' ' HB3' ' A' ' 60' ' ' ALA . 10.4 p -117.26 126.59 74.64 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.575 0 CA-C-O 121.083 0.468 . . . . 73.01 110.24 176.068 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 29' ' ' HIS . . . . . 0.433 ' O ' HG13 ' A' ' 33' ' ' ILE . 41.2 t60 -103.46 149.74 24.54 Favored 'General case' 0 C--N 1.324 -0.529 0 N-CA-C 109.452 -0.573 . . . . 73.41 109.452 -176.754 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 30' ' ' PHE . . . . . 0.438 ' HA ' HD12 ' A' ' 33' ' ' ILE . 42.2 p90 -58.44 -27.29 64.22 Favored 'General case' 0 N--CA 1.467 0.403 0 CA-C-O 120.819 0.342 . . . . 74.32 111.607 -175.657 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 6.7 m -72.98 -14.13 61.38 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 116.409 -0.36 . . . . 74.51 111.283 179.005 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -106.88 -17.65 14.14 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.921 0.391 . . . . 63.21 111.058 -178.466 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.438 HD12 ' HA ' ' A' ' 30' ' ' PHE . 66.5 mt -71.22 144.82 13.06 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 CA-C-N 116.032 -0.531 . . . . 73.45 110.49 177.989 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 34' ' ' GLN . . . . . 0.47 ' HG3' ' O ' ' A' ' 34' ' ' GLN . 2.8 pt20 . . . . . 0 C--N 1.33 -0.263 0 N-CA-C 109.581 -0.526 . . . . 72.33 109.581 172.909 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 51.4 p . . . . . 0 N--CA 1.453 -0.319 0 N-CA-C 112.206 0.446 . . . . 74.13 112.206 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -88.77 103.64 16.16 Favored 'General case' 0 C--N 1.326 -0.439 0 N-CA-C 108.376 -0.972 . . . . 61.12 108.376 168.968 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 20.5 t70 -76.72 150.85 36.24 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 116.058 -0.519 . . . . 55.05 111.527 -169.718 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 83.6 mt-10 -61.59 112.82 2.38 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 115.629 -0.714 . . . . 72.24 110.552 -179.593 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 124.29 -12.87 7.96 Favored Glycine 0 N--CA 1.445 -0.758 0 C-N-CA 120.796 -0.716 . . . . 61.42 111.547 -177.203 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 6.5 tp-100 -80.06 143.15 34.25 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-O 120.857 0.36 . . . . 64.01 110.312 178.678 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -99.5 118.75 36.77 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 116.023 -0.535 . . . . 41.11 110.188 179.515 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 27.4 m -123.57 163.01 23.48 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.696 0 CA-C-N 116.227 -0.442 . . . . 70.11 111.11 -176.754 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 1.6 p -117.25 139.86 50.27 Favored 'General case' 0 C--N 1.321 -0.64 0 N-CA-C 108.91 -0.774 . . . . 74.31 108.91 176.548 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 33.5 p90 -141.24 159.18 42.76 Favored 'General case' 0 C--N 1.317 -0.823 0 C-N-CA 120.3 -0.56 . . . . 72.24 111.616 -175.26 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 4.9 t70 -88.14 103.16 15.49 Favored 'General case' 0 C--N 1.321 -0.657 0 N-CA-C 108.645 -0.872 . . . . 64.23 108.645 174.975 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 7.7 p -63.79 123.13 15.99 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 CA-C-O 121.295 0.569 . . . . 71.35 111.846 -173.09 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 52' ' ' GLU . . . . . 0.548 ' HB3' ' HG2' ' A' ' 59' ' ' GLN . 7.8 tp10 -117.52 139.86 50.38 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 115.648 -0.705 . . . . 63.41 110.067 178.997 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 10.8 tp10 -101.31 146.32 27.71 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-N 115.956 -0.565 . . . . 64.33 109.626 -179.701 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -144.83 -175.79 18.29 Favored Glycine 0 N--CA 1.45 -0.417 0 C-N-CA 120.709 -0.757 . . . . 40.03 112.527 -177.88 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 50.2 mt-30 -75.11 -34.15 61.67 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 120.755 0.312 . . . . 73.23 110.85 179.757 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 35.0 mtp-105 -77.1 -33.31 56.93 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-O 121.022 0.439 . . . . 74.21 110.436 174.39 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 146.87 -155.8 26.71 Favored Glycine 0 N--CA 1.448 -0.504 0 CA-C-N 115.904 -0.589 . . . . 31.05 111.798 -178.223 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 59.7 Cg_endo -74.26 137.13 23.07 Favored 'Trans proline' 0 C--O 1.234 0.298 0 C-N-CA 122.582 2.188 . . . . 73.55 112.775 -177.752 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 59' ' ' GLN . . . . . 0.548 ' HG2' ' HB3' ' A' ' 52' ' ' GLU . 17.0 pm0 -131.35 154.75 48.26 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 116.101 -0.499 . . . . 72.24 109.835 175.142 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 60' ' ' ALA . . . . . 0.434 ' HB3' ' HB ' ' A' ' 28' ' ' VAL . . . -101.77 106.53 17.54 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 116.294 -0.412 . . . . 55.04 110.993 -177.132 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -111.28 149.1 31.54 Favored 'General case' 0 C--N 1.321 -0.655 0 N-CA-C 109.263 -0.643 . . . . 33.32 109.263 175.082 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 86.5 m-20 57.06 82.79 0.11 Allowed 'General case' 0 N--CA 1.466 0.354 0 CA-C-O 121.304 0.573 . . . . 52.25 110.499 -178.459 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 46.4 t -103.54 134.48 44.61 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.588 0 CA-C-N 115.871 -0.604 . . . . 55.44 111.327 -174.985 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 76.8 mt-30 -130.71 178.2 6.82 Favored 'General case' 0 C--N 1.325 -0.484 0 N-CA-C 109.189 -0.671 . . . . 51.35 109.189 175.381 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 50.7 mtmt -96.81 144.18 27.02 Favored 'General case' 0 C--N 1.323 -0.554 0 N-CA-C 110.028 -0.36 . . . . 74.45 110.028 178.074 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 0.98 0 CA-C-O 118.519 -0.753 . . . . 61.15 110.274 -179.922 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 N--CA 1.452 -0.335 0 N-CA-C 109.994 -0.373 . . . . 62.24 109.994 . . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 3' ' ' GLN . . . . . 0.455 ' HG2' HG22 ' A' ' 48' ' ' THR . 50.3 mt-30 -105.85 130.67 53.77 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-N 116.029 -0.532 . . . . 64.44 109.8 174.491 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -150.49 172.9 30.21 Favored Glycine 0 N--CA 1.443 -0.844 0 C-N-CA 120.794 -0.717 . . . . 61.22 111.683 178.571 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 5' ' ' THR . . . . . 0.542 ' O ' ' HG2' ' A' ' 19' ' ' GLU . 24.3 m -122.65 135.76 54.69 Favored 'General case' 0 C--N 1.317 -0.829 0 N-CA-C 110.167 -0.309 . . . . 74.44 110.167 179.067 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 46.4 t -72.41 119.06 18.4 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.633 0 CA-C-N 116.741 -0.209 . . . . 72.13 110.524 -179.114 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 7' ' ' LYS . . . . . 0.572 ' CE ' ' HB3' ' A' ' 19' ' ' GLU . 97.7 mttt -66.01 -62.59 1.41 Allowed 'General case' 0 CA--C 1.52 -0.193 0 CA-C-O 121.7 0.762 . . . . 73.14 109.223 175.896 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 8' ' ' TRP . . . . . . . . . . . . . 55.1 p-90 -160.45 156.06 25.42 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-N 114.393 -1.276 . . . . 64.35 108.053 177.571 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 9' ' ' PHE . . . . . 0.412 ' CE2' ' HB2' ' A' ' 11' ' ' ALA . 2.1 p90 -136.03 138.52 42.28 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-O 121.603 0.716 . . . . 75.11 111.858 -174.113 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 10' ' ' ASN . . . . . 0.559 ' HB3' ' HG2' ' A' ' 13' ' ' LYS . 16.6 m120 -84.12 77.52 9.93 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 115.115 -0.948 . . . . 72.15 109.115 177.009 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 11' ' ' ALA . . . . . 0.412 ' HB2' ' CE2' ' A' ' 9' ' ' PHE . . . -54.12 -38.43 65.43 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.212 -0.904 . . . . 72.33 112.367 -175.07 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -90.75 -14.28 32.35 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 116.492 -0.322 . . . . 64.2 111.697 -175.288 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 13' ' ' LYS . . . . . 0.559 ' HG2' ' HB3' ' A' ' 10' ' ' ASN . 59.6 mmtt -90.55 -36.39 14.5 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 121.191 0.52 . . . . 72.31 109.649 177.017 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 99.59 32.88 5.54 Favored Glycine 0 N--CA 1.447 -0.619 0 CA-C-N 115.698 -0.683 . . . . 62.01 111.636 -177.676 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 74.0 m-85 -140.19 168.82 18.91 Favored 'General case' 0 C--N 1.329 -0.312 0 N-CA-C 110.152 -0.314 . . . . 72.11 110.152 -177.941 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -171.12 161.34 33.96 Favored Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.542 -0.837 . . . . 65.21 112.437 177.764 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 97.4 m-85 -123.93 120.21 31.86 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-O 121.033 0.444 . . . . 75.05 110.908 -179.847 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.4 HG21 ' CE2' ' A' ' 49' ' ' PHE . 54.0 mt -105.12 135.95 41.0 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.616 0 CA-C-N 115.869 -0.605 . . . . 74.25 109.74 178.981 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 19' ' ' GLU . . . . . 0.572 ' HB3' ' CE ' ' A' ' 7' ' ' LYS . 11.6 pt-20 -94.81 128.64 41.69 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 121.404 0.621 . . . . 73.44 111.654 -177.461 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 20' ' ' ARG . . . . . 0.48 ' HB3' ' HB3' ' A' ' 24' ' ' ASP . 18.6 ttt180 -89.67 177.13 6.61 Favored 'General case' 0 C--N 1.323 -0.548 0 N-CA-C 108.289 -1.004 . . . . 74.53 108.289 171.697 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 44.6 mt-10 -61.04 -12.05 10.41 Favored 'General case' 0 N--CA 1.467 0.409 0 N-CA-C 112.098 0.407 . . . . 73.33 112.098 -178.787 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 82.6 m-20 -98.05 -4.22 36.46 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.89 0.376 . . . . 73.43 111.239 177.826 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 82.42 3.17 90.64 Favored Glycine 0 N--CA 1.449 -0.461 0 N-CA-C 110.337 -1.105 . . . . 65.44 110.337 -168.657 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 24' ' ' ASP . . . . . 0.48 ' HB3' ' HB3' ' A' ' 20' ' ' ARG . 33.6 t70 -56.3 98.73 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 114.61 -0.795 . . . . 55.44 110.721 -179.062 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 12.4 m-20 -56.5 100.44 0.04 OUTLIER 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 114.964 -1.016 . . . . 73.2 111.698 174.999 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.506 HG12 ' HB2' ' A' ' 60' ' ' ALA . 21.4 t -83.1 116.6 27.55 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.743 0 N-CA-C 108.761 -0.829 . . . . 72.55 108.761 172.883 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 27' ' ' PHE . . . . . . . . . . . . . 81.1 t80 -83.22 116.15 22.26 Favored 'General case' 0 C--N 1.32 -0.682 0 CA-C-N 115.894 -0.594 . . . . 75.3 111.021 -173.414 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 9.0 p -105.73 148.91 9.61 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.581 0 N-CA-C 109.534 -0.543 . . . . 70.2 109.534 175.901 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 29' ' ' HIS . . . . . 0.447 ' O ' HG13 ' A' ' 33' ' ' ILE . 2.7 p80 -140.19 163.88 31.56 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 116.277 -0.419 . . . . 72.33 110.58 -174.173 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 31.3 p90 -53.18 -33.0 50.79 Favored 'General case' 0 N--CA 1.47 0.536 0 N-CA-C 112.871 0.693 . . . . 73.4 112.871 -174.001 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 27.5 m -84.92 34.23 0.54 Allowed 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 121.174 0.511 . . . . 72.44 110.906 176.866 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -160.57 -33.56 0.05 Allowed 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 115.826 -0.625 . . . . 63.54 110.729 -179.364 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.447 HG13 ' O ' ' A' ' 29' ' ' HIS . 71.7 mt -63.7 143.37 15.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.065 -0.516 . . . . 75.44 110.461 176.195 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 88.4 mt-30 . . . . . 0 C--N 1.329 -0.293 0 N-CA-C 109.792 -0.448 . . . . 75.32 109.792 172.117 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 15.2 m . . . . . 0 N--CA 1.454 -0.243 0 CA-C-O 120.947 0.403 . . . . 72.14 111.619 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 92.2 mt -82.16 74.35 9.15 Favored 'General case' 0 C--N 1.324 -0.51 0 N-CA-C 108.797 -0.816 . . . . 75.21 108.797 171.415 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 27.6 t70 -55.38 139.88 41.64 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 115.18 -0.918 . . . . 75.32 112.051 -172.467 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 7.8 pt-20 -64.66 129.72 40.87 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-N 115.428 -0.806 . . . . 71.24 110.582 179.121 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 97.15 -10.22 65.54 Favored Glycine 0 N--CA 1.45 -0.403 0 C-N-CA 120.871 -0.68 . . . . 34.42 112.036 -177.202 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 54.0 tp60 -81.78 135.35 35.47 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-O 120.767 0.318 . . . . 71.55 110.558 178.769 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -85.35 138.54 32.22 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 116.117 -0.492 . . . . 70.34 110.097 176.043 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 16.6 m -136.98 144.84 31.08 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.605 0 CA-C-N 116.348 -0.387 . . . . 73.14 111.25 -177.415 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 48' ' ' THR . . . . . 0.455 HG22 ' HG2' ' A' ' 3' ' ' GLN . 24.7 p -104.58 122.74 46.23 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-N 115.753 -0.658 . . . . 74.03 109.571 173.633 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 49' ' ' PHE . . . . . 0.48 ' HA ' ' O ' ' A' ' 62' ' ' ASN . 38.8 p90 -141.09 157.3 45.49 Favored 'General case' 0 C--N 1.32 -0.701 0 CA-C-O 120.701 0.286 . . . . 63.53 111.206 -172.403 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 30.2 m-20 -90.48 149.49 22.19 Favored 'General case' 0 C--N 1.321 -0.674 0 N-CA-C 109.684 -0.488 . . . . 71.44 109.684 172.357 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 5.4 p -110.44 117.14 54.16 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.628 0 CA-C-O 121.428 0.633 . . . . 71.24 111.549 -175.28 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 52' ' ' GLU . . . . . 0.653 ' HB2' ' HB2' ' A' ' 59' ' ' GLN . 6.9 mm-40 -94.76 133.43 38.46 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 115.432 -0.804 . . . . 73.54 109.476 174.456 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 8.5 pt-20 -82.04 97.82 8.33 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-O 121.354 0.597 . . . . 72.5 110.86 -179.33 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -90.02 151.84 21.89 Favored Glycine 0 N--CA 1.446 -0.685 0 C-N-CA 120.736 -0.745 . . . . 74.41 111.671 179.041 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 49.8 mt-30 -58.38 -25.96 62.65 Favored 'General case' 0 C--N 1.327 -0.375 0 N-CA-C 112.377 0.51 . . . . 71.44 112.377 -177.182 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 81.4 mtt180 -130.49 26.86 5.06 Favored 'General case' 0 C--N 1.327 -0.41 0 N-CA-C 111.716 0.265 . . . . 61.21 111.716 -177.217 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 150.22 153.32 6.06 Favored Glycine 0 N--CA 1.449 -0.441 0 C-N-CA 120.128 -1.034 . . . . 45.02 113.074 177.319 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 7.2 Cg_exo -72.59 124.42 9.8 Favored 'Trans proline' 0 N--CA 1.46 -0.478 0 C-N-CA 122.834 2.356 . . . . 74.0 111.475 177.449 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 59' ' ' GLN . . . . . 0.653 ' HB2' ' HB2' ' A' ' 52' ' ' GLU . 95.2 mt-30 -94.53 123.44 37.96 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-N 116.243 -0.435 . . . . 70.42 110.664 -179.029 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 60' ' ' ALA . . . . . 0.506 ' HB2' HG12 ' A' ' 26' ' ' VAL . . . -78.99 106.59 11.14 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 116.308 -0.405 . . . . 72.41 109.946 176.244 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -116.86 139.48 50.57 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 116.311 -0.404 . . . . 62.45 110.033 -179.928 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 62' ' ' ASN . . . . . 0.48 ' O ' ' HA ' ' A' ' 49' ' ' PHE . 76.8 m-20 60.31 92.26 0.05 OUTLIER 'General case' 0 C--O 1.236 0.358 0 O-C-N 123.595 0.56 . . . . 74.31 110.008 -176.116 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 40.7 t -114.3 136.59 50.35 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.547 0 CA-C-N 115.469 -0.787 . . . . 72.15 110.55 -175.16 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 64' ' ' GLN . . . . . 0.429 ' HB3' ' OG1' ' A' ' 48' ' ' THR . 31.0 tt0 -121.5 149.14 43.51 Favored 'General case' 0 C--N 1.319 -0.737 0 N-CA-C 109.624 -0.51 . . . . 64.3 109.624 176.403 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 48.4 mttp -91.49 123.83 35.2 Favored 'General case' 0 C--N 1.324 -0.502 0 N-CA-C 110.112 -0.329 . . . . 73.43 110.112 178.491 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.246 0.886 0 CA-C-O 118.602 -0.713 . . . . 75.12 110.647 -179.942 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 60.7 mm-40 . . . . . 0 C--O 1.238 0.471 0 CA-C-O 121.388 0.613 . . . . 75.21 111.837 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 35.3 tt0 -120.91 136.28 54.99 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-N 115.34 -0.845 . . . . 74.55 109.478 174.756 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -151.9 164.49 30.4 Favored Glycine 0 N--CA 1.444 -0.788 0 N-CA-C 111.368 -0.693 . . . . 64.31 111.368 179.027 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 5' ' ' THR . . . . . 0.54 HG21 ' HE3' ' A' ' 7' ' ' LYS . 5.4 m -103.38 125.32 49.92 Favored 'General case' 0 C--N 1.318 -0.802 0 CA-C-N 116.984 0.392 . . . . 74.21 110.825 -178.623 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.488 HG22 HG12 ' A' ' 18' ' ' ILE . 46.1 t -81.52 90.47 1.94 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 N-CA-C 109.099 -0.704 . . . . 73.44 109.099 175.473 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 7' ' ' LYS . . . . . 0.54 ' HE3' HG21 ' A' ' 5' ' ' THR . 27.9 mmtp -78.02 -51.9 9.62 Favored 'General case' 0 C--N 1.323 -0.587 0 CA-C-N 115.818 -0.628 . . . . 61.0 111.584 -176.155 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 8' ' ' TRP . . . . . . . . . . . . . 8.8 p90 -133.12 122.25 23.81 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-O 121.41 0.624 . . . . 72.22 110.992 178.113 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 22.2 p90 -111.6 123.43 50.21 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-N 115.343 -0.844 . . . . 64.05 109.544 178.434 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 16.7 t-20 -88.39 76.18 8.34 Favored 'General case' 0 C--N 1.317 -0.806 0 CA-C-O 121.503 0.668 . . . . 61.44 109.893 -176.737 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -67.75 -7.93 31.39 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.241 -0.89 . . . . 73.53 110.442 178.438 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 27.3 mt-10 -70.45 -33.41 71.26 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 115.306 -0.861 . . . . 74.05 110.595 179.081 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 13' ' ' LYS . . . . . 0.423 ' HB2' ' CE1' ' A' ' 15' ' ' PHE . 74.3 mmtt -116.25 -29.66 6.18 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.235 -0.439 . . . . 52.34 111.296 -178.47 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 14' ' ' GLY . . . . . 0.618 ' HA2' ' CE2' ' A' ' 30' ' ' PHE . . . 117.52 24.83 3.33 Favored Glycine 0 N--CA 1.452 -0.265 0 C-N-CA 120.178 -1.011 . . . . 64.41 113.773 175.842 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 15' ' ' PHE . . . . . 0.423 ' CE1' ' HB2' ' A' ' 13' ' ' LYS . 54.9 p90 -142.1 -174.11 4.01 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 116.921 0.361 . . . . 75.52 110.124 179.334 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -169.65 170.39 42.68 Favored Glycine 0 N--CA 1.449 -0.454 0 C-N-CA 120.358 -0.925 . . . . 53.03 112.147 177.713 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 98.2 m-85 -120.17 126.59 51.04 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 121.054 0.454 . . . . 75.53 110.81 -179.728 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.488 HG12 HG22 ' A' ' 6' ' ' VAL . 62.9 mt -110.81 129.21 66.42 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.572 0 CA-C-N 115.777 -0.647 . . . . 64.14 110.179 179.724 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 7.0 pt-20 -79.71 113.26 17.73 Favored 'General case' 0 C--N 1.326 -0.436 0 N-CA-C 109.665 -0.494 . . . . 63.1 109.665 175.673 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 20' ' ' ARG . . . . . 0.409 ' HD3' ' OD2' ' A' ' 24' ' ' ASP . 73.0 ttt-85 -113.02 111.15 21.68 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 116.06 -0.518 . . . . 71.34 111.332 -175.604 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 10.7 mm-40 47.3 -89.6 0.01 OUTLIER 'General case' 0 N--CA 1.47 0.537 0 N-CA-C 114.158 1.17 . . . . 74.25 114.158 169.725 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 23.6 t-20 -70.51 -31.38 68.44 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 121.12 0.486 . . . . 53.41 111.27 -174.018 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 130.51 -1.67 5.66 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.728 -0.748 . . . . 62.44 111.255 -176.405 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 24' ' ' ASP . . . . . 0.409 ' OD2' ' HD3' ' A' ' 20' ' ' ARG . 2.6 p-10 -67.92 94.35 0.47 Allowed 'General case' 0 C--N 1.323 -0.565 0 CA-C-O 121.355 0.597 . . . . 61.34 110.185 175.937 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 5.7 p-10 -57.02 123.58 15.68 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 114.989 -1.005 . . . . 75.2 110.751 176.938 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 46.4 t -97.22 135.05 32.77 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.658 0 CA-C-N 115.614 -0.721 . . . . 72.22 110.326 -179.764 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 27' ' ' PHE . . . . . . . . . . . . . 32.5 t80 -80.77 105.58 12.12 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 116.142 -0.481 . . . . 72.35 110.161 -179.188 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.403 HG23 HG21 ' A' ' 63' ' ' VAL . 9.9 p -99.74 158.87 3.7 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.516 0 N-CA-C 110.011 -0.366 . . . . 65.44 110.011 179.522 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 1.1 p80 -147.89 159.49 43.8 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.534 -0.303 . . . . 71.52 110.29 -178.414 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 30' ' ' PHE . . . . . 0.618 ' CE2' ' HA2' ' A' ' 14' ' ' GLY . 23.0 m-85 -56.82 -37.14 70.8 Favored 'General case' 0 N--CA 1.468 0.443 0 N-CA-C 112.76 0.652 . . . . 72.4 112.76 -173.767 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 12.7 t -70.97 -3.31 18.75 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 120.893 0.377 . . . . 42.45 111.269 -178.157 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 32' ' ' ALA . . . . . 0.427 ' HB1' HG23 ' A' ' 63' ' ' VAL . . . -107.08 -34.13 7.25 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.75 0.31 . . . . 61.45 110.668 177.015 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.511 ' HA ' ' HB ' ' A' ' 63' ' ' VAL . 61.2 mt -65.17 140.27 20.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.109 -0.496 . . . . 72.22 110.708 179.041 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 11.3 pt20 . . . . . 0 CA--C 1.537 0.443 0 N-CA-C 112.359 0.503 . . . . 55.12 112.359 -177.488 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 18.6 m . . . . . 0 N--CA 1.451 -0.409 0 CA-C-O 120.682 0.277 . . . . 74.22 110.457 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 41' ' ' LEU . . . . . 0.431 HD22 ' HA ' ' A' ' 41' ' ' LEU . 1.9 tm? -62.85 125.87 25.42 Favored 'General case' 0 C--N 1.326 -0.433 0 N-CA-C 109.078 -0.712 . . . . 63.22 109.078 178.374 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 18.1 m-20 -60.16 119.76 8.47 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 116.245 -0.434 . . . . 74.2 110.974 -176.627 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 8.2 pt-20 -67.18 119.5 12.2 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-O 121.34 0.59 . . . . 64.54 110.145 177.616 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 112.49 -4.61 26.43 Favored Glycine 0 N--CA 1.445 -0.713 0 N-CA-C 111.179 -0.768 . . . . 51.15 111.179 -174.532 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 5.8 tp-100 -72.67 132.91 44.31 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 120.874 0.369 . . . . 75.25 110.946 179.73 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -86.08 115.07 23.44 Favored 'General case' 0 C--N 1.325 -0.465 0 N-CA-C 108.89 -0.781 . . . . 44.13 108.89 173.073 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 0.51 ' HA ' ' HA ' ' A' ' 65' ' ' LYS . 29.3 m -110.27 155.29 11.6 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.811 0 CA-C-O 121.316 0.579 . . . . 51.43 111.51 -174.945 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 48' ' ' THR . . . . . 0.5 HG23 ' HB2' ' A' ' 66' ' ' ALA . 45.4 p -121.15 112.31 18.52 Favored 'General case' 0 C--N 1.318 -0.773 0 CA-C-N 115.322 -0.854 . . . . 73.15 108.832 175.376 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 49' ' ' PHE . . . . . 0.407 ' HA ' ' O ' ' A' ' 62' ' ' ASN . 35.4 p90 -127.07 171.98 10.9 Favored 'General case' 0 C--N 1.319 -0.748 0 CA-C-N 115.95 -0.568 . . . . 71.13 111.323 -170.969 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 62.9 m-20 -96.12 138.43 33.75 Favored 'General case' 0 C--N 1.322 -0.598 0 N-CA-C 109.065 -0.717 . . . . 73.45 109.065 169.935 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 12.5 p -102.31 134.67 42.39 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.721 0 CA-C-O 121.008 0.432 . . . . 63.2 111.27 -174.767 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 40.1 mt-10 -122.35 148.81 44.6 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 116.066 -0.515 . . . . 73.44 110.24 175.889 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 36.5 mt-10 -106.07 123.41 47.96 Favored 'General case' 0 C--N 1.319 -0.736 0 N-CA-C 109.61 -0.515 . . . . 71.33 109.61 177.401 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -118.46 -178.99 17.06 Favored Glycine 0 N--CA 1.445 -0.74 0 C-N-CA 120.669 -0.777 . . . . 74.54 112.287 -178.512 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -67.64 -29.45 68.76 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 120.772 0.32 . . . . 73.25 111.548 -179.755 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 22.0 ttt180 -85.03 -27.62 26.27 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.184 -0.462 . . . . 73.03 110.448 179.455 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 148.73 -164.87 29.16 Favored Glycine 0 N--CA 1.446 -0.645 0 C-N-CA 120.893 -0.67 . . . . 71.14 111.864 -179.282 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 56.4 Cg_endo -72.41 126.85 11.97 Favored 'Trans proline' 0 N--CA 1.463 -0.288 0 C-N-CA 122.702 2.268 . . . . 52.13 112.388 179.595 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 11.5 pt20 -123.72 154.33 39.61 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-N 115.851 -0.613 . . . . 72.51 110.152 -179.974 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -99.57 135.25 41.27 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 116.383 -0.371 . . . . 44.42 111.168 -177.958 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -131.97 149.63 52.38 Favored 'General case' 0 C--N 1.324 -0.529 0 N-CA-C 108.829 -0.804 . . . . 71.42 108.829 174.461 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 62' ' ' ASN . . . . . 0.407 ' O ' ' HA ' ' A' ' 49' ' ' PHE . 55.5 m-20 53.57 75.57 0.26 Allowed 'General case' 0 C--O 1.239 0.504 0 N-CA-C 110.028 -0.36 . . . . 73.12 110.028 -174.999 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.511 ' HB ' ' HA ' ' A' ' 33' ' ' ILE . 59.4 t -101.9 101.99 12.89 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.517 0 CA-C-O 121.171 0.51 . . . . 73.52 110.947 -176.191 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 50.8 mt-30 -107.48 170.27 8.07 Favored 'General case' 0 C--N 1.32 -0.707 0 N-CA-C 108.593 -0.892 . . . . 74.33 108.593 175.791 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 65' ' ' LYS . . . . . 0.51 ' HA ' ' HA ' ' A' ' 47' ' ' VAL . 21.9 pttp -93.58 169.1 10.59 Favored 'General case' 0 C--N 1.321 -0.66 0 C-N-CA 120.477 -0.489 . . . . 70.14 110.277 179.658 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 66' ' ' ALA . . . . . 0.5 ' HB2' HG23 ' A' ' 48' ' ' THR . . . . . . . . 0 C--O 1.246 0.907 0 CA-C-O 118.275 -0.869 . . . . 52.24 109.96 176.241 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 6.9 mp0 . . . . . 0 N--CA 1.451 -0.382 0 CA-C-O 120.656 0.265 . . . . 65.41 110.572 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 27.0 tt0 -90.34 98.94 12.07 Favored 'General case' 0 C--N 1.322 -0.614 0 N-CA-C 109.085 -0.709 . . . . 73.5 109.085 174.567 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -120.91 163.42 14.41 Favored Glycine 0 N--CA 1.446 -0.667 0 C-N-CA 120.575 -0.821 . . . . 75.4 112.668 -174.591 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 5' ' ' THR . . . . . 0.461 ' O ' ' HG2' ' A' ' 19' ' ' GLU . 0.2 OUTLIER -105.23 129.53 53.58 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-O 121.028 0.442 . . . . 74.1 110.969 179.826 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.552 ' HA ' ' HA ' ' A' ' 18' ' ' ILE . 17.0 t -71.06 121.66 21.44 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.582 0 CA-C-N 116.08 -0.509 . . . . 61.42 110.451 179.684 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 50.5 mttp -74.33 -49.48 22.7 Favored 'General case' 0 C--N 1.329 -0.302 0 C-N-CA 120.719 -0.392 . . . . 54.44 110.433 177.677 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 8' ' ' TRP . . . . . . . . . . . . . 14.9 p-90 -161.99 163.74 28.74 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.91 -0.586 . . . . 74.51 109.671 179.469 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 10.9 p90 -145.02 121.1 10.75 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-O 121.31 0.576 . . . . 71.43 111.098 -178.131 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 52.2 t-20 -82.73 86.43 6.88 Favored 'General case' 0 C--N 1.321 -0.631 0 N-CA-C 109.267 -0.642 . . . . 61.41 109.267 177.226 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -72.84 -5.33 37.47 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.303 -0.862 . . . . 64.35 111.748 -179.644 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 9.8 mm-40 -86.25 -19.4 30.01 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-O 120.977 0.418 . . . . 63.32 110.253 177.355 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 43.4 mmtm -108.76 -48.04 3.37 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 115.945 -0.571 . . . . 65.34 110.047 176.71 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 115.76 43.83 0.67 Allowed Glycine 0 N--CA 1.442 -0.929 0 C-N-CA 120.765 -0.731 . . . . 63.13 112.174 -179.134 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 43.8 p90 -152.03 161.29 42.87 Favored 'General case' 0 C--N 1.328 -0.349 0 N-CA-C 110.183 -0.302 . . . . 74.22 110.183 176.926 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -154.02 171.1 32.66 Favored Glycine 0 N--CA 1.448 -0.548 0 C-N-CA 120.877 -0.678 . . . . 74.11 112.166 179.88 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 80.9 m-85 -124.04 116.78 23.36 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-O 121.049 0.452 . . . . 75.11 110.75 179.591 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.552 ' HA ' ' HA ' ' A' ' 6' ' ' VAL . 11.3 mt -109.94 123.02 65.48 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.524 0 N-CA-C 108.715 -0.846 . . . . 75.52 108.715 178.63 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 19' ' ' GLU . . . . . 0.5 ' HA ' ' HA ' ' A' ' 25' ' ' ASP . 16.7 pt-20 -76.15 138.43 40.71 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-O 121.404 0.621 . . . . 73.33 112.092 -170.549 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 20' ' ' ARG . . . . . 0.602 ' HB3' ' HB3' ' A' ' 24' ' ' ASP . 78.1 ttt180 -91.73 161.33 14.93 Favored 'General case' 0 C--N 1.321 -0.659 0 N-CA-C 108.51 -0.922 . . . . 62.44 108.51 171.126 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 21' ' ' GLU . . . . . 0.506 ' OE1' ' HG2' ' A' ' 20' ' ' ARG . 0.0 OUTLIER -71.1 6.45 1.62 Allowed 'General case' 0 CA--C 1.537 0.455 0 N-CA-C 112.745 0.646 . . . . 71.03 112.745 -173.559 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 9.4 m-80 -108.63 5.29 24.82 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-O 120.792 0.33 . . . . 73.41 110.895 175.31 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 84.88 0.86 89.07 Favored Glycine 0 N--CA 1.453 -0.227 0 N-CA-C 110.572 -1.011 . . . . 54.4 110.572 -172.89 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 24' ' ' ASP . . . . . 0.602 ' HB3' ' HB3' ' A' ' 20' ' ' ARG . 31.5 t70 -76.07 87.49 2.97 Favored 'General case' 0 C--N 1.321 -0.669 0 CA-C-N 114.631 -0.784 . . . . 53.43 109.946 -178.859 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.5 ' HA ' ' HA ' ' A' ' 19' ' ' GLU . 55.9 m-20 -64.5 110.69 2.39 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 116.02 -0.537 . . . . 54.5 110.647 179.121 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.442 HG13 ' HB2' ' A' ' 58' ' ' PRO . 28.2 t -85.2 130.01 36.88 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.492 0 CA-C-N 115.639 -0.709 . . . . 54.23 110.977 -175.281 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 27' ' ' PHE . . . . . . . . . . . . . 85.3 t80 -84.87 122.84 29.75 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.745 -0.661 . . . . 74.2 110.816 -178.48 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.568 ' HB ' ' HB3' ' A' ' 60' ' ' ALA . 12.3 p -120.47 145.62 26.58 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.574 0 CA-C-N 116.591 -0.277 . . . . 61.43 110.276 178.249 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 29' ' ' HIS . . . . . 0.478 ' O ' HG13 ' A' ' 33' ' ' ILE . 6.6 t60 -111.7 157.44 20.48 Favored 'General case' 0 C--N 1.327 -0.381 0 N-CA-C 109.432 -0.581 . . . . 63.12 109.432 -179.706 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 33.6 p90 -51.57 -40.18 59.28 Favored 'General case' 0 N--CA 1.471 0.582 0 N-CA-C 113.367 0.877 . . . . 73.32 113.367 -170.471 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 29.5 t -83.6 -6.95 59.58 Favored 'General case' 0 C--N 1.33 -0.282 0 C-N-CA 120.691 -0.404 . . . . 61.14 111.262 -176.056 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -93.67 -20.22 20.37 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-O 121.43 0.634 . . . . 50.34 109.457 174.791 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.478 HG13 ' O ' ' A' ' 29' ' ' HIS . 52.0 mt -75.53 154.28 6.2 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.408 0 CA-C-N 114.979 -1.01 . . . . 74.33 109.335 174.782 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 34' ' ' GLN . . . . . 0.405 ' HB3' ' O ' ' A' ' 63' ' ' VAL . 14.1 pt20 . . . . . 0 C--N 1.321 -0.633 0 CA-C-O 121.052 0.453 . . . . 63.44 110.728 179.299 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 18.4 p . . . . . 0 N--CA 1.448 -0.561 0 N-CA-C 109.961 -0.385 . . . . 73.44 109.961 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 3.8 mm? -81.02 126.83 31.89 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 116.289 -0.414 . . . . 74.23 110.365 -179.503 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 42' ' ' ASP . . . . . 0.802 ' HB2' ' HB2' ' A' ' 45' ' ' GLN . 5.4 m-20 -65.11 143.93 57.57 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.801 -0.636 . . . . 74.31 110.18 178.98 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 43' ' ' GLU . . . . . 0.426 ' H ' ' HG3' ' A' ' 43' ' ' GLU . 0.1 OUTLIER -80.01 90.69 5.4 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-O 122.528 1.156 . . . . 70.13 109.332 174.737 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 130.65 0.5 5.29 Favored Glycine 0 N--CA 1.445 -0.713 0 CA-C-N 114.007 -1.451 . . . . 63.12 110.539 -169.148 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 45' ' ' GLN . . . . . 0.802 ' HB2' ' HB2' ' A' ' 42' ' ' ASP . 6.7 tp-100 -78.07 140.78 39.11 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.381 -0.41 . . . . 75.53 110.291 177.828 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -101.98 120.56 40.61 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 116.207 -0.451 . . . . 51.34 110.533 179.442 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 17.8 m -132.94 158.78 43.37 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.564 0 CA-C-N 116.181 -0.463 . . . . 74.24 110.72 -179.134 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 48' ' ' THR . . . . . 0.603 HG23 ' HB2' ' A' ' 66' ' ' ALA . 37.1 p -103.16 99.64 9.52 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 121.33 0.586 . . . . 64.41 110.876 -178.681 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 49' ' ' PHE . . . . . 0.428 ' HA ' ' O ' ' A' ' 62' ' ' ASN . 42.0 p90 -105.62 167.6 9.65 Favored 'General case' 0 C--N 1.315 -0.911 0 CA-C-N 115.635 -0.711 . . . . 74.22 109.732 -179.796 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 4.6 t70 -117.34 111.8 19.86 Favored 'General case' 0 C--N 1.319 -0.731 0 C-N-CA 120.197 -0.601 . . . . 72.33 110.351 172.703 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 9.1 p -69.15 125.67 27.58 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-O 121.707 0.765 . . . . 74.02 112.275 -176.407 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 6.4 mm-40 -102.69 134.14 46.56 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-N 115.314 -0.857 . . . . 62.33 108.995 172.467 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 15.4 pt-20 -87.77 127.03 35.32 Favored 'General case' 0 C--N 1.32 -0.709 0 C-N-CA 120.447 -0.501 . . . . 62.25 110.047 177.499 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -153.53 -158.39 8.56 Favored Glycine 0 N--CA 1.447 -0.625 0 C-N-CA 120.224 -0.989 . . . . 63.15 113.007 -178.42 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 39.8 mt-30 -66.28 -24.53 66.58 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.865 0.364 . . . . 63.44 111.276 -175.85 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -93.89 9.36 37.67 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 116.283 -0.417 . . . . 41.45 110.46 179.158 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 81.34 -115.92 4.11 Favored Glycine 0 N--CA 1.444 -0.791 0 N-CA-C 110.754 -0.939 . . . . 63.25 110.754 -174.504 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 58' ' ' PRO . . . . . 0.442 ' HB2' HG13 ' A' ' 26' ' ' VAL . 89.3 Cg_endo -81.53 109.01 2.0 Favored 'Trans proline' 0 N--CA 1.455 -0.749 0 C-N-CA 122.482 2.121 . . . . 74.34 112.005 175.217 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 51.1 tt0 -115.51 118.17 32.42 Favored 'General case' 0 C--N 1.322 -0.594 0 N-CA-C 109.455 -0.572 . . . . 75.02 109.455 176.947 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 60' ' ' ALA . . . . . 0.568 ' HB3' ' HB ' ' A' ' 28' ' ' VAL . . . -78.67 123.94 27.67 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-O 121.004 0.431 . . . . 64.42 111.818 -173.029 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -124.75 145.7 49.58 Favored 'General case' 0 C--N 1.321 -0.667 0 N-CA-C 109.14 -0.689 . . . . 63.33 109.14 173.325 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 62' ' ' ASN . . . . . 0.428 ' O ' ' HA ' ' A' ' 49' ' ' PHE . 47.3 m-80 60.61 87.83 0.09 Allowed 'General case' 0 C--O 1.236 0.394 0 CA-C-O 121.321 0.581 . . . . 73.51 110.704 -175.57 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.405 ' O ' ' HB3' ' A' ' 34' ' ' GLN . 58.0 t -100.29 106.72 19.7 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.547 0 CA-C-N 115.443 -0.799 . . . . 63.14 109.407 176.132 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 48.7 mt-30 -103.98 160.38 14.87 Favored 'General case' 0 C--N 1.319 -0.741 0 CA-C-N 116.086 -0.507 . . . . 75.13 110.665 -177.191 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 9.7 mtpm? -77.07 136.43 38.66 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 115.928 -0.578 . . . . 72.11 109.731 176.481 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 66' ' ' ALA . . . . . 0.603 ' HB2' HG23 ' A' ' 48' ' ' THR . . . . . . . . 0 C--O 1.248 1.006 0 CA-C-O 118.666 -0.683 . . . . 42.25 110.19 -179.505 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 4.5 mm-40 . . . . . 0 C--O 1.236 0.38 0 CA-C-O 121.484 0.659 . . . . 74.13 111.299 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 24.1 tt0 -86.57 125.16 33.6 Favored 'General case' 0 N--CA 1.448 -0.528 0 CA-C-N 115.077 -0.965 . . . . 74.13 110.067 177.633 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -136.52 150.4 20.49 Favored Glycine 0 N--CA 1.442 -0.936 0 N-CA-C 111.311 -0.716 . . . . 74.12 111.311 176.435 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 5' ' ' THR . . . . . 0.435 ' O ' ' HG2' ' A' ' 19' ' ' GLU . 0.7 OUTLIER -98.13 130.39 44.9 Favored 'General case' 0 C--N 1.319 -0.758 0 CA-C-O 120.672 0.272 . . . . 71.1 110.672 177.763 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 47.3 t -65.54 122.23 16.09 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.491 0 N-CA-C 109.857 -0.423 . . . . 51.23 109.857 176.547 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 7' ' ' LYS . . . . . 0.41 ' HG2' ' OE1' ' A' ' 19' ' ' GLU . 27.6 mtpp -78.33 -60.81 2.22 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 121.209 0.528 . . . . 73.12 109.604 179.788 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 8' ' ' TRP . . . . . . . . . . . . . 19.0 p90 -152.07 156.4 39.84 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 115.465 -0.789 . . . . 65.45 109.214 175.79 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 17.9 p90 -127.09 112.57 15.34 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-O 121.607 0.718 . . . . 65.22 111.055 -174.931 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 77.8 m-20 -86.67 73.5 10.02 Favored 'General case' 0 C--N 1.32 -0.696 0 CA-C-N 115.682 -0.69 . . . . 71.53 109.608 179.537 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -61.58 -25.52 67.38 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 115.553 -0.749 . . . . 72.32 111.118 -177.981 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 26.6 mt-10 -58.82 -36.87 75.23 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.531 -0.758 . . . . 74.42 110.864 179.287 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 28.2 mmtp -104.92 -18.33 14.23 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 116.024 -0.534 . . . . 71.33 111.007 -177.967 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 95.87 28.76 9.13 Favored Glycine 0 N--CA 1.449 -0.5 0 C-N-CA 120.748 -0.739 . . . . 73.12 113.491 174.399 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 50.2 p90 -150.69 156.4 41.25 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 117.155 0.478 . . . . 65.32 110.65 177.451 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -137.43 176.86 20.29 Favored Glycine 0 N--CA 1.447 -0.615 0 C-N-CA 121.075 -0.583 . . . . 54.11 111.736 178.64 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 75.8 m-85 -126.26 127.5 45.72 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 121.273 0.559 . . . . 73.34 110.948 179.54 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.412 ' HB ' ' HB ' ' A' ' 26' ' ' VAL . 64.3 mt -110.18 143.68 19.74 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.618 0 CA-C-N 115.408 -0.815 . . . . 73.53 109.845 179.191 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 19' ' ' GLU . . . . . 0.435 ' HG2' ' O ' ' A' ' 5' ' ' THR . 7.6 pt-20 -96.63 108.8 21.47 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 121.573 0.701 . . . . 75.44 110.649 177.213 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 20' ' ' ARG . . . . . 0.423 ' HG2' ' N ' ' A' ' 21' ' ' GLU . 61.3 ttt180 -97.0 162.87 13.2 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 114.954 -1.021 . . . . 65.45 110.123 -176.749 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 21' ' ' GLU . . . . . 0.423 ' N ' ' HG2' ' A' ' 20' ' ' ARG . 19.2 mm-40 -51.88 -41.65 62.07 Favored 'General case' 0 CA--C 1.531 0.241 0 CA-C-O 121.156 0.503 . . . . 74.13 111.002 176.618 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 15.3 m120 -111.09 26.34 10.8 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.983 -0.553 . . . . 62.55 111.761 -175.257 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 179.14 111.81 0.32 Allowed Glycine 0 C--O 1.225 -0.415 0 C-N-CA 119.86 -1.162 . . . . 44.45 113.084 -179.888 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 31.8 t70 -74.53 6.4 3.82 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-O 121.472 0.653 . . . . 61.34 111.05 -176.294 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 10.4 p-10 -152.04 93.21 1.8 Allowed 'General case' 0 C--N 1.324 -0.539 0 CA-C-O 121.882 0.849 . . . . 72.54 111.096 -178.768 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.412 ' HB ' ' HB ' ' A' ' 18' ' ' ILE . 89.0 t -102.59 121.18 53.38 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 CA-C-N 115.042 -0.981 . . . . 71.22 109.784 175.216 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 27' ' ' PHE . . . . . 0.485 ' O ' ' HA ' ' A' ' 59' ' ' GLN . 78.1 t80 -78.6 120.37 23.19 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 116.024 -0.534 . . . . 73.01 110.535 -178.558 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.485 ' HB ' ' HB3' ' A' ' 60' ' ' ALA . 8.7 p -128.7 136.05 60.82 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.728 0 CA-C-O 120.964 0.412 . . . . 74.41 111.277 179.516 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 29' ' ' HIS . . . . . 0.483 ' O ' HG13 ' A' ' 33' ' ' ILE . 3.2 m-70 -96.99 142.92 28.36 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 116.14 -0.482 . . . . 73.4 110.024 175.307 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 30' ' ' PHE . . . . . 0.436 ' HE2' ' HB3' ' A' ' 40' ' ' SER . 17.7 m-85 -62.28 -28.59 69.83 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-O 120.704 0.287 . . . . 73.41 111.216 -179.545 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 16.5 t -74.92 -12.44 60.35 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 121.0 0.429 . . . . 73.11 110.877 177.897 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 32' ' ' ALA . . . . . 0.476 ' HB1' ' HA ' ' A' ' 61' ' ' ALA . . . -97.67 -24.26 15.58 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 121.095 0.474 . . . . 52.43 110.464 178.858 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.501 HG23 ' HB ' ' A' ' 63' ' ' VAL . 31.8 mt -68.61 163.48 3.15 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.4 0 CA-C-N 115.86 -0.609 . . . . 75.55 109.936 176.233 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 34' ' ' GLN . . . . . 0.452 ' N ' HG22 ' A' ' 33' ' ' ILE . 2.1 pt20 . . . . . 0 N--CA 1.466 0.358 0 CA-C-O 120.73 0.3 . . . . 64.22 111.703 179.426 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 40' ' ' SER . . . . . 0.436 ' HB3' ' HE2' ' A' ' 30' ' ' PHE . 13.8 p . . . . . 0 C--O 1.234 0.282 0 CA-C-O 121.036 0.446 . . . . 71.24 111.751 . . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 41' ' ' LEU . . . . . 0.542 HD12 ' HG2' ' A' ' 45' ' ' GLN . 4.4 mm? -103.33 145.28 30.21 Favored 'General case' 0 C--N 1.325 -0.488 0 N-CA-C 109.397 -0.594 . . . . 73.35 109.397 174.858 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 6.5 m-20 -76.08 156.87 33.5 Favored 'General case' 0 C--N 1.32 -0.691 0 CA-C-N 116.112 -0.495 . . . . 62.01 111.29 -174.752 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 6.3 pt-20 -68.01 133.21 48.66 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-N 116.051 -0.522 . . . . 62.42 109.962 175.648 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 87.02 0.23 85.65 Favored Glycine 0 N--CA 1.446 -0.676 0 C-N-CA 120.558 -0.83 . . . . 73.31 112.146 -177.246 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 45' ' ' GLN . . . . . 0.542 ' HG2' HD12 ' A' ' 41' ' ' LEU . 24.3 tp60 -74.72 115.96 14.89 Favored 'General case' 0 C--N 1.328 -0.368 0 N-CA-C 109.637 -0.505 . . . . 73.44 109.637 176.9 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -74.84 116.07 15.14 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 116.049 -0.523 . . . . 64.43 110.125 177.14 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 0.505 HG12 ' HA ' ' A' ' 65' ' ' LYS . 27.5 m -122.13 150.15 25.58 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.737 0 CA-C-N 116.068 -0.515 . . . . 63.22 110.751 -179.44 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 59.0 p -106.9 119.01 38.19 Favored 'General case' 0 C--N 1.318 -0.777 0 N-CA-C 108.928 -0.767 . . . . 73.42 108.928 175.062 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 29.8 p90 -127.99 151.34 49.25 Favored 'General case' 0 C--N 1.319 -0.74 0 CA-C-O 120.932 0.396 . . . . 70.11 111.745 -172.135 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 17.8 t70 -82.66 120.4 25.52 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.809 -0.632 . . . . 62.54 109.306 174.397 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 49.6 t -83.33 115.94 26.56 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.63 0 CA-C-N 116.063 -0.517 . . . . 43.43 111.622 -174.044 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 34.6 tt0 -108.82 104.74 14.07 Favored 'General case' 0 C--N 1.323 -0.585 0 N-CA-C 109.471 -0.566 . . . . 75.44 109.471 174.417 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 5.9 pt-20 -90.98 108.19 19.69 Favored 'General case' 0 C--N 1.318 -0.785 0 CA-C-O 121.363 0.602 . . . . 72.44 110.639 -179.42 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -118.85 -171.4 15.03 Favored Glycine 0 N--CA 1.445 -0.72 0 CA-C-N 115.428 -0.805 . . . . 63.32 111.888 -178.856 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 10.7 mm100 -78.62 77.9 5.09 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 121.33 0.586 . . . . 62.01 110.621 -177.573 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 4.6 ptp85 170.75 -26.49 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 114.534 -1.212 . . . . 62.44 108.973 -178.954 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 139.32 -170.23 24.21 Favored Glycine 0 N--CA 1.443 -0.857 0 N-CA-C 110.812 -0.915 . . . . 71.23 110.812 -179.673 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 72.3 Cg_endo -78.56 111.44 3.0 Favored 'Trans proline' 0 N--CA 1.455 -0.742 0 C-N-CA 122.077 1.851 . . . . 70.5 111.77 177.264 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 59' ' ' GLN . . . . . 0.485 ' HA ' ' O ' ' A' ' 27' ' ' PHE . 15.0 pt20 -104.34 135.77 45.17 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-O 121.137 0.494 . . . . 71.15 109.881 176.009 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 60' ' ' ALA . . . . . 0.485 ' HB3' ' HB ' ' A' ' 28' ' ' VAL . . . -90.09 123.5 34.0 Favored 'General case' 0 C--N 1.321 -0.669 0 CA-C-N 115.879 -0.6 . . . . 53.4 111.457 -173.995 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 61' ' ' ALA . . . . . 0.476 ' HA ' ' HB1' ' A' ' 32' ' ' ALA . . . -124.09 150.5 44.95 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-N 115.463 -0.79 . . . . 63.32 108.878 175.373 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 30.8 m-80 56.45 74.06 0.41 Allowed 'General case' 0 C--N 1.329 -0.301 0 N-CA-C 109.313 -0.625 . . . . 72.31 109.313 -176.155 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.501 ' HB ' HG23 ' A' ' 33' ' ' ILE . 40.5 t -105.37 103.5 15.46 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.599 0 CA-C-N 115.786 -0.643 . . . . 71.43 110.858 -175.304 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 69.5 mt-30 -111.64 129.96 55.92 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 116.193 -0.458 . . . . 72.24 109.774 179.29 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 65' ' ' LYS . . . . . 0.505 ' HA ' HG12 ' A' ' 47' ' ' VAL . 18.2 pttp -62.75 153.51 32.5 Favored 'General case' 0 C--N 1.327 -0.386 0 N-CA-C 110.294 -0.261 . . . . 73.23 110.294 -178.495 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 0.992 0 CA-C-O 118.193 -0.908 . . . . 72.34 109.802 176.261 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 2' ' ' GLU . . . . . 0.541 ' HB2' ' O ' ' A' ' 49' ' ' PHE . 1.7 mp0 . . . . . 0 C--O 1.234 0.247 0 CA-C-O 121.325 0.583 . . . . 75.12 111.114 . . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 3' ' ' GLN . . . . . 0.681 ' HG2' HG22 ' A' ' 48' ' ' THR . 47.8 mt-30 -106.82 120.1 41.12 Favored 'General case' 0 C--N 1.32 -0.711 0 CA-C-N 115.702 -0.681 . . . . 73.13 109.619 178.086 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -143.81 -164.26 10.29 Favored Glycine 0 N--CA 1.447 -0.57 0 C-N-CA 120.611 -0.804 . . . . 62.22 112.303 -176.706 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 5' ' ' THR . . . . . 0.509 ' O ' ' HG2' ' A' ' 19' ' ' GLU . 42.7 m -139.76 134.64 32.13 Favored 'General case' 0 C--N 1.319 -0.746 0 CA-C-O 120.674 0.273 . . . . 65.23 110.589 -178.879 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.403 HG21 ' HB3' ' A' ' 41' ' ' LEU . 47.4 t -68.58 135.63 28.03 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.487 0 CA-C-O 120.773 0.32 . . . . 63.21 110.343 -179.774 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 7' ' ' LYS . . . . . 0.47 ' HE3' ' HA ' ' A' ' 7' ' ' LYS . 0.0 OUTLIER -108.13 -72.69 0.71 Allowed 'General case' 0 C--N 1.324 -0.518 0 CA-C-O 120.966 0.412 . . . . 71.03 110.723 177.632 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 8' ' ' TRP . . . . . . . . . . . . . 46.0 m95 -127.43 125.99 41.58 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 116.082 -0.508 . . . . 75.03 110.134 -176.499 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 4.6 p90 -112.92 93.95 4.67 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-O 121.67 0.748 . . . . 73.24 110.861 179.866 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 66.2 t30 -92.93 59.33 3.15 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-O 121.892 0.853 . . . . 72.14 109.11 -179.738 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -68.83 -15.12 63.41 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 114.751 -1.113 . . . . 62.02 112.115 -173.067 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 20.5 mt-10 -74.32 -26.79 60.37 Favored 'General case' 0 C--N 1.326 -0.44 0 C-N-CA 120.713 -0.395 . . . . 74.12 110.693 178.205 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 3.8 mmmp? -97.03 -26.48 14.99 Favored 'General case' 0 C--N 1.328 -0.352 0 N-CA-C 109.68 -0.489 . . . . 73.11 109.68 175.064 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 115.82 23.79 4.2 Favored Glycine 0 N--CA 1.449 -0.488 0 C-N-CA 120.306 -0.95 . . . . 61.5 114.265 169.937 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 55.9 p90 -151.08 162.63 40.48 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 117.576 0.688 . . . . 72.01 111.455 179.897 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -153.93 171.18 32.6 Favored Glycine 0 N--CA 1.444 -0.788 0 C-N-CA 120.998 -0.62 . . . . 64.41 111.771 178.299 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 94.9 m-85 -125.69 121.71 34.25 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-O 120.914 0.388 . . . . 72.52 110.965 -178.604 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 59.6 mt -114.7 127.63 72.13 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.574 0 N-CA-C 108.752 -0.832 . . . . 70.25 108.752 174.484 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 19' ' ' GLU . . . . . 0.509 ' HG2' ' O ' ' A' ' 5' ' ' THR . 17.1 pt-20 -86.66 137.19 32.67 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-O 121.517 0.675 . . . . 72.13 112.294 -171.074 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 20' ' ' ARG . . . . . 0.797 ' HB3' ' HB2' ' A' ' 24' ' ' ASP . 10.3 tpt180 -100.41 169.31 9.19 Favored 'General case' 0 C--N 1.325 -0.485 0 N-CA-C 108.215 -1.031 . . . . 71.44 108.215 169.769 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 44.2 mt-10 -58.44 -22.81 55.7 Favored 'General case' 0 CA--C 1.538 0.506 0 N-CA-C 114.029 1.122 . . . . 71.41 114.029 -171.54 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 7.3 m-80 -94.81 3.09 55.42 Favored 'General case' 0 N--CA 1.467 0.421 0 CA-C-O 120.964 0.411 . . . . 73.42 110.43 -179.333 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 92.97 8.61 61.61 Favored Glycine 0 N--CA 1.45 -0.414 0 N-CA-C 111.131 -0.788 . . . . 71.25 111.131 -174.242 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 24' ' ' ASP . . . . . 0.797 ' HB2' ' HB3' ' A' ' 20' ' ' ARG . 1.6 m-20 -61.06 97.45 0.06 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.193 -0.503 . . . . 74.45 110.168 -178.84 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 40.3 m-20 -67.55 98.53 0.68 Allowed 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 116.264 -0.425 . . . . 72.44 110.0 173.669 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 26.4 t -79.19 128.16 38.68 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.665 0 CA-C-N 116.069 -0.514 . . . . 74.33 109.69 178.595 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 27' ' ' PHE . . . . . . . . . . . . . 17.7 t80 -84.48 108.24 17.16 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 115.957 -0.565 . . . . 73.51 110.437 -173.062 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.504 ' HB ' ' HB3' ' A' ' 60' ' ' ALA . 12.2 p -101.62 151.34 5.64 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.487 0 CA-C-O 121.141 0.496 . . . . 72.23 110.828 -178.545 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 29' ' ' HIS . . . . . 0.472 ' O ' HG13 ' A' ' 33' ' ' ILE . 17.8 m170 -118.09 149.53 40.86 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.798 -0.637 . . . . 60.31 109.422 176.697 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 30' ' ' PHE . . . . . 0.504 ' HA ' HD12 ' A' ' 33' ' ' ILE . 49.3 p90 -68.58 -23.31 64.47 Favored 'General case' 0 N--CA 1.463 0.22 0 CA-C-O 120.955 0.407 . . . . 75.14 110.471 -177.363 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 23.0 t -71.86 -25.14 61.83 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 115.864 -0.607 . . . . 75.25 110.063 176.682 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 32' ' ' ALA . . . . . 0.48 ' HB1' ' HA ' ' A' ' 61' ' ' ALA . . . -92.13 -19.99 21.71 Favored 'General case' 0 C--O 1.235 0.302 0 CA-C-N 115.964 -0.562 . . . . 64.41 110.863 -179.656 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.504 HD12 ' HA ' ' A' ' 30' ' ' PHE . 77.3 mt -65.42 116.4 4.61 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 CA-C-N 116.156 -0.474 . . . . 74.11 110.114 176.567 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 4.7 pp0? . . . . . 0 C--N 1.328 -0.366 0 CA-C-N 116.184 -0.462 . . . . 72.53 111.246 -176.531 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 47.3 m . . . . . 0 N--CA 1.453 -0.286 0 CA-C-O 120.804 0.335 . . . . 72.33 110.608 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 41' ' ' LEU . . . . . 0.403 ' HB3' HG21 ' A' ' 6' ' ' VAL . 94.7 mt -124.2 121.24 34.56 Favored 'General case' 0 C--N 1.325 -0.468 0 N-CA-C 108.908 -0.775 . . . . 64.11 108.908 175.825 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 12.1 m-20 -64.19 127.39 31.23 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-O 121.351 0.596 . . . . 62.15 111.495 -175.924 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 6.2 pt-20 -63.04 119.57 9.74 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 115.226 -0.897 . . . . 60.13 111.12 179.98 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 100.66 -5.49 56.87 Favored Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.705 -0.76 . . . . 54.14 112.667 179.167 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 59.2 tp60 -80.98 133.9 35.59 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 120.615 0.245 . . . . 74.52 110.489 -178.778 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -77.15 130.81 37.82 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.352 -0.386 . . . . 71.24 110.022 175.221 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 0.437 HG12 ' HA ' ' A' ' 65' ' ' LYS . 17.5 m -135.19 153.56 34.28 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.492 0 CA-C-O 121.025 0.441 . . . . 75.3 111.289 -176.05 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 48' ' ' THR . . . . . 0.681 HG22 ' HG2' ' A' ' 3' ' ' GLN . 46.3 p -114.18 107.75 16.04 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-N 115.582 -0.735 . . . . 62.03 109.223 175.719 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 49' ' ' PHE . . . . . 0.561 ' HA ' ' O ' ' A' ' 62' ' ' ASN . 37.0 p90 -119.53 167.38 12.03 Favored 'General case' 0 C--N 1.315 -0.899 0 CA-C-N 115.847 -0.615 . . . . 74.1 110.412 -173.515 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 38.7 t70 -107.04 129.21 54.84 Favored 'General case' 0 C--N 1.316 -0.85 0 C-N-CA 120.777 -0.369 . . . . 75.23 110.305 176.016 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 51' ' ' VAL . . . . . 0.461 ' HB ' ' HG2' ' A' ' 2' ' ' GLU . 7.3 p -77.26 120.8 28.4 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 CA-C-O 121.533 0.682 . . . . 63.55 111.388 -176.976 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -110.37 157.89 19.04 Favored 'General case' 0 C--N 1.323 -0.581 0 N-CA-C 108.721 -0.844 . . . . 70.03 108.721 179.541 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 1.3 mm-40 -95.78 110.32 22.49 Favored 'General case' 0 C--N 1.319 -0.725 0 CA-C-O 121.03 0.443 . . . . 61.14 110.835 -178.319 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -99.56 157.16 19.85 Favored Glycine 0 N--CA 1.443 -0.892 0 N-CA-C 111.139 -0.785 . . . . 63.54 111.139 177.033 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 78.5 mt-30 -77.7 7.07 6.19 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 117.014 0.407 . . . . 75.53 111.69 -178.276 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 99.1 mtt180 -127.79 10.28 6.52 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 120.922 0.392 . . . . 75.21 110.023 175.313 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 129.29 176.89 14.61 Favored Glycine 0 N--CA 1.446 -0.634 0 C-N-CA 120.854 -0.688 . . . . 62.24 111.713 -177.412 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 18.3 Cg_endo -60.1 124.45 15.27 Favored 'Trans proline' 0 C--O 1.235 0.349 0 C-N-CA 122.827 2.351 . . . . 74.21 112.067 179.471 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 6.8 tt0 -104.45 144.35 31.78 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 115.682 -0.69 . . . . 72.51 110.101 -177.003 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 60' ' ' ALA . . . . . 0.504 ' HB3' ' HB ' ' A' ' 28' ' ' VAL . . . -91.43 106.81 18.76 Favored 'General case' 0 C--N 1.32 -0.696 0 CA-C-O 120.89 0.376 . . . . 63.13 110.81 178.585 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 61' ' ' ALA . . . . . 0.48 ' HA ' ' HB1' ' A' ' 32' ' ' ALA . . . -117.18 164.38 14.86 Favored 'General case' 0 C--N 1.32 -0.687 0 N-CA-C 108.769 -0.826 . . . . 74.24 108.769 176.31 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 62' ' ' ASN . . . . . 0.561 ' O ' ' HA ' ' A' ' 49' ' ' PHE . 85.0 m-20 47.89 66.41 1.05 Allowed 'General case' 0 N--CA 1.465 0.289 0 CA-C-O 120.83 0.347 . . . . 75.45 110.304 -177.766 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 29.4 t -93.93 89.3 2.56 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 CA-C-N 116.09 -0.505 . . . . 73.15 110.636 -176.66 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 19.9 mt-30 -82.35 129.66 34.92 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 115.866 -0.606 . . . . 64.42 110.479 -179.47 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 65' ' ' LYS . . . . . 0.437 ' HA ' HG12 ' A' ' 47' ' ' VAL . 50.7 mtmt -81.83 137.84 35.2 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 116.532 -0.303 . . . . 74.0 110.262 178.989 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.251 1.133 0 CA-C-O 118.289 -0.862 . . . . 54.04 110.157 178.325 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 40.6 mt-10 . . . . . 0 N--CA 1.452 -0.361 0 CA-C-O 120.735 0.302 . . . . 74.4 110.266 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 35.1 tt0 -91.57 123.77 35.23 Favored 'General case' 0 C--N 1.322 -0.595 0 N-CA-C 109.48 -0.563 . . . . 72.03 109.48 177.759 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 4' ' ' GLY . . . . . 0.545 ' HA3' ' HE2' ' A' ' 49' ' ' PHE . . . -138.88 152.65 22.29 Favored Glycine 0 N--CA 1.444 -0.788 0 C-N-CA 120.818 -0.706 . . . . 74.54 111.829 -178.903 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 5' ' ' THR . . . . . 0.425 ' HA ' ' HA ' ' A' ' 46' ' ' ALA . 9.6 m -85.57 131.05 34.43 Favored 'General case' 0 C--N 1.318 -0.761 0 CA-C-O 120.635 0.255 . . . . 65.41 110.908 -177.855 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 60.6 t -65.78 115.86 4.37 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 N-CA-C 109.507 -0.553 . . . . 64.21 109.507 174.761 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 9.3 mmmm -86.12 -62.08 1.6 Allowed 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 115.943 -0.571 . . . . 64.5 109.976 -178.493 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 8' ' ' TRP . . . . . . . . . . . . . 94.4 m95 -141.78 135.08 29.34 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 116.012 -0.54 . . . . 73.35 110.08 -179.638 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 62.7 t80 -118.93 98.4 6.17 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-O 121.217 0.532 . . . . 63.12 109.707 178.12 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 43.4 t30 -82.12 81.84 7.9 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-O 121.556 0.693 . . . . 72.41 110.262 -177.635 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -70.89 -10.4 59.56 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.103 -0.953 . . . . 72.44 111.143 179.732 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 31.2 mm-40 -69.77 -16.39 63.29 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.086 -0.507 . . . . 63.44 110.266 177.447 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 13' ' ' LYS . . . . . 0.585 ' HE3' ' HA ' ' A' ' 13' ' ' LYS . 0.0 OUTLIER -130.01 -35.17 1.63 Allowed 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.132 -0.486 . . . . 64.41 111.263 179.564 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 111.25 28.51 3.79 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.648 -0.787 . . . . 75.52 112.907 178.206 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 31.3 p90 -148.03 176.23 10.35 Favored 'General case' 0 C--N 1.323 -0.561 0 O-C-N 122.493 -0.416 . . . . 74.4 109.965 177.641 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -174.79 -168.43 35.46 Favored Glycine 0 N--CA 1.445 -0.733 0 C-N-CA 120.292 -0.956 . . . . 73.22 112.27 -179.974 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 17' ' ' PHE . . . . . 0.5 ' HB3' ' HB3' ' A' ' 25' ' ' ASP . 88.0 m-85 -127.47 124.42 38.32 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-O 120.949 0.404 . . . . 64.42 110.504 -178.166 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 40.2 mt -121.72 117.81 53.71 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.663 0 N-CA-C 108.38 -0.97 . . . . 73.45 108.38 175.063 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 19' ' ' GLU . . . . . 0.642 ' HA ' ' HA ' ' A' ' 25' ' ' ASP . 6.7 pt-20 -78.11 137.67 38.33 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-O 121.64 0.733 . . . . 60.21 112.449 -168.543 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 20' ' ' ARG . . . . . 0.593 ' HB3' ' HB3' ' A' ' 24' ' ' ASP . 62.7 ttt180 -80.3 164.02 23.5 Favored 'General case' 0 C--N 1.32 -0.688 0 N-CA-C 107.691 -1.226 . . . . 73.11 107.691 168.129 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 43.4 mt-10 -63.53 -12.51 32.92 Favored 'General case' 0 N--CA 1.468 0.466 0 N-CA-C 112.53 0.567 . . . . 72.23 112.53 -173.718 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 10.4 m120 -87.29 3.64 45.95 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-O 120.901 0.382 . . . . 72.04 110.774 178.637 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 85.46 2.39 87.35 Favored Glycine 0 N--CA 1.452 -0.271 0 N-CA-C 110.752 -0.939 . . . . 72.32 110.752 -173.164 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 24' ' ' ASP . . . . . 0.593 ' HB3' ' HB3' ' A' ' 20' ' ' ARG . 38.3 t70 -75.32 90.51 2.64 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 114.551 -0.825 . . . . 74.32 110.463 -176.909 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.642 ' HA ' ' HA ' ' A' ' 19' ' ' GLU . 42.8 m-20 -60.82 104.16 0.33 Allowed 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.107 -0.497 . . . . 75.35 110.248 176.28 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.461 HG13 ' HB2' ' A' ' 58' ' ' PRO . 22.1 t -81.01 132.52 31.39 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 CA-C-N 116.016 -0.538 . . . . 63.35 110.229 -177.851 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 27' ' ' PHE . . . . . . . . . . . . . 85.7 t80 -76.64 104.28 7.06 Favored 'General case' 0 C--O 1.238 0.452 0 CA-C-O 121.134 0.492 . . . . 72.05 110.881 -177.189 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.585 ' HA ' ' HB3' ' A' ' 60' ' ' ALA . 9.6 p -88.3 145.71 7.12 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.638 0 N-CA-C 109.392 -0.595 . . . . 53.3 109.392 177.464 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 29' ' ' HIS . . . . . 0.499 ' O ' HG13 ' A' ' 33' ' ' ILE . 13.4 p80 -142.05 143.73 33.25 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 116.563 -0.29 . . . . 73.42 110.997 -173.64 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 52.1 p90 -58.14 -23.37 54.89 Favored 'General case' 0 N--CA 1.469 0.488 0 N-CA-C 113.03 0.752 . . . . 74.1 113.03 -172.838 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 2.7 p -77.57 -0.05 24.86 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-O 121.0 0.429 . . . . 55.03 111.576 -179.355 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -126.26 -24.9 3.6 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.149 -0.478 . . . . 75.34 110.689 175.337 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.499 HG13 ' O ' ' A' ' 29' ' ' HIS . 64.1 mt -68.95 118.47 13.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.293 -0.412 . . . . 72.32 110.872 179.686 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 2.5 pp0? . . . . . 0 C--N 1.324 -0.503 0 CA-C-O 121.58 0.705 . . . . 75.44 109.508 172.798 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 39.6 m . . . . . 0 N--CA 1.45 -0.458 0 CA-C-O 120.924 0.392 . . . . 75.01 111.122 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 9.9 mp -94.02 131.76 39.19 Favored 'General case' 0 C--N 1.324 -0.532 0 N-CA-C 108.891 -0.781 . . . . 60.21 108.891 174.39 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 21.3 m-20 -96.82 128.1 43.44 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-O 120.775 0.321 . . . . 70.5 110.388 -173.858 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 2.0 pp20? -61.92 143.19 56.82 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 116.063 -0.517 . . . . 70.54 110.737 -179.047 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 99.11 -22.72 39.51 Favored Glycine 0 N--CA 1.447 -0.568 0 C-N-CA 120.74 -0.743 . . . . 53.32 111.847 -175.525 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 45' ' ' GLN . . . . . 0.456 ' HA ' ' OE1' ' A' ' 45' ' ' GLN . 6.1 tp60 -87.95 140.36 29.58 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.713 0.292 . . . . 74.4 110.315 178.334 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 0.425 ' HA ' ' HA ' ' A' ' 5' ' ' THR . . . -102.93 125.44 49.69 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-N 116.476 -0.329 . . . . 35.33 110.818 -179.869 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 30.7 m -118.2 171.51 6.43 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.561 0 CA-C-N 116.315 -0.402 . . . . 73.3 110.467 178.64 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 21.6 p -107.39 112.79 25.76 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-O 121.218 0.532 . . . . 74.11 110.954 -179.899 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 49' ' ' PHE . . . . . 0.545 ' HE2' ' HA3' ' A' ' 4' ' ' GLY . 41.5 p90 -121.89 161.16 23.29 Favored 'General case' 0 C--N 1.317 -0.833 0 CA-C-N 115.619 -0.719 . . . . 74.34 109.851 -178.219 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 19.7 t70 -109.06 128.29 54.85 Favored 'General case' 0 C--N 1.316 -0.875 0 CA-C-O 120.99 0.424 . . . . 54.2 110.311 174.128 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 98.9 t -77.22 104.8 5.46 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 CA-C-O 121.108 0.48 . . . . 71.34 110.878 -177.873 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -87.15 145.89 26.24 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 115.409 -0.814 . . . . 71.23 109.19 179.523 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 70.9 mm-40 -84.25 98.2 9.84 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-N 116.153 -0.476 . . . . 75.53 111.368 -175.641 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -81.39 164.77 45.88 Favored Glycine 0 N--CA 1.446 -0.69 0 C-N-CA 120.837 -0.697 . . . . 64.24 111.546 176.65 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 26.8 pt20 -69.32 -23.63 63.82 Favored 'General case' 0 C--N 1.324 -0.508 0 N-CA-C 112.207 0.447 . . . . 74.21 112.207 -175.664 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 9.5 ptm180 -132.1 16.57 4.61 Favored 'General case' 0 C--N 1.328 -0.346 0 C-N-CA 120.326 -0.55 . . . . 73.41 112.033 -179.26 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 157.69 -178.18 34.13 Favored Glycine 0 N--CA 1.449 -0.444 0 C-N-CA 120.018 -1.087 . . . . 63.24 112.702 179.282 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 58' ' ' PRO . . . . . 0.461 ' HB2' HG13 ' A' ' 26' ' ' VAL . 73.4 Cg_endo -75.56 128.59 11.17 Favored 'Trans proline' 0 C--O 1.235 0.341 0 C-N-CA 122.834 2.356 . . . . 33.13 112.89 -177.738 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 90.5 mt-30 -112.61 135.32 53.47 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 115.965 -0.561 . . . . 70.52 109.92 176.665 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 60' ' ' ALA . . . . . 0.585 ' HB3' ' HA ' ' A' ' 28' ' ' VAL . . . -85.21 105.19 15.72 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-O 120.899 0.381 . . . . 75.44 111.037 -178.931 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -115.29 168.78 9.66 Favored 'General case' 0 C--N 1.319 -0.722 0 N-CA-C 108.615 -0.883 . . . . 71.43 108.615 174.931 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 62' ' ' ASN . . . . . 0.516 ' O ' ' HA ' ' A' ' 49' ' ' PHE . 87.1 m-20 51.03 75.5 0.19 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.981 0.42 . . . . 55.23 109.958 -175.714 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 22.0 t -98.83 93.25 3.06 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 CA-C-N 115.969 -0.559 . . . . 43.23 109.526 -177.285 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 40.4 mt-30 -98.12 148.78 23.2 Favored 'General case' 0 C--N 1.32 -0.705 0 CA-C-N 115.923 -0.581 . . . . 75.01 110.567 -175.96 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 94.9 mttt -76.86 129.12 35.78 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 115.871 -0.604 . . . . 73.2 110.439 -179.795 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.077 0 CA-C-O 118.366 -0.826 . . . . 75.41 109.457 175.856 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 4.4 mp0 . . . . . 0 C--O 1.233 0.211 0 CA-C-O 121.029 0.442 . . . . 73.51 111.151 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 3' ' ' GLN . . . . . 0.564 ' HG2' HG22 ' A' ' 48' ' ' THR . 66.6 mt-30 -98.47 111.43 23.79 Favored 'General case' 0 C--N 1.326 -0.445 0 N-CA-C 109.037 -0.727 . . . . 73.11 109.037 173.422 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 4' ' ' GLY . . . . . 0.707 ' HA3' ' HE2' ' A' ' 49' ' ' PHE . . . -122.1 162.3 15.93 Favored Glycine 0 N--CA 1.447 -0.613 0 C-N-CA 120.101 -1.047 . . . . 71.11 112.984 -174.217 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 8.3 m -98.45 131.03 45.04 Favored 'General case' 0 C--N 1.321 -0.635 0 N-CA-C 110.033 -0.358 . . . . 64.12 110.033 177.948 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 59.7 t -70.17 118.48 14.71 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.436 0 CA-C-N 116.602 -0.272 . . . . 72.14 110.619 179.365 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 7' ' ' LYS . . . . . 1.032 ' HE2' ' HB3' ' A' ' 19' ' ' GLU . 70.7 mmtt -70.77 -72.58 0.2 Allowed 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 121.238 0.542 . . . . 73.22 109.803 176.62 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 8' ' ' TRP . . . . . 0.556 ' HA ' ' HG3' ' A' ' 43' ' ' GLU . 24.5 m-90 -143.85 127.23 16.81 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 114.939 -1.028 . . . . 74.44 109.005 178.558 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 54.3 t80 -105.82 103.08 12.51 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-O 121.243 0.544 . . . . 71.11 110.359 179.547 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 39.2 m-80 -83.9 78.46 9.72 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 115.785 -0.643 . . . . 75.45 110.104 -179.666 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -59.61 -30.86 68.99 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.025 -0.534 . . . . 75.41 110.59 178.029 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 24.7 mt-10 -64.61 -38.91 92.64 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.401 -0.818 . . . . 73.22 110.616 178.158 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 48.7 mmtm -90.6 -24.44 20.55 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.683 -0.69 . . . . 65.05 110.691 -174.201 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 96.15 18.62 30.87 Favored Glycine 0 N--CA 1.445 -0.738 0 C-N-CA 120.806 -0.711 . . . . 54.4 112.845 177.608 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 46.7 p90 -156.83 163.72 38.88 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 117.074 0.437 . . . . 74.32 110.803 179.855 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -148.95 177.12 27.4 Favored Glycine 0 N--CA 1.445 -0.703 0 C-N-CA 120.813 -0.708 . . . . 73.34 111.983 179.289 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 96.8 m-85 -123.98 131.15 53.52 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 120.76 0.314 . . . . 75.54 110.307 177.949 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.446 HD13 HG21 ' A' ' 47' ' ' VAL . 33.0 mt -122.88 146.61 27.9 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.695 0 N-CA-C 109.115 -0.698 . . . . 72.22 109.115 178.149 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 19' ' ' GLU . . . . . 1.032 ' HB3' ' HE2' ' A' ' 7' ' ' LYS . 12.9 pt-20 -99.79 129.23 45.88 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-O 121.351 0.596 . . . . 71.02 111.785 -178.52 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 20' ' ' ARG . . . . . 0.436 ' HG2' ' N ' ' A' ' 21' ' ' GLU . 27.9 ttm180 -98.3 153.81 18.26 Favored 'General case' 0 C--N 1.322 -0.609 0 N-CA-C 108.381 -0.97 . . . . 50.23 108.381 170.727 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 21' ' ' GLU . . . . . 0.436 ' N ' ' HG2' ' A' ' 20' ' ' ARG . 43.9 mt-10 -52.02 -34.44 42.96 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 121.047 0.451 . . . . 61.43 110.491 177.61 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 8.5 t-20 -123.9 58.58 1.16 Allowed 'General case' 0 N--CA 1.453 -0.311 0 CA-C-N 115.85 -0.613 . . . . 75.23 109.41 175.358 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 164.65 78.88 0.04 OUTLIER Glycine 0 N--CA 1.45 -0.369 0 N-CA-C 111.217 -0.753 . . . . 40.13 111.217 179.543 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 30.6 t70 -65.71 -2.84 3.97 Favored 'General case' 0 C--N 1.326 -0.445 0 N-CA-C 112.606 0.595 . . . . 64.14 112.606 -169.51 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 10.2 p-10 -144.73 93.67 2.44 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-O 121.813 0.816 . . . . 71.01 111.854 -178.575 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 38.9 t -104.12 128.74 57.26 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.492 0 CA-C-N 115.525 -0.761 . . . . 73.23 109.628 174.579 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 27' ' ' PHE . . . . . . . . . . . . . 42.7 t80 -83.61 106.52 15.4 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-O 120.716 0.293 . . . . 65.44 110.326 -177.28 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.586 HG23 HG21 ' A' ' 63' ' ' VAL . 12.5 p -99.38 143.9 12.81 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 CA-C-O 121.149 0.5 . . . . 71.11 111.354 -176.248 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 54.2 m80 -97.27 133.78 41.43 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.543 -0.753 . . . . 75.0 109.996 177.871 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 6.1 p90 -63.95 -26.46 68.6 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.803 0.335 . . . . 75.32 111.105 -176.837 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 28.2 t -89.57 -14.35 35.26 Favored 'General case' 0 CA--C 1.533 0.291 0 CA-C-N 116.355 -0.384 . . . . 73.13 110.436 179.689 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -83.22 -23.09 32.94 Favored 'General case' 0 C--O 1.233 0.224 0 CA-C-O 121.383 0.611 . . . . 63.12 109.9 178.117 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.541 ' HA ' ' HB ' ' A' ' 63' ' ' VAL . 53.1 mt -76.31 138.37 20.83 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.497 0 CA-C-N 115.542 -0.754 . . . . 72.35 109.51 172.113 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 34' ' ' GLN . . . . . 0.408 ' OE1' ' HG3' ' A' ' 65' ' ' LYS . 0.3 OUTLIER . . . . . 0 C--N 1.329 -0.287 0 CA-C-O 121.397 0.618 . . . . 73.42 111.554 176.946 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 13.0 m . . . . . 0 N--CA 1.451 -0.397 0 CA-C-O 120.819 0.343 . . . . 71.13 110.368 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 41' ' ' LEU . . . . . 0.529 HD21 HG21 ' A' ' 33' ' ' ILE . 3.7 mm? -74.96 107.69 7.2 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 116.298 -0.41 . . . . 73.2 110.215 178.606 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 32.5 t70 -58.98 135.08 57.5 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.76 -0.655 . . . . 73.15 111.267 -177.549 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 43' ' ' GLU . . . . . 0.556 ' HG3' ' HA ' ' A' ' 8' ' ' TRP . 17.9 mp0 -53.93 124.72 16.27 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 115.957 -0.565 . . . . 74.4 110.619 177.809 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 99.35 -0.68 57.11 Favored Glycine 0 N--CA 1.449 -0.481 0 C-N-CA 120.627 -0.796 . . . . 42.43 112.804 -179.908 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 58.7 tp60 -83.43 149.97 26.34 Favored 'General case' 0 C--N 1.325 -0.495 0 N-CA-C 109.918 -0.401 . . . . 70.35 109.918 178.423 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -90.8 140.49 29.74 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-N 116.554 -0.294 . . . . 75.31 110.246 177.21 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 0.446 HG21 HD13 ' A' ' 18' ' ' ILE . 16.0 m -139.0 153.59 25.01 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 CA-C-O 120.913 0.387 . . . . 72.24 110.396 177.579 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 48' ' ' THR . . . . . 0.659 HG23 ' HB2' ' A' ' 66' ' ' ALA . 34.4 p -106.47 101.88 11.31 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-O 121.323 0.582 . . . . 75.12 110.121 178.275 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 49' ' ' PHE . . . . . 0.707 ' HE2' ' HA3' ' A' ' 4' ' ' GLY . 42.1 p90 -111.55 147.47 35.33 Favored 'General case' 0 C--N 1.317 -0.821 0 CA-C-N 115.609 -0.723 . . . . 74.13 110.666 -174.455 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 36.2 t0 -101.92 160.96 14.04 Favored 'General case' 0 C--N 1.316 -0.855 0 C-N-CA 120.357 -0.537 . . . . 73.5 109.706 172.279 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 67.4 t -109.66 119.37 58.77 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.701 0 CA-C-O 120.922 0.392 . . . . 62.54 111.459 -172.822 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 27.6 tt0 -111.11 111.31 22.3 Favored 'General case' 0 C--N 1.321 -0.642 0 N-CA-C 109.094 -0.706 . . . . 73.21 109.094 173.338 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 26.9 mt-10 -69.59 137.08 52.02 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-O 121.203 0.525 . . . . 72.13 112.091 -177.709 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -118.9 -158.04 10.6 Favored Glycine 0 N--CA 1.441 -1.026 0 N-CA-C 110.001 -1.239 . . . . 74.42 110.001 170.844 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 50.0 tt0 -99.43 -25.6 14.41 Favored 'General case' 0 C--N 1.319 -0.752 0 CA-C-N 117.162 0.481 . . . . 72.24 110.498 179.728 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 10.9 mmm180 -97.64 -5.23 35.86 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 116.292 -0.413 . . . . 65.13 111.191 178.561 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 151.39 -179.61 27.89 Favored Glycine 0 N--CA 1.444 -0.795 0 C-N-CA 120.62 -0.8 . . . . 63.34 112.311 178.527 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 8.9 Cg_endo -87.41 119.02 1.37 Allowed 'Trans proline' 0 N--CA 1.45 -1.057 0 C-N-CA 123.235 2.623 . . . . 74.1 112.18 178.931 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 15.8 pt20 -95.39 133.91 38.8 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-N 116.098 -0.501 . . . . 75.2 109.852 177.654 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 60' ' ' ALA . . . . . 0.572 ' HB3' ' HA ' ' A' ' 28' ' ' VAL . . . -76.27 112.13 12.43 Favored 'General case' 0 C--N 1.321 -0.645 0 CA-C-N 116.128 -0.487 . . . . 40.34 110.76 -178.885 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -112.91 153.3 28.18 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 115.493 -0.776 . . . . 54.12 109.011 176.583 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 95.1 m-20 52.48 77.3 0.16 Allowed 'General case' 0 C--O 1.235 0.341 0 CA-C-O 121.279 0.561 . . . . 64.33 110.337 -175.426 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.586 HG21 HG23 ' A' ' 28' ' ' VAL . 36.9 t -109.59 107.16 22.19 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 CA-C-N 115.686 -0.688 . . . . 72.1 110.174 -179.67 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 64' ' ' GLN . . . . . 0.516 ' HB2' ' OG1' ' A' ' 48' ' ' THR . 15.3 mt-30 -99.41 178.54 4.85 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 115.434 -0.803 . . . . 75.11 110.163 -177.154 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 65' ' ' LYS . . . . . 0.408 ' HG3' ' OE1' ' A' ' 34' ' ' GLN . 56.0 mttp -89.05 149.47 23.21 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-O 120.733 0.301 . . . . 52.3 110.588 -178.494 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 66' ' ' ALA . . . . . 0.659 ' HB2' HG23 ' A' ' 48' ' ' THR . . . . . . . . 0 C--O 1.251 1.165 0 CA-C-O 117.974 -1.012 . . . . 73.13 109.615 177.304 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 1.4 mp0 . . . . . 0 C--O 1.235 0.336 0 CA-C-O 121.051 0.453 . . . . 73.43 111.235 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 3' ' ' GLN . . . . . 0.504 ' HB3' HG22 ' A' ' 48' ' ' THR . 0.9 OUTLIER -93.54 127.34 39.16 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 115.725 -0.671 . . . . 53.51 109.83 173.485 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -136.74 160.3 24.8 Favored Glycine 0 N--CA 1.445 -0.709 0 C-N-CA 120.887 -0.673 . . . . 55.32 111.566 -179.853 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -96.48 133.35 41.04 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-O 121.266 0.555 . . . . 72.24 111.421 -179.336 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 45.6 t -68.81 116.06 8.54 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.556 0 CA-C-N 115.824 -0.625 . . . . 71.11 110.034 177.759 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 7' ' ' LYS . . . . . 0.832 ' HE3' ' HA ' ' A' ' 7' ' ' LYS . 0.1 OUTLIER -83.04 -62.59 1.55 Allowed 'General case' 0 C--N 1.324 -0.507 0 CA-C-O 121.24 0.543 . . . . 73.03 109.705 -178.827 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 8' ' ' TRP . . . . . . . . . . . . . 99.5 m95 -126.72 146.94 50.03 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 115.365 -0.834 . . . . 70.14 109.727 -179.963 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 9' ' ' PHE . . . . . 0.52 ' CE2' ' HA ' ' A' ' 40' ' ' SER . 68.1 t80 -140.21 98.05 3.36 Favored 'General case' 0 C--N 1.318 -0.773 0 CA-C-O 121.093 0.473 . . . . 75.2 110.432 176.356 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 91.4 m-20 -82.2 82.57 7.69 Favored 'General case' 0 C--N 1.323 -0.57 0 N-CA-C 109.285 -0.635 . . . . 74.52 109.285 178.813 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -59.08 -33.74 71.16 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.574 -0.739 . . . . 71.14 111.297 -178.476 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 36.7 mt-10 -70.1 -26.22 63.87 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 116.066 -0.515 . . . . 72.2 110.892 -178.733 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 47.9 mmtm -91.44 -29.72 16.88 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.188 -0.46 . . . . 54.31 110.179 175.999 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 90.99 17.4 51.5 Favored Glycine 0 N--CA 1.447 -0.623 0 CA-C-N 115.853 -0.612 . . . . 64.44 111.655 -178.895 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 74.3 m-85 -138.15 144.46 40.77 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-O 120.864 0.364 . . . . 73.45 110.489 -176.568 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -131.16 168.64 21.98 Favored Glycine 0 N--CA 1.444 -0.787 0 C-N-CA 120.438 -0.887 . . . . 73.01 112.109 -178.621 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 17' ' ' PHE . . . . . 0.453 ' HA ' ' O ' ' A' ' 26' ' ' VAL . 76.6 m-85 -127.47 118.9 24.92 Favored 'General case' 0 C--N 1.322 -0.603 0 N-CA-C 109.757 -0.46 . . . . 74.04 109.757 -179.972 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.431 HG21 ' CE2' ' A' ' 49' ' ' PHE . 63.5 mt -109.05 141.82 23.28 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.659 0 CA-C-N 115.992 -0.549 . . . . 71.53 110.402 -177.526 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 19' ' ' GLU . . . . . 0.63 ' OE1' ' HG2' ' A' ' 7' ' ' LYS . 7.9 pt-20 -92.87 101.42 13.79 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 121.377 0.608 . . . . 72.34 110.476 178.372 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 20' ' ' ARG . . . . . 0.613 ' HG2' ' OE1' ' A' ' 21' ' ' GLU . 12.4 ttp180 -96.41 158.48 15.42 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 115.854 -0.612 . . . . 74.21 109.544 -179.503 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 21' ' ' GLU . . . . . 0.613 ' OE1' ' HG2' ' A' ' 20' ' ' ARG . 0.0 OUTLIER -57.29 -38.02 73.33 Favored 'General case' 0 N--CA 1.466 0.326 0 N-CA-C 112.155 0.428 . . . . 53.3 112.155 -177.931 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 41.3 m-80 -115.3 36.6 3.85 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-O 120.991 0.424 . . . . 72.34 110.181 174.949 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -170.38 82.19 0.09 OUTLIER Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.624 -0.798 . . . . 75.15 112.444 179.846 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 37.4 t70 -63.71 -2.98 1.97 Allowed 'General case' 0 N--CA 1.469 0.48 0 CA-C-O 121.09 0.471 . . . . 72.44 111.916 -177.039 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 17.5 t70 -152.97 88.55 1.33 Allowed 'General case' 0 C--N 1.325 -0.485 0 CA-C-O 121.105 0.479 . . . . 64.21 109.829 -179.328 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.453 ' O ' ' HA ' ' A' ' 17' ' ' PHE . 58.8 t -102.97 123.72 56.55 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 CA-C-N 116.005 -0.543 . . . . 74.4 110.43 179.374 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 27' ' ' PHE . . . . . 0.467 ' O ' ' HA ' ' A' ' 59' ' ' GLN . 62.7 t80 -85.45 102.46 13.48 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 115.612 -0.722 . . . . 72.22 110.277 -177.025 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.473 HG23 ' HB3' ' A' ' 60' ' ' ALA . 10.2 p -95.77 146.74 6.66 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.505 0 CA-C-O 120.94 0.4 . . . . 73.21 110.796 -177.453 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 17.3 m-70 -103.83 141.01 36.86 Favored 'General case' 0 C--O 1.234 0.24 0 CA-C-N 115.982 -0.554 . . . . 74.5 111.341 -175.841 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 41.2 p90 -55.91 -36.38 67.63 Favored 'General case' 0 N--CA 1.467 0.412 0 CA-C-N 115.838 -0.619 . . . . 73.12 112.177 -179.941 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 33.0 t -82.07 -10.52 59.18 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 116.707 -0.224 . . . . 63.14 111.17 -177.075 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 32' ' ' ALA . . . . . 0.54 ' HB1' ' HA ' ' A' ' 61' ' ' ALA . . . -92.81 -22.84 19.09 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 121.248 0.547 . . . . 70.34 109.99 178.829 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.546 ' HA ' ' HB ' ' A' ' 63' ' ' VAL . 67.3 mt -87.68 126.63 41.26 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.468 0 CA-C-N 115.503 -0.771 . . . . 74.23 110.318 177.012 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 34' ' ' GLN . . . . . 0.426 ' H ' ' HG3' ' A' ' 34' ' ' GLN . 2.3 pp0? . . . . . 0 C--N 1.323 -0.586 0 CA-C-O 121.502 0.668 . . . . 74.51 109.457 172.639 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 40' ' ' SER . . . . . 0.52 ' HA ' ' CE2' ' A' ' 9' ' ' PHE . 23.5 p . . . . . 0 N--CA 1.448 -0.551 0 N-CA-C 109.981 -0.378 . . . . 65.32 109.981 . . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 52.0 mt -70.64 137.29 49.78 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-O 120.996 0.427 . . . . 70.5 110.648 179.196 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 42' ' ' ASP . . . . . 0.442 ' HB3' ' HB2' ' A' ' 45' ' ' GLN . 22.7 t70 -74.64 136.93 41.94 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 115.573 -0.74 . . . . 63.45 110.638 -176.322 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 8.4 pt-20 -65.81 115.25 5.74 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-O 121.25 0.548 . . . . 75.01 110.71 178.361 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 100.86 -1.54 55.35 Favored Glycine 0 N--CA 1.446 -0.635 0 C-N-CA 120.47 -0.871 . . . . 72.03 112.109 -178.218 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 45' ' ' GLN . . . . . 0.442 ' HB2' ' HB3' ' A' ' 42' ' ' ASP . 6.0 tp-100 -74.26 133.85 42.64 Favored 'General case' 0 C--N 1.327 -0.398 0 N-CA-C 109.974 -0.38 . . . . 73.23 109.974 175.802 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -90.23 123.66 34.21 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 116.186 -0.461 . . . . 33.2 110.454 179.784 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 0.495 HG23 ' HD2' ' A' ' 49' ' ' PHE . 21.1 m -127.62 153.56 37.02 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.596 0 CA-C-N 116.008 -0.542 . . . . 73.22 110.339 178.748 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 48' ' ' THR . . . . . 0.504 HG22 ' HB3' ' A' ' 3' ' ' GLN . 63.7 p -106.96 111.23 23.63 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-O 121.261 0.553 . . . . 62.04 109.733 179.609 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 49' ' ' PHE . . . . . 0.495 ' HD2' HG23 ' A' ' 47' ' ' VAL . 29.5 p90 -128.61 160.53 32.14 Favored 'General case' 0 C--N 1.318 -0.771 0 CA-C-N 116.138 -0.483 . . . . 73.54 111.171 -172.543 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 71.0 m-20 -105.02 115.09 29.69 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 116.157 -0.474 . . . . 70.14 110.435 175.536 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 51' ' ' VAL . . . . . 0.478 HG21 ' HD3' ' A' ' 20' ' ' ARG . 65.3 t -77.43 120.71 28.48 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.599 0 CA-C-O 121.052 0.454 . . . . 73.23 110.936 -177.459 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 9.2 tp10 -99.44 125.69 45.21 Favored 'General case' 0 N--CA 1.444 -0.769 0 N-CA-C 108.984 -0.747 . . . . 70.5 108.984 175.43 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 10.0 pt-20 -88.11 141.11 28.83 Favored 'General case' 0 C--N 1.317 -0.806 0 CA-C-N 116.16 -0.473 . . . . 72.23 110.806 -175.797 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -162.64 -171.46 28.87 Favored Glycine 0 N--CA 1.446 -0.669 0 C-N-CA 120.851 -0.69 . . . . 53.41 112.081 178.706 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 34.9 tt0 -58.35 -38.57 77.48 Favored 'General case' 0 C--N 1.326 -0.444 0 C-N-CA 122.488 0.315 . . . . 72.42 111.218 179.557 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 18.0 mmm180 -75.98 4.36 8.46 Favored 'General case' 0 C--N 1.328 -0.337 0 N-CA-C 111.708 0.262 . . . . 74.34 111.708 179.999 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 93.51 -136.82 13.28 Favored Glycine 0 N--CA 1.444 -0.818 0 C-N-CA 120.942 -0.647 . . . . 75.44 112.034 178.928 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 1.8 Cg_endo -83.05 108.94 1.63 Allowed 'Trans proline' 0 N--CA 1.454 -0.832 0 C-N-CA 123.132 2.554 . . . . 54.43 112.015 -179.69 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 59' ' ' GLN . . . . . 0.467 ' HA ' ' O ' ' A' ' 27' ' ' PHE . 47.6 mt-30 -110.17 117.27 33.25 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-O 120.906 0.384 . . . . 71.42 110.081 177.827 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 60' ' ' ALA . . . . . 0.473 ' HB3' HG23 ' A' ' 28' ' ' VAL . . . -77.72 119.05 20.7 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-O 121.078 0.466 . . . . 74.03 111.308 -175.852 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 61' ' ' ALA . . . . . 0.54 ' HA ' ' HB1' ' A' ' 32' ' ' ALA . . . -120.77 167.91 12.0 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 115.425 -0.807 . . . . 73.14 109.001 175.362 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 62' ' ' ASN . . . . . 0.49 ' O ' ' HA ' ' A' ' 49' ' ' PHE . 37.4 m-20 47.28 74.46 0.16 Allowed 'General case' 0 C--O 1.236 0.393 0 O-C-N 123.265 0.353 . . . . 73.55 110.314 -176.885 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.546 ' HB ' ' HA ' ' A' ' 33' ' ' ILE . 57.9 t -96.63 104.13 15.49 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.511 0 CA-C-N 116.337 -0.392 . . . . 65.15 110.817 -177.19 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 6.6 tp-100 -104.65 165.31 11.15 Favored 'General case' 0 C--N 1.321 -0.649 0 N-CA-C 109.127 -0.694 . . . . 75.54 109.127 178.093 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 86.0 mttt -80.78 176.57 9.69 Favored 'General case' 0 C--N 1.321 -0.635 0 N-CA-C 110.09 -0.337 . . . . 75.22 110.09 178.103 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 66' ' ' ALA . . . . . 0.459 ' HB2' HG23 ' A' ' 48' ' ' THR . . . . . . . . 0 C--O 1.249 1.052 0 CA-C-O 118.612 -0.709 . . . . 40.42 109.876 175.603 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 34.3 mm-40 . . . . . 0 C--O 1.233 0.192 0 CA-C-O 120.811 0.339 . . . . 64.2 110.307 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 3' ' ' GLN . . . . . 0.957 ' HG2' HG22 ' A' ' 48' ' ' THR . 88.3 mt-30 -124.72 111.78 15.97 Favored 'General case' 0 C--N 1.321 -0.648 0 N-CA-C 109.418 -0.586 . . . . 72.23 109.418 176.308 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -137.87 163.47 25.57 Favored Glycine 0 N--CA 1.446 -0.653 0 C-N-CA 120.363 -0.922 . . . . 44.41 112.143 -176.029 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 5' ' ' THR . . . . . 0.553 ' HA ' ' HA ' ' A' ' 46' ' ' ALA . 22.0 m -106.67 130.44 54.4 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-O 120.516 0.198 . . . . 73.23 110.734 -178.431 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.531 HG22 HG12 ' A' ' 18' ' ' ILE . 42.7 t -70.65 120.67 18.95 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 N-CA-C 109.964 -0.384 . . . . 70.13 109.964 178.009 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 7' ' ' LYS . . . . . 0.714 ' HD2' ' HB3' ' A' ' 19' ' ' GLU . 27.2 mtpp -98.81 -34.05 10.65 Favored 'General case' 0 C--N 1.327 -0.393 0 C-N-CA 120.91 -0.316 . . . . 74.12 110.682 -179.305 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 8' ' ' TRP . . . . . . . . . . . . . 10.5 m-90 -140.0 110.82 6.83 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.067 -0.515 . . . . 72.44 110.361 179.791 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 65.2 t80 -101.88 91.99 4.61 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-O 121.194 0.521 . . . . 71.45 109.848 177.546 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 90.3 m-20 -79.15 84.97 5.07 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-O 121.238 0.542 . . . . 74.12 109.976 -178.037 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -60.41 -40.67 91.84 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.065 -0.97 . . . . 72.42 112.021 -175.761 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 42.7 mt-10 -81.81 0.45 39.25 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 121.134 0.492 . . . . 73.31 111.181 -176.786 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 70.5 mmtt -103.95 -28.07 11.78 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 115.782 -0.644 . . . . 63.13 109.38 170.695 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 82.08 19.26 65.38 Favored Glycine 0 N--CA 1.448 -0.554 0 N-CA-C 111.156 -0.778 . . . . 73.12 111.156 -175.854 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 48.8 m-85 -135.81 154.86 51.07 Favored 'General case' 0 C--N 1.325 -0.483 0 N-CA-C 110.2 -0.296 . . . . 73.15 110.2 -176.127 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -140.07 146.56 18.08 Favored Glycine 0 N--CA 1.447 -0.59 0 C-N-CA 120.524 -0.846 . . . . 73.14 112.14 -179.599 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 97.6 m-85 -104.47 111.88 24.71 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 121.051 0.453 . . . . 71.24 110.486 178.771 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.531 HG12 HG22 ' A' ' 6' ' ' VAL . 55.2 mt -104.48 135.36 42.67 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.589 0 CA-C-N 115.579 -0.737 . . . . 60.32 109.829 -179.493 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 19' ' ' GLU . . . . . 0.714 ' HB3' ' HD2' ' A' ' 7' ' ' LYS . 14.0 pt-20 -83.29 162.18 21.22 Favored 'General case' 0 C--N 1.327 -0.377 0 C-N-CA 120.265 -0.574 . . . . 72.41 110.686 -178.837 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 20' ' ' ARG . . . . . 0.425 ' HG2' ' H ' ' A' ' 21' ' ' GLU . 39.0 ttt180 -144.64 175.9 9.81 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 115.969 -0.56 . . . . 72.33 109.755 -173.255 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 21' ' ' GLU . . . . . 0.433 ' HG3' ' N ' ' A' ' 22' ' ' ASN . 7.8 pt-20 -45.71 -49.45 14.65 Favored 'General case' 0 N--CA 1.469 0.507 0 N-CA-C 113.046 0.758 . . . . 72.14 113.046 -177.488 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 22' ' ' ASN . . . . . 0.433 ' N ' ' HG3' ' A' ' 21' ' ' GLU . 14.9 t-20 -97.9 12.43 34.1 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-O 121.361 0.601 . . . . 61.2 110.761 -174.646 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 79.28 9.92 86.53 Favored Glycine 0 N--CA 1.452 -0.243 0 C-N-CA 120.528 -0.844 . . . . 72.13 111.124 -173.923 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 25.2 t70 -67.14 90.93 0.21 Allowed 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 114.8 -0.7 . . . . 53.41 110.062 179.871 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 4.8 p-10 -60.84 119.15 7.66 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 121.631 0.729 . . . . 74.23 111.451 -178.819 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.509 HG12 ' HB2' ' A' ' 60' ' ' ALA . 31.3 t -89.88 127.98 42.13 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.58 0 CA-C-N 115.049 -0.978 . . . . 53.12 110.179 -179.864 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 27' ' ' PHE . . . . . . . . . . . . . 43.4 t80 -92.67 100.18 12.73 Favored 'General case' 0 C--N 1.321 -0.674 0 CA-C-N 115.582 -0.735 . . . . 71.4 110.333 -175.854 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.546 ' HA ' ' HB3' ' A' ' 60' ' ' ALA . 11.8 p -89.06 142.52 12.76 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 CA-C-O 120.708 0.289 . . . . 73.34 110.345 178.812 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 29' ' ' HIS . . . . . 0.418 ' O ' HG13 ' A' ' 33' ' ' ILE . 7.9 p80 -118.87 142.12 48.03 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.389 -0.369 . . . . 72.52 110.832 -178.484 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 30' ' ' PHE . . . . . 0.519 ' HA ' HD12 ' A' ' 33' ' ' ILE . 43.9 p90 -52.43 -32.54 39.83 Favored 'General case' 0 N--CA 1.468 0.443 0 CA-C-N 115.501 -0.772 . . . . 64.02 112.934 -173.648 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 1.9 p -71.06 -9.19 57.61 Favored 'General case' 0 C--N 1.323 -0.585 0 N-CA-C 111.911 0.337 . . . . 74.3 111.911 -179.046 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 32' ' ' ALA . . . . . 0.417 ' HB1' ' HA ' ' A' ' 61' ' ' ALA . . . -122.07 -7.05 8.9 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-O 120.916 0.389 . . . . 61.54 110.941 177.905 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.519 HD12 ' HA ' ' A' ' 30' ' ' PHE . 68.3 mt -67.77 136.5 26.46 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.386 0 CA-C-N 116.21 -0.45 . . . . 73.4 110.115 175.78 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 24.0 pt20 . . . . . 0 C--N 1.327 -0.395 0 CA-C-O 121.434 0.635 . . . . 71.1 110.967 177.541 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 3.7 p . . . . . 0 N--CA 1.447 -0.583 0 CA-C-O 121.104 0.478 . . . . 62.52 111.844 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 93.2 mt -85.62 81.47 8.64 Favored 'General case' 0 C--N 1.327 -0.394 0 N-CA-C 108.726 -0.842 . . . . 52.21 108.726 172.884 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 69.3 m-20 -73.97 172.21 12.04 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-O 122.038 0.923 . . . . 73.43 112.911 -169.677 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 43' ' ' GLU . . . . . 0.524 ' CD ' ' H ' ' A' ' 43' ' ' GLU . 22.2 mp0 -60.64 132.96 55.55 Favored 'General case' 0 N--CA 1.448 -0.554 0 CA-C-N 114.139 -1.391 . . . . 72.35 110.163 -178.44 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 98.99 -5.94 59.77 Favored Glycine 0 N--CA 1.446 -0.686 0 C-N-CA 120.711 -0.757 . . . . 53.1 112.713 178.102 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 3.4 tm0? -92.16 126.08 37.1 Favored 'General case' 0 C--N 1.328 -0.354 0 N-CA-C 109.566 -0.531 . . . . 75.23 109.566 176.751 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 0.553 ' HA ' ' HA ' ' A' ' 5' ' ' THR . . . -97.95 113.09 24.83 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-O 120.944 0.402 . . . . 75.13 110.675 178.795 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 23.2 m -106.26 160.95 5.74 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 CA-C-N 115.952 -0.567 . . . . 74.35 111.087 -178.44 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 48' ' ' THR . . . . . 0.957 HG22 ' HG2' ' A' ' 3' ' ' GLN . 53.8 p -106.79 126.13 51.89 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 115.748 -0.66 . . . . 73.45 109.411 175.743 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 49' ' ' PHE . . . . . 0.474 ' HA ' ' O ' ' A' ' 62' ' ' ASN . 33.4 p90 -142.0 167.49 22.01 Favored 'General case' 0 C--N 1.317 -0.813 0 CA-C-O 120.954 0.407 . . . . 62.21 111.33 -173.435 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 33.1 t70 -106.55 148.64 28.01 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.747 -0.66 . . . . 74.25 109.947 175.841 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 62.6 t -82.22 105.76 12.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-O 120.953 0.406 . . . . 71.0 111.137 -178.782 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 52' ' ' GLU . . . . . 0.428 ' HB2' ' HB3' ' A' ' 61' ' ' ALA . 40.6 tt0 -82.49 123.76 29.46 Favored 'General case' 0 C--N 1.319 -0.721 0 N-CA-C 108.881 -0.785 . . . . 54.44 108.881 174.459 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 43.5 mt-10 -87.94 109.55 19.88 Favored 'General case' 0 C--N 1.319 -0.731 0 CA-C-N 115.974 -0.557 . . . . 71.33 110.804 -174.901 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -138.16 166.8 25.12 Favored Glycine 0 N--CA 1.446 -0.663 0 CA-C-N 115.454 -0.793 . . . . 71.34 111.577 -179.579 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 72.6 mt-30 -79.97 82.95 5.95 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 121.343 0.592 . . . . 72.44 111.245 -175.843 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 56' ' ' ARG . . . . . 0.437 HH11 ' HD3' ' A' ' 56' ' ' ARG . 9.1 ptp180 -179.77 -32.01 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 114.764 -1.107 . . . . 74.05 109.326 177.893 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 144.95 -152.11 24.19 Favored Glycine 0 N--CA 1.448 -0.553 0 N-CA-C 110.737 -0.945 . . . . 32.32 110.737 -178.183 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 55.5 Cg_endo -70.98 105.2 1.64 Allowed 'Trans proline' 0 N--CA 1.46 -0.472 0 C-N-CA 122.158 1.906 . . . . 51.3 111.537 176.871 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 20.3 tt0 -97.8 139.04 34.26 Favored 'General case' 0 C--N 1.322 -0.596 0 N-CA-C 108.63 -0.878 . . . . 64.4 108.63 179.071 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 60' ' ' ALA . . . . . 0.546 ' HB3' ' HA ' ' A' ' 28' ' ' VAL . . . -96.11 120.42 36.37 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-O 121.255 0.55 . . . . 73.24 112.105 -174.835 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 61' ' ' ALA . . . . . 0.428 ' HB3' ' HB2' ' A' ' 52' ' ' GLU . . . -135.57 163.1 30.89 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 115.05 -0.977 . . . . 74.33 108.62 173.777 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 62' ' ' ASN . . . . . 0.474 ' O ' ' HA ' ' A' ' 49' ' ' PHE . 88.5 m-20 54.65 77.34 0.21 Allowed 'General case' 0 C--O 1.236 0.348 0 CA-C-O 121.067 0.46 . . . . 62.31 109.855 -174.494 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 45.9 t -112.67 121.38 64.87 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 CA-C-N 115.643 -0.708 . . . . 72.31 110.787 -175.998 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 5.1 tp60 -115.61 146.58 41.66 Favored 'General case' 0 C--N 1.323 -0.566 0 N-CA-C 109.29 -0.633 . . . . 62.23 109.29 177.642 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 19.4 ttpp -84.01 137.8 33.43 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 120.931 0.396 . . . . 64.45 111.481 -176.867 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 0.987 0 CA-C-O 118.202 -0.904 . . . . 51.42 108.882 171.109 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 2' ' ' GLU . . . . . 0.469 ' O ' ' HA ' ' A' ' 48' ' ' THR . 5.0 mp0 . . . . . 0 N--CA 1.453 -0.28 0 N-CA-C 109.283 -0.636 . . . . 73.21 109.283 . . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 17.9 mp0 -63.96 136.32 57.24 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.033 -0.985 . . . . 73.24 112.606 -173.968 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -153.09 163.38 30.52 Favored Glycine 0 N--CA 1.441 -1.003 0 N-CA-C 109.419 -1.473 . . . . 51.23 109.419 172.657 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 5' ' ' THR . . . . . 0.41 ' O ' ' HG2' ' A' ' 19' ' ' GLU . 13.9 m -122.46 127.53 49.72 Favored 'General case' 0 C--N 1.316 -0.861 0 CA-C-N 118.04 0.92 . . . . 64.3 110.886 -178.174 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 61.5 t -64.93 120.7 12.44 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.462 0 CA-C-N 116.22 -0.445 . . . . 63.53 111.115 -178.026 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 7' ' ' LYS . . . . . 1.072 ' HE2' ' HB3' ' A' ' 19' ' ' GLU . 66.3 mmtt -74.93 -70.49 0.41 Allowed 'General case' 0 C--N 1.328 -0.344 0 N-CA-C 109.219 -0.66 . . . . 72.24 109.219 175.309 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 8' ' ' TRP . . . . . . . . . . . . . 15.6 m95 -140.36 128.35 22.08 Favored 'General case' 0 C--O 1.235 0.317 0 CA-C-N 115.059 -0.973 . . . . 71.43 108.786 -179.537 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 22.8 p90 -99.52 103.69 15.45 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-O 121.702 0.763 . . . . 74.13 109.706 177.377 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 10' ' ' ASN . . . . . 0.862 ' HB3' ' HG3' ' A' ' 13' ' ' LYS . 37.8 m-80 -91.45 63.79 4.91 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 115.775 -0.648 . . . . 63.21 110.557 -176.958 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -64.07 -26.29 68.48 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 115.609 -0.723 . . . . 65.21 110.435 178.732 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 4.1 mm-40 -71.64 -13.27 61.7 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 115.726 -0.67 . . . . 72.23 110.509 178.684 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 13' ' ' LYS . . . . . 0.862 ' HG3' ' HB3' ' A' ' 10' ' ' ASN . 1.7 mmpt? -112.97 -37.85 4.68 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.895 -0.593 . . . . 63.54 110.395 -176.99 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 14' ' ' GLY . . . . . 0.408 ' O ' ' HD1' ' A' ' 30' ' ' PHE . . . 116.85 15.61 6.7 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.956 -0.64 . . . . 73.42 112.835 178.474 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 45.3 p90 -151.49 -176.36 5.56 Favored 'General case' 0 C--N 1.324 -0.543 0 O-C-N 122.543 -0.386 . . . . 71.03 110.667 179.96 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -164.55 169.99 39.51 Favored Glycine 0 N--CA 1.445 -0.743 0 C-N-CA 120.915 -0.66 . . . . 73.14 111.795 177.581 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 96.6 m-85 -123.76 130.12 52.13 Favored 'General case' 0 C--N 1.323 -0.585 0 N-CA-C 109.979 -0.378 . . . . 73.15 109.979 178.695 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 61.0 mt -127.57 135.35 63.45 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.768 0 N-CA-C 109.701 -0.481 . . . . 62.43 109.701 178.308 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 19' ' ' GLU . . . . . 1.072 ' HB3' ' HE2' ' A' ' 7' ' ' LYS . 8.5 pt-20 -91.5 135.61 33.72 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-O 121.212 0.529 . . . . 65.14 110.811 179.451 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 20' ' ' ARG . . . . . 0.658 ' HB2' ' HZ ' ' A' ' 49' ' ' PHE . 45.5 ttt180 -133.93 161.75 33.94 Favored 'General case' 0 C--N 1.315 -0.928 0 N-CA-C 108.576 -0.898 . . . . 72.42 108.576 174.78 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 21' ' ' GLU . . . . . 0.408 ' HG2' ' H ' ' A' ' 21' ' ' GLU . 7.1 mm-40 -35.87 -57.47 0.67 Allowed 'General case' 0 N--CA 1.468 0.444 0 O-C-N 124.038 0.836 . . . . 73.41 110.806 178.025 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 34.9 t30 -110.06 76.92 1.02 Allowed 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 115.704 -0.68 . . . . 62.5 109.749 172.409 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 23' ' ' GLY . . . . . 0.583 ' O ' HG23 ' A' ' 26' ' ' VAL . . . 152.24 72.44 0.01 OUTLIER Glycine 0 N--CA 1.446 -0.674 0 C-N-CA 120.541 -0.838 . . . . 74.1 112.213 174.032 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 25.2 t70 -68.17 -1.79 6.76 Favored 'General case' 0 C--N 1.321 -0.663 0 CA-C-O 121.183 0.516 . . . . 50.41 111.062 -176.278 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 7.0 p-10 -142.65 31.49 1.47 Allowed 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 116.246 -0.434 . . . . 74.11 110.929 -174.988 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.583 HG23 ' O ' ' A' ' 23' ' ' GLY . 79.2 t -53.28 121.83 2.73 Favored 'Isoleucine or valine' 0 C--O 1.234 0.269 0 CA-C-O 121.109 0.48 . . . . 72.04 110.743 179.588 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 27' ' ' PHE . . . . . . . . . . . . . 42.6 t80 -84.21 116.74 23.1 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 115.583 -0.735 . . . . 74.12 110.603 -174.413 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.511 HG21 HG21 ' A' ' 63' ' ' VAL . 9.0 p -110.68 156.1 11.86 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.59 0 CA-C-N 116.339 -0.392 . . . . 75.32 110.281 179.853 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 92.7 m-70 -108.82 157.27 18.74 Favored 'General case' 0 C--O 1.239 0.513 0 N-CA-C 110.011 -0.366 . . . . 54.44 110.011 -179.674 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 30' ' ' PHE . . . . . 0.408 ' HD1' ' O ' ' A' ' 14' ' ' GLY . 50.8 p90 -61.65 -34.48 75.78 Favored 'General case' 0 N--CA 1.464 0.234 0 CA-C-N 116.54 -0.3 . . . . 74.25 111.605 -175.847 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 26.8 t -92.43 2.68 56.52 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 121.053 0.454 . . . . 74.21 110.589 -179.045 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -93.38 -29.9 15.37 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 121.168 0.509 . . . . 44.13 110.151 177.127 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.585 ' HA ' ' HB ' ' A' ' 63' ' ' VAL . 59.1 mt -72.66 137.89 22.56 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.386 0 CA-C-N 115.608 -0.724 . . . . 73.31 109.992 174.277 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 5.1 pp0? . . . . . 0 C--N 1.329 -0.318 0 N-CA-C 110.061 -0.348 . . . . 73.35 110.061 178.236 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 20.0 m . . . . . 0 N--CA 1.45 -0.472 0 N-CA-C 110.034 -0.358 . . . . 71.34 110.034 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 98.4 mt -66.35 143.13 57.35 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 116.013 -0.539 . . . . 64.21 110.93 -177.882 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 35.4 t70 -68.07 149.38 49.73 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-N 115.462 -0.79 . . . . 71.32 112.176 -172.808 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 7.6 pt-20 -65.25 135.63 55.62 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 115.751 -0.658 . . . . 73.04 110.518 179.312 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 89.74 -1.23 80.89 Favored Glycine 0 N--CA 1.447 -0.583 0 C-N-CA 120.66 -0.781 . . . . 53.14 112.233 -177.18 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 6.5 tp-100 -82.92 141.49 32.14 Favored 'General case' 0 C--O 1.237 0.439 0 CA-C-O 120.732 0.301 . . . . 74.23 110.36 176.984 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -82.38 117.41 22.42 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 115.824 -0.626 . . . . 65.31 110.257 178.244 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 29.5 m -117.01 166.93 10.83 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.711 0 CA-C-N 115.727 -0.67 . . . . 62.52 110.884 -178.071 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 48' ' ' THR . . . . . 0.726 HG23 ' HB2' ' A' ' 66' ' ' ALA . 9.6 p -132.91 103.15 5.92 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-O 121.296 0.569 . . . . 63.41 110.106 178.461 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 49' ' ' PHE . . . . . 0.658 ' HZ ' ' HB2' ' A' ' 20' ' ' ARG . 36.5 p90 -117.16 166.82 11.79 Favored 'General case' 0 C--N 1.318 -0.792 0 CA-C-O 121.072 0.463 . . . . 74.03 111.751 -172.399 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 35.5 t70 -96.91 128.06 43.5 Favored 'General case' 0 C--N 1.32 -0.68 0 N-CA-C 109.016 -0.735 . . . . 73.14 109.016 174.169 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 7.4 p -80.62 118.0 27.56 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.564 0 CA-C-O 121.538 0.685 . . . . 73.42 111.254 -174.746 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 44.0 tt0 -89.14 113.16 24.3 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-N 115.419 -0.81 . . . . 74.03 109.109 176.942 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 13.9 mm-40 -73.62 86.13 1.62 Allowed 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 115.983 -0.553 . . . . 75.02 109.875 178.248 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -88.64 160.8 30.48 Favored Glycine 0 N--CA 1.443 -0.858 0 C-N-CA 120.88 -0.676 . . . . 61.11 112.331 -177.523 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 36.7 tt0 -84.77 0.34 50.99 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-O 121.392 0.615 . . . . 73.21 109.854 -179.295 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 90.8 mtm180 -119.84 15.64 12.6 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.597 -0.729 . . . . 71.52 110.855 179.184 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 121.68 169.17 13.56 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.884 -0.674 . . . . 60.31 112.182 -179.769 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 37.7 Cg_endo -68.03 118.41 5.6 Favored 'Trans proline' 0 C--N 1.344 0.291 0 C-N-CA 122.532 2.155 . . . . 51.42 111.768 177.249 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 49.9 mt-30 -119.45 164.31 15.96 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 116.325 -0.398 . . . . 62.33 110.429 -177.791 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -111.65 125.15 53.65 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-O 121.255 0.55 . . . . 75.3 111.943 -174.048 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -128.57 142.97 50.89 Favored 'General case' 0 C--N 1.321 -0.63 0 CA-C-N 115.3 -0.863 . . . . 65.51 109.005 174.426 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 39.4 m-80 56.53 78.57 0.21 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 121.216 0.532 . . . . 72.45 110.448 -175.899 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.585 ' HB ' ' HA ' ' A' ' 33' ' ' ILE . 51.8 t -101.42 109.59 26.14 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.519 0 CA-C-N 115.892 -0.594 . . . . 54.03 110.803 -177.965 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 86.7 mt-30 -94.06 -172.24 2.77 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 116.192 -0.458 . . . . 74.1 110.105 177.983 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 61.9 tttm -116.45 139.64 50.23 Favored 'General case' 0 C--N 1.321 -0.641 0 N-CA-C 109.303 -0.629 . . . . 71.34 109.303 178.508 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 66' ' ' ALA . . . . . 0.726 ' HB2' HG23 ' A' ' 48' ' ' THR . . . . . . . . 0 C--O 1.248 1.006 0 CA-C-O 118.795 -0.621 . . . . 75.01 110.557 -178.614 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 21.9 ttt . . . . . 0 N--CA 1.479 1.019 0 N-CA-C 109.423 -0.584 . . . . 52.33 109.423 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 2' ' ' GLU . . . . . 0.943 ' HG3' HH12 ' A' ' 20' ' ' ARG . 0.1 OUTLIER -90.06 83.28 6.07 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 115.842 -0.617 . . . . 74.42 111.209 -172.919 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 41.1 mt-30 -96.54 148.52 22.75 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.539 -0.755 . . . . 51.42 110.123 178.481 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -155.91 153.7 24.95 Favored Glycine 0 N--CA 1.445 -0.726 0 C-N-CA 120.934 -0.651 . . . . 71.33 111.866 177.114 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 4.7 m -104.57 134.81 47.12 Favored 'General case' 0 C--N 1.319 -0.752 0 N-CA-C 109.812 -0.44 . . . . 73.12 109.812 178.124 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 61.8 t -68.13 112.18 3.01 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.609 0 CA-C-O 120.745 0.307 . . . . 63.52 110.41 177.952 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 7' ' ' LYS . . . . . 0.683 ' HD3' ' HB3' ' A' ' 19' ' ' GLU . 12.3 mmmm -71.3 -68.5 0.44 Allowed 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.831 -0.622 . . . . 62.45 109.822 179.159 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 8' ' ' TRP . . . . . . . . . . . . . 4.6 p-90 -153.06 149.01 27.68 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-N 115.462 -0.79 . . . . 74.33 109.32 177.774 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 9' ' ' PHE . . . . . 0.419 ' CE2' ' HA ' ' A' ' 40' ' ' SER . 68.5 t80 -114.59 120.15 39.21 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-O 121.001 0.429 . . . . 74.21 111.563 -173.227 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 10' ' ' ASN . . . . . 0.454 ' HB3' ' HB2' ' A' ' 13' ' ' LYS . 15.3 m120 -81.92 78.31 8.64 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.669 -0.696 . . . . 74.21 109.472 176.261 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -61.71 -37.64 84.92 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 115.905 -0.589 . . . . 14.0 111.303 -177.114 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 32.0 mm-40 -76.8 -11.33 59.81 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.379 -0.373 . . . . 73.34 111.554 -178.925 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 13' ' ' LYS . . . . . 0.487 ' HB3' ' HD2' ' A' ' 15' ' ' PHE . 70.1 mmtt -99.79 -33.69 10.47 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-O 121.072 0.463 . . . . 73.32 110.553 176.839 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 89.85 24.28 30.53 Favored Glycine 0 N--CA 1.448 -0.536 0 N-CA-C 111.075 -0.81 . . . . 75.14 111.075 -174.147 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 15' ' ' PHE . . . . . 0.487 ' HD2' ' HB3' ' A' ' 13' ' ' LYS . 64.3 m-85 -136.92 173.73 11.38 Favored 'General case' 0 C--N 1.324 -0.519 0 N-CA-C 109.549 -0.538 . . . . 73.32 109.549 -178.338 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -160.98 167.56 36.02 Favored Glycine 0 N--CA 1.447 -0.6 0 C-N-CA 120.281 -0.962 . . . . 64.41 112.285 178.543 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 96.2 m-85 -119.67 119.67 34.39 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-O 121.105 0.478 . . . . 73.54 110.668 179.095 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 56.4 mt -112.76 124.95 69.91 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.657 0 N-CA-C 109.187 -0.671 . . . . 62.13 109.187 177.72 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 19' ' ' GLU . . . . . 0.683 ' HB3' ' HD3' ' A' ' 7' ' ' LYS . 10.3 pt-20 -71.88 140.38 49.25 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-O 121.342 0.592 . . . . 73.41 111.468 -173.792 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 20' ' ' ARG . . . . . 0.943 HH12 ' HG3' ' A' ' 2' ' ' GLU . 9.7 tpt180 -90.84 172.98 8.24 Favored 'General case' 0 C--N 1.32 -0.7 0 N-CA-C 107.521 -1.289 . . . . 35.3 107.521 167.107 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 21' ' ' GLU . . . . . 0.575 ' OE2' ' HG3' ' A' ' 20' ' ' ARG . 0.0 OUTLIER -59.79 -23.15 63.05 Favored 'General case' 0 N--CA 1.467 0.413 0 CA-C-N 118.383 0.538 . . . . 61.32 112.327 -172.93 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 91.9 m-20 -101.4 17.79 21.76 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.855 0.36 . . . . 42.51 111.594 179.005 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 80.15 2.08 88.59 Favored Glycine 0 N--CA 1.452 -0.253 0 C-N-CA 120.943 -0.646 . . . . 40.52 112.751 176.897 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 28.4 t70 -69.19 97.85 0.96 Allowed 'General case' 0 C--N 1.323 -0.557 0 N-CA-C 109.955 -0.387 . . . . 63.51 109.955 179.712 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.47 ' OD1' ' HG3' ' A' ' 7' ' ' LYS . 52.5 m-20 -53.66 113.67 1.27 Allowed 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.331 -0.85 . . . . 74.14 111.119 176.363 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.608 HG12 ' HB2' ' A' ' 60' ' ' ALA . 25.3 t -89.27 135.56 25.66 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.602 0 CA-C-N 115.663 -0.698 . . . . 73.23 109.457 176.316 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 27' ' ' PHE . . . . . . . . . . . . . 40.4 t80 -90.72 109.65 20.83 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 120.988 0.423 . . . . 74.34 110.79 -172.894 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.436 ' HA ' ' HB3' ' A' ' 60' ' ' ALA . 7.9 p -97.52 151.45 4.29 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 CA-C-N 116.185 -0.461 . . . . 44.32 110.508 -179.434 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 29' ' ' HIS . . . . . 0.44 ' HA ' ' HD1' ' A' ' 15' ' ' PHE . 86.9 m-70 -115.46 158.53 22.4 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.175 -0.466 . . . . 62.11 110.969 -175.924 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 34.3 p90 -61.69 -31.34 71.47 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.029 -0.532 . . . . 72.24 111.774 179.742 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 8.0 t -94.43 12.85 25.72 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 121.433 0.635 . . . . 62.53 109.977 -179.628 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 32' ' ' ALA . . . . . 0.72 ' HB1' ' HA ' ' A' ' 61' ' ' ALA . . . -112.68 -28.85 7.65 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 115.701 -0.681 . . . . 60.31 110.124 178.132 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 55.7 mt -80.33 139.01 18.82 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.53 0 CA-C-N 115.443 -0.799 . . . . 51.32 109.926 177.126 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 34' ' ' GLN . . . . . 0.415 ' HG3' ' O ' ' A' ' 34' ' ' GLN . 10.5 pt20 -75.7 90.31 2.84 Favored 'General case' 0 N--CA 1.45 -0.432 0 CA-C-O 121.395 0.617 . . . . 63.31 109.518 173.436 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.42 ' O ' ' HE2' ' A' ' 39' ' ' LYS . . . -74.34 61.61 2.29 Favored Glycine 0 N--CA 1.449 -0.451 0 CA-C-N 115.534 -0.757 . . . . 52.34 112.086 -179.115 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 18.1 t70 -92.61 110.33 21.76 Favored 'General case' 0 C--N 1.318 -0.764 0 N-CA-C 109.434 -0.58 . . . . 71.34 109.434 179.064 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 94.01 -57.94 2.11 Favored Glycine 0 N--CA 1.447 -0.573 0 C-N-CA 120.932 -0.652 . . . . 34.53 111.763 -176.98 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 29.7 p90 -146.14 149.61 34.33 Favored 'General case' 0 C--N 1.325 -0.479 0 N-CA-C 110.237 -0.283 . . . . 65.24 110.237 178.743 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 39' ' ' LYS . . . . . 0.44 ' HD2' ' N ' ' A' ' 39' ' ' LYS . 0.5 OUTLIER -102.43 75.55 1.47 Allowed 'General case' 0 C--N 1.324 -0.534 0 CA-C-O 121.196 0.522 . . . . 74.21 110.102 179.791 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 40' ' ' SER . . . . . 0.419 ' HA ' ' CE2' ' A' ' 9' ' ' PHE . 66.4 m -157.43 154.83 29.43 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 115.781 -0.645 . . . . 51.21 109.939 178.908 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 87.6 mt -110.96 126.52 54.85 Favored 'General case' 0 C--N 1.321 -0.642 0 N-CA-C 109.328 -0.619 . . . . 75.33 109.328 174.301 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 36.0 t70 -69.44 112.91 6.29 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-O 121.001 0.429 . . . . 71.13 109.95 179.991 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 55.6 mt-10 -65.57 120.46 12.94 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 115.956 -0.565 . . . . 52.33 110.35 -176.89 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 105.22 -13.07 48.56 Favored Glycine 0 N--CA 1.449 -0.498 0 C-N-CA 121.014 -0.612 . . . . 32.41 111.903 -175.305 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 6.2 tp-100 -83.64 145.6 28.72 Favored 'General case' 0 C--O 1.235 0.318 0 CA-C-O 120.795 0.331 . . . . 64.21 110.272 -179.855 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -100.22 135.21 42.0 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 116.161 -0.472 . . . . 74.23 110.465 178.743 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 8.9 m -141.68 -175.93 0.9 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.493 0 CA-C-N 116.096 -0.502 . . . . 54.34 110.537 179.444 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 19.8 p -124.54 157.97 34.06 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 115.971 -0.559 . . . . 60.43 109.693 177.302 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 37.8 p90 -156.48 151.07 25.7 Favored 'General case' 0 C--N 1.321 -0.637 0 C-N-CA 120.56 -0.456 . . . . 73.13 111.545 -176.748 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 50' ' ' ASP . . . . . 0.736 ' HB3' ' HB2' ' A' ' 62' ' ' ASN . 26.3 t70 -91.35 94.4 9.49 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 115.834 -0.621 . . . . 75.24 109.697 174.562 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 7.6 p -73.56 133.63 31.29 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.55 0 CA-C-N 115.871 -0.604 . . . . 64.22 111.079 -176.399 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 25.7 mt-10 -119.31 171.69 8.14 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 115.847 -0.615 . . . . 74.32 110.155 179.273 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 10.8 pt-20 -72.08 149.51 44.76 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.834 -0.621 . . . . 72.52 110.87 179.968 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 54' ' ' GLY . . . . . 0.48 ' HA3' ' O ' ' A' ' 57' ' ' GLY . . . -155.02 124.98 1.6 Allowed Glycine 0 N--CA 1.445 -0.715 0 CA-C-N 115.87 -0.604 . . . . 32.53 111.804 178.387 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 35.4 tt0 -61.49 -33.08 73.17 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-O 120.654 0.264 . . . . 64.21 111.306 -177.535 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 22.2 mmt180 -114.47 25.98 10.6 Favored 'General case' 0 C--N 1.327 -0.375 0 N-CA-C 111.741 0.274 . . . . 72.22 111.741 -179.515 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 57' ' ' GLY . . . . . 0.48 ' O ' ' HA3' ' A' ' 54' ' ' GLY . . . 139.86 157.25 7.19 Favored Glycine 0 N--CA 1.448 -0.55 0 C-N-CA 120.319 -0.943 . . . . 60.23 112.378 176.757 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 58' ' ' PRO . . . . . 0.567 ' HG2' ' HA ' ' A' ' 26' ' ' VAL . 37.5 Cg_endo -66.47 127.2 16.85 Favored 'Trans proline' 0 C--O 1.234 0.323 0 C-N-CA 122.629 2.219 . . . . 63.23 111.517 -179.758 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 26.9 tt0 -88.72 107.86 19.17 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 116.039 -0.528 . . . . 52.23 110.728 -176.841 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 60' ' ' ALA . . . . . 0.608 ' HB2' HG12 ' A' ' 26' ' ' VAL . . . -79.2 97.75 6.34 Favored 'General case' 0 C--N 1.323 -0.575 0 N-CA-C 109.728 -0.471 . . . . 71.23 109.728 175.879 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 61' ' ' ALA . . . . . 0.72 ' HA ' ' HB1' ' A' ' 32' ' ' ALA . . . -111.44 165.83 11.64 Favored 'General case' 0 C--N 1.319 -0.74 0 CA-C-N 115.829 -0.623 . . . . 61.51 110.017 -179.994 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 62' ' ' ASN . . . . . 0.736 ' HB2' ' HB3' ' A' ' 50' ' ' ASP . 56.3 m-20 48.37 65.89 1.21 Allowed 'General case' 0 C--N 1.33 -0.271 0 O-C-N 123.727 0.642 . . . . 72.41 111.03 174.915 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 58.7 t -77.26 120.64 28.12 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.464 0 CA-C-N 116.086 -0.507 . . . . 72.52 110.493 -178.603 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 77.2 mm-40 -108.12 133.76 51.94 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-N 115.827 -0.624 . . . . 74.21 110.058 179.694 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 96.8 mttt -73.92 134.41 43.19 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 116.194 -0.457 . . . . 61.31 110.503 -179.397 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.246 0.87 0 CA-C-O 118.346 -0.835 . . . . 60.41 110.326 -179.783 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 1' ' ' MET . . . . . 0.432 ' N ' ' HA ' ' A' ' 50' ' ' ASP . 23.6 mmt . . . . . 0 N--CA 1.484 1.23 0 CA-C-O 120.994 0.426 . . . . 72.24 110.387 . . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 11.1 mp0 -112.0 157.39 20.78 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 116.284 -0.416 . . . . 64.32 110.254 -172.702 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 3' ' ' GLN . . . . . 0.49 ' HA ' ' O ' ' A' ' 47' ' ' VAL . 28.6 tt0 -92.65 131.17 37.98 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 116.38 -0.373 . . . . 53.22 110.065 176.733 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 4' ' ' GLY . . . . . 0.412 ' HA3' ' HE2' ' A' ' 49' ' ' PHE . . . -146.16 151.62 23.83 Favored Glycine 0 N--CA 1.446 -0.685 0 C-N-CA 120.872 -0.68 . . . . 65.32 112.292 -179.58 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 5' ' ' THR . . . . . 0.42 ' O ' ' HG2' ' A' ' 19' ' ' GLU . 0.2 OUTLIER -89.0 125.8 35.14 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-O 120.659 0.266 . . . . 73.42 110.923 -177.287 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.863 ' HA ' HG13 ' A' ' 18' ' ' ILE . 31.2 t -68.55 102.53 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.495 0 N-CA-C 110.098 -0.334 . . . . 60.01 110.098 176.623 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 8.8 mmmm -72.59 -68.29 0.49 Allowed 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 116.296 -0.411 . . . . 60.13 110.672 -177.531 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 8' ' ' TRP . . . . . . . . . . . . . 80.7 m95 -135.32 131.69 36.76 Favored 'General case' 0 C--N 1.323 -0.546 0 N-CA-C 109.755 -0.461 . . . . 70.44 109.755 178.286 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 9' ' ' PHE . . . . . 0.487 ' HA ' ' HA3' ' A' ' 16' ' ' GLY . 73.3 t80 -134.42 104.35 6.09 Favored 'General case' 0 C--N 1.318 -0.765 0 CA-C-O 120.912 0.387 . . . . 73.43 110.125 176.939 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 10' ' ' ASN . . . . . 0.628 ' OD1' ' HG2' ' A' ' 13' ' ' LYS . 16.7 t-20 -78.53 86.64 4.53 Favored 'General case' 0 C--N 1.321 -0.639 0 N-CA-C 109.305 -0.628 . . . . 64.52 109.305 178.897 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -66.31 -15.76 63.49 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 115.243 -0.89 . . . . 63.41 111.494 -177.17 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 32.7 mt-10 -68.01 -38.46 82.65 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.142 -0.481 . . . . 62.24 109.983 177.867 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 13' ' ' LYS . . . . . 0.628 ' HG2' ' OD1' ' A' ' 10' ' ' ASN . 28.9 mmtp -98.2 -30.45 12.63 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 116.112 -0.494 . . . . 74.05 109.946 179.955 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 104.9 20.73 9.61 Favored Glycine 0 N--CA 1.448 -0.555 0 C-N-CA 120.746 -0.74 . . . . 61.23 113.068 175.857 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 39.7 p90 -147.08 162.59 38.52 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 117.157 0.478 . . . . 73.42 110.853 -178.857 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.487 ' HA3' ' HA ' ' A' ' 9' ' ' PHE . . . -168.45 -164.15 23.66 Favored Glycine 0 N--CA 1.444 -0.823 0 C-N-CA 120.665 -0.778 . . . . 72.11 112.064 178.857 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 91.9 m-85 -133.83 124.3 26.28 Favored 'General case' 0 C--N 1.322 -0.61 0 N-CA-C 109.408 -0.59 . . . . 74.02 109.408 -178.005 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.863 HG13 ' HA ' ' A' ' 6' ' ' VAL . 11.0 tt -116.51 158.22 17.07 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.96 0 N-CA-C 109.095 -0.706 . . . . 51.45 109.095 -177.712 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 19' ' ' GLU . . . . . 0.42 ' HG2' ' O ' ' A' ' 5' ' ' THR . 19.8 pt-20 -106.49 134.13 50.1 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 121.375 0.607 . . . . 71.12 111.229 -178.148 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 20' ' ' ARG . . . . . . . . . . . . . 14.3 ttt180 -97.35 157.98 15.7 Favored 'General case' 0 C--N 1.317 -0.83 0 N-CA-C 108.224 -1.028 . . . . 63.32 108.224 172.026 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 31.7 mt-10 -44.0 -40.65 4.87 Favored 'General case' 0 N--CA 1.467 0.416 0 O-C-N 123.503 0.502 . . . . 74.54 110.885 -179.499 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 23.1 t-20 -127.59 73.62 1.46 Allowed 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 115.89 -0.595 . . . . 72.51 109.784 171.498 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 164.61 94.99 0.1 Allowed Glycine 0 C--O 1.227 -0.306 0 C-N-CA 120.41 -0.9 . . . . 71.32 112.843 175.846 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 13.3 m-20 -78.44 18.16 0.58 Allowed 'General case' 0 N--CA 1.468 0.458 0 N-CA-C 111.877 0.325 . . . . 75.05 111.877 -178.02 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 36.5 t70 -142.7 85.24 1.88 Allowed 'General case' 0 C--N 1.321 -0.671 0 CA-C-O 120.999 0.428 . . . . 71.44 110.824 -177.724 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.457 ' HB ' HG22 ' A' ' 18' ' ' ILE . 47.2 t -125.48 124.04 66.08 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.526 0 CA-C-N 115.609 -0.723 . . . . 61.3 109.185 174.94 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 27' ' ' PHE . . . . . . . . . . . . . 70.6 t80 -83.44 104.36 13.52 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-O 121.321 0.581 . . . . 52.14 110.834 -175.328 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.439 ' HA ' ' HB3' ' A' ' 60' ' ' ALA . 13.5 p -93.77 142.05 13.9 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.664 0 CA-C-N 115.851 -0.613 . . . . 75.23 109.788 179.089 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 29' ' ' HIS . . . . . 0.437 ' CE1' ' HB2' ' A' ' 32' ' ' ALA . 3.7 p80 -140.53 142.55 35.19 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.761 0.315 . . . . 74.34 111.017 -175.976 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 17.2 p90 -60.49 -25.14 65.84 Favored 'General case' 0 N--CA 1.469 0.476 0 CA-C-N 115.8 -0.636 . . . . 65.1 112.706 -170.775 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 11.6 p -77.87 -8.0 57.47 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-O 121.028 0.442 . . . . 43.21 111.587 -178.11 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 32' ' ' ALA . . . . . 0.688 ' HB1' ' HA ' ' A' ' 61' ' ' ALA . . . -113.81 -23.53 9.61 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 120.921 0.391 . . . . 63.3 111.074 179.178 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.437 HD13 ' HB2' ' A' ' 41' ' ' LEU . 56.9 mt -69.07 150.51 10.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 N-CA-C 109.556 -0.535 . . . . 74.53 109.556 174.104 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 34' ' ' GLN . . . . . 0.415 HE21 ' HA ' ' A' ' 64' ' ' GLN . 4.8 pp0? -112.42 139.14 48.23 Favored 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 109.45 -0.574 . . . . 64.23 109.45 175.056 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -162.66 158.63 30.86 Favored Glycine 0 N--CA 1.446 -0.674 0 C-N-CA 120.753 -0.737 . . . . 63.1 111.779 -178.289 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 33.9 t70 -101.41 99.46 9.8 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-O 120.952 0.405 . . . . 62.32 110.391 -178.09 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 94.81 -55.84 1.9 Allowed Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 121.045 -0.598 . . . . 72.23 112.404 -179.358 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 72.1 m-85 -115.05 145.44 42.3 Favored 'General case' 0 C--N 1.323 -0.577 0 N-CA-C 109.889 -0.411 . . . . 70.22 109.889 179.593 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 13.9 mmmm -101.91 5.54 40.94 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-O 120.993 0.425 . . . . 75.44 110.815 -177.899 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 13.3 p -68.98 127.22 32.34 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 115.832 -0.622 . . . . 73.24 110.705 179.088 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 41' ' ' LEU . . . . . 0.437 ' HB2' HD13 ' A' ' 33' ' ' ILE . 12.6 tp -92.63 146.81 23.38 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 116.029 -0.532 . . . . 74.14 109.675 178.699 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 42' ' ' ASP . . . . . 0.856 ' HB2' ' HB2' ' A' ' 45' ' ' GLN . 2.1 m-20 -73.92 124.81 26.88 Favored 'General case' 0 C--N 1.318 -0.787 0 CA-C-N 115.837 -0.62 . . . . 72.35 110.885 -175.108 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 9.3 pt-20 -69.47 131.34 44.58 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-O 120.845 0.355 . . . . 64.2 110.164 177.456 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 82.24 4.06 90.34 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.863 -0.684 . . . . 64.42 112.113 -177.65 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 45' ' ' GLN . . . . . 0.856 ' HB2' ' HB2' ' A' ' 42' ' ' ASP . 24.6 tp60 -80.91 126.32 31.22 Favored 'General case' 0 C--N 1.326 -0.455 0 N-CA-C 110.109 -0.33 . . . . 70.12 110.109 -179.693 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 0.438 ' O ' ' HB3' ' A' ' 66' ' ' ALA . . . -86.88 83.15 7.59 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-O 121.042 0.449 . . . . 42.12 110.048 176.006 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 0.507 HG12 ' HA ' ' A' ' 65' ' ' LYS . 19.1 m -89.85 167.98 1.59 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.578 0 CA-C-N 115.631 -0.713 . . . . 70.12 111.734 -173.563 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 48' ' ' THR . . . . . 0.497 ' OG1' ' HB3' ' A' ' 64' ' ' GLN . 4.9 p -112.4 107.32 16.08 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 115.959 -0.564 . . . . 74.51 110.145 177.379 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 49' ' ' PHE . . . . . 0.582 ' HA ' ' O ' ' A' ' 62' ' ' ASN . 38.2 p90 -122.17 160.57 24.85 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 115.838 -0.619 . . . . 73.53 111.234 -173.063 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 50' ' ' ASP . . . . . 0.432 ' HA ' ' N ' ' A' ' 1' ' ' MET . 22.6 t70 -107.67 115.59 30.43 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-O 121.07 0.462 . . . . 72.11 110.563 175.058 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 66.5 t -66.65 132.51 32.02 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.498 0 CA-C-N 115.734 -0.667 . . . . 63.52 112.12 -174.692 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 52' ' ' GLU . . . . . 1.044 ' HB2' ' HB2' ' A' ' 59' ' ' GLN . 34.4 mt-10 -94.27 159.55 15.08 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.736 -0.666 . . . . 73.22 109.675 174.309 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 39.1 mt-10 -114.72 110.63 20.03 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-N 116.38 -0.373 . . . . 74.43 110.353 178.382 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -126.49 170.8 18.26 Favored Glycine 0 N--CA 1.448 -0.515 0 C-N-CA 120.878 -0.677 . . . . 34.21 112.092 -179.802 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 67.8 mt-30 -92.98 69.3 4.5 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-O 121.365 0.602 . . . . 74.15 110.034 -177.852 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 15.8 ptp180 178.59 -30.47 0.01 OUTLIER 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 114.741 -1.118 . . . . 72.51 108.921 -176.154 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 162.71 -179.54 37.92 Favored Glycine 0 N--CA 1.44 -1.098 0 N-CA-C 110.325 -1.11 . . . . 65.52 110.325 178.486 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 57.5 Cg_endo -76.34 128.12 10.24 Favored 'Trans proline' 0 N--CA 1.454 -0.822 0 C-N-CA 121.884 1.723 . . . . 60.15 111.161 175.228 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 59' ' ' GLN . . . . . 1.044 ' HB2' ' HB2' ' A' ' 52' ' ' GLU . 9.4 mm100 -93.4 169.73 10.14 Favored 'General case' 0 C--N 1.321 -0.639 0 N-CA-C 109.0 -0.741 . . . . 71.13 109.0 178.591 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 60' ' ' ALA . . . . . 0.439 ' HB3' ' HA ' ' A' ' 28' ' ' VAL . . . -124.75 111.33 15.42 Favored 'General case' 0 C--N 1.319 -0.745 0 C-N-CA 120.719 -0.393 . . . . 73.13 111.327 179.308 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 61' ' ' ALA . . . . . 0.688 ' HA ' ' HB1' ' A' ' 32' ' ' ALA . . . -123.11 159.35 28.71 Favored 'General case' 0 CA--C 1.515 -0.379 0 CA-C-N 115.984 -0.553 . . . . 74.41 110.161 177.156 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 62' ' ' ASN . . . . . 0.582 ' O ' ' HA ' ' A' ' 49' ' ' PHE . 94.9 m-20 53.65 78.3 0.16 Allowed 'General case' 0 CA--C 1.517 -0.304 0 CA-C-O 121.274 0.559 . . . . 63.45 109.569 -177.481 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.404 HG11 HD21 ' A' ' 41' ' ' LEU . 44.1 t -107.8 101.72 12.93 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.611 0 CA-C-N 115.147 -0.933 . . . . 60.24 110.572 -175.995 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 64' ' ' GLN . . . . . 0.497 ' HB3' ' OG1' ' A' ' 48' ' ' THR . 8.3 tt0 -85.3 124.13 31.57 Favored 'General case' 0 C--N 1.319 -0.728 0 CA-C-N 115.959 -0.564 . . . . 64.13 110.066 -179.382 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 65' ' ' LYS . . . . . 0.507 ' HA ' HG12 ' A' ' 47' ' ' VAL . 42.9 mttm -68.16 127.39 32.72 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.346 -0.388 . . . . 74.21 110.263 -179.289 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 66' ' ' ALA . . . . . 0.438 ' HB3' ' O ' ' A' ' 46' ' ' ALA . . . . . . . . 0 C--O 1.246 0.898 0 CA-C-O 118.091 -0.956 . . . . 52.13 110.444 -178.615 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 24.6 mmt . . . . . 0 N--CA 1.483 1.178 0 N-CA-C 109.618 -0.512 . . . . 75.12 109.618 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -152.43 31.31 0.53 Allowed 'General case' 0 C--N 1.323 -0.554 0 CA-C-O 121.122 0.486 . . . . 63.34 111.164 -170.457 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 35.1 tt0 -88.35 116.29 26.46 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 115.832 -0.622 . . . . 74.44 110.237 177.58 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -126.91 -174.33 13.77 Favored Glycine 0 N--CA 1.449 -0.472 0 N-CA-C 110.99 -0.844 . . . . 63.54 110.99 177.727 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 5' ' ' THR . . . . . 0.538 ' O ' ' HG2' ' A' ' 19' ' ' GLU . 10.1 m -130.09 132.19 46.05 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-N 117.3 0.55 . . . . 71.22 110.682 179.515 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 60.3 t -76.22 119.83 25.08 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.446 0 CA-C-N 116.495 -0.321 . . . . 73.53 110.169 -179.286 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 7' ' ' LYS . . . . . 0.964 ' HE3' ' HA ' ' A' ' 7' ' ' LYS . 0.0 OUTLIER -92.97 -68.22 0.81 Allowed 'General case' 0 C--N 1.325 -0.467 0 CA-C-O 120.92 0.391 . . . . 74.25 110.797 179.113 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 8' ' ' TRP . . . . . . . . . . . . . 63.7 m95 -112.79 126.53 55.53 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 116.078 -0.51 . . . . 75.14 109.73 -177.917 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 9' ' ' PHE . . . . . 0.407 ' CE2' ' HB2' ' A' ' 11' ' ' ALA . 54.1 t80 -125.07 91.14 3.37 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-O 121.201 0.525 . . . . 72.33 110.542 -176.807 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 18.2 m120 -87.47 78.36 8.64 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-O 121.426 0.631 . . . . 63.41 109.815 -179.945 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 11' ' ' ALA . . . . . 0.407 ' HB2' ' CE2' ' A' ' 9' ' ' PHE . . . -63.71 -32.57 74.1 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 115.136 -0.938 . . . . 63.31 110.833 -179.292 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 42.9 mt-10 -76.89 -8.86 58.14 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.112 -0.494 . . . . 64.02 111.026 179.426 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 13' ' ' LYS . . . . . 0.419 ' HB3' ' CE2' ' A' ' 15' ' ' PHE . 75.5 mmtt -107.75 -26.06 10.98 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 120.938 0.399 . . . . 73.02 110.28 178.948 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 96.61 20.69 23.83 Favored Glycine 0 N--CA 1.449 -0.482 0 C-N-CA 120.942 -0.647 . . . . 71.45 113.017 175.779 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 15' ' ' PHE . . . . . 0.419 ' CE2' ' HB3' ' A' ' 13' ' ' LYS . 31.5 p90 -155.09 167.11 31.45 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-O 120.982 0.42 . . . . 71.11 111.262 179.104 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -157.84 168.49 34.44 Favored Glycine 0 N--CA 1.445 -0.719 0 CA-C-N 115.819 -0.628 . . . . 74.23 112.021 180.0 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 91.4 m-85 -121.13 118.6 30.11 Favored 'General case' 0 C--N 1.321 -0.63 0 CA-C-O 120.885 0.374 . . . . 74.23 110.543 -178.459 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 55.2 mt -104.16 124.51 58.65 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 N-CA-C 109.601 -0.518 . . . . 70.34 109.601 177.711 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 19' ' ' GLU . . . . . 0.538 ' HG2' ' O ' ' A' ' 5' ' ' THR . 14.6 pt-20 -82.8 130.29 35.11 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-O 121.436 0.636 . . . . 73.51 111.525 -173.12 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 20' ' ' ARG . . . . . 0.413 ' HB3' ' HB3' ' A' ' 24' ' ' ASP . 16.2 ttp180 -113.15 158.82 19.93 Favored 'General case' 0 C--N 1.324 -0.532 0 N-CA-C 108.839 -0.801 . . . . 63.33 108.839 175.03 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 5.6 mm-40 -49.36 -36.43 21.57 Favored 'General case' 0 N--CA 1.472 0.657 0 N-CA-C 113.961 1.097 . . . . 62.33 113.961 -168.951 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 61.7 t30 -84.16 12.49 6.4 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 121.189 0.519 . . . . 72.0 111.321 -175.667 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 76.39 10.2 85.66 Favored Glycine 0 N--CA 1.454 -0.103 0 N-CA-C 110.508 -1.037 . . . . 73.24 110.508 -173.185 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 24' ' ' ASP . . . . . 0.413 ' HB3' ' HB3' ' A' ' 20' ' ' ARG . 17.7 t70 -76.75 90.12 3.42 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-N 114.417 -0.892 . . . . 43.5 109.894 -177.714 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 12.1 p-10 -70.59 114.16 8.41 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-O 121.592 0.71 . . . . 75.43 110.734 178.845 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 23.8 t -84.53 122.55 38.15 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.683 0 CA-C-N 115.185 -0.916 . . . . 74.42 109.839 179.721 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 27' ' ' PHE . . . . . . . . . . . . . 70.8 t80 -85.36 109.31 18.31 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 115.855 -0.611 . . . . 72.0 110.831 -174.997 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.485 ' HB ' ' HB3' ' A' ' 60' ' ' ALA . 11.3 p -96.06 147.14 6.28 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.596 0 N-CA-C 109.867 -0.42 . . . . 54.51 109.867 178.256 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 29' ' ' HIS . . . . . 0.494 ' O ' HG13 ' A' ' 33' ' ' ILE . 5.7 p80 -128.02 153.53 46.66 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 120.741 0.305 . . . . 72.13 110.902 -176.911 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 48.0 p90 -57.26 -29.34 63.75 Favored 'General case' 0 N--CA 1.468 0.447 0 N-CA-C 113.489 0.922 . . . . 74.52 113.489 -170.192 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 21.9 m -76.64 -1.2 26.5 Favored 'General case' 0 C--N 1.326 -0.45 0 C-N-CA 120.93 -0.308 . . . . 71.22 111.245 -179.998 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 32' ' ' ALA . . . . . 0.597 ' HB1' ' HA ' ' A' ' 61' ' ' ALA . . . -125.02 -11.36 7.09 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.874 0.369 . . . . 73.01 110.919 177.631 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.494 HG13 ' O ' ' A' ' 29' ' ' HIS . 85.9 mt -77.49 137.93 21.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.114 -0.494 . . . . 74.12 110.837 178.372 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 7.6 pt20 -69.27 110.56 4.68 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.974 0.416 . . . . 65.45 109.947 173.527 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -148.25 54.61 0.51 Allowed Glycine 0 N--CA 1.448 -0.516 0 C-N-CA 120.303 -0.951 . . . . 44.14 112.915 -177.889 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 36' ' ' ASP . . . . . 0.703 ' HB2' ' HD3' ' A' ' 39' ' ' LYS . 5.4 m-20 -76.7 71.72 3.3 Favored 'General case' 0 C--N 1.329 -0.288 0 N-CA-C 109.718 -0.475 . . . . 74.43 109.718 177.096 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 75.58 -77.22 1.26 Allowed Glycine 0 N--CA 1.445 -0.706 0 C-N-CA 120.787 -0.721 . . . . 73.54 112.309 -178.935 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 41.4 p90 -105.61 17.4 23.87 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 120.928 0.394 . . . . 64.5 112.036 -174.343 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 39' ' ' LYS . . . . . 0.703 ' HD3' ' HB2' ' A' ' 36' ' ' ASP . 1.9 mptm? -94.17 134.55 36.5 Favored 'General case' 0 C--N 1.321 -0.631 0 N-CA-C 109.616 -0.513 . . . . 71.2 109.616 174.882 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 14.7 p -159.8 170.18 22.03 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-O 120.925 0.393 . . . . 72.03 110.71 -179.159 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 3.7 mm? -110.43 158.17 18.78 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 116.101 -0.499 . . . . 64.32 109.851 177.202 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 28.3 t70 -118.3 137.77 52.84 Favored 'General case' 0 C--N 1.321 -0.636 0 N-CA-C 109.634 -0.506 . . . . 75.41 109.634 -177.562 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 8.5 pt-20 -71.14 116.99 12.08 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-O 121.523 0.677 . . . . 63.5 110.072 179.73 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 105.54 6.2 38.6 Favored Glycine 0 N--CA 1.445 -0.723 0 CA-C-N 115.69 -0.687 . . . . 70.13 111.463 -174.002 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 62.2 tp60 -92.11 132.09 36.86 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 120.743 0.306 . . . . 71.3 110.877 179.05 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -78.66 132.14 36.94 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 116.01 -0.541 . . . . 72.41 109.561 173.504 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 25.5 m -137.81 153.66 28.0 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.634 0 CA-C-N 116.064 -0.516 . . . . 60.51 111.699 -177.191 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 9.4 p -113.1 111.79 22.74 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-N 115.872 -0.604 . . . . 72.33 109.78 174.754 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 49' ' ' PHE . . . . . 0.421 ' HA ' ' O ' ' A' ' 62' ' ' ASN . 39.5 p90 -120.81 161.93 20.65 Favored 'General case' 0 C--N 1.319 -0.729 0 CA-C-N 115.959 -0.564 . . . . 73.2 110.569 -172.551 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 33.1 t70 -93.15 118.0 30.72 Favored 'General case' 0 C--N 1.32 -0.711 0 N-CA-C 109.491 -0.559 . . . . 71.33 109.491 173.978 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 5.1 p -78.23 109.13 12.54 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.65 0 CA-C-O 121.67 0.748 . . . . 73.41 111.06 -176.539 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 9.7 tp10 -92.75 119.88 32.57 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-N 115.375 -0.83 . . . . 62.21 108.886 175.583 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 12.9 pt-20 -107.15 124.89 50.36 Favored 'General case' 0 C--N 1.317 -0.821 0 CA-C-O 120.897 0.38 . . . . 63.44 110.227 -179.923 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -146.78 -142.25 3.69 Favored Glycine 0 N--CA 1.448 -0.525 0 C-N-CA 120.615 -0.802 . . . . 71.54 112.281 -179.751 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 16.4 mm100 -77.64 -26.36 50.42 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-O 120.982 0.42 . . . . 73.43 110.451 -178.465 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 24.4 mmm180 -87.35 4.51 42.68 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 116.082 -0.508 . . . . 74.5 110.351 -179.445 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 89.36 -138.39 14.64 Favored Glycine 0 N--CA 1.446 -0.646 0 C-N-CA 120.928 -0.653 . . . . 64.55 111.618 -178.361 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 89.2 Cg_endo -84.73 104.86 0.96 Allowed 'Trans proline' 0 N--CA 1.455 -0.749 0 C-N-CA 122.701 2.267 . . . . 64.14 112.329 177.455 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 12.3 pt20 -112.52 135.62 53.01 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-O 121.144 0.497 . . . . 72.5 110.017 177.551 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 60' ' ' ALA . . . . . 0.485 ' HB3' ' HB ' ' A' ' 28' ' ' VAL . . . -86.34 128.12 34.89 Favored 'General case' 0 C--N 1.319 -0.758 0 CA-C-O 121.149 0.499 . . . . 55.31 111.708 -172.743 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 61' ' ' ALA . . . . . 0.597 ' HA ' ' HB1' ' A' ' 32' ' ' ALA . . . -130.21 143.63 50.89 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 115.436 -0.802 . . . . 74.12 109.282 174.016 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 62' ' ' ASN . . . . . 0.421 ' O ' ' HA ' ' A' ' 49' ' ' PHE . 45.0 m-80 59.45 87.23 0.08 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 121.244 0.545 . . . . 71.45 110.391 -176.965 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 47.8 t -105.39 111.14 33.49 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.591 0 CA-C-N 115.721 -0.672 . . . . 71.13 110.273 -176.883 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 71.9 mt-30 -107.93 142.53 37.9 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-N 116.149 -0.478 . . . . 74.32 109.944 -179.73 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 46.0 mttp -77.48 144.22 37.9 Favored 'General case' 0 C--N 1.325 -0.492 0 C-N-CA 120.868 -0.333 . . . . 73.4 110.422 179.567 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.247 0.958 0 CA-C-O 118.781 -0.628 . . . . 52.31 110.413 178.077 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 54.2 tpp . . . . . 0 N--CA 1.483 1.19 0 CA-C-O 120.707 0.289 . . . . 54.21 111.025 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 2' ' ' GLU . . . . . 0.607 ' HG2' HG23 ' A' ' 51' ' ' VAL . 4.8 mp0 -85.6 101.07 12.39 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 121.125 0.488 . . . . 73.4 111.318 -178.178 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 3' ' ' GLN . . . . . 0.663 ' HG2' HG22 ' A' ' 48' ' ' THR . 79.7 mt-30 -97.49 122.95 41.13 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.732 -0.667 . . . . 74.31 109.638 172.209 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -138.14 178.31 19.33 Favored Glycine 0 N--CA 1.445 -0.721 0 N-CA-C 111.136 -0.786 . . . . 62.24 111.136 179.178 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 5' ' ' THR . . . . . 0.422 ' O ' ' HG2' ' A' ' 19' ' ' GLU . 13.1 m -125.11 130.54 52.42 Favored 'General case' 0 C--N 1.315 -0.919 0 CA-C-N 117.28 0.54 . . . . 74.55 110.512 178.088 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 61.3 t -72.58 108.57 4.06 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.472 0 CA-C-N 116.376 -0.375 . . . . 64.2 110.01 178.813 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 7' ' ' LYS . . . . . 0.444 ' HB3' ' CE3' ' A' ' 8' ' ' TRP . 6.5 mmtm -73.62 -48.48 32.23 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 116.26 -0.427 . . . . 75.53 110.208 177.622 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 8' ' ' TRP . . . . . 0.542 ' HE1' ' HD2' ' A' ' 17' ' ' PHE . 15.6 p90 -164.14 158.92 19.76 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.661 -0.7 . . . . 75.31 110.075 177.763 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 9' ' ' PHE . . . . . 0.415 ' HD1' ' HA3' ' A' ' 16' ' ' GLY . 71.4 t80 -134.33 106.48 7.12 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 116.264 -0.426 . . . . 74.44 110.12 178.622 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 87.8 m-20 -76.71 85.09 3.34 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 116.048 -0.524 . . . . 54.44 109.821 179.791 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -62.39 -38.11 88.36 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 115.519 -0.764 . . . . 62.24 111.492 -177.234 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 42.0 mt-10 -72.55 -14.41 61.63 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 116.253 -0.43 . . . . 72.23 111.056 -179.571 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 32.2 mmmt -101.21 -26.32 13.69 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.88 0.372 . . . . 65.44 110.225 177.922 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 100.15 7.3 52.61 Favored Glycine 0 N--CA 1.45 -0.427 0 C-N-CA 120.83 -0.7 . . . . 63.23 113.253 175.423 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 41.0 p90 -151.16 154.96 37.91 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-O 121.125 0.488 . . . . 75.33 111.602 -176.077 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.415 ' HA3' ' HD1' ' A' ' 9' ' ' PHE . . . -135.95 178.45 18.71 Favored Glycine 0 N--CA 1.444 -0.803 0 N-CA-C 111.055 -0.818 . . . . 62.34 111.055 178.65 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 17' ' ' PHE . . . . . 0.542 ' HD2' ' HE1' ' A' ' 8' ' ' TRP . 79.9 m-85 -131.28 123.23 27.92 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-O 121.197 0.522 . . . . 55.23 111.243 -177.975 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 64.5 mt -106.43 126.48 62.15 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 CA-C-N 115.482 -0.781 . . . . 54.24 109.144 176.803 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 19' ' ' GLU . . . . . 0.422 ' HG2' ' O ' ' A' ' 5' ' ' THR . 17.2 pt-20 -79.53 139.36 37.58 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-O 121.327 0.584 . . . . 75.31 112.299 -173.464 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 20' ' ' ARG . . . . . . . . . . . . . 10.0 tpt180 -109.83 166.61 10.79 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.082 -0.963 . . . . 64.1 108.94 174.846 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 21' ' ' GLU . . . . . 0.453 ' CD ' ' H ' ' A' ' 21' ' ' GLU . 2.3 mp0 -43.95 -48.68 8.62 Favored 'General case' 0 N--CA 1.472 0.635 0 N-CA-C 112.397 0.518 . . . . 75.1 112.397 179.409 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 74.6 m-20 -71.41 -7.08 44.97 Favored 'General case' 0 N--CA 1.468 0.429 0 CA-C-N 116.295 -0.411 . . . . 74.34 112.025 -174.9 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 90.01 7.63 67.94 Favored Glycine 0 N--CA 1.45 -0.387 0 N-CA-C 110.084 -1.206 . . . . 52.13 110.084 -170.145 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 13.0 t70 -70.28 93.2 0.83 Allowed 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 114.486 -0.857 . . . . 73.0 109.953 -179.262 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.405 ' HB2' ' HB3' ' A' ' 17' ' ' PHE . 13.4 p-10 -65.76 101.92 0.69 Allowed 'General case' 0 C--N 1.321 -0.644 0 CA-C-N 115.549 -0.75 . . . . 54.11 110.65 176.848 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 40.0 t -71.01 130.41 34.95 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.587 0 CA-C-N 115.444 -0.798 . . . . 71.24 110.547 -178.487 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 27' ' ' PHE . . . . . . . . . . . . . 63.1 t80 -79.39 108.64 13.07 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 116.079 -0.51 . . . . 65.25 110.147 -178.294 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 9.3 p -111.16 141.5 26.33 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.598 0 N-CA-C 110.061 -0.348 . . . . 65.15 110.061 179.242 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 29' ' ' HIS . . . . . 0.555 ' O ' HG13 ' A' ' 33' ' ' ILE . 6.0 p80 -128.94 145.75 51.15 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.795 0.331 . . . . 52.13 110.863 -177.03 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 37.5 p90 -58.82 -27.69 65.31 Favored 'General case' 0 N--CA 1.467 0.421 0 CA-C-N 115.679 -0.691 . . . . 73.42 112.294 -171.227 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 1.5 p -79.03 6.64 8.91 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-O 120.744 0.307 . . . . 74.23 111.707 -179.331 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -129.25 -14.74 4.26 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 121.002 0.429 . . . . 72.21 110.879 175.287 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.755 HD13 HD21 ' A' ' 41' ' ' LEU . 24.9 mt -80.45 161.68 3.86 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.164 -0.471 . . . . 65.52 110.089 176.263 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 34' ' ' GLN . . . . . 0.682 ' NE2' ' HA ' ' A' ' 64' ' ' GLN . 26.5 pt20 -87.14 -173.75 4.57 Favored 'General case' 0 C--N 1.327 -0.383 0 N-CA-C 110.107 -0.331 . . . . 43.23 110.107 177.485 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -143.29 62.61 0.5 Allowed Glycine 0 N--CA 1.449 -0.471 0 C-N-CA 120.72 -0.752 . . . . 50.52 112.276 178.086 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 13.9 p-10 -94.98 118.01 31.1 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-O 121.434 0.635 . . . . 74.55 110.445 -179.55 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 81.75 -61.42 4.65 Favored Glycine 0 N--CA 1.45 -0.367 0 N-CA-C 111.41 -0.676 . . . . 42.31 111.41 -175.054 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 65.5 m-85 -137.58 165.93 25.13 Favored 'General case' 0 C--N 1.325 -0.481 0 N-CA-C 109.292 -0.633 . . . . 61.54 109.292 175.618 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 39' ' ' LYS . . . . . 0.4 ' HD2' ' N ' ' A' ' 39' ' ' LYS . 1.0 OUTLIER -99.84 28.54 4.7 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-O 121.71 0.767 . . . . 71.42 109.613 176.048 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 37.4 m -132.74 151.2 52.04 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 115.168 -0.924 . . . . 64.41 109.676 178.123 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 41' ' ' LEU . . . . . 0.755 HD21 HD13 ' A' ' 33' ' ' ILE . 3.5 mm? -91.22 148.01 22.65 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 116.346 -0.388 . . . . 72.3 110.758 -176.708 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 4.8 m-20 -91.61 113.35 25.6 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 115.797 -0.638 . . . . 63.35 109.293 175.452 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 4.5 mp0 -62.97 129.82 42.06 Favored 'General case' 0 C--N 1.321 -0.669 0 CA-C-N 116.061 -0.518 . . . . 62.23 110.422 -179.305 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 97.89 -7.88 63.09 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 121.042 -0.599 . . . . 63.14 112.102 -178.263 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 7.8 tp-100 -84.15 123.85 30.52 Favored 'General case' 0 C--N 1.324 -0.523 0 N-CA-C 110.173 -0.306 . . . . 60.34 110.173 179.83 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -68.1 135.28 51.94 Favored 'General case' 0 C--N 1.328 -0.345 0 N-CA-C 109.403 -0.592 . . . . 75.2 109.403 172.623 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 0.546 HG12 ' HA ' ' A' ' 65' ' ' LYS . 21.1 m -134.24 154.05 36.9 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.771 0 CA-C-O 121.214 0.53 . . . . 75.32 111.501 -175.704 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 48' ' ' THR . . . . . 0.663 HG22 ' HG2' ' A' ' 3' ' ' GLN . 33.0 p -113.72 117.13 30.66 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 115.503 -0.771 . . . . 73.43 109.433 174.68 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 49' ' ' PHE . . . . . 0.424 ' HA ' ' O ' ' A' ' 62' ' ' ASN . 40.8 p90 -129.76 170.37 13.93 Favored 'General case' 0 C--N 1.316 -0.872 0 CA-C-N 115.966 -0.561 . . . . 72.31 110.913 -173.148 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 38.8 t70 -112.01 143.87 42.3 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-N 115.864 -0.607 . . . . 63.34 109.813 174.306 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 51' ' ' VAL . . . . . 0.607 HG23 ' HG2' ' A' ' 2' ' ' GLU . 84.7 t -94.88 121.52 45.54 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.553 0 CA-C-O 121.165 0.507 . . . . 73.32 110.875 -178.528 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 52' ' ' GLU . . . . . 0.582 ' HB3' ' HG3' ' A' ' 59' ' ' GLN . 0.0 OUTLIER -94.24 141.97 27.94 Favored 'General case' 0 C--N 1.321 -0.648 0 N-CA-C 108.849 -0.797 . . . . 64.45 108.849 174.288 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 4.9 pt-20 -111.93 106.37 15.05 Favored 'General case' 0 C--N 1.316 -0.855 0 CA-C-O 121.287 0.565 . . . . 73.1 111.0 -174.557 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -126.76 -169.58 12.76 Favored Glycine 0 N--CA 1.448 -0.538 0 C-N-CA 120.852 -0.69 . . . . 44.13 112.019 -179.403 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 44.7 mt-30 -76.77 -3.1 36.48 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.952 0.406 . . . . 63.2 111.109 -178.095 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 56' ' ' ARG . . . . . 0.423 HH11 ' HD2' ' A' ' 56' ' ' ARG . 17.7 mmm180 -100.24 3.82 43.83 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-O 120.95 0.405 . . . . 72.33 110.496 176.416 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 94.28 -142.43 16.02 Favored Glycine 0 N--CA 1.446 -0.644 0 C-N-CA 120.843 -0.694 . . . . 33.21 111.872 -178.364 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 74.3 Cg_endo -79.97 106.93 2.0 Favored 'Trans proline' 0 N--CA 1.458 -0.597 0 C-N-CA 122.76 2.306 . . . . 75.02 112.703 -179.309 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 59' ' ' GLN . . . . . 0.582 ' HG3' ' HB3' ' A' ' 52' ' ' GLU . 4.1 pt20 -111.7 126.43 55.03 Favored 'General case' 0 C--N 1.322 -0.627 0 CA-C-N 115.778 -0.646 . . . . 74.21 109.655 177.701 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -80.05 130.47 35.28 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-O 121.024 0.44 . . . . 20.05 111.464 -174.871 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -135.13 145.35 47.75 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 115.452 -0.795 . . . . 33.1 109.321 177.717 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 62' ' ' ASN . . . . . 0.424 ' O ' ' HA ' ' A' ' 49' ' ' PHE . 89.2 m-20 59.59 82.99 0.14 Allowed 'General case' 0 C--N 1.327 -0.398 0 CA-C-O 121.164 0.507 . . . . 75.53 110.225 -176.621 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.407 HG13 ' HB3' ' A' ' 49' ' ' PHE . 39.2 t -113.06 106.35 20.57 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.511 0 CA-C-N 115.545 -0.752 . . . . 63.31 110.394 -177.061 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 64' ' ' GLN . . . . . 0.682 ' HA ' ' NE2' ' A' ' 34' ' ' GLN . 53.4 mt-30 -99.73 145.32 27.79 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 116.401 -0.363 . . . . 75.43 110.395 -179.349 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 65' ' ' LYS . . . . . 0.546 ' HA ' HG12 ' A' ' 47' ' ' VAL . 28.4 mtmm -82.61 136.4 34.81 Favored 'General case' 0 C--N 1.324 -0.54 0 N-CA-C 110.076 -0.342 . . . . 75.02 110.076 -179.864 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.247 0.941 0 CA-C-O 118.843 -0.599 . . . . 53.03 110.485 -179.108 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 1' ' ' MET . . . . . 0.528 ' N ' ' HA ' ' A' ' 50' ' ' ASP . 92.9 mtp . . . . . 0 N--CA 1.483 1.194 0 CA-C-O 120.54 0.209 . . . . 73.53 111.046 . . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 2.2 mp0 -96.52 178.74 5.24 Favored 'General case' 0 C--O 1.237 0.447 0 CA-C-O 121.215 0.531 . . . . 72.22 111.676 -172.608 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 3' ' ' GLN . . . . . 0.472 ' HG2' HG22 ' A' ' 48' ' ' THR . 65.8 mt-30 -91.95 143.6 26.32 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.341 -0.845 . . . . 60.52 110.248 179.612 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 4' ' ' GLY . . . . . 0.68 ' HA3' ' HE2' ' A' ' 49' ' ' PHE . . . -159.26 150.86 21.58 Favored Glycine 0 N--CA 1.447 -0.626 0 C-N-CA 120.932 -0.652 . . . . 70.11 111.917 178.252 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 5' ' ' THR . . . . . 0.543 ' HA ' ' HA ' ' A' ' 46' ' ' ALA . 3.5 m -98.02 133.47 42.44 Favored 'General case' 0 C--N 1.32 -0.703 0 CA-C-O 120.563 0.22 . . . . 43.42 110.438 -179.029 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 51.2 t -68.16 103.62 0.71 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 N-CA-C 109.541 -0.54 . . . . 73.42 109.541 175.068 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 7' ' ' LYS . . . . . 0.764 ' HD3' ' HB3' ' A' ' 19' ' ' GLU . 31.0 mmmt -61.56 -60.7 3.3 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 121.342 0.591 . . . . 71.1 110.543 -176.706 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 8' ' ' TRP . . . . . . . . . . . . . 28.7 p90 -156.42 136.47 12.77 Favored 'General case' 0 C--N 1.319 -0.726 0 CA-C-N 115.349 -0.841 . . . . 74.23 109.533 176.695 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 9' ' ' PHE . . . . . 0.514 ' HA ' ' HA3' ' A' ' 16' ' ' GLY . 70.7 t80 -132.41 113.13 12.79 Favored 'General case' 0 C--N 1.317 -0.807 0 CA-C-O 121.09 0.471 . . . . 65.1 110.287 -177.033 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 2.6 m-20 -78.0 80.26 4.44 Favored 'General case' 0 C--N 1.322 -0.624 0 N-CA-C 108.892 -0.781 . . . . 74.32 108.892 176.014 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -60.53 -33.26 72.39 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 121.079 0.466 . . . . 73.31 110.918 -178.386 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 12' ' ' GLU . . . . . 0.434 ' HG3' ' HG2' ' A' ' 13' ' ' LYS . 6.8 pt-20 -67.71 -25.12 65.5 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 115.462 -0.79 . . . . 64.22 111.555 -179.824 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 13' ' ' LYS . . . . . 0.434 ' HG2' ' HG3' ' A' ' 12' ' ' GLU . 47.5 mmtm -110.06 -15.4 14.04 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-O 120.845 0.355 . . . . 73.01 111.222 -176.881 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 94.06 20.37 30.88 Favored Glycine 0 N--CA 1.449 -0.456 0 C-N-CA 120.995 -0.621 . . . . 73.31 114.148 170.237 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 43.2 p90 -153.62 156.44 37.94 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 117.67 0.735 . . . . 74.4 111.384 -179.321 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.514 ' HA3' ' HA ' ' A' ' 9' ' ' PHE . . . -167.73 -169.75 31.65 Favored Glycine 0 N--CA 1.45 -0.398 0 N-CA-C 111.883 -0.487 . . . . 52.12 111.883 178.389 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 88.1 m-85 -133.09 139.29 47.05 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 121.122 0.487 . . . . 60.24 111.309 -179.068 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 56.9 mt -119.93 145.33 26.36 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.547 0 N-CA-C 108.908 -0.775 . . . . 73.13 108.908 176.697 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 19' ' ' GLU . . . . . 0.764 ' HB3' ' HD3' ' A' ' 7' ' ' LYS . 20.9 pt-20 -89.37 158.22 17.86 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-O 121.15 0.5 . . . . 65.05 111.045 -177.123 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 20' ' ' ARG . . . . . 0.6 ' HD3' ' HB3' ' A' ' 24' ' ' ASP . 70.4 ttt180 -134.15 158.72 42.94 Favored 'General case' 0 C--N 1.32 -0.674 0 N-CA-C 108.523 -0.918 . . . . 75.13 108.523 179.146 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 44.1 mt-10 -48.2 -50.92 27.41 Favored 'General case' 0 N--CA 1.466 0.336 0 N-CA-C 113.229 0.825 . . . . 74.31 113.229 -172.316 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 57.8 m-80 -87.5 20.58 2.84 Favored 'General case' 0 C--N 1.327 -0.405 0 N-CA-C 111.878 0.325 . . . . 60.24 111.878 -173.964 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 76.16 10.55 85.32 Favored Glycine 0 C--N 1.33 0.234 0 C-N-CA 120.605 -0.807 . . . . 70.03 111.731 -178.897 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 24' ' ' ASP . . . . . 0.6 ' HB3' ' HD3' ' A' ' 20' ' ' ARG . 38.5 t70 -76.95 84.06 3.49 Favored 'General case' 0 C--N 1.322 -0.622 0 N-CA-C 109.772 -0.455 . . . . 75.24 109.772 -179.571 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 8.1 p-10 -58.62 127.56 32.76 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 121.361 0.6 . . . . 64.02 111.123 -176.467 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.545 ' HA ' ' HB2' ' A' ' 58' ' ' PRO . 17.1 t -105.64 124.37 60.62 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.615 0 CA-C-N 115.424 -0.807 . . . . 64.24 110.216 -176.453 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 27' ' ' PHE . . . . . . . . . . . . . 91.9 t80 -82.57 131.21 35.22 Favored 'General case' 0 C--N 1.326 -0.453 0 N-CA-C 110.063 -0.347 . . . . 73.23 110.063 179.944 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 9.8 p -123.3 137.41 56.72 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-O 121.278 0.561 . . . . 72.31 111.006 -179.481 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 22.0 t60 -115.02 151.77 33.62 Favored 'General case' 0 C--N 1.324 -0.504 0 N-CA-C 108.142 -1.059 . . . . 64.1 108.142 176.844 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 17.3 p90 -60.2 -20.15 57.43 Favored 'General case' 0 N--CA 1.472 0.661 0 N-CA-C 112.555 0.576 . . . . 74.41 112.555 -172.052 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 23.1 t -90.14 -9.06 49.68 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 120.892 0.377 . . . . 62.44 110.633 -179.166 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -103.99 -25.46 13.0 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 121.075 0.464 . . . . 72.11 110.747 -179.129 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.661 HD11 HD22 ' A' ' 41' ' ' LEU . 15.4 tt -77.55 163.75 3.71 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.55 0 N-CA-C 108.863 -0.792 . . . . 72.01 108.863 175.726 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 34' ' ' GLN . . . . . 0.518 ' HG2' ' O ' ' A' ' 34' ' ' GLN . 18.8 pm0 -76.55 66.82 2.61 Favored 'General case' 0 CA--C 1.533 0.321 0 CA-C-O 121.774 0.797 . . . . 75.3 111.646 -176.121 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -78.46 66.23 3.28 Favored Glycine 0 N--CA 1.448 -0.512 0 N-CA-C 110.906 -0.878 . . . . 74.3 110.906 174.769 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 36' ' ' ASP . . . . . 0.728 ' HB3' ' HD3' ' A' ' 39' ' ' LYS . 14.1 t70 -74.37 83.81 1.94 Allowed 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 120.991 0.424 . . . . 74.4 110.459 -177.379 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 75.85 -72.48 1.8 Allowed Glycine 0 N--CA 1.45 -0.4 0 N-CA-C 111.459 -0.656 . . . . 71.31 111.459 -176.958 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 72.7 m-85 -146.31 83.05 1.61 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.925 0.393 . . . . 73.31 110.15 176.93 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 39' ' ' LYS . . . . . 0.728 ' HD3' ' HB3' ' A' ' 36' ' ' ASP . 10.6 mptt -132.65 105.58 7.28 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 116.157 -0.474 . . . . 51.21 110.567 176.468 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 22.0 p -105.37 122.62 46.35 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-O 121.062 0.458 . . . . 61.41 110.229 175.705 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 41' ' ' LEU . . . . . 0.661 HD22 HD11 ' A' ' 33' ' ' ILE . 10.7 mp -83.28 126.06 32.26 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 116.158 -0.474 . . . . 74.32 110.241 178.786 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 28.5 t70 -75.51 139.58 42.26 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-N 115.595 -0.73 . . . . 71.35 110.616 -177.342 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 3.0 mp0 -61.22 105.72 0.53 Allowed 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.96 0.41 . . . . 70.42 110.317 178.142 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 126.49 -10.25 7.24 Favored Glycine 0 N--CA 1.447 -0.587 0 CA-C-N 115.871 -0.604 . . . . 63.24 111.731 -175.049 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 7.1 tt0 -77.37 127.49 32.65 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.846 0.355 . . . . 74.32 110.63 178.061 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 0.543 ' HA ' ' HA ' ' A' ' 5' ' ' THR . . . -92.39 130.43 38.07 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 116.201 -0.454 . . . . 61.01 110.371 177.747 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 0.414 HG12 ' HA ' ' A' ' 65' ' ' LYS . 15.5 m -137.37 174.39 11.57 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 CA-C-O 120.949 0.405 . . . . 62.42 111.316 -177.058 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 48' ' ' THR . . . . . 0.472 HG22 ' HG2' ' A' ' 3' ' ' GLN . 23.5 p -111.69 114.06 26.84 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 115.836 -0.62 . . . . 74.34 109.67 176.425 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 49' ' ' PHE . . . . . 0.68 ' HE2' ' HA3' ' A' ' 4' ' ' GLY . 39.7 p90 -125.17 165.38 18.35 Favored 'General case' 0 C--N 1.317 -0.823 0 CA-C-N 116.094 -0.503 . . . . 74.05 110.302 -174.322 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 50' ' ' ASP . . . . . 0.528 ' HA ' ' N ' ' A' ' 1' ' ' MET . 22.0 t0 -108.43 151.1 26.5 Favored 'General case' 0 C--N 1.317 -0.808 0 C-N-CA 119.992 -0.683 . . . . 54.43 109.883 173.646 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 51' ' ' VAL . . . . . 0.407 HG21 ' CZ ' ' A' ' 20' ' ' ARG . 61.1 t -105.13 109.35 27.42 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.779 0 CA-C-O 121.089 0.471 . . . . 72.22 110.593 -176.332 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 44.3 tt0 -81.85 96.31 7.59 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-N 115.41 -0.813 . . . . 63.33 109.062 175.463 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 6.7 pt-20 -74.67 90.62 2.3 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-O 121.519 0.676 . . . . 72.41 109.576 176.612 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -121.49 -144.58 6.94 Favored Glycine 0 N--CA 1.444 -0.772 0 CA-C-N 115.164 -0.926 . . . . 32.42 112.282 -177.925 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 55' ' ' GLN . . . . . 0.571 ' O ' ' HG2' ' A' ' 56' ' ' ARG . 6.6 tp-100 -80.86 82.29 6.89 Favored 'General case' 0 C--N 1.323 -0.552 0 N-CA-C 111.59 0.218 . . . . 74.25 111.59 -175.418 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 56' ' ' ARG . . . . . 0.571 ' HG2' ' O ' ' A' ' 55' ' ' GLN . 2.3 mmm180 156.73 -36.35 0.01 OUTLIER 'General case' 0 N--CA 1.478 0.974 0 C-N-CA 125.881 1.672 . . . . 72.51 108.498 173.109 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 57' ' ' GLY . . . . . 0.443 ' HA3' ' HD3' ' A' ' 58' ' ' PRO . . . 138.09 -120.05 1.93 Allowed Glycine 0 N--CA 1.445 -0.746 0 CA-C-N 115.186 -0.916 . . . . 72.15 111.712 -178.581 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 58' ' ' PRO . . . . . 0.545 ' HB2' ' HA ' ' A' ' 26' ' ' VAL . 2.9 Cg_endo -80.96 100.35 1.19 Allowed 'Trans proline' 0 N--CA 1.458 -0.574 0 C-N-CA 123.179 2.586 . . . . 64.32 112.721 -178.405 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 64.1 mt-30 -104.76 126.3 51.7 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 115.93 -0.577 . . . . 62.42 109.631 176.016 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -74.77 115.48 14.4 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-O 120.626 0.25 . . . . 72.22 110.784 -177.536 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -136.36 142.12 43.77 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 116.195 -0.457 . . . . 73.14 110.058 178.754 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 42.1 m-80 58.48 85.48 0.09 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 121.38 0.609 . . . . 52.44 110.492 -179.61 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.586 HG13 ' HB3' ' A' ' 49' ' ' PHE . 17.8 t -112.23 131.68 63.02 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.612 0 CA-C-N 115.737 -0.665 . . . . 61.41 110.284 -176.999 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 6.5 tp-100 -128.4 147.11 50.63 Favored 'General case' 0 C--N 1.32 -0.677 0 N-CA-C 109.896 -0.409 . . . . 73.25 109.896 179.063 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 65' ' ' LYS . . . . . 0.414 ' HA ' HG12 ' A' ' 47' ' ' VAL . 60.2 mttm -65.06 144.99 56.9 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-O 120.671 0.272 . . . . 63.43 110.359 177.533 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.039 0 CA-C-O 118.723 -0.656 . . . . 64.4 110.785 -179.06 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 66.5 mtt . . . . . 0 N--CA 1.477 0.898 0 CA-C-O 121.188 0.518 . . . . 73.23 109.789 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 1.3 pm0 -110.59 18.14 20.01 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 115.569 -0.742 . . . . 73.53 111.808 -172.622 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 46.6 tt0 -87.84 116.68 26.16 Favored 'General case' 0 C--N 1.321 -0.652 0 N-CA-C 109.471 -0.566 . . . . 64.34 109.471 174.657 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -132.39 153.8 20.76 Favored Glycine 0 N--CA 1.445 -0.749 0 C-N-CA 120.314 -0.946 . . . . 63.14 112.367 -177.768 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 5' ' ' THR . . . . . 0.508 ' O ' ' HG3' ' A' ' 19' ' ' GLU . 2.8 m -98.49 129.69 45.08 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-O 120.72 0.295 . . . . 73.22 110.273 178.933 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.435 HG22 HG12 ' A' ' 18' ' ' ILE . 61.7 t -79.75 118.4 27.22 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.606 0 O-C-N 122.357 -0.215 . . . . 62.15 110.462 178.815 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 7' ' ' LYS . . . . . 0.516 ' NZ ' ' HB3' ' A' ' 19' ' ' GLU . 49.3 mttp -74.18 -65.21 0.87 Allowed 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.926 0.393 . . . . 75.21 110.501 178.053 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 8' ' ' TRP . . . . . . . . . . . . . 90.6 m95 -144.87 160.86 40.61 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 115.821 -0.627 . . . . 75.42 111.211 -176.768 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 14.1 p90 -120.89 106.38 11.58 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 115.503 -0.771 . . . . 64.41 110.527 179.16 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 2.3 m-20 -84.95 77.12 10.17 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-N 115.944 -0.571 . . . . 71.34 109.805 -179.407 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 11' ' ' ALA . . . . . 0.517 ' HA ' ' HE2' ' A' ' 30' ' ' PHE . . . -63.63 -28.2 69.75 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.589 -0.732 . . . . 61.2 111.268 -178.804 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 65.6 mm-40 -74.87 -13.59 60.57 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 116.2 -0.455 . . . . 63.34 111.314 178.8 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 13' ' ' LYS . . . . . 0.516 ' HB3' ' CE2' ' A' ' 15' ' ' PHE . 31.2 mmmt -109.76 -30.09 8.02 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 116.297 -0.411 . . . . 71.44 111.053 -179.012 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 102.12 17.66 19.72 Favored Glycine 0 N--CA 1.449 -0.476 0 C-N-CA 120.632 -0.794 . . . . 63.42 112.668 177.389 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 15' ' ' PHE . . . . . 0.516 ' CE2' ' HB3' ' A' ' 13' ' ' LYS . 26.7 p90 -152.71 172.47 16.62 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 120.629 0.252 . . . . 73.0 110.736 -179.618 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -140.85 175.04 22.37 Favored Glycine 0 N--CA 1.446 -0.652 0 C-N-CA 121.06 -0.591 . . . . 65.11 111.77 178.887 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 97.5 m-85 -120.81 116.45 25.23 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-O 120.933 0.397 . . . . 65.1 111.171 -178.636 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.573 ' O ' ' HA ' ' A' ' 25' ' ' ASP . 36.7 mt -102.57 165.09 3.05 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.581 0 N-CA-C 107.816 -1.179 . . . . 61.22 107.816 173.202 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 19' ' ' GLU . . . . . 0.516 ' HB3' ' NZ ' ' A' ' 7' ' ' LYS . 0.3 OUTLIER -130.31 163.22 27.29 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-N 118.857 0.753 . . . . 71.5 111.364 179.05 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 20' ' ' ARG . . . . . . . . . . . . . 15.6 ttp180 -126.17 -163.23 1.2 Allowed 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 115.573 -0.739 . . . . 70.14 109.464 -178.902 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -64.14 -37.54 87.81 Favored 'General case' 0 C--N 1.329 -0.312 0 N-CA-C 112.277 0.473 . . . . 70.3 112.277 -172.776 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 87.6 m-20 -93.59 13.43 22.02 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-O 120.713 0.292 . . . . 71.13 111.113 -177.877 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 74.2 20.44 79.65 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.329 -0.938 . . . . 64.31 110.764 -173.558 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 14.4 t70 -72.08 93.1 1.38 Allowed 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 115.132 -0.534 . . . . 74.3 109.823 -179.017 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.573 ' HA ' ' O ' ' A' ' 18' ' ' ILE . 2.3 m-20 -60.46 121.03 11.07 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.642 -0.708 . . . . 72.02 111.594 178.58 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 36.6 t -96.69 131.48 43.38 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.62 0 CA-C-N 115.013 -0.994 . . . . 73.25 109.897 179.945 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 27' ' ' PHE . . . . . . . . . . . . . 47.4 t80 -83.49 98.7 9.68 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 116.144 -0.48 . . . . 61.11 110.525 -175.817 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.537 ' HB ' ' HB3' ' A' ' 60' ' ' ALA . 13.2 p -98.82 138.66 22.67 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 CA-C-O 121.069 0.461 . . . . 74.03 111.072 -177.782 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 21.1 m-70 -99.29 139.19 35.31 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 116.064 -0.517 . . . . 74.01 110.112 176.81 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 30' ' ' PHE . . . . . 0.628 ' HD1' HD12 ' A' ' 33' ' ' ILE . 20.4 m-85 -65.74 -26.2 67.62 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.643 0.258 . . . . 75.34 110.819 179.008 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 38.3 t -72.36 -16.97 61.87 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-O 121.111 0.481 . . . . 72.12 110.48 175.805 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 32' ' ' ALA . . . . . 0.546 ' HB1' ' HA ' ' A' ' 61' ' ' ALA . . . -94.61 -20.01 19.96 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 121.085 0.469 . . . . 65.11 110.049 177.033 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.706 HG12 HG21 ' A' ' 63' ' ' VAL . 54.6 mt -82.02 135.32 25.2 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.465 0 CA-C-N 115.807 -0.633 . . . . 72.44 110.078 175.443 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 12.7 pt20 -70.98 89.47 0.79 Allowed 'General case' 0 C--N 1.324 -0.534 0 CA-C-O 121.259 0.552 . . . . 54.32 110.563 176.377 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.469 ' HA2' ' O ' ' A' ' 38' ' ' PHE . . . -84.07 59.95 4.89 Favored Glycine 0 N--CA 1.449 -0.465 0 C-N-CA 121.121 -0.561 . . . . 54.34 112.693 -178.492 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -65.54 -68.53 0.36 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.517 0.199 . . . . 74.31 110.968 179.119 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -108.28 -20.92 7.95 Favored Glycine 0 N--CA 1.447 -0.574 0 C-N-CA 120.763 -0.732 . . . . 72.42 111.786 176.152 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 38' ' ' PHE . . . . . 0.469 ' O ' ' HA2' ' A' ' 35' ' ' GLY . 95.7 m-85 -128.2 127.24 42.53 Favored 'General case' 0 C--N 1.326 -0.437 0 N-CA-C 110.25 -0.278 . . . . 75.33 110.25 -179.805 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 13.5 mptt -87.84 -0.01 56.4 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 116.274 -0.421 . . . . 64.4 111.253 -179.798 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 42.0 m -155.26 162.51 40.88 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 116.496 -0.32 . . . . 72.31 110.368 -177.465 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 3.5 mm? -107.52 162.23 14.13 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.29 -0.413 . . . . 72.21 110.136 178.568 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 42' ' ' ASP . . . . . 0.493 ' HB2' ' HB2' ' A' ' 45' ' ' GLN . 5.9 m-20 -69.62 157.23 37.61 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 116.017 -0.538 . . . . 73.31 111.1 179.967 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -77.18 105.74 8.46 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-O 121.521 0.677 . . . . 70.45 110.039 176.018 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 108.96 5.48 30.84 Favored Glycine 0 N--CA 1.446 -0.657 0 CA-C-N 115.678 -0.692 . . . . 24.05 111.656 -174.014 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 45' ' ' GLN . . . . . 0.493 ' HB2' ' HB2' ' A' ' 42' ' ' ASP . 58.4 tp60 -80.78 130.68 35.2 Favored 'General case' 0 C--N 1.326 -0.424 0 N-CA-C 109.993 -0.373 . . . . 75.43 109.993 178.944 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -102.46 127.71 49.39 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-O 120.778 0.323 . . . . 64.42 110.721 179.764 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 17.5 m -136.02 172.59 15.28 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.562 0 CA-C-N 115.961 -0.563 . . . . 51.24 110.528 -179.109 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 20.4 p -116.66 115.01 24.86 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 116.177 -0.465 . . . . 64.32 110.328 179.476 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 33.1 p90 -117.42 163.36 16.49 Favored 'General case' 0 C--N 1.319 -0.752 0 CA-C-O 121.157 0.503 . . . . 73.33 111.925 -174.137 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 25.8 t70 -86.07 136.72 33.12 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 115.861 -0.609 . . . . 70.34 109.585 172.908 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 3.7 p -81.83 114.46 22.78 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.499 0 CA-C-O 121.913 0.863 . . . . 74.44 112.06 -174.632 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 9.6 tp10 -108.93 162.0 14.62 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 114.763 -1.108 . . . . 62.13 108.374 175.693 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 39.1 mt-10 -122.59 169.18 11.29 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-O 121.159 0.504 . . . . 52.42 111.517 -179.999 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -162.48 158.25 30.33 Favored Glycine 0 N--CA 1.443 -0.897 0 N-CA-C 110.736 -0.946 . . . . 62.2 110.736 179.046 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 20.6 pt20 -75.73 9.32 2.37 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 117.093 0.447 . . . . 74.43 111.929 -177.088 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 69.3 mtm180 -130.19 15.32 5.65 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 121.005 0.431 . . . . 72.23 110.285 174.654 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 129.21 -179.68 16.54 Favored Glycine 0 N--CA 1.45 -0.427 0 C-N-CA 120.651 -0.785 . . . . 54.22 112.083 179.871 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo -74.6 146.27 34.23 Favored 'Trans proline' 0 N--CA 1.461 -0.428 0 C-N-CA 122.508 2.138 . . . . 71.1 112.427 -179.055 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 42.3 mt-30 -118.5 162.22 18.71 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 115.952 -0.567 . . . . 75.22 110.013 178.335 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 60' ' ' ALA . . . . . 0.537 ' HB3' ' HB ' ' A' ' 28' ' ' VAL . . . -118.35 125.29 49.73 Favored 'General case' 0 C--N 1.318 -0.794 0 CA-C-O 121.047 0.451 . . . . 73.2 111.039 -179.672 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 61' ' ' ALA . . . . . 0.546 ' HA ' ' HB1' ' A' ' 32' ' ' ALA . . . -127.81 164.59 21.86 Favored 'General case' 0 C--N 1.321 -0.673 0 N-CA-C 108.763 -0.829 . . . . 75.04 108.763 175.871 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 39.7 m-80 48.25 76.87 0.11 Allowed 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 121.032 0.444 . . . . 74.05 110.989 -177.843 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.706 HG21 HG12 ' A' ' 33' ' ' ILE . 46.6 t -89.21 92.08 3.86 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.67 0 CA-C-N 116.042 -0.526 . . . . 72.33 110.142 -178.751 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -80.38 125.82 30.39 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 115.434 -0.803 . . . . 73.05 109.368 -177.868 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 52.9 mttp -64.25 137.54 57.98 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.301 -0.409 . . . . 62.44 110.381 -177.403 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.251 1.135 0 CA-C-O 118.439 -0.791 . . . . 74.22 109.927 179.496 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 1' ' ' MET . . . . . 0.548 ' HA ' ' O ' ' A' ' 49' ' ' PHE . 64.7 mtt . . . . . 0 N--CA 1.479 1.009 0 CA-C-O 120.697 0.284 . . . . 72.44 110.676 . . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 2.8 mp0 -117.16 170.74 8.44 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 121.04 0.448 . . . . 71.1 110.619 176.82 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 84.0 mt-30 -95.15 126.83 40.75 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 115.357 -0.838 . . . . 75.24 109.482 176.813 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 4' ' ' GLY . . . . . 0.681 ' HA3' ' HE2' ' A' ' 49' ' ' PHE . . . -140.83 151.11 22.22 Favored Glycine 0 N--CA 1.445 -0.756 0 C-N-CA 120.291 -0.956 . . . . 72.11 112.533 -177.985 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 5' ' ' THR . . . . . 0.452 ' O ' ' HG2' ' A' ' 19' ' ' GLU . 7.4 m -107.15 125.82 51.58 Favored 'General case' 0 C--N 1.319 -0.75 0 N-CA-C 110.21 -0.293 . . . . 72.34 110.21 -179.718 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 48.3 t -68.01 117.39 9.76 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 N-CA-C 110.168 -0.308 . . . . 72.03 110.168 179.705 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 7' ' ' LYS . . . . . 0.632 ' HD3' ' HB3' ' A' ' 19' ' ' GLU . 30.1 mmmt -75.55 -56.37 4.76 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 121.405 0.622 . . . . 61.44 109.329 179.422 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 8' ' ' TRP . . . . . 0.789 ' HZ3' ' HB2' ' A' ' 10' ' ' ASN . 63.5 p-90 -164.71 157.95 17.21 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-N 114.849 -1.069 . . . . 45.12 108.921 175.927 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 11.3 p90 -129.04 115.1 17.24 Favored 'General case' 0 C--N 1.317 -0.816 0 CA-C-O 121.596 0.713 . . . . 73.21 110.805 -176.593 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 10' ' ' ASN . . . . . 0.789 ' HB2' ' HZ3' ' A' ' 8' ' ' TRP . 34.1 t30 -86.72 71.86 10.28 Favored 'General case' 0 C--N 1.319 -0.729 0 N-CA-C 108.527 -0.916 . . . . 72.54 108.527 179.008 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -62.83 -32.15 73.3 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 114.709 -1.132 . . . . 72.13 112.536 -171.284 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 33.1 mt-10 -75.53 -9.76 58.86 Favored 'General case' 0 C--N 1.326 -0.429 0 C-N-CA 120.905 -0.318 . . . . 73.23 111.252 -177.458 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 30.7 mmmt -110.92 -11.75 14.31 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 121.174 0.511 . . . . 52.4 110.124 174.253 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 95.21 15.83 43.08 Favored Glycine 0 N--CA 1.447 -0.596 0 C-N-CA 120.805 -0.712 . . . . 65.41 114.414 169.91 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 54.6 p90 -145.8 155.3 42.84 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 117.941 0.871 . . . . 75.24 111.601 -179.254 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -140.64 166.82 25.76 Favored Glycine 0 N--CA 1.445 -0.728 0 N-CA-C 111.078 -0.809 . . . . 71.22 111.078 177.422 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 79.0 m-85 -120.89 121.92 39.12 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-O 121.201 0.524 . . . . 74.43 111.201 -178.323 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 56.4 mt -111.25 139.59 34.55 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.615 0 CA-C-N 115.331 -0.85 . . . . 71.12 109.459 178.166 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 19' ' ' GLU . . . . . 0.632 ' HB3' ' HD3' ' A' ' 7' ' ' LYS . 9.1 pt-20 -88.6 134.36 33.9 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 120.896 0.379 . . . . 71.25 110.523 179.008 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 20' ' ' ARG . . . . . . . . . . . . . 27.8 ttp180 -121.84 152.01 40.02 Favored 'General case' 0 C--N 1.322 -0.63 0 N-CA-C 108.996 -0.742 . . . . 74.03 108.996 174.13 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 21' ' ' GLU . . . . . 0.435 ' HG3' ' H ' ' A' ' 21' ' ' GLU . 0.0 OUTLIER -50.71 -40.81 55.12 Favored 'General case' 0 N--CA 1.463 0.189 0 O-C-N 123.279 0.362 . . . . 73.14 111.795 -177.83 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 6.2 m-20 -109.44 65.75 0.62 Allowed 'General case' 0 C--N 1.322 -0.63 0 CA-C-O 121.004 0.431 . . . . 72.31 110.339 171.62 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 132.85 94.88 0.57 Allowed Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.816 -0.707 . . . . 61.04 112.227 174.257 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 24' ' ' ASP . . . . . 0.527 ' HA ' ' HA ' ' A' ' 19' ' ' GLU . 3.9 p30 -71.0 6.41 1.58 Allowed 'General case' 0 N--CA 1.468 0.432 0 CA-C-O 120.962 0.41 . . . . 71.41 111.48 -178.108 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 7.2 p-10 -122.6 88.59 2.96 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-O 121.708 0.766 . . . . 70.25 110.916 -177.266 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.434 HG12 ' HB2' ' A' ' 60' ' ' ALA . 55.9 t -112.34 118.59 58.17 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.621 0 CA-C-N 115.431 -0.804 . . . . 71.31 109.565 173.769 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 27' ' ' PHE . . . . . 0.458 ' O ' ' HA ' ' A' ' 59' ' ' GLN . 63.1 t80 -82.08 105.09 12.9 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 115.773 -0.648 . . . . 73.44 110.484 -176.183 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 12.2 p -100.03 133.95 41.24 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.603 0 CA-C-O 121.207 0.527 . . . . 73.25 110.531 179.122 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 85.8 t60 -91.87 133.05 36.01 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 115.843 -0.617 . . . . 62.33 109.855 -178.226 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 14.0 p90 -56.39 -36.39 68.82 Favored 'General case' 0 N--CA 1.467 0.399 0 N-CA-C 111.938 0.347 . . . . 74.21 111.938 -174.015 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 6.9 t -87.31 6.44 33.47 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 121.293 0.568 . . . . 43.12 110.644 -177.763 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -105.67 -19.7 13.68 Favored 'General case' 0 C--N 1.326 -0.447 0 N-CA-C 109.144 -0.687 . . . . 34.22 109.144 173.216 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.405 ' O ' ' HG3' ' A' ' 39' ' ' LYS . 69.2 mt -74.72 105.45 3.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 114.998 -1.001 . . . . 75.31 110.271 175.329 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 34' ' ' GLN . . . . . 0.405 ' O ' ' HE3' ' A' ' 65' ' ' LYS . 0.9 OUTLIER -79.75 71.26 6.39 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 121.854 0.835 . . . . 62.54 109.943 175.478 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -74.13 163.26 54.52 Favored Glycine 0 N--CA 1.448 -0.519 0 CA-C-N 115.104 -0.953 . . . . 73.03 112.469 -178.597 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 21.7 t70 -93.89 105.13 17.16 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-O 120.795 0.331 . . . . 61.42 110.124 -178.94 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 92.28 -53.51 2.81 Favored Glycine 0 N--CA 1.449 -0.438 0 N-CA-C 111.64 -0.584 . . . . 50.13 111.64 -179.554 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 97.8 m-85 -133.82 147.19 51.19 Favored 'General case' 0 C--N 1.325 -0.497 0 N-CA-C 109.519 -0.549 . . . . 64.14 109.519 177.157 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 39' ' ' LYS . . . . . 0.405 ' HG3' ' O ' ' A' ' 33' ' ' ILE . 13.9 mptt -73.55 91.69 1.85 Allowed 'General case' 0 C--N 1.323 -0.575 0 CA-C-O 121.054 0.454 . . . . 63.35 110.408 179.22 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 22.8 p -165.85 154.91 11.71 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 115.561 -0.745 . . . . 52.4 110.114 -179.954 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 95.1 mt -132.39 130.48 40.72 Favored 'General case' 0 C--N 1.325 -0.483 0 N-CA-C 109.277 -0.638 . . . . 74.41 109.277 176.318 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 3.4 m-20 -55.88 125.05 19.73 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 121.205 0.526 . . . . 75.43 111.557 -179.36 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 7.6 pt-20 -66.95 123.27 19.72 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-N 115.834 -0.621 . . . . 71.52 109.831 175.895 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 101.81 5.76 50.4 Favored Glycine 0 N--CA 1.448 -0.502 0 C-N-CA 121.032 -0.604 . . . . 32.03 111.648 -173.229 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 7.5 tp60 -102.84 138.03 40.26 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.652 0.263 . . . . 74.21 110.521 178.603 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -92.16 131.91 37.03 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 116.293 -0.412 . . . . 43.12 110.427 176.329 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 24.0 m -134.77 173.84 13.89 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 CA-C-N 116.121 -0.49 . . . . 72.21 110.308 -179.793 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 19.3 p -117.34 115.69 25.74 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-O 121.185 0.517 . . . . 54.41 110.805 179.431 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 49' ' ' PHE . . . . . 0.681 ' HE2' ' HA3' ' A' ' 4' ' ' GLY . 38.0 p90 -120.63 152.72 37.8 Favored 'General case' 0 C--N 1.319 -0.76 0 CA-C-N 115.74 -0.664 . . . . 72.11 110.325 -177.523 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 50' ' ' ASP . . . . . 0.43 ' HA ' ' HA ' ' A' ' 1' ' ' MET . 22.7 t70 -97.64 116.76 30.47 Favored 'General case' 0 C--N 1.322 -0.596 0 N-CA-C 109.224 -0.658 . . . . 54.4 109.224 174.883 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 9.9 p -77.86 140.71 16.57 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.497 0 CA-C-O 121.52 0.676 . . . . 61.44 111.637 -170.553 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 52' ' ' GLU . . . . . 0.457 ' HB3' ' HG3' ' A' ' 59' ' ' GLN . 32.6 tt0 -137.38 156.91 47.66 Favored 'General case' 0 C--N 1.32 -0.688 0 N-CA-C 108.163 -1.051 . . . . 75.21 108.163 175.173 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 53' ' ' GLU . . . . . 0.42 ' HA ' ' O ' ' A' ' 57' ' ' GLY . 0.0 OUTLIER -149.49 -177.78 6.05 Favored 'General case' 0 C--N 1.32 -0.708 0 O-C-N 122.092 -0.38 . . . . 73.54 110.794 -178.487 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 143.94 -101.78 0.26 Allowed Glycine 0 N--CA 1.442 -0.933 0 C-N-CA 120.62 -0.8 . . . . 65.14 113.132 177.669 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 35.3 tt0 -80.14 -23.88 40.82 Favored 'General case' 0 C--N 1.326 -0.443 0 N-CA-C 112.361 0.504 . . . . 71.21 112.361 -168.925 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 2.0 ptp180 -137.95 43.39 2.23 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-O 121.07 0.462 . . . . 75.23 111.733 -178.591 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 57' ' ' GLY . . . . . 0.42 ' O ' ' HA ' ' A' ' 53' ' ' GLU . . . 76.07 -157.38 48.42 Favored Glycine 0 N--CA 1.449 -0.454 0 C-N-CA 120.842 -0.694 . . . . 72.02 113.127 174.667 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 1.7 Cg_endo -81.43 110.39 2.21 Favored 'Trans proline' 0 N--CA 1.455 -0.776 0 C-N-CA 123.242 2.628 . . . . 63.21 112.053 -178.999 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 59' ' ' GLN . . . . . 0.458 ' HA ' ' O ' ' A' ' 27' ' ' PHE . 16.8 pt20 -105.45 139.11 40.57 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 115.892 -0.595 . . . . 71.31 109.97 179.091 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 60' ' ' ALA . . . . . 0.434 ' HB2' HG12 ' A' ' 26' ' ' VAL . . . -89.8 109.35 20.35 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 116.178 -0.465 . . . . 74.43 110.997 -179.344 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -111.41 149.9 30.56 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-N 115.825 -0.625 . . . . 74.51 109.519 176.315 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 94.9 m-20 51.49 80.17 0.09 Allowed 'General case' 0 C--O 1.235 0.321 0 CA-C-O 121.286 0.565 . . . . 71.11 110.841 -176.76 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 38.9 t -102.88 103.97 15.88 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.589 0 CA-C-N 115.732 -0.667 . . . . 74.42 110.245 -179.355 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 54.4 mt-30 -94.9 160.54 14.54 Favored 'General case' 0 C--N 1.319 -0.735 0 CA-C-N 115.918 -0.583 . . . . 71.15 110.52 -179.647 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 65' ' ' LYS . . . . . 0.405 ' HE3' ' O ' ' A' ' 34' ' ' GLN . 0.7 OUTLIER -82.77 171.35 14.05 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 115.717 -0.674 . . . . 52.45 110.894 -176.773 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.097 0 CA-C-O 118.413 -0.803 . . . . 51.33 109.544 177.172 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 1' ' ' MET . . . . . 0.603 ' N ' ' HA ' ' A' ' 50' ' ' ASP . 65.8 mtt . . . . . 0 N--CA 1.484 1.249 0 CA-C-O 121.005 0.431 . . . . 60.15 110.683 . . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 56.9 mp0 -84.28 151.08 25.0 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-O 121.268 0.556 . . . . 63.44 111.871 -174.877 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -96.79 112.78 24.39 Favored 'General case' 0 C--N 1.323 -0.545 0 N-CA-C 108.095 -1.076 . . . . 72.03 108.095 172.956 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 4' ' ' GLY . . . . . 0.474 ' HA3' ' HE2' ' A' ' 49' ' ' PHE . . . -137.61 168.53 24.43 Favored Glycine 0 N--CA 1.447 -0.608 0 C-N-CA 120.392 -0.908 . . . . 63.12 112.558 -175.864 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 5' ' ' THR . . . . . 0.408 ' O ' ' HG2' ' A' ' 19' ' ' GLU . 26.9 m -108.24 134.26 51.33 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-O 120.634 0.254 . . . . 74.22 110.457 -179.024 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 47.8 t -68.75 112.7 3.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 CA-C-O 120.772 0.32 . . . . 55.33 110.378 178.494 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 48.3 mtpt -71.76 -70.86 0.3 Allowed 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 115.808 -0.633 . . . . 74.2 110.21 179.887 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 8' ' ' TRP . . . . . . . . . . . . . 92.1 m95 -139.4 132.61 29.81 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 115.094 -0.957 . . . . 72.33 108.819 178.117 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 9' ' ' PHE . . . . . 0.499 ' HD1' ' HA3' ' A' ' 16' ' ' GLY . 59.4 t80 -132.22 102.1 5.64 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-O 121.272 0.558 . . . . 72.43 110.822 179.15 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 19.0 m120 -80.99 84.8 6.38 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 115.583 -0.735 . . . . 74.53 109.534 176.444 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -61.66 -33.25 73.63 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 115.393 -0.821 . . . . 54.44 111.074 179.055 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 44.3 mt-10 -69.6 -25.9 64.19 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.015 -0.538 . . . . 73.13 110.73 179.532 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 75.7 mmtt -92.24 -35.53 13.74 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.219 -0.446 . . . . 63.2 110.187 -179.948 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 110.12 14.11 14.14 Favored Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 120.965 -0.636 . . . . 44.31 113.35 175.574 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 50.0 p90 -152.73 162.08 41.73 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 117.157 0.479 . . . . 74.54 111.451 -177.546 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.499 ' HA3' ' HD1' ' A' ' 9' ' ' PHE . . . -163.38 178.25 39.04 Favored Glycine 0 N--CA 1.446 -0.692 0 C-N-CA 120.885 -0.674 . . . . 31.12 112.197 179.071 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 90.8 m-85 -126.28 127.76 46.1 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-O 120.7 0.286 . . . . 74.31 110.507 -178.967 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 46.3 mt -112.93 129.91 67.72 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.497 0 N-CA-C 109.151 -0.685 . . . . 74.34 109.151 175.787 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 19' ' ' GLU . . . . . 0.408 ' HG2' ' O ' ' A' ' 5' ' ' THR . 11.1 pt-20 -73.7 139.88 45.65 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 121.502 0.668 . . . . 73.03 111.559 -171.851 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 20' ' ' ARG . . . . . . . . . . . . . 43.5 ttt180 -112.48 141.2 46.51 Favored 'General case' 0 C--N 1.319 -0.733 0 N-CA-C 107.434 -1.321 . . . . 60.44 107.434 175.035 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 16.1 pt-20 -55.67 -26.57 45.47 Favored 'General case' 0 C--N 1.327 -0.406 0 N-CA-C 112.85 0.685 . . . . 64.44 112.85 -170.116 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 28.6 t-20 -79.69 -19.58 48.62 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-O 120.845 0.355 . . . . 73.42 111.434 -178.813 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 106.48 -9.33 41.49 Favored Glycine 0 CA--C 1.511 -0.157 0 N-CA-C 111.229 -0.748 . . . . 74.51 111.229 -174.514 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 36.5 t70 -80.32 72.24 7.16 Favored 'General case' 0 C--N 1.322 -0.615 0 N-CA-C 109.279 -0.638 . . . . 71.4 109.279 176.294 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 10.1 p-10 -70.28 138.07 51.26 Favored 'General case' 0 C--N 1.333 -0.14 0 CA-C-O 121.52 0.676 . . . . 62.52 110.811 -172.899 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.529 HG13 ' HB2' ' A' ' 58' ' ' PRO . 4.3 t -94.57 138.98 19.4 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.55 0 CA-C-N 115.187 -0.915 . . . . 65.21 111.4 -167.734 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 27' ' ' PHE . . . . . . . . . . . . . 50.4 t80 -92.27 111.72 23.39 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.769 -0.65 . . . . 74.02 110.461 -177.449 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.539 ' HB ' ' HB3' ' A' ' 60' ' ' ALA . 14.8 p -95.86 148.49 5.22 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.381 0 CA-C-O 120.905 0.383 . . . . 74.05 111.325 -175.462 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 28.0 m170 -114.31 145.72 41.42 Favored 'General case' 0 C--O 1.236 0.343 0 CA-C-N 116.151 -0.477 . . . . 62.41 109.889 177.623 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 20.5 p90 -62.19 -26.24 68.24 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 121.11 0.481 . . . . 73.53 110.46 177.659 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 4.2 m -81.56 -14.36 56.93 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 115.77 -0.65 . . . . 65.43 110.875 179.277 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 32' ' ' ALA . . . . . 0.559 ' HB1' ' HA ' ' A' ' 61' ' ' ALA . . . -94.51 -21.3 18.97 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 121.044 0.449 . . . . 64.14 110.819 -176.709 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 44.9 mt -71.04 155.8 7.39 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-N 115.777 -0.647 . . . . 74.23 110.188 174.534 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 14.5 pt20 -70.51 102.97 2.35 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 121.226 0.536 . . . . 72.22 110.458 175.755 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -79.03 77.1 1.85 Allowed Glycine 0 N--CA 1.447 -0.573 0 CA-C-N 115.752 -0.658 . . . . 71.52 112.92 -175.815 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 34.7 t70 -121.61 98.15 5.83 Favored 'General case' 0 C--N 1.323 -0.556 0 N-CA-C 109.639 -0.504 . . . . 72.03 109.639 174.21 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 72.79 -150.32 44.42 Favored Glycine 0 N--CA 1.446 -0.636 0 C-N-CA 120.749 -0.739 . . . . 61.12 111.435 -174.983 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 88.6 m-85 -110.92 65.38 0.62 Allowed 'General case' 0 C--N 1.321 -0.664 0 CA-C-O 121.468 0.651 . . . . 61.22 110.597 178.028 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 91.7 mttt -101.67 86.69 2.98 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 115.333 -0.849 . . . . 53.42 109.611 178.196 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 22.9 t -84.32 178.9 7.59 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 115.479 -0.782 . . . . 75.42 111.181 -172.829 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 81.7 mt -95.94 119.04 33.72 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 116.013 -0.54 . . . . 64.02 109.892 177.385 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 42' ' ' ASP . . . . . 0.626 ' HB3' ' HB2' ' A' ' 45' ' ' GLN . 30.7 t70 -82.43 139.93 33.72 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-N 115.942 -0.572 . . . . 65.15 111.048 -175.988 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 6.8 pt-20 -66.11 116.72 7.5 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 115.84 -0.618 . . . . 71.05 110.846 178.383 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 87.3 18.9 56.55 Favored Glycine 0 N--CA 1.448 -0.508 0 C-N-CA 120.642 -0.79 . . . . 53.55 112.182 -177.77 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 45' ' ' GLN . . . . . 0.626 ' HB2' ' HB3' ' A' ' 42' ' ' ASP . 35.6 tt0 -99.22 135.5 40.54 Favored 'General case' 0 C--N 1.326 -0.451 0 N-CA-C 110.208 -0.293 . . . . 71.24 110.208 178.497 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -85.52 129.01 34.92 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 116.36 -0.382 . . . . 62.12 110.271 177.807 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 16.6 m -138.36 153.62 26.61 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.518 0 CA-C-O 120.988 0.423 . . . . 74.11 111.01 -177.927 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 20.7 p -102.51 104.87 15.33 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 115.994 -0.548 . . . . 73.51 109.814 175.988 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 49' ' ' PHE . . . . . 0.474 ' HE2' ' HA3' ' A' ' 4' ' ' GLY . 41.8 p90 -110.74 158.51 18.57 Favored 'General case' 0 C--N 1.316 -0.852 0 CA-C-N 115.449 -0.796 . . . . 74.13 110.174 -174.994 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 50' ' ' ASP . . . . . 0.603 ' HA ' ' N ' ' A' ' 1' ' ' MET . 19.7 t0 -104.61 151.77 23.24 Favored 'General case' 0 C--N 1.317 -0.842 0 C-N-CA 120.074 -0.65 . . . . 71.03 109.958 173.552 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 4.9 p -103.17 112.41 36.52 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.599 0 CA-C-O 121.405 0.621 . . . . 44.14 111.194 -173.57 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 49.8 mm-40 -109.85 112.88 25.19 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-N 115.586 -0.733 . . . . 72.24 109.689 177.613 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 53' ' ' GLU . . . . . 0.536 ' HA ' ' O ' ' A' ' 57' ' ' GLY . 8.1 pt-20 -76.81 115.47 16.62 Favored 'General case' 0 C--N 1.325 -0.498 0 C-N-CA 120.211 -0.595 . . . . 75.44 109.941 177.202 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 54' ' ' GLY . . . . . 0.514 ' HA3' ' NE2' ' A' ' 59' ' ' GLN . . . -122.57 -121.2 2.68 Favored Glycine 0 N--CA 1.445 -0.736 0 C-N-CA 120.354 -0.927 . . . . 45.13 113.365 -174.658 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -84.77 1.68 45.6 Favored 'General case' 0 C--N 1.329 -0.311 0 N-CA-C 112.157 0.429 . . . . 71.1 112.157 -169.632 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 10.2 ptp180 -158.87 28.39 0.22 Allowed 'General case' 0 C--N 1.325 -0.457 0 CA-C-O 120.748 0.308 . . . . 75.42 111.237 177.678 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 57' ' ' GLY . . . . . 0.536 ' O ' ' HA ' ' A' ' 53' ' ' GLU . . . 93.29 -132.81 11.4 Favored Glycine 0 N--CA 1.444 -0.784 0 C-N-CA 120.44 -0.886 . . . . 74.42 112.18 -179.054 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 58' ' ' PRO . . . . . 0.529 ' HB2' HG13 ' A' ' 26' ' ' VAL . 33.0 Cg_endo -64.32 106.66 0.72 Allowed 'Trans proline' 0 CA--C 1.529 0.239 0 C-N-CA 122.837 2.358 . . . . 64.4 113.323 -174.806 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 59' ' ' GLN . . . . . 0.514 ' NE2' ' HA3' ' A' ' 54' ' ' GLY . 22.2 mt-30 -112.53 128.41 56.34 Favored 'General case' 0 C--N 1.323 -0.567 0 N-CA-C 109.011 -0.737 . . . . 74.34 109.011 173.615 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 60' ' ' ALA . . . . . 0.539 ' HB3' ' HB ' ' A' ' 28' ' ' VAL . . . -82.13 115.1 21.09 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-O 120.984 0.421 . . . . 33.04 110.955 -176.127 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 61' ' ' ALA . . . . . 0.559 ' HA ' ' HB1' ' A' ' 32' ' ' ALA . . . -130.89 154.14 48.4 Favored 'General case' 0 C--N 1.319 -0.75 0 N-CA-C 108.845 -0.798 . . . . 75.1 108.845 176.818 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 90.2 m-20 57.84 73.93 0.45 Allowed 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 121.492 0.663 . . . . 70.24 109.967 -176.125 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 45.3 t -100.21 103.71 15.16 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.664 0 CA-C-N 115.357 -0.838 . . . . 33.11 109.813 179.857 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 6.3 tp-100 -91.63 143.19 26.82 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-N 116.027 -0.533 . . . . 74.12 110.673 -176.941 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 66.8 mmtt -72.72 130.22 40.01 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 115.684 -0.689 . . . . 73.24 109.992 177.817 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.251 1.167 0 CA-C-O 118.432 -0.794 . . . . 75.01 110.53 -178.164 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 1' ' ' MET . . . . . 0.597 ' HA ' ' HA ' ' A' ' 50' ' ' ASP . 27.9 ttt . . . . . 0 N--CA 1.475 0.783 0 CA-C-O 121.364 0.602 . . . . 51.31 109.602 . . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 1.7 pm0 -143.72 175.33 10.06 Favored 'General case' 0 C--N 1.319 -0.722 0 CA-C-N 115.437 -0.801 . . . . 70.44 110.275 -175.348 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -100.24 128.74 46.25 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-O 121.215 0.531 . . . . 74.42 110.616 179.31 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -131.14 164.7 23.29 Favored Glycine 0 N--CA 1.444 -0.774 0 CA-C-N 115.803 -0.635 . . . . 63.31 111.751 -179.17 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 21.3 m -105.38 122.87 46.86 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-O 120.542 0.21 . . . . 72.41 110.707 -178.775 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 58.7 t -64.37 114.36 2.21 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.227 0 CA-C-N 116.392 -0.367 . . . . 72.5 110.547 -179.331 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 4.5 mmmm -95.28 -53.16 3.88 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 115.859 -0.609 . . . . 75.2 110.255 -178.832 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 8' ' ' TRP . . . . . 0.464 ' HB2' ' HB2' ' A' ' 17' ' ' PHE . 76.5 m95 -118.11 130.63 56.24 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 115.687 -0.688 . . . . 74.32 110.082 179.793 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 9' ' ' PHE . . . . . 0.439 ' CE2' ' HB2' ' A' ' 11' ' ' ALA . 62.6 t80 -128.66 84.37 2.23 Favored 'General case' 0 C--N 1.318 -0.781 0 CA-C-O 121.282 0.563 . . . . 74.31 109.692 178.862 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 10' ' ' ASN . . . . . 0.797 ' HB3' ' HB2' ' A' ' 13' ' ' LYS . 44.0 m-80 -87.53 74.35 9.31 Favored 'General case' 0 C--N 1.321 -0.663 0 CA-C-N 115.909 -0.587 . . . . 73.35 110.021 -177.61 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 11' ' ' ALA . . . . . 0.676 ' HA ' ' CZ ' ' A' ' 30' ' ' PHE . . . -61.07 -39.61 90.53 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.277 -0.874 . . . . 74.15 111.409 -177.296 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 47.0 mt-10 -84.22 -11.4 56.56 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 116.085 -0.507 . . . . 64.02 111.173 -177.947 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 13' ' ' LYS . . . . . 0.797 ' HB2' ' HB3' ' A' ' 10' ' ' ASN . 5.2 mmtp -98.6 -28.41 13.57 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 116.274 -0.421 . . . . 74.43 110.586 -177.02 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 102.2 22.65 9.69 Favored Glycine 0 N--CA 1.448 -0.526 0 C-N-CA 120.652 -0.785 . . . . 64.3 113.396 174.287 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 15' ' ' PHE . . . . . 0.454 ' O ' ' HB2' ' A' ' 10' ' ' ASN . 52.5 p90 -163.38 171.49 15.96 Favored 'General case' 0 N--CA 1.463 0.222 0 CA-C-N 117.451 0.625 . . . . 72.33 111.067 179.649 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -153.98 172.14 32.65 Favored Glycine 0 N--CA 1.445 -0.701 0 C-N-CA 120.827 -0.701 . . . . 61.53 112.119 179.976 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 17' ' ' PHE . . . . . 0.792 ' HB3' ' HB3' ' A' ' 25' ' ' ASP . 92.6 m-85 -134.63 122.82 22.82 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 120.802 0.334 . . . . 73.43 110.269 179.472 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 35.3 mt -122.41 117.44 52.09 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.593 0 CA-C-N 116.103 -0.499 . . . . 72.4 109.734 179.164 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 19' ' ' GLU . . . . . 0.417 ' HA ' ' HA ' ' A' ' 25' ' ' ASP . 22.8 pt-20 -79.41 148.31 32.01 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-O 121.257 0.551 . . . . 61.23 112.17 -170.976 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 20' ' ' ARG . . . . . 0.423 ' HG2' ' HG2' ' A' ' 21' ' ' GLU . 14.4 ttm180 -118.61 123.51 45.17 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 115.42 -0.809 . . . . 75.14 109.684 170.681 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 21' ' ' GLU . . . . . 0.423 ' HG2' ' HG2' ' A' ' 20' ' ' ARG . 43.1 mm-40 50.78 -90.02 0.02 OUTLIER 'General case' 0 N--CA 1.474 0.738 0 N-CA-C 113.407 0.891 . . . . 73.34 113.407 173.094 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 1.6 m-20 -58.31 -19.11 32.22 Favored 'General case' 0 N--CA 1.467 0.408 0 C-N-CA 123.847 0.859 . . . . 62.01 111.79 -175.215 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 104.35 19.92 10.9 Favored Glycine 0 N--CA 1.442 -0.951 0 N-CA-C 110.015 -1.234 . . . . 42.33 110.015 -170.604 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 5.3 t70 -71.69 90.01 1.04 Allowed 'General case' 0 N--CA 1.45 -0.434 0 N-CA-C 109.0 -0.741 . . . . 73.24 109.0 178.089 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.792 ' HB3' ' HB3' ' A' ' 17' ' ' PHE . 62.0 m-20 -63.37 104.32 0.6 Allowed 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 115.756 -0.656 . . . . 52.42 110.613 -179.553 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 59.3 t -74.48 132.36 33.49 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.598 0 CA-C-N 115.602 -0.726 . . . . 64.11 110.0 179.009 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 27' ' ' PHE . . . . . 0.493 ' O ' ' HA ' ' A' ' 59' ' ' GLN . 78.5 t80 -82.73 127.61 33.58 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 116.089 -0.505 . . . . 64.02 110.441 -177.261 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.545 ' HB ' ' HB3' ' A' ' 60' ' ' ALA . 14.2 p -131.35 147.64 32.8 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 CA-C-O 121.02 0.438 . . . . 63.32 111.647 -177.416 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 21.9 m170 -108.64 159.57 16.62 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.991 -0.549 . . . . 72.52 109.684 174.759 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 30' ' ' PHE . . . . . 0.676 ' CZ ' ' HA ' ' A' ' 11' ' ' ALA . 52.4 m-85 -71.95 -14.28 61.87 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-O 120.702 0.287 . . . . 62.15 111.309 -179.723 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 13.8 t -71.35 -22.13 61.94 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-O 121.337 0.589 . . . . 51.42 110.07 174.725 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -100.83 -22.53 14.81 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 115.846 -0.615 . . . . 73.32 110.487 179.387 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 70.6 mt -76.93 145.77 9.7 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 CA-C-N 115.883 -0.599 . . . . 75.31 109.452 174.521 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 4.1 pt20 -68.92 100.4 1.19 Allowed 'General case' 0 C--N 1.327 -0.412 0 CA-C-O 121.455 0.645 . . . . 62.15 110.626 177.373 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -100.1 68.34 0.52 Allowed Glycine 0 N--CA 1.445 -0.708 0 C-N-CA 120.937 -0.649 . . . . 63.14 111.978 -178.914 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 6.2 m-20 -78.1 79.21 4.57 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-O 120.765 0.316 . . . . 54.21 110.41 177.316 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 71.82 -99.56 0.85 Allowed Glycine 0 N--CA 1.447 -0.606 0 C-N-CA 120.75 -0.738 . . . . 71.31 111.601 -178.004 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 93.8 m-85 -118.65 101.41 8.09 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-O 121.089 0.471 . . . . 71.23 110.567 178.954 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 75.2 mmtt -126.18 152.06 46.5 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 115.733 -0.667 . . . . 74.32 109.227 176.755 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 42.1 m -149.17 125.62 10.93 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-O 120.887 0.375 . . . . 44.25 110.986 -179.889 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 3.2 mm? -90.62 139.01 31.11 Favored 'General case' 0 C--N 1.324 -0.534 0 N-CA-C 109.228 -0.656 . . . . 73.43 109.228 175.021 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 30.9 t70 -90.23 146.76 24.0 Favored 'General case' 0 C--N 1.319 -0.729 0 C-N-CA 120.87 -0.332 . . . . 74.11 110.334 -178.792 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 37.4 mt-10 -70.97 102.01 2.31 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 116.319 -0.401 . . . . 63.13 109.932 178.293 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 123.03 1.19 9.59 Favored Glycine 0 N--CA 1.45 -0.433 0 CA-C-N 115.784 -0.644 . . . . 74.54 111.672 -173.272 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 52.1 tp60 -87.49 139.81 30.16 Favored 'General case' 0 N--CA 1.464 0.247 0 C-N-CA 122.247 0.219 . . . . 70.24 110.873 -179.734 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -90.54 131.68 36.13 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 121.084 0.469 . . . . 53.35 110.732 176.696 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 21.6 m -132.06 167.06 27.3 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 CA-C-N 116.062 -0.517 . . . . 72.13 110.782 -178.871 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 3.4 p -120.97 114.95 22.27 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-O 121.185 0.517 . . . . 62.24 110.211 179.312 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 49' ' ' PHE . . . . . 0.495 ' O ' ' HA ' ' A' ' 1' ' ' MET . 38.8 p90 -134.78 166.1 23.74 Favored 'General case' 0 C--N 1.319 -0.76 0 CA-C-N 115.949 -0.568 . . . . 73.45 110.348 -173.802 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 50' ' ' ASP . . . . . 0.597 ' HA ' ' HA ' ' A' ' 1' ' ' MET . 39.1 t0 -106.84 121.62 44.77 Favored 'General case' 0 C--N 1.324 -0.538 0 C-N-CA 120.4 -0.52 . . . . 71.32 110.447 175.253 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 86.5 t -77.83 117.16 22.54 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.55 0 CA-C-O 120.986 0.422 . . . . 74.55 111.294 -178.842 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 52' ' ' GLU . . . . . 0.66 ' HB3' ' HG3' ' A' ' 59' ' ' GLN . 8.9 tp10 -94.12 116.79 29.25 Favored 'General case' 0 C--N 1.321 -0.652 0 N-CA-C 108.904 -0.776 . . . . 74.35 108.904 174.022 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 47.5 mt-10 -92.78 95.73 9.72 Favored 'General case' 0 C--N 1.319 -0.721 0 CA-C-O 121.128 0.49 . . . . 71.34 110.107 179.837 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -103.61 -143.49 12.76 Favored Glycine 0 N--CA 1.445 -0.701 0 CA-C-N 115.597 -0.729 . . . . 52.42 112.68 -176.629 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -86.42 -40.41 15.4 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 121.008 0.432 . . . . 62.35 110.723 -175.381 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 77.2 mtm180 -108.23 81.94 1.56 Allowed 'General case' 0 C--N 1.322 -0.614 0 CA-C-N 116.273 -0.421 . . . . 62.34 111.305 -176.262 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 68.9 -171.29 38.92 Favored Glycine 0 N--CA 1.448 -0.507 0 CA-C-N 115.619 -0.719 . . . . 63.53 112.93 178.22 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 87.3 Cg_endo -86.94 123.62 2.05 Favored 'Trans proline' 0 N--CA 1.453 -0.857 0 C-N-CA 122.829 2.353 . . . . 75.44 111.764 175.752 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 59' ' ' GLN . . . . . 0.66 ' HG3' ' HB3' ' A' ' 52' ' ' GLU . 18.9 pt20 -109.3 126.91 53.86 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-N 116.212 -0.449 . . . . 51.44 109.852 178.181 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 60' ' ' ALA . . . . . 0.545 ' HB3' ' HB ' ' A' ' 28' ' ' VAL . . . -79.42 117.58 20.52 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-O 120.837 0.351 . . . . 64.41 110.802 -178.771 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -110.87 128.62 55.86 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 116.013 -0.54 . . . . 63.13 109.816 178.524 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 49.4 m-80 63.78 96.38 0.04 OUTLIER 'General case' 0 C--O 1.235 0.312 0 O-C-N 123.577 0.548 . . . . 71.43 110.674 -176.521 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.472 HG21 HG21 ' A' ' 28' ' ' VAL . 48.8 t -110.66 107.15 22.21 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.474 0 CA-C-N 115.661 -0.699 . . . . 65.11 110.746 179.718 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 64' ' ' GLN . . . . . 0.404 ' HG2' ' N ' ' A' ' 65' ' ' LYS . 34.4 tt0 -102.09 168.35 9.44 Favored 'General case' 0 C--N 1.324 -0.542 0 N-CA-C 108.816 -0.809 . . . . 75.12 108.816 177.556 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 65' ' ' LYS . . . . . 0.404 ' N ' ' HG2' ' A' ' 64' ' ' GLN . 55.3 mtmt -103.78 155.29 18.72 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-O 120.801 0.334 . . . . 74.44 110.658 -179.125 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.251 1.135 0 CA-C-O 118.656 -0.688 . . . . 71.3 109.79 177.691 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 27.0 ptt? . . . . . 0 N--CA 1.483 1.177 0 CA-C-O 120.847 0.356 . . . . 70.24 110.842 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 2' ' ' GLU . . . . . 0.427 ' CD ' ' H ' ' A' ' 2' ' ' GLU . 1.8 pm0 -88.36 114.16 24.7 Favored 'General case' 0 C--O 1.239 0.514 0 CA-C-O 121.457 0.646 . . . . 51.4 110.822 -179.732 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -119.13 162.73 18.14 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 115.002 -0.999 . . . . 72.31 110.073 -179.297 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -160.65 165.24 34.99 Favored Glycine 0 N--CA 1.442 -0.95 0 C-N-CA 120.889 -0.672 . . . . 72.35 111.72 178.072 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 5' ' ' THR . . . . . 0.465 ' O ' ' HG2' ' A' ' 19' ' ' GLU . 28.2 m -100.48 137.87 38.3 Favored 'General case' 0 C--N 1.319 -0.726 0 N-CA-C 110.06 -0.348 . . . . 74.4 110.06 178.451 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 48.1 t -68.62 108.36 1.55 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 N-CA-C 109.793 -0.447 . . . . 64.02 109.793 175.783 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 7' ' ' LYS . . . . . 0.614 ' HA ' ' HE3' ' A' ' 7' ' ' LYS . 0.0 OUTLIER -75.2 -56.15 5.01 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-O 120.93 0.395 . . . . 73.35 110.426 178.313 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 8' ' ' TRP . . . . . . . . . . . . . 4.1 p90 -156.98 136.98 12.6 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 115.749 -0.66 . . . . 75.03 110.205 179.162 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 17.5 p90 -124.35 108.55 12.32 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-O 121.807 0.813 . . . . 74.41 110.157 178.515 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 41.2 t-20 -85.93 86.83 7.35 Favored 'General case' 0 C--N 1.318 -0.761 0 CA-C-O 121.477 0.656 . . . . 74.2 109.401 -178.778 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -57.77 -32.46 67.52 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 114.914 -1.039 . . . . 73.21 111.623 179.182 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 74.2 mm-40 -64.08 -31.25 72.38 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 120.857 0.36 . . . . 70.45 111.132 178.848 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 13' ' ' LYS . . . . . 0.458 ' HB3' ' CE2' ' A' ' 15' ' ' PHE . 0.1 OUTLIER -92.28 -17.77 24.3 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.894 -0.594 . . . . 73.41 110.746 179.047 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 86.77 19.24 56.75 Favored Glycine 0 N--CA 1.447 -0.585 0 C-N-CA 120.82 -0.705 . . . . 75.32 112.898 177.635 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 15' ' ' PHE . . . . . 0.458 ' CE2' ' HB3' ' A' ' 13' ' ' LYS . 31.0 p90 -157.78 156.66 31.94 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 121.133 0.492 . . . . 54.45 111.443 179.587 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -134.87 -179.24 16.31 Favored Glycine 0 N--CA 1.442 -0.906 0 N-CA-C 111.291 -0.724 . . . . 73.52 111.291 178.671 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 17' ' ' PHE . . . . . 0.421 ' HA ' ' O ' ' A' ' 26' ' ' VAL . 97.2 m-85 -132.35 127.65 35.98 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-O 121.305 0.574 . . . . 75.24 111.266 -179.538 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 63.4 mt -101.32 138.86 24.11 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.569 0 CA-C-N 115.209 -0.905 . . . . 73.51 109.344 177.864 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 19' ' ' GLU . . . . . 0.495 ' HB3' ' HG3' ' A' ' 7' ' ' LYS . 11.7 pt-20 -82.86 134.84 35.08 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-O 121.196 0.522 . . . . 73.34 111.303 -177.022 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 20' ' ' ARG . . . . . 0.754 ' HD2' ' H ' ' A' ' 21' ' ' GLU . 0.1 OUTLIER -113.22 -177.96 3.26 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 115.904 -0.589 . . . . 72.14 109.775 178.506 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 21' ' ' GLU . . . . . 0.754 ' H ' ' HD2' ' A' ' 20' ' ' ARG . 10.0 pt-20 -59.51 -37.18 77.64 Favored 'General case' 0 C--N 1.327 -0.387 0 N-CA-C 112.93 0.715 . . . . 72.45 112.93 -173.205 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 22' ' ' ASN . . . . . 0.422 ' ND2' ' HG3' ' A' ' 21' ' ' GLU . 29.3 m-80 -94.21 5.67 51.03 Favored 'General case' 0 C--N 1.328 -0.346 0 O-C-N 122.096 -0.377 . . . . 72.41 110.805 -178.306 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 84.97 20.02 58.39 Favored Glycine 0 N--CA 1.447 -0.584 0 N-CA-C 110.236 -1.145 . . . . 31.11 110.236 -170.509 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 24' ' ' ASP . . . . . 0.457 ' HB2' ' CB ' ' A' ' 20' ' ' ARG . 3.8 m-20 -67.15 95.02 0.38 Allowed 'General case' 0 N--CA 1.45 -0.448 0 CA-C-N 114.879 -0.66 . . . . 73.4 109.463 179.59 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 11.1 p-10 -63.65 100.81 0.3 Allowed 'General case' 0 C--N 1.32 -0.676 0 CA-C-O 121.833 0.825 . . . . 60.43 110.309 175.97 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.421 ' O ' ' HA ' ' A' ' 17' ' ' PHE . 44.9 t -78.38 120.76 29.91 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 CA-C-N 115.15 -0.932 . . . . 72.12 110.756 -177.273 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 27' ' ' PHE . . . . . . . . . . . . . 68.9 t80 -73.34 113.16 10.11 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 115.65 -0.705 . . . . 54.13 110.433 -179.092 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.434 ' HB ' ' HB3' ' A' ' 60' ' ' ALA . 10.4 p -117.26 126.59 74.64 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.575 0 CA-C-O 121.083 0.468 . . . . 73.01 110.24 176.068 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 29' ' ' HIS . . . . . 0.433 ' O ' HG13 ' A' ' 33' ' ' ILE . 41.2 t60 -103.46 149.74 24.54 Favored 'General case' 0 C--N 1.324 -0.529 0 N-CA-C 109.452 -0.573 . . . . 73.41 109.452 -176.754 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 30' ' ' PHE . . . . . 0.438 ' HA ' HD12 ' A' ' 33' ' ' ILE . 42.2 p90 -58.44 -27.29 64.22 Favored 'General case' 0 N--CA 1.467 0.403 0 CA-C-O 120.819 0.342 . . . . 74.32 111.607 -175.657 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 6.7 m -72.98 -14.13 61.38 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 116.409 -0.36 . . . . 74.51 111.283 179.005 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -106.88 -17.65 14.14 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.921 0.391 . . . . 63.21 111.058 -178.466 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.438 HD12 ' HA ' ' A' ' 30' ' ' PHE . 66.5 mt -71.22 144.82 13.06 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 CA-C-N 116.032 -0.531 . . . . 73.45 110.49 177.989 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 34' ' ' GLN . . . . . 0.47 ' HG3' ' O ' ' A' ' 34' ' ' GLN . 2.8 pt20 -66.47 103.96 1.15 Allowed 'General case' 0 C--N 1.33 -0.263 0 N-CA-C 109.581 -0.526 . . . . 72.33 109.581 172.909 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.52 ' HA2' ' CG ' ' A' ' 39' ' ' LYS . . . -145.52 130.39 3.79 Favored Glycine 0 N--CA 1.442 -0.912 0 C-N-CA 119.633 -1.27 . . . . 74.03 114.054 -174.474 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 6.5 m-20 -83.03 80.56 9.01 Favored 'General case' 0 C--N 1.324 -0.543 0 N-CA-C 107.761 -1.2 . . . . 70.44 107.761 167.434 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 80.7 -73.32 2.56 Favored Glycine 0 N--CA 1.443 -0.895 0 N-CA-C 109.979 -1.248 . . . . 71.45 109.979 -167.137 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 68.2 m-85 -146.72 130.0 16.62 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-O 120.792 0.33 . . . . 73.43 110.27 173.403 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 39' ' ' LYS . . . . . 0.52 ' CG ' ' HA2' ' A' ' 35' ' ' GLY . 12.1 mmmm -125.69 128.16 47.37 Favored 'General case' 0 C--N 1.326 -0.456 0 N-CA-C 109.16 -0.681 . . . . 74.32 109.16 174.867 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 51.4 p -87.06 104.0 15.91 Favored 'General case' 0 C--N 1.32 -0.685 0 N-CA-C 112.206 0.446 . . . . 74.13 112.206 -173.725 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -88.77 103.64 16.16 Favored 'General case' 0 C--N 1.326 -0.439 0 N-CA-C 108.376 -0.972 . . . . 61.12 108.376 168.968 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 20.5 t70 -76.72 150.85 36.24 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 116.058 -0.519 . . . . 55.05 111.527 -169.718 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 83.6 mt-10 -61.59 112.82 2.38 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 115.629 -0.714 . . . . 72.24 110.552 -179.593 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 124.29 -12.87 7.96 Favored Glycine 0 N--CA 1.445 -0.758 0 C-N-CA 120.796 -0.716 . . . . 61.42 111.547 -177.203 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 6.5 tp-100 -80.06 143.15 34.25 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-O 120.857 0.36 . . . . 64.01 110.312 178.678 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -99.5 118.75 36.77 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 116.023 -0.535 . . . . 41.11 110.188 179.515 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 27.4 m -123.57 163.01 23.48 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.696 0 CA-C-N 116.227 -0.442 . . . . 70.11 111.11 -176.754 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 1.6 p -117.25 139.86 50.27 Favored 'General case' 0 C--N 1.321 -0.64 0 N-CA-C 108.91 -0.774 . . . . 74.31 108.91 176.548 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 33.5 p90 -141.24 159.18 42.76 Favored 'General case' 0 C--N 1.317 -0.823 0 C-N-CA 120.3 -0.56 . . . . 72.24 111.616 -175.26 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 4.9 t70 -88.14 103.16 15.49 Favored 'General case' 0 C--N 1.321 -0.657 0 N-CA-C 108.645 -0.872 . . . . 64.23 108.645 174.975 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 7.7 p -63.79 123.13 15.99 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 CA-C-O 121.295 0.569 . . . . 71.35 111.846 -173.09 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 52' ' ' GLU . . . . . 0.548 ' HB3' ' HG2' ' A' ' 59' ' ' GLN . 7.8 tp10 -117.52 139.86 50.38 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 115.648 -0.705 . . . . 63.41 110.067 178.997 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 10.8 tp10 -101.31 146.32 27.71 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-N 115.956 -0.565 . . . . 64.33 109.626 -179.701 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -144.83 -175.79 18.29 Favored Glycine 0 N--CA 1.45 -0.417 0 C-N-CA 120.709 -0.757 . . . . 40.03 112.527 -177.88 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 50.2 mt-30 -75.11 -34.15 61.67 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 120.755 0.312 . . . . 73.23 110.85 179.757 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 35.0 mtp-105 -77.1 -33.31 56.93 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-O 121.022 0.439 . . . . 74.21 110.436 174.39 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 146.87 -155.8 26.71 Favored Glycine 0 N--CA 1.448 -0.504 0 CA-C-N 115.904 -0.589 . . . . 31.05 111.798 -178.223 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 59.7 Cg_endo -74.26 137.13 23.07 Favored 'Trans proline' 0 C--O 1.234 0.298 0 C-N-CA 122.582 2.188 . . . . 73.55 112.775 -177.752 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 59' ' ' GLN . . . . . 0.548 ' HG2' ' HB3' ' A' ' 52' ' ' GLU . 17.0 pm0 -131.35 154.75 48.26 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 116.101 -0.499 . . . . 72.24 109.835 175.142 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 60' ' ' ALA . . . . . 0.434 ' HB3' ' HB ' ' A' ' 28' ' ' VAL . . . -101.77 106.53 17.54 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 116.294 -0.412 . . . . 55.04 110.993 -177.132 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -111.28 149.1 31.54 Favored 'General case' 0 C--N 1.321 -0.655 0 N-CA-C 109.263 -0.643 . . . . 33.32 109.263 175.082 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 86.5 m-20 57.06 82.79 0.11 Allowed 'General case' 0 N--CA 1.466 0.354 0 CA-C-O 121.304 0.573 . . . . 52.25 110.499 -178.459 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 46.4 t -103.54 134.48 44.61 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.588 0 CA-C-N 115.871 -0.604 . . . . 55.44 111.327 -174.985 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 76.8 mt-30 -130.71 178.2 6.82 Favored 'General case' 0 C--N 1.325 -0.484 0 N-CA-C 109.189 -0.671 . . . . 51.35 109.189 175.381 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 50.7 mtmt -96.81 144.18 27.02 Favored 'General case' 0 C--N 1.323 -0.554 0 N-CA-C 110.028 -0.36 . . . . 74.45 110.028 178.074 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 0.98 0 CA-C-O 118.519 -0.753 . . . . 61.15 110.274 -179.922 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 1' ' ' MET . . . . . 0.454 ' N ' ' HA ' ' A' ' 50' ' ' ASP . 21.1 ptp . . . . . 0 N--CA 1.478 0.935 0 CA-C-O 121.153 0.501 . . . . 64.44 109.926 . . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -91.37 157.7 16.95 Favored 'General case' 0 N--CA 1.452 -0.335 0 CA-C-N 115.653 -0.703 . . . . 62.24 109.994 -174.105 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 3' ' ' GLN . . . . . 0.455 ' HG2' HG22 ' A' ' 48' ' ' THR . 50.3 mt-30 -105.85 130.67 53.77 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-N 116.029 -0.532 . . . . 64.44 109.8 174.491 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -150.49 172.9 30.21 Favored Glycine 0 N--CA 1.443 -0.844 0 C-N-CA 120.794 -0.717 . . . . 61.22 111.683 178.571 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 5' ' ' THR . . . . . 0.542 ' O ' ' HG2' ' A' ' 19' ' ' GLU . 24.3 m -122.65 135.76 54.69 Favored 'General case' 0 C--N 1.317 -0.829 0 N-CA-C 110.167 -0.309 . . . . 74.44 110.167 179.067 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 46.4 t -72.41 119.06 18.4 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.633 0 CA-C-N 116.741 -0.209 . . . . 72.13 110.524 -179.114 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 7' ' ' LYS . . . . . 0.572 ' CE ' ' HB3' ' A' ' 19' ' ' GLU . 97.7 mttt -66.01 -62.59 1.41 Allowed 'General case' 0 CA--C 1.52 -0.193 0 CA-C-O 121.7 0.762 . . . . 73.14 109.223 175.896 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 8' ' ' TRP . . . . . . . . . . . . . 55.1 p-90 -160.45 156.06 25.42 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-N 114.393 -1.276 . . . . 64.35 108.053 177.571 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 9' ' ' PHE . . . . . 0.412 ' CE2' ' HB2' ' A' ' 11' ' ' ALA . 2.1 p90 -136.03 138.52 42.28 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-O 121.603 0.716 . . . . 75.11 111.858 -174.113 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 10' ' ' ASN . . . . . 0.559 ' HB3' ' HG2' ' A' ' 13' ' ' LYS . 16.6 m120 -84.12 77.52 9.93 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 115.115 -0.948 . . . . 72.15 109.115 177.009 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 11' ' ' ALA . . . . . 0.412 ' HB2' ' CE2' ' A' ' 9' ' ' PHE . . . -54.12 -38.43 65.43 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.212 -0.904 . . . . 72.33 112.367 -175.07 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -90.75 -14.28 32.35 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 116.492 -0.322 . . . . 64.2 111.697 -175.288 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 13' ' ' LYS . . . . . 0.559 ' HG2' ' HB3' ' A' ' 10' ' ' ASN . 59.6 mmtt -90.55 -36.39 14.5 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 121.191 0.52 . . . . 72.31 109.649 177.017 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 99.59 32.88 5.54 Favored Glycine 0 N--CA 1.447 -0.619 0 CA-C-N 115.698 -0.683 . . . . 62.01 111.636 -177.676 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 74.0 m-85 -140.19 168.82 18.91 Favored 'General case' 0 C--N 1.329 -0.312 0 N-CA-C 110.152 -0.314 . . . . 72.11 110.152 -177.941 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -171.12 161.34 33.96 Favored Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.542 -0.837 . . . . 65.21 112.437 177.764 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 97.4 m-85 -123.93 120.21 31.86 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-O 121.033 0.444 . . . . 75.05 110.908 -179.847 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.4 HG21 ' CE2' ' A' ' 49' ' ' PHE . 54.0 mt -105.12 135.95 41.0 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.616 0 CA-C-N 115.869 -0.605 . . . . 74.25 109.74 178.981 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 19' ' ' GLU . . . . . 0.572 ' HB3' ' CE ' ' A' ' 7' ' ' LYS . 11.6 pt-20 -94.81 128.64 41.69 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 121.404 0.621 . . . . 73.44 111.654 -177.461 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 20' ' ' ARG . . . . . 0.48 ' HB3' ' HB3' ' A' ' 24' ' ' ASP . 18.6 ttt180 -89.67 177.13 6.61 Favored 'General case' 0 C--N 1.323 -0.548 0 N-CA-C 108.289 -1.004 . . . . 74.53 108.289 171.697 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 44.6 mt-10 -61.04 -12.05 10.41 Favored 'General case' 0 N--CA 1.467 0.409 0 N-CA-C 112.098 0.407 . . . . 73.33 112.098 -178.787 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 82.6 m-20 -98.05 -4.22 36.46 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.89 0.376 . . . . 73.43 111.239 177.826 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 82.42 3.17 90.64 Favored Glycine 0 N--CA 1.449 -0.461 0 N-CA-C 110.337 -1.105 . . . . 65.44 110.337 -168.657 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 24' ' ' ASP . . . . . 0.48 ' HB3' ' HB3' ' A' ' 20' ' ' ARG . 33.6 t70 -56.3 98.73 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 114.61 -0.795 . . . . 55.44 110.721 -179.062 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 12.4 m-20 -56.5 100.44 0.04 OUTLIER 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 114.964 -1.016 . . . . 73.2 111.698 174.999 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.506 HG12 ' HB2' ' A' ' 60' ' ' ALA . 21.4 t -83.1 116.6 27.55 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.743 0 N-CA-C 108.761 -0.829 . . . . 72.55 108.761 172.883 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 27' ' ' PHE . . . . . . . . . . . . . 81.1 t80 -83.22 116.15 22.26 Favored 'General case' 0 C--N 1.32 -0.682 0 CA-C-N 115.894 -0.594 . . . . 75.3 111.021 -173.414 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 9.0 p -105.73 148.91 9.61 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.581 0 N-CA-C 109.534 -0.543 . . . . 70.2 109.534 175.901 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 29' ' ' HIS . . . . . 0.447 ' O ' HG13 ' A' ' 33' ' ' ILE . 2.7 p80 -140.19 163.88 31.56 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 116.277 -0.419 . . . . 72.33 110.58 -174.173 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 31.3 p90 -53.18 -33.0 50.79 Favored 'General case' 0 N--CA 1.47 0.536 0 N-CA-C 112.871 0.693 . . . . 73.4 112.871 -174.001 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 27.5 m -84.92 34.23 0.54 Allowed 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 121.174 0.511 . . . . 72.44 110.906 176.866 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -160.57 -33.56 0.05 Allowed 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 115.826 -0.625 . . . . 63.54 110.729 -179.364 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.447 HG13 ' O ' ' A' ' 29' ' ' HIS . 71.7 mt -63.7 143.37 15.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.065 -0.516 . . . . 75.44 110.461 176.195 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 34' ' ' GLN . . . . . 0.504 ' O ' ' HA ' ' A' ' 39' ' ' LYS . 88.4 mt-30 -53.69 113.33 1.15 Allowed 'General case' 0 C--N 1.329 -0.293 0 N-CA-C 109.792 -0.448 . . . . 75.32 109.792 172.117 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -101.54 -31.32 5.55 Favored Glycine 0 N--CA 1.45 -0.431 0 C-N-CA 120.321 -0.943 . . . . 52.34 112.266 -178.839 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 9.7 m-20 -106.38 115.4 30.15 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-O 120.882 0.372 . . . . 62.11 110.099 -178.797 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 116.06 -123.3 5.83 Favored Glycine 0 N--CA 1.446 -0.667 0 N-CA-C 111.126 -0.79 . . . . 74.23 111.126 -175.407 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 72.9 m-85 -96.46 93.51 6.86 Favored 'General case' 0 C--N 1.325 -0.499 0 N-CA-C 109.628 -0.508 . . . . 65.44 109.628 175.899 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 39' ' ' LYS . . . . . 0.504 ' HA ' ' O ' ' A' ' 34' ' ' GLN . 0.0 OUTLIER -74.98 -29.34 60.87 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 116.098 -0.501 . . . . 75.21 111.901 -173.182 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 15.2 m -67.88 108.12 2.89 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-O 120.947 0.403 . . . . 72.14 111.619 -174.01 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 92.2 mt -82.16 74.35 9.15 Favored 'General case' 0 C--N 1.324 -0.51 0 N-CA-C 108.797 -0.816 . . . . 75.21 108.797 171.415 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 27.6 t70 -55.38 139.88 41.64 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 115.18 -0.918 . . . . 75.32 112.051 -172.467 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 7.8 pt-20 -64.66 129.72 40.87 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-N 115.428 -0.806 . . . . 71.24 110.582 179.121 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 97.15 -10.22 65.54 Favored Glycine 0 N--CA 1.45 -0.403 0 C-N-CA 120.871 -0.68 . . . . 34.42 112.036 -177.202 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 54.0 tp60 -81.78 135.35 35.47 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-O 120.767 0.318 . . . . 71.55 110.558 178.769 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -85.35 138.54 32.22 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 116.117 -0.492 . . . . 70.34 110.097 176.043 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 16.6 m -136.98 144.84 31.08 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.605 0 CA-C-N 116.348 -0.387 . . . . 73.14 111.25 -177.415 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 48' ' ' THR . . . . . 0.455 HG22 ' HG2' ' A' ' 3' ' ' GLN . 24.7 p -104.58 122.74 46.23 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-N 115.753 -0.658 . . . . 74.03 109.571 173.633 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 49' ' ' PHE . . . . . 0.48 ' HA ' ' O ' ' A' ' 62' ' ' ASN . 38.8 p90 -141.09 157.3 45.49 Favored 'General case' 0 C--N 1.32 -0.701 0 CA-C-O 120.701 0.286 . . . . 63.53 111.206 -172.403 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 50' ' ' ASP . . . . . 0.454 ' HA ' ' N ' ' A' ' 1' ' ' MET . 30.2 m-20 -90.48 149.49 22.19 Favored 'General case' 0 C--N 1.321 -0.674 0 N-CA-C 109.684 -0.488 . . . . 71.44 109.684 172.357 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 5.4 p -110.44 117.14 54.16 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.628 0 CA-C-O 121.428 0.633 . . . . 71.24 111.549 -175.28 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 52' ' ' GLU . . . . . 0.653 ' HB2' ' HB2' ' A' ' 59' ' ' GLN . 6.9 mm-40 -94.76 133.43 38.46 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 115.432 -0.804 . . . . 73.54 109.476 174.456 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 8.5 pt-20 -82.04 97.82 8.33 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-O 121.354 0.597 . . . . 72.5 110.86 -179.33 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -90.02 151.84 21.89 Favored Glycine 0 N--CA 1.446 -0.685 0 C-N-CA 120.736 -0.745 . . . . 74.41 111.671 179.041 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 49.8 mt-30 -58.38 -25.96 62.65 Favored 'General case' 0 C--N 1.327 -0.375 0 N-CA-C 112.377 0.51 . . . . 71.44 112.377 -177.182 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 81.4 mtt180 -130.49 26.86 5.06 Favored 'General case' 0 C--N 1.327 -0.41 0 N-CA-C 111.716 0.265 . . . . 61.21 111.716 -177.217 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 150.22 153.32 6.06 Favored Glycine 0 N--CA 1.449 -0.441 0 C-N-CA 120.128 -1.034 . . . . 45.02 113.074 177.319 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 7.2 Cg_exo -72.59 124.42 9.8 Favored 'Trans proline' 0 N--CA 1.46 -0.478 0 C-N-CA 122.834 2.356 . . . . 74.0 111.475 177.449 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 59' ' ' GLN . . . . . 0.653 ' HB2' ' HB2' ' A' ' 52' ' ' GLU . 95.2 mt-30 -94.53 123.44 37.96 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-N 116.243 -0.435 . . . . 70.42 110.664 -179.029 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 60' ' ' ALA . . . . . 0.506 ' HB2' HG12 ' A' ' 26' ' ' VAL . . . -78.99 106.59 11.14 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 116.308 -0.405 . . . . 72.41 109.946 176.244 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -116.86 139.48 50.57 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 116.311 -0.404 . . . . 62.45 110.033 -179.928 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 62' ' ' ASN . . . . . 0.48 ' O ' ' HA ' ' A' ' 49' ' ' PHE . 76.8 m-20 60.31 92.26 0.05 OUTLIER 'General case' 0 C--O 1.236 0.358 0 O-C-N 123.595 0.56 . . . . 74.31 110.008 -176.116 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 40.7 t -114.3 136.59 50.35 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.547 0 CA-C-N 115.469 -0.787 . . . . 72.15 110.55 -175.16 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 64' ' ' GLN . . . . . 0.429 ' HB3' ' OG1' ' A' ' 48' ' ' THR . 31.0 tt0 -121.5 149.14 43.51 Favored 'General case' 0 C--N 1.319 -0.737 0 N-CA-C 109.624 -0.51 . . . . 64.3 109.624 176.403 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 48.4 mttp -91.49 123.83 35.2 Favored 'General case' 0 C--N 1.324 -0.502 0 N-CA-C 110.112 -0.329 . . . . 73.43 110.112 178.491 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.246 0.886 0 CA-C-O 118.602 -0.713 . . . . 75.12 110.647 -179.942 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 27.2 ttt . . . . . 0 N--CA 1.483 1.178 0 CA-C-O 120.931 0.396 . . . . 73.12 110.852 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 60.7 mm-40 -81.48 69.7 8.18 Favored 'General case' 0 C--O 1.238 0.471 0 CA-C-O 121.388 0.613 . . . . 75.21 111.837 -178.979 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 35.3 tt0 -120.91 136.28 54.99 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-N 115.34 -0.845 . . . . 74.55 109.478 174.756 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -151.9 164.49 30.4 Favored Glycine 0 N--CA 1.444 -0.788 0 N-CA-C 111.368 -0.693 . . . . 64.31 111.368 179.027 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 5' ' ' THR . . . . . 0.54 HG21 ' HE3' ' A' ' 7' ' ' LYS . 5.4 m -103.38 125.32 49.92 Favored 'General case' 0 C--N 1.318 -0.802 0 CA-C-N 116.984 0.392 . . . . 74.21 110.825 -178.623 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.488 HG22 HG12 ' A' ' 18' ' ' ILE . 46.1 t -81.52 90.47 1.94 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 N-CA-C 109.099 -0.704 . . . . 73.44 109.099 175.473 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 7' ' ' LYS . . . . . 0.54 ' HE3' HG21 ' A' ' 5' ' ' THR . 27.9 mmtp -78.02 -51.9 9.62 Favored 'General case' 0 C--N 1.323 -0.587 0 CA-C-N 115.818 -0.628 . . . . 61.0 111.584 -176.155 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 8' ' ' TRP . . . . . . . . . . . . . 8.8 p90 -133.12 122.25 23.81 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-O 121.41 0.624 . . . . 72.22 110.992 178.113 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 22.2 p90 -111.6 123.43 50.21 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-N 115.343 -0.844 . . . . 64.05 109.544 178.434 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 16.7 t-20 -88.39 76.18 8.34 Favored 'General case' 0 C--N 1.317 -0.806 0 CA-C-O 121.503 0.668 . . . . 61.44 109.893 -176.737 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -67.75 -7.93 31.39 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.241 -0.89 . . . . 73.53 110.442 178.438 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 27.3 mt-10 -70.45 -33.41 71.26 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 115.306 -0.861 . . . . 74.05 110.595 179.081 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 13' ' ' LYS . . . . . 0.423 ' HB2' ' CE1' ' A' ' 15' ' ' PHE . 74.3 mmtt -116.25 -29.66 6.18 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.235 -0.439 . . . . 52.34 111.296 -178.47 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 14' ' ' GLY . . . . . 0.618 ' HA2' ' CE2' ' A' ' 30' ' ' PHE . . . 117.52 24.83 3.33 Favored Glycine 0 N--CA 1.452 -0.265 0 C-N-CA 120.178 -1.011 . . . . 64.41 113.773 175.842 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 15' ' ' PHE . . . . . 0.423 ' CE1' ' HB2' ' A' ' 13' ' ' LYS . 54.9 p90 -142.1 -174.11 4.01 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 116.921 0.361 . . . . 75.52 110.124 179.334 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -169.65 170.39 42.68 Favored Glycine 0 N--CA 1.449 -0.454 0 C-N-CA 120.358 -0.925 . . . . 53.03 112.147 177.713 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 98.2 m-85 -120.17 126.59 51.04 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 121.054 0.454 . . . . 75.53 110.81 -179.728 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.488 HG12 HG22 ' A' ' 6' ' ' VAL . 62.9 mt -110.81 129.21 66.42 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.572 0 CA-C-N 115.777 -0.647 . . . . 64.14 110.179 179.724 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 7.0 pt-20 -79.71 113.26 17.73 Favored 'General case' 0 C--N 1.326 -0.436 0 N-CA-C 109.665 -0.494 . . . . 63.1 109.665 175.673 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 20' ' ' ARG . . . . . 0.409 ' HD3' ' OD2' ' A' ' 24' ' ' ASP . 73.0 ttt-85 -113.02 111.15 21.68 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 116.06 -0.518 . . . . 71.34 111.332 -175.604 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 10.7 mm-40 47.3 -89.6 0.01 OUTLIER 'General case' 0 N--CA 1.47 0.537 0 N-CA-C 114.158 1.17 . . . . 74.25 114.158 169.725 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 23.6 t-20 -70.51 -31.38 68.44 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 121.12 0.486 . . . . 53.41 111.27 -174.018 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 130.51 -1.67 5.66 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.728 -0.748 . . . . 62.44 111.255 -176.405 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 24' ' ' ASP . . . . . 0.409 ' OD2' ' HD3' ' A' ' 20' ' ' ARG . 2.6 p-10 -67.92 94.35 0.47 Allowed 'General case' 0 C--N 1.323 -0.565 0 CA-C-O 121.355 0.597 . . . . 61.34 110.185 175.937 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 5.7 p-10 -57.02 123.58 15.68 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 114.989 -1.005 . . . . 75.2 110.751 176.938 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 46.4 t -97.22 135.05 32.77 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.658 0 CA-C-N 115.614 -0.721 . . . . 72.22 110.326 -179.764 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 27' ' ' PHE . . . . . . . . . . . . . 32.5 t80 -80.77 105.58 12.12 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 116.142 -0.481 . . . . 72.35 110.161 -179.188 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.403 HG23 HG21 ' A' ' 63' ' ' VAL . 9.9 p -99.74 158.87 3.7 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.516 0 N-CA-C 110.011 -0.366 . . . . 65.44 110.011 179.522 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 1.1 p80 -147.89 159.49 43.8 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.534 -0.303 . . . . 71.52 110.29 -178.414 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 30' ' ' PHE . . . . . 0.618 ' CE2' ' HA2' ' A' ' 14' ' ' GLY . 23.0 m-85 -56.82 -37.14 70.8 Favored 'General case' 0 N--CA 1.468 0.443 0 N-CA-C 112.76 0.652 . . . . 72.4 112.76 -173.767 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 12.7 t -70.97 -3.31 18.75 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 120.893 0.377 . . . . 42.45 111.269 -178.157 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 32' ' ' ALA . . . . . 0.427 ' HB1' HG23 ' A' ' 63' ' ' VAL . . . -107.08 -34.13 7.25 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.75 0.31 . . . . 61.45 110.668 177.015 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.511 ' HA ' ' HB ' ' A' ' 63' ' ' VAL . 61.2 mt -65.17 140.27 20.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.109 -0.496 . . . . 72.22 110.708 179.041 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 11.3 pt20 -74.36 23.35 0.09 Allowed 'General case' 0 CA--C 1.537 0.443 0 N-CA-C 112.359 0.503 . . . . 55.12 112.359 -177.488 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -83.16 116.62 4.25 Favored Glycine 0 N--CA 1.449 -0.498 0 C-N-CA 120.617 -0.801 . . . . 74.54 112.003 -179.689 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 14.7 t70 -81.98 111.26 17.99 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.741 0.305 . . . . 34.41 110.512 178.825 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 75.41 -118.9 5.66 Favored Glycine 0 N--CA 1.446 -0.665 0 C-N-CA 120.969 -0.634 . . . . 62.12 112.076 179.915 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 97.5 m-85 -106.06 90.25 3.31 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-O 120.946 0.403 . . . . 74.43 110.515 -179.189 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 32.1 mmmt -130.57 146.58 52.11 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.785 -0.643 . . . . 61.33 109.66 177.367 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 18.6 m -109.05 113.69 26.78 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-O 120.682 0.277 . . . . 74.22 110.457 -179.691 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 41' ' ' LEU . . . . . 0.431 HD22 ' HA ' ' A' ' 41' ' ' LEU . 1.9 tm? -62.85 125.87 25.42 Favored 'General case' 0 C--N 1.326 -0.433 0 N-CA-C 109.078 -0.712 . . . . 63.22 109.078 178.374 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 18.1 m-20 -60.16 119.76 8.47 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 116.245 -0.434 . . . . 74.2 110.974 -176.627 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 8.2 pt-20 -67.18 119.5 12.2 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-O 121.34 0.59 . . . . 64.54 110.145 177.616 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 112.49 -4.61 26.43 Favored Glycine 0 N--CA 1.445 -0.713 0 N-CA-C 111.179 -0.768 . . . . 51.15 111.179 -174.532 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 5.8 tp-100 -72.67 132.91 44.31 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 120.874 0.369 . . . . 75.25 110.946 179.73 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -86.08 115.07 23.44 Favored 'General case' 0 C--N 1.325 -0.465 0 N-CA-C 108.89 -0.781 . . . . 44.13 108.89 173.073 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 0.51 ' HA ' ' HA ' ' A' ' 65' ' ' LYS . 29.3 m -110.27 155.29 11.6 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.811 0 CA-C-O 121.316 0.579 . . . . 51.43 111.51 -174.945 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 48' ' ' THR . . . . . 0.5 HG23 ' HB2' ' A' ' 66' ' ' ALA . 45.4 p -121.15 112.31 18.52 Favored 'General case' 0 C--N 1.318 -0.773 0 CA-C-N 115.322 -0.854 . . . . 73.15 108.832 175.376 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 49' ' ' PHE . . . . . 0.407 ' HA ' ' O ' ' A' ' 62' ' ' ASN . 35.4 p90 -127.07 171.98 10.9 Favored 'General case' 0 C--N 1.319 -0.748 0 CA-C-N 115.95 -0.568 . . . . 71.13 111.323 -170.969 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 62.9 m-20 -96.12 138.43 33.75 Favored 'General case' 0 C--N 1.322 -0.598 0 N-CA-C 109.065 -0.717 . . . . 73.45 109.065 169.935 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 12.5 p -102.31 134.67 42.39 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.721 0 CA-C-O 121.008 0.432 . . . . 63.2 111.27 -174.767 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 40.1 mt-10 -122.35 148.81 44.6 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 116.066 -0.515 . . . . 73.44 110.24 175.889 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 36.5 mt-10 -106.07 123.41 47.96 Favored 'General case' 0 C--N 1.319 -0.736 0 N-CA-C 109.61 -0.515 . . . . 71.33 109.61 177.401 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -118.46 -178.99 17.06 Favored Glycine 0 N--CA 1.445 -0.74 0 C-N-CA 120.669 -0.777 . . . . 74.54 112.287 -178.512 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -67.64 -29.45 68.76 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 120.772 0.32 . . . . 73.25 111.548 -179.755 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 22.0 ttt180 -85.03 -27.62 26.27 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.184 -0.462 . . . . 73.03 110.448 179.455 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 148.73 -164.87 29.16 Favored Glycine 0 N--CA 1.446 -0.645 0 C-N-CA 120.893 -0.67 . . . . 71.14 111.864 -179.282 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 56.4 Cg_endo -72.41 126.85 11.97 Favored 'Trans proline' 0 N--CA 1.463 -0.288 0 C-N-CA 122.702 2.268 . . . . 52.13 112.388 179.595 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 11.5 pt20 -123.72 154.33 39.61 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-N 115.851 -0.613 . . . . 72.51 110.152 -179.974 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -99.57 135.25 41.27 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 116.383 -0.371 . . . . 44.42 111.168 -177.958 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -131.97 149.63 52.38 Favored 'General case' 0 C--N 1.324 -0.529 0 N-CA-C 108.829 -0.804 . . . . 71.42 108.829 174.461 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 62' ' ' ASN . . . . . 0.407 ' O ' ' HA ' ' A' ' 49' ' ' PHE . 55.5 m-20 53.57 75.57 0.26 Allowed 'General case' 0 C--O 1.239 0.504 0 N-CA-C 110.028 -0.36 . . . . 73.12 110.028 -174.999 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.511 ' HB ' ' HA ' ' A' ' 33' ' ' ILE . 59.4 t -101.9 101.99 12.89 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.517 0 CA-C-O 121.171 0.51 . . . . 73.52 110.947 -176.191 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 50.8 mt-30 -107.48 170.27 8.07 Favored 'General case' 0 C--N 1.32 -0.707 0 N-CA-C 108.593 -0.892 . . . . 74.33 108.593 175.791 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 65' ' ' LYS . . . . . 0.51 ' HA ' ' HA ' ' A' ' 47' ' ' VAL . 21.9 pttp -93.58 169.1 10.59 Favored 'General case' 0 C--N 1.321 -0.66 0 C-N-CA 120.477 -0.489 . . . . 70.14 110.277 179.658 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 66' ' ' ALA . . . . . 0.5 ' HB2' HG23 ' A' ' 48' ' ' THR . . . . . . . . 0 C--O 1.246 0.907 0 CA-C-O 118.275 -0.869 . . . . 52.24 109.96 176.241 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 1' ' ' MET . . . . . 0.435 ' HG2' ' OE2' ' A' ' 2' ' ' GLU . 22.3 ptp . . . . . 0 N--CA 1.486 1.326 0 CA-C-O 121.113 0.483 . . . . 73.31 110.075 . . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 2' ' ' GLU . . . . . 0.435 ' OE2' ' HG2' ' A' ' 1' ' ' MET . 6.9 mp0 -94.05 128.35 40.36 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 115.982 -0.554 . . . . 65.41 110.572 -169.887 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 27.0 tt0 -90.34 98.94 12.07 Favored 'General case' 0 C--N 1.322 -0.614 0 N-CA-C 109.085 -0.709 . . . . 73.5 109.085 174.567 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -120.91 163.42 14.41 Favored Glycine 0 N--CA 1.446 -0.667 0 C-N-CA 120.575 -0.821 . . . . 75.4 112.668 -174.591 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 5' ' ' THR . . . . . 0.461 ' O ' ' HG2' ' A' ' 19' ' ' GLU . 0.2 OUTLIER -105.23 129.53 53.58 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-O 121.028 0.442 . . . . 74.1 110.969 179.826 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.552 ' HA ' ' HA ' ' A' ' 18' ' ' ILE . 17.0 t -71.06 121.66 21.44 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.582 0 CA-C-N 116.08 -0.509 . . . . 61.42 110.451 179.684 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 50.5 mttp -74.33 -49.48 22.7 Favored 'General case' 0 C--N 1.329 -0.302 0 C-N-CA 120.719 -0.392 . . . . 54.44 110.433 177.677 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 8' ' ' TRP . . . . . . . . . . . . . 14.9 p-90 -161.99 163.74 28.74 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.91 -0.586 . . . . 74.51 109.671 179.469 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 10.9 p90 -145.02 121.1 10.75 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-O 121.31 0.576 . . . . 71.43 111.098 -178.131 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 52.2 t-20 -82.73 86.43 6.88 Favored 'General case' 0 C--N 1.321 -0.631 0 N-CA-C 109.267 -0.642 . . . . 61.41 109.267 177.226 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -72.84 -5.33 37.47 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.303 -0.862 . . . . 64.35 111.748 -179.644 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 9.8 mm-40 -86.25 -19.4 30.01 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-O 120.977 0.418 . . . . 63.32 110.253 177.355 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 43.4 mmtm -108.76 -48.04 3.37 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 115.945 -0.571 . . . . 65.34 110.047 176.71 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 115.76 43.83 0.67 Allowed Glycine 0 N--CA 1.442 -0.929 0 C-N-CA 120.765 -0.731 . . . . 63.13 112.174 -179.134 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 43.8 p90 -152.03 161.29 42.87 Favored 'General case' 0 C--N 1.328 -0.349 0 N-CA-C 110.183 -0.302 . . . . 74.22 110.183 176.926 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -154.02 171.1 32.66 Favored Glycine 0 N--CA 1.448 -0.548 0 C-N-CA 120.877 -0.678 . . . . 74.11 112.166 179.88 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 80.9 m-85 -124.04 116.78 23.36 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-O 121.049 0.452 . . . . 75.11 110.75 179.591 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.552 ' HA ' ' HA ' ' A' ' 6' ' ' VAL . 11.3 mt -109.94 123.02 65.48 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.524 0 N-CA-C 108.715 -0.846 . . . . 75.52 108.715 178.63 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 19' ' ' GLU . . . . . 0.5 ' HA ' ' HA ' ' A' ' 25' ' ' ASP . 16.7 pt-20 -76.15 138.43 40.71 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-O 121.404 0.621 . . . . 73.33 112.092 -170.549 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 20' ' ' ARG . . . . . 0.602 ' HB3' ' HB3' ' A' ' 24' ' ' ASP . 78.1 ttt180 -91.73 161.33 14.93 Favored 'General case' 0 C--N 1.321 -0.659 0 N-CA-C 108.51 -0.922 . . . . 62.44 108.51 171.126 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 21' ' ' GLU . . . . . 0.506 ' OE1' ' HG2' ' A' ' 20' ' ' ARG . 0.0 OUTLIER -71.1 6.45 1.62 Allowed 'General case' 0 CA--C 1.537 0.455 0 N-CA-C 112.745 0.646 . . . . 71.03 112.745 -173.559 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 9.4 m-80 -108.63 5.29 24.82 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-O 120.792 0.33 . . . . 73.41 110.895 175.31 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 84.88 0.86 89.07 Favored Glycine 0 N--CA 1.453 -0.227 0 N-CA-C 110.572 -1.011 . . . . 54.4 110.572 -172.89 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 24' ' ' ASP . . . . . 0.602 ' HB3' ' HB3' ' A' ' 20' ' ' ARG . 31.5 t70 -76.07 87.49 2.97 Favored 'General case' 0 C--N 1.321 -0.669 0 CA-C-N 114.631 -0.784 . . . . 53.43 109.946 -178.859 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.5 ' HA ' ' HA ' ' A' ' 19' ' ' GLU . 55.9 m-20 -64.5 110.69 2.39 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 116.02 -0.537 . . . . 54.5 110.647 179.121 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.442 HG13 ' HB2' ' A' ' 58' ' ' PRO . 28.2 t -85.2 130.01 36.88 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.492 0 CA-C-N 115.639 -0.709 . . . . 54.23 110.977 -175.281 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 27' ' ' PHE . . . . . . . . . . . . . 85.3 t80 -84.87 122.84 29.75 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.745 -0.661 . . . . 74.2 110.816 -178.48 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.568 ' HB ' ' HB3' ' A' ' 60' ' ' ALA . 12.3 p -120.47 145.62 26.58 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.574 0 CA-C-N 116.591 -0.277 . . . . 61.43 110.276 178.249 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 29' ' ' HIS . . . . . 0.478 ' O ' HG13 ' A' ' 33' ' ' ILE . 6.6 t60 -111.7 157.44 20.48 Favored 'General case' 0 C--N 1.327 -0.381 0 N-CA-C 109.432 -0.581 . . . . 63.12 109.432 -179.706 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 33.6 p90 -51.57 -40.18 59.28 Favored 'General case' 0 N--CA 1.471 0.582 0 N-CA-C 113.367 0.877 . . . . 73.32 113.367 -170.471 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 29.5 t -83.6 -6.95 59.58 Favored 'General case' 0 C--N 1.33 -0.282 0 C-N-CA 120.691 -0.404 . . . . 61.14 111.262 -176.056 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -93.67 -20.22 20.37 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-O 121.43 0.634 . . . . 50.34 109.457 174.791 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.478 HG13 ' O ' ' A' ' 29' ' ' HIS . 52.0 mt -75.53 154.28 6.2 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.408 0 CA-C-N 114.979 -1.01 . . . . 74.33 109.335 174.782 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 34' ' ' GLN . . . . . 0.405 ' HB3' ' O ' ' A' ' 63' ' ' VAL . 3.8 pt20 -69.43 128.0 35.01 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-O 121.052 0.453 . . . . 63.44 110.728 179.299 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -85.27 -9.53 79.52 Favored Glycine 0 N--CA 1.45 -0.429 0 C-N-CA 120.438 -0.887 . . . . 70.41 111.36 176.566 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 5.7 m-20 -124.61 146.57 49.0 Favored 'General case' 0 C--N 1.324 -0.537 0 N-CA-C 109.222 -0.658 . . . . 63.41 109.222 179.849 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 104.99 -88.68 0.6 Allowed Glycine 0 N--CA 1.448 -0.507 0 N-CA-C 111.164 -0.774 . . . . 74.45 111.164 -175.419 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 77.3 m-85 -112.96 109.57 19.08 Favored 'General case' 0 C--N 1.323 -0.565 0 N-CA-C 109.773 -0.455 . . . . 75.42 109.773 174.903 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -72.37 -15.43 61.86 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 121.262 0.553 . . . . 61.32 110.076 179.005 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 18.4 p -142.2 115.25 8.78 Favored 'General case' 0 N--CA 1.448 -0.561 0 CA-C-N 115.608 -0.724 . . . . 73.44 109.961 176.093 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 3.8 mm? -81.02 126.83 31.89 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 116.289 -0.414 . . . . 74.23 110.365 -179.503 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 42' ' ' ASP . . . . . 0.802 ' HB2' ' HB2' ' A' ' 45' ' ' GLN . 5.4 m-20 -65.11 143.93 57.57 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.801 -0.636 . . . . 74.31 110.18 178.98 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 43' ' ' GLU . . . . . 0.426 ' H ' ' HG3' ' A' ' 43' ' ' GLU . 0.1 OUTLIER -80.01 90.69 5.4 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-O 122.528 1.156 . . . . 70.13 109.332 174.737 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 130.65 0.5 5.29 Favored Glycine 0 N--CA 1.445 -0.713 0 CA-C-N 114.007 -1.451 . . . . 63.12 110.539 -169.148 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 45' ' ' GLN . . . . . 0.802 ' HB2' ' HB2' ' A' ' 42' ' ' ASP . 6.7 tp-100 -78.07 140.78 39.11 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.381 -0.41 . . . . 75.53 110.291 177.828 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -101.98 120.56 40.61 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 116.207 -0.451 . . . . 51.34 110.533 179.442 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 17.8 m -132.94 158.78 43.37 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.564 0 CA-C-N 116.181 -0.463 . . . . 74.24 110.72 -179.134 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 48' ' ' THR . . . . . 0.603 HG23 ' HB2' ' A' ' 66' ' ' ALA . 37.1 p -103.16 99.64 9.52 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 121.33 0.586 . . . . 64.41 110.876 -178.681 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 49' ' ' PHE . . . . . 0.428 ' HA ' ' O ' ' A' ' 62' ' ' ASN . 42.0 p90 -105.62 167.6 9.65 Favored 'General case' 0 C--N 1.315 -0.911 0 CA-C-N 115.635 -0.711 . . . . 74.22 109.732 -179.796 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 4.6 t70 -117.34 111.8 19.86 Favored 'General case' 0 C--N 1.319 -0.731 0 C-N-CA 120.197 -0.601 . . . . 72.33 110.351 172.703 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 9.1 p -69.15 125.67 27.58 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-O 121.707 0.765 . . . . 74.02 112.275 -176.407 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 6.4 mm-40 -102.69 134.14 46.56 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-N 115.314 -0.857 . . . . 62.33 108.995 172.467 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 15.4 pt-20 -87.77 127.03 35.32 Favored 'General case' 0 C--N 1.32 -0.709 0 C-N-CA 120.447 -0.501 . . . . 62.25 110.047 177.499 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -153.53 -158.39 8.56 Favored Glycine 0 N--CA 1.447 -0.625 0 C-N-CA 120.224 -0.989 . . . . 63.15 113.007 -178.42 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 39.8 mt-30 -66.28 -24.53 66.58 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.865 0.364 . . . . 63.44 111.276 -175.85 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -93.89 9.36 37.67 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 116.283 -0.417 . . . . 41.45 110.46 179.158 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 81.34 -115.92 4.11 Favored Glycine 0 N--CA 1.444 -0.791 0 N-CA-C 110.754 -0.939 . . . . 63.25 110.754 -174.504 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 58' ' ' PRO . . . . . 0.442 ' HB2' HG13 ' A' ' 26' ' ' VAL . 89.3 Cg_endo -81.53 109.01 2.0 Favored 'Trans proline' 0 N--CA 1.455 -0.749 0 C-N-CA 122.482 2.121 . . . . 74.34 112.005 175.217 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 51.1 tt0 -115.51 118.17 32.42 Favored 'General case' 0 C--N 1.322 -0.594 0 N-CA-C 109.455 -0.572 . . . . 75.02 109.455 176.947 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 60' ' ' ALA . . . . . 0.568 ' HB3' ' HB ' ' A' ' 28' ' ' VAL . . . -78.67 123.94 27.67 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-O 121.004 0.431 . . . . 64.42 111.818 -173.029 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -124.75 145.7 49.58 Favored 'General case' 0 C--N 1.321 -0.667 0 N-CA-C 109.14 -0.689 . . . . 63.33 109.14 173.325 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 62' ' ' ASN . . . . . 0.428 ' O ' ' HA ' ' A' ' 49' ' ' PHE . 47.3 m-80 60.61 87.83 0.09 Allowed 'General case' 0 C--O 1.236 0.394 0 CA-C-O 121.321 0.581 . . . . 73.51 110.704 -175.57 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.405 ' O ' ' HB3' ' A' ' 34' ' ' GLN . 58.0 t -100.29 106.72 19.7 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.547 0 CA-C-N 115.443 -0.799 . . . . 63.14 109.407 176.132 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 48.7 mt-30 -103.98 160.38 14.87 Favored 'General case' 0 C--N 1.319 -0.741 0 CA-C-N 116.086 -0.507 . . . . 75.13 110.665 -177.191 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 9.7 mtpm? -77.07 136.43 38.66 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 115.928 -0.578 . . . . 72.11 109.731 176.481 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 66' ' ' ALA . . . . . 0.603 ' HB2' HG23 ' A' ' 48' ' ' THR . . . . . . . . 0 C--O 1.248 1.006 0 CA-C-O 118.666 -0.683 . . . . 42.25 110.19 -179.505 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.479 1.003 0 N-CA-C 110.12 -0.326 . . . . 65.31 110.12 . . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 4.5 mm-40 53.21 61.47 3.14 Favored 'General case' 0 C--O 1.236 0.38 0 O-C-N 123.783 0.677 . . . . 74.13 111.299 175.729 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 24.1 tt0 -86.57 125.16 33.6 Favored 'General case' 0 N--CA 1.448 -0.528 0 CA-C-N 115.077 -0.965 . . . . 74.13 110.067 177.633 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -136.52 150.4 20.49 Favored Glycine 0 N--CA 1.442 -0.936 0 N-CA-C 111.311 -0.716 . . . . 74.12 111.311 176.435 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 5' ' ' THR . . . . . 0.435 ' O ' ' HG2' ' A' ' 19' ' ' GLU . 0.7 OUTLIER -98.13 130.39 44.9 Favored 'General case' 0 C--N 1.319 -0.758 0 CA-C-O 120.672 0.272 . . . . 71.1 110.672 177.763 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 47.3 t -65.54 122.23 16.09 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.491 0 N-CA-C 109.857 -0.423 . . . . 51.23 109.857 176.547 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 7' ' ' LYS . . . . . 0.41 ' HG2' ' OE1' ' A' ' 19' ' ' GLU . 27.6 mtpp -78.33 -60.81 2.22 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 121.209 0.528 . . . . 73.12 109.604 179.788 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 8' ' ' TRP . . . . . . . . . . . . . 19.0 p90 -152.07 156.4 39.84 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 115.465 -0.789 . . . . 65.45 109.214 175.79 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 17.9 p90 -127.09 112.57 15.34 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-O 121.607 0.718 . . . . 65.22 111.055 -174.931 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 77.8 m-20 -86.67 73.5 10.02 Favored 'General case' 0 C--N 1.32 -0.696 0 CA-C-N 115.682 -0.69 . . . . 71.53 109.608 179.537 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -61.58 -25.52 67.38 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 115.553 -0.749 . . . . 72.32 111.118 -177.981 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 26.6 mt-10 -58.82 -36.87 75.23 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.531 -0.758 . . . . 74.42 110.864 179.287 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 28.2 mmtp -104.92 -18.33 14.23 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 116.024 -0.534 . . . . 71.33 111.007 -177.967 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 95.87 28.76 9.13 Favored Glycine 0 N--CA 1.449 -0.5 0 C-N-CA 120.748 -0.739 . . . . 73.12 113.491 174.399 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 50.2 p90 -150.69 156.4 41.25 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 117.155 0.478 . . . . 65.32 110.65 177.451 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -137.43 176.86 20.29 Favored Glycine 0 N--CA 1.447 -0.615 0 C-N-CA 121.075 -0.583 . . . . 54.11 111.736 178.64 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 75.8 m-85 -126.26 127.5 45.72 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 121.273 0.559 . . . . 73.34 110.948 179.54 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.412 ' HB ' ' HB ' ' A' ' 26' ' ' VAL . 64.3 mt -110.18 143.68 19.74 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.618 0 CA-C-N 115.408 -0.815 . . . . 73.53 109.845 179.191 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 19' ' ' GLU . . . . . 0.435 ' HG2' ' O ' ' A' ' 5' ' ' THR . 7.6 pt-20 -96.63 108.8 21.47 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 121.573 0.701 . . . . 75.44 110.649 177.213 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 20' ' ' ARG . . . . . 0.423 ' HG2' ' N ' ' A' ' 21' ' ' GLU . 61.3 ttt180 -97.0 162.87 13.2 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 114.954 -1.021 . . . . 65.45 110.123 -176.749 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 21' ' ' GLU . . . . . 0.423 ' N ' ' HG2' ' A' ' 20' ' ' ARG . 19.2 mm-40 -51.88 -41.65 62.07 Favored 'General case' 0 CA--C 1.531 0.241 0 CA-C-O 121.156 0.503 . . . . 74.13 111.002 176.618 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 15.3 m120 -111.09 26.34 10.8 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.983 -0.553 . . . . 62.55 111.761 -175.257 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 179.14 111.81 0.32 Allowed Glycine 0 C--O 1.225 -0.415 0 C-N-CA 119.86 -1.162 . . . . 44.45 113.084 -179.888 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 31.8 t70 -74.53 6.4 3.82 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-O 121.472 0.653 . . . . 61.34 111.05 -176.294 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 10.4 p-10 -152.04 93.21 1.8 Allowed 'General case' 0 C--N 1.324 -0.539 0 CA-C-O 121.882 0.849 . . . . 72.54 111.096 -178.768 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.412 ' HB ' ' HB ' ' A' ' 18' ' ' ILE . 89.0 t -102.59 121.18 53.38 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 CA-C-N 115.042 -0.981 . . . . 71.22 109.784 175.216 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 27' ' ' PHE . . . . . 0.485 ' O ' ' HA ' ' A' ' 59' ' ' GLN . 78.1 t80 -78.6 120.37 23.19 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 116.024 -0.534 . . . . 73.01 110.535 -178.558 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.485 ' HB ' ' HB3' ' A' ' 60' ' ' ALA . 8.7 p -128.7 136.05 60.82 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.728 0 CA-C-O 120.964 0.412 . . . . 74.41 111.277 179.516 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 29' ' ' HIS . . . . . 0.483 ' O ' HG13 ' A' ' 33' ' ' ILE . 3.2 m-70 -96.99 142.92 28.36 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 116.14 -0.482 . . . . 73.4 110.024 175.307 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 30' ' ' PHE . . . . . 0.436 ' HE2' ' HB3' ' A' ' 40' ' ' SER . 17.7 m-85 -62.28 -28.59 69.83 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-O 120.704 0.287 . . . . 73.41 111.216 -179.545 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 16.5 t -74.92 -12.44 60.35 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 121.0 0.429 . . . . 73.11 110.877 177.897 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 32' ' ' ALA . . . . . 0.476 ' HB1' ' HA ' ' A' ' 61' ' ' ALA . . . -97.67 -24.26 15.58 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 121.095 0.474 . . . . 52.43 110.464 178.858 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.501 HG23 ' HB ' ' A' ' 63' ' ' VAL . 31.8 mt -68.61 163.48 3.15 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.4 0 CA-C-N 115.86 -0.609 . . . . 75.55 109.936 176.233 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 34' ' ' GLN . . . . . 0.452 ' N ' HG22 ' A' ' 33' ' ' ILE . 2.1 pt20 -72.19 10.62 0.72 Allowed 'General case' 0 N--CA 1.466 0.358 0 CA-C-O 120.73 0.3 . . . . 64.22 111.703 179.426 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.41 ' H ' ' C ' ' A' ' 33' ' ' ILE . . . -65.21 114.96 7.19 Favored Glycine 0 N--CA 1.446 -0.634 0 C-N-CA 121.092 -0.575 . . . . 71.11 112.402 -175.599 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 22.6 t70 -62.05 112.28 2.28 Favored 'General case' 0 C--N 1.327 -0.403 0 N-CA-C 109.235 -0.654 . . . . 51.33 109.235 176.062 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 76.83 -99.45 1.38 Allowed Glycine 0 N--CA 1.447 -0.568 0 N-CA-C 110.49 -1.044 . . . . 23.24 110.49 -170.6 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 53.4 m-85 -146.58 100.66 3.37 Favored 'General case' 0 C--N 1.325 -0.477 0 N-CA-C 109.765 -0.458 . . . . 73.24 109.765 173.583 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 54.7 mtpt -125.22 135.01 52.14 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.163 -0.472 . . . . 72.55 110.205 -177.355 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 40' ' ' SER . . . . . 0.436 ' HB3' ' HE2' ' A' ' 30' ' ' PHE . 13.8 p -91.95 149.56 21.48 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-O 121.036 0.446 . . . . 71.24 111.751 -175.862 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 41' ' ' LEU . . . . . 0.542 HD12 ' HG2' ' A' ' 45' ' ' GLN . 4.4 mm? -103.33 145.28 30.21 Favored 'General case' 0 C--N 1.325 -0.488 0 N-CA-C 109.397 -0.594 . . . . 73.35 109.397 174.858 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 6.5 m-20 -76.08 156.87 33.5 Favored 'General case' 0 C--N 1.32 -0.691 0 CA-C-N 116.112 -0.495 . . . . 62.01 111.29 -174.752 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 6.3 pt-20 -68.01 133.21 48.66 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-N 116.051 -0.522 . . . . 62.42 109.962 175.648 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 87.02 0.23 85.65 Favored Glycine 0 N--CA 1.446 -0.676 0 C-N-CA 120.558 -0.83 . . . . 73.31 112.146 -177.246 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 45' ' ' GLN . . . . . 0.542 ' HG2' HD12 ' A' ' 41' ' ' LEU . 24.3 tp60 -74.72 115.96 14.89 Favored 'General case' 0 C--N 1.328 -0.368 0 N-CA-C 109.637 -0.505 . . . . 73.44 109.637 176.9 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -74.84 116.07 15.14 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 116.049 -0.523 . . . . 64.43 110.125 177.14 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 0.505 HG12 ' HA ' ' A' ' 65' ' ' LYS . 27.5 m -122.13 150.15 25.58 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.737 0 CA-C-N 116.068 -0.515 . . . . 63.22 110.751 -179.44 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 59.0 p -106.9 119.01 38.19 Favored 'General case' 0 C--N 1.318 -0.777 0 N-CA-C 108.928 -0.767 . . . . 73.42 108.928 175.062 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 29.8 p90 -127.99 151.34 49.25 Favored 'General case' 0 C--N 1.319 -0.74 0 CA-C-O 120.932 0.396 . . . . 70.11 111.745 -172.135 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 17.8 t70 -82.66 120.4 25.52 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.809 -0.632 . . . . 62.54 109.306 174.397 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 49.6 t -83.33 115.94 26.56 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.63 0 CA-C-N 116.063 -0.517 . . . . 43.43 111.622 -174.044 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 34.6 tt0 -108.82 104.74 14.07 Favored 'General case' 0 C--N 1.323 -0.585 0 N-CA-C 109.471 -0.566 . . . . 75.44 109.471 174.417 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 5.9 pt-20 -90.98 108.19 19.69 Favored 'General case' 0 C--N 1.318 -0.785 0 CA-C-O 121.363 0.602 . . . . 72.44 110.639 -179.42 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -118.85 -171.4 15.03 Favored Glycine 0 N--CA 1.445 -0.72 0 CA-C-N 115.428 -0.805 . . . . 63.32 111.888 -178.856 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 10.7 mm100 -78.62 77.9 5.09 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 121.33 0.586 . . . . 62.01 110.621 -177.573 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 4.6 ptp85 170.75 -26.49 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 114.534 -1.212 . . . . 62.44 108.973 -178.954 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 139.32 -170.23 24.21 Favored Glycine 0 N--CA 1.443 -0.857 0 N-CA-C 110.812 -0.915 . . . . 71.23 110.812 -179.673 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 72.3 Cg_endo -78.56 111.44 3.0 Favored 'Trans proline' 0 N--CA 1.455 -0.742 0 C-N-CA 122.077 1.851 . . . . 70.5 111.77 177.264 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 59' ' ' GLN . . . . . 0.485 ' HA ' ' O ' ' A' ' 27' ' ' PHE . 15.0 pt20 -104.34 135.77 45.17 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-O 121.137 0.494 . . . . 71.15 109.881 176.009 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 60' ' ' ALA . . . . . 0.485 ' HB3' ' HB ' ' A' ' 28' ' ' VAL . . . -90.09 123.5 34.0 Favored 'General case' 0 C--N 1.321 -0.669 0 CA-C-N 115.879 -0.6 . . . . 53.4 111.457 -173.995 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 61' ' ' ALA . . . . . 0.476 ' HA ' ' HB1' ' A' ' 32' ' ' ALA . . . -124.09 150.5 44.95 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-N 115.463 -0.79 . . . . 63.32 108.878 175.373 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 30.8 m-80 56.45 74.06 0.41 Allowed 'General case' 0 C--N 1.329 -0.301 0 N-CA-C 109.313 -0.625 . . . . 72.31 109.313 -176.155 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.501 ' HB ' HG23 ' A' ' 33' ' ' ILE . 40.5 t -105.37 103.5 15.46 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.599 0 CA-C-N 115.786 -0.643 . . . . 71.43 110.858 -175.304 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 69.5 mt-30 -111.64 129.96 55.92 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 116.193 -0.458 . . . . 72.24 109.774 179.29 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 65' ' ' LYS . . . . . 0.505 ' HA ' HG12 ' A' ' 47' ' ' VAL . 18.2 pttp -62.75 153.51 32.5 Favored 'General case' 0 C--N 1.327 -0.386 0 N-CA-C 110.294 -0.261 . . . . 73.23 110.294 -178.495 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 0.992 0 CA-C-O 118.193 -0.908 . . . . 72.34 109.802 176.261 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 15.1 tpt . . . . . 0 N--CA 1.481 1.104 0 CA-C-O 120.773 0.321 . . . . 72.33 110.986 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 2' ' ' GLU . . . . . 0.541 ' HB2' ' O ' ' A' ' 49' ' ' PHE . 1.7 mp0 -81.01 101.98 9.89 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 121.325 0.583 . . . . 75.12 111.114 -178.854 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 3' ' ' GLN . . . . . 0.681 ' HG2' HG22 ' A' ' 48' ' ' THR . 47.8 mt-30 -106.82 120.1 41.12 Favored 'General case' 0 C--N 1.32 -0.711 0 CA-C-N 115.702 -0.681 . . . . 73.13 109.619 178.086 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -143.81 -164.26 10.29 Favored Glycine 0 N--CA 1.447 -0.57 0 C-N-CA 120.611 -0.804 . . . . 62.22 112.303 -176.706 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 5' ' ' THR . . . . . 0.509 ' O ' ' HG2' ' A' ' 19' ' ' GLU . 42.7 m -139.76 134.64 32.13 Favored 'General case' 0 C--N 1.319 -0.746 0 CA-C-O 120.674 0.273 . . . . 65.23 110.589 -178.879 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.403 HG21 ' HB3' ' A' ' 41' ' ' LEU . 47.4 t -68.58 135.63 28.03 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.487 0 CA-C-O 120.773 0.32 . . . . 63.21 110.343 -179.774 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 7' ' ' LYS . . . . . 0.47 ' HE3' ' HA ' ' A' ' 7' ' ' LYS . 0.0 OUTLIER -108.13 -72.69 0.71 Allowed 'General case' 0 C--N 1.324 -0.518 0 CA-C-O 120.966 0.412 . . . . 71.03 110.723 177.632 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 8' ' ' TRP . . . . . . . . . . . . . 46.0 m95 -127.43 125.99 41.58 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 116.082 -0.508 . . . . 75.03 110.134 -176.499 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 4.6 p90 -112.92 93.95 4.67 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-O 121.67 0.748 . . . . 73.24 110.861 179.866 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 66.2 t30 -92.93 59.33 3.15 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-O 121.892 0.853 . . . . 72.14 109.11 -179.738 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -68.83 -15.12 63.41 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 114.751 -1.113 . . . . 62.02 112.115 -173.067 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 20.5 mt-10 -74.32 -26.79 60.37 Favored 'General case' 0 C--N 1.326 -0.44 0 C-N-CA 120.713 -0.395 . . . . 74.12 110.693 178.205 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 3.8 mmmp? -97.03 -26.48 14.99 Favored 'General case' 0 C--N 1.328 -0.352 0 N-CA-C 109.68 -0.489 . . . . 73.11 109.68 175.064 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 115.82 23.79 4.2 Favored Glycine 0 N--CA 1.449 -0.488 0 C-N-CA 120.306 -0.95 . . . . 61.5 114.265 169.937 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 55.9 p90 -151.08 162.63 40.48 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 117.576 0.688 . . . . 72.01 111.455 179.897 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -153.93 171.18 32.6 Favored Glycine 0 N--CA 1.444 -0.788 0 C-N-CA 120.998 -0.62 . . . . 64.41 111.771 178.299 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 94.9 m-85 -125.69 121.71 34.25 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-O 120.914 0.388 . . . . 72.52 110.965 -178.604 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 59.6 mt -114.7 127.63 72.13 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.574 0 N-CA-C 108.752 -0.832 . . . . 70.25 108.752 174.484 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 19' ' ' GLU . . . . . 0.509 ' HG2' ' O ' ' A' ' 5' ' ' THR . 17.1 pt-20 -86.66 137.19 32.67 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-O 121.517 0.675 . . . . 72.13 112.294 -171.074 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 20' ' ' ARG . . . . . 0.797 ' HB3' ' HB2' ' A' ' 24' ' ' ASP . 10.3 tpt180 -100.41 169.31 9.19 Favored 'General case' 0 C--N 1.325 -0.485 0 N-CA-C 108.215 -1.031 . . . . 71.44 108.215 169.769 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 44.2 mt-10 -58.44 -22.81 55.7 Favored 'General case' 0 CA--C 1.538 0.506 0 N-CA-C 114.029 1.122 . . . . 71.41 114.029 -171.54 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 7.3 m-80 -94.81 3.09 55.42 Favored 'General case' 0 N--CA 1.467 0.421 0 CA-C-O 120.964 0.411 . . . . 73.42 110.43 -179.333 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 92.97 8.61 61.61 Favored Glycine 0 N--CA 1.45 -0.414 0 N-CA-C 111.131 -0.788 . . . . 71.25 111.131 -174.242 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 24' ' ' ASP . . . . . 0.797 ' HB2' ' HB3' ' A' ' 20' ' ' ARG . 1.6 m-20 -61.06 97.45 0.06 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.193 -0.503 . . . . 74.45 110.168 -178.84 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 40.3 m-20 -67.55 98.53 0.68 Allowed 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 116.264 -0.425 . . . . 72.44 110.0 173.669 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 26.4 t -79.19 128.16 38.68 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.665 0 CA-C-N 116.069 -0.514 . . . . 74.33 109.69 178.595 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 27' ' ' PHE . . . . . . . . . . . . . 17.7 t80 -84.48 108.24 17.16 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 115.957 -0.565 . . . . 73.51 110.437 -173.062 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.504 ' HB ' ' HB3' ' A' ' 60' ' ' ALA . 12.2 p -101.62 151.34 5.64 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.487 0 CA-C-O 121.141 0.496 . . . . 72.23 110.828 -178.545 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 29' ' ' HIS . . . . . 0.472 ' O ' HG13 ' A' ' 33' ' ' ILE . 17.8 m170 -118.09 149.53 40.86 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.798 -0.637 . . . . 60.31 109.422 176.697 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 30' ' ' PHE . . . . . 0.504 ' HA ' HD12 ' A' ' 33' ' ' ILE . 49.3 p90 -68.58 -23.31 64.47 Favored 'General case' 0 N--CA 1.463 0.22 0 CA-C-O 120.955 0.407 . . . . 75.14 110.471 -177.363 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 23.0 t -71.86 -25.14 61.83 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 115.864 -0.607 . . . . 75.25 110.063 176.682 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 32' ' ' ALA . . . . . 0.48 ' HB1' ' HA ' ' A' ' 61' ' ' ALA . . . -92.13 -19.99 21.71 Favored 'General case' 0 C--O 1.235 0.302 0 CA-C-N 115.964 -0.562 . . . . 64.41 110.863 -179.656 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.633 HG22 ' H ' ' A' ' 35' ' ' GLY . 77.3 mt -65.42 116.4 4.61 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 CA-C-N 116.156 -0.474 . . . . 74.11 110.114 176.567 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 4.7 pp0? -87.95 14.32 9.16 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.184 -0.462 . . . . 72.53 111.246 -176.531 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.633 ' H ' HG22 ' A' ' 33' ' ' ILE . . . -53.95 121.81 20.38 Favored Glycine 0 N--CA 1.453 -0.187 0 CA-C-N 115.846 -0.615 . . . . 72.01 112.156 -178.952 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 11.4 p-10 -77.73 129.45 35.52 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-O 121.278 0.561 . . . . 74.11 111.065 -176.844 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 98.43 -53.48 1.15 Allowed Glycine 0 N--CA 1.448 -0.533 0 C-N-CA 120.841 -0.695 . . . . 53.01 112.379 179.57 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 39.7 p90 -146.61 150.54 35.68 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-O 120.69 0.281 . . . . 65.34 110.6 -177.917 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 73.5 mmtt -86.94 86.54 7.33 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.911 0.386 . . . . 73.22 110.615 -179.799 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 47.3 m -153.42 147.05 25.09 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 116.384 -0.371 . . . . 72.33 110.608 177.812 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 41' ' ' LEU . . . . . 0.403 ' HB3' HG21 ' A' ' 6' ' ' VAL . 94.7 mt -124.2 121.24 34.56 Favored 'General case' 0 C--N 1.325 -0.468 0 N-CA-C 108.908 -0.775 . . . . 64.11 108.908 175.825 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 12.1 m-20 -64.19 127.39 31.23 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-O 121.351 0.596 . . . . 62.15 111.495 -175.924 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 6.2 pt-20 -63.04 119.57 9.74 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 115.226 -0.897 . . . . 60.13 111.12 179.98 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 100.66 -5.49 56.87 Favored Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.705 -0.76 . . . . 54.14 112.667 179.167 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 59.2 tp60 -80.98 133.9 35.59 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 120.615 0.245 . . . . 74.52 110.489 -178.778 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -77.15 130.81 37.82 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.352 -0.386 . . . . 71.24 110.022 175.221 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 0.437 HG12 ' HA ' ' A' ' 65' ' ' LYS . 17.5 m -135.19 153.56 34.28 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.492 0 CA-C-O 121.025 0.441 . . . . 75.3 111.289 -176.05 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 48' ' ' THR . . . . . 0.681 HG22 ' HG2' ' A' ' 3' ' ' GLN . 46.3 p -114.18 107.75 16.04 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-N 115.582 -0.735 . . . . 62.03 109.223 175.719 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 49' ' ' PHE . . . . . 0.561 ' HA ' ' O ' ' A' ' 62' ' ' ASN . 37.0 p90 -119.53 167.38 12.03 Favored 'General case' 0 C--N 1.315 -0.899 0 CA-C-N 115.847 -0.615 . . . . 74.1 110.412 -173.515 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 38.7 t70 -107.04 129.21 54.84 Favored 'General case' 0 C--N 1.316 -0.85 0 C-N-CA 120.777 -0.369 . . . . 75.23 110.305 176.016 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 51' ' ' VAL . . . . . 0.461 ' HB ' ' HG2' ' A' ' 2' ' ' GLU . 7.3 p -77.26 120.8 28.4 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 CA-C-O 121.533 0.682 . . . . 63.55 111.388 -176.976 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -110.37 157.89 19.04 Favored 'General case' 0 C--N 1.323 -0.581 0 N-CA-C 108.721 -0.844 . . . . 70.03 108.721 179.541 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 1.3 mm-40 -95.78 110.32 22.49 Favored 'General case' 0 C--N 1.319 -0.725 0 CA-C-O 121.03 0.443 . . . . 61.14 110.835 -178.319 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -99.56 157.16 19.85 Favored Glycine 0 N--CA 1.443 -0.892 0 N-CA-C 111.139 -0.785 . . . . 63.54 111.139 177.033 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 78.5 mt-30 -77.7 7.07 6.19 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 117.014 0.407 . . . . 75.53 111.69 -178.276 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 99.1 mtt180 -127.79 10.28 6.52 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 120.922 0.392 . . . . 75.21 110.023 175.313 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 129.29 176.89 14.61 Favored Glycine 0 N--CA 1.446 -0.634 0 C-N-CA 120.854 -0.688 . . . . 62.24 111.713 -177.412 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 18.3 Cg_endo -60.1 124.45 15.27 Favored 'Trans proline' 0 C--O 1.235 0.349 0 C-N-CA 122.827 2.351 . . . . 74.21 112.067 179.471 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 6.8 tt0 -104.45 144.35 31.78 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 115.682 -0.69 . . . . 72.51 110.101 -177.003 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 60' ' ' ALA . . . . . 0.504 ' HB3' ' HB ' ' A' ' 28' ' ' VAL . . . -91.43 106.81 18.76 Favored 'General case' 0 C--N 1.32 -0.696 0 CA-C-O 120.89 0.376 . . . . 63.13 110.81 178.585 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 61' ' ' ALA . . . . . 0.48 ' HA ' ' HB1' ' A' ' 32' ' ' ALA . . . -117.18 164.38 14.86 Favored 'General case' 0 C--N 1.32 -0.687 0 N-CA-C 108.769 -0.826 . . . . 74.24 108.769 176.31 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 62' ' ' ASN . . . . . 0.561 ' O ' ' HA ' ' A' ' 49' ' ' PHE . 85.0 m-20 47.89 66.41 1.05 Allowed 'General case' 0 N--CA 1.465 0.289 0 CA-C-O 120.83 0.347 . . . . 75.45 110.304 -177.766 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 29.4 t -93.93 89.3 2.56 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 CA-C-N 116.09 -0.505 . . . . 73.15 110.636 -176.66 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 19.9 mt-30 -82.35 129.66 34.92 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 115.866 -0.606 . . . . 64.42 110.479 -179.47 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 65' ' ' LYS . . . . . 0.437 ' HA ' HG12 ' A' ' 47' ' ' VAL . 50.7 mtmt -81.83 137.84 35.2 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 116.532 -0.303 . . . . 74.0 110.262 178.989 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.251 1.133 0 CA-C-O 118.289 -0.862 . . . . 54.04 110.157 178.325 . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 60.8 mtt . . . . . 0 N--CA 1.481 1.112 0 CA-C-O 120.765 0.317 . . . . 73.45 110.358 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 40.6 mt-10 -133.34 150.76 51.84 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 116.187 -0.461 . . . . 74.4 110.266 -179.366 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 35.1 tt0 -91.57 123.77 35.23 Favored 'General case' 0 C--N 1.322 -0.595 0 N-CA-C 109.48 -0.563 . . . . 72.03 109.48 177.759 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 4' ' ' GLY . . . . . 0.545 ' HA3' ' HE2' ' A' ' 49' ' ' PHE . . . -138.88 152.65 22.29 Favored Glycine 0 N--CA 1.444 -0.788 0 C-N-CA 120.818 -0.706 . . . . 74.54 111.829 -178.903 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 5' ' ' THR . . . . . 0.425 ' HA ' ' HA ' ' A' ' 46' ' ' ALA . 9.6 m -85.57 131.05 34.43 Favored 'General case' 0 C--N 1.318 -0.761 0 CA-C-O 120.635 0.255 . . . . 65.41 110.908 -177.855 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 60.6 t -65.78 115.86 4.37 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 N-CA-C 109.507 -0.553 . . . . 64.21 109.507 174.761 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 9.3 mmmm -86.12 -62.08 1.6 Allowed 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 115.943 -0.571 . . . . 64.5 109.976 -178.493 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 8' ' ' TRP . . . . . . . . . . . . . 94.4 m95 -141.78 135.08 29.34 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 116.012 -0.54 . . . . 73.35 110.08 -179.638 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 62.7 t80 -118.93 98.4 6.17 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-O 121.217 0.532 . . . . 63.12 109.707 178.12 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 43.4 t30 -82.12 81.84 7.9 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-O 121.556 0.693 . . . . 72.41 110.262 -177.635 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -70.89 -10.4 59.56 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.103 -0.953 . . . . 72.44 111.143 179.732 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 31.2 mm-40 -69.77 -16.39 63.29 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.086 -0.507 . . . . 63.44 110.266 177.447 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 13' ' ' LYS . . . . . 0.585 ' HE3' ' HA ' ' A' ' 13' ' ' LYS . 0.0 OUTLIER -130.01 -35.17 1.63 Allowed 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.132 -0.486 . . . . 64.41 111.263 179.564 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 111.25 28.51 3.79 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.648 -0.787 . . . . 75.52 112.907 178.206 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 31.3 p90 -148.03 176.23 10.35 Favored 'General case' 0 C--N 1.323 -0.561 0 O-C-N 122.493 -0.416 . . . . 74.4 109.965 177.641 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -174.79 -168.43 35.46 Favored Glycine 0 N--CA 1.445 -0.733 0 C-N-CA 120.292 -0.956 . . . . 73.22 112.27 -179.974 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 17' ' ' PHE . . . . . 0.5 ' HB3' ' HB3' ' A' ' 25' ' ' ASP . 88.0 m-85 -127.47 124.42 38.32 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-O 120.949 0.404 . . . . 64.42 110.504 -178.166 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 40.2 mt -121.72 117.81 53.71 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.663 0 N-CA-C 108.38 -0.97 . . . . 73.45 108.38 175.063 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 19' ' ' GLU . . . . . 0.642 ' HA ' ' HA ' ' A' ' 25' ' ' ASP . 6.7 pt-20 -78.11 137.67 38.33 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-O 121.64 0.733 . . . . 60.21 112.449 -168.543 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 20' ' ' ARG . . . . . 0.593 ' HB3' ' HB3' ' A' ' 24' ' ' ASP . 62.7 ttt180 -80.3 164.02 23.5 Favored 'General case' 0 C--N 1.32 -0.688 0 N-CA-C 107.691 -1.226 . . . . 73.11 107.691 168.129 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 43.4 mt-10 -63.53 -12.51 32.92 Favored 'General case' 0 N--CA 1.468 0.466 0 N-CA-C 112.53 0.567 . . . . 72.23 112.53 -173.718 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 10.4 m120 -87.29 3.64 45.95 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-O 120.901 0.382 . . . . 72.04 110.774 178.637 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 85.46 2.39 87.35 Favored Glycine 0 N--CA 1.452 -0.271 0 N-CA-C 110.752 -0.939 . . . . 72.32 110.752 -173.164 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 24' ' ' ASP . . . . . 0.593 ' HB3' ' HB3' ' A' ' 20' ' ' ARG . 38.3 t70 -75.32 90.51 2.64 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 114.551 -0.825 . . . . 74.32 110.463 -176.909 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.642 ' HA ' ' HA ' ' A' ' 19' ' ' GLU . 42.8 m-20 -60.82 104.16 0.33 Allowed 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.107 -0.497 . . . . 75.35 110.248 176.28 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.461 HG13 ' HB2' ' A' ' 58' ' ' PRO . 22.1 t -81.01 132.52 31.39 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 CA-C-N 116.016 -0.538 . . . . 63.35 110.229 -177.851 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 27' ' ' PHE . . . . . . . . . . . . . 85.7 t80 -76.64 104.28 7.06 Favored 'General case' 0 C--O 1.238 0.452 0 CA-C-O 121.134 0.492 . . . . 72.05 110.881 -177.189 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.585 ' HA ' ' HB3' ' A' ' 60' ' ' ALA . 9.6 p -88.3 145.71 7.12 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.638 0 N-CA-C 109.392 -0.595 . . . . 53.3 109.392 177.464 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 29' ' ' HIS . . . . . 0.499 ' O ' HG13 ' A' ' 33' ' ' ILE . 13.4 p80 -142.05 143.73 33.25 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 116.563 -0.29 . . . . 73.42 110.997 -173.64 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 52.1 p90 -58.14 -23.37 54.89 Favored 'General case' 0 N--CA 1.469 0.488 0 N-CA-C 113.03 0.752 . . . . 74.1 113.03 -172.838 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 2.7 p -77.57 -0.05 24.86 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-O 121.0 0.429 . . . . 55.03 111.576 -179.355 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -126.26 -24.9 3.6 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.149 -0.478 . . . . 75.34 110.689 175.337 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.499 HG13 ' O ' ' A' ' 29' ' ' HIS . 64.1 mt -68.95 118.47 13.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.293 -0.412 . . . . 72.32 110.872 179.686 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 2.5 pp0? -83.03 102.76 11.98 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-O 121.58 0.705 . . . . 75.44 109.508 172.798 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -82.82 56.54 5.05 Favored Glycine 0 N--CA 1.449 -0.45 0 CA-C-N 115.612 -0.722 . . . . 72.13 112.216 -175.76 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 27.4 t70 -78.74 102.96 8.37 Favored 'General case' 0 C--N 1.319 -0.737 0 CA-C-O 120.835 0.35 . . . . 63.33 110.479 -179.376 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 110.69 -91.33 0.61 Allowed Glycine 0 N--CA 1.448 -0.53 0 C-N-CA 121.101 -0.571 . . . . 72.33 111.722 -178.656 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 84.6 m-85 -122.37 135.8 54.77 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-O 120.859 0.361 . . . . 75.24 110.179 177.932 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 13.8 mptt -86.65 53.55 2.86 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-N 116.146 -0.479 . . . . 70.43 110.03 -178.902 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 39.6 m -149.86 110.68 4.31 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 116.154 -0.475 . . . . 75.01 111.122 -177.79 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 9.9 mp -94.02 131.76 39.19 Favored 'General case' 0 C--N 1.324 -0.532 0 N-CA-C 108.891 -0.781 . . . . 60.21 108.891 174.39 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 21.3 m-20 -96.82 128.1 43.44 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-O 120.775 0.321 . . . . 70.5 110.388 -173.858 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 2.0 pp20? -61.92 143.19 56.82 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 116.063 -0.517 . . . . 70.54 110.737 -179.047 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 99.11 -22.72 39.51 Favored Glycine 0 N--CA 1.447 -0.568 0 C-N-CA 120.74 -0.743 . . . . 53.32 111.847 -175.525 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 45' ' ' GLN . . . . . 0.456 ' HA ' ' OE1' ' A' ' 45' ' ' GLN . 6.1 tp60 -87.95 140.36 29.58 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.713 0.292 . . . . 74.4 110.315 178.334 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 0.425 ' HA ' ' HA ' ' A' ' 5' ' ' THR . . . -102.93 125.44 49.69 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-N 116.476 -0.329 . . . . 35.33 110.818 -179.869 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 30.7 m -118.2 171.51 6.43 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.561 0 CA-C-N 116.315 -0.402 . . . . 73.3 110.467 178.64 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 21.6 p -107.39 112.79 25.76 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-O 121.218 0.532 . . . . 74.11 110.954 -179.899 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 49' ' ' PHE . . . . . 0.545 ' HE2' ' HA3' ' A' ' 4' ' ' GLY . 41.5 p90 -121.89 161.16 23.29 Favored 'General case' 0 C--N 1.317 -0.833 0 CA-C-N 115.619 -0.719 . . . . 74.34 109.851 -178.219 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 19.7 t70 -109.06 128.29 54.85 Favored 'General case' 0 C--N 1.316 -0.875 0 CA-C-O 120.99 0.424 . . . . 54.2 110.311 174.128 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 98.9 t -77.22 104.8 5.46 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 CA-C-O 121.108 0.48 . . . . 71.34 110.878 -177.873 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -87.15 145.89 26.24 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 115.409 -0.814 . . . . 71.23 109.19 179.523 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 70.9 mm-40 -84.25 98.2 9.84 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-N 116.153 -0.476 . . . . 75.53 111.368 -175.641 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -81.39 164.77 45.88 Favored Glycine 0 N--CA 1.446 -0.69 0 C-N-CA 120.837 -0.697 . . . . 64.24 111.546 176.65 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 26.8 pt20 -69.32 -23.63 63.82 Favored 'General case' 0 C--N 1.324 -0.508 0 N-CA-C 112.207 0.447 . . . . 74.21 112.207 -175.664 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 9.5 ptm180 -132.1 16.57 4.61 Favored 'General case' 0 C--N 1.328 -0.346 0 C-N-CA 120.326 -0.55 . . . . 73.41 112.033 -179.26 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 157.69 -178.18 34.13 Favored Glycine 0 N--CA 1.449 -0.444 0 C-N-CA 120.018 -1.087 . . . . 63.24 112.702 179.282 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 58' ' ' PRO . . . . . 0.461 ' HB2' HG13 ' A' ' 26' ' ' VAL . 73.4 Cg_endo -75.56 128.59 11.17 Favored 'Trans proline' 0 C--O 1.235 0.341 0 C-N-CA 122.834 2.356 . . . . 33.13 112.89 -177.738 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 90.5 mt-30 -112.61 135.32 53.47 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 115.965 -0.561 . . . . 70.52 109.92 176.665 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 60' ' ' ALA . . . . . 0.585 ' HB3' ' HA ' ' A' ' 28' ' ' VAL . . . -85.21 105.19 15.72 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-O 120.899 0.381 . . . . 75.44 111.037 -178.931 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -115.29 168.78 9.66 Favored 'General case' 0 C--N 1.319 -0.722 0 N-CA-C 108.615 -0.883 . . . . 71.43 108.615 174.931 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 62' ' ' ASN . . . . . 0.516 ' O ' ' HA ' ' A' ' 49' ' ' PHE . 87.1 m-20 51.03 75.5 0.19 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.981 0.42 . . . . 55.23 109.958 -175.714 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 22.0 t -98.83 93.25 3.06 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 CA-C-N 115.969 -0.559 . . . . 43.23 109.526 -177.285 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 40.4 mt-30 -98.12 148.78 23.2 Favored 'General case' 0 C--N 1.32 -0.705 0 CA-C-N 115.923 -0.581 . . . . 75.01 110.567 -175.96 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 94.9 mttt -76.86 129.12 35.78 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 115.871 -0.604 . . . . 73.2 110.439 -179.795 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.077 0 CA-C-O 118.366 -0.826 . . . . 75.41 109.457 175.856 . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 1' ' ' MET . . . . . 0.647 ' N ' ' HA ' ' A' ' 50' ' ' ASP . 26.0 ptm . . . . . 0 N--CA 1.482 1.16 0 CA-C-O 120.718 0.294 . . . . 71.04 111.268 . . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 4.4 mp0 -105.55 165.7 10.96 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 121.029 0.442 . . . . 73.51 111.151 -175.351 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 3' ' ' GLN . . . . . 0.564 ' HG2' HG22 ' A' ' 48' ' ' THR . 66.6 mt-30 -98.47 111.43 23.79 Favored 'General case' 0 C--N 1.326 -0.445 0 N-CA-C 109.037 -0.727 . . . . 73.11 109.037 173.422 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 4' ' ' GLY . . . . . 0.707 ' HA3' ' HE2' ' A' ' 49' ' ' PHE . . . -122.1 162.3 15.93 Favored Glycine 0 N--CA 1.447 -0.613 0 C-N-CA 120.101 -1.047 . . . . 71.11 112.984 -174.217 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 8.3 m -98.45 131.03 45.04 Favored 'General case' 0 C--N 1.321 -0.635 0 N-CA-C 110.033 -0.358 . . . . 64.12 110.033 177.948 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 59.7 t -70.17 118.48 14.71 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.436 0 CA-C-N 116.602 -0.272 . . . . 72.14 110.619 179.365 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 7' ' ' LYS . . . . . 1.032 ' HE2' ' HB3' ' A' ' 19' ' ' GLU . 70.7 mmtt -70.77 -72.58 0.2 Allowed 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 121.238 0.542 . . . . 73.22 109.803 176.62 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 8' ' ' TRP . . . . . 0.556 ' HA ' ' HG3' ' A' ' 43' ' ' GLU . 24.5 m-90 -143.85 127.23 16.81 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 114.939 -1.028 . . . . 74.44 109.005 178.558 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 54.3 t80 -105.82 103.08 12.51 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-O 121.243 0.544 . . . . 71.11 110.359 179.547 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 39.2 m-80 -83.9 78.46 9.72 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 115.785 -0.643 . . . . 75.45 110.104 -179.666 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -59.61 -30.86 68.99 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.025 -0.534 . . . . 75.41 110.59 178.029 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 24.7 mt-10 -64.61 -38.91 92.64 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.401 -0.818 . . . . 73.22 110.616 178.158 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 48.7 mmtm -90.6 -24.44 20.55 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.683 -0.69 . . . . 65.05 110.691 -174.201 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 96.15 18.62 30.87 Favored Glycine 0 N--CA 1.445 -0.738 0 C-N-CA 120.806 -0.711 . . . . 54.4 112.845 177.608 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 46.7 p90 -156.83 163.72 38.88 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 117.074 0.437 . . . . 74.32 110.803 179.855 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -148.95 177.12 27.4 Favored Glycine 0 N--CA 1.445 -0.703 0 C-N-CA 120.813 -0.708 . . . . 73.34 111.983 179.289 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 96.8 m-85 -123.98 131.15 53.52 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 120.76 0.314 . . . . 75.54 110.307 177.949 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.446 HD13 HG21 ' A' ' 47' ' ' VAL . 33.0 mt -122.88 146.61 27.9 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.695 0 N-CA-C 109.115 -0.698 . . . . 72.22 109.115 178.149 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 19' ' ' GLU . . . . . 1.032 ' HB3' ' HE2' ' A' ' 7' ' ' LYS . 12.9 pt-20 -99.79 129.23 45.88 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-O 121.351 0.596 . . . . 71.02 111.785 -178.52 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 20' ' ' ARG . . . . . 0.436 ' HG2' ' N ' ' A' ' 21' ' ' GLU . 27.9 ttm180 -98.3 153.81 18.26 Favored 'General case' 0 C--N 1.322 -0.609 0 N-CA-C 108.381 -0.97 . . . . 50.23 108.381 170.727 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 21' ' ' GLU . . . . . 0.436 ' N ' ' HG2' ' A' ' 20' ' ' ARG . 43.9 mt-10 -52.02 -34.44 42.96 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 121.047 0.451 . . . . 61.43 110.491 177.61 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 8.5 t-20 -123.9 58.58 1.16 Allowed 'General case' 0 N--CA 1.453 -0.311 0 CA-C-N 115.85 -0.613 . . . . 75.23 109.41 175.358 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 164.65 78.88 0.04 OUTLIER Glycine 0 N--CA 1.45 -0.369 0 N-CA-C 111.217 -0.753 . . . . 40.13 111.217 179.543 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 30.6 t70 -65.71 -2.84 3.97 Favored 'General case' 0 C--N 1.326 -0.445 0 N-CA-C 112.606 0.595 . . . . 64.14 112.606 -169.51 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 10.2 p-10 -144.73 93.67 2.44 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-O 121.813 0.816 . . . . 71.01 111.854 -178.575 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 38.9 t -104.12 128.74 57.26 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.492 0 CA-C-N 115.525 -0.761 . . . . 73.23 109.628 174.579 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 27' ' ' PHE . . . . . . . . . . . . . 42.7 t80 -83.61 106.52 15.4 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-O 120.716 0.293 . . . . 65.44 110.326 -177.28 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.586 HG23 HG21 ' A' ' 63' ' ' VAL . 12.5 p -99.38 143.9 12.81 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 CA-C-O 121.149 0.5 . . . . 71.11 111.354 -176.248 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 54.2 m80 -97.27 133.78 41.43 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.543 -0.753 . . . . 75.0 109.996 177.871 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 6.1 p90 -63.95 -26.46 68.6 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.803 0.335 . . . . 75.32 111.105 -176.837 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 28.2 t -89.57 -14.35 35.26 Favored 'General case' 0 CA--C 1.533 0.291 0 CA-C-N 116.355 -0.384 . . . . 73.13 110.436 179.689 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -83.22 -23.09 32.94 Favored 'General case' 0 C--O 1.233 0.224 0 CA-C-O 121.383 0.611 . . . . 63.12 109.9 178.117 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.541 ' HA ' ' HB ' ' A' ' 63' ' ' VAL . 53.1 mt -76.31 138.37 20.83 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.497 0 CA-C-N 115.542 -0.754 . . . . 72.35 109.51 172.113 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 34' ' ' GLN . . . . . 0.408 ' OE1' ' HG3' ' A' ' 65' ' ' LYS . 0.3 OUTLIER -75.93 59.84 1.31 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 121.397 0.618 . . . . 73.42 111.554 176.946 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -69.05 141.14 35.43 Favored Glycine 0 N--CA 1.446 -0.646 0 CA-C-N 115.841 -0.618 . . . . 41.3 112.376 -179.373 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -77.98 84.11 4.27 Favored 'General case' 0 C--N 1.324 -0.532 0 N-CA-C 109.95 -0.389 . . . . 71.05 109.95 177.332 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 75.16 -68.77 1.99 Allowed Glycine 0 N--CA 1.451 -0.346 0 N-CA-C 111.491 -0.644 . . . . 72.13 111.491 -176.125 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 44.1 t80 -152.26 93.81 1.85 Allowed 'General case' 0 C--N 1.321 -0.664 0 N-CA-C 108.505 -0.924 . . . . 74.44 108.505 174.965 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 41.1 tptt -114.15 115.87 28.19 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 116.241 -0.436 . . . . 72.12 110.569 -173.239 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 13.0 m -85.27 115.35 22.99 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-N 116.044 -0.525 . . . . 71.13 110.368 179.138 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 41' ' ' LEU . . . . . 0.529 HD21 HG21 ' A' ' 33' ' ' ILE . 3.7 mm? -74.96 107.69 7.2 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 116.298 -0.41 . . . . 73.2 110.215 178.606 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 32.5 t70 -58.98 135.08 57.5 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.76 -0.655 . . . . 73.15 111.267 -177.549 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 43' ' ' GLU . . . . . 0.556 ' HG3' ' HA ' ' A' ' 8' ' ' TRP . 17.9 mp0 -53.93 124.72 16.27 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 115.957 -0.565 . . . . 74.4 110.619 177.809 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 99.35 -0.68 57.11 Favored Glycine 0 N--CA 1.449 -0.481 0 C-N-CA 120.627 -0.796 . . . . 42.43 112.804 -179.908 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 58.7 tp60 -83.43 149.97 26.34 Favored 'General case' 0 C--N 1.325 -0.495 0 N-CA-C 109.918 -0.401 . . . . 70.35 109.918 178.423 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -90.8 140.49 29.74 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-N 116.554 -0.294 . . . . 75.31 110.246 177.21 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 0.446 HG21 HD13 ' A' ' 18' ' ' ILE . 16.0 m -139.0 153.59 25.01 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 CA-C-O 120.913 0.387 . . . . 72.24 110.396 177.579 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 48' ' ' THR . . . . . 0.659 HG23 ' HB2' ' A' ' 66' ' ' ALA . 34.4 p -106.47 101.88 11.31 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-O 121.323 0.582 . . . . 75.12 110.121 178.275 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 49' ' ' PHE . . . . . 0.707 ' HE2' ' HA3' ' A' ' 4' ' ' GLY . 42.1 p90 -111.55 147.47 35.33 Favored 'General case' 0 C--N 1.317 -0.821 0 CA-C-N 115.609 -0.723 . . . . 74.13 110.666 -174.455 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 50' ' ' ASP . . . . . 0.647 ' HA ' ' N ' ' A' ' 1' ' ' MET . 36.2 t0 -101.92 160.96 14.04 Favored 'General case' 0 C--N 1.316 -0.855 0 C-N-CA 120.357 -0.537 . . . . 73.5 109.706 172.279 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 67.4 t -109.66 119.37 58.77 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.701 0 CA-C-O 120.922 0.392 . . . . 62.54 111.459 -172.822 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 27.6 tt0 -111.11 111.31 22.3 Favored 'General case' 0 C--N 1.321 -0.642 0 N-CA-C 109.094 -0.706 . . . . 73.21 109.094 173.338 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 26.9 mt-10 -69.59 137.08 52.02 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-O 121.203 0.525 . . . . 72.13 112.091 -177.709 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -118.9 -158.04 10.6 Favored Glycine 0 N--CA 1.441 -1.026 0 N-CA-C 110.001 -1.239 . . . . 74.42 110.001 170.844 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 50.0 tt0 -99.43 -25.6 14.41 Favored 'General case' 0 C--N 1.319 -0.752 0 CA-C-N 117.162 0.481 . . . . 72.24 110.498 179.728 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 10.9 mmm180 -97.64 -5.23 35.86 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 116.292 -0.413 . . . . 65.13 111.191 178.561 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 151.39 -179.61 27.89 Favored Glycine 0 N--CA 1.444 -0.795 0 C-N-CA 120.62 -0.8 . . . . 63.34 112.311 178.527 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 8.9 Cg_endo -87.41 119.02 1.37 Allowed 'Trans proline' 0 N--CA 1.45 -1.057 0 C-N-CA 123.235 2.623 . . . . 74.1 112.18 178.931 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 15.8 pt20 -95.39 133.91 38.8 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-N 116.098 -0.501 . . . . 75.2 109.852 177.654 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 60' ' ' ALA . . . . . 0.572 ' HB3' ' HA ' ' A' ' 28' ' ' VAL . . . -76.27 112.13 12.43 Favored 'General case' 0 C--N 1.321 -0.645 0 CA-C-N 116.128 -0.487 . . . . 40.34 110.76 -178.885 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -112.91 153.3 28.18 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 115.493 -0.776 . . . . 54.12 109.011 176.583 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 95.1 m-20 52.48 77.3 0.16 Allowed 'General case' 0 C--O 1.235 0.341 0 CA-C-O 121.279 0.561 . . . . 64.33 110.337 -175.426 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.586 HG21 HG23 ' A' ' 28' ' ' VAL . 36.9 t -109.59 107.16 22.19 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 CA-C-N 115.686 -0.688 . . . . 72.1 110.174 -179.67 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 64' ' ' GLN . . . . . 0.516 ' HB2' ' OG1' ' A' ' 48' ' ' THR . 15.3 mt-30 -99.41 178.54 4.85 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 115.434 -0.803 . . . . 75.11 110.163 -177.154 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 65' ' ' LYS . . . . . 0.408 ' HG3' ' OE1' ' A' ' 34' ' ' GLN . 56.0 mttp -89.05 149.47 23.21 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-O 120.733 0.301 . . . . 52.3 110.588 -178.494 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 66' ' ' ALA . . . . . 0.659 ' HB2' HG23 ' A' ' 48' ' ' THR . . . . . . . . 0 C--O 1.251 1.165 0 CA-C-O 117.974 -1.012 . . . . 73.13 109.615 177.304 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 1.9 mpt? . . . . . 0 N--CA 1.482 1.174 0 CA-C-O 120.826 0.346 . . . . 75.22 110.156 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 2' ' ' GLU . . . . . 0.508 ' H ' ' CD ' ' A' ' 2' ' ' GLU . 1.4 mp0 -61.94 143.35 56.6 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 115.68 -0.691 . . . . 73.43 111.235 -176.113 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 3' ' ' GLN . . . . . 0.504 ' HB3' HG22 ' A' ' 48' ' ' THR . 0.9 OUTLIER -93.54 127.34 39.16 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 115.725 -0.671 . . . . 53.51 109.83 173.485 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -136.74 160.3 24.8 Favored Glycine 0 N--CA 1.445 -0.709 0 C-N-CA 120.887 -0.673 . . . . 55.32 111.566 -179.853 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -96.48 133.35 41.04 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-O 121.266 0.555 . . . . 72.24 111.421 -179.336 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 45.6 t -68.81 116.06 8.54 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.556 0 CA-C-N 115.824 -0.625 . . . . 71.11 110.034 177.759 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 7' ' ' LYS . . . . . 0.832 ' HE3' ' HA ' ' A' ' 7' ' ' LYS . 0.1 OUTLIER -83.04 -62.59 1.55 Allowed 'General case' 0 C--N 1.324 -0.507 0 CA-C-O 121.24 0.543 . . . . 73.03 109.705 -178.827 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 8' ' ' TRP . . . . . . . . . . . . . 99.5 m95 -126.72 146.94 50.03 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 115.365 -0.834 . . . . 70.14 109.727 -179.963 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 9' ' ' PHE . . . . . 0.52 ' CE2' ' HA ' ' A' ' 40' ' ' SER . 68.1 t80 -140.21 98.05 3.36 Favored 'General case' 0 C--N 1.318 -0.773 0 CA-C-O 121.093 0.473 . . . . 75.2 110.432 176.356 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 91.4 m-20 -82.2 82.57 7.69 Favored 'General case' 0 C--N 1.323 -0.57 0 N-CA-C 109.285 -0.635 . . . . 74.52 109.285 178.813 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -59.08 -33.74 71.16 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.574 -0.739 . . . . 71.14 111.297 -178.476 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 36.7 mt-10 -70.1 -26.22 63.87 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 116.066 -0.515 . . . . 72.2 110.892 -178.733 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 47.9 mmtm -91.44 -29.72 16.88 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.188 -0.46 . . . . 54.31 110.179 175.999 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 90.99 17.4 51.5 Favored Glycine 0 N--CA 1.447 -0.623 0 CA-C-N 115.853 -0.612 . . . . 64.44 111.655 -178.895 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 74.3 m-85 -138.15 144.46 40.77 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-O 120.864 0.364 . . . . 73.45 110.489 -176.568 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -131.16 168.64 21.98 Favored Glycine 0 N--CA 1.444 -0.787 0 C-N-CA 120.438 -0.887 . . . . 73.01 112.109 -178.621 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 17' ' ' PHE . . . . . 0.453 ' HA ' ' O ' ' A' ' 26' ' ' VAL . 76.6 m-85 -127.47 118.9 24.92 Favored 'General case' 0 C--N 1.322 -0.603 0 N-CA-C 109.757 -0.46 . . . . 74.04 109.757 -179.972 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.431 HG21 ' CE2' ' A' ' 49' ' ' PHE . 63.5 mt -109.05 141.82 23.28 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.659 0 CA-C-N 115.992 -0.549 . . . . 71.53 110.402 -177.526 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 19' ' ' GLU . . . . . 0.63 ' OE1' ' HG2' ' A' ' 7' ' ' LYS . 7.9 pt-20 -92.87 101.42 13.79 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 121.377 0.608 . . . . 72.34 110.476 178.372 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 20' ' ' ARG . . . . . 0.613 ' HG2' ' OE1' ' A' ' 21' ' ' GLU . 12.4 ttp180 -96.41 158.48 15.42 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 115.854 -0.612 . . . . 74.21 109.544 -179.503 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 21' ' ' GLU . . . . . 0.613 ' OE1' ' HG2' ' A' ' 20' ' ' ARG . 0.0 OUTLIER -57.29 -38.02 73.33 Favored 'General case' 0 N--CA 1.466 0.326 0 N-CA-C 112.155 0.428 . . . . 53.3 112.155 -177.931 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 41.3 m-80 -115.3 36.6 3.85 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-O 120.991 0.424 . . . . 72.34 110.181 174.949 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -170.38 82.19 0.09 OUTLIER Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.624 -0.798 . . . . 75.15 112.444 179.846 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 37.4 t70 -63.71 -2.98 1.97 Allowed 'General case' 0 N--CA 1.469 0.48 0 CA-C-O 121.09 0.471 . . . . 72.44 111.916 -177.039 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 17.5 t70 -152.97 88.55 1.33 Allowed 'General case' 0 C--N 1.325 -0.485 0 CA-C-O 121.105 0.479 . . . . 64.21 109.829 -179.328 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.453 ' O ' ' HA ' ' A' ' 17' ' ' PHE . 58.8 t -102.97 123.72 56.55 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 CA-C-N 116.005 -0.543 . . . . 74.4 110.43 179.374 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 27' ' ' PHE . . . . . 0.467 ' O ' ' HA ' ' A' ' 59' ' ' GLN . 62.7 t80 -85.45 102.46 13.48 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 115.612 -0.722 . . . . 72.22 110.277 -177.025 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.473 HG23 ' HB3' ' A' ' 60' ' ' ALA . 10.2 p -95.77 146.74 6.66 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.505 0 CA-C-O 120.94 0.4 . . . . 73.21 110.796 -177.453 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 17.3 m-70 -103.83 141.01 36.86 Favored 'General case' 0 C--O 1.234 0.24 0 CA-C-N 115.982 -0.554 . . . . 74.5 111.341 -175.841 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 41.2 p90 -55.91 -36.38 67.63 Favored 'General case' 0 N--CA 1.467 0.412 0 CA-C-N 115.838 -0.619 . . . . 73.12 112.177 -179.941 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 33.0 t -82.07 -10.52 59.18 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 116.707 -0.224 . . . . 63.14 111.17 -177.075 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 32' ' ' ALA . . . . . 0.54 ' HB1' ' HA ' ' A' ' 61' ' ' ALA . . . -92.81 -22.84 19.09 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 121.248 0.547 . . . . 70.34 109.99 178.829 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.546 ' HA ' ' HB ' ' A' ' 63' ' ' VAL . 67.3 mt -87.68 126.63 41.26 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.468 0 CA-C-N 115.503 -0.771 . . . . 74.23 110.318 177.012 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 34' ' ' GLN . . . . . 0.426 ' H ' ' HG3' ' A' ' 34' ' ' GLN . 2.3 pp0? -86.64 109.46 19.18 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-O 121.502 0.668 . . . . 74.51 109.457 172.639 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -81.89 62.2 4.56 Favored Glycine 0 N--CA 1.449 -0.459 0 CA-C-N 115.751 -0.659 . . . . 45.21 112.709 -175.485 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 31.0 t70 -74.98 109.69 8.65 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-O 120.772 0.32 . . . . 75.12 110.493 179.254 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 80.77 -53.95 4.61 Favored Glycine 0 N--CA 1.45 -0.407 0 CA-C-N 115.957 -0.565 . . . . 24.3 112.059 -178.957 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 84.1 m-85 -117.59 120.41 37.97 Favored 'General case' 0 C--N 1.324 -0.529 0 N-CA-C 109.901 -0.407 . . . . 74.43 109.901 179.111 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 4.4 mptp? -82.38 -30.93 29.97 Favored 'General case' 0 C--N 1.324 -0.528 0 N-CA-C 109.325 -0.62 . . . . 70.4 109.325 176.842 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 40' ' ' SER . . . . . 0.52 ' HA ' ' CE2' ' A' ' 9' ' ' PHE . 23.5 p -93.46 116.23 28.76 Favored 'General case' 0 N--CA 1.448 -0.551 0 CA-C-N 115.467 -0.788 . . . . 65.32 109.981 173.803 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 52.0 mt -70.64 137.29 49.78 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-O 120.996 0.427 . . . . 70.5 110.648 179.196 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 42' ' ' ASP . . . . . 0.442 ' HB3' ' HB2' ' A' ' 45' ' ' GLN . 22.7 t70 -74.64 136.93 41.94 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 115.573 -0.74 . . . . 63.45 110.638 -176.322 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 8.4 pt-20 -65.81 115.25 5.74 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-O 121.25 0.548 . . . . 75.01 110.71 178.361 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 100.86 -1.54 55.35 Favored Glycine 0 N--CA 1.446 -0.635 0 C-N-CA 120.47 -0.871 . . . . 72.03 112.109 -178.218 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 45' ' ' GLN . . . . . 0.442 ' HB2' ' HB3' ' A' ' 42' ' ' ASP . 6.0 tp-100 -74.26 133.85 42.64 Favored 'General case' 0 C--N 1.327 -0.398 0 N-CA-C 109.974 -0.38 . . . . 73.23 109.974 175.802 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -90.23 123.66 34.21 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 116.186 -0.461 . . . . 33.2 110.454 179.784 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 0.495 HG23 ' HD2' ' A' ' 49' ' ' PHE . 21.1 m -127.62 153.56 37.02 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.596 0 CA-C-N 116.008 -0.542 . . . . 73.22 110.339 178.748 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 48' ' ' THR . . . . . 0.504 HG22 ' HB3' ' A' ' 3' ' ' GLN . 63.7 p -106.96 111.23 23.63 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-O 121.261 0.553 . . . . 62.04 109.733 179.609 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 49' ' ' PHE . . . . . 0.495 ' HD2' HG23 ' A' ' 47' ' ' VAL . 29.5 p90 -128.61 160.53 32.14 Favored 'General case' 0 C--N 1.318 -0.771 0 CA-C-N 116.138 -0.483 . . . . 73.54 111.171 -172.543 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 71.0 m-20 -105.02 115.09 29.69 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 116.157 -0.474 . . . . 70.14 110.435 175.536 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 51' ' ' VAL . . . . . 0.478 HG21 ' HD3' ' A' ' 20' ' ' ARG . 65.3 t -77.43 120.71 28.48 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.599 0 CA-C-O 121.052 0.454 . . . . 73.23 110.936 -177.459 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 9.2 tp10 -99.44 125.69 45.21 Favored 'General case' 0 N--CA 1.444 -0.769 0 N-CA-C 108.984 -0.747 . . . . 70.5 108.984 175.43 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 10.0 pt-20 -88.11 141.11 28.83 Favored 'General case' 0 C--N 1.317 -0.806 0 CA-C-N 116.16 -0.473 . . . . 72.23 110.806 -175.797 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -162.64 -171.46 28.87 Favored Glycine 0 N--CA 1.446 -0.669 0 C-N-CA 120.851 -0.69 . . . . 53.41 112.081 178.706 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 34.9 tt0 -58.35 -38.57 77.48 Favored 'General case' 0 C--N 1.326 -0.444 0 C-N-CA 122.488 0.315 . . . . 72.42 111.218 179.557 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 18.0 mmm180 -75.98 4.36 8.46 Favored 'General case' 0 C--N 1.328 -0.337 0 N-CA-C 111.708 0.262 . . . . 74.34 111.708 179.999 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 93.51 -136.82 13.28 Favored Glycine 0 N--CA 1.444 -0.818 0 C-N-CA 120.942 -0.647 . . . . 75.44 112.034 178.928 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 1.8 Cg_endo -83.05 108.94 1.63 Allowed 'Trans proline' 0 N--CA 1.454 -0.832 0 C-N-CA 123.132 2.554 . . . . 54.43 112.015 -179.69 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 59' ' ' GLN . . . . . 0.467 ' HA ' ' O ' ' A' ' 27' ' ' PHE . 47.6 mt-30 -110.17 117.27 33.25 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-O 120.906 0.384 . . . . 71.42 110.081 177.827 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 60' ' ' ALA . . . . . 0.473 ' HB3' HG23 ' A' ' 28' ' ' VAL . . . -77.72 119.05 20.7 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-O 121.078 0.466 . . . . 74.03 111.308 -175.852 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 61' ' ' ALA . . . . . 0.54 ' HA ' ' HB1' ' A' ' 32' ' ' ALA . . . -120.77 167.91 12.0 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 115.425 -0.807 . . . . 73.14 109.001 175.362 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 62' ' ' ASN . . . . . 0.49 ' O ' ' HA ' ' A' ' 49' ' ' PHE . 37.4 m-20 47.28 74.46 0.16 Allowed 'General case' 0 C--O 1.236 0.393 0 O-C-N 123.265 0.353 . . . . 73.55 110.314 -176.885 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.546 ' HB ' ' HA ' ' A' ' 33' ' ' ILE . 57.9 t -96.63 104.13 15.49 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.511 0 CA-C-N 116.337 -0.392 . . . . 65.15 110.817 -177.19 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 6.6 tp-100 -104.65 165.31 11.15 Favored 'General case' 0 C--N 1.321 -0.649 0 N-CA-C 109.127 -0.694 . . . . 75.54 109.127 178.093 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 86.0 mttt -80.78 176.57 9.69 Favored 'General case' 0 C--N 1.321 -0.635 0 N-CA-C 110.09 -0.337 . . . . 75.22 110.09 178.103 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 66' ' ' ALA . . . . . 0.459 ' HB2' HG23 ' A' ' 48' ' ' THR . . . . . . . . 0 C--O 1.249 1.052 0 CA-C-O 118.612 -0.709 . . . . 40.42 109.876 175.603 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 56.8 ttp . . . . . 0 N--CA 1.482 1.15 0 N-CA-C 110.289 -0.263 . . . . 70.34 110.289 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 34.3 mm-40 -100.35 145.17 28.48 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-O 120.811 0.339 . . . . 64.2 110.307 -179.32 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 3' ' ' GLN . . . . . 0.957 ' HG2' HG22 ' A' ' 48' ' ' THR . 88.3 mt-30 -124.72 111.78 15.97 Favored 'General case' 0 C--N 1.321 -0.648 0 N-CA-C 109.418 -0.586 . . . . 72.23 109.418 176.308 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -137.87 163.47 25.57 Favored Glycine 0 N--CA 1.446 -0.653 0 C-N-CA 120.363 -0.922 . . . . 44.41 112.143 -176.029 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 5' ' ' THR . . . . . 0.553 ' HA ' ' HA ' ' A' ' 46' ' ' ALA . 22.0 m -106.67 130.44 54.4 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-O 120.516 0.198 . . . . 73.23 110.734 -178.431 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.531 HG22 HG12 ' A' ' 18' ' ' ILE . 42.7 t -70.65 120.67 18.95 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 N-CA-C 109.964 -0.384 . . . . 70.13 109.964 178.009 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 7' ' ' LYS . . . . . 0.714 ' HD2' ' HB3' ' A' ' 19' ' ' GLU . 27.2 mtpp -98.81 -34.05 10.65 Favored 'General case' 0 C--N 1.327 -0.393 0 C-N-CA 120.91 -0.316 . . . . 74.12 110.682 -179.305 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 8' ' ' TRP . . . . . . . . . . . . . 10.5 m-90 -140.0 110.82 6.83 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.067 -0.515 . . . . 72.44 110.361 179.791 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 65.2 t80 -101.88 91.99 4.61 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-O 121.194 0.521 . . . . 71.45 109.848 177.546 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 90.3 m-20 -79.15 84.97 5.07 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-O 121.238 0.542 . . . . 74.12 109.976 -178.037 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -60.41 -40.67 91.84 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.065 -0.97 . . . . 72.42 112.021 -175.761 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 42.7 mt-10 -81.81 0.45 39.25 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 121.134 0.492 . . . . 73.31 111.181 -176.786 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 70.5 mmtt -103.95 -28.07 11.78 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 115.782 -0.644 . . . . 63.13 109.38 170.695 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 82.08 19.26 65.38 Favored Glycine 0 N--CA 1.448 -0.554 0 N-CA-C 111.156 -0.778 . . . . 73.12 111.156 -175.854 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 48.8 m-85 -135.81 154.86 51.07 Favored 'General case' 0 C--N 1.325 -0.483 0 N-CA-C 110.2 -0.296 . . . . 73.15 110.2 -176.127 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -140.07 146.56 18.08 Favored Glycine 0 N--CA 1.447 -0.59 0 C-N-CA 120.524 -0.846 . . . . 73.14 112.14 -179.599 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 97.6 m-85 -104.47 111.88 24.71 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 121.051 0.453 . . . . 71.24 110.486 178.771 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.531 HG12 HG22 ' A' ' 6' ' ' VAL . 55.2 mt -104.48 135.36 42.67 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.589 0 CA-C-N 115.579 -0.737 . . . . 60.32 109.829 -179.493 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 19' ' ' GLU . . . . . 0.714 ' HB3' ' HD2' ' A' ' 7' ' ' LYS . 14.0 pt-20 -83.29 162.18 21.22 Favored 'General case' 0 C--N 1.327 -0.377 0 C-N-CA 120.265 -0.574 . . . . 72.41 110.686 -178.837 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 20' ' ' ARG . . . . . 0.425 ' HG2' ' H ' ' A' ' 21' ' ' GLU . 39.0 ttt180 -144.64 175.9 9.81 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 115.969 -0.56 . . . . 72.33 109.755 -173.255 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 21' ' ' GLU . . . . . 0.433 ' HG3' ' N ' ' A' ' 22' ' ' ASN . 7.8 pt-20 -45.71 -49.45 14.65 Favored 'General case' 0 N--CA 1.469 0.507 0 N-CA-C 113.046 0.758 . . . . 72.14 113.046 -177.488 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 22' ' ' ASN . . . . . 0.433 ' N ' ' HG3' ' A' ' 21' ' ' GLU . 14.9 t-20 -97.9 12.43 34.1 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-O 121.361 0.601 . . . . 61.2 110.761 -174.646 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 79.28 9.92 86.53 Favored Glycine 0 N--CA 1.452 -0.243 0 C-N-CA 120.528 -0.844 . . . . 72.13 111.124 -173.923 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 25.2 t70 -67.14 90.93 0.21 Allowed 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 114.8 -0.7 . . . . 53.41 110.062 179.871 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 4.8 p-10 -60.84 119.15 7.66 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 121.631 0.729 . . . . 74.23 111.451 -178.819 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.509 HG12 ' HB2' ' A' ' 60' ' ' ALA . 31.3 t -89.88 127.98 42.13 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.58 0 CA-C-N 115.049 -0.978 . . . . 53.12 110.179 -179.864 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 27' ' ' PHE . . . . . . . . . . . . . 43.4 t80 -92.67 100.18 12.73 Favored 'General case' 0 C--N 1.321 -0.674 0 CA-C-N 115.582 -0.735 . . . . 71.4 110.333 -175.854 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.546 ' HA ' ' HB3' ' A' ' 60' ' ' ALA . 11.8 p -89.06 142.52 12.76 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 CA-C-O 120.708 0.289 . . . . 73.34 110.345 178.812 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 29' ' ' HIS . . . . . 0.418 ' O ' HG13 ' A' ' 33' ' ' ILE . 7.9 p80 -118.87 142.12 48.03 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.389 -0.369 . . . . 72.52 110.832 -178.484 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 30' ' ' PHE . . . . . 0.519 ' HA ' HD12 ' A' ' 33' ' ' ILE . 43.9 p90 -52.43 -32.54 39.83 Favored 'General case' 0 N--CA 1.468 0.443 0 CA-C-N 115.501 -0.772 . . . . 64.02 112.934 -173.648 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 1.9 p -71.06 -9.19 57.61 Favored 'General case' 0 C--N 1.323 -0.585 0 N-CA-C 111.911 0.337 . . . . 74.3 111.911 -179.046 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 32' ' ' ALA . . . . . 0.417 ' HB1' ' HA ' ' A' ' 61' ' ' ALA . . . -122.07 -7.05 8.9 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-O 120.916 0.389 . . . . 61.54 110.941 177.905 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.519 HD12 ' HA ' ' A' ' 30' ' ' PHE . 68.3 mt -67.77 136.5 26.46 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.386 0 CA-C-N 116.21 -0.45 . . . . 73.4 110.115 175.78 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 24.0 pt20 -64.75 102.11 0.55 Allowed 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 121.434 0.635 . . . . 71.1 110.967 177.541 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -91.36 17.89 54.16 Favored Glycine 0 N--CA 1.45 -0.413 0 C-N-CA 120.847 -0.692 . . . . 71.34 111.967 179.143 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 22.4 t70 -90.5 105.81 18.07 Favored 'General case' 0 C--N 1.325 -0.491 0 N-CA-C 109.902 -0.407 . . . . 73.32 109.902 -179.711 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 93.66 -102.63 2.93 Favored Glycine 0 N--CA 1.446 -0.674 0 C-N-CA 120.757 -0.735 . . . . 71.24 112.001 -177.855 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 99.1 m-85 -90.57 117.46 29.26 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 120.814 0.34 . . . . 74.24 110.392 178.767 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 39' ' ' LYS . . . . . 0.427 ' H ' ' HD3' ' A' ' 39' ' ' LYS . 0.0 OUTLIER -83.09 -8.92 59.46 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-O 121.118 0.485 . . . . 64.03 110.357 179.494 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 3.7 p -103.37 92.66 4.59 Favored 'General case' 0 N--CA 1.447 -0.583 0 CA-C-N 115.974 -0.557 . . . . 62.52 111.844 -176.1 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 93.2 mt -85.62 81.47 8.64 Favored 'General case' 0 C--N 1.327 -0.394 0 N-CA-C 108.726 -0.842 . . . . 52.21 108.726 172.884 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 69.3 m-20 -73.97 172.21 12.04 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-O 122.038 0.923 . . . . 73.43 112.911 -169.677 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 43' ' ' GLU . . . . . 0.524 ' CD ' ' H ' ' A' ' 43' ' ' GLU . 22.2 mp0 -60.64 132.96 55.55 Favored 'General case' 0 N--CA 1.448 -0.554 0 CA-C-N 114.139 -1.391 . . . . 72.35 110.163 -178.44 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 98.99 -5.94 59.77 Favored Glycine 0 N--CA 1.446 -0.686 0 C-N-CA 120.711 -0.757 . . . . 53.1 112.713 178.102 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 3.4 tm0? -92.16 126.08 37.1 Favored 'General case' 0 C--N 1.328 -0.354 0 N-CA-C 109.566 -0.531 . . . . 75.23 109.566 176.751 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 0.553 ' HA ' ' HA ' ' A' ' 5' ' ' THR . . . -97.95 113.09 24.83 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-O 120.944 0.402 . . . . 75.13 110.675 178.795 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 23.2 m -106.26 160.95 5.74 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 CA-C-N 115.952 -0.567 . . . . 74.35 111.087 -178.44 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 48' ' ' THR . . . . . 0.957 HG22 ' HG2' ' A' ' 3' ' ' GLN . 53.8 p -106.79 126.13 51.89 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 115.748 -0.66 . . . . 73.45 109.411 175.743 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 49' ' ' PHE . . . . . 0.474 ' HA ' ' O ' ' A' ' 62' ' ' ASN . 33.4 p90 -142.0 167.49 22.01 Favored 'General case' 0 C--N 1.317 -0.813 0 CA-C-O 120.954 0.407 . . . . 62.21 111.33 -173.435 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 33.1 t70 -106.55 148.64 28.01 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.747 -0.66 . . . . 74.25 109.947 175.841 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 62.6 t -82.22 105.76 12.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-O 120.953 0.406 . . . . 71.0 111.137 -178.782 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 52' ' ' GLU . . . . . 0.428 ' HB2' ' HB3' ' A' ' 61' ' ' ALA . 40.6 tt0 -82.49 123.76 29.46 Favored 'General case' 0 C--N 1.319 -0.721 0 N-CA-C 108.881 -0.785 . . . . 54.44 108.881 174.459 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 43.5 mt-10 -87.94 109.55 19.88 Favored 'General case' 0 C--N 1.319 -0.731 0 CA-C-N 115.974 -0.557 . . . . 71.33 110.804 -174.901 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -138.16 166.8 25.12 Favored Glycine 0 N--CA 1.446 -0.663 0 CA-C-N 115.454 -0.793 . . . . 71.34 111.577 -179.579 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 72.6 mt-30 -79.97 82.95 5.95 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 121.343 0.592 . . . . 72.44 111.245 -175.843 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 56' ' ' ARG . . . . . 0.437 HH11 ' HD3' ' A' ' 56' ' ' ARG . 9.1 ptp180 -179.77 -32.01 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 114.764 -1.107 . . . . 74.05 109.326 177.893 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 144.95 -152.11 24.19 Favored Glycine 0 N--CA 1.448 -0.553 0 N-CA-C 110.737 -0.945 . . . . 32.32 110.737 -178.183 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 55.5 Cg_endo -70.98 105.2 1.64 Allowed 'Trans proline' 0 N--CA 1.46 -0.472 0 C-N-CA 122.158 1.906 . . . . 51.3 111.537 176.871 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 20.3 tt0 -97.8 139.04 34.26 Favored 'General case' 0 C--N 1.322 -0.596 0 N-CA-C 108.63 -0.878 . . . . 64.4 108.63 179.071 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 60' ' ' ALA . . . . . 0.546 ' HB3' ' HA ' ' A' ' 28' ' ' VAL . . . -96.11 120.42 36.37 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-O 121.255 0.55 . . . . 73.24 112.105 -174.835 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 61' ' ' ALA . . . . . 0.428 ' HB3' ' HB2' ' A' ' 52' ' ' GLU . . . -135.57 163.1 30.89 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 115.05 -0.977 . . . . 74.33 108.62 173.777 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 62' ' ' ASN . . . . . 0.474 ' O ' ' HA ' ' A' ' 49' ' ' PHE . 88.5 m-20 54.65 77.34 0.21 Allowed 'General case' 0 C--O 1.236 0.348 0 CA-C-O 121.067 0.46 . . . . 62.31 109.855 -174.494 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 45.9 t -112.67 121.38 64.87 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 CA-C-N 115.643 -0.708 . . . . 72.31 110.787 -175.998 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 5.1 tp60 -115.61 146.58 41.66 Favored 'General case' 0 C--N 1.323 -0.566 0 N-CA-C 109.29 -0.633 . . . . 62.23 109.29 177.642 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 19.4 ttpp -84.01 137.8 33.43 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 120.931 0.396 . . . . 64.45 111.481 -176.867 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 0.987 0 CA-C-O 118.202 -0.904 . . . . 51.42 108.882 171.109 . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 1.4 mpt? . . . . . 0 N--CA 1.481 1.087 0 CA-C-O 121.177 0.513 . . . . 73.24 110.133 . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 2' ' ' GLU . . . . . 0.469 ' O ' ' HA ' ' A' ' 48' ' ' THR . 5.0 mp0 -114.24 14.99 18.21 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-N 115.752 -0.658 . . . . 73.21 109.283 -179.453 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 17.9 mp0 -63.96 136.32 57.24 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.033 -0.985 . . . . 73.24 112.606 -173.968 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -153.09 163.38 30.52 Favored Glycine 0 N--CA 1.441 -1.003 0 N-CA-C 109.419 -1.473 . . . . 51.23 109.419 172.657 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 5' ' ' THR . . . . . 0.41 ' O ' ' HG2' ' A' ' 19' ' ' GLU . 13.9 m -122.46 127.53 49.72 Favored 'General case' 0 C--N 1.316 -0.861 0 CA-C-N 118.04 0.92 . . . . 64.3 110.886 -178.174 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 61.5 t -64.93 120.7 12.44 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.462 0 CA-C-N 116.22 -0.445 . . . . 63.53 111.115 -178.026 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 7' ' ' LYS . . . . . 1.072 ' HE2' ' HB3' ' A' ' 19' ' ' GLU . 66.3 mmtt -74.93 -70.49 0.41 Allowed 'General case' 0 C--N 1.328 -0.344 0 N-CA-C 109.219 -0.66 . . . . 72.24 109.219 175.309 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 8' ' ' TRP . . . . . . . . . . . . . 15.6 m95 -140.36 128.35 22.08 Favored 'General case' 0 C--O 1.235 0.317 0 CA-C-N 115.059 -0.973 . . . . 71.43 108.786 -179.537 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 22.8 p90 -99.52 103.69 15.45 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-O 121.702 0.763 . . . . 74.13 109.706 177.377 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 10' ' ' ASN . . . . . 0.862 ' HB3' ' HG3' ' A' ' 13' ' ' LYS . 37.8 m-80 -91.45 63.79 4.91 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 115.775 -0.648 . . . . 63.21 110.557 -176.958 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -64.07 -26.29 68.48 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 115.609 -0.723 . . . . 65.21 110.435 178.732 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 4.1 mm-40 -71.64 -13.27 61.7 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 115.726 -0.67 . . . . 72.23 110.509 178.684 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 13' ' ' LYS . . . . . 0.862 ' HG3' ' HB3' ' A' ' 10' ' ' ASN . 1.7 mmpt? -112.97 -37.85 4.68 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.895 -0.593 . . . . 63.54 110.395 -176.99 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 14' ' ' GLY . . . . . 0.408 ' O ' ' HD1' ' A' ' 30' ' ' PHE . . . 116.85 15.61 6.7 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.956 -0.64 . . . . 73.42 112.835 178.474 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 45.3 p90 -151.49 -176.36 5.56 Favored 'General case' 0 C--N 1.324 -0.543 0 O-C-N 122.543 -0.386 . . . . 71.03 110.667 179.96 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -164.55 169.99 39.51 Favored Glycine 0 N--CA 1.445 -0.743 0 C-N-CA 120.915 -0.66 . . . . 73.14 111.795 177.581 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 96.6 m-85 -123.76 130.12 52.13 Favored 'General case' 0 C--N 1.323 -0.585 0 N-CA-C 109.979 -0.378 . . . . 73.15 109.979 178.695 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 61.0 mt -127.57 135.35 63.45 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.768 0 N-CA-C 109.701 -0.481 . . . . 62.43 109.701 178.308 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 19' ' ' GLU . . . . . 1.072 ' HB3' ' HE2' ' A' ' 7' ' ' LYS . 8.5 pt-20 -91.5 135.61 33.72 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-O 121.212 0.529 . . . . 65.14 110.811 179.451 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 20' ' ' ARG . . . . . 0.658 ' HB2' ' HZ ' ' A' ' 49' ' ' PHE . 45.5 ttt180 -133.93 161.75 33.94 Favored 'General case' 0 C--N 1.315 -0.928 0 N-CA-C 108.576 -0.898 . . . . 72.42 108.576 174.78 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 21' ' ' GLU . . . . . 0.408 ' HG2' ' H ' ' A' ' 21' ' ' GLU . 7.1 mm-40 -35.87 -57.47 0.67 Allowed 'General case' 0 N--CA 1.468 0.444 0 O-C-N 124.038 0.836 . . . . 73.41 110.806 178.025 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 34.9 t30 -110.06 76.92 1.02 Allowed 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 115.704 -0.68 . . . . 62.5 109.749 172.409 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 23' ' ' GLY . . . . . 0.583 ' O ' HG23 ' A' ' 26' ' ' VAL . . . 152.24 72.44 0.01 OUTLIER Glycine 0 N--CA 1.446 -0.674 0 C-N-CA 120.541 -0.838 . . . . 74.1 112.213 174.032 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 25.2 t70 -68.17 -1.79 6.76 Favored 'General case' 0 C--N 1.321 -0.663 0 CA-C-O 121.183 0.516 . . . . 50.41 111.062 -176.278 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 7.0 p-10 -142.65 31.49 1.47 Allowed 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 116.246 -0.434 . . . . 74.11 110.929 -174.988 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.583 HG23 ' O ' ' A' ' 23' ' ' GLY . 79.2 t -53.28 121.83 2.73 Favored 'Isoleucine or valine' 0 C--O 1.234 0.269 0 CA-C-O 121.109 0.48 . . . . 72.04 110.743 179.588 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 27' ' ' PHE . . . . . . . . . . . . . 42.6 t80 -84.21 116.74 23.1 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 115.583 -0.735 . . . . 74.12 110.603 -174.413 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.511 HG21 HG21 ' A' ' 63' ' ' VAL . 9.0 p -110.68 156.1 11.86 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.59 0 CA-C-N 116.339 -0.392 . . . . 75.32 110.281 179.853 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 92.7 m-70 -108.82 157.27 18.74 Favored 'General case' 0 C--O 1.239 0.513 0 N-CA-C 110.011 -0.366 . . . . 54.44 110.011 -179.674 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 30' ' ' PHE . . . . . 0.408 ' HD1' ' O ' ' A' ' 14' ' ' GLY . 50.8 p90 -61.65 -34.48 75.78 Favored 'General case' 0 N--CA 1.464 0.234 0 CA-C-N 116.54 -0.3 . . . . 74.25 111.605 -175.847 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 26.8 t -92.43 2.68 56.52 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 121.053 0.454 . . . . 74.21 110.589 -179.045 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -93.38 -29.9 15.37 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 121.168 0.509 . . . . 44.13 110.151 177.127 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.585 ' HA ' ' HB ' ' A' ' 63' ' ' VAL . 59.1 mt -72.66 137.89 22.56 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.386 0 CA-C-N 115.608 -0.724 . . . . 73.31 109.992 174.277 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 5.1 pp0? -71.66 146.51 48.23 Favored 'General case' 0 C--N 1.329 -0.318 0 N-CA-C 110.061 -0.348 . . . . 73.35 110.061 178.236 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 164.41 133.12 1.44 Allowed Glycine 0 N--CA 1.442 -0.955 0 C-N-CA 120.749 -0.739 . . . . 51.35 111.947 179.299 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 9.2 m-20 -65.26 106.42 1.34 Allowed 'General case' 0 C--N 1.326 -0.428 0 N-CA-C 109.735 -0.469 . . . . 72.45 109.735 178.307 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 78.4 -95.36 1.32 Allowed Glycine 0 N--CA 1.446 -0.636 0 N-CA-C 111.077 -0.809 . . . . 50.14 111.077 -173.737 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 38' ' ' PHE . . . . . 0.424 ' O ' ' HD2' ' A' ' 39' ' ' LYS . 74.1 m-85 -138.04 94.5 2.89 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 120.873 0.368 . . . . 64.4 110.406 176.379 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 39' ' ' LYS . . . . . 0.424 ' HD2' ' O ' ' A' ' 38' ' ' PHE . 13.1 mptt -125.95 88.41 2.85 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 116.159 -0.473 . . . . 72.11 110.497 177.509 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 20.0 m -76.21 121.82 23.46 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-N 115.902 -0.59 . . . . 71.34 110.034 177.594 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 98.4 mt -66.35 143.13 57.35 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 116.013 -0.539 . . . . 64.21 110.93 -177.882 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 35.4 t70 -68.07 149.38 49.73 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-N 115.462 -0.79 . . . . 71.32 112.176 -172.808 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 7.6 pt-20 -65.25 135.63 55.62 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 115.751 -0.658 . . . . 73.04 110.518 179.312 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 89.74 -1.23 80.89 Favored Glycine 0 N--CA 1.447 -0.583 0 C-N-CA 120.66 -0.781 . . . . 53.14 112.233 -177.18 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 6.5 tp-100 -82.92 141.49 32.14 Favored 'General case' 0 C--O 1.237 0.439 0 CA-C-O 120.732 0.301 . . . . 74.23 110.36 176.984 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -82.38 117.41 22.42 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 115.824 -0.626 . . . . 65.31 110.257 178.244 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 29.5 m -117.01 166.93 10.83 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.711 0 CA-C-N 115.727 -0.67 . . . . 62.52 110.884 -178.071 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 48' ' ' THR . . . . . 0.726 HG23 ' HB2' ' A' ' 66' ' ' ALA . 9.6 p -132.91 103.15 5.92 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-O 121.296 0.569 . . . . 63.41 110.106 178.461 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 49' ' ' PHE . . . . . 0.658 ' HZ ' ' HB2' ' A' ' 20' ' ' ARG . 36.5 p90 -117.16 166.82 11.79 Favored 'General case' 0 C--N 1.318 -0.792 0 CA-C-O 121.072 0.463 . . . . 74.03 111.751 -172.399 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 35.5 t70 -96.91 128.06 43.5 Favored 'General case' 0 C--N 1.32 -0.68 0 N-CA-C 109.016 -0.735 . . . . 73.14 109.016 174.169 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 7.4 p -80.62 118.0 27.56 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.564 0 CA-C-O 121.538 0.685 . . . . 73.42 111.254 -174.746 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 44.0 tt0 -89.14 113.16 24.3 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-N 115.419 -0.81 . . . . 74.03 109.109 176.942 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 13.9 mm-40 -73.62 86.13 1.62 Allowed 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 115.983 -0.553 . . . . 75.02 109.875 178.248 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -88.64 160.8 30.48 Favored Glycine 0 N--CA 1.443 -0.858 0 C-N-CA 120.88 -0.676 . . . . 61.11 112.331 -177.523 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 36.7 tt0 -84.77 0.34 50.99 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-O 121.392 0.615 . . . . 73.21 109.854 -179.295 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 90.8 mtm180 -119.84 15.64 12.6 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.597 -0.729 . . . . 71.52 110.855 179.184 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 121.68 169.17 13.56 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.884 -0.674 . . . . 60.31 112.182 -179.769 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 37.7 Cg_endo -68.03 118.41 5.6 Favored 'Trans proline' 0 C--N 1.344 0.291 0 C-N-CA 122.532 2.155 . . . . 51.42 111.768 177.249 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 49.9 mt-30 -119.45 164.31 15.96 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 116.325 -0.398 . . . . 62.33 110.429 -177.791 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -111.65 125.15 53.65 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-O 121.255 0.55 . . . . 75.3 111.943 -174.048 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -128.57 142.97 50.89 Favored 'General case' 0 C--N 1.321 -0.63 0 CA-C-N 115.3 -0.863 . . . . 65.51 109.005 174.426 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 39.4 m-80 56.53 78.57 0.21 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 121.216 0.532 . . . . 72.45 110.448 -175.899 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.585 ' HB ' ' HA ' ' A' ' 33' ' ' ILE . 51.8 t -101.42 109.59 26.14 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.519 0 CA-C-N 115.892 -0.594 . . . . 54.03 110.803 -177.965 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 86.7 mt-30 -94.06 -172.24 2.77 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 116.192 -0.458 . . . . 74.1 110.105 177.983 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 61.9 tttm -116.45 139.64 50.23 Favored 'General case' 0 C--N 1.321 -0.641 0 N-CA-C 109.303 -0.629 . . . . 71.34 109.303 178.508 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 66' ' ' ALA . . . . . 0.726 ' HB2' HG23 ' A' ' 48' ' ' THR . . . . . . . . 0 C--O 1.248 1.006 0 CA-C-O 118.795 -0.621 . . . . 75.01 110.557 -178.614 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 2' ' ' GLU . . . . . 0.943 ' HG3' HH12 ' A' ' 20' ' ' ARG . 0.1 OUTLIER . . . . . 0 C--O 1.235 0.337 0 CA-C-O 121.06 0.457 . . . . 74.42 111.209 . . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 41.1 mt-30 -96.54 148.52 22.75 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.539 -0.755 . . . . 51.42 110.123 178.481 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -155.91 153.7 24.95 Favored Glycine 0 N--CA 1.445 -0.726 0 C-N-CA 120.934 -0.651 . . . . 71.33 111.866 177.114 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 4.7 m -104.57 134.81 47.12 Favored 'General case' 0 C--N 1.319 -0.752 0 N-CA-C 109.812 -0.44 . . . . 73.12 109.812 178.124 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 61.8 t -68.13 112.18 3.01 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.609 0 CA-C-O 120.745 0.307 . . . . 63.52 110.41 177.952 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 7' ' ' LYS . . . . . 0.683 ' HD3' ' HB3' ' A' ' 19' ' ' GLU . 12.3 mmmm -71.3 -68.5 0.44 Allowed 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.831 -0.622 . . . . 62.45 109.822 179.159 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 8' ' ' TRP . . . . . . . . . . . . . 4.6 p-90 -153.06 149.01 27.68 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-N 115.462 -0.79 . . . . 74.33 109.32 177.774 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . 0.419 ' CE2' ' HA ' ' A' ' 40' ' ' SER . 68.5 t80 -114.59 120.15 39.21 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-O 121.001 0.429 . . . . 74.21 111.563 -173.227 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 10' ' ' ASN . . . . . 0.454 ' HB3' ' HB2' ' A' ' 13' ' ' LYS . 15.3 m120 -81.92 78.31 8.64 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.669 -0.696 . . . . 74.21 109.472 176.261 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -61.71 -37.64 84.92 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 115.905 -0.589 . . . . 14.0 111.303 -177.114 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 32.0 mm-40 -76.8 -11.33 59.81 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.379 -0.373 . . . . 73.34 111.554 -178.925 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' LYS . . . . . 0.487 ' HB3' ' HD2' ' A' ' 15' ' ' PHE . 70.1 mmtt -99.79 -33.69 10.47 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-O 121.072 0.463 . . . . 73.32 110.553 176.839 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 89.85 24.28 30.53 Favored Glycine 0 N--CA 1.448 -0.536 0 N-CA-C 111.075 -0.81 . . . . 75.14 111.075 -174.147 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . 0.487 ' HD2' ' HB3' ' A' ' 13' ' ' LYS . 64.3 m-85 -136.92 173.73 11.38 Favored 'General case' 0 C--N 1.324 -0.519 0 N-CA-C 109.549 -0.538 . . . . 73.32 109.549 -178.338 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -160.98 167.56 36.02 Favored Glycine 0 N--CA 1.447 -0.6 0 C-N-CA 120.281 -0.962 . . . . 64.41 112.285 178.543 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 96.2 m-85 -119.67 119.67 34.39 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-O 121.105 0.478 . . . . 73.54 110.668 179.095 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 56.4 mt -112.76 124.95 69.91 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.657 0 N-CA-C 109.187 -0.671 . . . . 62.13 109.187 177.72 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' GLU . . . . . 0.683 ' HB3' ' HD3' ' A' ' 7' ' ' LYS . 10.3 pt-20 -71.88 140.38 49.25 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-O 121.342 0.592 . . . . 73.41 111.468 -173.792 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' ARG . . . . . 0.943 HH12 ' HG3' ' A' ' 2' ' ' GLU . 9.7 tpt180 -90.84 172.98 8.24 Favored 'General case' 0 C--N 1.32 -0.7 0 N-CA-C 107.521 -1.289 . . . . 35.3 107.521 167.107 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . 0.575 ' OE2' ' HG3' ' A' ' 20' ' ' ARG . 0.0 OUTLIER -59.79 -23.15 63.05 Favored 'General case' 0 N--CA 1.467 0.413 0 CA-C-N 118.383 0.538 . . . . 61.32 112.327 -172.93 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 91.9 m-20 -101.4 17.79 21.76 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.855 0.36 . . . . 42.51 111.594 179.005 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 80.15 2.08 88.59 Favored Glycine 0 N--CA 1.452 -0.253 0 C-N-CA 120.943 -0.646 . . . . 40.52 112.751 176.897 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 28.4 t70 -69.19 97.85 0.96 Allowed 'General case' 0 C--N 1.323 -0.557 0 N-CA-C 109.955 -0.387 . . . . 63.51 109.955 179.712 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.47 ' OD1' ' HG3' ' A' ' 7' ' ' LYS . 52.5 m-20 -53.66 113.67 1.27 Allowed 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.331 -0.85 . . . . 74.14 111.119 176.363 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.608 HG12 ' HB2' ' A' ' 60' ' ' ALA . 25.3 t -89.27 135.56 25.66 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.602 0 CA-C-N 115.663 -0.698 . . . . 73.23 109.457 176.316 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 27' ' ' PHE . . . . . . . . . . . . . 40.4 t80 -90.72 109.65 20.83 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 120.988 0.423 . . . . 74.34 110.79 -172.894 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.436 ' HA ' ' HB3' ' A' ' 60' ' ' ALA . 7.9 p -97.52 151.45 4.29 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 CA-C-N 116.185 -0.461 . . . . 44.32 110.508 -179.434 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 29' ' ' HIS . . . . . 0.44 ' HA ' ' HD1' ' A' ' 15' ' ' PHE . 34.0 m80 -115.46 158.53 22.4 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.175 -0.466 . . . . 62.11 110.969 -175.924 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 34.3 p90 -61.69 -31.34 71.47 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.029 -0.532 . . . . 72.24 111.774 179.742 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 8.0 t -94.43 12.85 25.72 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 121.433 0.635 . . . . 62.53 109.977 -179.628 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . 0.72 ' HB1' ' HA ' ' A' ' 61' ' ' ALA . . . -112.68 -28.85 7.65 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 115.701 -0.681 . . . . 60.31 110.124 178.132 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 55.7 mt -80.33 139.01 18.82 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.53 0 CA-C-N 115.443 -0.799 . . . . 51.32 109.926 177.126 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 34' ' ' GLN . . . . . 0.415 ' HG3' ' O ' ' A' ' 34' ' ' GLN . 10.5 pt20 . . . . . 0 N--CA 1.45 -0.432 0 CA-C-O 121.395 0.617 . . . . 63.31 109.518 173.436 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . 0.419 ' HA ' ' CE2' ' A' ' 9' ' ' PHE . 66.4 m . . . . . 0 N--CA 1.453 -0.305 0 N-CA-C 109.939 -0.393 . . . . 51.21 109.939 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 87.6 mt -110.96 126.52 54.85 Favored 'General case' 0 C--N 1.321 -0.642 0 N-CA-C 109.328 -0.619 . . . . 75.33 109.328 174.301 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 36.0 t70 -69.44 112.91 6.29 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-O 121.001 0.429 . . . . 71.13 109.95 179.991 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 55.6 mt-10 -65.57 120.46 12.94 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 115.956 -0.565 . . . . 52.33 110.35 -176.89 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 105.22 -13.07 48.56 Favored Glycine 0 N--CA 1.449 -0.498 0 C-N-CA 121.014 -0.612 . . . . 32.41 111.903 -175.305 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 6.2 tp-100 -83.64 145.6 28.72 Favored 'General case' 0 C--O 1.235 0.318 0 CA-C-O 120.795 0.331 . . . . 64.21 110.272 -179.855 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -100.22 135.21 42.0 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 116.161 -0.472 . . . . 74.23 110.465 178.743 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 8.9 m -141.68 -175.93 0.9 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.493 0 CA-C-N 116.096 -0.502 . . . . 54.34 110.537 179.444 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 19.8 p -124.54 157.97 34.06 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 115.971 -0.559 . . . . 60.43 109.693 177.302 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 37.8 p90 -156.48 151.07 25.7 Favored 'General case' 0 C--N 1.321 -0.637 0 C-N-CA 120.56 -0.456 . . . . 73.13 111.545 -176.748 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . 0.736 ' HB3' ' HB2' ' A' ' 62' ' ' ASN . 26.3 t70 -91.35 94.4 9.49 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 115.834 -0.621 . . . . 75.24 109.697 174.562 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 7.6 p -73.56 133.63 31.29 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.55 0 CA-C-N 115.871 -0.604 . . . . 64.22 111.079 -176.399 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 25.7 mt-10 -119.31 171.69 8.14 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 115.847 -0.615 . . . . 74.32 110.155 179.273 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 10.8 pt-20 -72.08 149.51 44.76 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.834 -0.621 . . . . 72.52 110.87 179.968 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . 0.48 ' HA3' ' O ' ' A' ' 57' ' ' GLY . . . -155.02 124.98 1.6 Allowed Glycine 0 N--CA 1.445 -0.715 0 CA-C-N 115.87 -0.604 . . . . 32.53 111.804 178.387 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 35.4 tt0 -61.49 -33.08 73.17 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-O 120.654 0.264 . . . . 64.21 111.306 -177.535 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 22.2 mmt180 -114.47 25.98 10.6 Favored 'General case' 0 C--N 1.327 -0.375 0 N-CA-C 111.741 0.274 . . . . 72.22 111.741 -179.515 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . 0.48 ' O ' ' HA3' ' A' ' 54' ' ' GLY . . . 139.86 157.25 7.19 Favored Glycine 0 N--CA 1.448 -0.55 0 C-N-CA 120.319 -0.943 . . . . 60.23 112.378 176.757 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . 0.567 ' HG2' ' HA ' ' A' ' 26' ' ' VAL . 37.5 Cg_endo -66.47 127.2 16.85 Favored 'Trans proline' 0 C--O 1.234 0.323 0 C-N-CA 122.629 2.219 . . . . 63.23 111.517 -179.758 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 26.9 tt0 -88.72 107.86 19.17 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 116.039 -0.528 . . . . 52.23 110.728 -176.841 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . 0.608 ' HB2' HG12 ' A' ' 26' ' ' VAL . . . -79.2 97.75 6.34 Favored 'General case' 0 C--N 1.323 -0.575 0 N-CA-C 109.728 -0.471 . . . . 71.23 109.728 175.879 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 61' ' ' ALA . . . . . 0.72 ' HA ' ' HB1' ' A' ' 32' ' ' ALA . . . -111.44 165.83 11.64 Favored 'General case' 0 C--N 1.319 -0.74 0 CA-C-N 115.829 -0.623 . . . . 61.51 110.017 -179.994 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 62' ' ' ASN . . . . . 0.736 ' HB2' ' HB3' ' A' ' 50' ' ' ASP . 56.3 m-20 48.37 65.89 1.21 Allowed 'General case' 0 C--N 1.33 -0.271 0 O-C-N 123.727 0.642 . . . . 72.41 111.03 174.915 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 58.7 t -77.26 120.64 28.12 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.464 0 CA-C-N 116.086 -0.507 . . . . 72.52 110.493 -178.603 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 77.2 mm-40 -108.12 133.76 51.94 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-N 115.827 -0.624 . . . . 74.21 110.058 179.694 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 96.8 mttt -73.92 134.41 43.19 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 116.194 -0.457 . . . . 61.31 110.503 -179.397 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.246 0.87 0 CA-C-O 118.346 -0.835 . . . . 60.41 110.326 -179.783 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 11.1 mp0 . . . . . 0 N--CA 1.453 -0.297 0 N-CA-C 110.254 -0.276 . . . . 64.32 110.254 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 3' ' ' GLN . . . . . 0.49 ' HA ' ' O ' ' A' ' 47' ' ' VAL . 28.6 tt0 -92.65 131.17 37.98 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 116.38 -0.373 . . . . 53.22 110.065 176.733 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . 0.412 ' HA3' ' HE2' ' A' ' 49' ' ' PHE . . . -146.16 151.62 23.83 Favored Glycine 0 N--CA 1.446 -0.685 0 C-N-CA 120.872 -0.68 . . . . 65.32 112.292 -179.58 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . 0.42 ' O ' ' HG2' ' A' ' 19' ' ' GLU . 0.2 OUTLIER -89.0 125.8 35.14 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-O 120.659 0.266 . . . . 73.42 110.923 -177.287 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.863 ' HA ' HG13 ' A' ' 18' ' ' ILE . 31.2 t -68.55 102.53 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.495 0 N-CA-C 110.098 -0.334 . . . . 60.01 110.098 176.623 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 8.8 mmmm -72.59 -68.29 0.49 Allowed 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 116.296 -0.411 . . . . 60.13 110.672 -177.531 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 8' ' ' TRP . . . . . . . . . . . . . 80.7 m95 -135.32 131.69 36.76 Favored 'General case' 0 C--N 1.323 -0.546 0 N-CA-C 109.755 -0.461 . . . . 70.44 109.755 178.286 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . 0.487 ' HA ' ' HA3' ' A' ' 16' ' ' GLY . 73.3 t80 -134.42 104.35 6.09 Favored 'General case' 0 C--N 1.318 -0.765 0 CA-C-O 120.912 0.387 . . . . 73.43 110.125 176.939 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 10' ' ' ASN . . . . . 0.628 ' OD1' ' HG2' ' A' ' 13' ' ' LYS . 16.7 t-20 -78.53 86.64 4.53 Favored 'General case' 0 C--N 1.321 -0.639 0 N-CA-C 109.305 -0.628 . . . . 64.52 109.305 178.897 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -66.31 -15.76 63.49 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 115.243 -0.89 . . . . 63.41 111.494 -177.17 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 32.7 mt-10 -68.01 -38.46 82.65 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.142 -0.481 . . . . 62.24 109.983 177.867 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' LYS . . . . . 0.628 ' HG2' ' OD1' ' A' ' 10' ' ' ASN . 28.9 mmtp -98.2 -30.45 12.63 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 116.112 -0.494 . . . . 74.05 109.946 179.955 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 104.9 20.73 9.61 Favored Glycine 0 N--CA 1.448 -0.555 0 C-N-CA 120.746 -0.74 . . . . 61.23 113.068 175.857 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 39.7 p90 -147.08 162.59 38.52 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 117.157 0.478 . . . . 73.42 110.853 -178.857 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.487 ' HA3' ' HA ' ' A' ' 9' ' ' PHE . . . -168.45 -164.15 23.66 Favored Glycine 0 N--CA 1.444 -0.823 0 C-N-CA 120.665 -0.778 . . . . 72.11 112.064 178.857 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 91.9 m-85 -133.83 124.3 26.28 Favored 'General case' 0 C--N 1.322 -0.61 0 N-CA-C 109.408 -0.59 . . . . 74.02 109.408 -178.005 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.863 HG13 ' HA ' ' A' ' 6' ' ' VAL . 11.0 tt -116.51 158.22 17.07 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.96 0 N-CA-C 109.095 -0.706 . . . . 51.45 109.095 -177.712 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' GLU . . . . . 0.42 ' HG2' ' O ' ' A' ' 5' ' ' THR . 19.8 pt-20 -106.49 134.13 50.1 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 121.375 0.607 . . . . 71.12 111.229 -178.148 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' ARG . . . . . . . . . . . . . 14.3 ttt180 -97.35 157.98 15.7 Favored 'General case' 0 C--N 1.317 -0.83 0 N-CA-C 108.224 -1.028 . . . . 63.32 108.224 172.026 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 31.7 mt-10 -44.0 -40.65 4.87 Favored 'General case' 0 N--CA 1.467 0.416 0 O-C-N 123.503 0.502 . . . . 74.54 110.885 -179.499 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 23.1 t-20 -127.59 73.62 1.46 Allowed 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 115.89 -0.595 . . . . 72.51 109.784 171.498 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 164.61 94.99 0.1 Allowed Glycine 0 C--O 1.227 -0.306 0 C-N-CA 120.41 -0.9 . . . . 71.32 112.843 175.846 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 13.3 m-20 -78.44 18.16 0.58 Allowed 'General case' 0 N--CA 1.468 0.458 0 N-CA-C 111.877 0.325 . . . . 75.05 111.877 -178.02 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 36.5 t70 -142.7 85.24 1.88 Allowed 'General case' 0 C--N 1.321 -0.671 0 CA-C-O 120.999 0.428 . . . . 71.44 110.824 -177.724 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.457 ' HB ' HG22 ' A' ' 18' ' ' ILE . 47.2 t -125.48 124.04 66.08 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.526 0 CA-C-N 115.609 -0.723 . . . . 61.3 109.185 174.94 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 27' ' ' PHE . . . . . . . . . . . . . 70.6 t80 -83.44 104.36 13.52 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-O 121.321 0.581 . . . . 52.14 110.834 -175.328 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.439 ' HA ' ' HB3' ' A' ' 60' ' ' ALA . 13.5 p -93.77 142.05 13.9 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.664 0 CA-C-N 115.851 -0.613 . . . . 75.23 109.788 179.089 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 29' ' ' HIS . . . . . 0.437 ' CE1' ' HB2' ' A' ' 32' ' ' ALA . 3.7 p80 -140.53 142.55 35.19 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.761 0.315 . . . . 74.34 111.017 -175.976 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 17.2 p90 -60.49 -25.14 65.84 Favored 'General case' 0 N--CA 1.469 0.476 0 CA-C-N 115.8 -0.636 . . . . 65.1 112.706 -170.775 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 11.6 p -77.87 -8.0 57.47 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-O 121.028 0.442 . . . . 43.21 111.587 -178.11 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . 0.688 ' HB1' ' HA ' ' A' ' 61' ' ' ALA . . . -113.81 -23.53 9.61 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 120.921 0.391 . . . . 63.3 111.074 179.178 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.437 HD13 ' HB2' ' A' ' 41' ' ' LEU . 56.9 mt -69.07 150.51 10.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 N-CA-C 109.556 -0.535 . . . . 74.53 109.556 174.104 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 34' ' ' GLN . . . . . 0.415 HE21 ' HA ' ' A' ' 64' ' ' GLN . 4.8 pp0? . . . . . 0 C--N 1.326 -0.449 0 N-CA-C 109.45 -0.574 . . . . 64.23 109.45 175.056 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 13.3 p . . . . . 0 N--CA 1.45 -0.425 0 CA-C-O 121.068 0.461 . . . . 73.24 110.705 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . 0.437 ' HB2' HD13 ' A' ' 33' ' ' ILE . 12.6 tp -92.63 146.81 23.38 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 116.029 -0.532 . . . . 74.14 109.675 178.699 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 42' ' ' ASP . . . . . 0.856 ' HB2' ' HB2' ' A' ' 45' ' ' GLN . 2.1 m-20 -73.92 124.81 26.88 Favored 'General case' 0 C--N 1.318 -0.787 0 CA-C-N 115.837 -0.62 . . . . 72.35 110.885 -175.108 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 9.3 pt-20 -69.47 131.34 44.58 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-O 120.845 0.355 . . . . 64.2 110.164 177.456 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 82.24 4.06 90.34 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.863 -0.684 . . . . 64.42 112.113 -177.65 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 45' ' ' GLN . . . . . 0.856 ' HB2' ' HB2' ' A' ' 42' ' ' ASP . 24.6 tp60 -80.91 126.32 31.22 Favored 'General case' 0 C--N 1.326 -0.455 0 N-CA-C 110.109 -0.33 . . . . 70.12 110.109 -179.693 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 0.438 ' O ' ' HB3' ' A' ' 66' ' ' ALA . . . -86.88 83.15 7.59 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-O 121.042 0.449 . . . . 42.12 110.048 176.006 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 0.507 HG12 ' HA ' ' A' ' 65' ' ' LYS . 19.1 m -89.85 167.98 1.59 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.578 0 CA-C-N 115.631 -0.713 . . . . 70.12 111.734 -173.563 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 48' ' ' THR . . . . . 0.497 ' OG1' ' HB3' ' A' ' 64' ' ' GLN . 4.9 p -112.4 107.32 16.08 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 115.959 -0.564 . . . . 74.51 110.145 177.379 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 49' ' ' PHE . . . . . 0.582 ' HA ' ' O ' ' A' ' 62' ' ' ASN . 38.2 p90 -122.17 160.57 24.85 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 115.838 -0.619 . . . . 73.53 111.234 -173.063 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 22.6 t70 -107.67 115.59 30.43 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-O 121.07 0.462 . . . . 72.11 110.563 175.058 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 66.5 t -66.65 132.51 32.02 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.498 0 CA-C-N 115.734 -0.667 . . . . 63.52 112.12 -174.692 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 52' ' ' GLU . . . . . 1.044 ' HB2' ' HB2' ' A' ' 59' ' ' GLN . 34.4 mt-10 -94.27 159.55 15.08 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.736 -0.666 . . . . 73.22 109.675 174.309 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 39.1 mt-10 -114.72 110.63 20.03 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-N 116.38 -0.373 . . . . 74.43 110.353 178.382 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -126.49 170.8 18.26 Favored Glycine 0 N--CA 1.448 -0.515 0 C-N-CA 120.878 -0.677 . . . . 34.21 112.092 -179.802 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 18.3 mt-30 -92.98 69.3 4.5 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-O 121.365 0.602 . . . . 74.15 110.034 -177.852 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 15.8 ptp180 178.59 -30.47 0.01 OUTLIER 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 114.741 -1.118 . . . . 72.51 108.921 -176.154 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 162.71 -179.54 37.92 Favored Glycine 0 N--CA 1.44 -1.098 0 N-CA-C 110.325 -1.11 . . . . 65.52 110.325 178.486 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 57.5 Cg_endo -76.34 128.12 10.24 Favored 'Trans proline' 0 N--CA 1.454 -0.822 0 C-N-CA 121.884 1.723 . . . . 60.15 111.161 175.228 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . 1.044 ' HB2' ' HB2' ' A' ' 52' ' ' GLU . 9.4 mm100 -93.4 169.73 10.14 Favored 'General case' 0 C--N 1.321 -0.639 0 N-CA-C 109.0 -0.741 . . . . 71.13 109.0 178.591 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . 0.439 ' HB3' ' HA ' ' A' ' 28' ' ' VAL . . . -124.75 111.33 15.42 Favored 'General case' 0 C--N 1.319 -0.745 0 C-N-CA 120.719 -0.393 . . . . 73.13 111.327 179.308 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 61' ' ' ALA . . . . . 0.688 ' HA ' ' HB1' ' A' ' 32' ' ' ALA . . . -123.11 159.35 28.71 Favored 'General case' 0 CA--C 1.515 -0.379 0 CA-C-N 115.984 -0.553 . . . . 74.41 110.161 177.156 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 62' ' ' ASN . . . . . 0.582 ' O ' ' HA ' ' A' ' 49' ' ' PHE . 94.9 m-20 53.65 78.3 0.16 Allowed 'General case' 0 CA--C 1.517 -0.304 0 CA-C-O 121.274 0.559 . . . . 63.45 109.569 -177.481 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.404 HG11 HD21 ' A' ' 41' ' ' LEU . 44.1 t -107.8 101.72 12.93 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.611 0 CA-C-N 115.147 -0.933 . . . . 60.24 110.572 -175.995 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 64' ' ' GLN . . . . . 0.497 ' HB3' ' OG1' ' A' ' 48' ' ' THR . 8.3 tt0 -85.3 124.13 31.57 Favored 'General case' 0 C--N 1.319 -0.728 0 CA-C-N 115.959 -0.564 . . . . 64.13 110.066 -179.382 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . 0.507 ' HA ' HG12 ' A' ' 47' ' ' VAL . 42.9 mttm -68.16 127.39 32.72 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.346 -0.388 . . . . 74.21 110.263 -179.289 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 66' ' ' ALA . . . . . 0.438 ' HB3' ' O ' ' A' ' 46' ' ' ALA . . . . . . . . 0 C--O 1.246 0.898 0 CA-C-O 118.091 -0.956 . . . . 52.13 110.444 -178.615 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 C--O 1.236 0.383 0 CA-C-O 121.122 0.486 . . . . 63.34 111.164 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 35.1 tt0 -88.35 116.29 26.46 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 115.832 -0.622 . . . . 74.44 110.237 177.58 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -126.91 -174.33 13.77 Favored Glycine 0 N--CA 1.449 -0.472 0 N-CA-C 110.99 -0.844 . . . . 63.54 110.99 177.727 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . 0.538 ' O ' ' HG2' ' A' ' 19' ' ' GLU . 10.1 m -130.09 132.19 46.05 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-N 117.3 0.55 . . . . 71.22 110.682 179.515 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 60.3 t -76.22 119.83 25.08 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.446 0 CA-C-N 116.495 -0.321 . . . . 73.53 110.169 -179.286 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 7' ' ' LYS . . . . . 0.964 ' HE3' ' HA ' ' A' ' 7' ' ' LYS . 0.0 OUTLIER -92.97 -68.22 0.81 Allowed 'General case' 0 C--N 1.325 -0.467 0 CA-C-O 120.92 0.391 . . . . 74.25 110.797 179.113 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 8' ' ' TRP . . . . . . . . . . . . . 63.7 m95 -112.79 126.53 55.53 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 116.078 -0.51 . . . . 75.14 109.73 -177.917 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . 0.407 ' CE2' ' HB2' ' A' ' 11' ' ' ALA . 54.1 t80 -125.07 91.14 3.37 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-O 121.201 0.525 . . . . 72.33 110.542 -176.807 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 18.2 m120 -87.47 78.36 8.64 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-O 121.426 0.631 . . . . 63.41 109.815 -179.945 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . 0.407 ' HB2' ' CE2' ' A' ' 9' ' ' PHE . . . -63.71 -32.57 74.1 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 115.136 -0.938 . . . . 63.31 110.833 -179.292 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 42.9 mt-10 -76.89 -8.86 58.14 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.112 -0.494 . . . . 64.02 111.026 179.426 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' LYS . . . . . 0.419 ' HB3' ' CE2' ' A' ' 15' ' ' PHE . 75.5 mmtt -107.75 -26.06 10.98 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 120.938 0.399 . . . . 73.02 110.28 178.948 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 96.61 20.69 23.83 Favored Glycine 0 N--CA 1.449 -0.482 0 C-N-CA 120.942 -0.647 . . . . 71.45 113.017 175.779 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . 0.419 ' CE2' ' HB3' ' A' ' 13' ' ' LYS . 31.5 p90 -155.09 167.11 31.45 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-O 120.982 0.42 . . . . 71.11 111.262 179.104 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -157.84 168.49 34.44 Favored Glycine 0 N--CA 1.445 -0.719 0 CA-C-N 115.819 -0.628 . . . . 74.23 112.021 180.0 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 91.4 m-85 -121.13 118.6 30.11 Favored 'General case' 0 C--N 1.321 -0.63 0 CA-C-O 120.885 0.374 . . . . 74.23 110.543 -178.459 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 55.2 mt -104.16 124.51 58.65 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 N-CA-C 109.601 -0.518 . . . . 70.34 109.601 177.711 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' GLU . . . . . 0.538 ' HG2' ' O ' ' A' ' 5' ' ' THR . 14.6 pt-20 -82.8 130.29 35.11 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-O 121.436 0.636 . . . . 73.51 111.525 -173.12 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' ARG . . . . . 0.413 ' HB3' ' HB3' ' A' ' 24' ' ' ASP . 16.2 ttp180 -113.15 158.82 19.93 Favored 'General case' 0 C--N 1.324 -0.532 0 N-CA-C 108.839 -0.801 . . . . 63.33 108.839 175.03 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 5.6 mm-40 -49.36 -36.43 21.57 Favored 'General case' 0 N--CA 1.472 0.657 0 N-CA-C 113.961 1.097 . . . . 62.33 113.961 -168.951 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 61.7 t30 -84.16 12.49 6.4 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 121.189 0.519 . . . . 72.0 111.321 -175.667 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 76.39 10.2 85.66 Favored Glycine 0 N--CA 1.454 -0.103 0 N-CA-C 110.508 -1.037 . . . . 73.24 110.508 -173.185 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . 0.413 ' HB3' ' HB3' ' A' ' 20' ' ' ARG . 17.7 t70 -76.75 90.12 3.42 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-N 114.417 -0.892 . . . . 43.5 109.894 -177.714 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 12.1 p-10 -70.59 114.16 8.41 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-O 121.592 0.71 . . . . 75.43 110.734 178.845 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 23.8 t -84.53 122.55 38.15 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.683 0 CA-C-N 115.185 -0.916 . . . . 74.42 109.839 179.721 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 27' ' ' PHE . . . . . . . . . . . . . 70.8 t80 -85.36 109.31 18.31 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 115.855 -0.611 . . . . 72.0 110.831 -174.997 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.485 ' HB ' ' HB3' ' A' ' 60' ' ' ALA . 11.3 p -96.06 147.14 6.28 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.596 0 N-CA-C 109.867 -0.42 . . . . 54.51 109.867 178.256 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 29' ' ' HIS . . . . . 0.494 ' O ' HG13 ' A' ' 33' ' ' ILE . 5.7 p80 -128.02 153.53 46.66 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 120.741 0.305 . . . . 72.13 110.902 -176.911 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 48.0 p90 -57.26 -29.34 63.75 Favored 'General case' 0 N--CA 1.468 0.447 0 N-CA-C 113.489 0.922 . . . . 74.52 113.489 -170.192 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 21.9 m -76.64 -1.2 26.5 Favored 'General case' 0 C--N 1.326 -0.45 0 C-N-CA 120.93 -0.308 . . . . 71.22 111.245 -179.998 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . 0.597 ' HB1' ' HA ' ' A' ' 61' ' ' ALA . . . -125.02 -11.36 7.09 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.874 0.369 . . . . 73.01 110.919 177.631 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.494 HG13 ' O ' ' A' ' 29' ' ' HIS . 85.9 mt -77.49 137.93 21.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.114 -0.494 . . . . 74.12 110.837 178.372 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 7.6 pt20 . . . . . 0 C--N 1.329 -0.291 0 CA-C-O 120.974 0.416 . . . . 65.45 109.947 173.527 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 14.7 p . . . . . 0 N--CA 1.452 -0.37 0 CA-C-O 120.925 0.393 . . . . 72.03 110.71 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 3.7 mm? -110.43 158.17 18.78 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 116.101 -0.499 . . . . 64.32 109.851 177.202 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 28.3 t70 -118.3 137.77 52.84 Favored 'General case' 0 C--N 1.321 -0.636 0 N-CA-C 109.634 -0.506 . . . . 75.41 109.634 -177.562 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 8.5 pt-20 -71.14 116.99 12.08 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-O 121.523 0.677 . . . . 63.5 110.072 179.73 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 105.54 6.2 38.6 Favored Glycine 0 N--CA 1.445 -0.723 0 CA-C-N 115.69 -0.687 . . . . 70.13 111.463 -174.002 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 62.2 tp60 -92.11 132.09 36.86 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 120.743 0.306 . . . . 71.3 110.877 179.05 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -78.66 132.14 36.94 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 116.01 -0.541 . . . . 72.41 109.561 173.504 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 25.5 m -137.81 153.66 28.0 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.634 0 CA-C-N 116.064 -0.516 . . . . 60.51 111.699 -177.191 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 9.4 p -113.1 111.79 22.74 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-N 115.872 -0.604 . . . . 72.33 109.78 174.754 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 49' ' ' PHE . . . . . 0.421 ' HA ' ' O ' ' A' ' 62' ' ' ASN . 39.5 p90 -120.81 161.93 20.65 Favored 'General case' 0 C--N 1.319 -0.729 0 CA-C-N 115.959 -0.564 . . . . 73.2 110.569 -172.551 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 33.1 t70 -93.15 118.0 30.72 Favored 'General case' 0 C--N 1.32 -0.711 0 N-CA-C 109.491 -0.559 . . . . 71.33 109.491 173.978 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 5.1 p -78.23 109.13 12.54 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.65 0 CA-C-O 121.67 0.748 . . . . 73.41 111.06 -176.539 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 9.7 tp10 -92.75 119.88 32.57 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-N 115.375 -0.83 . . . . 62.21 108.886 175.583 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 12.9 pt-20 -107.15 124.89 50.36 Favored 'General case' 0 C--N 1.317 -0.821 0 CA-C-O 120.897 0.38 . . . . 63.44 110.227 -179.923 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -146.78 -142.25 3.69 Favored Glycine 0 N--CA 1.448 -0.525 0 C-N-CA 120.615 -0.802 . . . . 71.54 112.281 -179.751 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 16.4 mm100 -77.64 -26.36 50.42 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-O 120.982 0.42 . . . . 73.43 110.451 -178.465 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 24.4 mmm180 -87.35 4.51 42.68 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 116.082 -0.508 . . . . 74.5 110.351 -179.445 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 89.36 -138.39 14.64 Favored Glycine 0 N--CA 1.446 -0.646 0 C-N-CA 120.928 -0.653 . . . . 64.55 111.618 -178.361 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 89.2 Cg_endo -84.73 104.86 0.96 Allowed 'Trans proline' 0 N--CA 1.455 -0.749 0 C-N-CA 122.701 2.267 . . . . 64.14 112.329 177.455 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 12.3 pt20 -112.52 135.62 53.01 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-O 121.144 0.497 . . . . 72.5 110.017 177.551 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . 0.485 ' HB3' ' HB ' ' A' ' 28' ' ' VAL . . . -86.34 128.12 34.89 Favored 'General case' 0 C--N 1.319 -0.758 0 CA-C-O 121.149 0.499 . . . . 55.31 111.708 -172.743 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 61' ' ' ALA . . . . . 0.597 ' HA ' ' HB1' ' A' ' 32' ' ' ALA . . . -130.21 143.63 50.89 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 115.436 -0.802 . . . . 74.12 109.282 174.016 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 62' ' ' ASN . . . . . 0.421 ' O ' ' HA ' ' A' ' 49' ' ' PHE . 45.0 m-80 59.45 87.23 0.08 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 121.244 0.545 . . . . 71.45 110.391 -176.965 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 47.8 t -105.39 111.14 33.49 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.591 0 CA-C-N 115.721 -0.672 . . . . 71.13 110.273 -176.883 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 24.6 mt-30 -107.93 142.53 37.9 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-N 116.149 -0.478 . . . . 74.32 109.944 -179.73 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 46.0 mttp -77.48 144.22 37.9 Favored 'General case' 0 C--N 1.325 -0.492 0 C-N-CA 120.868 -0.333 . . . . 73.4 110.422 179.567 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.247 0.958 0 CA-C-O 118.781 -0.628 . . . . 52.31 110.413 178.077 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 2' ' ' GLU . . . . . 0.607 ' HG2' HG23 ' A' ' 51' ' ' VAL . 4.8 mp0 . . . . . 0 C--O 1.234 0.248 0 CA-C-O 121.125 0.488 . . . . 73.4 111.318 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 3' ' ' GLN . . . . . 0.663 ' HG2' HG22 ' A' ' 48' ' ' THR . 79.7 mt-30 -97.49 122.95 41.13 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.732 -0.667 . . . . 74.31 109.638 172.209 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -138.14 178.31 19.33 Favored Glycine 0 N--CA 1.445 -0.721 0 N-CA-C 111.136 -0.786 . . . . 62.24 111.136 179.178 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . 0.422 ' O ' ' HG2' ' A' ' 19' ' ' GLU . 13.1 m -125.11 130.54 52.42 Favored 'General case' 0 C--N 1.315 -0.919 0 CA-C-N 117.28 0.54 . . . . 74.55 110.512 178.088 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 61.3 t -72.58 108.57 4.06 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.472 0 CA-C-N 116.376 -0.375 . . . . 64.2 110.01 178.813 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 7' ' ' LYS . . . . . 0.444 ' HB3' ' CE3' ' A' ' 8' ' ' TRP . 6.5 mmtm -73.62 -48.48 32.23 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 116.26 -0.427 . . . . 75.53 110.208 177.622 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 8' ' ' TRP . . . . . 0.542 ' HE1' ' HD2' ' A' ' 17' ' ' PHE . 15.6 p90 -164.14 158.92 19.76 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.661 -0.7 . . . . 75.31 110.075 177.763 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . 0.415 ' HD1' ' HA3' ' A' ' 16' ' ' GLY . 71.4 t80 -134.33 106.48 7.12 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 116.264 -0.426 . . . . 74.44 110.12 178.622 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 87.8 m-20 -76.71 85.09 3.34 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 116.048 -0.524 . . . . 54.44 109.821 179.791 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -62.39 -38.11 88.36 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 115.519 -0.764 . . . . 62.24 111.492 -177.234 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 42.0 mt-10 -72.55 -14.41 61.63 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 116.253 -0.43 . . . . 72.23 111.056 -179.571 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 32.2 mmmt -101.21 -26.32 13.69 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.88 0.372 . . . . 65.44 110.225 177.922 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 100.15 7.3 52.61 Favored Glycine 0 N--CA 1.45 -0.427 0 C-N-CA 120.83 -0.7 . . . . 63.23 113.253 175.423 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 41.0 p90 -151.16 154.96 37.91 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-O 121.125 0.488 . . . . 75.33 111.602 -176.077 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.415 ' HA3' ' HD1' ' A' ' 9' ' ' PHE . . . -135.95 178.45 18.71 Favored Glycine 0 N--CA 1.444 -0.803 0 N-CA-C 111.055 -0.818 . . . . 62.34 111.055 178.65 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . 0.542 ' HD2' ' HE1' ' A' ' 8' ' ' TRP . 79.9 m-85 -131.28 123.23 27.92 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-O 121.197 0.522 . . . . 55.23 111.243 -177.975 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 64.5 mt -106.43 126.48 62.15 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 CA-C-N 115.482 -0.781 . . . . 54.24 109.144 176.803 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' GLU . . . . . 0.422 ' HG2' ' O ' ' A' ' 5' ' ' THR . 17.2 pt-20 -79.53 139.36 37.58 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-O 121.327 0.584 . . . . 75.31 112.299 -173.464 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' ARG . . . . . . . . . . . . . 10.0 tpt180 -109.83 166.61 10.79 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.082 -0.963 . . . . 64.1 108.94 174.846 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . 0.453 ' CD ' ' H ' ' A' ' 21' ' ' GLU . 2.3 mp0 -43.95 -48.68 8.62 Favored 'General case' 0 N--CA 1.472 0.635 0 N-CA-C 112.397 0.518 . . . . 75.1 112.397 179.409 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 74.6 m-20 -71.41 -7.08 44.97 Favored 'General case' 0 N--CA 1.468 0.429 0 CA-C-N 116.295 -0.411 . . . . 74.34 112.025 -174.9 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 90.01 7.63 67.94 Favored Glycine 0 N--CA 1.45 -0.387 0 N-CA-C 110.084 -1.206 . . . . 52.13 110.084 -170.145 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 13.0 t70 -70.28 93.2 0.83 Allowed 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 114.486 -0.857 . . . . 73.0 109.953 -179.262 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.405 ' HB2' ' HB3' ' A' ' 17' ' ' PHE . 13.4 p-10 -65.76 101.92 0.69 Allowed 'General case' 0 C--N 1.321 -0.644 0 CA-C-N 115.549 -0.75 . . . . 54.11 110.65 176.848 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 40.0 t -71.01 130.41 34.95 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.587 0 CA-C-N 115.444 -0.798 . . . . 71.24 110.547 -178.487 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 27' ' ' PHE . . . . . . . . . . . . . 63.1 t80 -79.39 108.64 13.07 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 116.079 -0.51 . . . . 65.25 110.147 -178.294 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 9.3 p -111.16 141.5 26.33 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.598 0 N-CA-C 110.061 -0.348 . . . . 65.15 110.061 179.242 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 29' ' ' HIS . . . . . 0.555 ' O ' HG13 ' A' ' 33' ' ' ILE . 6.0 p80 -128.94 145.75 51.15 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.795 0.331 . . . . 52.13 110.863 -177.03 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 37.5 p90 -58.82 -27.69 65.31 Favored 'General case' 0 N--CA 1.467 0.421 0 CA-C-N 115.679 -0.691 . . . . 73.42 112.294 -171.227 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 1.5 p -79.03 6.64 8.91 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-O 120.744 0.307 . . . . 74.23 111.707 -179.331 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -129.25 -14.74 4.26 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 121.002 0.429 . . . . 72.21 110.879 175.287 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.755 HD13 HD21 ' A' ' 41' ' ' LEU . 24.9 mt -80.45 161.68 3.86 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.164 -0.471 . . . . 65.52 110.089 176.263 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 34' ' ' GLN . . . . . 0.682 ' NE2' ' HA ' ' A' ' 64' ' ' GLN . 26.5 pt20 . . . . . 0 C--N 1.327 -0.383 0 N-CA-C 110.107 -0.331 . . . . 43.23 110.107 177.485 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 37.4 m . . . . . 0 N--CA 1.449 -0.493 0 N-CA-C 109.676 -0.49 . . . . 64.41 109.676 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . 0.755 HD21 HD13 ' A' ' 33' ' ' ILE . 3.5 mm? -91.22 148.01 22.65 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 116.346 -0.388 . . . . 72.3 110.758 -176.708 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 4.8 m-20 -91.61 113.35 25.6 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 115.797 -0.638 . . . . 63.35 109.293 175.452 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 4.5 mp0 -62.97 129.82 42.06 Favored 'General case' 0 C--N 1.321 -0.669 0 CA-C-N 116.061 -0.518 . . . . 62.23 110.422 -179.305 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 97.89 -7.88 63.09 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 121.042 -0.599 . . . . 63.14 112.102 -178.263 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 29.6 tp60 -84.15 123.85 30.52 Favored 'General case' 0 C--N 1.324 -0.523 0 N-CA-C 110.173 -0.306 . . . . 60.34 110.173 179.83 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -68.1 135.28 51.94 Favored 'General case' 0 C--N 1.328 -0.345 0 N-CA-C 109.403 -0.592 . . . . 75.2 109.403 172.623 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 0.546 HG12 ' HA ' ' A' ' 65' ' ' LYS . 21.1 m -134.24 154.05 36.9 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.771 0 CA-C-O 121.214 0.53 . . . . 75.32 111.501 -175.704 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 48' ' ' THR . . . . . 0.663 HG22 ' HG2' ' A' ' 3' ' ' GLN . 33.0 p -113.72 117.13 30.66 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 115.503 -0.771 . . . . 73.43 109.433 174.68 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 49' ' ' PHE . . . . . 0.424 ' HA ' ' O ' ' A' ' 62' ' ' ASN . 40.8 p90 -129.76 170.37 13.93 Favored 'General case' 0 C--N 1.316 -0.872 0 CA-C-N 115.966 -0.561 . . . . 72.31 110.913 -173.148 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 38.8 t70 -112.01 143.87 42.3 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-N 115.864 -0.607 . . . . 63.34 109.813 174.306 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . 0.607 HG23 ' HG2' ' A' ' 2' ' ' GLU . 84.7 t -94.88 121.52 45.54 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.553 0 CA-C-O 121.165 0.507 . . . . 73.32 110.875 -178.528 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 52' ' ' GLU . . . . . 0.582 ' HB3' ' HG3' ' A' ' 59' ' ' GLN . 0.0 OUTLIER -94.24 141.97 27.94 Favored 'General case' 0 C--N 1.321 -0.648 0 N-CA-C 108.849 -0.797 . . . . 64.45 108.849 174.288 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 4.9 pt-20 -111.93 106.37 15.05 Favored 'General case' 0 C--N 1.316 -0.855 0 CA-C-O 121.287 0.565 . . . . 73.1 111.0 -174.557 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -126.76 -169.58 12.76 Favored Glycine 0 N--CA 1.448 -0.538 0 C-N-CA 120.852 -0.69 . . . . 44.13 112.019 -179.403 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 44.7 mt-30 -76.77 -3.1 36.48 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.952 0.406 . . . . 63.2 111.109 -178.095 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 56' ' ' ARG . . . . . 0.423 HH11 ' HD2' ' A' ' 56' ' ' ARG . 17.7 mmm180 -100.24 3.82 43.83 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-O 120.95 0.405 . . . . 72.33 110.496 176.416 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 94.28 -142.43 16.02 Favored Glycine 0 N--CA 1.446 -0.644 0 C-N-CA 120.843 -0.694 . . . . 33.21 111.872 -178.364 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 74.3 Cg_endo -79.97 106.93 2.0 Favored 'Trans proline' 0 N--CA 1.458 -0.597 0 C-N-CA 122.76 2.306 . . . . 75.02 112.703 -179.309 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . 0.582 ' HG3' ' HB3' ' A' ' 52' ' ' GLU . 4.1 pt20 -111.7 126.43 55.03 Favored 'General case' 0 C--N 1.322 -0.627 0 CA-C-N 115.778 -0.646 . . . . 74.21 109.655 177.701 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -80.05 130.47 35.28 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-O 121.024 0.44 . . . . 20.05 111.464 -174.871 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -135.13 145.35 47.75 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 115.452 -0.795 . . . . 33.1 109.321 177.717 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 62' ' ' ASN . . . . . 0.424 ' O ' ' HA ' ' A' ' 49' ' ' PHE . 89.2 m-20 59.59 82.99 0.14 Allowed 'General case' 0 C--N 1.327 -0.398 0 CA-C-O 121.164 0.507 . . . . 75.53 110.225 -176.621 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.407 HG13 ' HB3' ' A' ' 49' ' ' PHE . 39.2 t -113.06 106.35 20.57 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.511 0 CA-C-N 115.545 -0.752 . . . . 63.31 110.394 -177.061 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 64' ' ' GLN . . . . . 0.682 ' HA ' ' NE2' ' A' ' 34' ' ' GLN . 53.4 mt-30 -99.73 145.32 27.79 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 116.401 -0.363 . . . . 75.43 110.395 -179.349 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . 0.546 ' HA ' HG12 ' A' ' 47' ' ' VAL . 28.4 mtmm -82.61 136.4 34.81 Favored 'General case' 0 C--N 1.324 -0.54 0 N-CA-C 110.076 -0.342 . . . . 75.02 110.076 -179.864 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.247 0.941 0 CA-C-O 118.843 -0.599 . . . . 53.03 110.485 -179.108 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 2.2 mp0 . . . . . 0 C--O 1.237 0.447 0 CA-C-O 121.215 0.531 . . . . 72.22 111.676 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 3' ' ' GLN . . . . . 0.472 ' HG2' HG22 ' A' ' 48' ' ' THR . 65.8 mt-30 -91.95 143.6 26.32 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.341 -0.845 . . . . 60.52 110.248 179.612 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . 0.68 ' HA3' ' HE2' ' A' ' 49' ' ' PHE . . . -159.26 150.86 21.58 Favored Glycine 0 N--CA 1.447 -0.626 0 C-N-CA 120.932 -0.652 . . . . 70.11 111.917 178.252 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . 0.543 ' HA ' ' HA ' ' A' ' 46' ' ' ALA . 3.5 m -98.02 133.47 42.44 Favored 'General case' 0 C--N 1.32 -0.703 0 CA-C-O 120.563 0.22 . . . . 43.42 110.438 -179.029 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 51.2 t -68.16 103.62 0.71 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 N-CA-C 109.541 -0.54 . . . . 73.42 109.541 175.068 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 7' ' ' LYS . . . . . 0.764 ' HD3' ' HB3' ' A' ' 19' ' ' GLU . 31.0 mmmt -61.56 -60.7 3.3 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 121.342 0.591 . . . . 71.1 110.543 -176.706 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 8' ' ' TRP . . . . . . . . . . . . . 28.7 p90 -156.42 136.47 12.77 Favored 'General case' 0 C--N 1.319 -0.726 0 CA-C-N 115.349 -0.841 . . . . 74.23 109.533 176.695 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . 0.514 ' HA ' ' HA3' ' A' ' 16' ' ' GLY . 70.7 t80 -132.41 113.13 12.79 Favored 'General case' 0 C--N 1.317 -0.807 0 CA-C-O 121.09 0.471 . . . . 65.1 110.287 -177.033 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 2.6 m-20 -78.0 80.26 4.44 Favored 'General case' 0 C--N 1.322 -0.624 0 N-CA-C 108.892 -0.781 . . . . 74.32 108.892 176.014 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -60.53 -33.26 72.39 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 121.079 0.466 . . . . 73.31 110.918 -178.386 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' GLU . . . . . 0.434 ' HG3' ' HG2' ' A' ' 13' ' ' LYS . 6.8 pt-20 -67.71 -25.12 65.5 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 115.462 -0.79 . . . . 64.22 111.555 -179.824 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' LYS . . . . . 0.434 ' HG2' ' HG3' ' A' ' 12' ' ' GLU . 47.5 mmtm -110.06 -15.4 14.04 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-O 120.845 0.355 . . . . 73.01 111.222 -176.881 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 94.06 20.37 30.88 Favored Glycine 0 N--CA 1.449 -0.456 0 C-N-CA 120.995 -0.621 . . . . 73.31 114.148 170.237 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 43.2 p90 -153.62 156.44 37.94 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 117.67 0.735 . . . . 74.4 111.384 -179.321 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.514 ' HA3' ' HA ' ' A' ' 9' ' ' PHE . . . -167.73 -169.75 31.65 Favored Glycine 0 N--CA 1.45 -0.398 0 N-CA-C 111.883 -0.487 . . . . 52.12 111.883 178.389 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 88.1 m-85 -133.09 139.29 47.05 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 121.122 0.487 . . . . 60.24 111.309 -179.068 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 56.9 mt -119.93 145.33 26.36 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.547 0 N-CA-C 108.908 -0.775 . . . . 73.13 108.908 176.697 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' GLU . . . . . 0.764 ' HB3' ' HD3' ' A' ' 7' ' ' LYS . 20.9 pt-20 -89.37 158.22 17.86 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-O 121.15 0.5 . . . . 65.05 111.045 -177.123 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' ARG . . . . . 0.6 ' HD3' ' HB3' ' A' ' 24' ' ' ASP . 70.4 ttt180 -134.15 158.72 42.94 Favored 'General case' 0 C--N 1.32 -0.674 0 N-CA-C 108.523 -0.918 . . . . 75.13 108.523 179.146 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 44.1 mt-10 -48.2 -50.92 27.41 Favored 'General case' 0 N--CA 1.466 0.336 0 N-CA-C 113.229 0.825 . . . . 74.31 113.229 -172.316 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 57.8 m-80 -87.5 20.58 2.84 Favored 'General case' 0 C--N 1.327 -0.405 0 N-CA-C 111.878 0.325 . . . . 60.24 111.878 -173.964 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 76.16 10.55 85.32 Favored Glycine 0 C--N 1.33 0.234 0 C-N-CA 120.605 -0.807 . . . . 70.03 111.731 -178.897 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . 0.6 ' HB3' ' HD3' ' A' ' 20' ' ' ARG . 38.5 t70 -76.95 84.06 3.49 Favored 'General case' 0 C--N 1.322 -0.622 0 N-CA-C 109.772 -0.455 . . . . 75.24 109.772 -179.571 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 8.1 p-10 -58.62 127.56 32.76 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 121.361 0.6 . . . . 64.02 111.123 -176.467 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.545 ' HA ' ' HB2' ' A' ' 58' ' ' PRO . 17.1 t -105.64 124.37 60.62 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.615 0 CA-C-N 115.424 -0.807 . . . . 64.24 110.216 -176.453 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 27' ' ' PHE . . . . . . . . . . . . . 91.9 t80 -82.57 131.21 35.22 Favored 'General case' 0 C--N 1.326 -0.453 0 N-CA-C 110.063 -0.347 . . . . 73.23 110.063 179.944 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 9.8 p -123.3 137.41 56.72 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-O 121.278 0.561 . . . . 72.31 111.006 -179.481 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 22.0 t60 -115.02 151.77 33.62 Favored 'General case' 0 C--N 1.324 -0.504 0 N-CA-C 108.142 -1.059 . . . . 64.1 108.142 176.844 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 17.3 p90 -60.2 -20.15 57.43 Favored 'General case' 0 N--CA 1.472 0.661 0 N-CA-C 112.555 0.576 . . . . 74.41 112.555 -172.052 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 23.1 t -90.14 -9.06 49.68 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 120.892 0.377 . . . . 62.44 110.633 -179.166 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -103.99 -25.46 13.0 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 121.075 0.464 . . . . 72.11 110.747 -179.129 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.661 HD11 HD22 ' A' ' 41' ' ' LEU . 15.4 tt -77.55 163.75 3.71 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.55 0 N-CA-C 108.863 -0.792 . . . . 72.01 108.863 175.726 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 34' ' ' GLN . . . . . 0.518 ' O ' ' HG2' ' A' ' 34' ' ' GLN . 18.8 pm0 . . . . . 0 CA--C 1.533 0.321 0 CA-C-O 121.774 0.797 . . . . 75.3 111.646 -176.121 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 22.0 p . . . . . 0 N--CA 1.45 -0.449 0 CA-C-O 121.062 0.458 . . . . 61.41 110.229 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . 0.661 HD22 HD11 ' A' ' 33' ' ' ILE . 10.7 mp -83.28 126.06 32.26 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 116.158 -0.474 . . . . 74.32 110.241 178.786 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 28.5 t70 -75.51 139.58 42.26 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-N 115.595 -0.73 . . . . 71.35 110.616 -177.342 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 3.0 mp0 -61.22 105.72 0.53 Allowed 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.96 0.41 . . . . 70.42 110.317 178.142 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 126.49 -10.25 7.24 Favored Glycine 0 N--CA 1.447 -0.587 0 CA-C-N 115.871 -0.604 . . . . 63.24 111.731 -175.049 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 7.1 tt0 -77.37 127.49 32.65 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.846 0.355 . . . . 74.32 110.63 178.061 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 0.543 ' HA ' ' HA ' ' A' ' 5' ' ' THR . . . -92.39 130.43 38.07 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 116.201 -0.454 . . . . 61.01 110.371 177.747 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 0.414 HG12 ' HA ' ' A' ' 65' ' ' LYS . 15.5 m -137.37 174.39 11.57 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 CA-C-O 120.949 0.405 . . . . 62.42 111.316 -177.058 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 48' ' ' THR . . . . . 0.472 HG22 ' HG2' ' A' ' 3' ' ' GLN . 23.5 p -111.69 114.06 26.84 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 115.836 -0.62 . . . . 74.34 109.67 176.425 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 49' ' ' PHE . . . . . 0.68 ' HE2' ' HA3' ' A' ' 4' ' ' GLY . 39.7 p90 -125.17 165.38 18.35 Favored 'General case' 0 C--N 1.317 -0.823 0 CA-C-N 116.094 -0.503 . . . . 74.05 110.302 -174.322 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 22.0 t0 -108.43 151.1 26.5 Favored 'General case' 0 C--N 1.317 -0.808 0 C-N-CA 119.992 -0.683 . . . . 54.43 109.883 173.646 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . 0.407 HG21 ' CZ ' ' A' ' 20' ' ' ARG . 61.1 t -105.13 109.35 27.42 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.779 0 CA-C-O 121.089 0.471 . . . . 72.22 110.593 -176.332 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 44.3 tt0 -81.85 96.31 7.59 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-N 115.41 -0.813 . . . . 63.33 109.062 175.463 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 6.7 pt-20 -74.67 90.62 2.3 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-O 121.519 0.676 . . . . 72.41 109.576 176.612 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -121.49 -144.58 6.94 Favored Glycine 0 N--CA 1.444 -0.772 0 CA-C-N 115.164 -0.926 . . . . 32.42 112.282 -177.925 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 55' ' ' GLN . . . . . 0.571 ' O ' ' HG2' ' A' ' 56' ' ' ARG . 6.6 tp-100 -80.86 82.29 6.89 Favored 'General case' 0 C--N 1.323 -0.552 0 N-CA-C 111.59 0.218 . . . . 74.25 111.59 -175.418 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 56' ' ' ARG . . . . . 0.571 ' HG2' ' O ' ' A' ' 55' ' ' GLN . 2.3 mmm180 156.73 -36.35 0.01 OUTLIER 'General case' 0 N--CA 1.478 0.974 0 C-N-CA 125.881 1.672 . . . . 72.51 108.498 173.109 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . 0.443 ' HA3' ' HD3' ' A' ' 58' ' ' PRO . . . 138.09 -120.05 1.93 Allowed Glycine 0 N--CA 1.445 -0.746 0 CA-C-N 115.186 -0.916 . . . . 72.15 111.712 -178.581 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . 0.545 ' HB2' ' HA ' ' A' ' 26' ' ' VAL . 2.9 Cg_endo -80.96 100.35 1.19 Allowed 'Trans proline' 0 N--CA 1.458 -0.574 0 C-N-CA 123.179 2.586 . . . . 64.32 112.721 -178.405 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 22.1 mt-30 -104.76 126.3 51.7 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 115.93 -0.577 . . . . 62.42 109.631 176.016 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -74.77 115.48 14.4 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-O 120.626 0.25 . . . . 72.22 110.784 -177.536 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -136.36 142.12 43.77 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 116.195 -0.457 . . . . 73.14 110.058 178.754 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 42.1 m-80 58.48 85.48 0.09 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 121.38 0.609 . . . . 52.44 110.492 -179.61 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.586 HG13 ' HB3' ' A' ' 49' ' ' PHE . 17.8 t -112.23 131.68 63.02 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.612 0 CA-C-N 115.737 -0.665 . . . . 61.41 110.284 -176.999 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 6.5 tp-100 -128.4 147.11 50.63 Favored 'General case' 0 C--N 1.32 -0.677 0 N-CA-C 109.896 -0.409 . . . . 73.25 109.896 179.063 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . 0.414 ' HA ' HG12 ' A' ' 47' ' ' VAL . 60.2 mttm -65.06 144.99 56.9 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-O 120.671 0.272 . . . . 63.43 110.359 177.533 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.039 0 CA-C-O 118.723 -0.656 . . . . 64.4 110.785 -179.06 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 1.3 pm0 . . . . . 0 C--O 1.234 0.265 0 CA-C-O 120.787 0.327 . . . . 73.53 111.808 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 7.5 tt0 -87.84 116.68 26.16 Favored 'General case' 0 C--N 1.321 -0.652 0 N-CA-C 109.471 -0.566 . . . . 64.34 109.471 174.657 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -132.39 153.8 20.76 Favored Glycine 0 N--CA 1.445 -0.749 0 C-N-CA 120.314 -0.946 . . . . 63.14 112.367 -177.768 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . 0.508 ' O ' ' HG3' ' A' ' 19' ' ' GLU . 2.8 m -98.49 129.69 45.08 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-O 120.72 0.295 . . . . 73.22 110.273 178.933 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.435 HG22 HG12 ' A' ' 18' ' ' ILE . 61.7 t -79.75 118.4 27.22 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.606 0 O-C-N 122.357 -0.215 . . . . 62.15 110.462 178.815 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 7' ' ' LYS . . . . . 0.516 ' NZ ' ' HB3' ' A' ' 19' ' ' GLU . 49.3 mttp -74.18 -65.21 0.87 Allowed 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.926 0.393 . . . . 75.21 110.501 178.053 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 8' ' ' TRP . . . . . . . . . . . . . 90.6 m95 -144.87 160.86 40.61 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 115.821 -0.627 . . . . 75.42 111.211 -176.768 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 14.1 p90 -120.89 106.38 11.58 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 115.503 -0.771 . . . . 64.41 110.527 179.16 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 2.3 m-20 -84.95 77.12 10.17 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-N 115.944 -0.571 . . . . 71.34 109.805 -179.407 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . 0.517 ' HA ' ' HE2' ' A' ' 30' ' ' PHE . . . -63.63 -28.2 69.75 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.589 -0.732 . . . . 61.2 111.268 -178.804 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 65.6 mm-40 -74.87 -13.59 60.57 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 116.2 -0.455 . . . . 63.34 111.314 178.8 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' LYS . . . . . 0.516 ' HB3' ' CE2' ' A' ' 15' ' ' PHE . 31.2 mmmt -109.76 -30.09 8.02 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 116.297 -0.411 . . . . 71.44 111.053 -179.012 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 102.12 17.66 19.72 Favored Glycine 0 N--CA 1.449 -0.476 0 C-N-CA 120.632 -0.794 . . . . 63.42 112.668 177.389 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . 0.516 ' CE2' ' HB3' ' A' ' 13' ' ' LYS . 26.7 p90 -152.71 172.47 16.62 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 120.629 0.252 . . . . 73.0 110.736 -179.618 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -140.85 175.04 22.37 Favored Glycine 0 N--CA 1.446 -0.652 0 C-N-CA 121.06 -0.591 . . . . 65.11 111.77 178.887 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 97.5 m-85 -120.81 116.45 25.23 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-O 120.933 0.397 . . . . 65.1 111.171 -178.636 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.573 ' O ' ' HA ' ' A' ' 25' ' ' ASP . 36.7 mt -102.57 165.09 3.05 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.581 0 N-CA-C 107.816 -1.179 . . . . 61.22 107.816 173.202 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' GLU . . . . . 0.516 ' HB3' ' NZ ' ' A' ' 7' ' ' LYS . 0.3 OUTLIER -130.31 163.22 27.29 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-N 118.857 0.753 . . . . 71.5 111.364 179.05 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' ARG . . . . . . . . . . . . . 15.6 ttp180 -126.17 -163.23 1.2 Allowed 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 115.573 -0.739 . . . . 70.14 109.464 -178.902 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -64.14 -37.54 87.81 Favored 'General case' 0 C--N 1.329 -0.312 0 N-CA-C 112.277 0.473 . . . . 70.3 112.277 -172.776 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 87.6 m-20 -93.59 13.43 22.02 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-O 120.713 0.292 . . . . 71.13 111.113 -177.877 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 74.2 20.44 79.65 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.329 -0.938 . . . . 64.31 110.764 -173.558 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 14.4 t70 -72.08 93.1 1.38 Allowed 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 115.132 -0.534 . . . . 74.3 109.823 -179.017 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.573 ' HA ' ' O ' ' A' ' 18' ' ' ILE . 2.3 m-20 -60.46 121.03 11.07 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.642 -0.708 . . . . 72.02 111.594 178.58 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 36.6 t -96.69 131.48 43.38 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.62 0 CA-C-N 115.013 -0.994 . . . . 73.25 109.897 179.945 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 27' ' ' PHE . . . . . . . . . . . . . 47.4 t80 -83.49 98.7 9.68 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 116.144 -0.48 . . . . 61.11 110.525 -175.817 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.537 ' HB ' ' HB3' ' A' ' 60' ' ' ALA . 13.2 p -98.82 138.66 22.67 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 CA-C-O 121.069 0.461 . . . . 74.03 111.072 -177.782 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 6.9 m80 -99.29 139.19 35.31 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 116.064 -0.517 . . . . 74.01 110.112 176.81 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 30' ' ' PHE . . . . . 0.628 ' HD1' HD12 ' A' ' 33' ' ' ILE . 20.4 m-85 -65.74 -26.2 67.62 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.643 0.258 . . . . 75.34 110.819 179.008 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 38.3 t -72.36 -16.97 61.87 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-O 121.111 0.481 . . . . 72.12 110.48 175.805 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . 0.546 ' HB1' ' HA ' ' A' ' 61' ' ' ALA . . . -94.61 -20.01 19.96 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 121.085 0.469 . . . . 65.11 110.049 177.033 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.706 HG12 HG21 ' A' ' 63' ' ' VAL . 54.6 mt -82.02 135.32 25.2 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.465 0 CA-C-N 115.807 -0.633 . . . . 72.44 110.078 175.443 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 12.7 pt20 . . . . . 0 C--N 1.324 -0.534 0 CA-C-O 121.259 0.552 . . . . 54.32 110.563 176.377 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 42.0 m . . . . . 0 N--CA 1.455 -0.18 0 N-CA-C 110.368 -0.234 . . . . 72.31 110.368 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 3.5 mm? -107.52 162.23 14.13 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.29 -0.413 . . . . 72.21 110.136 178.568 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 42' ' ' ASP . . . . . 0.493 ' HB2' ' HB2' ' A' ' 45' ' ' GLN . 5.9 m-20 -69.62 157.23 37.61 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 116.017 -0.538 . . . . 73.31 111.1 179.967 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -77.18 105.74 8.46 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-O 121.521 0.677 . . . . 70.45 110.039 176.018 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 108.96 5.48 30.84 Favored Glycine 0 N--CA 1.446 -0.657 0 CA-C-N 115.678 -0.692 . . . . 24.05 111.656 -174.014 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 45' ' ' GLN . . . . . 0.493 ' HB2' ' HB2' ' A' ' 42' ' ' ASP . 8.6 tp-100 -80.78 130.68 35.2 Favored 'General case' 0 C--N 1.326 -0.424 0 N-CA-C 109.993 -0.373 . . . . 75.43 109.993 178.944 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -102.46 127.71 49.39 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-O 120.778 0.323 . . . . 64.42 110.721 179.764 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 17.5 m -136.02 172.59 15.28 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.562 0 CA-C-N 115.961 -0.563 . . . . 51.24 110.528 -179.109 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 20.4 p -116.66 115.01 24.86 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 116.177 -0.465 . . . . 64.32 110.328 179.476 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 33.1 p90 -117.42 163.36 16.49 Favored 'General case' 0 C--N 1.319 -0.752 0 CA-C-O 121.157 0.503 . . . . 73.33 111.925 -174.137 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 25.8 t70 -86.07 136.72 33.12 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 115.861 -0.609 . . . . 70.34 109.585 172.908 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 3.7 p -81.83 114.46 22.78 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.499 0 CA-C-O 121.913 0.863 . . . . 74.44 112.06 -174.632 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 9.6 tp10 -108.93 162.0 14.62 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 114.763 -1.108 . . . . 62.13 108.374 175.693 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 39.1 mt-10 -122.59 169.18 11.29 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-O 121.159 0.504 . . . . 52.42 111.517 -179.999 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -162.48 158.25 30.33 Favored Glycine 0 N--CA 1.443 -0.897 0 N-CA-C 110.736 -0.946 . . . . 62.2 110.736 179.046 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 20.6 pt20 -75.73 9.32 2.37 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 117.093 0.447 . . . . 74.43 111.929 -177.088 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 69.3 mtm180 -130.19 15.32 5.65 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 121.005 0.431 . . . . 72.23 110.285 174.654 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 129.21 -179.68 16.54 Favored Glycine 0 N--CA 1.45 -0.427 0 C-N-CA 120.651 -0.785 . . . . 54.22 112.083 179.871 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo -74.6 146.27 34.23 Favored 'Trans proline' 0 N--CA 1.461 -0.428 0 C-N-CA 122.508 2.138 . . . . 71.1 112.427 -179.055 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 42.3 mt-30 -118.5 162.22 18.71 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 115.952 -0.567 . . . . 75.22 110.013 178.335 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . 0.537 ' HB3' ' HB ' ' A' ' 28' ' ' VAL . . . -118.35 125.29 49.73 Favored 'General case' 0 C--N 1.318 -0.794 0 CA-C-O 121.047 0.451 . . . . 73.2 111.039 -179.672 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 61' ' ' ALA . . . . . 0.546 ' HA ' ' HB1' ' A' ' 32' ' ' ALA . . . -127.81 164.59 21.86 Favored 'General case' 0 C--N 1.321 -0.673 0 N-CA-C 108.763 -0.829 . . . . 75.04 108.763 175.871 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 39.7 m-80 48.25 76.87 0.11 Allowed 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 121.032 0.444 . . . . 74.05 110.989 -177.843 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.706 HG21 HG12 ' A' ' 33' ' ' ILE . 46.6 t -89.21 92.08 3.86 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.67 0 CA-C-N 116.042 -0.526 . . . . 72.33 110.142 -178.751 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -80.38 125.82 30.39 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 115.434 -0.803 . . . . 73.05 109.368 -177.868 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 52.9 mttp -64.25 137.54 57.98 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.301 -0.409 . . . . 62.44 110.381 -177.403 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.251 1.135 0 CA-C-O 118.439 -0.791 . . . . 74.22 109.927 179.496 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 2.8 mp0 . . . . . 0 C--O 1.235 0.313 0 CA-C-O 121.04 0.448 . . . . 71.1 110.619 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 84.0 mt-30 -95.15 126.83 40.75 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 115.357 -0.838 . . . . 75.24 109.482 176.813 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . 0.681 ' HA3' ' HE2' ' A' ' 49' ' ' PHE . . . -140.83 151.11 22.22 Favored Glycine 0 N--CA 1.445 -0.756 0 C-N-CA 120.291 -0.956 . . . . 72.11 112.533 -177.985 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . 0.452 ' O ' ' HG2' ' A' ' 19' ' ' GLU . 7.4 m -107.15 125.82 51.58 Favored 'General case' 0 C--N 1.319 -0.75 0 N-CA-C 110.21 -0.293 . . . . 72.34 110.21 -179.718 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 48.3 t -68.01 117.39 9.76 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 N-CA-C 110.168 -0.308 . . . . 72.03 110.168 179.705 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 7' ' ' LYS . . . . . 0.632 ' HD3' ' HB3' ' A' ' 19' ' ' GLU . 30.1 mmmt -75.55 -56.37 4.76 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 121.405 0.622 . . . . 61.44 109.329 179.422 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 8' ' ' TRP . . . . . 0.789 ' HZ3' ' HB2' ' A' ' 10' ' ' ASN . 63.5 p-90 -164.71 157.95 17.21 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-N 114.849 -1.069 . . . . 45.12 108.921 175.927 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 11.3 p90 -129.04 115.1 17.24 Favored 'General case' 0 C--N 1.317 -0.816 0 CA-C-O 121.596 0.713 . . . . 73.21 110.805 -176.593 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 10' ' ' ASN . . . . . 0.789 ' HB2' ' HZ3' ' A' ' 8' ' ' TRP . 34.1 t30 -86.72 71.86 10.28 Favored 'General case' 0 C--N 1.319 -0.729 0 N-CA-C 108.527 -0.916 . . . . 72.54 108.527 179.008 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -62.83 -32.15 73.3 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 114.709 -1.132 . . . . 72.13 112.536 -171.284 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 33.1 mt-10 -75.53 -9.76 58.86 Favored 'General case' 0 C--N 1.326 -0.429 0 C-N-CA 120.905 -0.318 . . . . 73.23 111.252 -177.458 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 30.7 mmmt -110.92 -11.75 14.31 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 121.174 0.511 . . . . 52.4 110.124 174.253 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 95.21 15.83 43.08 Favored Glycine 0 N--CA 1.447 -0.596 0 C-N-CA 120.805 -0.712 . . . . 65.41 114.414 169.91 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 54.6 p90 -145.8 155.3 42.84 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 117.941 0.871 . . . . 75.24 111.601 -179.254 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -140.64 166.82 25.76 Favored Glycine 0 N--CA 1.445 -0.728 0 N-CA-C 111.078 -0.809 . . . . 71.22 111.078 177.422 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 79.0 m-85 -120.89 121.92 39.12 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-O 121.201 0.524 . . . . 74.43 111.201 -178.323 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 56.4 mt -111.25 139.59 34.55 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.615 0 CA-C-N 115.331 -0.85 . . . . 71.12 109.459 178.166 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' GLU . . . . . 0.632 ' HB3' ' HD3' ' A' ' 7' ' ' LYS . 9.1 pt-20 -88.6 134.36 33.9 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 120.896 0.379 . . . . 71.25 110.523 179.008 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' ARG . . . . . . . . . . . . . 27.8 ttp180 -121.84 152.01 40.02 Favored 'General case' 0 C--N 1.322 -0.63 0 N-CA-C 108.996 -0.742 . . . . 74.03 108.996 174.13 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . 0.435 ' HG3' ' H ' ' A' ' 21' ' ' GLU . 0.0 OUTLIER -50.71 -40.81 55.12 Favored 'General case' 0 N--CA 1.463 0.189 0 O-C-N 123.279 0.362 . . . . 73.14 111.795 -177.83 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -109.44 65.75 0.62 Allowed 'General case' 0 C--N 1.322 -0.63 0 CA-C-O 121.004 0.431 . . . . 72.31 110.339 171.62 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 132.85 94.88 0.57 Allowed Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.816 -0.707 . . . . 61.04 112.227 174.257 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . 0.527 ' HA ' ' HA ' ' A' ' 19' ' ' GLU . 3.9 p30 -71.0 6.41 1.58 Allowed 'General case' 0 N--CA 1.468 0.432 0 CA-C-O 120.962 0.41 . . . . 71.41 111.48 -178.108 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 7.2 p-10 -122.6 88.59 2.96 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-O 121.708 0.766 . . . . 70.25 110.916 -177.266 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.434 HG12 ' HB2' ' A' ' 60' ' ' ALA . 55.9 t -112.34 118.59 58.17 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.621 0 CA-C-N 115.431 -0.804 . . . . 71.31 109.565 173.769 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 27' ' ' PHE . . . . . 0.458 ' O ' ' HA ' ' A' ' 59' ' ' GLN . 63.1 t80 -82.08 105.09 12.9 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 115.773 -0.648 . . . . 73.44 110.484 -176.183 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 12.2 p -100.03 133.95 41.24 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.603 0 CA-C-O 121.207 0.527 . . . . 73.25 110.531 179.122 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 85.8 t60 -91.87 133.05 36.01 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 115.843 -0.617 . . . . 62.33 109.855 -178.226 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 14.0 p90 -56.39 -36.39 68.82 Favored 'General case' 0 N--CA 1.467 0.399 0 N-CA-C 111.938 0.347 . . . . 74.21 111.938 -174.015 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 6.9 t -87.31 6.44 33.47 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 121.293 0.568 . . . . 43.12 110.644 -177.763 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -105.67 -19.7 13.68 Favored 'General case' 0 C--N 1.326 -0.447 0 N-CA-C 109.144 -0.687 . . . . 34.22 109.144 173.216 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 69.2 mt -74.72 105.45 3.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 114.998 -1.001 . . . . 75.31 110.271 175.329 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 34' ' ' GLN . . . . . 0.405 ' O ' ' HE3' ' A' ' 65' ' ' LYS . 0.9 OUTLIER . . . . . 0 C--N 1.325 -0.494 0 CA-C-O 121.854 0.835 . . . . 62.54 109.943 175.478 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 22.8 p . . . . . 0 N--CA 1.451 -0.381 0 N-CA-C 110.114 -0.328 . . . . 52.4 110.114 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 95.1 mt -132.39 130.48 40.72 Favored 'General case' 0 C--N 1.325 -0.483 0 N-CA-C 109.277 -0.638 . . . . 74.41 109.277 176.318 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 3.4 m-20 -55.88 125.05 19.73 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 121.205 0.526 . . . . 75.43 111.557 -179.36 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 7.6 pt-20 -66.95 123.27 19.72 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-N 115.834 -0.621 . . . . 71.52 109.831 175.895 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 101.81 5.76 50.4 Favored Glycine 0 N--CA 1.448 -0.502 0 C-N-CA 121.032 -0.604 . . . . 32.03 111.648 -173.229 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 7.5 tp60 -102.84 138.03 40.26 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.652 0.263 . . . . 74.21 110.521 178.603 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -92.16 131.91 37.03 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 116.293 -0.412 . . . . 43.12 110.427 176.329 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 24.0 m -134.77 173.84 13.89 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 CA-C-N 116.121 -0.49 . . . . 72.21 110.308 -179.793 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 19.3 p -117.34 115.69 25.74 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-O 121.185 0.517 . . . . 54.41 110.805 179.431 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 49' ' ' PHE . . . . . 0.681 ' HE2' ' HA3' ' A' ' 4' ' ' GLY . 38.0 p90 -120.63 152.72 37.8 Favored 'General case' 0 C--N 1.319 -0.76 0 CA-C-N 115.74 -0.664 . . . . 72.11 110.325 -177.523 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 22.7 t70 -97.64 116.76 30.47 Favored 'General case' 0 C--N 1.322 -0.596 0 N-CA-C 109.224 -0.658 . . . . 54.4 109.224 174.883 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 9.9 p -77.86 140.71 16.57 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.497 0 CA-C-O 121.52 0.676 . . . . 61.44 111.637 -170.553 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 52' ' ' GLU . . . . . 0.457 ' HB3' ' HG3' ' A' ' 59' ' ' GLN . 32.6 tt0 -137.38 156.91 47.66 Favored 'General case' 0 C--N 1.32 -0.688 0 N-CA-C 108.163 -1.051 . . . . 75.21 108.163 175.173 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . 0.42 ' HA ' ' O ' ' A' ' 57' ' ' GLY . 0.0 OUTLIER -149.49 -177.78 6.05 Favored 'General case' 0 C--N 1.32 -0.708 0 O-C-N 122.092 -0.38 . . . . 73.54 110.794 -178.487 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 143.94 -101.78 0.26 Allowed Glycine 0 N--CA 1.442 -0.933 0 C-N-CA 120.62 -0.8 . . . . 65.14 113.132 177.669 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 35.3 tt0 -80.14 -23.88 40.82 Favored 'General case' 0 C--N 1.326 -0.443 0 N-CA-C 112.361 0.504 . . . . 71.21 112.361 -168.925 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 2.0 ptp180 -137.95 43.39 2.23 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-O 121.07 0.462 . . . . 75.23 111.733 -178.591 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . 0.42 ' O ' ' HA ' ' A' ' 53' ' ' GLU . . . 76.07 -157.38 48.42 Favored Glycine 0 N--CA 1.449 -0.454 0 C-N-CA 120.842 -0.694 . . . . 72.02 113.127 174.667 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 1.7 Cg_endo -81.43 110.39 2.21 Favored 'Trans proline' 0 N--CA 1.455 -0.776 0 C-N-CA 123.242 2.628 . . . . 63.21 112.053 -178.999 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . 0.458 ' HA ' ' O ' ' A' ' 27' ' ' PHE . 16.8 pt20 -105.45 139.11 40.57 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 115.892 -0.595 . . . . 71.31 109.97 179.091 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . 0.434 ' HB2' HG12 ' A' ' 26' ' ' VAL . . . -89.8 109.35 20.35 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 116.178 -0.465 . . . . 74.43 110.997 -179.344 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -111.41 149.9 30.56 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-N 115.825 -0.625 . . . . 74.51 109.519 176.315 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 94.9 m-20 51.49 80.17 0.09 Allowed 'General case' 0 C--O 1.235 0.321 0 CA-C-O 121.286 0.565 . . . . 71.11 110.841 -176.76 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 38.9 t -102.88 103.97 15.88 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.589 0 CA-C-N 115.732 -0.667 . . . . 74.42 110.245 -179.355 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 54.4 mt-30 -94.9 160.54 14.54 Favored 'General case' 0 C--N 1.319 -0.735 0 CA-C-N 115.918 -0.583 . . . . 71.15 110.52 -179.647 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . 0.405 ' HE3' ' O ' ' A' ' 34' ' ' GLN . 0.7 OUTLIER -82.77 171.35 14.05 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 115.717 -0.674 . . . . 52.45 110.894 -176.773 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.097 0 CA-C-O 118.413 -0.803 . . . . 51.33 109.544 177.172 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 56.9 mp0 . . . . . 0 N--CA 1.451 -0.424 0 CA-C-O 121.268 0.556 . . . . 63.44 111.871 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -96.79 112.78 24.39 Favored 'General case' 0 C--N 1.323 -0.545 0 N-CA-C 108.095 -1.076 . . . . 72.03 108.095 172.956 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . 0.474 ' HA3' ' HE2' ' A' ' 49' ' ' PHE . . . -137.61 168.53 24.43 Favored Glycine 0 N--CA 1.447 -0.608 0 C-N-CA 120.392 -0.908 . . . . 63.12 112.558 -175.864 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . 0.408 ' O ' ' HG2' ' A' ' 19' ' ' GLU . 26.9 m -108.24 134.26 51.33 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-O 120.634 0.254 . . . . 74.22 110.457 -179.024 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 47.8 t -68.75 112.7 3.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 CA-C-O 120.772 0.32 . . . . 55.33 110.378 178.494 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 48.3 mtpt -71.76 -70.86 0.3 Allowed 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 115.808 -0.633 . . . . 74.2 110.21 179.887 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 8' ' ' TRP . . . . . . . . . . . . . 92.1 m95 -139.4 132.61 29.81 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 115.094 -0.957 . . . . 72.33 108.819 178.117 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . 0.499 ' HD1' ' HA3' ' A' ' 16' ' ' GLY . 59.4 t80 -132.22 102.1 5.64 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-O 121.272 0.558 . . . . 72.43 110.822 179.15 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 19.0 m120 -80.99 84.8 6.38 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 115.583 -0.735 . . . . 74.53 109.534 176.444 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -61.66 -33.25 73.63 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 115.393 -0.821 . . . . 54.44 111.074 179.055 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 44.3 mt-10 -69.6 -25.9 64.19 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.015 -0.538 . . . . 73.13 110.73 179.532 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 75.7 mmtt -92.24 -35.53 13.74 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.219 -0.446 . . . . 63.2 110.187 -179.948 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 110.12 14.11 14.14 Favored Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 120.965 -0.636 . . . . 44.31 113.35 175.574 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 50.0 p90 -152.73 162.08 41.73 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 117.157 0.479 . . . . 74.54 111.451 -177.546 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.499 ' HA3' ' HD1' ' A' ' 9' ' ' PHE . . . -163.38 178.25 39.04 Favored Glycine 0 N--CA 1.446 -0.692 0 C-N-CA 120.885 -0.674 . . . . 31.12 112.197 179.071 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 90.8 m-85 -126.28 127.76 46.1 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-O 120.7 0.286 . . . . 74.31 110.507 -178.967 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 46.3 mt -112.93 129.91 67.72 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.497 0 N-CA-C 109.151 -0.685 . . . . 74.34 109.151 175.787 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' GLU . . . . . 0.408 ' HG2' ' O ' ' A' ' 5' ' ' THR . 11.1 pt-20 -73.7 139.88 45.65 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 121.502 0.668 . . . . 73.03 111.559 -171.851 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' ARG . . . . . . . . . . . . . 43.5 ttt180 -112.48 141.2 46.51 Favored 'General case' 0 C--N 1.319 -0.733 0 N-CA-C 107.434 -1.321 . . . . 60.44 107.434 175.035 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 16.1 pt-20 -55.67 -26.57 45.47 Favored 'General case' 0 C--N 1.327 -0.406 0 N-CA-C 112.85 0.685 . . . . 64.44 112.85 -170.116 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 28.6 t-20 -79.69 -19.58 48.62 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-O 120.845 0.355 . . . . 73.42 111.434 -178.813 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 106.48 -9.33 41.49 Favored Glycine 0 CA--C 1.511 -0.157 0 N-CA-C 111.229 -0.748 . . . . 74.51 111.229 -174.514 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 36.5 t70 -80.32 72.24 7.16 Favored 'General case' 0 C--N 1.322 -0.615 0 N-CA-C 109.279 -0.638 . . . . 71.4 109.279 176.294 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 10.1 p-10 -70.28 138.07 51.26 Favored 'General case' 0 C--N 1.333 -0.14 0 CA-C-O 121.52 0.676 . . . . 62.52 110.811 -172.899 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.529 HG13 ' HB2' ' A' ' 58' ' ' PRO . 4.3 t -94.57 138.98 19.4 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.55 0 CA-C-N 115.187 -0.915 . . . . 65.21 111.4 -167.734 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 27' ' ' PHE . . . . . . . . . . . . . 50.4 t80 -92.27 111.72 23.39 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.769 -0.65 . . . . 74.02 110.461 -177.449 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.539 ' HB ' ' HB3' ' A' ' 60' ' ' ALA . 14.8 p -95.86 148.49 5.22 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.381 0 CA-C-O 120.905 0.383 . . . . 74.05 111.325 -175.462 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 28.0 m170 -114.31 145.72 41.42 Favored 'General case' 0 C--O 1.236 0.343 0 CA-C-N 116.151 -0.477 . . . . 62.41 109.889 177.623 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 20.5 p90 -62.19 -26.24 68.24 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 121.11 0.481 . . . . 73.53 110.46 177.659 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 4.2 m -81.56 -14.36 56.93 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 115.77 -0.65 . . . . 65.43 110.875 179.277 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . 0.559 ' HB1' ' HA ' ' A' ' 61' ' ' ALA . . . -94.51 -21.3 18.97 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 121.044 0.449 . . . . 64.14 110.819 -176.709 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 44.9 mt -71.04 155.8 7.39 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-N 115.777 -0.647 . . . . 74.23 110.188 174.534 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 14.5 pt20 . . . . . 0 C--N 1.328 -0.368 0 CA-C-O 121.226 0.536 . . . . 72.22 110.458 175.755 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 22.9 t . . . . . 0 C--O 1.235 0.298 0 CA-C-O 121.022 0.439 . . . . 75.42 111.181 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 81.7 mt -95.94 119.04 33.72 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 116.013 -0.54 . . . . 64.02 109.892 177.385 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 42' ' ' ASP . . . . . 0.626 ' HB3' ' HB2' ' A' ' 45' ' ' GLN . 30.7 t70 -82.43 139.93 33.72 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-N 115.942 -0.572 . . . . 65.15 111.048 -175.988 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 6.8 pt-20 -66.11 116.72 7.5 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 115.84 -0.618 . . . . 71.05 110.846 178.383 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 87.3 18.9 56.55 Favored Glycine 0 N--CA 1.448 -0.508 0 C-N-CA 120.642 -0.79 . . . . 53.55 112.182 -177.77 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 45' ' ' GLN . . . . . 0.626 ' HB2' ' HB3' ' A' ' 42' ' ' ASP . 35.6 tt0 -99.22 135.5 40.54 Favored 'General case' 0 C--N 1.326 -0.451 0 N-CA-C 110.208 -0.293 . . . . 71.24 110.208 178.497 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -85.52 129.01 34.92 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 116.36 -0.382 . . . . 62.12 110.271 177.807 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 16.6 m -138.36 153.62 26.61 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.518 0 CA-C-O 120.988 0.423 . . . . 74.11 111.01 -177.927 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 20.7 p -102.51 104.87 15.33 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 115.994 -0.548 . . . . 73.51 109.814 175.988 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 49' ' ' PHE . . . . . 0.474 ' HE2' ' HA3' ' A' ' 4' ' ' GLY . 41.8 p90 -110.74 158.51 18.57 Favored 'General case' 0 C--N 1.316 -0.852 0 CA-C-N 115.449 -0.796 . . . . 74.13 110.174 -174.994 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 19.7 t0 -104.61 151.77 23.24 Favored 'General case' 0 C--N 1.317 -0.842 0 C-N-CA 120.074 -0.65 . . . . 71.03 109.958 173.552 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 4.9 p -103.17 112.41 36.52 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.599 0 CA-C-O 121.405 0.621 . . . . 44.14 111.194 -173.57 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 49.8 mm-40 -109.85 112.88 25.19 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-N 115.586 -0.733 . . . . 72.24 109.689 177.613 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . 0.536 ' HA ' ' O ' ' A' ' 57' ' ' GLY . 8.1 pt-20 -76.81 115.47 16.62 Favored 'General case' 0 C--N 1.325 -0.498 0 C-N-CA 120.211 -0.595 . . . . 75.44 109.941 177.202 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . 0.514 ' HA3' ' NE2' ' A' ' 59' ' ' GLN . . . -122.57 -121.2 2.68 Favored Glycine 0 N--CA 1.445 -0.736 0 C-N-CA 120.354 -0.927 . . . . 45.13 113.365 -174.658 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -84.77 1.68 45.6 Favored 'General case' 0 C--N 1.329 -0.311 0 N-CA-C 112.157 0.429 . . . . 71.1 112.157 -169.632 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 10.2 ptp180 -158.87 28.39 0.22 Allowed 'General case' 0 C--N 1.325 -0.457 0 CA-C-O 120.748 0.308 . . . . 75.42 111.237 177.678 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . 0.536 ' O ' ' HA ' ' A' ' 53' ' ' GLU . . . 93.29 -132.81 11.4 Favored Glycine 0 N--CA 1.444 -0.784 0 C-N-CA 120.44 -0.886 . . . . 74.42 112.18 -179.054 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . 0.529 ' HB2' HG13 ' A' ' 26' ' ' VAL . 33.0 Cg_endo -64.32 106.66 0.72 Allowed 'Trans proline' 0 CA--C 1.529 0.239 0 C-N-CA 122.837 2.358 . . . . 64.4 113.323 -174.806 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . 0.514 ' NE2' ' HA3' ' A' ' 54' ' ' GLY . 22.2 mt-30 -112.53 128.41 56.34 Favored 'General case' 0 C--N 1.323 -0.567 0 N-CA-C 109.011 -0.737 . . . . 74.34 109.011 173.615 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . 0.539 ' HB3' ' HB ' ' A' ' 28' ' ' VAL . . . -82.13 115.1 21.09 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-O 120.984 0.421 . . . . 33.04 110.955 -176.127 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 61' ' ' ALA . . . . . 0.559 ' HA ' ' HB1' ' A' ' 32' ' ' ALA . . . -130.89 154.14 48.4 Favored 'General case' 0 C--N 1.319 -0.75 0 N-CA-C 108.845 -0.798 . . . . 75.1 108.845 176.818 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 90.2 m-20 57.84 73.93 0.45 Allowed 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 121.492 0.663 . . . . 70.24 109.967 -176.125 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 45.3 t -100.21 103.71 15.16 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.664 0 CA-C-N 115.357 -0.838 . . . . 33.11 109.813 179.857 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 6.3 tp-100 -91.63 143.19 26.82 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-N 116.027 -0.533 . . . . 74.12 110.673 -176.941 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 66.8 mmtt -72.72 130.22 40.01 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 115.684 -0.689 . . . . 73.24 109.992 177.817 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.251 1.167 0 CA-C-O 118.432 -0.794 . . . . 75.01 110.53 -178.164 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 1.7 pm0 . . . . . 0 N--CA 1.448 -0.531 0 N-CA-C 110.275 -0.269 . . . . 70.44 110.275 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -100.24 128.74 46.25 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-O 121.215 0.531 . . . . 74.42 110.616 179.31 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -131.14 164.7 23.29 Favored Glycine 0 N--CA 1.444 -0.774 0 CA-C-N 115.803 -0.635 . . . . 63.31 111.751 -179.17 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 21.3 m -105.38 122.87 46.86 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-O 120.542 0.21 . . . . 72.41 110.707 -178.775 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 58.7 t -64.37 114.36 2.21 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.227 0 CA-C-N 116.392 -0.367 . . . . 72.5 110.547 -179.331 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 4.5 mmmm -95.28 -53.16 3.88 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 115.859 -0.609 . . . . 75.2 110.255 -178.832 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 8' ' ' TRP . . . . . 0.464 ' HB2' ' HB2' ' A' ' 17' ' ' PHE . 76.5 m95 -118.11 130.63 56.24 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 115.687 -0.688 . . . . 74.32 110.082 179.793 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . 0.439 ' CE2' ' HB2' ' A' ' 11' ' ' ALA . 62.6 t80 -128.66 84.37 2.23 Favored 'General case' 0 C--N 1.318 -0.781 0 CA-C-O 121.282 0.563 . . . . 74.31 109.692 178.862 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 10' ' ' ASN . . . . . 0.797 ' HB3' ' HB2' ' A' ' 13' ' ' LYS . 44.0 m-80 -87.53 74.35 9.31 Favored 'General case' 0 C--N 1.321 -0.663 0 CA-C-N 115.909 -0.587 . . . . 73.35 110.021 -177.61 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . 0.676 ' HA ' ' CZ ' ' A' ' 30' ' ' PHE . . . -61.07 -39.61 90.53 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.277 -0.874 . . . . 74.15 111.409 -177.296 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 47.0 mt-10 -84.22 -11.4 56.56 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 116.085 -0.507 . . . . 64.02 111.173 -177.947 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' LYS . . . . . 0.797 ' HB2' ' HB3' ' A' ' 10' ' ' ASN . 5.2 mmtp -98.6 -28.41 13.57 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 116.274 -0.421 . . . . 74.43 110.586 -177.02 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 102.2 22.65 9.69 Favored Glycine 0 N--CA 1.448 -0.526 0 C-N-CA 120.652 -0.785 . . . . 64.3 113.396 174.287 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . 0.454 ' O ' ' HB2' ' A' ' 10' ' ' ASN . 52.5 p90 -163.38 171.49 15.96 Favored 'General case' 0 N--CA 1.463 0.222 0 CA-C-N 117.451 0.625 . . . . 72.33 111.067 179.649 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -153.98 172.14 32.65 Favored Glycine 0 N--CA 1.445 -0.701 0 C-N-CA 120.827 -0.701 . . . . 61.53 112.119 179.976 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . 0.792 ' HB3' ' HB3' ' A' ' 25' ' ' ASP . 92.6 m-85 -134.63 122.82 22.82 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 120.802 0.334 . . . . 73.43 110.269 179.472 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 35.3 mt -122.41 117.44 52.09 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.593 0 CA-C-N 116.103 -0.499 . . . . 72.4 109.734 179.164 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' GLU . . . . . 0.417 ' HA ' ' HA ' ' A' ' 25' ' ' ASP . 22.8 pt-20 -79.41 148.31 32.01 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-O 121.257 0.551 . . . . 61.23 112.17 -170.976 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' ARG . . . . . 0.423 ' HG2' ' HG2' ' A' ' 21' ' ' GLU . 14.4 ttm180 -118.61 123.51 45.17 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 115.42 -0.809 . . . . 75.14 109.684 170.681 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . 0.423 ' HG2' ' HG2' ' A' ' 20' ' ' ARG . 43.1 mm-40 50.78 -90.02 0.02 OUTLIER 'General case' 0 N--CA 1.474 0.738 0 N-CA-C 113.407 0.891 . . . . 73.34 113.407 173.094 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 1.6 m-20 -58.31 -19.11 32.22 Favored 'General case' 0 N--CA 1.467 0.408 0 C-N-CA 123.847 0.859 . . . . 62.01 111.79 -175.215 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 104.35 19.92 10.9 Favored Glycine 0 N--CA 1.442 -0.951 0 N-CA-C 110.015 -1.234 . . . . 42.33 110.015 -170.604 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 5.3 t70 -71.69 90.01 1.04 Allowed 'General case' 0 N--CA 1.45 -0.434 0 N-CA-C 109.0 -0.741 . . . . 73.24 109.0 178.089 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.792 ' HB3' ' HB3' ' A' ' 17' ' ' PHE . 62.0 m-20 -63.37 104.32 0.6 Allowed 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 115.756 -0.656 . . . . 52.42 110.613 -179.553 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 59.3 t -74.48 132.36 33.49 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.598 0 CA-C-N 115.602 -0.726 . . . . 64.11 110.0 179.009 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 27' ' ' PHE . . . . . 0.493 ' O ' ' HA ' ' A' ' 59' ' ' GLN . 78.5 t80 -82.73 127.61 33.58 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 116.089 -0.505 . . . . 64.02 110.441 -177.261 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.545 ' HB ' ' HB3' ' A' ' 60' ' ' ALA . 14.2 p -131.35 147.64 32.8 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 CA-C-O 121.02 0.438 . . . . 63.32 111.647 -177.416 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 21.9 m170 -108.64 159.57 16.62 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.991 -0.549 . . . . 72.52 109.684 174.759 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 30' ' ' PHE . . . . . 0.676 ' CZ ' ' HA ' ' A' ' 11' ' ' ALA . 52.4 m-85 -71.95 -14.28 61.87 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-O 120.702 0.287 . . . . 62.15 111.309 -179.723 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 13.8 t -71.35 -22.13 61.94 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-O 121.337 0.589 . . . . 51.42 110.07 174.725 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -100.83 -22.53 14.81 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 115.846 -0.615 . . . . 73.32 110.487 179.387 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 70.6 mt -76.93 145.77 9.7 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 CA-C-N 115.883 -0.599 . . . . 75.31 109.452 174.521 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 34' ' ' GLN . . . . . 0.423 ' NE2' ' HG3' ' A' ' 65' ' ' LYS . 23.3 pt20 . . . . . 0 C--N 1.327 -0.412 0 CA-C-O 121.455 0.645 . . . . 62.15 110.626 177.373 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 42.1 m . . . . . 0 N--CA 1.454 -0.234 0 CA-C-O 120.887 0.375 . . . . 44.25 110.986 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 3.2 mm? -90.62 139.01 31.11 Favored 'General case' 0 C--N 1.324 -0.534 0 N-CA-C 109.228 -0.656 . . . . 73.43 109.228 175.021 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 30.9 t70 -90.23 146.76 24.0 Favored 'General case' 0 C--N 1.319 -0.729 0 C-N-CA 120.87 -0.332 . . . . 74.11 110.334 -178.792 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 37.4 mt-10 -70.97 102.01 2.31 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 116.319 -0.401 . . . . 63.13 109.932 178.293 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 123.03 1.19 9.59 Favored Glycine 0 N--CA 1.45 -0.433 0 CA-C-N 115.784 -0.644 . . . . 74.54 111.672 -173.272 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 52.1 tp60 -87.49 139.81 30.16 Favored 'General case' 0 N--CA 1.464 0.247 0 C-N-CA 122.247 0.219 . . . . 70.24 110.873 -179.734 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -90.54 131.68 36.13 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 121.084 0.469 . . . . 53.35 110.732 176.696 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 21.6 m -132.06 167.06 27.3 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 CA-C-N 116.062 -0.517 . . . . 72.13 110.782 -178.871 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 3.4 p -120.97 114.95 22.27 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-O 121.185 0.517 . . . . 62.24 110.211 179.312 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 38.8 p90 -134.78 166.1 23.74 Favored 'General case' 0 C--N 1.319 -0.76 0 CA-C-N 115.949 -0.568 . . . . 73.45 110.348 -173.802 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 39.1 t0 -106.84 121.62 44.77 Favored 'General case' 0 C--N 1.324 -0.538 0 C-N-CA 120.4 -0.52 . . . . 71.32 110.447 175.253 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 86.5 t -77.83 117.16 22.54 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.55 0 CA-C-O 120.986 0.422 . . . . 74.55 111.294 -178.842 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 52' ' ' GLU . . . . . 0.66 ' HB3' ' HG3' ' A' ' 59' ' ' GLN . 8.9 tp10 -94.12 116.79 29.25 Favored 'General case' 0 C--N 1.321 -0.652 0 N-CA-C 108.904 -0.776 . . . . 74.35 108.904 174.022 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 47.5 mt-10 -92.78 95.73 9.72 Favored 'General case' 0 C--N 1.319 -0.721 0 CA-C-O 121.128 0.49 . . . . 71.34 110.107 179.837 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -103.61 -143.49 12.76 Favored Glycine 0 N--CA 1.445 -0.701 0 CA-C-N 115.597 -0.729 . . . . 52.42 112.68 -176.629 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -86.42 -40.41 15.4 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 121.008 0.432 . . . . 62.35 110.723 -175.381 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 77.2 mtm180 -108.23 81.94 1.56 Allowed 'General case' 0 C--N 1.322 -0.614 0 CA-C-N 116.273 -0.421 . . . . 62.34 111.305 -176.262 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 68.9 -171.29 38.92 Favored Glycine 0 N--CA 1.448 -0.507 0 CA-C-N 115.619 -0.719 . . . . 63.53 112.93 178.22 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 87.3 Cg_endo -86.94 123.62 2.05 Favored 'Trans proline' 0 N--CA 1.453 -0.857 0 C-N-CA 122.829 2.353 . . . . 75.44 111.764 175.752 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . 0.66 ' HG3' ' HB3' ' A' ' 52' ' ' GLU . 3.6 pt20 -109.3 126.91 53.86 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-N 116.212 -0.449 . . . . 51.44 109.852 178.181 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . 0.545 ' HB3' ' HB ' ' A' ' 28' ' ' VAL . . . -79.42 117.58 20.52 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-O 120.837 0.351 . . . . 64.41 110.802 -178.771 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -110.87 128.62 55.86 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 116.013 -0.54 . . . . 63.13 109.816 178.524 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 49.4 m-80 63.78 96.38 0.04 OUTLIER 'General case' 0 C--O 1.235 0.312 0 O-C-N 123.577 0.548 . . . . 71.43 110.674 -176.521 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.472 HG21 HG21 ' A' ' 28' ' ' VAL . 48.8 t -110.66 107.15 22.21 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.474 0 CA-C-N 115.661 -0.699 . . . . 65.11 110.746 179.718 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 64' ' ' GLN . . . . . 0.404 ' HG2' ' N ' ' A' ' 65' ' ' LYS . 34.4 tt0 -102.09 168.35 9.44 Favored 'General case' 0 C--N 1.324 -0.542 0 N-CA-C 108.816 -0.809 . . . . 75.12 108.816 177.556 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . 0.423 ' HG3' ' NE2' ' A' ' 34' ' ' GLN . 55.3 mtmt -103.78 155.29 18.72 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-O 120.801 0.334 . . . . 74.44 110.658 -179.125 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.251 1.135 0 CA-C-O 118.656 -0.688 . . . . 71.3 109.79 177.691 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 1.8 pm0 . . . . . 0 C--O 1.239 0.514 0 CA-C-O 121.457 0.646 . . . . 51.4 110.822 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -119.13 162.73 18.14 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 115.002 -0.999 . . . . 72.31 110.073 -179.297 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -160.65 165.24 34.99 Favored Glycine 0 N--CA 1.442 -0.95 0 C-N-CA 120.889 -0.672 . . . . 72.35 111.72 178.072 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . 0.465 ' O ' ' HG2' ' A' ' 19' ' ' GLU . 28.2 m -100.48 137.87 38.3 Favored 'General case' 0 C--N 1.319 -0.726 0 N-CA-C 110.06 -0.348 . . . . 74.4 110.06 178.451 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 48.1 t -68.62 108.36 1.55 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 N-CA-C 109.793 -0.447 . . . . 64.02 109.793 175.783 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 7' ' ' LYS . . . . . 0.614 ' HA ' ' HE3' ' A' ' 7' ' ' LYS . 0.0 OUTLIER -75.2 -56.15 5.01 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-O 120.93 0.395 . . . . 73.35 110.426 178.313 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 8' ' ' TRP . . . . . . . . . . . . . 4.1 p90 -156.98 136.98 12.6 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 115.749 -0.66 . . . . 75.03 110.205 179.162 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 17.5 p90 -124.35 108.55 12.32 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-O 121.807 0.813 . . . . 74.41 110.157 178.515 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 41.2 t-20 -85.93 86.83 7.35 Favored 'General case' 0 C--N 1.318 -0.761 0 CA-C-O 121.477 0.656 . . . . 74.2 109.401 -178.778 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -57.77 -32.46 67.52 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 114.914 -1.039 . . . . 73.21 111.623 179.182 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 74.2 mm-40 -64.08 -31.25 72.38 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 120.857 0.36 . . . . 70.45 111.132 178.848 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' LYS . . . . . 0.458 ' HB3' ' CE2' ' A' ' 15' ' ' PHE . 0.1 OUTLIER -92.28 -17.77 24.3 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.894 -0.594 . . . . 73.41 110.746 179.047 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 86.77 19.24 56.75 Favored Glycine 0 N--CA 1.447 -0.585 0 C-N-CA 120.82 -0.705 . . . . 75.32 112.898 177.635 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . 0.458 ' CE2' ' HB3' ' A' ' 13' ' ' LYS . 31.0 p90 -157.78 156.66 31.94 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 121.133 0.492 . . . . 54.45 111.443 179.587 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -134.87 -179.24 16.31 Favored Glycine 0 N--CA 1.442 -0.906 0 N-CA-C 111.291 -0.724 . . . . 73.52 111.291 178.671 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . 0.421 ' HA ' ' O ' ' A' ' 26' ' ' VAL . 97.2 m-85 -132.35 127.65 35.98 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-O 121.305 0.574 . . . . 75.24 111.266 -179.538 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 63.4 mt -101.32 138.86 24.11 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.569 0 CA-C-N 115.209 -0.905 . . . . 73.51 109.344 177.864 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' GLU . . . . . 0.495 ' HB3' ' HG3' ' A' ' 7' ' ' LYS . 11.7 pt-20 -82.86 134.84 35.08 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-O 121.196 0.522 . . . . 73.34 111.303 -177.022 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' ARG . . . . . 0.754 ' HD2' ' H ' ' A' ' 21' ' ' GLU . 0.1 OUTLIER -113.22 -177.96 3.26 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 115.904 -0.589 . . . . 72.14 109.775 178.506 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . 0.754 ' H ' ' HD2' ' A' ' 20' ' ' ARG . 10.0 pt-20 -59.51 -37.18 77.64 Favored 'General case' 0 C--N 1.327 -0.387 0 N-CA-C 112.93 0.715 . . . . 72.45 112.93 -173.205 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 22' ' ' ASN . . . . . 0.422 ' ND2' ' HG3' ' A' ' 21' ' ' GLU . 29.3 m-80 -94.21 5.67 51.03 Favored 'General case' 0 C--N 1.328 -0.346 0 O-C-N 122.096 -0.377 . . . . 72.41 110.805 -178.306 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 84.97 20.02 58.39 Favored Glycine 0 N--CA 1.447 -0.584 0 N-CA-C 110.236 -1.145 . . . . 31.11 110.236 -170.509 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . 0.457 ' HB2' ' CB ' ' A' ' 20' ' ' ARG . 3.8 m-20 -67.15 95.02 0.38 Allowed 'General case' 0 N--CA 1.45 -0.448 0 CA-C-N 114.879 -0.66 . . . . 73.4 109.463 179.59 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 11.1 p-10 -63.65 100.81 0.3 Allowed 'General case' 0 C--N 1.32 -0.676 0 CA-C-O 121.833 0.825 . . . . 60.43 110.309 175.97 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.421 ' O ' ' HA ' ' A' ' 17' ' ' PHE . 44.9 t -78.38 120.76 29.91 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 CA-C-N 115.15 -0.932 . . . . 72.12 110.756 -177.273 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 27' ' ' PHE . . . . . . . . . . . . . 68.9 t80 -73.34 113.16 10.11 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 115.65 -0.705 . . . . 54.13 110.433 -179.092 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.434 ' HB ' ' HB3' ' A' ' 60' ' ' ALA . 10.4 p -117.26 126.59 74.64 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.575 0 CA-C-O 121.083 0.468 . . . . 73.01 110.24 176.068 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 29' ' ' HIS . . . . . 0.433 ' O ' HG13 ' A' ' 33' ' ' ILE . 41.2 t60 -103.46 149.74 24.54 Favored 'General case' 0 C--N 1.324 -0.529 0 N-CA-C 109.452 -0.573 . . . . 73.41 109.452 -176.754 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 30' ' ' PHE . . . . . 0.438 ' HA ' HD12 ' A' ' 33' ' ' ILE . 42.2 p90 -58.44 -27.29 64.22 Favored 'General case' 0 N--CA 1.467 0.403 0 CA-C-O 120.819 0.342 . . . . 74.32 111.607 -175.657 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 6.7 m -72.98 -14.13 61.38 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 116.409 -0.36 . . . . 74.51 111.283 179.005 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -106.88 -17.65 14.14 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.921 0.391 . . . . 63.21 111.058 -178.466 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.438 HD12 ' HA ' ' A' ' 30' ' ' PHE . 66.5 mt -71.22 144.82 13.06 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 CA-C-N 116.032 -0.531 . . . . 73.45 110.49 177.989 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 34' ' ' GLN . . . . . 0.47 ' HG3' ' O ' ' A' ' 34' ' ' GLN . 21.6 pt20 . . . . . 0 C--N 1.33 -0.263 0 N-CA-C 109.581 -0.526 . . . . 72.33 109.581 172.909 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 51.4 p . . . . . 0 N--CA 1.453 -0.319 0 N-CA-C 112.206 0.446 . . . . 74.13 112.206 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -88.77 103.64 16.16 Favored 'General case' 0 C--N 1.326 -0.439 0 N-CA-C 108.376 -0.972 . . . . 61.12 108.376 168.968 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 20.5 t70 -76.72 150.85 36.24 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 116.058 -0.519 . . . . 55.05 111.527 -169.718 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 83.6 mt-10 -61.59 112.82 2.38 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 115.629 -0.714 . . . . 72.24 110.552 -179.593 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 124.29 -12.87 7.96 Favored Glycine 0 N--CA 1.445 -0.758 0 C-N-CA 120.796 -0.716 . . . . 61.42 111.547 -177.203 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 6.5 tp-100 -80.06 143.15 34.25 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-O 120.857 0.36 . . . . 64.01 110.312 178.678 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -99.5 118.75 36.77 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 116.023 -0.535 . . . . 41.11 110.188 179.515 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 27.4 m -123.57 163.01 23.48 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.696 0 CA-C-N 116.227 -0.442 . . . . 70.11 111.11 -176.754 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 1.6 p -117.25 139.86 50.27 Favored 'General case' 0 C--N 1.321 -0.64 0 N-CA-C 108.91 -0.774 . . . . 74.31 108.91 176.548 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 33.5 p90 -141.24 159.18 42.76 Favored 'General case' 0 C--N 1.317 -0.823 0 C-N-CA 120.3 -0.56 . . . . 72.24 111.616 -175.26 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 4.9 t70 -88.14 103.16 15.49 Favored 'General case' 0 C--N 1.321 -0.657 0 N-CA-C 108.645 -0.872 . . . . 64.23 108.645 174.975 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 7.7 p -63.79 123.13 15.99 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 CA-C-O 121.295 0.569 . . . . 71.35 111.846 -173.09 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 52' ' ' GLU . . . . . 0.548 ' HB3' ' HG2' ' A' ' 59' ' ' GLN . 7.8 tp10 -117.52 139.86 50.38 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 115.648 -0.705 . . . . 63.41 110.067 178.997 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 10.8 tp10 -101.31 146.32 27.71 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-N 115.956 -0.565 . . . . 64.33 109.626 -179.701 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -144.83 -175.79 18.29 Favored Glycine 0 N--CA 1.45 -0.417 0 C-N-CA 120.709 -0.757 . . . . 40.03 112.527 -177.88 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 50.2 mt-30 -75.11 -34.15 61.67 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 120.755 0.312 . . . . 73.23 110.85 179.757 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 35.0 mtp-105 -77.1 -33.31 56.93 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-O 121.022 0.439 . . . . 74.21 110.436 174.39 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 146.87 -155.8 26.71 Favored Glycine 0 N--CA 1.448 -0.504 0 CA-C-N 115.904 -0.589 . . . . 31.05 111.798 -178.223 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 59.7 Cg_endo -74.26 137.13 23.07 Favored 'Trans proline' 0 C--O 1.234 0.298 0 C-N-CA 122.582 2.188 . . . . 73.55 112.775 -177.752 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . 0.548 ' HG2' ' HB3' ' A' ' 52' ' ' GLU . 0.0 OUTLIER -131.35 154.75 48.26 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 116.101 -0.499 . . . . 72.24 109.835 175.142 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . 0.434 ' HB3' ' HB ' ' A' ' 28' ' ' VAL . . . -101.77 106.53 17.54 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 116.294 -0.412 . . . . 55.04 110.993 -177.132 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -111.28 149.1 31.54 Favored 'General case' 0 C--N 1.321 -0.655 0 N-CA-C 109.263 -0.643 . . . . 33.32 109.263 175.082 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 86.5 m-20 57.06 82.79 0.11 Allowed 'General case' 0 N--CA 1.466 0.354 0 CA-C-O 121.304 0.573 . . . . 52.25 110.499 -178.459 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 46.4 t -103.54 134.48 44.61 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.588 0 CA-C-N 115.871 -0.604 . . . . 55.44 111.327 -174.985 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 28.0 mt-30 -130.71 178.2 6.82 Favored 'General case' 0 C--N 1.325 -0.484 0 N-CA-C 109.189 -0.671 . . . . 51.35 109.189 175.381 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . 0.437 ' HG3' HE22 ' A' ' 34' ' ' GLN . 50.7 mtmt -96.81 144.18 27.02 Favored 'General case' 0 C--N 1.323 -0.554 0 N-CA-C 110.028 -0.36 . . . . 74.45 110.028 178.074 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 0.98 0 CA-C-O 118.519 -0.753 . . . . 61.15 110.274 -179.922 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 N--CA 1.452 -0.335 0 N-CA-C 109.994 -0.373 . . . . 62.24 109.994 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 3' ' ' GLN . . . . . 0.455 ' HG2' HG22 ' A' ' 48' ' ' THR . 50.3 mt-30 -105.85 130.67 53.77 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-N 116.029 -0.532 . . . . 64.44 109.8 174.491 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -150.49 172.9 30.21 Favored Glycine 0 N--CA 1.443 -0.844 0 C-N-CA 120.794 -0.717 . . . . 61.22 111.683 178.571 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . 0.542 ' O ' ' HG2' ' A' ' 19' ' ' GLU . 24.3 m -122.65 135.76 54.69 Favored 'General case' 0 C--N 1.317 -0.829 0 N-CA-C 110.167 -0.309 . . . . 74.44 110.167 179.067 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 46.4 t -72.41 119.06 18.4 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.633 0 CA-C-N 116.741 -0.209 . . . . 72.13 110.524 -179.114 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 7' ' ' LYS . . . . . 0.572 ' CE ' ' HB3' ' A' ' 19' ' ' GLU . 97.7 mttt -66.01 -62.59 1.41 Allowed 'General case' 0 CA--C 1.52 -0.193 0 CA-C-O 121.7 0.762 . . . . 73.14 109.223 175.896 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 8' ' ' TRP . . . . . . . . . . . . . 55.1 p-90 -160.45 156.06 25.42 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-N 114.393 -1.276 . . . . 64.35 108.053 177.571 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . 0.412 ' CE2' ' HB2' ' A' ' 11' ' ' ALA . 2.1 p90 -136.03 138.52 42.28 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-O 121.603 0.716 . . . . 75.11 111.858 -174.113 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 10' ' ' ASN . . . . . 0.559 ' HB3' ' HG2' ' A' ' 13' ' ' LYS . 16.6 m120 -84.12 77.52 9.93 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 115.115 -0.948 . . . . 72.15 109.115 177.009 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . 0.412 ' HB2' ' CE2' ' A' ' 9' ' ' PHE . . . -54.12 -38.43 65.43 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.212 -0.904 . . . . 72.33 112.367 -175.07 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -90.75 -14.28 32.35 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 116.492 -0.322 . . . . 64.2 111.697 -175.288 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 13' ' ' LYS . . . . . 0.559 ' HG2' ' HB3' ' A' ' 10' ' ' ASN . 59.6 mmtt -90.55 -36.39 14.5 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 121.191 0.52 . . . . 72.31 109.649 177.017 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 99.59 32.88 5.54 Favored Glycine 0 N--CA 1.447 -0.619 0 CA-C-N 115.698 -0.683 . . . . 62.01 111.636 -177.676 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 74.0 m-85 -140.19 168.82 18.91 Favored 'General case' 0 C--N 1.329 -0.312 0 N-CA-C 110.152 -0.314 . . . . 72.11 110.152 -177.941 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -171.12 161.34 33.96 Favored Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.542 -0.837 . . . . 65.21 112.437 177.764 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 97.4 m-85 -123.93 120.21 31.86 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-O 121.033 0.444 . . . . 75.05 110.908 -179.847 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.4 HG21 ' CE2' ' A' ' 49' ' ' PHE . 54.0 mt -105.12 135.95 41.0 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.616 0 CA-C-N 115.869 -0.605 . . . . 74.25 109.74 178.981 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 19' ' ' GLU . . . . . 0.572 ' HB3' ' CE ' ' A' ' 7' ' ' LYS . 11.6 pt-20 -94.81 128.64 41.69 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 121.404 0.621 . . . . 73.44 111.654 -177.461 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 20' ' ' ARG . . . . . 0.48 ' HB3' ' HB3' ' A' ' 24' ' ' ASP . 18.6 ttt180 -89.67 177.13 6.61 Favored 'General case' 0 C--N 1.323 -0.548 0 N-CA-C 108.289 -1.004 . . . . 74.53 108.289 171.697 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 44.6 mt-10 -61.04 -12.05 10.41 Favored 'General case' 0 N--CA 1.467 0.409 0 N-CA-C 112.098 0.407 . . . . 73.33 112.098 -178.787 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 82.6 m-20 -98.05 -4.22 36.46 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.89 0.376 . . . . 73.43 111.239 177.826 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 82.42 3.17 90.64 Favored Glycine 0 N--CA 1.449 -0.461 0 N-CA-C 110.337 -1.105 . . . . 65.44 110.337 -168.657 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . 0.48 ' HB3' ' HB3' ' A' ' 20' ' ' ARG . 33.6 t70 -56.3 98.73 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 114.61 -0.795 . . . . 55.44 110.721 -179.062 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 12.4 m-20 -56.5 100.44 0.04 OUTLIER 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 114.964 -1.016 . . . . 73.2 111.698 174.999 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.506 HG12 ' HB2' ' A' ' 60' ' ' ALA . 21.4 t -83.1 116.6 27.55 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.743 0 N-CA-C 108.761 -0.829 . . . . 72.55 108.761 172.883 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 27' ' ' PHE . . . . . . . . . . . . . 81.1 t80 -83.22 116.15 22.26 Favored 'General case' 0 C--N 1.32 -0.682 0 CA-C-N 115.894 -0.594 . . . . 75.3 111.021 -173.414 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 9.0 p -105.73 148.91 9.61 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.581 0 N-CA-C 109.534 -0.543 . . . . 70.2 109.534 175.901 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 29' ' ' HIS . . . . . 0.447 ' O ' HG13 ' A' ' 33' ' ' ILE . 2.7 p80 -140.19 163.88 31.56 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 116.277 -0.419 . . . . 72.33 110.58 -174.173 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 31.3 p90 -53.18 -33.0 50.79 Favored 'General case' 0 N--CA 1.47 0.536 0 N-CA-C 112.871 0.693 . . . . 73.4 112.871 -174.001 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 27.5 m -84.92 34.23 0.54 Allowed 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 121.174 0.511 . . . . 72.44 110.906 176.866 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -160.57 -33.56 0.05 Allowed 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 115.826 -0.625 . . . . 63.54 110.729 -179.364 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.447 HG13 ' O ' ' A' ' 29' ' ' HIS . 71.7 mt -63.7 143.37 15.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.065 -0.516 . . . . 75.44 110.461 176.195 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 88.4 mt-30 . . . . . 0 C--N 1.329 -0.293 0 N-CA-C 109.792 -0.448 . . . . 75.32 109.792 172.117 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 15.2 m . . . . . 0 N--CA 1.454 -0.243 0 CA-C-O 120.947 0.403 . . . . 72.14 111.619 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 92.2 mt -82.16 74.35 9.15 Favored 'General case' 0 C--N 1.324 -0.51 0 N-CA-C 108.797 -0.816 . . . . 75.21 108.797 171.415 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 27.6 t70 -55.38 139.88 41.64 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 115.18 -0.918 . . . . 75.32 112.051 -172.467 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 7.8 pt-20 -64.66 129.72 40.87 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-N 115.428 -0.806 . . . . 71.24 110.582 179.121 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 97.15 -10.22 65.54 Favored Glycine 0 N--CA 1.45 -0.403 0 C-N-CA 120.871 -0.68 . . . . 34.42 112.036 -177.202 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 54.0 tp60 -81.78 135.35 35.47 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-O 120.767 0.318 . . . . 71.55 110.558 178.769 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -85.35 138.54 32.22 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 116.117 -0.492 . . . . 70.34 110.097 176.043 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 16.6 m -136.98 144.84 31.08 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.605 0 CA-C-N 116.348 -0.387 . . . . 73.14 111.25 -177.415 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 48' ' ' THR . . . . . 0.455 HG22 ' HG2' ' A' ' 3' ' ' GLN . 24.7 p -104.58 122.74 46.23 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-N 115.753 -0.658 . . . . 74.03 109.571 173.633 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 49' ' ' PHE . . . . . 0.48 ' HA ' ' O ' ' A' ' 62' ' ' ASN . 38.8 p90 -141.09 157.3 45.49 Favored 'General case' 0 C--N 1.32 -0.701 0 CA-C-O 120.701 0.286 . . . . 63.53 111.206 -172.403 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 30.2 m-20 -90.48 149.49 22.19 Favored 'General case' 0 C--N 1.321 -0.674 0 N-CA-C 109.684 -0.488 . . . . 71.44 109.684 172.357 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 5.4 p -110.44 117.14 54.16 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.628 0 CA-C-O 121.428 0.633 . . . . 71.24 111.549 -175.28 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 52' ' ' GLU . . . . . 0.653 ' HB2' ' HB2' ' A' ' 59' ' ' GLN . 6.9 mm-40 -94.76 133.43 38.46 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 115.432 -0.804 . . . . 73.54 109.476 174.456 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 8.5 pt-20 -82.04 97.82 8.33 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-O 121.354 0.597 . . . . 72.5 110.86 -179.33 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -90.02 151.84 21.89 Favored Glycine 0 N--CA 1.446 -0.685 0 C-N-CA 120.736 -0.745 . . . . 74.41 111.671 179.041 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 49.8 mt-30 -58.38 -25.96 62.65 Favored 'General case' 0 C--N 1.327 -0.375 0 N-CA-C 112.377 0.51 . . . . 71.44 112.377 -177.182 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 81.4 mtt180 -130.49 26.86 5.06 Favored 'General case' 0 C--N 1.327 -0.41 0 N-CA-C 111.716 0.265 . . . . 61.21 111.716 -177.217 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 150.22 153.32 6.06 Favored Glycine 0 N--CA 1.449 -0.441 0 C-N-CA 120.128 -1.034 . . . . 45.02 113.074 177.319 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 7.2 Cg_exo -72.59 124.42 9.8 Favored 'Trans proline' 0 N--CA 1.46 -0.478 0 C-N-CA 122.834 2.356 . . . . 74.0 111.475 177.449 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . 0.653 ' HB2' ' HB2' ' A' ' 52' ' ' GLU . 26.0 mt-30 -94.53 123.44 37.96 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-N 116.243 -0.435 . . . . 70.42 110.664 -179.029 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . 0.506 ' HB2' HG12 ' A' ' 26' ' ' VAL . . . -78.99 106.59 11.14 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 116.308 -0.405 . . . . 72.41 109.946 176.244 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -116.86 139.48 50.57 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 116.311 -0.404 . . . . 62.45 110.033 -179.928 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 62' ' ' ASN . . . . . 0.48 ' O ' ' HA ' ' A' ' 49' ' ' PHE . 76.8 m-20 60.31 92.26 0.05 OUTLIER 'General case' 0 C--O 1.236 0.358 0 O-C-N 123.595 0.56 . . . . 74.31 110.008 -176.116 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 40.7 t -114.3 136.59 50.35 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.547 0 CA-C-N 115.469 -0.787 . . . . 72.15 110.55 -175.16 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 64' ' ' GLN . . . . . 0.429 ' HB3' ' OG1' ' A' ' 48' ' ' THR . 31.0 tt0 -121.5 149.14 43.51 Favored 'General case' 0 C--N 1.319 -0.737 0 N-CA-C 109.624 -0.51 . . . . 64.3 109.624 176.403 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 48.4 mttp -91.49 123.83 35.2 Favored 'General case' 0 C--N 1.324 -0.502 0 N-CA-C 110.112 -0.329 . . . . 73.43 110.112 178.491 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.246 0.886 0 CA-C-O 118.602 -0.713 . . . . 75.12 110.647 -179.942 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 60.7 mm-40 . . . . . 0 C--O 1.238 0.471 0 CA-C-O 121.388 0.613 . . . . 75.21 111.837 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 35.3 tt0 -120.91 136.28 54.99 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-N 115.34 -0.845 . . . . 74.55 109.478 174.756 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -151.9 164.49 30.4 Favored Glycine 0 N--CA 1.444 -0.788 0 N-CA-C 111.368 -0.693 . . . . 64.31 111.368 179.027 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . 0.54 HG21 ' HE3' ' A' ' 7' ' ' LYS . 5.4 m -103.38 125.32 49.92 Favored 'General case' 0 C--N 1.318 -0.802 0 CA-C-N 116.984 0.392 . . . . 74.21 110.825 -178.623 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.488 HG22 HG12 ' A' ' 18' ' ' ILE . 46.1 t -81.52 90.47 1.94 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 N-CA-C 109.099 -0.704 . . . . 73.44 109.099 175.473 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 7' ' ' LYS . . . . . 0.54 ' HE3' HG21 ' A' ' 5' ' ' THR . 27.9 mmtp -78.02 -51.9 9.62 Favored 'General case' 0 C--N 1.323 -0.587 0 CA-C-N 115.818 -0.628 . . . . 61.0 111.584 -176.155 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 8' ' ' TRP . . . . . . . . . . . . . 8.8 p90 -133.12 122.25 23.81 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-O 121.41 0.624 . . . . 72.22 110.992 178.113 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 22.2 p90 -111.6 123.43 50.21 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-N 115.343 -0.844 . . . . 64.05 109.544 178.434 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 16.7 t-20 -88.39 76.18 8.34 Favored 'General case' 0 C--N 1.317 -0.806 0 CA-C-O 121.503 0.668 . . . . 61.44 109.893 -176.737 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -67.75 -7.93 31.39 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.241 -0.89 . . . . 73.53 110.442 178.438 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 27.3 mt-10 -70.45 -33.41 71.26 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 115.306 -0.861 . . . . 74.05 110.595 179.081 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 13' ' ' LYS . . . . . 0.423 ' HB2' ' CE1' ' A' ' 15' ' ' PHE . 74.3 mmtt -116.25 -29.66 6.18 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.235 -0.439 . . . . 52.34 111.296 -178.47 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . 0.618 ' HA2' ' CE2' ' A' ' 30' ' ' PHE . . . 117.52 24.83 3.33 Favored Glycine 0 N--CA 1.452 -0.265 0 C-N-CA 120.178 -1.011 . . . . 64.41 113.773 175.842 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . 0.423 ' CE1' ' HB2' ' A' ' 13' ' ' LYS . 54.9 p90 -142.1 -174.11 4.01 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 116.921 0.361 . . . . 75.52 110.124 179.334 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -169.65 170.39 42.68 Favored Glycine 0 N--CA 1.449 -0.454 0 C-N-CA 120.358 -0.925 . . . . 53.03 112.147 177.713 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 98.2 m-85 -120.17 126.59 51.04 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 121.054 0.454 . . . . 75.53 110.81 -179.728 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.488 HG12 HG22 ' A' ' 6' ' ' VAL . 62.9 mt -110.81 129.21 66.42 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.572 0 CA-C-N 115.777 -0.647 . . . . 64.14 110.179 179.724 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 7.0 pt-20 -79.71 113.26 17.73 Favored 'General case' 0 C--N 1.326 -0.436 0 N-CA-C 109.665 -0.494 . . . . 63.1 109.665 175.673 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 20' ' ' ARG . . . . . 0.409 ' HD3' ' OD2' ' A' ' 24' ' ' ASP . 73.0 ttt-85 -113.02 111.15 21.68 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 116.06 -0.518 . . . . 71.34 111.332 -175.604 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 10.7 mm-40 47.3 -89.6 0.01 OUTLIER 'General case' 0 N--CA 1.47 0.537 0 N-CA-C 114.158 1.17 . . . . 74.25 114.158 169.725 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 23.6 t-20 -70.51 -31.38 68.44 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 121.12 0.486 . . . . 53.41 111.27 -174.018 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 130.51 -1.67 5.66 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.728 -0.748 . . . . 62.44 111.255 -176.405 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . 0.409 ' OD2' ' HD3' ' A' ' 20' ' ' ARG . 2.6 p-10 -67.92 94.35 0.47 Allowed 'General case' 0 C--N 1.323 -0.565 0 CA-C-O 121.355 0.597 . . . . 61.34 110.185 175.937 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 5.7 p-10 -57.02 123.58 15.68 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 114.989 -1.005 . . . . 75.2 110.751 176.938 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 46.4 t -97.22 135.05 32.77 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.658 0 CA-C-N 115.614 -0.721 . . . . 72.22 110.326 -179.764 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 27' ' ' PHE . . . . . . . . . . . . . 32.5 t80 -80.77 105.58 12.12 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 116.142 -0.481 . . . . 72.35 110.161 -179.188 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.403 HG23 HG21 ' A' ' 63' ' ' VAL . 9.9 p -99.74 158.87 3.7 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.516 0 N-CA-C 110.011 -0.366 . . . . 65.44 110.011 179.522 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 1.1 p80 -147.89 159.49 43.8 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.534 -0.303 . . . . 71.52 110.29 -178.414 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 30' ' ' PHE . . . . . 0.618 ' CE2' ' HA2' ' A' ' 14' ' ' GLY . 23.0 m-85 -56.82 -37.14 70.8 Favored 'General case' 0 N--CA 1.468 0.443 0 N-CA-C 112.76 0.652 . . . . 72.4 112.76 -173.767 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 12.7 t -70.97 -3.31 18.75 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 120.893 0.377 . . . . 42.45 111.269 -178.157 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . 0.427 ' HB1' HG23 ' A' ' 63' ' ' VAL . . . -107.08 -34.13 7.25 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.75 0.31 . . . . 61.45 110.668 177.015 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.511 ' HA ' ' HB ' ' A' ' 63' ' ' VAL . 61.2 mt -65.17 140.27 20.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.109 -0.496 . . . . 72.22 110.708 179.041 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 11.3 pt20 . . . . . 0 CA--C 1.537 0.443 0 N-CA-C 112.359 0.503 . . . . 55.12 112.359 -177.488 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 18.6 m . . . . . 0 N--CA 1.451 -0.409 0 CA-C-O 120.682 0.277 . . . . 74.22 110.457 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . 0.431 HD22 ' HA ' ' A' ' 41' ' ' LEU . 1.9 tm? -62.85 125.87 25.42 Favored 'General case' 0 C--N 1.326 -0.433 0 N-CA-C 109.078 -0.712 . . . . 63.22 109.078 178.374 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 18.1 m-20 -60.16 119.76 8.47 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 116.245 -0.434 . . . . 74.2 110.974 -176.627 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 8.2 pt-20 -67.18 119.5 12.2 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-O 121.34 0.59 . . . . 64.54 110.145 177.616 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 112.49 -4.61 26.43 Favored Glycine 0 N--CA 1.445 -0.713 0 N-CA-C 111.179 -0.768 . . . . 51.15 111.179 -174.532 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 5.8 tp-100 -72.67 132.91 44.31 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 120.874 0.369 . . . . 75.25 110.946 179.73 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -86.08 115.07 23.44 Favored 'General case' 0 C--N 1.325 -0.465 0 N-CA-C 108.89 -0.781 . . . . 44.13 108.89 173.073 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 0.51 ' HA ' ' HA ' ' A' ' 65' ' ' LYS . 29.3 m -110.27 155.29 11.6 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.811 0 CA-C-O 121.316 0.579 . . . . 51.43 111.51 -174.945 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 48' ' ' THR . . . . . 0.5 HG23 ' HB2' ' A' ' 66' ' ' ALA . 45.4 p -121.15 112.31 18.52 Favored 'General case' 0 C--N 1.318 -0.773 0 CA-C-N 115.322 -0.854 . . . . 73.15 108.832 175.376 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 49' ' ' PHE . . . . . 0.407 ' HA ' ' O ' ' A' ' 62' ' ' ASN . 35.4 p90 -127.07 171.98 10.9 Favored 'General case' 0 C--N 1.319 -0.748 0 CA-C-N 115.95 -0.568 . . . . 71.13 111.323 -170.969 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 62.9 m-20 -96.12 138.43 33.75 Favored 'General case' 0 C--N 1.322 -0.598 0 N-CA-C 109.065 -0.717 . . . . 73.45 109.065 169.935 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 12.5 p -102.31 134.67 42.39 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.721 0 CA-C-O 121.008 0.432 . . . . 63.2 111.27 -174.767 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 40.1 mt-10 -122.35 148.81 44.6 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 116.066 -0.515 . . . . 73.44 110.24 175.889 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 36.5 mt-10 -106.07 123.41 47.96 Favored 'General case' 0 C--N 1.319 -0.736 0 N-CA-C 109.61 -0.515 . . . . 71.33 109.61 177.401 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -118.46 -178.99 17.06 Favored Glycine 0 N--CA 1.445 -0.74 0 C-N-CA 120.669 -0.777 . . . . 74.54 112.287 -178.512 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -67.64 -29.45 68.76 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 120.772 0.32 . . . . 73.25 111.548 -179.755 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 22.0 ttt180 -85.03 -27.62 26.27 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.184 -0.462 . . . . 73.03 110.448 179.455 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 148.73 -164.87 29.16 Favored Glycine 0 N--CA 1.446 -0.645 0 C-N-CA 120.893 -0.67 . . . . 71.14 111.864 -179.282 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 56.4 Cg_endo -72.41 126.85 11.97 Favored 'Trans proline' 0 N--CA 1.463 -0.288 0 C-N-CA 122.702 2.268 . . . . 52.13 112.388 179.595 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 11.5 pt20 -123.72 154.33 39.61 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-N 115.851 -0.613 . . . . 72.51 110.152 -179.974 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -99.57 135.25 41.27 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 116.383 -0.371 . . . . 44.42 111.168 -177.958 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -131.97 149.63 52.38 Favored 'General case' 0 C--N 1.324 -0.529 0 N-CA-C 108.829 -0.804 . . . . 71.42 108.829 174.461 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 62' ' ' ASN . . . . . 0.407 ' O ' ' HA ' ' A' ' 49' ' ' PHE . 55.5 m-20 53.57 75.57 0.26 Allowed 'General case' 0 C--O 1.239 0.504 0 N-CA-C 110.028 -0.36 . . . . 73.12 110.028 -174.999 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.511 ' HB ' ' HA ' ' A' ' 33' ' ' ILE . 59.4 t -101.9 101.99 12.89 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.517 0 CA-C-O 121.171 0.51 . . . . 73.52 110.947 -176.191 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 50.8 mt-30 -107.48 170.27 8.07 Favored 'General case' 0 C--N 1.32 -0.707 0 N-CA-C 108.593 -0.892 . . . . 74.33 108.593 175.791 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . 0.51 ' HA ' ' HA ' ' A' ' 47' ' ' VAL . 21.9 pttp -93.58 169.1 10.59 Favored 'General case' 0 C--N 1.321 -0.66 0 C-N-CA 120.477 -0.489 . . . . 70.14 110.277 179.658 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 66' ' ' ALA . . . . . 0.5 ' HB2' HG23 ' A' ' 48' ' ' THR . . . . . . . . 0 C--O 1.246 0.907 0 CA-C-O 118.275 -0.869 . . . . 52.24 109.96 176.241 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 6.9 mp0 . . . . . 0 N--CA 1.451 -0.382 0 CA-C-O 120.656 0.265 . . . . 65.41 110.572 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 27.0 tt0 -90.34 98.94 12.07 Favored 'General case' 0 C--N 1.322 -0.614 0 N-CA-C 109.085 -0.709 . . . . 73.5 109.085 174.567 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -120.91 163.42 14.41 Favored Glycine 0 N--CA 1.446 -0.667 0 C-N-CA 120.575 -0.821 . . . . 75.4 112.668 -174.591 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . 0.461 ' O ' ' HG2' ' A' ' 19' ' ' GLU . 0.2 OUTLIER -105.23 129.53 53.58 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-O 121.028 0.442 . . . . 74.1 110.969 179.826 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.552 ' HA ' ' HA ' ' A' ' 18' ' ' ILE . 17.0 t -71.06 121.66 21.44 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.582 0 CA-C-N 116.08 -0.509 . . . . 61.42 110.451 179.684 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 50.5 mttp -74.33 -49.48 22.7 Favored 'General case' 0 C--N 1.329 -0.302 0 C-N-CA 120.719 -0.392 . . . . 54.44 110.433 177.677 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 8' ' ' TRP . . . . . . . . . . . . . 14.9 p-90 -161.99 163.74 28.74 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.91 -0.586 . . . . 74.51 109.671 179.469 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 10.9 p90 -145.02 121.1 10.75 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-O 121.31 0.576 . . . . 71.43 111.098 -178.131 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 52.2 t-20 -82.73 86.43 6.88 Favored 'General case' 0 C--N 1.321 -0.631 0 N-CA-C 109.267 -0.642 . . . . 61.41 109.267 177.226 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -72.84 -5.33 37.47 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.303 -0.862 . . . . 64.35 111.748 -179.644 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 9.8 mm-40 -86.25 -19.4 30.01 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-O 120.977 0.418 . . . . 63.32 110.253 177.355 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 43.4 mmtm -108.76 -48.04 3.37 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 115.945 -0.571 . . . . 65.34 110.047 176.71 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 115.76 43.83 0.67 Allowed Glycine 0 N--CA 1.442 -0.929 0 C-N-CA 120.765 -0.731 . . . . 63.13 112.174 -179.134 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 43.8 p90 -152.03 161.29 42.87 Favored 'General case' 0 C--N 1.328 -0.349 0 N-CA-C 110.183 -0.302 . . . . 74.22 110.183 176.926 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -154.02 171.1 32.66 Favored Glycine 0 N--CA 1.448 -0.548 0 C-N-CA 120.877 -0.678 . . . . 74.11 112.166 179.88 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 80.9 m-85 -124.04 116.78 23.36 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-O 121.049 0.452 . . . . 75.11 110.75 179.591 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.552 ' HA ' ' HA ' ' A' ' 6' ' ' VAL . 11.3 mt -109.94 123.02 65.48 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.524 0 N-CA-C 108.715 -0.846 . . . . 75.52 108.715 178.63 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 19' ' ' GLU . . . . . 0.5 ' HA ' ' HA ' ' A' ' 25' ' ' ASP . 16.7 pt-20 -76.15 138.43 40.71 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-O 121.404 0.621 . . . . 73.33 112.092 -170.549 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 20' ' ' ARG . . . . . 0.602 ' HB3' ' HB3' ' A' ' 24' ' ' ASP . 78.1 ttt180 -91.73 161.33 14.93 Favored 'General case' 0 C--N 1.321 -0.659 0 N-CA-C 108.51 -0.922 . . . . 62.44 108.51 171.126 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . 0.506 ' OE1' ' HG2' ' A' ' 20' ' ' ARG . 0.0 OUTLIER -71.1 6.45 1.62 Allowed 'General case' 0 CA--C 1.537 0.455 0 N-CA-C 112.745 0.646 . . . . 71.03 112.745 -173.559 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 9.4 m-80 -108.63 5.29 24.82 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-O 120.792 0.33 . . . . 73.41 110.895 175.31 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 84.88 0.86 89.07 Favored Glycine 0 N--CA 1.453 -0.227 0 N-CA-C 110.572 -1.011 . . . . 54.4 110.572 -172.89 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . 0.602 ' HB3' ' HB3' ' A' ' 20' ' ' ARG . 31.5 t70 -76.07 87.49 2.97 Favored 'General case' 0 C--N 1.321 -0.669 0 CA-C-N 114.631 -0.784 . . . . 53.43 109.946 -178.859 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.5 ' HA ' ' HA ' ' A' ' 19' ' ' GLU . 55.9 m-20 -64.5 110.69 2.39 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 116.02 -0.537 . . . . 54.5 110.647 179.121 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.442 HG13 ' HB2' ' A' ' 58' ' ' PRO . 28.2 t -85.2 130.01 36.88 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.492 0 CA-C-N 115.639 -0.709 . . . . 54.23 110.977 -175.281 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 27' ' ' PHE . . . . . . . . . . . . . 85.3 t80 -84.87 122.84 29.75 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.745 -0.661 . . . . 74.2 110.816 -178.48 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.568 ' HB ' ' HB3' ' A' ' 60' ' ' ALA . 12.3 p -120.47 145.62 26.58 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.574 0 CA-C-N 116.591 -0.277 . . . . 61.43 110.276 178.249 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 29' ' ' HIS . . . . . 0.478 ' O ' HG13 ' A' ' 33' ' ' ILE . 2.0 t-160 -111.7 157.44 20.48 Favored 'General case' 0 C--N 1.327 -0.381 0 N-CA-C 109.432 -0.581 . . . . 63.12 109.432 -179.706 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 33.6 p90 -51.57 -40.18 59.28 Favored 'General case' 0 N--CA 1.471 0.582 0 N-CA-C 113.367 0.877 . . . . 73.32 113.367 -170.471 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 29.5 t -83.6 -6.95 59.58 Favored 'General case' 0 C--N 1.33 -0.282 0 C-N-CA 120.691 -0.404 . . . . 61.14 111.262 -176.056 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -93.67 -20.22 20.37 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-O 121.43 0.634 . . . . 50.34 109.457 174.791 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.478 HG13 ' O ' ' A' ' 29' ' ' HIS . 52.0 mt -75.53 154.28 6.2 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.408 0 CA-C-N 114.979 -1.01 . . . . 74.33 109.335 174.782 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 34' ' ' GLN . . . . . 0.405 ' HB3' ' O ' ' A' ' 63' ' ' VAL . 3.8 pt20 . . . . . 0 C--N 1.321 -0.633 0 CA-C-O 121.052 0.453 . . . . 63.44 110.728 179.299 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 18.4 p . . . . . 0 N--CA 1.448 -0.561 0 N-CA-C 109.961 -0.385 . . . . 73.44 109.961 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 3.8 mm? -81.02 126.83 31.89 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 116.289 -0.414 . . . . 74.23 110.365 -179.503 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 42' ' ' ASP . . . . . 0.802 ' HB2' ' HB2' ' A' ' 45' ' ' GLN . 5.4 m-20 -65.11 143.93 57.57 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.801 -0.636 . . . . 74.31 110.18 178.98 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . 0.426 ' H ' ' HG3' ' A' ' 43' ' ' GLU . 0.1 OUTLIER -80.01 90.69 5.4 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-O 122.528 1.156 . . . . 70.13 109.332 174.737 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 130.65 0.5 5.29 Favored Glycine 0 N--CA 1.445 -0.713 0 CA-C-N 114.007 -1.451 . . . . 63.12 110.539 -169.148 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 45' ' ' GLN . . . . . 0.802 ' HB2' ' HB2' ' A' ' 42' ' ' ASP . 6.7 tp-100 -78.07 140.78 39.11 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.381 -0.41 . . . . 75.53 110.291 177.828 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -101.98 120.56 40.61 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 116.207 -0.451 . . . . 51.34 110.533 179.442 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 17.8 m -132.94 158.78 43.37 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.564 0 CA-C-N 116.181 -0.463 . . . . 74.24 110.72 -179.134 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 48' ' ' THR . . . . . 0.603 HG23 ' HB2' ' A' ' 66' ' ' ALA . 37.1 p -103.16 99.64 9.52 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 121.33 0.586 . . . . 64.41 110.876 -178.681 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 49' ' ' PHE . . . . . 0.428 ' HA ' ' O ' ' A' ' 62' ' ' ASN . 42.0 p90 -105.62 167.6 9.65 Favored 'General case' 0 C--N 1.315 -0.911 0 CA-C-N 115.635 -0.711 . . . . 74.22 109.732 -179.796 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 4.6 t70 -117.34 111.8 19.86 Favored 'General case' 0 C--N 1.319 -0.731 0 C-N-CA 120.197 -0.601 . . . . 72.33 110.351 172.703 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 9.1 p -69.15 125.67 27.58 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-O 121.707 0.765 . . . . 74.02 112.275 -176.407 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 6.4 mm-40 -102.69 134.14 46.56 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-N 115.314 -0.857 . . . . 62.33 108.995 172.467 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 15.4 pt-20 -87.77 127.03 35.32 Favored 'General case' 0 C--N 1.32 -0.709 0 C-N-CA 120.447 -0.501 . . . . 62.25 110.047 177.499 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -153.53 -158.39 8.56 Favored Glycine 0 N--CA 1.447 -0.625 0 C-N-CA 120.224 -0.989 . . . . 63.15 113.007 -178.42 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 39.8 mt-30 -66.28 -24.53 66.58 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.865 0.364 . . . . 63.44 111.276 -175.85 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -93.89 9.36 37.67 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 116.283 -0.417 . . . . 41.45 110.46 179.158 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 81.34 -115.92 4.11 Favored Glycine 0 N--CA 1.444 -0.791 0 N-CA-C 110.754 -0.939 . . . . 63.25 110.754 -174.504 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . 0.442 ' HB2' HG13 ' A' ' 26' ' ' VAL . 89.3 Cg_endo -81.53 109.01 2.0 Favored 'Trans proline' 0 N--CA 1.455 -0.749 0 C-N-CA 122.482 2.121 . . . . 74.34 112.005 175.217 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 51.1 tt0 -115.51 118.17 32.42 Favored 'General case' 0 C--N 1.322 -0.594 0 N-CA-C 109.455 -0.572 . . . . 75.02 109.455 176.947 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . 0.568 ' HB3' ' HB ' ' A' ' 28' ' ' VAL . . . -78.67 123.94 27.67 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-O 121.004 0.431 . . . . 64.42 111.818 -173.029 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -124.75 145.7 49.58 Favored 'General case' 0 C--N 1.321 -0.667 0 N-CA-C 109.14 -0.689 . . . . 63.33 109.14 173.325 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 62' ' ' ASN . . . . . 0.428 ' O ' ' HA ' ' A' ' 49' ' ' PHE . 47.3 m-80 60.61 87.83 0.09 Allowed 'General case' 0 C--O 1.236 0.394 0 CA-C-O 121.321 0.581 . . . . 73.51 110.704 -175.57 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.405 ' O ' ' HB3' ' A' ' 34' ' ' GLN . 58.0 t -100.29 106.72 19.7 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.547 0 CA-C-N 115.443 -0.799 . . . . 63.14 109.407 176.132 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 48.7 mt-30 -103.98 160.38 14.87 Favored 'General case' 0 C--N 1.319 -0.741 0 CA-C-N 116.086 -0.507 . . . . 75.13 110.665 -177.191 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 9.7 mtpm? -77.07 136.43 38.66 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 115.928 -0.578 . . . . 72.11 109.731 176.481 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 66' ' ' ALA . . . . . 0.603 ' HB2' HG23 ' A' ' 48' ' ' THR . . . . . . . . 0 C--O 1.248 1.006 0 CA-C-O 118.666 -0.683 . . . . 42.25 110.19 -179.505 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 4.5 mm-40 . . . . . 0 C--O 1.236 0.38 0 CA-C-O 121.484 0.659 . . . . 74.13 111.299 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 24.1 tt0 -86.57 125.16 33.6 Favored 'General case' 0 N--CA 1.448 -0.528 0 CA-C-N 115.077 -0.965 . . . . 74.13 110.067 177.633 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -136.52 150.4 20.49 Favored Glycine 0 N--CA 1.442 -0.936 0 N-CA-C 111.311 -0.716 . . . . 74.12 111.311 176.435 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . 0.435 ' O ' ' HG2' ' A' ' 19' ' ' GLU . 0.7 OUTLIER -98.13 130.39 44.9 Favored 'General case' 0 C--N 1.319 -0.758 0 CA-C-O 120.672 0.272 . . . . 71.1 110.672 177.763 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 47.3 t -65.54 122.23 16.09 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.491 0 N-CA-C 109.857 -0.423 . . . . 51.23 109.857 176.547 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 7' ' ' LYS . . . . . 0.41 ' HG2' ' OE1' ' A' ' 19' ' ' GLU . 27.6 mtpp -78.33 -60.81 2.22 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 121.209 0.528 . . . . 73.12 109.604 179.788 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 8' ' ' TRP . . . . . . . . . . . . . 19.0 p90 -152.07 156.4 39.84 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 115.465 -0.789 . . . . 65.45 109.214 175.79 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 17.9 p90 -127.09 112.57 15.34 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-O 121.607 0.718 . . . . 65.22 111.055 -174.931 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 77.8 m-20 -86.67 73.5 10.02 Favored 'General case' 0 C--N 1.32 -0.696 0 CA-C-N 115.682 -0.69 . . . . 71.53 109.608 179.537 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -61.58 -25.52 67.38 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 115.553 -0.749 . . . . 72.32 111.118 -177.981 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 26.6 mt-10 -58.82 -36.87 75.23 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.531 -0.758 . . . . 74.42 110.864 179.287 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 28.2 mmtp -104.92 -18.33 14.23 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 116.024 -0.534 . . . . 71.33 111.007 -177.967 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 95.87 28.76 9.13 Favored Glycine 0 N--CA 1.449 -0.5 0 C-N-CA 120.748 -0.739 . . . . 73.12 113.491 174.399 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 50.2 p90 -150.69 156.4 41.25 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 117.155 0.478 . . . . 65.32 110.65 177.451 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -137.43 176.86 20.29 Favored Glycine 0 N--CA 1.447 -0.615 0 C-N-CA 121.075 -0.583 . . . . 54.11 111.736 178.64 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 75.8 m-85 -126.26 127.5 45.72 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 121.273 0.559 . . . . 73.34 110.948 179.54 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.412 ' HB ' ' HB ' ' A' ' 26' ' ' VAL . 64.3 mt -110.18 143.68 19.74 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.618 0 CA-C-N 115.408 -0.815 . . . . 73.53 109.845 179.191 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 19' ' ' GLU . . . . . 0.435 ' HG2' ' O ' ' A' ' 5' ' ' THR . 7.6 pt-20 -96.63 108.8 21.47 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 121.573 0.701 . . . . 75.44 110.649 177.213 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 20' ' ' ARG . . . . . 0.423 ' HG2' ' N ' ' A' ' 21' ' ' GLU . 61.3 ttt180 -97.0 162.87 13.2 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 114.954 -1.021 . . . . 65.45 110.123 -176.749 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . 0.423 ' N ' ' HG2' ' A' ' 20' ' ' ARG . 19.2 mm-40 -51.88 -41.65 62.07 Favored 'General case' 0 CA--C 1.531 0.241 0 CA-C-O 121.156 0.503 . . . . 74.13 111.002 176.618 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 15.3 m120 -111.09 26.34 10.8 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.983 -0.553 . . . . 62.55 111.761 -175.257 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 179.14 111.81 0.32 Allowed Glycine 0 C--O 1.225 -0.415 0 C-N-CA 119.86 -1.162 . . . . 44.45 113.084 -179.888 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 31.8 t70 -74.53 6.4 3.82 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-O 121.472 0.653 . . . . 61.34 111.05 -176.294 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 10.4 p-10 -152.04 93.21 1.8 Allowed 'General case' 0 C--N 1.324 -0.539 0 CA-C-O 121.882 0.849 . . . . 72.54 111.096 -178.768 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.412 ' HB ' ' HB ' ' A' ' 18' ' ' ILE . 89.0 t -102.59 121.18 53.38 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 CA-C-N 115.042 -0.981 . . . . 71.22 109.784 175.216 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 27' ' ' PHE . . . . . 0.485 ' O ' ' HA ' ' A' ' 59' ' ' GLN . 78.1 t80 -78.6 120.37 23.19 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 116.024 -0.534 . . . . 73.01 110.535 -178.558 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.485 ' HB ' ' HB3' ' A' ' 60' ' ' ALA . 8.7 p -128.7 136.05 60.82 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.728 0 CA-C-O 120.964 0.412 . . . . 74.41 111.277 179.516 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 29' ' ' HIS . . . . . 0.483 ' O ' HG13 ' A' ' 33' ' ' ILE . 3.2 m-70 -96.99 142.92 28.36 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 116.14 -0.482 . . . . 73.4 110.024 175.307 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 30' ' ' PHE . . . . . 0.436 ' HE2' ' HB3' ' A' ' 40' ' ' SER . 17.7 m-85 -62.28 -28.59 69.83 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-O 120.704 0.287 . . . . 73.41 111.216 -179.545 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 16.5 t -74.92 -12.44 60.35 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 121.0 0.429 . . . . 73.11 110.877 177.897 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . 0.476 ' HB1' ' HA ' ' A' ' 61' ' ' ALA . . . -97.67 -24.26 15.58 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 121.095 0.474 . . . . 52.43 110.464 178.858 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.501 HG23 ' HB ' ' A' ' 63' ' ' VAL . 31.8 mt -68.61 163.48 3.15 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.4 0 CA-C-N 115.86 -0.609 . . . . 75.55 109.936 176.233 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 34' ' ' GLN . . . . . 0.472 ' NE2' ' H ' ' A' ' 65' ' ' LYS . 24.9 pt20 . . . . . 0 N--CA 1.466 0.358 0 CA-C-O 120.73 0.3 . . . . 64.22 111.703 179.426 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . 0.436 ' HB3' ' HE2' ' A' ' 30' ' ' PHE . 13.8 p . . . . . 0 C--O 1.234 0.282 0 CA-C-O 121.036 0.446 . . . . 71.24 111.751 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . 0.542 HD12 ' HG2' ' A' ' 45' ' ' GLN . 4.4 mm? -103.33 145.28 30.21 Favored 'General case' 0 C--N 1.325 -0.488 0 N-CA-C 109.397 -0.594 . . . . 73.35 109.397 174.858 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 6.5 m-20 -76.08 156.87 33.5 Favored 'General case' 0 C--N 1.32 -0.691 0 CA-C-N 116.112 -0.495 . . . . 62.01 111.29 -174.752 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 6.3 pt-20 -68.01 133.21 48.66 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-N 116.051 -0.522 . . . . 62.42 109.962 175.648 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 87.02 0.23 85.65 Favored Glycine 0 N--CA 1.446 -0.676 0 C-N-CA 120.558 -0.83 . . . . 73.31 112.146 -177.246 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 45' ' ' GLN . . . . . 0.542 ' HG2' HD12 ' A' ' 41' ' ' LEU . 24.3 tp60 -74.72 115.96 14.89 Favored 'General case' 0 C--N 1.328 -0.368 0 N-CA-C 109.637 -0.505 . . . . 73.44 109.637 176.9 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -74.84 116.07 15.14 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 116.049 -0.523 . . . . 64.43 110.125 177.14 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 0.505 HG12 ' HA ' ' A' ' 65' ' ' LYS . 27.5 m -122.13 150.15 25.58 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.737 0 CA-C-N 116.068 -0.515 . . . . 63.22 110.751 -179.44 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 59.0 p -106.9 119.01 38.19 Favored 'General case' 0 C--N 1.318 -0.777 0 N-CA-C 108.928 -0.767 . . . . 73.42 108.928 175.062 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 29.8 p90 -127.99 151.34 49.25 Favored 'General case' 0 C--N 1.319 -0.74 0 CA-C-O 120.932 0.396 . . . . 70.11 111.745 -172.135 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 17.8 t70 -82.66 120.4 25.52 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.809 -0.632 . . . . 62.54 109.306 174.397 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 49.6 t -83.33 115.94 26.56 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.63 0 CA-C-N 116.063 -0.517 . . . . 43.43 111.622 -174.044 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 34.6 tt0 -108.82 104.74 14.07 Favored 'General case' 0 C--N 1.323 -0.585 0 N-CA-C 109.471 -0.566 . . . . 75.44 109.471 174.417 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 5.9 pt-20 -90.98 108.19 19.69 Favored 'General case' 0 C--N 1.318 -0.785 0 CA-C-O 121.363 0.602 . . . . 72.44 110.639 -179.42 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -118.85 -171.4 15.03 Favored Glycine 0 N--CA 1.445 -0.72 0 CA-C-N 115.428 -0.805 . . . . 63.32 111.888 -178.856 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 10.7 mm100 -78.62 77.9 5.09 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 121.33 0.586 . . . . 62.01 110.621 -177.573 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 4.6 ptp85 170.75 -26.49 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 114.534 -1.212 . . . . 62.44 108.973 -178.954 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 139.32 -170.23 24.21 Favored Glycine 0 N--CA 1.443 -0.857 0 N-CA-C 110.812 -0.915 . . . . 71.23 110.812 -179.673 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 72.3 Cg_endo -78.56 111.44 3.0 Favored 'Trans proline' 0 N--CA 1.455 -0.742 0 C-N-CA 122.077 1.851 . . . . 70.5 111.77 177.264 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . 0.485 ' HA ' ' O ' ' A' ' 27' ' ' PHE . 15.0 pt20 -104.34 135.77 45.17 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-O 121.137 0.494 . . . . 71.15 109.881 176.009 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . 0.485 ' HB3' ' HB ' ' A' ' 28' ' ' VAL . . . -90.09 123.5 34.0 Favored 'General case' 0 C--N 1.321 -0.669 0 CA-C-N 115.879 -0.6 . . . . 53.4 111.457 -173.995 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 61' ' ' ALA . . . . . 0.476 ' HA ' ' HB1' ' A' ' 32' ' ' ALA . . . -124.09 150.5 44.95 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-N 115.463 -0.79 . . . . 63.32 108.878 175.373 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 30.8 m-80 56.45 74.06 0.41 Allowed 'General case' 0 C--N 1.329 -0.301 0 N-CA-C 109.313 -0.625 . . . . 72.31 109.313 -176.155 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.501 ' HB ' HG23 ' A' ' 33' ' ' ILE . 40.5 t -105.37 103.5 15.46 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.599 0 CA-C-N 115.786 -0.643 . . . . 71.43 110.858 -175.304 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 23.1 mt-30 -111.64 129.96 55.92 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 116.193 -0.458 . . . . 72.24 109.774 179.29 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . 0.505 ' HA ' HG12 ' A' ' 47' ' ' VAL . 18.2 pttp -62.75 153.51 32.5 Favored 'General case' 0 C--N 1.327 -0.386 0 N-CA-C 110.294 -0.261 . . . . 73.23 110.294 -178.495 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 0.992 0 CA-C-O 118.193 -0.908 . . . . 72.34 109.802 176.261 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 2' ' ' GLU . . . . . 0.541 ' HB2' ' O ' ' A' ' 49' ' ' PHE . 1.7 mp0 . . . . . 0 C--O 1.234 0.247 0 CA-C-O 121.325 0.583 . . . . 75.12 111.114 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 3' ' ' GLN . . . . . 0.681 ' HG2' HG22 ' A' ' 48' ' ' THR . 47.8 mt-30 -106.82 120.1 41.12 Favored 'General case' 0 C--N 1.32 -0.711 0 CA-C-N 115.702 -0.681 . . . . 73.13 109.619 178.086 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -143.81 -164.26 10.29 Favored Glycine 0 N--CA 1.447 -0.57 0 C-N-CA 120.611 -0.804 . . . . 62.22 112.303 -176.706 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . 0.509 ' O ' ' HG2' ' A' ' 19' ' ' GLU . 42.7 m -139.76 134.64 32.13 Favored 'General case' 0 C--N 1.319 -0.746 0 CA-C-O 120.674 0.273 . . . . 65.23 110.589 -178.879 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.403 HG21 ' HB3' ' A' ' 41' ' ' LEU . 47.4 t -68.58 135.63 28.03 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.487 0 CA-C-O 120.773 0.32 . . . . 63.21 110.343 -179.774 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 7' ' ' LYS . . . . . 0.47 ' HE3' ' HA ' ' A' ' 7' ' ' LYS . 0.0 OUTLIER -108.13 -72.69 0.71 Allowed 'General case' 0 C--N 1.324 -0.518 0 CA-C-O 120.966 0.412 . . . . 71.03 110.723 177.632 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 8' ' ' TRP . . . . . . . . . . . . . 46.0 m95 -127.43 125.99 41.58 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 116.082 -0.508 . . . . 75.03 110.134 -176.499 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 4.6 p90 -112.92 93.95 4.67 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-O 121.67 0.748 . . . . 73.24 110.861 179.866 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 10' ' ' ASN . . . . . 0.415 ' HA ' HD22 ' A' ' 10' ' ' ASN . 2.0 t-20 -92.93 59.33 3.15 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-O 121.892 0.853 . . . . 72.14 109.11 -179.738 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -68.83 -15.12 63.41 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 114.751 -1.113 . . . . 62.02 112.115 -173.067 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 20.5 mt-10 -74.32 -26.79 60.37 Favored 'General case' 0 C--N 1.326 -0.44 0 C-N-CA 120.713 -0.395 . . . . 74.12 110.693 178.205 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 3.8 mmmp? -97.03 -26.48 14.99 Favored 'General case' 0 C--N 1.328 -0.352 0 N-CA-C 109.68 -0.489 . . . . 73.11 109.68 175.064 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 115.82 23.79 4.2 Favored Glycine 0 N--CA 1.449 -0.488 0 C-N-CA 120.306 -0.95 . . . . 61.5 114.265 169.937 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 55.9 p90 -151.08 162.63 40.48 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 117.576 0.688 . . . . 72.01 111.455 179.897 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -153.93 171.18 32.6 Favored Glycine 0 N--CA 1.444 -0.788 0 C-N-CA 120.998 -0.62 . . . . 64.41 111.771 178.299 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 94.9 m-85 -125.69 121.71 34.25 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-O 120.914 0.388 . . . . 72.52 110.965 -178.604 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 59.6 mt -114.7 127.63 72.13 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.574 0 N-CA-C 108.752 -0.832 . . . . 70.25 108.752 174.484 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 19' ' ' GLU . . . . . 0.509 ' HG2' ' O ' ' A' ' 5' ' ' THR . 17.1 pt-20 -86.66 137.19 32.67 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-O 121.517 0.675 . . . . 72.13 112.294 -171.074 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 20' ' ' ARG . . . . . 0.797 ' HB3' ' HB2' ' A' ' 24' ' ' ASP . 10.3 tpt180 -100.41 169.31 9.19 Favored 'General case' 0 C--N 1.325 -0.485 0 N-CA-C 108.215 -1.031 . . . . 71.44 108.215 169.769 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 44.2 mt-10 -58.44 -22.81 55.7 Favored 'General case' 0 CA--C 1.538 0.506 0 N-CA-C 114.029 1.122 . . . . 71.41 114.029 -171.54 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 7.3 m-80 -94.81 3.09 55.42 Favored 'General case' 0 N--CA 1.467 0.421 0 CA-C-O 120.964 0.411 . . . . 73.42 110.43 -179.333 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 92.97 8.61 61.61 Favored Glycine 0 N--CA 1.45 -0.414 0 N-CA-C 111.131 -0.788 . . . . 71.25 111.131 -174.242 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . 0.797 ' HB2' ' HB3' ' A' ' 20' ' ' ARG . 1.6 m-20 -61.06 97.45 0.06 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.193 -0.503 . . . . 74.45 110.168 -178.84 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 40.3 m-20 -67.55 98.53 0.68 Allowed 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 116.264 -0.425 . . . . 72.44 110.0 173.669 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 26.4 t -79.19 128.16 38.68 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.665 0 CA-C-N 116.069 -0.514 . . . . 74.33 109.69 178.595 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 27' ' ' PHE . . . . . . . . . . . . . 17.7 t80 -84.48 108.24 17.16 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 115.957 -0.565 . . . . 73.51 110.437 -173.062 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.504 ' HB ' ' HB3' ' A' ' 60' ' ' ALA . 12.2 p -101.62 151.34 5.64 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.487 0 CA-C-O 121.141 0.496 . . . . 72.23 110.828 -178.545 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 29' ' ' HIS . . . . . 0.472 ' O ' HG13 ' A' ' 33' ' ' ILE . 17.8 m170 -118.09 149.53 40.86 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.798 -0.637 . . . . 60.31 109.422 176.697 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 30' ' ' PHE . . . . . 0.504 ' HA ' HD12 ' A' ' 33' ' ' ILE . 49.3 p90 -68.58 -23.31 64.47 Favored 'General case' 0 N--CA 1.463 0.22 0 CA-C-O 120.955 0.407 . . . . 75.14 110.471 -177.363 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 23.0 t -71.86 -25.14 61.83 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 115.864 -0.607 . . . . 75.25 110.063 176.682 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . 0.48 ' HB1' ' HA ' ' A' ' 61' ' ' ALA . . . -92.13 -19.99 21.71 Favored 'General case' 0 C--O 1.235 0.302 0 CA-C-N 115.964 -0.562 . . . . 64.41 110.863 -179.656 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.504 HD12 ' HA ' ' A' ' 30' ' ' PHE . 77.3 mt -65.42 116.4 4.61 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 CA-C-N 116.156 -0.474 . . . . 74.11 110.114 176.567 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 4.7 pp0? . . . . . 0 C--N 1.328 -0.366 0 CA-C-N 116.184 -0.462 . . . . 72.53 111.246 -176.531 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 47.3 m . . . . . 0 N--CA 1.453 -0.286 0 CA-C-O 120.804 0.335 . . . . 72.33 110.608 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . 0.403 ' HB3' HG21 ' A' ' 6' ' ' VAL . 94.7 mt -124.2 121.24 34.56 Favored 'General case' 0 C--N 1.325 -0.468 0 N-CA-C 108.908 -0.775 . . . . 64.11 108.908 175.825 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 12.1 m-20 -64.19 127.39 31.23 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-O 121.351 0.596 . . . . 62.15 111.495 -175.924 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 6.2 pt-20 -63.04 119.57 9.74 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 115.226 -0.897 . . . . 60.13 111.12 179.98 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 100.66 -5.49 56.87 Favored Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.705 -0.76 . . . . 54.14 112.667 179.167 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 59.2 tp60 -80.98 133.9 35.59 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 120.615 0.245 . . . . 74.52 110.489 -178.778 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -77.15 130.81 37.82 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.352 -0.386 . . . . 71.24 110.022 175.221 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 0.437 HG12 ' HA ' ' A' ' 65' ' ' LYS . 17.5 m -135.19 153.56 34.28 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.492 0 CA-C-O 121.025 0.441 . . . . 75.3 111.289 -176.05 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 48' ' ' THR . . . . . 0.681 HG22 ' HG2' ' A' ' 3' ' ' GLN . 46.3 p -114.18 107.75 16.04 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-N 115.582 -0.735 . . . . 62.03 109.223 175.719 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 49' ' ' PHE . . . . . 0.561 ' HA ' ' O ' ' A' ' 62' ' ' ASN . 37.0 p90 -119.53 167.38 12.03 Favored 'General case' 0 C--N 1.315 -0.899 0 CA-C-N 115.847 -0.615 . . . . 74.1 110.412 -173.515 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 38.7 t70 -107.04 129.21 54.84 Favored 'General case' 0 C--N 1.316 -0.85 0 C-N-CA 120.777 -0.369 . . . . 75.23 110.305 176.016 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . 0.461 ' HB ' ' HG2' ' A' ' 2' ' ' GLU . 7.3 p -77.26 120.8 28.4 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 CA-C-O 121.533 0.682 . . . . 63.55 111.388 -176.976 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -110.37 157.89 19.04 Favored 'General case' 0 C--N 1.323 -0.581 0 N-CA-C 108.721 -0.844 . . . . 70.03 108.721 179.541 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 1.3 mm-40 -95.78 110.32 22.49 Favored 'General case' 0 C--N 1.319 -0.725 0 CA-C-O 121.03 0.443 . . . . 61.14 110.835 -178.319 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -99.56 157.16 19.85 Favored Glycine 0 N--CA 1.443 -0.892 0 N-CA-C 111.139 -0.785 . . . . 63.54 111.139 177.033 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 78.5 mt-30 -77.7 7.07 6.19 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 117.014 0.407 . . . . 75.53 111.69 -178.276 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 99.1 mtt180 -127.79 10.28 6.52 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 120.922 0.392 . . . . 75.21 110.023 175.313 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 129.29 176.89 14.61 Favored Glycine 0 N--CA 1.446 -0.634 0 C-N-CA 120.854 -0.688 . . . . 62.24 111.713 -177.412 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 18.3 Cg_endo -60.1 124.45 15.27 Favored 'Trans proline' 0 C--O 1.235 0.349 0 C-N-CA 122.827 2.351 . . . . 74.21 112.067 179.471 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 6.8 tt0 -104.45 144.35 31.78 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 115.682 -0.69 . . . . 72.51 110.101 -177.003 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . 0.504 ' HB3' ' HB ' ' A' ' 28' ' ' VAL . . . -91.43 106.81 18.76 Favored 'General case' 0 C--N 1.32 -0.696 0 CA-C-O 120.89 0.376 . . . . 63.13 110.81 178.585 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 61' ' ' ALA . . . . . 0.48 ' HA ' ' HB1' ' A' ' 32' ' ' ALA . . . -117.18 164.38 14.86 Favored 'General case' 0 C--N 1.32 -0.687 0 N-CA-C 108.769 -0.826 . . . . 74.24 108.769 176.31 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 62' ' ' ASN . . . . . 0.561 ' O ' ' HA ' ' A' ' 49' ' ' PHE . 85.0 m-20 47.89 66.41 1.05 Allowed 'General case' 0 N--CA 1.465 0.289 0 CA-C-O 120.83 0.347 . . . . 75.45 110.304 -177.766 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 29.4 t -93.93 89.3 2.56 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 CA-C-N 116.09 -0.505 . . . . 73.15 110.636 -176.66 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 5.5 mt-30 -82.35 129.66 34.92 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 115.866 -0.606 . . . . 64.42 110.479 -179.47 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . 0.437 ' HA ' HG12 ' A' ' 47' ' ' VAL . 50.7 mtmt -81.83 137.84 35.2 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 116.532 -0.303 . . . . 74.0 110.262 178.989 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.251 1.133 0 CA-C-O 118.289 -0.862 . . . . 54.04 110.157 178.325 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 40.6 mt-10 . . . . . 0 N--CA 1.452 -0.361 0 CA-C-O 120.735 0.302 . . . . 74.4 110.266 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 35.1 tt0 -91.57 123.77 35.23 Favored 'General case' 0 C--N 1.322 -0.595 0 N-CA-C 109.48 -0.563 . . . . 72.03 109.48 177.759 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . 0.545 ' HA3' ' HE2' ' A' ' 49' ' ' PHE . . . -138.88 152.65 22.29 Favored Glycine 0 N--CA 1.444 -0.788 0 C-N-CA 120.818 -0.706 . . . . 74.54 111.829 -178.903 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . 0.425 ' HA ' ' HA ' ' A' ' 46' ' ' ALA . 9.6 m -85.57 131.05 34.43 Favored 'General case' 0 C--N 1.318 -0.761 0 CA-C-O 120.635 0.255 . . . . 65.41 110.908 -177.855 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 60.6 t -65.78 115.86 4.37 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 N-CA-C 109.507 -0.553 . . . . 64.21 109.507 174.761 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 9.3 mmmm -86.12 -62.08 1.6 Allowed 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 115.943 -0.571 . . . . 64.5 109.976 -178.493 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 8' ' ' TRP . . . . . . . . . . . . . 94.4 m95 -141.78 135.08 29.34 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 116.012 -0.54 . . . . 73.35 110.08 -179.638 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 62.7 t80 -118.93 98.4 6.17 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-O 121.217 0.532 . . . . 63.12 109.707 178.12 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 43.4 t30 -82.12 81.84 7.9 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-O 121.556 0.693 . . . . 72.41 110.262 -177.635 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -70.89 -10.4 59.56 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.103 -0.953 . . . . 72.44 111.143 179.732 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 31.2 mm-40 -69.77 -16.39 63.29 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.086 -0.507 . . . . 63.44 110.266 177.447 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 13' ' ' LYS . . . . . 0.585 ' HE3' ' HA ' ' A' ' 13' ' ' LYS . 0.0 OUTLIER -130.01 -35.17 1.63 Allowed 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.132 -0.486 . . . . 64.41 111.263 179.564 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 111.25 28.51 3.79 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.648 -0.787 . . . . 75.52 112.907 178.206 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 31.3 p90 -148.03 176.23 10.35 Favored 'General case' 0 C--N 1.323 -0.561 0 O-C-N 122.493 -0.416 . . . . 74.4 109.965 177.641 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -174.79 -168.43 35.46 Favored Glycine 0 N--CA 1.445 -0.733 0 C-N-CA 120.292 -0.956 . . . . 73.22 112.27 -179.974 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . 0.5 ' HB3' ' HB3' ' A' ' 25' ' ' ASP . 88.0 m-85 -127.47 124.42 38.32 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-O 120.949 0.404 . . . . 64.42 110.504 -178.166 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 40.2 mt -121.72 117.81 53.71 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.663 0 N-CA-C 108.38 -0.97 . . . . 73.45 108.38 175.063 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 19' ' ' GLU . . . . . 0.642 ' HA ' ' HA ' ' A' ' 25' ' ' ASP . 6.7 pt-20 -78.11 137.67 38.33 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-O 121.64 0.733 . . . . 60.21 112.449 -168.543 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 20' ' ' ARG . . . . . 0.593 ' HB3' ' HB3' ' A' ' 24' ' ' ASP . 62.7 ttt180 -80.3 164.02 23.5 Favored 'General case' 0 C--N 1.32 -0.688 0 N-CA-C 107.691 -1.226 . . . . 73.11 107.691 168.129 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 43.4 mt-10 -63.53 -12.51 32.92 Favored 'General case' 0 N--CA 1.468 0.466 0 N-CA-C 112.53 0.567 . . . . 72.23 112.53 -173.718 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 10.4 m120 -87.29 3.64 45.95 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-O 120.901 0.382 . . . . 72.04 110.774 178.637 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 85.46 2.39 87.35 Favored Glycine 0 N--CA 1.452 -0.271 0 N-CA-C 110.752 -0.939 . . . . 72.32 110.752 -173.164 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . 0.593 ' HB3' ' HB3' ' A' ' 20' ' ' ARG . 38.3 t70 -75.32 90.51 2.64 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 114.551 -0.825 . . . . 74.32 110.463 -176.909 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.642 ' HA ' ' HA ' ' A' ' 19' ' ' GLU . 42.8 m-20 -60.82 104.16 0.33 Allowed 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.107 -0.497 . . . . 75.35 110.248 176.28 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.461 HG13 ' HB2' ' A' ' 58' ' ' PRO . 22.1 t -81.01 132.52 31.39 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 CA-C-N 116.016 -0.538 . . . . 63.35 110.229 -177.851 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 27' ' ' PHE . . . . . . . . . . . . . 85.7 t80 -76.64 104.28 7.06 Favored 'General case' 0 C--O 1.238 0.452 0 CA-C-O 121.134 0.492 . . . . 72.05 110.881 -177.189 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.585 ' HA ' ' HB3' ' A' ' 60' ' ' ALA . 9.6 p -88.3 145.71 7.12 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.638 0 N-CA-C 109.392 -0.595 . . . . 53.3 109.392 177.464 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 29' ' ' HIS . . . . . 0.678 ' HE1' ' HB3' ' A' ' 59' ' ' GLN . 23.8 p-80 -142.05 143.73 33.25 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 116.563 -0.29 . . . . 73.42 110.997 -173.64 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 52.1 p90 -58.14 -23.37 54.89 Favored 'General case' 0 N--CA 1.469 0.488 0 N-CA-C 113.03 0.752 . . . . 74.1 113.03 -172.838 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . 0.412 ' OG ' ' HD2' ' A' ' 29' ' ' HIS . 2.7 p -77.57 -0.05 24.86 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-O 121.0 0.429 . . . . 55.03 111.576 -179.355 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -126.26 -24.9 3.6 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.149 -0.478 . . . . 75.34 110.689 175.337 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.499 HG13 ' O ' ' A' ' 29' ' ' HIS . 64.1 mt -68.95 118.47 13.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.293 -0.412 . . . . 72.32 110.872 179.686 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 2.5 pp0? . . . . . 0 C--N 1.324 -0.503 0 CA-C-O 121.58 0.705 . . . . 75.44 109.508 172.798 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 39.6 m . . . . . 0 N--CA 1.45 -0.458 0 CA-C-O 120.924 0.392 . . . . 75.01 111.122 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 9.9 mp -94.02 131.76 39.19 Favored 'General case' 0 C--N 1.324 -0.532 0 N-CA-C 108.891 -0.781 . . . . 60.21 108.891 174.39 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 21.3 m-20 -96.82 128.1 43.44 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-O 120.775 0.321 . . . . 70.5 110.388 -173.858 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 2.0 pp20? -61.92 143.19 56.82 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 116.063 -0.517 . . . . 70.54 110.737 -179.047 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 99.11 -22.72 39.51 Favored Glycine 0 N--CA 1.447 -0.568 0 C-N-CA 120.74 -0.743 . . . . 53.32 111.847 -175.525 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 45' ' ' GLN . . . . . 0.456 ' HA ' ' OE1' ' A' ' 45' ' ' GLN . 6.1 tp60 -87.95 140.36 29.58 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.713 0.292 . . . . 74.4 110.315 178.334 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 0.425 ' HA ' ' HA ' ' A' ' 5' ' ' THR . . . -102.93 125.44 49.69 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-N 116.476 -0.329 . . . . 35.33 110.818 -179.869 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 30.7 m -118.2 171.51 6.43 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.561 0 CA-C-N 116.315 -0.402 . . . . 73.3 110.467 178.64 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 21.6 p -107.39 112.79 25.76 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-O 121.218 0.532 . . . . 74.11 110.954 -179.899 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 49' ' ' PHE . . . . . 0.545 ' HE2' ' HA3' ' A' ' 4' ' ' GLY . 41.5 p90 -121.89 161.16 23.29 Favored 'General case' 0 C--N 1.317 -0.833 0 CA-C-N 115.619 -0.719 . . . . 74.34 109.851 -178.219 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 19.7 t70 -109.06 128.29 54.85 Favored 'General case' 0 C--N 1.316 -0.875 0 CA-C-O 120.99 0.424 . . . . 54.2 110.311 174.128 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 98.9 t -77.22 104.8 5.46 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 CA-C-O 121.108 0.48 . . . . 71.34 110.878 -177.873 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -87.15 145.89 26.24 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 115.409 -0.814 . . . . 71.23 109.19 179.523 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 70.9 mm-40 -84.25 98.2 9.84 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-N 116.153 -0.476 . . . . 75.53 111.368 -175.641 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -81.39 164.77 45.88 Favored Glycine 0 N--CA 1.446 -0.69 0 C-N-CA 120.837 -0.697 . . . . 64.24 111.546 176.65 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 26.8 pt20 -69.32 -23.63 63.82 Favored 'General case' 0 C--N 1.324 -0.508 0 N-CA-C 112.207 0.447 . . . . 74.21 112.207 -175.664 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 9.5 ptm180 -132.1 16.57 4.61 Favored 'General case' 0 C--N 1.328 -0.346 0 C-N-CA 120.326 -0.55 . . . . 73.41 112.033 -179.26 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 157.69 -178.18 34.13 Favored Glycine 0 N--CA 1.449 -0.444 0 C-N-CA 120.018 -1.087 . . . . 63.24 112.702 179.282 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . 0.461 ' HB2' HG13 ' A' ' 26' ' ' VAL . 73.4 Cg_endo -75.56 128.59 11.17 Favored 'Trans proline' 0 C--O 1.235 0.341 0 C-N-CA 122.834 2.356 . . . . 33.13 112.89 -177.738 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . 0.678 ' HB3' ' HE1' ' A' ' 29' ' ' HIS . 90.5 mt-30 -112.61 135.32 53.47 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 115.965 -0.561 . . . . 70.52 109.92 176.665 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . 0.585 ' HB3' ' HA ' ' A' ' 28' ' ' VAL . . . -85.21 105.19 15.72 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-O 120.899 0.381 . . . . 75.44 111.037 -178.931 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -115.29 168.78 9.66 Favored 'General case' 0 C--N 1.319 -0.722 0 N-CA-C 108.615 -0.883 . . . . 71.43 108.615 174.931 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 62' ' ' ASN . . . . . 0.516 ' O ' ' HA ' ' A' ' 49' ' ' PHE . 87.1 m-20 51.03 75.5 0.19 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.981 0.42 . . . . 55.23 109.958 -175.714 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 22.0 t -98.83 93.25 3.06 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 CA-C-N 115.969 -0.559 . . . . 43.23 109.526 -177.285 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 40.4 mt-30 -98.12 148.78 23.2 Favored 'General case' 0 C--N 1.32 -0.705 0 CA-C-N 115.923 -0.581 . . . . 75.01 110.567 -175.96 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 94.9 mttt -76.86 129.12 35.78 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 115.871 -0.604 . . . . 73.2 110.439 -179.795 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.077 0 CA-C-O 118.366 -0.826 . . . . 75.41 109.457 175.856 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 4.4 mp0 . . . . . 0 C--O 1.233 0.211 0 CA-C-O 121.029 0.442 . . . . 73.51 111.151 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 3' ' ' GLN . . . . . 0.564 ' HG2' HG22 ' A' ' 48' ' ' THR . 66.6 mt-30 -98.47 111.43 23.79 Favored 'General case' 0 C--N 1.326 -0.445 0 N-CA-C 109.037 -0.727 . . . . 73.11 109.037 173.422 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . 0.707 ' HA3' ' HE2' ' A' ' 49' ' ' PHE . . . -122.1 162.3 15.93 Favored Glycine 0 N--CA 1.447 -0.613 0 C-N-CA 120.101 -1.047 . . . . 71.11 112.984 -174.217 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 8.3 m -98.45 131.03 45.04 Favored 'General case' 0 C--N 1.321 -0.635 0 N-CA-C 110.033 -0.358 . . . . 64.12 110.033 177.948 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 59.7 t -70.17 118.48 14.71 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.436 0 CA-C-N 116.602 -0.272 . . . . 72.14 110.619 179.365 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 7' ' ' LYS . . . . . 1.032 ' HE2' ' HB3' ' A' ' 19' ' ' GLU . 70.7 mmtt -70.77 -72.58 0.2 Allowed 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 121.238 0.542 . . . . 73.22 109.803 176.62 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 8' ' ' TRP . . . . . 0.556 ' HA ' ' HG3' ' A' ' 43' ' ' GLU . 24.5 m-90 -143.85 127.23 16.81 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 114.939 -1.028 . . . . 74.44 109.005 178.558 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 54.3 t80 -105.82 103.08 12.51 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-O 121.243 0.544 . . . . 71.11 110.359 179.547 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 39.2 m-80 -83.9 78.46 9.72 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 115.785 -0.643 . . . . 75.45 110.104 -179.666 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -59.61 -30.86 68.99 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.025 -0.534 . . . . 75.41 110.59 178.029 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 24.7 mt-10 -64.61 -38.91 92.64 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.401 -0.818 . . . . 73.22 110.616 178.158 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 48.7 mmtm -90.6 -24.44 20.55 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.683 -0.69 . . . . 65.05 110.691 -174.201 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 96.15 18.62 30.87 Favored Glycine 0 N--CA 1.445 -0.738 0 C-N-CA 120.806 -0.711 . . . . 54.4 112.845 177.608 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 46.7 p90 -156.83 163.72 38.88 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 117.074 0.437 . . . . 74.32 110.803 179.855 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -148.95 177.12 27.4 Favored Glycine 0 N--CA 1.445 -0.703 0 C-N-CA 120.813 -0.708 . . . . 73.34 111.983 179.289 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 96.8 m-85 -123.98 131.15 53.52 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 120.76 0.314 . . . . 75.54 110.307 177.949 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.446 HD13 HG21 ' A' ' 47' ' ' VAL . 33.0 mt -122.88 146.61 27.9 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.695 0 N-CA-C 109.115 -0.698 . . . . 72.22 109.115 178.149 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 19' ' ' GLU . . . . . 1.032 ' HB3' ' HE2' ' A' ' 7' ' ' LYS . 12.9 pt-20 -99.79 129.23 45.88 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-O 121.351 0.596 . . . . 71.02 111.785 -178.52 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 20' ' ' ARG . . . . . 0.436 ' HG2' ' N ' ' A' ' 21' ' ' GLU . 27.9 ttm180 -98.3 153.81 18.26 Favored 'General case' 0 C--N 1.322 -0.609 0 N-CA-C 108.381 -0.97 . . . . 50.23 108.381 170.727 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . 0.436 ' N ' ' HG2' ' A' ' 20' ' ' ARG . 43.9 mt-10 -52.02 -34.44 42.96 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 121.047 0.451 . . . . 61.43 110.491 177.61 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 8.5 t-20 -123.9 58.58 1.16 Allowed 'General case' 0 N--CA 1.453 -0.311 0 CA-C-N 115.85 -0.613 . . . . 75.23 109.41 175.358 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 164.65 78.88 0.04 OUTLIER Glycine 0 N--CA 1.45 -0.369 0 N-CA-C 111.217 -0.753 . . . . 40.13 111.217 179.543 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 30.6 t70 -65.71 -2.84 3.97 Favored 'General case' 0 C--N 1.326 -0.445 0 N-CA-C 112.606 0.595 . . . . 64.14 112.606 -169.51 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 10.2 p-10 -144.73 93.67 2.44 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-O 121.813 0.816 . . . . 71.01 111.854 -178.575 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 38.9 t -104.12 128.74 57.26 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.492 0 CA-C-N 115.525 -0.761 . . . . 73.23 109.628 174.579 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 27' ' ' PHE . . . . . . . . . . . . . 42.7 t80 -83.61 106.52 15.4 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-O 120.716 0.293 . . . . 65.44 110.326 -177.28 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.586 HG23 HG21 ' A' ' 63' ' ' VAL . 12.5 p -99.38 143.9 12.81 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 CA-C-O 121.149 0.5 . . . . 71.11 111.354 -176.248 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 54.2 m80 -97.27 133.78 41.43 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.543 -0.753 . . . . 75.0 109.996 177.871 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 6.1 p90 -63.95 -26.46 68.6 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.803 0.335 . . . . 75.32 111.105 -176.837 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 28.2 t -89.57 -14.35 35.26 Favored 'General case' 0 CA--C 1.533 0.291 0 CA-C-N 116.355 -0.384 . . . . 73.13 110.436 179.689 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -83.22 -23.09 32.94 Favored 'General case' 0 C--O 1.233 0.224 0 CA-C-O 121.383 0.611 . . . . 63.12 109.9 178.117 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.541 ' HA ' ' HB ' ' A' ' 63' ' ' VAL . 53.1 mt -76.31 138.37 20.83 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.497 0 CA-C-N 115.542 -0.754 . . . . 72.35 109.51 172.113 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 34' ' ' GLN . . . . . 0.408 ' OE1' ' HG3' ' A' ' 65' ' ' LYS . 0.3 OUTLIER . . . . . 0 C--N 1.329 -0.287 0 CA-C-O 121.397 0.618 . . . . 73.42 111.554 176.946 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 13.0 m . . . . . 0 N--CA 1.451 -0.397 0 CA-C-O 120.819 0.343 . . . . 71.13 110.368 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . 0.529 HD21 HG21 ' A' ' 33' ' ' ILE . 3.7 mm? -74.96 107.69 7.2 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 116.298 -0.41 . . . . 73.2 110.215 178.606 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 32.5 t70 -58.98 135.08 57.5 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.76 -0.655 . . . . 73.15 111.267 -177.549 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . 0.556 ' HG3' ' HA ' ' A' ' 8' ' ' TRP . 17.9 mp0 -53.93 124.72 16.27 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 115.957 -0.565 . . . . 74.4 110.619 177.809 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 99.35 -0.68 57.11 Favored Glycine 0 N--CA 1.449 -0.481 0 C-N-CA 120.627 -0.796 . . . . 42.43 112.804 -179.908 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 58.7 tp60 -83.43 149.97 26.34 Favored 'General case' 0 C--N 1.325 -0.495 0 N-CA-C 109.918 -0.401 . . . . 70.35 109.918 178.423 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -90.8 140.49 29.74 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-N 116.554 -0.294 . . . . 75.31 110.246 177.21 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 0.446 HG21 HD13 ' A' ' 18' ' ' ILE . 16.0 m -139.0 153.59 25.01 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 CA-C-O 120.913 0.387 . . . . 72.24 110.396 177.579 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 48' ' ' THR . . . . . 0.659 HG23 ' HB2' ' A' ' 66' ' ' ALA . 34.4 p -106.47 101.88 11.31 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-O 121.323 0.582 . . . . 75.12 110.121 178.275 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 49' ' ' PHE . . . . . 0.707 ' HE2' ' HA3' ' A' ' 4' ' ' GLY . 42.1 p90 -111.55 147.47 35.33 Favored 'General case' 0 C--N 1.317 -0.821 0 CA-C-N 115.609 -0.723 . . . . 74.13 110.666 -174.455 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 36.2 t0 -101.92 160.96 14.04 Favored 'General case' 0 C--N 1.316 -0.855 0 C-N-CA 120.357 -0.537 . . . . 73.5 109.706 172.279 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 67.4 t -109.66 119.37 58.77 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.701 0 CA-C-O 120.922 0.392 . . . . 62.54 111.459 -172.822 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 27.6 tt0 -111.11 111.31 22.3 Favored 'General case' 0 C--N 1.321 -0.642 0 N-CA-C 109.094 -0.706 . . . . 73.21 109.094 173.338 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 26.9 mt-10 -69.59 137.08 52.02 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-O 121.203 0.525 . . . . 72.13 112.091 -177.709 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -118.9 -158.04 10.6 Favored Glycine 0 N--CA 1.441 -1.026 0 N-CA-C 110.001 -1.239 . . . . 74.42 110.001 170.844 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 50.0 tt0 -99.43 -25.6 14.41 Favored 'General case' 0 C--N 1.319 -0.752 0 CA-C-N 117.162 0.481 . . . . 72.24 110.498 179.728 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 10.9 mmm180 -97.64 -5.23 35.86 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 116.292 -0.413 . . . . 65.13 111.191 178.561 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 151.39 -179.61 27.89 Favored Glycine 0 N--CA 1.444 -0.795 0 C-N-CA 120.62 -0.8 . . . . 63.34 112.311 178.527 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 8.9 Cg_endo -87.41 119.02 1.37 Allowed 'Trans proline' 0 N--CA 1.45 -1.057 0 C-N-CA 123.235 2.623 . . . . 74.1 112.18 178.931 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 15.8 pt20 -95.39 133.91 38.8 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-N 116.098 -0.501 . . . . 75.2 109.852 177.654 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . 0.572 ' HB3' ' HA ' ' A' ' 28' ' ' VAL . . . -76.27 112.13 12.43 Favored 'General case' 0 C--N 1.321 -0.645 0 CA-C-N 116.128 -0.487 . . . . 40.34 110.76 -178.885 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -112.91 153.3 28.18 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 115.493 -0.776 . . . . 54.12 109.011 176.583 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 95.1 m-20 52.48 77.3 0.16 Allowed 'General case' 0 C--O 1.235 0.341 0 CA-C-O 121.279 0.561 . . . . 64.33 110.337 -175.426 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.586 HG21 HG23 ' A' ' 28' ' ' VAL . 36.9 t -109.59 107.16 22.19 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 CA-C-N 115.686 -0.688 . . . . 72.1 110.174 -179.67 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 64' ' ' GLN . . . . . 0.516 ' HB2' ' OG1' ' A' ' 48' ' ' THR . 1.5 mt-30 -99.41 178.54 4.85 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 115.434 -0.803 . . . . 75.11 110.163 -177.154 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . 0.408 ' HG3' ' OE1' ' A' ' 34' ' ' GLN . 56.0 mttp -89.05 149.47 23.21 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-O 120.733 0.301 . . . . 52.3 110.588 -178.494 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 66' ' ' ALA . . . . . 0.659 ' HB2' HG23 ' A' ' 48' ' ' THR . . . . . . . . 0 C--O 1.251 1.165 0 CA-C-O 117.974 -1.012 . . . . 73.13 109.615 177.304 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 1.4 mp0 . . . . . 0 C--O 1.235 0.336 0 CA-C-O 121.051 0.453 . . . . 73.43 111.235 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 3' ' ' GLN . . . . . 0.504 ' HB3' HG22 ' A' ' 48' ' ' THR . 0.9 OUTLIER -93.54 127.34 39.16 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 115.725 -0.671 . . . . 53.51 109.83 173.485 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -136.74 160.3 24.8 Favored Glycine 0 N--CA 1.445 -0.709 0 C-N-CA 120.887 -0.673 . . . . 55.32 111.566 -179.853 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -96.48 133.35 41.04 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-O 121.266 0.555 . . . . 72.24 111.421 -179.336 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 45.6 t -68.81 116.06 8.54 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.556 0 CA-C-N 115.824 -0.625 . . . . 71.11 110.034 177.759 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 7' ' ' LYS . . . . . 0.832 ' HE3' ' HA ' ' A' ' 7' ' ' LYS . 0.1 OUTLIER -83.04 -62.59 1.55 Allowed 'General case' 0 C--N 1.324 -0.507 0 CA-C-O 121.24 0.543 . . . . 73.03 109.705 -178.827 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 8' ' ' TRP . . . . . . . . . . . . . 99.5 m95 -126.72 146.94 50.03 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 115.365 -0.834 . . . . 70.14 109.727 -179.963 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . 0.52 ' CE2' ' HA ' ' A' ' 40' ' ' SER . 68.1 t80 -140.21 98.05 3.36 Favored 'General case' 0 C--N 1.318 -0.773 0 CA-C-O 121.093 0.473 . . . . 75.2 110.432 176.356 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 91.4 m-20 -82.2 82.57 7.69 Favored 'General case' 0 C--N 1.323 -0.57 0 N-CA-C 109.285 -0.635 . . . . 74.52 109.285 178.813 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -59.08 -33.74 71.16 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.574 -0.739 . . . . 71.14 111.297 -178.476 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 36.7 mt-10 -70.1 -26.22 63.87 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 116.066 -0.515 . . . . 72.2 110.892 -178.733 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 47.9 mmtm -91.44 -29.72 16.88 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.188 -0.46 . . . . 54.31 110.179 175.999 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 90.99 17.4 51.5 Favored Glycine 0 N--CA 1.447 -0.623 0 CA-C-N 115.853 -0.612 . . . . 64.44 111.655 -178.895 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 74.3 m-85 -138.15 144.46 40.77 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-O 120.864 0.364 . . . . 73.45 110.489 -176.568 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -131.16 168.64 21.98 Favored Glycine 0 N--CA 1.444 -0.787 0 C-N-CA 120.438 -0.887 . . . . 73.01 112.109 -178.621 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . 0.453 ' HA ' ' O ' ' A' ' 26' ' ' VAL . 76.6 m-85 -127.47 118.9 24.92 Favored 'General case' 0 C--N 1.322 -0.603 0 N-CA-C 109.757 -0.46 . . . . 74.04 109.757 -179.972 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.431 HG21 ' CE2' ' A' ' 49' ' ' PHE . 63.5 mt -109.05 141.82 23.28 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.659 0 CA-C-N 115.992 -0.549 . . . . 71.53 110.402 -177.526 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 19' ' ' GLU . . . . . 0.63 ' OE1' ' HG2' ' A' ' 7' ' ' LYS . 7.9 pt-20 -92.87 101.42 13.79 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 121.377 0.608 . . . . 72.34 110.476 178.372 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 20' ' ' ARG . . . . . 0.613 ' HG2' ' OE1' ' A' ' 21' ' ' GLU . 12.4 ttp180 -96.41 158.48 15.42 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 115.854 -0.612 . . . . 74.21 109.544 -179.503 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . 0.613 ' OE1' ' HG2' ' A' ' 20' ' ' ARG . 0.0 OUTLIER -57.29 -38.02 73.33 Favored 'General case' 0 N--CA 1.466 0.326 0 N-CA-C 112.155 0.428 . . . . 53.3 112.155 -177.931 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 41.3 m-80 -115.3 36.6 3.85 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-O 120.991 0.424 . . . . 72.34 110.181 174.949 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -170.38 82.19 0.09 OUTLIER Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.624 -0.798 . . . . 75.15 112.444 179.846 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 37.4 t70 -63.71 -2.98 1.97 Allowed 'General case' 0 N--CA 1.469 0.48 0 CA-C-O 121.09 0.471 . . . . 72.44 111.916 -177.039 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 17.5 t70 -152.97 88.55 1.33 Allowed 'General case' 0 C--N 1.325 -0.485 0 CA-C-O 121.105 0.479 . . . . 64.21 109.829 -179.328 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.453 ' O ' ' HA ' ' A' ' 17' ' ' PHE . 58.8 t -102.97 123.72 56.55 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 CA-C-N 116.005 -0.543 . . . . 74.4 110.43 179.374 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 27' ' ' PHE . . . . . 0.467 ' O ' ' HA ' ' A' ' 59' ' ' GLN . 62.7 t80 -85.45 102.46 13.48 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 115.612 -0.722 . . . . 72.22 110.277 -177.025 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.473 HG23 ' HB3' ' A' ' 60' ' ' ALA . 10.2 p -95.77 146.74 6.66 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.505 0 CA-C-O 120.94 0.4 . . . . 73.21 110.796 -177.453 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 17.3 m-70 -103.83 141.01 36.86 Favored 'General case' 0 C--O 1.234 0.24 0 CA-C-N 115.982 -0.554 . . . . 74.5 111.341 -175.841 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 41.2 p90 -55.91 -36.38 67.63 Favored 'General case' 0 N--CA 1.467 0.412 0 CA-C-N 115.838 -0.619 . . . . 73.12 112.177 -179.941 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 33.0 t -82.07 -10.52 59.18 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 116.707 -0.224 . . . . 63.14 111.17 -177.075 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . 0.54 ' HB1' ' HA ' ' A' ' 61' ' ' ALA . . . -92.81 -22.84 19.09 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 121.248 0.547 . . . . 70.34 109.99 178.829 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.546 ' HA ' ' HB ' ' A' ' 63' ' ' VAL . 67.3 mt -87.68 126.63 41.26 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.468 0 CA-C-N 115.503 -0.771 . . . . 74.23 110.318 177.012 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 34' ' ' GLN . . . . . 0.426 ' H ' ' HG3' ' A' ' 34' ' ' GLN . 2.3 pp0? . . . . . 0 C--N 1.323 -0.586 0 CA-C-O 121.502 0.668 . . . . 74.51 109.457 172.639 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . 0.52 ' HA ' ' CE2' ' A' ' 9' ' ' PHE . 23.5 p . . . . . 0 N--CA 1.448 -0.551 0 N-CA-C 109.981 -0.378 . . . . 65.32 109.981 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 52.0 mt -70.64 137.29 49.78 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-O 120.996 0.427 . . . . 70.5 110.648 179.196 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 42' ' ' ASP . . . . . 0.442 ' HB3' ' HB2' ' A' ' 45' ' ' GLN . 22.7 t70 -74.64 136.93 41.94 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 115.573 -0.74 . . . . 63.45 110.638 -176.322 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 8.4 pt-20 -65.81 115.25 5.74 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-O 121.25 0.548 . . . . 75.01 110.71 178.361 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 100.86 -1.54 55.35 Favored Glycine 0 N--CA 1.446 -0.635 0 C-N-CA 120.47 -0.871 . . . . 72.03 112.109 -178.218 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 45' ' ' GLN . . . . . 0.442 ' HB2' ' HB3' ' A' ' 42' ' ' ASP . 6.0 tp-100 -74.26 133.85 42.64 Favored 'General case' 0 C--N 1.327 -0.398 0 N-CA-C 109.974 -0.38 . . . . 73.23 109.974 175.802 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -90.23 123.66 34.21 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 116.186 -0.461 . . . . 33.2 110.454 179.784 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 0.495 HG23 ' HD2' ' A' ' 49' ' ' PHE . 21.1 m -127.62 153.56 37.02 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.596 0 CA-C-N 116.008 -0.542 . . . . 73.22 110.339 178.748 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 48' ' ' THR . . . . . 0.504 HG22 ' HB3' ' A' ' 3' ' ' GLN . 63.7 p -106.96 111.23 23.63 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-O 121.261 0.553 . . . . 62.04 109.733 179.609 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 49' ' ' PHE . . . . . 0.495 ' HD2' HG23 ' A' ' 47' ' ' VAL . 29.5 p90 -128.61 160.53 32.14 Favored 'General case' 0 C--N 1.318 -0.771 0 CA-C-N 116.138 -0.483 . . . . 73.54 111.171 -172.543 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 71.0 m-20 -105.02 115.09 29.69 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 116.157 -0.474 . . . . 70.14 110.435 175.536 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . 0.478 HG21 ' HD3' ' A' ' 20' ' ' ARG . 65.3 t -77.43 120.71 28.48 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.599 0 CA-C-O 121.052 0.454 . . . . 73.23 110.936 -177.459 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 9.2 tp10 -99.44 125.69 45.21 Favored 'General case' 0 N--CA 1.444 -0.769 0 N-CA-C 108.984 -0.747 . . . . 70.5 108.984 175.43 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 10.0 pt-20 -88.11 141.11 28.83 Favored 'General case' 0 C--N 1.317 -0.806 0 CA-C-N 116.16 -0.473 . . . . 72.23 110.806 -175.797 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -162.64 -171.46 28.87 Favored Glycine 0 N--CA 1.446 -0.669 0 C-N-CA 120.851 -0.69 . . . . 53.41 112.081 178.706 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 34.9 tt0 -58.35 -38.57 77.48 Favored 'General case' 0 C--N 1.326 -0.444 0 C-N-CA 122.488 0.315 . . . . 72.42 111.218 179.557 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 18.0 mmm180 -75.98 4.36 8.46 Favored 'General case' 0 C--N 1.328 -0.337 0 N-CA-C 111.708 0.262 . . . . 74.34 111.708 179.999 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 93.51 -136.82 13.28 Favored Glycine 0 N--CA 1.444 -0.818 0 C-N-CA 120.942 -0.647 . . . . 75.44 112.034 178.928 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 1.8 Cg_endo -83.05 108.94 1.63 Allowed 'Trans proline' 0 N--CA 1.454 -0.832 0 C-N-CA 123.132 2.554 . . . . 54.43 112.015 -179.69 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . 0.467 ' HA ' ' O ' ' A' ' 27' ' ' PHE . 47.6 mt-30 -110.17 117.27 33.25 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-O 120.906 0.384 . . . . 71.42 110.081 177.827 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . 0.473 ' HB3' HG23 ' A' ' 28' ' ' VAL . . . -77.72 119.05 20.7 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-O 121.078 0.466 . . . . 74.03 111.308 -175.852 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 61' ' ' ALA . . . . . 0.54 ' HA ' ' HB1' ' A' ' 32' ' ' ALA . . . -120.77 167.91 12.0 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 115.425 -0.807 . . . . 73.14 109.001 175.362 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 62' ' ' ASN . . . . . 0.49 ' O ' ' HA ' ' A' ' 49' ' ' PHE . 37.4 m-20 47.28 74.46 0.16 Allowed 'General case' 0 C--O 1.236 0.393 0 O-C-N 123.265 0.353 . . . . 73.55 110.314 -176.885 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.546 ' HB ' ' HA ' ' A' ' 33' ' ' ILE . 57.9 t -96.63 104.13 15.49 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.511 0 CA-C-N 116.337 -0.392 . . . . 65.15 110.817 -177.19 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 6.6 tp-100 -104.65 165.31 11.15 Favored 'General case' 0 C--N 1.321 -0.649 0 N-CA-C 109.127 -0.694 . . . . 75.54 109.127 178.093 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 86.0 mttt -80.78 176.57 9.69 Favored 'General case' 0 C--N 1.321 -0.635 0 N-CA-C 110.09 -0.337 . . . . 75.22 110.09 178.103 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 66' ' ' ALA . . . . . 0.459 ' HB2' HG23 ' A' ' 48' ' ' THR . . . . . . . . 0 C--O 1.249 1.052 0 CA-C-O 118.612 -0.709 . . . . 40.42 109.876 175.603 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 34.3 mm-40 . . . . . 0 C--O 1.233 0.192 0 CA-C-O 120.811 0.339 . . . . 64.2 110.307 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 3' ' ' GLN . . . . . 0.957 ' HG2' HG22 ' A' ' 48' ' ' THR . 88.3 mt-30 -124.72 111.78 15.97 Favored 'General case' 0 C--N 1.321 -0.648 0 N-CA-C 109.418 -0.586 . . . . 72.23 109.418 176.308 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -137.87 163.47 25.57 Favored Glycine 0 N--CA 1.446 -0.653 0 C-N-CA 120.363 -0.922 . . . . 44.41 112.143 -176.029 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . 0.553 ' HA ' ' HA ' ' A' ' 46' ' ' ALA . 22.0 m -106.67 130.44 54.4 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-O 120.516 0.198 . . . . 73.23 110.734 -178.431 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.531 HG22 HG12 ' A' ' 18' ' ' ILE . 42.7 t -70.65 120.67 18.95 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 N-CA-C 109.964 -0.384 . . . . 70.13 109.964 178.009 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 7' ' ' LYS . . . . . 0.714 ' HD2' ' HB3' ' A' ' 19' ' ' GLU . 27.2 mtpp -98.81 -34.05 10.65 Favored 'General case' 0 C--N 1.327 -0.393 0 C-N-CA 120.91 -0.316 . . . . 74.12 110.682 -179.305 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 8' ' ' TRP . . . . . . . . . . . . . 10.5 m-90 -140.0 110.82 6.83 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.067 -0.515 . . . . 72.44 110.361 179.791 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 65.2 t80 -101.88 91.99 4.61 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-O 121.194 0.521 . . . . 71.45 109.848 177.546 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 90.3 m-20 -79.15 84.97 5.07 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-O 121.238 0.542 . . . . 74.12 109.976 -178.037 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -60.41 -40.67 91.84 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.065 -0.97 . . . . 72.42 112.021 -175.761 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 42.7 mt-10 -81.81 0.45 39.25 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 121.134 0.492 . . . . 73.31 111.181 -176.786 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 70.5 mmtt -103.95 -28.07 11.78 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 115.782 -0.644 . . . . 63.13 109.38 170.695 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 82.08 19.26 65.38 Favored Glycine 0 N--CA 1.448 -0.554 0 N-CA-C 111.156 -0.778 . . . . 73.12 111.156 -175.854 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 48.8 m-85 -135.81 154.86 51.07 Favored 'General case' 0 C--N 1.325 -0.483 0 N-CA-C 110.2 -0.296 . . . . 73.15 110.2 -176.127 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -140.07 146.56 18.08 Favored Glycine 0 N--CA 1.447 -0.59 0 C-N-CA 120.524 -0.846 . . . . 73.14 112.14 -179.599 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 97.6 m-85 -104.47 111.88 24.71 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 121.051 0.453 . . . . 71.24 110.486 178.771 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.531 HG12 HG22 ' A' ' 6' ' ' VAL . 55.2 mt -104.48 135.36 42.67 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.589 0 CA-C-N 115.579 -0.737 . . . . 60.32 109.829 -179.493 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 19' ' ' GLU . . . . . 0.714 ' HB3' ' HD2' ' A' ' 7' ' ' LYS . 14.0 pt-20 -83.29 162.18 21.22 Favored 'General case' 0 C--N 1.327 -0.377 0 C-N-CA 120.265 -0.574 . . . . 72.41 110.686 -178.837 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 20' ' ' ARG . . . . . 0.425 ' HG2' ' H ' ' A' ' 21' ' ' GLU . 39.0 ttt180 -144.64 175.9 9.81 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 115.969 -0.56 . . . . 72.33 109.755 -173.255 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . 0.433 ' HG3' ' N ' ' A' ' 22' ' ' ASN . 7.8 pt-20 -45.71 -49.45 14.65 Favored 'General case' 0 N--CA 1.469 0.507 0 N-CA-C 113.046 0.758 . . . . 72.14 113.046 -177.488 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 22' ' ' ASN . . . . . 0.433 ' N ' ' HG3' ' A' ' 21' ' ' GLU . 14.9 t-20 -97.9 12.43 34.1 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-O 121.361 0.601 . . . . 61.2 110.761 -174.646 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 79.28 9.92 86.53 Favored Glycine 0 N--CA 1.452 -0.243 0 C-N-CA 120.528 -0.844 . . . . 72.13 111.124 -173.923 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 25.2 t70 -67.14 90.93 0.21 Allowed 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 114.8 -0.7 . . . . 53.41 110.062 179.871 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 4.8 p-10 -60.84 119.15 7.66 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 121.631 0.729 . . . . 74.23 111.451 -178.819 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.509 HG12 ' HB2' ' A' ' 60' ' ' ALA . 31.3 t -89.88 127.98 42.13 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.58 0 CA-C-N 115.049 -0.978 . . . . 53.12 110.179 -179.864 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 27' ' ' PHE . . . . . . . . . . . . . 43.4 t80 -92.67 100.18 12.73 Favored 'General case' 0 C--N 1.321 -0.674 0 CA-C-N 115.582 -0.735 . . . . 71.4 110.333 -175.854 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.546 ' HA ' ' HB3' ' A' ' 60' ' ' ALA . 11.8 p -89.06 142.52 12.76 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 CA-C-O 120.708 0.289 . . . . 73.34 110.345 178.812 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 29' ' ' HIS . . . . . 0.418 ' O ' HG13 ' A' ' 33' ' ' ILE . 7.9 p80 -118.87 142.12 48.03 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.389 -0.369 . . . . 72.52 110.832 -178.484 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 30' ' ' PHE . . . . . 0.519 ' HA ' HD12 ' A' ' 33' ' ' ILE . 43.9 p90 -52.43 -32.54 39.83 Favored 'General case' 0 N--CA 1.468 0.443 0 CA-C-N 115.501 -0.772 . . . . 64.02 112.934 -173.648 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 1.9 p -71.06 -9.19 57.61 Favored 'General case' 0 C--N 1.323 -0.585 0 N-CA-C 111.911 0.337 . . . . 74.3 111.911 -179.046 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . 0.417 ' HB1' ' HA ' ' A' ' 61' ' ' ALA . . . -122.07 -7.05 8.9 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-O 120.916 0.389 . . . . 61.54 110.941 177.905 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.519 HD12 ' HA ' ' A' ' 30' ' ' PHE . 68.3 mt -67.77 136.5 26.46 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.386 0 CA-C-N 116.21 -0.45 . . . . 73.4 110.115 175.78 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 24.0 pt20 . . . . . 0 C--N 1.327 -0.395 0 CA-C-O 121.434 0.635 . . . . 71.1 110.967 177.541 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 3.7 p . . . . . 0 N--CA 1.447 -0.583 0 CA-C-O 121.104 0.478 . . . . 62.52 111.844 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 93.2 mt -85.62 81.47 8.64 Favored 'General case' 0 C--N 1.327 -0.394 0 N-CA-C 108.726 -0.842 . . . . 52.21 108.726 172.884 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 69.3 m-20 -73.97 172.21 12.04 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-O 122.038 0.923 . . . . 73.43 112.911 -169.677 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . 0.524 ' CD ' ' H ' ' A' ' 43' ' ' GLU . 22.2 mp0 -60.64 132.96 55.55 Favored 'General case' 0 N--CA 1.448 -0.554 0 CA-C-N 114.139 -1.391 . . . . 72.35 110.163 -178.44 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 98.99 -5.94 59.77 Favored Glycine 0 N--CA 1.446 -0.686 0 C-N-CA 120.711 -0.757 . . . . 53.1 112.713 178.102 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 3.4 tm0? -92.16 126.08 37.1 Favored 'General case' 0 C--N 1.328 -0.354 0 N-CA-C 109.566 -0.531 . . . . 75.23 109.566 176.751 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 0.553 ' HA ' ' HA ' ' A' ' 5' ' ' THR . . . -97.95 113.09 24.83 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-O 120.944 0.402 . . . . 75.13 110.675 178.795 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 23.2 m -106.26 160.95 5.74 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 CA-C-N 115.952 -0.567 . . . . 74.35 111.087 -178.44 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 48' ' ' THR . . . . . 0.957 HG22 ' HG2' ' A' ' 3' ' ' GLN . 53.8 p -106.79 126.13 51.89 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 115.748 -0.66 . . . . 73.45 109.411 175.743 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 49' ' ' PHE . . . . . 0.474 ' HA ' ' O ' ' A' ' 62' ' ' ASN . 33.4 p90 -142.0 167.49 22.01 Favored 'General case' 0 C--N 1.317 -0.813 0 CA-C-O 120.954 0.407 . . . . 62.21 111.33 -173.435 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 33.1 t70 -106.55 148.64 28.01 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.747 -0.66 . . . . 74.25 109.947 175.841 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 62.6 t -82.22 105.76 12.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-O 120.953 0.406 . . . . 71.0 111.137 -178.782 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 52' ' ' GLU . . . . . 0.428 ' HB2' ' HB3' ' A' ' 61' ' ' ALA . 40.6 tt0 -82.49 123.76 29.46 Favored 'General case' 0 C--N 1.319 -0.721 0 N-CA-C 108.881 -0.785 . . . . 54.44 108.881 174.459 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 43.5 mt-10 -87.94 109.55 19.88 Favored 'General case' 0 C--N 1.319 -0.731 0 CA-C-N 115.974 -0.557 . . . . 71.33 110.804 -174.901 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -138.16 166.8 25.12 Favored Glycine 0 N--CA 1.446 -0.663 0 CA-C-N 115.454 -0.793 . . . . 71.34 111.577 -179.579 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 72.6 mt-30 -79.97 82.95 5.95 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 121.343 0.592 . . . . 72.44 111.245 -175.843 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 56' ' ' ARG . . . . . 0.437 HH11 ' HD3' ' A' ' 56' ' ' ARG . 9.1 ptp180 -179.77 -32.01 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 114.764 -1.107 . . . . 74.05 109.326 177.893 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 144.95 -152.11 24.19 Favored Glycine 0 N--CA 1.448 -0.553 0 N-CA-C 110.737 -0.945 . . . . 32.32 110.737 -178.183 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 55.5 Cg_endo -70.98 105.2 1.64 Allowed 'Trans proline' 0 N--CA 1.46 -0.472 0 C-N-CA 122.158 1.906 . . . . 51.3 111.537 176.871 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 20.3 tt0 -97.8 139.04 34.26 Favored 'General case' 0 C--N 1.322 -0.596 0 N-CA-C 108.63 -0.878 . . . . 64.4 108.63 179.071 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . 0.546 ' HB3' ' HA ' ' A' ' 28' ' ' VAL . . . -96.11 120.42 36.37 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-O 121.255 0.55 . . . . 73.24 112.105 -174.835 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 61' ' ' ALA . . . . . 0.428 ' HB3' ' HB2' ' A' ' 52' ' ' GLU . . . -135.57 163.1 30.89 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 115.05 -0.977 . . . . 74.33 108.62 173.777 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 62' ' ' ASN . . . . . 0.474 ' O ' ' HA ' ' A' ' 49' ' ' PHE . 88.5 m-20 54.65 77.34 0.21 Allowed 'General case' 0 C--O 1.236 0.348 0 CA-C-O 121.067 0.46 . . . . 62.31 109.855 -174.494 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 45.9 t -112.67 121.38 64.87 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 CA-C-N 115.643 -0.708 . . . . 72.31 110.787 -175.998 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 5.1 tp60 -115.61 146.58 41.66 Favored 'General case' 0 C--N 1.323 -0.566 0 N-CA-C 109.29 -0.633 . . . . 62.23 109.29 177.642 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 19.4 ttpp -84.01 137.8 33.43 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 120.931 0.396 . . . . 64.45 111.481 -176.867 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 0.987 0 CA-C-O 118.202 -0.904 . . . . 51.42 108.882 171.109 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 2' ' ' GLU . . . . . 0.469 ' O ' ' HA ' ' A' ' 48' ' ' THR . 5.0 mp0 . . . . . 0 N--CA 1.453 -0.28 0 N-CA-C 109.283 -0.636 . . . . 73.21 109.283 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 17.9 mp0 -63.96 136.32 57.24 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.033 -0.985 . . . . 73.24 112.606 -173.968 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -153.09 163.38 30.52 Favored Glycine 0 N--CA 1.441 -1.003 0 N-CA-C 109.419 -1.473 . . . . 51.23 109.419 172.657 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . 0.41 ' O ' ' HG2' ' A' ' 19' ' ' GLU . 13.9 m -122.46 127.53 49.72 Favored 'General case' 0 C--N 1.316 -0.861 0 CA-C-N 118.04 0.92 . . . . 64.3 110.886 -178.174 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 61.5 t -64.93 120.7 12.44 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.462 0 CA-C-N 116.22 -0.445 . . . . 63.53 111.115 -178.026 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 7' ' ' LYS . . . . . 1.072 ' HE2' ' HB3' ' A' ' 19' ' ' GLU . 66.3 mmtt -74.93 -70.49 0.41 Allowed 'General case' 0 C--N 1.328 -0.344 0 N-CA-C 109.219 -0.66 . . . . 72.24 109.219 175.309 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 8' ' ' TRP . . . . . . . . . . . . . 15.6 m95 -140.36 128.35 22.08 Favored 'General case' 0 C--O 1.235 0.317 0 CA-C-N 115.059 -0.973 . . . . 71.43 108.786 -179.537 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 22.8 p90 -99.52 103.69 15.45 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-O 121.702 0.763 . . . . 74.13 109.706 177.377 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 10' ' ' ASN . . . . . 0.862 ' HB3' ' HG3' ' A' ' 13' ' ' LYS . 37.8 m-80 -91.45 63.79 4.91 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 115.775 -0.648 . . . . 63.21 110.557 -176.958 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -64.07 -26.29 68.48 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 115.609 -0.723 . . . . 65.21 110.435 178.732 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 4.1 mm-40 -71.64 -13.27 61.7 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 115.726 -0.67 . . . . 72.23 110.509 178.684 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 13' ' ' LYS . . . . . 0.862 ' HG3' ' HB3' ' A' ' 10' ' ' ASN . 1.7 mmpt? -112.97 -37.85 4.68 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.895 -0.593 . . . . 63.54 110.395 -176.99 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . 0.408 ' O ' ' HD1' ' A' ' 30' ' ' PHE . . . 116.85 15.61 6.7 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.956 -0.64 . . . . 73.42 112.835 178.474 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 45.3 p90 -151.49 -176.36 5.56 Favored 'General case' 0 C--N 1.324 -0.543 0 O-C-N 122.543 -0.386 . . . . 71.03 110.667 179.96 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -164.55 169.99 39.51 Favored Glycine 0 N--CA 1.445 -0.743 0 C-N-CA 120.915 -0.66 . . . . 73.14 111.795 177.581 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 96.6 m-85 -123.76 130.12 52.13 Favored 'General case' 0 C--N 1.323 -0.585 0 N-CA-C 109.979 -0.378 . . . . 73.15 109.979 178.695 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 61.0 mt -127.57 135.35 63.45 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.768 0 N-CA-C 109.701 -0.481 . . . . 62.43 109.701 178.308 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 19' ' ' GLU . . . . . 1.072 ' HB3' ' HE2' ' A' ' 7' ' ' LYS . 8.5 pt-20 -91.5 135.61 33.72 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-O 121.212 0.529 . . . . 65.14 110.811 179.451 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 20' ' ' ARG . . . . . 0.658 ' HB2' ' HZ ' ' A' ' 49' ' ' PHE . 45.5 ttt180 -133.93 161.75 33.94 Favored 'General case' 0 C--N 1.315 -0.928 0 N-CA-C 108.576 -0.898 . . . . 72.42 108.576 174.78 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . 0.408 ' HG2' ' H ' ' A' ' 21' ' ' GLU . 7.1 mm-40 -35.87 -57.47 0.67 Allowed 'General case' 0 N--CA 1.468 0.444 0 O-C-N 124.038 0.836 . . . . 73.41 110.806 178.025 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 34.9 t30 -110.06 76.92 1.02 Allowed 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 115.704 -0.68 . . . . 62.5 109.749 172.409 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . 0.583 ' O ' HG23 ' A' ' 26' ' ' VAL . . . 152.24 72.44 0.01 OUTLIER Glycine 0 N--CA 1.446 -0.674 0 C-N-CA 120.541 -0.838 . . . . 74.1 112.213 174.032 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 25.2 t70 -68.17 -1.79 6.76 Favored 'General case' 0 C--N 1.321 -0.663 0 CA-C-O 121.183 0.516 . . . . 50.41 111.062 -176.278 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 7.0 p-10 -142.65 31.49 1.47 Allowed 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 116.246 -0.434 . . . . 74.11 110.929 -174.988 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.583 HG23 ' O ' ' A' ' 23' ' ' GLY . 79.2 t -53.28 121.83 2.73 Favored 'Isoleucine or valine' 0 C--O 1.234 0.269 0 CA-C-O 121.109 0.48 . . . . 72.04 110.743 179.588 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 27' ' ' PHE . . . . . . . . . . . . . 42.6 t80 -84.21 116.74 23.1 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 115.583 -0.735 . . . . 74.12 110.603 -174.413 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.511 HG21 HG21 ' A' ' 63' ' ' VAL . 9.0 p -110.68 156.1 11.86 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.59 0 CA-C-N 116.339 -0.392 . . . . 75.32 110.281 179.853 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 92.7 m-70 -108.82 157.27 18.74 Favored 'General case' 0 C--O 1.239 0.513 0 N-CA-C 110.011 -0.366 . . . . 54.44 110.011 -179.674 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 30' ' ' PHE . . . . . 0.408 ' HD1' ' O ' ' A' ' 14' ' ' GLY . 50.8 p90 -61.65 -34.48 75.78 Favored 'General case' 0 N--CA 1.464 0.234 0 CA-C-N 116.54 -0.3 . . . . 74.25 111.605 -175.847 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 26.8 t -92.43 2.68 56.52 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 121.053 0.454 . . . . 74.21 110.589 -179.045 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -93.38 -29.9 15.37 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 121.168 0.509 . . . . 44.13 110.151 177.127 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.585 ' HA ' ' HB ' ' A' ' 63' ' ' VAL . 59.1 mt -72.66 137.89 22.56 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.386 0 CA-C-N 115.608 -0.724 . . . . 73.31 109.992 174.277 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 5.1 pp0? . . . . . 0 C--N 1.329 -0.318 0 N-CA-C 110.061 -0.348 . . . . 73.35 110.061 178.236 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 20.0 m . . . . . 0 N--CA 1.45 -0.472 0 N-CA-C 110.034 -0.358 . . . . 71.34 110.034 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 98.4 mt -66.35 143.13 57.35 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 116.013 -0.539 . . . . 64.21 110.93 -177.882 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 35.4 t70 -68.07 149.38 49.73 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-N 115.462 -0.79 . . . . 71.32 112.176 -172.808 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 7.6 pt-20 -65.25 135.63 55.62 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 115.751 -0.658 . . . . 73.04 110.518 179.312 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 89.74 -1.23 80.89 Favored Glycine 0 N--CA 1.447 -0.583 0 C-N-CA 120.66 -0.781 . . . . 53.14 112.233 -177.18 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 6.5 tp-100 -82.92 141.49 32.14 Favored 'General case' 0 C--O 1.237 0.439 0 CA-C-O 120.732 0.301 . . . . 74.23 110.36 176.984 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -82.38 117.41 22.42 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 115.824 -0.626 . . . . 65.31 110.257 178.244 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 29.5 m -117.01 166.93 10.83 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.711 0 CA-C-N 115.727 -0.67 . . . . 62.52 110.884 -178.071 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 48' ' ' THR . . . . . 0.726 HG23 ' HB2' ' A' ' 66' ' ' ALA . 9.6 p -132.91 103.15 5.92 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-O 121.296 0.569 . . . . 63.41 110.106 178.461 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 49' ' ' PHE . . . . . 0.658 ' HZ ' ' HB2' ' A' ' 20' ' ' ARG . 36.5 p90 -117.16 166.82 11.79 Favored 'General case' 0 C--N 1.318 -0.792 0 CA-C-O 121.072 0.463 . . . . 74.03 111.751 -172.399 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 35.5 t70 -96.91 128.06 43.5 Favored 'General case' 0 C--N 1.32 -0.68 0 N-CA-C 109.016 -0.735 . . . . 73.14 109.016 174.169 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 7.4 p -80.62 118.0 27.56 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.564 0 CA-C-O 121.538 0.685 . . . . 73.42 111.254 -174.746 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 44.0 tt0 -89.14 113.16 24.3 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-N 115.419 -0.81 . . . . 74.03 109.109 176.942 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 13.9 mm-40 -73.62 86.13 1.62 Allowed 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 115.983 -0.553 . . . . 75.02 109.875 178.248 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -88.64 160.8 30.48 Favored Glycine 0 N--CA 1.443 -0.858 0 C-N-CA 120.88 -0.676 . . . . 61.11 112.331 -177.523 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 36.7 tt0 -84.77 0.34 50.99 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-O 121.392 0.615 . . . . 73.21 109.854 -179.295 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 90.8 mtm180 -119.84 15.64 12.6 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.597 -0.729 . . . . 71.52 110.855 179.184 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 121.68 169.17 13.56 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.884 -0.674 . . . . 60.31 112.182 -179.769 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 37.7 Cg_endo -68.03 118.41 5.6 Favored 'Trans proline' 0 C--N 1.344 0.291 0 C-N-CA 122.532 2.155 . . . . 51.42 111.768 177.249 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 49.9 mt-30 -119.45 164.31 15.96 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 116.325 -0.398 . . . . 62.33 110.429 -177.791 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -111.65 125.15 53.65 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-O 121.255 0.55 . . . . 75.3 111.943 -174.048 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -128.57 142.97 50.89 Favored 'General case' 0 C--N 1.321 -0.63 0 CA-C-N 115.3 -0.863 . . . . 65.51 109.005 174.426 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 39.4 m-80 56.53 78.57 0.21 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 121.216 0.532 . . . . 72.45 110.448 -175.899 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.585 ' HB ' ' HA ' ' A' ' 33' ' ' ILE . 51.8 t -101.42 109.59 26.14 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.519 0 CA-C-N 115.892 -0.594 . . . . 54.03 110.803 -177.965 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 86.7 mt-30 -94.06 -172.24 2.77 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 116.192 -0.458 . . . . 74.1 110.105 177.983 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 61.9 tttm -116.45 139.64 50.23 Favored 'General case' 0 C--N 1.321 -0.641 0 N-CA-C 109.303 -0.629 . . . . 71.34 109.303 178.508 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 66' ' ' ALA . . . . . 0.726 ' HB2' HG23 ' A' ' 48' ' ' THR . . . . . . . . 0 C--O 1.248 1.006 0 CA-C-O 118.795 -0.621 . . . . 75.01 110.557 -178.614 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 21.9 ttt . . . . . 0 N--CA 1.479 1.019 0 N-CA-C 109.423 -0.584 . . . . 52.33 109.423 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . 0.943 ' HG3' HH12 ' A' ' 20' ' ' ARG . 0.1 OUTLIER -90.06 83.28 6.07 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 115.842 -0.617 . . . . 74.42 111.209 -172.919 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 41.1 mt-30 -96.54 148.52 22.75 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.539 -0.755 . . . . 51.42 110.123 178.481 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -155.91 153.7 24.95 Favored Glycine 0 N--CA 1.445 -0.726 0 C-N-CA 120.934 -0.651 . . . . 71.33 111.866 177.114 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 4.7 m -104.57 134.81 47.12 Favored 'General case' 0 C--N 1.319 -0.752 0 N-CA-C 109.812 -0.44 . . . . 73.12 109.812 178.124 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 61.8 t -68.13 112.18 3.01 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.609 0 CA-C-O 120.745 0.307 . . . . 63.52 110.41 177.952 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . 0.683 ' HD3' ' HB3' ' A' ' 19' ' ' GLU . 12.3 mmmm -71.3 -68.5 0.44 Allowed 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.831 -0.622 . . . . 62.45 109.822 179.159 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' TRP . . . . . . . . . . . . . 4.6 p-90 -153.06 149.01 27.68 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-N 115.462 -0.79 . . . . 74.33 109.32 177.774 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . 0.419 ' CE2' ' HA ' ' A' ' 40' ' ' SER . 68.5 t80 -114.59 120.15 39.21 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-O 121.001 0.429 . . . . 74.21 111.563 -173.227 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' ASN . . . . . 0.454 ' HB3' ' HB2' ' A' ' 13' ' ' LYS . 15.3 m120 -81.92 78.31 8.64 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.669 -0.696 . . . . 74.21 109.472 176.261 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -61.71 -37.64 84.92 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 115.905 -0.589 . . . . 14.0 111.303 -177.114 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 32.0 mm-40 -76.8 -11.33 59.81 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.379 -0.373 . . . . 73.34 111.554 -178.925 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . 0.487 ' HB3' ' HD2' ' A' ' 15' ' ' PHE . 70.1 mmtt -99.79 -33.69 10.47 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-O 121.072 0.463 . . . . 73.32 110.553 176.839 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 89.85 24.28 30.53 Favored Glycine 0 N--CA 1.448 -0.536 0 N-CA-C 111.075 -0.81 . . . . 75.14 111.075 -174.147 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . 0.487 ' HD2' ' HB3' ' A' ' 13' ' ' LYS . 64.3 m-85 -136.92 173.73 11.38 Favored 'General case' 0 C--N 1.324 -0.519 0 N-CA-C 109.549 -0.538 . . . . 73.32 109.549 -178.338 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -160.98 167.56 36.02 Favored Glycine 0 N--CA 1.447 -0.6 0 C-N-CA 120.281 -0.962 . . . . 64.41 112.285 178.543 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 96.2 m-85 -119.67 119.67 34.39 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-O 121.105 0.478 . . . . 73.54 110.668 179.095 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 56.4 mt -112.76 124.95 69.91 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.657 0 N-CA-C 109.187 -0.671 . . . . 62.13 109.187 177.72 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' GLU . . . . . 0.683 ' HB3' ' HD3' ' A' ' 7' ' ' LYS . 10.3 pt-20 -71.88 140.38 49.25 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-O 121.342 0.592 . . . . 73.41 111.468 -173.792 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' ARG . . . . . 0.943 HH12 ' HG3' ' A' ' 2' ' ' GLU . 9.7 tpt180 -90.84 172.98 8.24 Favored 'General case' 0 C--N 1.32 -0.7 0 N-CA-C 107.521 -1.289 . . . . 35.3 107.521 167.107 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . 0.575 ' OE2' ' HG3' ' A' ' 20' ' ' ARG . 0.0 OUTLIER -59.79 -23.15 63.05 Favored 'General case' 0 N--CA 1.467 0.413 0 CA-C-N 118.383 0.538 . . . . 61.32 112.327 -172.93 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 91.9 m-20 -101.4 17.79 21.76 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.855 0.36 . . . . 42.51 111.594 179.005 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 80.15 2.08 88.59 Favored Glycine 0 N--CA 1.452 -0.253 0 C-N-CA 120.943 -0.646 . . . . 40.52 112.751 176.897 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 28.4 t70 -69.19 97.85 0.96 Allowed 'General case' 0 C--N 1.323 -0.557 0 N-CA-C 109.955 -0.387 . . . . 63.51 109.955 179.712 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.47 ' OD1' ' HG3' ' A' ' 7' ' ' LYS . 52.5 m-20 -53.66 113.67 1.27 Allowed 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.331 -0.85 . . . . 74.14 111.119 176.363 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.608 HG12 ' HB2' ' A' ' 60' ' ' ALA . 25.3 t -89.27 135.56 25.66 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.602 0 CA-C-N 115.663 -0.698 . . . . 73.23 109.457 176.316 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' PHE . . . . . . . . . . . . . 40.4 t80 -90.72 109.65 20.83 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 120.988 0.423 . . . . 74.34 110.79 -172.894 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.436 ' HA ' ' HB3' ' A' ' 60' ' ' ALA . 7.9 p -97.52 151.45 4.29 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 CA-C-N 116.185 -0.461 . . . . 44.32 110.508 -179.434 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' HIS . . . . . 0.44 ' HA ' ' HD1' ' A' ' 15' ' ' PHE . 34.0 m80 -115.46 158.53 22.4 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.175 -0.466 . . . . 62.11 110.969 -175.924 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 34.3 p90 -61.69 -31.34 71.47 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.029 -0.532 . . . . 72.24 111.774 179.742 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 8.0 t -94.43 12.85 25.72 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 121.433 0.635 . . . . 62.53 109.977 -179.628 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . 0.72 ' HB1' ' HA ' ' A' ' 61' ' ' ALA . . . -112.68 -28.85 7.65 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 115.701 -0.681 . . . . 60.31 110.124 178.132 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 55.7 mt -80.33 139.01 18.82 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.53 0 CA-C-N 115.443 -0.799 . . . . 51.32 109.926 177.126 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' GLN . . . . . 0.415 ' HG3' ' O ' ' A' ' 34' ' ' GLN . 10.5 pt20 -75.7 90.31 2.84 Favored 'General case' 0 N--CA 1.45 -0.432 0 CA-C-O 121.395 0.617 . . . . 63.31 109.518 173.436 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.42 ' O ' ' HE2' ' A' ' 39' ' ' LYS . . . -74.34 61.61 2.29 Favored Glycine 0 N--CA 1.449 -0.451 0 CA-C-N 115.534 -0.757 . . . . 52.34 112.086 -179.115 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 18.1 t70 -92.61 110.33 21.76 Favored 'General case' 0 C--N 1.318 -0.764 0 N-CA-C 109.434 -0.58 . . . . 71.34 109.434 179.064 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 94.01 -57.94 2.11 Favored Glycine 0 N--CA 1.447 -0.573 0 C-N-CA 120.932 -0.652 . . . . 34.53 111.763 -176.98 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 29.7 p90 -146.14 149.61 34.33 Favored 'General case' 0 C--N 1.325 -0.479 0 N-CA-C 110.237 -0.283 . . . . 65.24 110.237 178.743 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' LYS . . . . . 0.44 ' HD2' ' N ' ' A' ' 39' ' ' LYS . 0.5 OUTLIER -102.43 75.55 1.47 Allowed 'General case' 0 C--N 1.324 -0.534 0 CA-C-O 121.196 0.522 . . . . 74.21 110.102 179.791 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . 0.419 ' HA ' ' CE2' ' A' ' 9' ' ' PHE . 66.4 m -157.43 154.83 29.43 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 115.781 -0.645 . . . . 51.21 109.939 178.908 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 87.6 mt -110.96 126.52 54.85 Favored 'General case' 0 C--N 1.321 -0.642 0 N-CA-C 109.328 -0.619 . . . . 75.33 109.328 174.301 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 36.0 t70 -69.44 112.91 6.29 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-O 121.001 0.429 . . . . 71.13 109.95 179.991 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 55.6 mt-10 -65.57 120.46 12.94 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 115.956 -0.565 . . . . 52.33 110.35 -176.89 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 105.22 -13.07 48.56 Favored Glycine 0 N--CA 1.449 -0.498 0 C-N-CA 121.014 -0.612 . . . . 32.41 111.903 -175.305 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 6.2 tp-100 -83.64 145.6 28.72 Favored 'General case' 0 C--O 1.235 0.318 0 CA-C-O 120.795 0.331 . . . . 64.21 110.272 -179.855 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -100.22 135.21 42.0 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 116.161 -0.472 . . . . 74.23 110.465 178.743 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 8.9 m -141.68 -175.93 0.9 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.493 0 CA-C-N 116.096 -0.502 . . . . 54.34 110.537 179.444 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 19.8 p -124.54 157.97 34.06 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 115.971 -0.559 . . . . 60.43 109.693 177.302 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 37.8 p90 -156.48 151.07 25.7 Favored 'General case' 0 C--N 1.321 -0.637 0 C-N-CA 120.56 -0.456 . . . . 73.13 111.545 -176.748 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . 0.736 ' HB3' ' HB2' ' A' ' 62' ' ' ASN . 26.3 t70 -91.35 94.4 9.49 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 115.834 -0.621 . . . . 75.24 109.697 174.562 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 7.6 p -73.56 133.63 31.29 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.55 0 CA-C-N 115.871 -0.604 . . . . 64.22 111.079 -176.399 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 25.7 mt-10 -119.31 171.69 8.14 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 115.847 -0.615 . . . . 74.32 110.155 179.273 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 10.8 pt-20 -72.08 149.51 44.76 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.834 -0.621 . . . . 72.52 110.87 179.968 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . 0.48 ' HA3' ' O ' ' A' ' 57' ' ' GLY . . . -155.02 124.98 1.6 Allowed Glycine 0 N--CA 1.445 -0.715 0 CA-C-N 115.87 -0.604 . . . . 32.53 111.804 178.387 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 35.4 tt0 -61.49 -33.08 73.17 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-O 120.654 0.264 . . . . 64.21 111.306 -177.535 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 22.2 mmt180 -114.47 25.98 10.6 Favored 'General case' 0 C--N 1.327 -0.375 0 N-CA-C 111.741 0.274 . . . . 72.22 111.741 -179.515 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . 0.48 ' O ' ' HA3' ' A' ' 54' ' ' GLY . . . 139.86 157.25 7.19 Favored Glycine 0 N--CA 1.448 -0.55 0 C-N-CA 120.319 -0.943 . . . . 60.23 112.378 176.757 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . 0.567 ' HG2' ' HA ' ' A' ' 26' ' ' VAL . 37.5 Cg_endo -66.47 127.2 16.85 Favored 'Trans proline' 0 C--O 1.234 0.323 0 C-N-CA 122.629 2.219 . . . . 63.23 111.517 -179.758 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 26.9 tt0 -88.72 107.86 19.17 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 116.039 -0.528 . . . . 52.23 110.728 -176.841 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . 0.608 ' HB2' HG12 ' A' ' 26' ' ' VAL . . . -79.2 97.75 6.34 Favored 'General case' 0 C--N 1.323 -0.575 0 N-CA-C 109.728 -0.471 . . . . 71.23 109.728 175.879 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . 0.72 ' HA ' ' HB1' ' A' ' 32' ' ' ALA . . . -111.44 165.83 11.64 Favored 'General case' 0 C--N 1.319 -0.74 0 CA-C-N 115.829 -0.623 . . . . 61.51 110.017 -179.994 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 62' ' ' ASN . . . . . 0.736 ' HB2' ' HB3' ' A' ' 50' ' ' ASP . 56.3 m-20 48.37 65.89 1.21 Allowed 'General case' 0 C--N 1.33 -0.271 0 O-C-N 123.727 0.642 . . . . 72.41 111.03 174.915 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 58.7 t -77.26 120.64 28.12 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.464 0 CA-C-N 116.086 -0.507 . . . . 72.52 110.493 -178.603 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 77.2 mm-40 -108.12 133.76 51.94 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-N 115.827 -0.624 . . . . 74.21 110.058 179.694 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 96.8 mttt -73.92 134.41 43.19 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 116.194 -0.457 . . . . 61.31 110.503 -179.397 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.246 0.87 0 CA-C-O 118.346 -0.835 . . . . 60.41 110.326 -179.783 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . 0.432 ' N ' ' HA ' ' A' ' 50' ' ' ASP . 23.6 mmt . . . . . 0 N--CA 1.484 1.23 0 CA-C-O 120.994 0.426 . . . . 72.24 110.387 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 11.1 mp0 -112.0 157.39 20.78 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 116.284 -0.416 . . . . 64.32 110.254 -172.702 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' GLN . . . . . 0.49 ' HA ' ' O ' ' A' ' 47' ' ' VAL . 28.6 tt0 -92.65 131.17 37.98 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 116.38 -0.373 . . . . 53.22 110.065 176.733 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . 0.412 ' HA3' ' HE2' ' A' ' 49' ' ' PHE . . . -146.16 151.62 23.83 Favored Glycine 0 N--CA 1.446 -0.685 0 C-N-CA 120.872 -0.68 . . . . 65.32 112.292 -179.58 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . 0.42 ' O ' ' HG2' ' A' ' 19' ' ' GLU . 0.2 OUTLIER -89.0 125.8 35.14 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-O 120.659 0.266 . . . . 73.42 110.923 -177.287 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.863 ' HA ' HG13 ' A' ' 18' ' ' ILE . 31.2 t -68.55 102.53 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.495 0 N-CA-C 110.098 -0.334 . . . . 60.01 110.098 176.623 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 8.8 mmmm -72.59 -68.29 0.49 Allowed 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 116.296 -0.411 . . . . 60.13 110.672 -177.531 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' TRP . . . . . . . . . . . . . 80.7 m95 -135.32 131.69 36.76 Favored 'General case' 0 C--N 1.323 -0.546 0 N-CA-C 109.755 -0.461 . . . . 70.44 109.755 178.286 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . 0.487 ' HA ' ' HA3' ' A' ' 16' ' ' GLY . 73.3 t80 -134.42 104.35 6.09 Favored 'General case' 0 C--N 1.318 -0.765 0 CA-C-O 120.912 0.387 . . . . 73.43 110.125 176.939 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' ASN . . . . . 0.628 ' OD1' ' HG2' ' A' ' 13' ' ' LYS . 16.7 t-20 -78.53 86.64 4.53 Favored 'General case' 0 C--N 1.321 -0.639 0 N-CA-C 109.305 -0.628 . . . . 64.52 109.305 178.897 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -66.31 -15.76 63.49 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 115.243 -0.89 . . . . 63.41 111.494 -177.17 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 32.7 mt-10 -68.01 -38.46 82.65 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.142 -0.481 . . . . 62.24 109.983 177.867 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . 0.628 ' HG2' ' OD1' ' A' ' 10' ' ' ASN . 28.9 mmtp -98.2 -30.45 12.63 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 116.112 -0.494 . . . . 74.05 109.946 179.955 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 104.9 20.73 9.61 Favored Glycine 0 N--CA 1.448 -0.555 0 C-N-CA 120.746 -0.74 . . . . 61.23 113.068 175.857 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 39.7 p90 -147.08 162.59 38.52 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 117.157 0.478 . . . . 73.42 110.853 -178.857 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.487 ' HA3' ' HA ' ' A' ' 9' ' ' PHE . . . -168.45 -164.15 23.66 Favored Glycine 0 N--CA 1.444 -0.823 0 C-N-CA 120.665 -0.778 . . . . 72.11 112.064 178.857 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 91.9 m-85 -133.83 124.3 26.28 Favored 'General case' 0 C--N 1.322 -0.61 0 N-CA-C 109.408 -0.59 . . . . 74.02 109.408 -178.005 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.863 HG13 ' HA ' ' A' ' 6' ' ' VAL . 11.0 tt -116.51 158.22 17.07 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.96 0 N-CA-C 109.095 -0.706 . . . . 51.45 109.095 -177.712 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' GLU . . . . . 0.42 ' HG2' ' O ' ' A' ' 5' ' ' THR . 19.8 pt-20 -106.49 134.13 50.1 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 121.375 0.607 . . . . 71.12 111.229 -178.148 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' ARG . . . . . . . . . . . . . 14.3 ttt180 -97.35 157.98 15.7 Favored 'General case' 0 C--N 1.317 -0.83 0 N-CA-C 108.224 -1.028 . . . . 63.32 108.224 172.026 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 31.7 mt-10 -44.0 -40.65 4.87 Favored 'General case' 0 N--CA 1.467 0.416 0 O-C-N 123.503 0.502 . . . . 74.54 110.885 -179.499 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 23.1 t-20 -127.59 73.62 1.46 Allowed 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 115.89 -0.595 . . . . 72.51 109.784 171.498 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 164.61 94.99 0.1 Allowed Glycine 0 C--O 1.227 -0.306 0 C-N-CA 120.41 -0.9 . . . . 71.32 112.843 175.846 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 13.3 m-20 -78.44 18.16 0.58 Allowed 'General case' 0 N--CA 1.468 0.458 0 N-CA-C 111.877 0.325 . . . . 75.05 111.877 -178.02 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 36.5 t70 -142.7 85.24 1.88 Allowed 'General case' 0 C--N 1.321 -0.671 0 CA-C-O 120.999 0.428 . . . . 71.44 110.824 -177.724 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.457 ' HB ' HG22 ' A' ' 18' ' ' ILE . 47.2 t -125.48 124.04 66.08 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.526 0 CA-C-N 115.609 -0.723 . . . . 61.3 109.185 174.94 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' PHE . . . . . . . . . . . . . 70.6 t80 -83.44 104.36 13.52 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-O 121.321 0.581 . . . . 52.14 110.834 -175.328 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.439 ' HA ' ' HB3' ' A' ' 60' ' ' ALA . 13.5 p -93.77 142.05 13.9 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.664 0 CA-C-N 115.851 -0.613 . . . . 75.23 109.788 179.089 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' HIS . . . . . 0.437 ' CE1' ' HB2' ' A' ' 32' ' ' ALA . 3.7 p80 -140.53 142.55 35.19 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.761 0.315 . . . . 74.34 111.017 -175.976 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 17.2 p90 -60.49 -25.14 65.84 Favored 'General case' 0 N--CA 1.469 0.476 0 CA-C-N 115.8 -0.636 . . . . 65.1 112.706 -170.775 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 11.6 p -77.87 -8.0 57.47 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-O 121.028 0.442 . . . . 43.21 111.587 -178.11 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . 0.688 ' HB1' ' HA ' ' A' ' 61' ' ' ALA . . . -113.81 -23.53 9.61 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 120.921 0.391 . . . . 63.3 111.074 179.178 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.437 HD13 ' HB2' ' A' ' 41' ' ' LEU . 56.9 mt -69.07 150.51 10.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 N-CA-C 109.556 -0.535 . . . . 74.53 109.556 174.104 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 34' ' ' GLN . . . . . 0.415 HE21 ' HA ' ' A' ' 64' ' ' GLN . 4.8 pp0? -112.42 139.14 48.23 Favored 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 109.45 -0.574 . . . . 64.23 109.45 175.056 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -162.66 158.63 30.86 Favored Glycine 0 N--CA 1.446 -0.674 0 C-N-CA 120.753 -0.737 . . . . 63.1 111.779 -178.289 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 33.9 t70 -101.41 99.46 9.8 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-O 120.952 0.405 . . . . 62.32 110.391 -178.09 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 94.81 -55.84 1.9 Allowed Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 121.045 -0.598 . . . . 72.23 112.404 -179.358 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 72.1 m-85 -115.05 145.44 42.3 Favored 'General case' 0 C--N 1.323 -0.577 0 N-CA-C 109.889 -0.411 . . . . 70.22 109.889 179.593 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 13.9 mmmm -101.91 5.54 40.94 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-O 120.993 0.425 . . . . 75.44 110.815 -177.899 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 13.3 p -68.98 127.22 32.34 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 115.832 -0.622 . . . . 73.24 110.705 179.088 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . 0.437 ' HB2' HD13 ' A' ' 33' ' ' ILE . 12.6 tp -92.63 146.81 23.38 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 116.029 -0.532 . . . . 74.14 109.675 178.699 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . 0.856 ' HB2' ' HB2' ' A' ' 45' ' ' GLN . 2.1 m-20 -73.92 124.81 26.88 Favored 'General case' 0 C--N 1.318 -0.787 0 CA-C-N 115.837 -0.62 . . . . 72.35 110.885 -175.108 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 9.3 pt-20 -69.47 131.34 44.58 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-O 120.845 0.355 . . . . 64.2 110.164 177.456 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 82.24 4.06 90.34 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.863 -0.684 . . . . 64.42 112.113 -177.65 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 45' ' ' GLN . . . . . 0.856 ' HB2' ' HB2' ' A' ' 42' ' ' ASP . 24.6 tp60 -80.91 126.32 31.22 Favored 'General case' 0 C--N 1.326 -0.455 0 N-CA-C 110.109 -0.33 . . . . 70.12 110.109 -179.693 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 0.438 ' O ' ' HB3' ' A' ' 66' ' ' ALA . . . -86.88 83.15 7.59 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-O 121.042 0.449 . . . . 42.12 110.048 176.006 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 0.507 HG12 ' HA ' ' A' ' 65' ' ' LYS . 19.1 m -89.85 167.98 1.59 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.578 0 CA-C-N 115.631 -0.713 . . . . 70.12 111.734 -173.563 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 48' ' ' THR . . . . . 0.497 ' OG1' ' HB3' ' A' ' 64' ' ' GLN . 4.9 p -112.4 107.32 16.08 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 115.959 -0.564 . . . . 74.51 110.145 177.379 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 49' ' ' PHE . . . . . 0.582 ' HA ' ' O ' ' A' ' 62' ' ' ASN . 38.2 p90 -122.17 160.57 24.85 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 115.838 -0.619 . . . . 73.53 111.234 -173.063 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . 0.432 ' HA ' ' N ' ' A' ' 1' ' ' MET . 22.6 t70 -107.67 115.59 30.43 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-O 121.07 0.462 . . . . 72.11 110.563 175.058 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 66.5 t -66.65 132.51 32.02 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.498 0 CA-C-N 115.734 -0.667 . . . . 63.52 112.12 -174.692 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . 1.044 ' HB2' ' HB2' ' A' ' 59' ' ' GLN . 34.4 mt-10 -94.27 159.55 15.08 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.736 -0.666 . . . . 73.22 109.675 174.309 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 39.1 mt-10 -114.72 110.63 20.03 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-N 116.38 -0.373 . . . . 74.43 110.353 178.382 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -126.49 170.8 18.26 Favored Glycine 0 N--CA 1.448 -0.515 0 C-N-CA 120.878 -0.677 . . . . 34.21 112.092 -179.802 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 18.3 mt-30 -92.98 69.3 4.5 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-O 121.365 0.602 . . . . 74.15 110.034 -177.852 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 15.8 ptp180 178.59 -30.47 0.01 OUTLIER 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 114.741 -1.118 . . . . 72.51 108.921 -176.154 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 162.71 -179.54 37.92 Favored Glycine 0 N--CA 1.44 -1.098 0 N-CA-C 110.325 -1.11 . . . . 65.52 110.325 178.486 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 57.5 Cg_endo -76.34 128.12 10.24 Favored 'Trans proline' 0 N--CA 1.454 -0.822 0 C-N-CA 121.884 1.723 . . . . 60.15 111.161 175.228 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . 1.044 ' HB2' ' HB2' ' A' ' 52' ' ' GLU . 9.4 mm100 -93.4 169.73 10.14 Favored 'General case' 0 C--N 1.321 -0.639 0 N-CA-C 109.0 -0.741 . . . . 71.13 109.0 178.591 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . 0.439 ' HB3' ' HA ' ' A' ' 28' ' ' VAL . . . -124.75 111.33 15.42 Favored 'General case' 0 C--N 1.319 -0.745 0 C-N-CA 120.719 -0.393 . . . . 73.13 111.327 179.308 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . 0.688 ' HA ' ' HB1' ' A' ' 32' ' ' ALA . . . -123.11 159.35 28.71 Favored 'General case' 0 CA--C 1.515 -0.379 0 CA-C-N 115.984 -0.553 . . . . 74.41 110.161 177.156 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 62' ' ' ASN . . . . . 0.582 ' O ' ' HA ' ' A' ' 49' ' ' PHE . 94.9 m-20 53.65 78.3 0.16 Allowed 'General case' 0 CA--C 1.517 -0.304 0 CA-C-O 121.274 0.559 . . . . 63.45 109.569 -177.481 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.404 HG11 HD21 ' A' ' 41' ' ' LEU . 44.1 t -107.8 101.72 12.93 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.611 0 CA-C-N 115.147 -0.933 . . . . 60.24 110.572 -175.995 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 64' ' ' GLN . . . . . 0.497 ' HB3' ' OG1' ' A' ' 48' ' ' THR . 8.3 tt0 -85.3 124.13 31.57 Favored 'General case' 0 C--N 1.319 -0.728 0 CA-C-N 115.959 -0.564 . . . . 64.13 110.066 -179.382 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . 0.507 ' HA ' HG12 ' A' ' 47' ' ' VAL . 42.9 mttm -68.16 127.39 32.72 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.346 -0.388 . . . . 74.21 110.263 -179.289 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 66' ' ' ALA . . . . . 0.438 ' HB3' ' O ' ' A' ' 46' ' ' ALA . . . . . . . . 0 C--O 1.246 0.898 0 CA-C-O 118.091 -0.956 . . . . 52.13 110.444 -178.615 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 24.6 mmt . . . . . 0 N--CA 1.483 1.178 0 N-CA-C 109.618 -0.512 . . . . 75.12 109.618 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -152.43 31.31 0.53 Allowed 'General case' 0 C--N 1.323 -0.554 0 CA-C-O 121.122 0.486 . . . . 63.34 111.164 -170.457 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 35.1 tt0 -88.35 116.29 26.46 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 115.832 -0.622 . . . . 74.44 110.237 177.58 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -126.91 -174.33 13.77 Favored Glycine 0 N--CA 1.449 -0.472 0 N-CA-C 110.99 -0.844 . . . . 63.54 110.99 177.727 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . 0.538 ' O ' ' HG2' ' A' ' 19' ' ' GLU . 10.1 m -130.09 132.19 46.05 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-N 117.3 0.55 . . . . 71.22 110.682 179.515 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 60.3 t -76.22 119.83 25.08 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.446 0 CA-C-N 116.495 -0.321 . . . . 73.53 110.169 -179.286 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . 0.964 ' HE3' ' HA ' ' A' ' 7' ' ' LYS . 0.0 OUTLIER -92.97 -68.22 0.81 Allowed 'General case' 0 C--N 1.325 -0.467 0 CA-C-O 120.92 0.391 . . . . 74.25 110.797 179.113 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' TRP . . . . . . . . . . . . . 63.7 m95 -112.79 126.53 55.53 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 116.078 -0.51 . . . . 75.14 109.73 -177.917 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . 0.407 ' CE2' ' HB2' ' A' ' 11' ' ' ALA . 54.1 t80 -125.07 91.14 3.37 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-O 121.201 0.525 . . . . 72.33 110.542 -176.807 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 18.2 m120 -87.47 78.36 8.64 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-O 121.426 0.631 . . . . 63.41 109.815 -179.945 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . 0.407 ' HB2' ' CE2' ' A' ' 9' ' ' PHE . . . -63.71 -32.57 74.1 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 115.136 -0.938 . . . . 63.31 110.833 -179.292 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 42.9 mt-10 -76.89 -8.86 58.14 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.112 -0.494 . . . . 64.02 111.026 179.426 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . 0.419 ' HB3' ' CE2' ' A' ' 15' ' ' PHE . 75.5 mmtt -107.75 -26.06 10.98 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 120.938 0.399 . . . . 73.02 110.28 178.948 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 96.61 20.69 23.83 Favored Glycine 0 N--CA 1.449 -0.482 0 C-N-CA 120.942 -0.647 . . . . 71.45 113.017 175.779 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . 0.419 ' CE2' ' HB3' ' A' ' 13' ' ' LYS . 31.5 p90 -155.09 167.11 31.45 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-O 120.982 0.42 . . . . 71.11 111.262 179.104 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -157.84 168.49 34.44 Favored Glycine 0 N--CA 1.445 -0.719 0 CA-C-N 115.819 -0.628 . . . . 74.23 112.021 180.0 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 91.4 m-85 -121.13 118.6 30.11 Favored 'General case' 0 C--N 1.321 -0.63 0 CA-C-O 120.885 0.374 . . . . 74.23 110.543 -178.459 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 55.2 mt -104.16 124.51 58.65 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 N-CA-C 109.601 -0.518 . . . . 70.34 109.601 177.711 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' GLU . . . . . 0.538 ' HG2' ' O ' ' A' ' 5' ' ' THR . 14.6 pt-20 -82.8 130.29 35.11 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-O 121.436 0.636 . . . . 73.51 111.525 -173.12 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' ARG . . . . . 0.413 ' HB3' ' HB3' ' A' ' 24' ' ' ASP . 16.2 ttp180 -113.15 158.82 19.93 Favored 'General case' 0 C--N 1.324 -0.532 0 N-CA-C 108.839 -0.801 . . . . 63.33 108.839 175.03 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 5.6 mm-40 -49.36 -36.43 21.57 Favored 'General case' 0 N--CA 1.472 0.657 0 N-CA-C 113.961 1.097 . . . . 62.33 113.961 -168.951 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 61.7 t30 -84.16 12.49 6.4 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 121.189 0.519 . . . . 72.0 111.321 -175.667 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 76.39 10.2 85.66 Favored Glycine 0 N--CA 1.454 -0.103 0 N-CA-C 110.508 -1.037 . . . . 73.24 110.508 -173.185 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . 0.413 ' HB3' ' HB3' ' A' ' 20' ' ' ARG . 17.7 t70 -76.75 90.12 3.42 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-N 114.417 -0.892 . . . . 43.5 109.894 -177.714 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 12.1 p-10 -70.59 114.16 8.41 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-O 121.592 0.71 . . . . 75.43 110.734 178.845 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 23.8 t -84.53 122.55 38.15 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.683 0 CA-C-N 115.185 -0.916 . . . . 74.42 109.839 179.721 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' PHE . . . . . . . . . . . . . 70.8 t80 -85.36 109.31 18.31 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 115.855 -0.611 . . . . 72.0 110.831 -174.997 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.485 ' HB ' ' HB3' ' A' ' 60' ' ' ALA . 11.3 p -96.06 147.14 6.28 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.596 0 N-CA-C 109.867 -0.42 . . . . 54.51 109.867 178.256 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' HIS . . . . . 0.494 ' O ' HG13 ' A' ' 33' ' ' ILE . 5.7 p80 -128.02 153.53 46.66 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 120.741 0.305 . . . . 72.13 110.902 -176.911 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 48.0 p90 -57.26 -29.34 63.75 Favored 'General case' 0 N--CA 1.468 0.447 0 N-CA-C 113.489 0.922 . . . . 74.52 113.489 -170.192 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 21.9 m -76.64 -1.2 26.5 Favored 'General case' 0 C--N 1.326 -0.45 0 C-N-CA 120.93 -0.308 . . . . 71.22 111.245 -179.998 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . 0.597 ' HB1' ' HA ' ' A' ' 61' ' ' ALA . . . -125.02 -11.36 7.09 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.874 0.369 . . . . 73.01 110.919 177.631 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.494 HG13 ' O ' ' A' ' 29' ' ' HIS . 85.9 mt -77.49 137.93 21.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.114 -0.494 . . . . 74.12 110.837 178.372 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 7.6 pt20 -69.27 110.56 4.68 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.974 0.416 . . . . 65.45 109.947 173.527 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -148.25 54.61 0.51 Allowed Glycine 0 N--CA 1.448 -0.516 0 C-N-CA 120.303 -0.951 . . . . 44.14 112.915 -177.889 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . 0.703 ' HB2' ' HD3' ' A' ' 39' ' ' LYS . 5.4 m-20 -76.7 71.72 3.3 Favored 'General case' 0 C--N 1.329 -0.288 0 N-CA-C 109.718 -0.475 . . . . 74.43 109.718 177.096 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 75.58 -77.22 1.26 Allowed Glycine 0 N--CA 1.445 -0.706 0 C-N-CA 120.787 -0.721 . . . . 73.54 112.309 -178.935 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 41.4 p90 -105.61 17.4 23.87 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 120.928 0.394 . . . . 64.5 112.036 -174.343 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 39' ' ' LYS . . . . . 0.703 ' HD3' ' HB2' ' A' ' 36' ' ' ASP . 1.9 mptm? -94.17 134.55 36.5 Favored 'General case' 0 C--N 1.321 -0.631 0 N-CA-C 109.616 -0.513 . . . . 71.2 109.616 174.882 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 14.7 p -159.8 170.18 22.03 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-O 120.925 0.393 . . . . 72.03 110.71 -179.159 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 3.7 mm? -110.43 158.17 18.78 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 116.101 -0.499 . . . . 64.32 109.851 177.202 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 28.3 t70 -118.3 137.77 52.84 Favored 'General case' 0 C--N 1.321 -0.636 0 N-CA-C 109.634 -0.506 . . . . 75.41 109.634 -177.562 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 8.5 pt-20 -71.14 116.99 12.08 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-O 121.523 0.677 . . . . 63.5 110.072 179.73 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 105.54 6.2 38.6 Favored Glycine 0 N--CA 1.445 -0.723 0 CA-C-N 115.69 -0.687 . . . . 70.13 111.463 -174.002 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 62.2 tp60 -92.11 132.09 36.86 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 120.743 0.306 . . . . 71.3 110.877 179.05 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -78.66 132.14 36.94 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 116.01 -0.541 . . . . 72.41 109.561 173.504 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 25.5 m -137.81 153.66 28.0 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.634 0 CA-C-N 116.064 -0.516 . . . . 60.51 111.699 -177.191 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 9.4 p -113.1 111.79 22.74 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-N 115.872 -0.604 . . . . 72.33 109.78 174.754 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 49' ' ' PHE . . . . . 0.421 ' HA ' ' O ' ' A' ' 62' ' ' ASN . 39.5 p90 -120.81 161.93 20.65 Favored 'General case' 0 C--N 1.319 -0.729 0 CA-C-N 115.959 -0.564 . . . . 73.2 110.569 -172.551 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 33.1 t70 -93.15 118.0 30.72 Favored 'General case' 0 C--N 1.32 -0.711 0 N-CA-C 109.491 -0.559 . . . . 71.33 109.491 173.978 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 5.1 p -78.23 109.13 12.54 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.65 0 CA-C-O 121.67 0.748 . . . . 73.41 111.06 -176.539 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 9.7 tp10 -92.75 119.88 32.57 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-N 115.375 -0.83 . . . . 62.21 108.886 175.583 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 12.9 pt-20 -107.15 124.89 50.36 Favored 'General case' 0 C--N 1.317 -0.821 0 CA-C-O 120.897 0.38 . . . . 63.44 110.227 -179.923 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -146.78 -142.25 3.69 Favored Glycine 0 N--CA 1.448 -0.525 0 C-N-CA 120.615 -0.802 . . . . 71.54 112.281 -179.751 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 16.4 mm100 -77.64 -26.36 50.42 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-O 120.982 0.42 . . . . 73.43 110.451 -178.465 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 24.4 mmm180 -87.35 4.51 42.68 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 116.082 -0.508 . . . . 74.5 110.351 -179.445 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 89.36 -138.39 14.64 Favored Glycine 0 N--CA 1.446 -0.646 0 C-N-CA 120.928 -0.653 . . . . 64.55 111.618 -178.361 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 89.2 Cg_endo -84.73 104.86 0.96 Allowed 'Trans proline' 0 N--CA 1.455 -0.749 0 C-N-CA 122.701 2.267 . . . . 64.14 112.329 177.455 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 12.3 pt20 -112.52 135.62 53.01 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-O 121.144 0.497 . . . . 72.5 110.017 177.551 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . 0.485 ' HB3' ' HB ' ' A' ' 28' ' ' VAL . . . -86.34 128.12 34.89 Favored 'General case' 0 C--N 1.319 -0.758 0 CA-C-O 121.149 0.499 . . . . 55.31 111.708 -172.743 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . 0.597 ' HA ' ' HB1' ' A' ' 32' ' ' ALA . . . -130.21 143.63 50.89 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 115.436 -0.802 . . . . 74.12 109.282 174.016 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 62' ' ' ASN . . . . . 0.421 ' O ' ' HA ' ' A' ' 49' ' ' PHE . 45.0 m-80 59.45 87.23 0.08 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 121.244 0.545 . . . . 71.45 110.391 -176.965 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 47.8 t -105.39 111.14 33.49 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.591 0 CA-C-N 115.721 -0.672 . . . . 71.13 110.273 -176.883 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 24.6 mt-30 -107.93 142.53 37.9 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-N 116.149 -0.478 . . . . 74.32 109.944 -179.73 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 46.0 mttp -77.48 144.22 37.9 Favored 'General case' 0 C--N 1.325 -0.492 0 C-N-CA 120.868 -0.333 . . . . 73.4 110.422 179.567 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.247 0.958 0 CA-C-O 118.781 -0.628 . . . . 52.31 110.413 178.077 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 54.2 tpp . . . . . 0 N--CA 1.483 1.19 0 CA-C-O 120.707 0.289 . . . . 54.21 111.025 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . 0.607 ' HG2' HG23 ' A' ' 51' ' ' VAL . 4.8 mp0 -85.6 101.07 12.39 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 121.125 0.488 . . . . 73.4 111.318 -178.178 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' GLN . . . . . 0.663 ' HG2' HG22 ' A' ' 48' ' ' THR . 79.7 mt-30 -97.49 122.95 41.13 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.732 -0.667 . . . . 74.31 109.638 172.209 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -138.14 178.31 19.33 Favored Glycine 0 N--CA 1.445 -0.721 0 N-CA-C 111.136 -0.786 . . . . 62.24 111.136 179.178 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . 0.422 ' O ' ' HG2' ' A' ' 19' ' ' GLU . 13.1 m -125.11 130.54 52.42 Favored 'General case' 0 C--N 1.315 -0.919 0 CA-C-N 117.28 0.54 . . . . 74.55 110.512 178.088 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 61.3 t -72.58 108.57 4.06 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.472 0 CA-C-N 116.376 -0.375 . . . . 64.2 110.01 178.813 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . 0.444 ' HB3' ' CE3' ' A' ' 8' ' ' TRP . 6.5 mmtm -73.62 -48.48 32.23 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 116.26 -0.427 . . . . 75.53 110.208 177.622 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' TRP . . . . . 0.542 ' HE1' ' HD2' ' A' ' 17' ' ' PHE . 15.6 p90 -164.14 158.92 19.76 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.661 -0.7 . . . . 75.31 110.075 177.763 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . 0.415 ' HD1' ' HA3' ' A' ' 16' ' ' GLY . 71.4 t80 -134.33 106.48 7.12 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 116.264 -0.426 . . . . 74.44 110.12 178.622 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 87.8 m-20 -76.71 85.09 3.34 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 116.048 -0.524 . . . . 54.44 109.821 179.791 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -62.39 -38.11 88.36 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 115.519 -0.764 . . . . 62.24 111.492 -177.234 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 42.0 mt-10 -72.55 -14.41 61.63 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 116.253 -0.43 . . . . 72.23 111.056 -179.571 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 32.2 mmmt -101.21 -26.32 13.69 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.88 0.372 . . . . 65.44 110.225 177.922 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 100.15 7.3 52.61 Favored Glycine 0 N--CA 1.45 -0.427 0 C-N-CA 120.83 -0.7 . . . . 63.23 113.253 175.423 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 41.0 p90 -151.16 154.96 37.91 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-O 121.125 0.488 . . . . 75.33 111.602 -176.077 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.415 ' HA3' ' HD1' ' A' ' 9' ' ' PHE . . . -135.95 178.45 18.71 Favored Glycine 0 N--CA 1.444 -0.803 0 N-CA-C 111.055 -0.818 . . . . 62.34 111.055 178.65 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . 0.542 ' HD2' ' HE1' ' A' ' 8' ' ' TRP . 79.9 m-85 -131.28 123.23 27.92 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-O 121.197 0.522 . . . . 55.23 111.243 -177.975 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 64.5 mt -106.43 126.48 62.15 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 CA-C-N 115.482 -0.781 . . . . 54.24 109.144 176.803 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' GLU . . . . . 0.422 ' HG2' ' O ' ' A' ' 5' ' ' THR . 17.2 pt-20 -79.53 139.36 37.58 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-O 121.327 0.584 . . . . 75.31 112.299 -173.464 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' ARG . . . . . . . . . . . . . 10.0 tpt180 -109.83 166.61 10.79 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.082 -0.963 . . . . 64.1 108.94 174.846 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . 0.453 ' CD ' ' H ' ' A' ' 21' ' ' GLU . 2.3 mp0 -43.95 -48.68 8.62 Favored 'General case' 0 N--CA 1.472 0.635 0 N-CA-C 112.397 0.518 . . . . 75.1 112.397 179.409 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 74.6 m-20 -71.41 -7.08 44.97 Favored 'General case' 0 N--CA 1.468 0.429 0 CA-C-N 116.295 -0.411 . . . . 74.34 112.025 -174.9 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 90.01 7.63 67.94 Favored Glycine 0 N--CA 1.45 -0.387 0 N-CA-C 110.084 -1.206 . . . . 52.13 110.084 -170.145 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 13.0 t70 -70.28 93.2 0.83 Allowed 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 114.486 -0.857 . . . . 73.0 109.953 -179.262 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.405 ' HB2' ' HB3' ' A' ' 17' ' ' PHE . 13.4 p-10 -65.76 101.92 0.69 Allowed 'General case' 0 C--N 1.321 -0.644 0 CA-C-N 115.549 -0.75 . . . . 54.11 110.65 176.848 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 40.0 t -71.01 130.41 34.95 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.587 0 CA-C-N 115.444 -0.798 . . . . 71.24 110.547 -178.487 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' PHE . . . . . . . . . . . . . 63.1 t80 -79.39 108.64 13.07 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 116.079 -0.51 . . . . 65.25 110.147 -178.294 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 9.3 p -111.16 141.5 26.33 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.598 0 N-CA-C 110.061 -0.348 . . . . 65.15 110.061 179.242 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' HIS . . . . . 0.555 ' O ' HG13 ' A' ' 33' ' ' ILE . 6.0 p80 -128.94 145.75 51.15 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.795 0.331 . . . . 52.13 110.863 -177.03 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 37.5 p90 -58.82 -27.69 65.31 Favored 'General case' 0 N--CA 1.467 0.421 0 CA-C-N 115.679 -0.691 . . . . 73.42 112.294 -171.227 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 1.5 p -79.03 6.64 8.91 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-O 120.744 0.307 . . . . 74.23 111.707 -179.331 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -129.25 -14.74 4.26 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 121.002 0.429 . . . . 72.21 110.879 175.287 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.755 HD13 HD21 ' A' ' 41' ' ' LEU . 24.9 mt -80.45 161.68 3.86 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.164 -0.471 . . . . 65.52 110.089 176.263 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 34' ' ' GLN . . . . . 0.682 ' NE2' ' HA ' ' A' ' 64' ' ' GLN . 26.5 pt20 -87.14 -173.75 4.57 Favored 'General case' 0 C--N 1.327 -0.383 0 N-CA-C 110.107 -0.331 . . . . 43.23 110.107 177.485 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -143.29 62.61 0.5 Allowed Glycine 0 N--CA 1.449 -0.471 0 C-N-CA 120.72 -0.752 . . . . 50.52 112.276 178.086 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 13.9 p-10 -94.98 118.01 31.1 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-O 121.434 0.635 . . . . 74.55 110.445 -179.55 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 81.75 -61.42 4.65 Favored Glycine 0 N--CA 1.45 -0.367 0 N-CA-C 111.41 -0.676 . . . . 42.31 111.41 -175.054 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 65.5 m-85 -137.58 165.93 25.13 Favored 'General case' 0 C--N 1.325 -0.481 0 N-CA-C 109.292 -0.633 . . . . 61.54 109.292 175.618 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 39' ' ' LYS . . . . . 0.4 ' HD2' ' N ' ' A' ' 39' ' ' LYS . 1.0 OUTLIER -99.84 28.54 4.7 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-O 121.71 0.767 . . . . 71.42 109.613 176.048 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 37.4 m -132.74 151.2 52.04 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 115.168 -0.924 . . . . 64.41 109.676 178.123 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . 0.755 HD21 HD13 ' A' ' 33' ' ' ILE . 3.5 mm? -91.22 148.01 22.65 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 116.346 -0.388 . . . . 72.3 110.758 -176.708 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 4.8 m-20 -91.61 113.35 25.6 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 115.797 -0.638 . . . . 63.35 109.293 175.452 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 4.5 mp0 -62.97 129.82 42.06 Favored 'General case' 0 C--N 1.321 -0.669 0 CA-C-N 116.061 -0.518 . . . . 62.23 110.422 -179.305 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 97.89 -7.88 63.09 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 121.042 -0.599 . . . . 63.14 112.102 -178.263 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 29.6 tp60 -84.15 123.85 30.52 Favored 'General case' 0 C--N 1.324 -0.523 0 N-CA-C 110.173 -0.306 . . . . 60.34 110.173 179.83 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -68.1 135.28 51.94 Favored 'General case' 0 C--N 1.328 -0.345 0 N-CA-C 109.403 -0.592 . . . . 75.2 109.403 172.623 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 0.546 HG12 ' HA ' ' A' ' 65' ' ' LYS . 21.1 m -134.24 154.05 36.9 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.771 0 CA-C-O 121.214 0.53 . . . . 75.32 111.501 -175.704 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 48' ' ' THR . . . . . 0.663 HG22 ' HG2' ' A' ' 3' ' ' GLN . 33.0 p -113.72 117.13 30.66 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 115.503 -0.771 . . . . 73.43 109.433 174.68 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 49' ' ' PHE . . . . . 0.424 ' HA ' ' O ' ' A' ' 62' ' ' ASN . 40.8 p90 -129.76 170.37 13.93 Favored 'General case' 0 C--N 1.316 -0.872 0 CA-C-N 115.966 -0.561 . . . . 72.31 110.913 -173.148 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 38.8 t70 -112.01 143.87 42.3 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-N 115.864 -0.607 . . . . 63.34 109.813 174.306 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . 0.607 HG23 ' HG2' ' A' ' 2' ' ' GLU . 84.7 t -94.88 121.52 45.54 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.553 0 CA-C-O 121.165 0.507 . . . . 73.32 110.875 -178.528 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . 0.582 ' HB3' ' HG3' ' A' ' 59' ' ' GLN . 0.0 OUTLIER -94.24 141.97 27.94 Favored 'General case' 0 C--N 1.321 -0.648 0 N-CA-C 108.849 -0.797 . . . . 64.45 108.849 174.288 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 4.9 pt-20 -111.93 106.37 15.05 Favored 'General case' 0 C--N 1.316 -0.855 0 CA-C-O 121.287 0.565 . . . . 73.1 111.0 -174.557 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -126.76 -169.58 12.76 Favored Glycine 0 N--CA 1.448 -0.538 0 C-N-CA 120.852 -0.69 . . . . 44.13 112.019 -179.403 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 44.7 mt-30 -76.77 -3.1 36.48 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.952 0.406 . . . . 63.2 111.109 -178.095 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 56' ' ' ARG . . . . . 0.423 HH11 ' HD2' ' A' ' 56' ' ' ARG . 17.7 mmm180 -100.24 3.82 43.83 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-O 120.95 0.405 . . . . 72.33 110.496 176.416 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 94.28 -142.43 16.02 Favored Glycine 0 N--CA 1.446 -0.644 0 C-N-CA 120.843 -0.694 . . . . 33.21 111.872 -178.364 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 74.3 Cg_endo -79.97 106.93 2.0 Favored 'Trans proline' 0 N--CA 1.458 -0.597 0 C-N-CA 122.76 2.306 . . . . 75.02 112.703 -179.309 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . 0.582 ' HG3' ' HB3' ' A' ' 52' ' ' GLU . 4.1 pt20 -111.7 126.43 55.03 Favored 'General case' 0 C--N 1.322 -0.627 0 CA-C-N 115.778 -0.646 . . . . 74.21 109.655 177.701 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -80.05 130.47 35.28 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-O 121.024 0.44 . . . . 20.05 111.464 -174.871 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -135.13 145.35 47.75 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 115.452 -0.795 . . . . 33.1 109.321 177.717 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 62' ' ' ASN . . . . . 0.424 ' O ' ' HA ' ' A' ' 49' ' ' PHE . 89.2 m-20 59.59 82.99 0.14 Allowed 'General case' 0 C--N 1.327 -0.398 0 CA-C-O 121.164 0.507 . . . . 75.53 110.225 -176.621 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.407 HG13 ' HB3' ' A' ' 49' ' ' PHE . 39.2 t -113.06 106.35 20.57 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.511 0 CA-C-N 115.545 -0.752 . . . . 63.31 110.394 -177.061 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 64' ' ' GLN . . . . . 0.682 ' HA ' ' NE2' ' A' ' 34' ' ' GLN . 53.4 mt-30 -99.73 145.32 27.79 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 116.401 -0.363 . . . . 75.43 110.395 -179.349 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . 0.546 ' HA ' HG12 ' A' ' 47' ' ' VAL . 28.4 mtmm -82.61 136.4 34.81 Favored 'General case' 0 C--N 1.324 -0.54 0 N-CA-C 110.076 -0.342 . . . . 75.02 110.076 -179.864 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.247 0.941 0 CA-C-O 118.843 -0.599 . . . . 53.03 110.485 -179.108 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . 0.528 ' N ' ' HA ' ' A' ' 50' ' ' ASP . 92.9 mtp . . . . . 0 N--CA 1.483 1.194 0 CA-C-O 120.54 0.209 . . . . 73.53 111.046 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 2.2 mp0 -96.52 178.74 5.24 Favored 'General case' 0 C--O 1.237 0.447 0 CA-C-O 121.215 0.531 . . . . 72.22 111.676 -172.608 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' GLN . . . . . 0.472 ' HG2' HG22 ' A' ' 48' ' ' THR . 65.8 mt-30 -91.95 143.6 26.32 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.341 -0.845 . . . . 60.52 110.248 179.612 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . 0.68 ' HA3' ' HE2' ' A' ' 49' ' ' PHE . . . -159.26 150.86 21.58 Favored Glycine 0 N--CA 1.447 -0.626 0 C-N-CA 120.932 -0.652 . . . . 70.11 111.917 178.252 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . 0.543 ' HA ' ' HA ' ' A' ' 46' ' ' ALA . 3.5 m -98.02 133.47 42.44 Favored 'General case' 0 C--N 1.32 -0.703 0 CA-C-O 120.563 0.22 . . . . 43.42 110.438 -179.029 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 51.2 t -68.16 103.62 0.71 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 N-CA-C 109.541 -0.54 . . . . 73.42 109.541 175.068 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . 0.764 ' HD3' ' HB3' ' A' ' 19' ' ' GLU . 31.0 mmmt -61.56 -60.7 3.3 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 121.342 0.591 . . . . 71.1 110.543 -176.706 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' TRP . . . . . . . . . . . . . 28.7 p90 -156.42 136.47 12.77 Favored 'General case' 0 C--N 1.319 -0.726 0 CA-C-N 115.349 -0.841 . . . . 74.23 109.533 176.695 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . 0.514 ' HA ' ' HA3' ' A' ' 16' ' ' GLY . 70.7 t80 -132.41 113.13 12.79 Favored 'General case' 0 C--N 1.317 -0.807 0 CA-C-O 121.09 0.471 . . . . 65.1 110.287 -177.033 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 2.6 m-20 -78.0 80.26 4.44 Favored 'General case' 0 C--N 1.322 -0.624 0 N-CA-C 108.892 -0.781 . . . . 74.32 108.892 176.014 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -60.53 -33.26 72.39 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 121.079 0.466 . . . . 73.31 110.918 -178.386 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . 0.434 ' HG3' ' HG2' ' A' ' 13' ' ' LYS . 6.8 pt-20 -67.71 -25.12 65.5 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 115.462 -0.79 . . . . 64.22 111.555 -179.824 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . 0.434 ' HG2' ' HG3' ' A' ' 12' ' ' GLU . 47.5 mmtm -110.06 -15.4 14.04 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-O 120.845 0.355 . . . . 73.01 111.222 -176.881 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 94.06 20.37 30.88 Favored Glycine 0 N--CA 1.449 -0.456 0 C-N-CA 120.995 -0.621 . . . . 73.31 114.148 170.237 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 43.2 p90 -153.62 156.44 37.94 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 117.67 0.735 . . . . 74.4 111.384 -179.321 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.514 ' HA3' ' HA ' ' A' ' 9' ' ' PHE . . . -167.73 -169.75 31.65 Favored Glycine 0 N--CA 1.45 -0.398 0 N-CA-C 111.883 -0.487 . . . . 52.12 111.883 178.389 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 88.1 m-85 -133.09 139.29 47.05 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 121.122 0.487 . . . . 60.24 111.309 -179.068 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 56.9 mt -119.93 145.33 26.36 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.547 0 N-CA-C 108.908 -0.775 . . . . 73.13 108.908 176.697 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' GLU . . . . . 0.764 ' HB3' ' HD3' ' A' ' 7' ' ' LYS . 20.9 pt-20 -89.37 158.22 17.86 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-O 121.15 0.5 . . . . 65.05 111.045 -177.123 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' ARG . . . . . 0.6 ' HD3' ' HB3' ' A' ' 24' ' ' ASP . 70.4 ttt180 -134.15 158.72 42.94 Favored 'General case' 0 C--N 1.32 -0.674 0 N-CA-C 108.523 -0.918 . . . . 75.13 108.523 179.146 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 44.1 mt-10 -48.2 -50.92 27.41 Favored 'General case' 0 N--CA 1.466 0.336 0 N-CA-C 113.229 0.825 . . . . 74.31 113.229 -172.316 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 57.8 m-80 -87.5 20.58 2.84 Favored 'General case' 0 C--N 1.327 -0.405 0 N-CA-C 111.878 0.325 . . . . 60.24 111.878 -173.964 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 76.16 10.55 85.32 Favored Glycine 0 C--N 1.33 0.234 0 C-N-CA 120.605 -0.807 . . . . 70.03 111.731 -178.897 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . 0.6 ' HB3' ' HD3' ' A' ' 20' ' ' ARG . 38.5 t70 -76.95 84.06 3.49 Favored 'General case' 0 C--N 1.322 -0.622 0 N-CA-C 109.772 -0.455 . . . . 75.24 109.772 -179.571 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 8.1 p-10 -58.62 127.56 32.76 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 121.361 0.6 . . . . 64.02 111.123 -176.467 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.545 ' HA ' ' HB2' ' A' ' 58' ' ' PRO . 17.1 t -105.64 124.37 60.62 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.615 0 CA-C-N 115.424 -0.807 . . . . 64.24 110.216 -176.453 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' PHE . . . . . . . . . . . . . 91.9 t80 -82.57 131.21 35.22 Favored 'General case' 0 C--N 1.326 -0.453 0 N-CA-C 110.063 -0.347 . . . . 73.23 110.063 179.944 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 9.8 p -123.3 137.41 56.72 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-O 121.278 0.561 . . . . 72.31 111.006 -179.481 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 22.0 t60 -115.02 151.77 33.62 Favored 'General case' 0 C--N 1.324 -0.504 0 N-CA-C 108.142 -1.059 . . . . 64.1 108.142 176.844 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 17.3 p90 -60.2 -20.15 57.43 Favored 'General case' 0 N--CA 1.472 0.661 0 N-CA-C 112.555 0.576 . . . . 74.41 112.555 -172.052 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 23.1 t -90.14 -9.06 49.68 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 120.892 0.377 . . . . 62.44 110.633 -179.166 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -103.99 -25.46 13.0 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 121.075 0.464 . . . . 72.11 110.747 -179.129 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.661 HD11 HD22 ' A' ' 41' ' ' LEU . 15.4 tt -77.55 163.75 3.71 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.55 0 N-CA-C 108.863 -0.792 . . . . 72.01 108.863 175.726 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 34' ' ' GLN . . . . . 0.518 ' HG2' ' O ' ' A' ' 34' ' ' GLN . 18.8 pm0 -76.55 66.82 2.61 Favored 'General case' 0 CA--C 1.533 0.321 0 CA-C-O 121.774 0.797 . . . . 75.3 111.646 -176.121 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -78.46 66.23 3.28 Favored Glycine 0 N--CA 1.448 -0.512 0 N-CA-C 110.906 -0.878 . . . . 74.3 110.906 174.769 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . 0.728 ' HB3' ' HD3' ' A' ' 39' ' ' LYS . 14.1 t70 -74.37 83.81 1.94 Allowed 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 120.991 0.424 . . . . 74.4 110.459 -177.379 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 75.85 -72.48 1.8 Allowed Glycine 0 N--CA 1.45 -0.4 0 N-CA-C 111.459 -0.656 . . . . 71.31 111.459 -176.958 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 72.7 m-85 -146.31 83.05 1.61 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.925 0.393 . . . . 73.31 110.15 176.93 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 39' ' ' LYS . . . . . 0.728 ' HD3' ' HB3' ' A' ' 36' ' ' ASP . 10.6 mptt -132.65 105.58 7.28 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 116.157 -0.474 . . . . 51.21 110.567 176.468 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 22.0 p -105.37 122.62 46.35 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-O 121.062 0.458 . . . . 61.41 110.229 175.705 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . 0.661 HD22 HD11 ' A' ' 33' ' ' ILE . 10.7 mp -83.28 126.06 32.26 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 116.158 -0.474 . . . . 74.32 110.241 178.786 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 28.5 t70 -75.51 139.58 42.26 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-N 115.595 -0.73 . . . . 71.35 110.616 -177.342 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 3.0 mp0 -61.22 105.72 0.53 Allowed 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.96 0.41 . . . . 70.42 110.317 178.142 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 126.49 -10.25 7.24 Favored Glycine 0 N--CA 1.447 -0.587 0 CA-C-N 115.871 -0.604 . . . . 63.24 111.731 -175.049 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 7.1 tt0 -77.37 127.49 32.65 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.846 0.355 . . . . 74.32 110.63 178.061 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 0.543 ' HA ' ' HA ' ' A' ' 5' ' ' THR . . . -92.39 130.43 38.07 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 116.201 -0.454 . . . . 61.01 110.371 177.747 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 0.414 HG12 ' HA ' ' A' ' 65' ' ' LYS . 15.5 m -137.37 174.39 11.57 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 CA-C-O 120.949 0.405 . . . . 62.42 111.316 -177.058 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 48' ' ' THR . . . . . 0.472 HG22 ' HG2' ' A' ' 3' ' ' GLN . 23.5 p -111.69 114.06 26.84 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 115.836 -0.62 . . . . 74.34 109.67 176.425 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 49' ' ' PHE . . . . . 0.68 ' HE2' ' HA3' ' A' ' 4' ' ' GLY . 39.7 p90 -125.17 165.38 18.35 Favored 'General case' 0 C--N 1.317 -0.823 0 CA-C-N 116.094 -0.503 . . . . 74.05 110.302 -174.322 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . 0.528 ' HA ' ' N ' ' A' ' 1' ' ' MET . 22.0 t0 -108.43 151.1 26.5 Favored 'General case' 0 C--N 1.317 -0.808 0 C-N-CA 119.992 -0.683 . . . . 54.43 109.883 173.646 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . 0.407 HG21 ' CZ ' ' A' ' 20' ' ' ARG . 61.1 t -105.13 109.35 27.42 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.779 0 CA-C-O 121.089 0.471 . . . . 72.22 110.593 -176.332 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 44.3 tt0 -81.85 96.31 7.59 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-N 115.41 -0.813 . . . . 63.33 109.062 175.463 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 6.7 pt-20 -74.67 90.62 2.3 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-O 121.519 0.676 . . . . 72.41 109.576 176.612 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -121.49 -144.58 6.94 Favored Glycine 0 N--CA 1.444 -0.772 0 CA-C-N 115.164 -0.926 . . . . 32.42 112.282 -177.925 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 55' ' ' GLN . . . . . 0.571 ' O ' ' HG2' ' A' ' 56' ' ' ARG . 6.6 tp-100 -80.86 82.29 6.89 Favored 'General case' 0 C--N 1.323 -0.552 0 N-CA-C 111.59 0.218 . . . . 74.25 111.59 -175.418 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 56' ' ' ARG . . . . . 0.571 ' HG2' ' O ' ' A' ' 55' ' ' GLN . 2.3 mmm180 156.73 -36.35 0.01 OUTLIER 'General case' 0 N--CA 1.478 0.974 0 C-N-CA 125.881 1.672 . . . . 72.51 108.498 173.109 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . 0.443 ' HA3' ' HD3' ' A' ' 58' ' ' PRO . . . 138.09 -120.05 1.93 Allowed Glycine 0 N--CA 1.445 -0.746 0 CA-C-N 115.186 -0.916 . . . . 72.15 111.712 -178.581 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . 0.545 ' HB2' ' HA ' ' A' ' 26' ' ' VAL . 2.9 Cg_endo -80.96 100.35 1.19 Allowed 'Trans proline' 0 N--CA 1.458 -0.574 0 C-N-CA 123.179 2.586 . . . . 64.32 112.721 -178.405 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 22.1 mt-30 -104.76 126.3 51.7 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 115.93 -0.577 . . . . 62.42 109.631 176.016 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -74.77 115.48 14.4 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-O 120.626 0.25 . . . . 72.22 110.784 -177.536 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -136.36 142.12 43.77 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 116.195 -0.457 . . . . 73.14 110.058 178.754 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 42.1 m-80 58.48 85.48 0.09 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 121.38 0.609 . . . . 52.44 110.492 -179.61 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.586 HG13 ' HB3' ' A' ' 49' ' ' PHE . 17.8 t -112.23 131.68 63.02 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.612 0 CA-C-N 115.737 -0.665 . . . . 61.41 110.284 -176.999 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 6.5 tp-100 -128.4 147.11 50.63 Favored 'General case' 0 C--N 1.32 -0.677 0 N-CA-C 109.896 -0.409 . . . . 73.25 109.896 179.063 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . 0.414 ' HA ' HG12 ' A' ' 47' ' ' VAL . 60.2 mttm -65.06 144.99 56.9 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-O 120.671 0.272 . . . . 63.43 110.359 177.533 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.039 0 CA-C-O 118.723 -0.656 . . . . 64.4 110.785 -179.06 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 66.5 mtt . . . . . 0 N--CA 1.477 0.898 0 CA-C-O 121.188 0.518 . . . . 73.23 109.789 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 1.3 pm0 -110.59 18.14 20.01 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 115.569 -0.742 . . . . 73.53 111.808 -172.622 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 7.5 tt0 -87.84 116.68 26.16 Favored 'General case' 0 C--N 1.321 -0.652 0 N-CA-C 109.471 -0.566 . . . . 64.34 109.471 174.657 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -132.39 153.8 20.76 Favored Glycine 0 N--CA 1.445 -0.749 0 C-N-CA 120.314 -0.946 . . . . 63.14 112.367 -177.768 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . 0.508 ' O ' ' HG3' ' A' ' 19' ' ' GLU . 2.8 m -98.49 129.69 45.08 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-O 120.72 0.295 . . . . 73.22 110.273 178.933 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.435 HG22 HG12 ' A' ' 18' ' ' ILE . 61.7 t -79.75 118.4 27.22 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.606 0 O-C-N 122.357 -0.215 . . . . 62.15 110.462 178.815 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . 0.516 ' NZ ' ' HB3' ' A' ' 19' ' ' GLU . 49.3 mttp -74.18 -65.21 0.87 Allowed 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.926 0.393 . . . . 75.21 110.501 178.053 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' TRP . . . . . . . . . . . . . 90.6 m95 -144.87 160.86 40.61 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 115.821 -0.627 . . . . 75.42 111.211 -176.768 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 14.1 p90 -120.89 106.38 11.58 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 115.503 -0.771 . . . . 64.41 110.527 179.16 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 2.3 m-20 -84.95 77.12 10.17 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-N 115.944 -0.571 . . . . 71.34 109.805 -179.407 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . 0.517 ' HA ' ' HE2' ' A' ' 30' ' ' PHE . . . -63.63 -28.2 69.75 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.589 -0.732 . . . . 61.2 111.268 -178.804 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 65.6 mm-40 -74.87 -13.59 60.57 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 116.2 -0.455 . . . . 63.34 111.314 178.8 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . 0.516 ' HB3' ' CE2' ' A' ' 15' ' ' PHE . 31.2 mmmt -109.76 -30.09 8.02 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 116.297 -0.411 . . . . 71.44 111.053 -179.012 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 102.12 17.66 19.72 Favored Glycine 0 N--CA 1.449 -0.476 0 C-N-CA 120.632 -0.794 . . . . 63.42 112.668 177.389 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . 0.516 ' CE2' ' HB3' ' A' ' 13' ' ' LYS . 26.7 p90 -152.71 172.47 16.62 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 120.629 0.252 . . . . 73.0 110.736 -179.618 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -140.85 175.04 22.37 Favored Glycine 0 N--CA 1.446 -0.652 0 C-N-CA 121.06 -0.591 . . . . 65.11 111.77 178.887 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 97.5 m-85 -120.81 116.45 25.23 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-O 120.933 0.397 . . . . 65.1 111.171 -178.636 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.573 ' O ' ' HA ' ' A' ' 25' ' ' ASP . 36.7 mt -102.57 165.09 3.05 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.581 0 N-CA-C 107.816 -1.179 . . . . 61.22 107.816 173.202 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' GLU . . . . . 0.516 ' HB3' ' NZ ' ' A' ' 7' ' ' LYS . 0.3 OUTLIER -130.31 163.22 27.29 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-N 118.857 0.753 . . . . 71.5 111.364 179.05 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' ARG . . . . . . . . . . . . . 15.6 ttp180 -126.17 -163.23 1.2 Allowed 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 115.573 -0.739 . . . . 70.14 109.464 -178.902 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -64.14 -37.54 87.81 Favored 'General case' 0 C--N 1.329 -0.312 0 N-CA-C 112.277 0.473 . . . . 70.3 112.277 -172.776 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 87.6 m-20 -93.59 13.43 22.02 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-O 120.713 0.292 . . . . 71.13 111.113 -177.877 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 74.2 20.44 79.65 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.329 -0.938 . . . . 64.31 110.764 -173.558 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 14.4 t70 -72.08 93.1 1.38 Allowed 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 115.132 -0.534 . . . . 74.3 109.823 -179.017 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.573 ' HA ' ' O ' ' A' ' 18' ' ' ILE . 2.3 m-20 -60.46 121.03 11.07 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.642 -0.708 . . . . 72.02 111.594 178.58 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 36.6 t -96.69 131.48 43.38 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.62 0 CA-C-N 115.013 -0.994 . . . . 73.25 109.897 179.945 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' PHE . . . . . . . . . . . . . 47.4 t80 -83.49 98.7 9.68 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 116.144 -0.48 . . . . 61.11 110.525 -175.817 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.537 ' HB ' ' HB3' ' A' ' 60' ' ' ALA . 13.2 p -98.82 138.66 22.67 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 CA-C-O 121.069 0.461 . . . . 74.03 111.072 -177.782 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 6.9 m80 -99.29 139.19 35.31 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 116.064 -0.517 . . . . 74.01 110.112 176.81 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' PHE . . . . . 0.628 ' HD1' HD12 ' A' ' 33' ' ' ILE . 20.4 m-85 -65.74 -26.2 67.62 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.643 0.258 . . . . 75.34 110.819 179.008 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 38.3 t -72.36 -16.97 61.87 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-O 121.111 0.481 . . . . 72.12 110.48 175.805 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . 0.546 ' HB1' ' HA ' ' A' ' 61' ' ' ALA . . . -94.61 -20.01 19.96 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 121.085 0.469 . . . . 65.11 110.049 177.033 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.706 HG12 HG21 ' A' ' 63' ' ' VAL . 54.6 mt -82.02 135.32 25.2 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.465 0 CA-C-N 115.807 -0.633 . . . . 72.44 110.078 175.443 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 12.7 pt20 -70.98 89.47 0.79 Allowed 'General case' 0 C--N 1.324 -0.534 0 CA-C-O 121.259 0.552 . . . . 54.32 110.563 176.377 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.469 ' HA2' ' O ' ' A' ' 38' ' ' PHE . . . -84.07 59.95 4.89 Favored Glycine 0 N--CA 1.449 -0.465 0 C-N-CA 121.121 -0.561 . . . . 54.34 112.693 -178.492 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -65.54 -68.53 0.36 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.517 0.199 . . . . 74.31 110.968 179.119 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -108.28 -20.92 7.95 Favored Glycine 0 N--CA 1.447 -0.574 0 C-N-CA 120.763 -0.732 . . . . 72.42 111.786 176.152 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . 0.469 ' O ' ' HA2' ' A' ' 35' ' ' GLY . 95.7 m-85 -128.2 127.24 42.53 Favored 'General case' 0 C--N 1.326 -0.437 0 N-CA-C 110.25 -0.278 . . . . 75.33 110.25 -179.805 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 13.5 mptt -87.84 -0.01 56.4 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 116.274 -0.421 . . . . 64.4 111.253 -179.798 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 42.0 m -155.26 162.51 40.88 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 116.496 -0.32 . . . . 72.31 110.368 -177.465 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 3.5 mm? -107.52 162.23 14.13 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.29 -0.413 . . . . 72.21 110.136 178.568 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . 0.493 ' HB2' ' HB2' ' A' ' 45' ' ' GLN . 5.9 m-20 -69.62 157.23 37.61 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 116.017 -0.538 . . . . 73.31 111.1 179.967 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -77.18 105.74 8.46 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-O 121.521 0.677 . . . . 70.45 110.039 176.018 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 108.96 5.48 30.84 Favored Glycine 0 N--CA 1.446 -0.657 0 CA-C-N 115.678 -0.692 . . . . 24.05 111.656 -174.014 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 45' ' ' GLN . . . . . 0.493 ' HB2' ' HB2' ' A' ' 42' ' ' ASP . 8.6 tp-100 -80.78 130.68 35.2 Favored 'General case' 0 C--N 1.326 -0.424 0 N-CA-C 109.993 -0.373 . . . . 75.43 109.993 178.944 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -102.46 127.71 49.39 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-O 120.778 0.323 . . . . 64.42 110.721 179.764 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 17.5 m -136.02 172.59 15.28 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.562 0 CA-C-N 115.961 -0.563 . . . . 51.24 110.528 -179.109 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 20.4 p -116.66 115.01 24.86 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 116.177 -0.465 . . . . 64.32 110.328 179.476 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 33.1 p90 -117.42 163.36 16.49 Favored 'General case' 0 C--N 1.319 -0.752 0 CA-C-O 121.157 0.503 . . . . 73.33 111.925 -174.137 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 25.8 t70 -86.07 136.72 33.12 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 115.861 -0.609 . . . . 70.34 109.585 172.908 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 3.7 p -81.83 114.46 22.78 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.499 0 CA-C-O 121.913 0.863 . . . . 74.44 112.06 -174.632 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 9.6 tp10 -108.93 162.0 14.62 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 114.763 -1.108 . . . . 62.13 108.374 175.693 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 39.1 mt-10 -122.59 169.18 11.29 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-O 121.159 0.504 . . . . 52.42 111.517 -179.999 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -162.48 158.25 30.33 Favored Glycine 0 N--CA 1.443 -0.897 0 N-CA-C 110.736 -0.946 . . . . 62.2 110.736 179.046 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 20.6 pt20 -75.73 9.32 2.37 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 117.093 0.447 . . . . 74.43 111.929 -177.088 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 69.3 mtm180 -130.19 15.32 5.65 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 121.005 0.431 . . . . 72.23 110.285 174.654 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 129.21 -179.68 16.54 Favored Glycine 0 N--CA 1.45 -0.427 0 C-N-CA 120.651 -0.785 . . . . 54.22 112.083 179.871 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo -74.6 146.27 34.23 Favored 'Trans proline' 0 N--CA 1.461 -0.428 0 C-N-CA 122.508 2.138 . . . . 71.1 112.427 -179.055 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 42.3 mt-30 -118.5 162.22 18.71 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 115.952 -0.567 . . . . 75.22 110.013 178.335 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . 0.537 ' HB3' ' HB ' ' A' ' 28' ' ' VAL . . . -118.35 125.29 49.73 Favored 'General case' 0 C--N 1.318 -0.794 0 CA-C-O 121.047 0.451 . . . . 73.2 111.039 -179.672 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . 0.546 ' HA ' ' HB1' ' A' ' 32' ' ' ALA . . . -127.81 164.59 21.86 Favored 'General case' 0 C--N 1.321 -0.673 0 N-CA-C 108.763 -0.829 . . . . 75.04 108.763 175.871 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 39.7 m-80 48.25 76.87 0.11 Allowed 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 121.032 0.444 . . . . 74.05 110.989 -177.843 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.706 HG21 HG12 ' A' ' 33' ' ' ILE . 46.6 t -89.21 92.08 3.86 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.67 0 CA-C-N 116.042 -0.526 . . . . 72.33 110.142 -178.751 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -80.38 125.82 30.39 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 115.434 -0.803 . . . . 73.05 109.368 -177.868 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 52.9 mttp -64.25 137.54 57.98 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.301 -0.409 . . . . 62.44 110.381 -177.403 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.251 1.135 0 CA-C-O 118.439 -0.791 . . . . 74.22 109.927 179.496 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . 0.548 ' HA ' ' O ' ' A' ' 49' ' ' PHE . 64.7 mtt . . . . . 0 N--CA 1.479 1.009 0 CA-C-O 120.697 0.284 . . . . 72.44 110.676 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 2.8 mp0 -117.16 170.74 8.44 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 121.04 0.448 . . . . 71.1 110.619 176.82 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 84.0 mt-30 -95.15 126.83 40.75 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 115.357 -0.838 . . . . 75.24 109.482 176.813 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . 0.681 ' HA3' ' HE2' ' A' ' 49' ' ' PHE . . . -140.83 151.11 22.22 Favored Glycine 0 N--CA 1.445 -0.756 0 C-N-CA 120.291 -0.956 . . . . 72.11 112.533 -177.985 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . 0.452 ' O ' ' HG2' ' A' ' 19' ' ' GLU . 7.4 m -107.15 125.82 51.58 Favored 'General case' 0 C--N 1.319 -0.75 0 N-CA-C 110.21 -0.293 . . . . 72.34 110.21 -179.718 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 48.3 t -68.01 117.39 9.76 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 N-CA-C 110.168 -0.308 . . . . 72.03 110.168 179.705 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . 0.632 ' HD3' ' HB3' ' A' ' 19' ' ' GLU . 30.1 mmmt -75.55 -56.37 4.76 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 121.405 0.622 . . . . 61.44 109.329 179.422 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' TRP . . . . . 0.789 ' HZ3' ' HB2' ' A' ' 10' ' ' ASN . 63.5 p-90 -164.71 157.95 17.21 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-N 114.849 -1.069 . . . . 45.12 108.921 175.927 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 11.3 p90 -129.04 115.1 17.24 Favored 'General case' 0 C--N 1.317 -0.816 0 CA-C-O 121.596 0.713 . . . . 73.21 110.805 -176.593 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' ASN . . . . . 0.789 ' HB2' ' HZ3' ' A' ' 8' ' ' TRP . 34.1 t30 -86.72 71.86 10.28 Favored 'General case' 0 C--N 1.319 -0.729 0 N-CA-C 108.527 -0.916 . . . . 72.54 108.527 179.008 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -62.83 -32.15 73.3 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 114.709 -1.132 . . . . 72.13 112.536 -171.284 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 33.1 mt-10 -75.53 -9.76 58.86 Favored 'General case' 0 C--N 1.326 -0.429 0 C-N-CA 120.905 -0.318 . . . . 73.23 111.252 -177.458 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 30.7 mmmt -110.92 -11.75 14.31 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 121.174 0.511 . . . . 52.4 110.124 174.253 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 95.21 15.83 43.08 Favored Glycine 0 N--CA 1.447 -0.596 0 C-N-CA 120.805 -0.712 . . . . 65.41 114.414 169.91 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 54.6 p90 -145.8 155.3 42.84 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 117.941 0.871 . . . . 75.24 111.601 -179.254 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -140.64 166.82 25.76 Favored Glycine 0 N--CA 1.445 -0.728 0 N-CA-C 111.078 -0.809 . . . . 71.22 111.078 177.422 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 79.0 m-85 -120.89 121.92 39.12 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-O 121.201 0.524 . . . . 74.43 111.201 -178.323 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 56.4 mt -111.25 139.59 34.55 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.615 0 CA-C-N 115.331 -0.85 . . . . 71.12 109.459 178.166 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' GLU . . . . . 0.632 ' HB3' ' HD3' ' A' ' 7' ' ' LYS . 9.1 pt-20 -88.6 134.36 33.9 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 120.896 0.379 . . . . 71.25 110.523 179.008 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' ARG . . . . . . . . . . . . . 27.8 ttp180 -121.84 152.01 40.02 Favored 'General case' 0 C--N 1.322 -0.63 0 N-CA-C 108.996 -0.742 . . . . 74.03 108.996 174.13 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . 0.435 ' HG3' ' H ' ' A' ' 21' ' ' GLU . 0.0 OUTLIER -50.71 -40.81 55.12 Favored 'General case' 0 N--CA 1.463 0.189 0 O-C-N 123.279 0.362 . . . . 73.14 111.795 -177.83 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -109.44 65.75 0.62 Allowed 'General case' 0 C--N 1.322 -0.63 0 CA-C-O 121.004 0.431 . . . . 72.31 110.339 171.62 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 132.85 94.88 0.57 Allowed Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.816 -0.707 . . . . 61.04 112.227 174.257 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . 0.527 ' HA ' ' HA ' ' A' ' 19' ' ' GLU . 3.9 p30 -71.0 6.41 1.58 Allowed 'General case' 0 N--CA 1.468 0.432 0 CA-C-O 120.962 0.41 . . . . 71.41 111.48 -178.108 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 7.2 p-10 -122.6 88.59 2.96 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-O 121.708 0.766 . . . . 70.25 110.916 -177.266 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.434 HG12 ' HB2' ' A' ' 60' ' ' ALA . 55.9 t -112.34 118.59 58.17 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.621 0 CA-C-N 115.431 -0.804 . . . . 71.31 109.565 173.769 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' PHE . . . . . 0.458 ' O ' ' HA ' ' A' ' 59' ' ' GLN . 63.1 t80 -82.08 105.09 12.9 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 115.773 -0.648 . . . . 73.44 110.484 -176.183 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 12.2 p -100.03 133.95 41.24 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.603 0 CA-C-O 121.207 0.527 . . . . 73.25 110.531 179.122 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 85.8 t60 -91.87 133.05 36.01 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 115.843 -0.617 . . . . 62.33 109.855 -178.226 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 14.0 p90 -56.39 -36.39 68.82 Favored 'General case' 0 N--CA 1.467 0.399 0 N-CA-C 111.938 0.347 . . . . 74.21 111.938 -174.015 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 6.9 t -87.31 6.44 33.47 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 121.293 0.568 . . . . 43.12 110.644 -177.763 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -105.67 -19.7 13.68 Favored 'General case' 0 C--N 1.326 -0.447 0 N-CA-C 109.144 -0.687 . . . . 34.22 109.144 173.216 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.405 ' O ' ' HG3' ' A' ' 39' ' ' LYS . 69.2 mt -74.72 105.45 3.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 114.998 -1.001 . . . . 75.31 110.271 175.329 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 34' ' ' GLN . . . . . 0.405 ' O ' ' HE3' ' A' ' 65' ' ' LYS . 0.9 OUTLIER -79.75 71.26 6.39 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 121.854 0.835 . . . . 62.54 109.943 175.478 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -74.13 163.26 54.52 Favored Glycine 0 N--CA 1.448 -0.519 0 CA-C-N 115.104 -0.953 . . . . 73.03 112.469 -178.597 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 21.7 t70 -93.89 105.13 17.16 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-O 120.795 0.331 . . . . 61.42 110.124 -178.94 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 92.28 -53.51 2.81 Favored Glycine 0 N--CA 1.449 -0.438 0 N-CA-C 111.64 -0.584 . . . . 50.13 111.64 -179.554 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 97.8 m-85 -133.82 147.19 51.19 Favored 'General case' 0 C--N 1.325 -0.497 0 N-CA-C 109.519 -0.549 . . . . 64.14 109.519 177.157 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 39' ' ' LYS . . . . . 0.405 ' HG3' ' O ' ' A' ' 33' ' ' ILE . 13.9 mptt -73.55 91.69 1.85 Allowed 'General case' 0 C--N 1.323 -0.575 0 CA-C-O 121.054 0.454 . . . . 63.35 110.408 179.22 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 22.8 p -165.85 154.91 11.71 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 115.561 -0.745 . . . . 52.4 110.114 -179.954 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 95.1 mt -132.39 130.48 40.72 Favored 'General case' 0 C--N 1.325 -0.483 0 N-CA-C 109.277 -0.638 . . . . 74.41 109.277 176.318 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 3.4 m-20 -55.88 125.05 19.73 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 121.205 0.526 . . . . 75.43 111.557 -179.36 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 7.6 pt-20 -66.95 123.27 19.72 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-N 115.834 -0.621 . . . . 71.52 109.831 175.895 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 101.81 5.76 50.4 Favored Glycine 0 N--CA 1.448 -0.502 0 C-N-CA 121.032 -0.604 . . . . 32.03 111.648 -173.229 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 7.5 tp60 -102.84 138.03 40.26 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.652 0.263 . . . . 74.21 110.521 178.603 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -92.16 131.91 37.03 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 116.293 -0.412 . . . . 43.12 110.427 176.329 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 24.0 m -134.77 173.84 13.89 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 CA-C-N 116.121 -0.49 . . . . 72.21 110.308 -179.793 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 19.3 p -117.34 115.69 25.74 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-O 121.185 0.517 . . . . 54.41 110.805 179.431 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 49' ' ' PHE . . . . . 0.681 ' HE2' ' HA3' ' A' ' 4' ' ' GLY . 38.0 p90 -120.63 152.72 37.8 Favored 'General case' 0 C--N 1.319 -0.76 0 CA-C-N 115.74 -0.664 . . . . 72.11 110.325 -177.523 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . 0.43 ' HA ' ' HA ' ' A' ' 1' ' ' MET . 22.7 t70 -97.64 116.76 30.47 Favored 'General case' 0 C--N 1.322 -0.596 0 N-CA-C 109.224 -0.658 . . . . 54.4 109.224 174.883 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 9.9 p -77.86 140.71 16.57 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.497 0 CA-C-O 121.52 0.676 . . . . 61.44 111.637 -170.553 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . 0.457 ' HB3' ' HG3' ' A' ' 59' ' ' GLN . 32.6 tt0 -137.38 156.91 47.66 Favored 'General case' 0 C--N 1.32 -0.688 0 N-CA-C 108.163 -1.051 . . . . 75.21 108.163 175.173 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . 0.42 ' HA ' ' O ' ' A' ' 57' ' ' GLY . 0.0 OUTLIER -149.49 -177.78 6.05 Favored 'General case' 0 C--N 1.32 -0.708 0 O-C-N 122.092 -0.38 . . . . 73.54 110.794 -178.487 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 143.94 -101.78 0.26 Allowed Glycine 0 N--CA 1.442 -0.933 0 C-N-CA 120.62 -0.8 . . . . 65.14 113.132 177.669 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 35.3 tt0 -80.14 -23.88 40.82 Favored 'General case' 0 C--N 1.326 -0.443 0 N-CA-C 112.361 0.504 . . . . 71.21 112.361 -168.925 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 2.0 ptp180 -137.95 43.39 2.23 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-O 121.07 0.462 . . . . 75.23 111.733 -178.591 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . 0.42 ' O ' ' HA ' ' A' ' 53' ' ' GLU . . . 76.07 -157.38 48.42 Favored Glycine 0 N--CA 1.449 -0.454 0 C-N-CA 120.842 -0.694 . . . . 72.02 113.127 174.667 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 1.7 Cg_endo -81.43 110.39 2.21 Favored 'Trans proline' 0 N--CA 1.455 -0.776 0 C-N-CA 123.242 2.628 . . . . 63.21 112.053 -178.999 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . 0.458 ' HA ' ' O ' ' A' ' 27' ' ' PHE . 16.8 pt20 -105.45 139.11 40.57 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 115.892 -0.595 . . . . 71.31 109.97 179.091 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . 0.434 ' HB2' HG12 ' A' ' 26' ' ' VAL . . . -89.8 109.35 20.35 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 116.178 -0.465 . . . . 74.43 110.997 -179.344 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -111.41 149.9 30.56 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-N 115.825 -0.625 . . . . 74.51 109.519 176.315 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 94.9 m-20 51.49 80.17 0.09 Allowed 'General case' 0 C--O 1.235 0.321 0 CA-C-O 121.286 0.565 . . . . 71.11 110.841 -176.76 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 38.9 t -102.88 103.97 15.88 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.589 0 CA-C-N 115.732 -0.667 . . . . 74.42 110.245 -179.355 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 54.4 mt-30 -94.9 160.54 14.54 Favored 'General case' 0 C--N 1.319 -0.735 0 CA-C-N 115.918 -0.583 . . . . 71.15 110.52 -179.647 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . 0.405 ' HE3' ' O ' ' A' ' 34' ' ' GLN . 0.7 OUTLIER -82.77 171.35 14.05 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 115.717 -0.674 . . . . 52.45 110.894 -176.773 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.097 0 CA-C-O 118.413 -0.803 . . . . 51.33 109.544 177.172 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . 0.603 ' N ' ' HA ' ' A' ' 50' ' ' ASP . 65.8 mtt . . . . . 0 N--CA 1.484 1.249 0 CA-C-O 121.005 0.431 . . . . 60.15 110.683 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 56.9 mp0 -84.28 151.08 25.0 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-O 121.268 0.556 . . . . 63.44 111.871 -174.877 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -96.79 112.78 24.39 Favored 'General case' 0 C--N 1.323 -0.545 0 N-CA-C 108.095 -1.076 . . . . 72.03 108.095 172.956 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . 0.474 ' HA3' ' HE2' ' A' ' 49' ' ' PHE . . . -137.61 168.53 24.43 Favored Glycine 0 N--CA 1.447 -0.608 0 C-N-CA 120.392 -0.908 . . . . 63.12 112.558 -175.864 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . 0.408 ' O ' ' HG2' ' A' ' 19' ' ' GLU . 26.9 m -108.24 134.26 51.33 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-O 120.634 0.254 . . . . 74.22 110.457 -179.024 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 47.8 t -68.75 112.7 3.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 CA-C-O 120.772 0.32 . . . . 55.33 110.378 178.494 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 48.3 mtpt -71.76 -70.86 0.3 Allowed 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 115.808 -0.633 . . . . 74.2 110.21 179.887 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' TRP . . . . . . . . . . . . . 92.1 m95 -139.4 132.61 29.81 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 115.094 -0.957 . . . . 72.33 108.819 178.117 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . 0.499 ' HD1' ' HA3' ' A' ' 16' ' ' GLY . 59.4 t80 -132.22 102.1 5.64 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-O 121.272 0.558 . . . . 72.43 110.822 179.15 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 19.0 m120 -80.99 84.8 6.38 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 115.583 -0.735 . . . . 74.53 109.534 176.444 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -61.66 -33.25 73.63 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 115.393 -0.821 . . . . 54.44 111.074 179.055 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 44.3 mt-10 -69.6 -25.9 64.19 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.015 -0.538 . . . . 73.13 110.73 179.532 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 75.7 mmtt -92.24 -35.53 13.74 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.219 -0.446 . . . . 63.2 110.187 -179.948 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 110.12 14.11 14.14 Favored Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 120.965 -0.636 . . . . 44.31 113.35 175.574 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 50.0 p90 -152.73 162.08 41.73 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 117.157 0.479 . . . . 74.54 111.451 -177.546 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.499 ' HA3' ' HD1' ' A' ' 9' ' ' PHE . . . -163.38 178.25 39.04 Favored Glycine 0 N--CA 1.446 -0.692 0 C-N-CA 120.885 -0.674 . . . . 31.12 112.197 179.071 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 90.8 m-85 -126.28 127.76 46.1 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-O 120.7 0.286 . . . . 74.31 110.507 -178.967 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 46.3 mt -112.93 129.91 67.72 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.497 0 N-CA-C 109.151 -0.685 . . . . 74.34 109.151 175.787 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' GLU . . . . . 0.408 ' HG2' ' O ' ' A' ' 5' ' ' THR . 11.1 pt-20 -73.7 139.88 45.65 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 121.502 0.668 . . . . 73.03 111.559 -171.851 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' ARG . . . . . . . . . . . . . 43.5 ttt180 -112.48 141.2 46.51 Favored 'General case' 0 C--N 1.319 -0.733 0 N-CA-C 107.434 -1.321 . . . . 60.44 107.434 175.035 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 16.1 pt-20 -55.67 -26.57 45.47 Favored 'General case' 0 C--N 1.327 -0.406 0 N-CA-C 112.85 0.685 . . . . 64.44 112.85 -170.116 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 28.6 t-20 -79.69 -19.58 48.62 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-O 120.845 0.355 . . . . 73.42 111.434 -178.813 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 106.48 -9.33 41.49 Favored Glycine 0 CA--C 1.511 -0.157 0 N-CA-C 111.229 -0.748 . . . . 74.51 111.229 -174.514 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 36.5 t70 -80.32 72.24 7.16 Favored 'General case' 0 C--N 1.322 -0.615 0 N-CA-C 109.279 -0.638 . . . . 71.4 109.279 176.294 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 10.1 p-10 -70.28 138.07 51.26 Favored 'General case' 0 C--N 1.333 -0.14 0 CA-C-O 121.52 0.676 . . . . 62.52 110.811 -172.899 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.529 HG13 ' HB2' ' A' ' 58' ' ' PRO . 4.3 t -94.57 138.98 19.4 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.55 0 CA-C-N 115.187 -0.915 . . . . 65.21 111.4 -167.734 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' PHE . . . . . . . . . . . . . 50.4 t80 -92.27 111.72 23.39 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.769 -0.65 . . . . 74.02 110.461 -177.449 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.539 ' HB ' ' HB3' ' A' ' 60' ' ' ALA . 14.8 p -95.86 148.49 5.22 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.381 0 CA-C-O 120.905 0.383 . . . . 74.05 111.325 -175.462 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 28.0 m170 -114.31 145.72 41.42 Favored 'General case' 0 C--O 1.236 0.343 0 CA-C-N 116.151 -0.477 . . . . 62.41 109.889 177.623 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 20.5 p90 -62.19 -26.24 68.24 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 121.11 0.481 . . . . 73.53 110.46 177.659 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 4.2 m -81.56 -14.36 56.93 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 115.77 -0.65 . . . . 65.43 110.875 179.277 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . 0.559 ' HB1' ' HA ' ' A' ' 61' ' ' ALA . . . -94.51 -21.3 18.97 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 121.044 0.449 . . . . 64.14 110.819 -176.709 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 44.9 mt -71.04 155.8 7.39 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-N 115.777 -0.647 . . . . 74.23 110.188 174.534 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 14.5 pt20 -70.51 102.97 2.35 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 121.226 0.536 . . . . 72.22 110.458 175.755 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -79.03 77.1 1.85 Allowed Glycine 0 N--CA 1.447 -0.573 0 CA-C-N 115.752 -0.658 . . . . 71.52 112.92 -175.815 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 34.7 t70 -121.61 98.15 5.83 Favored 'General case' 0 C--N 1.323 -0.556 0 N-CA-C 109.639 -0.504 . . . . 72.03 109.639 174.21 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 72.79 -150.32 44.42 Favored Glycine 0 N--CA 1.446 -0.636 0 C-N-CA 120.749 -0.739 . . . . 61.12 111.435 -174.983 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 88.6 m-85 -110.92 65.38 0.62 Allowed 'General case' 0 C--N 1.321 -0.664 0 CA-C-O 121.468 0.651 . . . . 61.22 110.597 178.028 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 91.7 mttt -101.67 86.69 2.98 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 115.333 -0.849 . . . . 53.42 109.611 178.196 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 22.9 t -84.32 178.9 7.59 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 115.479 -0.782 . . . . 75.42 111.181 -172.829 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 81.7 mt -95.94 119.04 33.72 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 116.013 -0.54 . . . . 64.02 109.892 177.385 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . 0.626 ' HB3' ' HB2' ' A' ' 45' ' ' GLN . 30.7 t70 -82.43 139.93 33.72 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-N 115.942 -0.572 . . . . 65.15 111.048 -175.988 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 6.8 pt-20 -66.11 116.72 7.5 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 115.84 -0.618 . . . . 71.05 110.846 178.383 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 87.3 18.9 56.55 Favored Glycine 0 N--CA 1.448 -0.508 0 C-N-CA 120.642 -0.79 . . . . 53.55 112.182 -177.77 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 45' ' ' GLN . . . . . 0.626 ' HB2' ' HB3' ' A' ' 42' ' ' ASP . 35.6 tt0 -99.22 135.5 40.54 Favored 'General case' 0 C--N 1.326 -0.451 0 N-CA-C 110.208 -0.293 . . . . 71.24 110.208 178.497 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -85.52 129.01 34.92 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 116.36 -0.382 . . . . 62.12 110.271 177.807 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 16.6 m -138.36 153.62 26.61 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.518 0 CA-C-O 120.988 0.423 . . . . 74.11 111.01 -177.927 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 20.7 p -102.51 104.87 15.33 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 115.994 -0.548 . . . . 73.51 109.814 175.988 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 49' ' ' PHE . . . . . 0.474 ' HE2' ' HA3' ' A' ' 4' ' ' GLY . 41.8 p90 -110.74 158.51 18.57 Favored 'General case' 0 C--N 1.316 -0.852 0 CA-C-N 115.449 -0.796 . . . . 74.13 110.174 -174.994 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . 0.603 ' HA ' ' N ' ' A' ' 1' ' ' MET . 19.7 t0 -104.61 151.77 23.24 Favored 'General case' 0 C--N 1.317 -0.842 0 C-N-CA 120.074 -0.65 . . . . 71.03 109.958 173.552 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 4.9 p -103.17 112.41 36.52 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.599 0 CA-C-O 121.405 0.621 . . . . 44.14 111.194 -173.57 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 49.8 mm-40 -109.85 112.88 25.19 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-N 115.586 -0.733 . . . . 72.24 109.689 177.613 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . 0.536 ' HA ' ' O ' ' A' ' 57' ' ' GLY . 8.1 pt-20 -76.81 115.47 16.62 Favored 'General case' 0 C--N 1.325 -0.498 0 C-N-CA 120.211 -0.595 . . . . 75.44 109.941 177.202 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . 0.514 ' HA3' ' NE2' ' A' ' 59' ' ' GLN . . . -122.57 -121.2 2.68 Favored Glycine 0 N--CA 1.445 -0.736 0 C-N-CA 120.354 -0.927 . . . . 45.13 113.365 -174.658 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -84.77 1.68 45.6 Favored 'General case' 0 C--N 1.329 -0.311 0 N-CA-C 112.157 0.429 . . . . 71.1 112.157 -169.632 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 10.2 ptp180 -158.87 28.39 0.22 Allowed 'General case' 0 C--N 1.325 -0.457 0 CA-C-O 120.748 0.308 . . . . 75.42 111.237 177.678 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . 0.536 ' O ' ' HA ' ' A' ' 53' ' ' GLU . . . 93.29 -132.81 11.4 Favored Glycine 0 N--CA 1.444 -0.784 0 C-N-CA 120.44 -0.886 . . . . 74.42 112.18 -179.054 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . 0.529 ' HB2' HG13 ' A' ' 26' ' ' VAL . 33.0 Cg_endo -64.32 106.66 0.72 Allowed 'Trans proline' 0 CA--C 1.529 0.239 0 C-N-CA 122.837 2.358 . . . . 64.4 113.323 -174.806 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . 0.514 ' NE2' ' HA3' ' A' ' 54' ' ' GLY . 22.2 mt-30 -112.53 128.41 56.34 Favored 'General case' 0 C--N 1.323 -0.567 0 N-CA-C 109.011 -0.737 . . . . 74.34 109.011 173.615 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . 0.539 ' HB3' ' HB ' ' A' ' 28' ' ' VAL . . . -82.13 115.1 21.09 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-O 120.984 0.421 . . . . 33.04 110.955 -176.127 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . 0.559 ' HA ' ' HB1' ' A' ' 32' ' ' ALA . . . -130.89 154.14 48.4 Favored 'General case' 0 C--N 1.319 -0.75 0 N-CA-C 108.845 -0.798 . . . . 75.1 108.845 176.818 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 90.2 m-20 57.84 73.93 0.45 Allowed 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 121.492 0.663 . . . . 70.24 109.967 -176.125 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 45.3 t -100.21 103.71 15.16 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.664 0 CA-C-N 115.357 -0.838 . . . . 33.11 109.813 179.857 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 6.3 tp-100 -91.63 143.19 26.82 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-N 116.027 -0.533 . . . . 74.12 110.673 -176.941 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 66.8 mmtt -72.72 130.22 40.01 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 115.684 -0.689 . . . . 73.24 109.992 177.817 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.251 1.167 0 CA-C-O 118.432 -0.794 . . . . 75.01 110.53 -178.164 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . 0.597 ' HA ' ' HA ' ' A' ' 50' ' ' ASP . 27.9 ttt . . . . . 0 N--CA 1.475 0.783 0 CA-C-O 121.364 0.602 . . . . 51.31 109.602 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 1.7 pm0 -143.72 175.33 10.06 Favored 'General case' 0 C--N 1.319 -0.722 0 CA-C-N 115.437 -0.801 . . . . 70.44 110.275 -175.348 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -100.24 128.74 46.25 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-O 121.215 0.531 . . . . 74.42 110.616 179.31 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -131.14 164.7 23.29 Favored Glycine 0 N--CA 1.444 -0.774 0 CA-C-N 115.803 -0.635 . . . . 63.31 111.751 -179.17 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 21.3 m -105.38 122.87 46.86 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-O 120.542 0.21 . . . . 72.41 110.707 -178.775 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 58.7 t -64.37 114.36 2.21 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.227 0 CA-C-N 116.392 -0.367 . . . . 72.5 110.547 -179.331 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 4.5 mmmm -95.28 -53.16 3.88 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 115.859 -0.609 . . . . 75.2 110.255 -178.832 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' TRP . . . . . 0.464 ' HB2' ' HB2' ' A' ' 17' ' ' PHE . 76.5 m95 -118.11 130.63 56.24 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 115.687 -0.688 . . . . 74.32 110.082 179.793 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . 0.439 ' CE2' ' HB2' ' A' ' 11' ' ' ALA . 62.6 t80 -128.66 84.37 2.23 Favored 'General case' 0 C--N 1.318 -0.781 0 CA-C-O 121.282 0.563 . . . . 74.31 109.692 178.862 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' ASN . . . . . 0.797 ' HB3' ' HB2' ' A' ' 13' ' ' LYS . 44.0 m-80 -87.53 74.35 9.31 Favored 'General case' 0 C--N 1.321 -0.663 0 CA-C-N 115.909 -0.587 . . . . 73.35 110.021 -177.61 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . 0.676 ' HA ' ' CZ ' ' A' ' 30' ' ' PHE . . . -61.07 -39.61 90.53 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.277 -0.874 . . . . 74.15 111.409 -177.296 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 47.0 mt-10 -84.22 -11.4 56.56 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 116.085 -0.507 . . . . 64.02 111.173 -177.947 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . 0.797 ' HB2' ' HB3' ' A' ' 10' ' ' ASN . 5.2 mmtp -98.6 -28.41 13.57 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 116.274 -0.421 . . . . 74.43 110.586 -177.02 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 102.2 22.65 9.69 Favored Glycine 0 N--CA 1.448 -0.526 0 C-N-CA 120.652 -0.785 . . . . 64.3 113.396 174.287 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . 0.454 ' O ' ' HB2' ' A' ' 10' ' ' ASN . 52.5 p90 -163.38 171.49 15.96 Favored 'General case' 0 N--CA 1.463 0.222 0 CA-C-N 117.451 0.625 . . . . 72.33 111.067 179.649 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -153.98 172.14 32.65 Favored Glycine 0 N--CA 1.445 -0.701 0 C-N-CA 120.827 -0.701 . . . . 61.53 112.119 179.976 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . 0.792 ' HB3' ' HB3' ' A' ' 25' ' ' ASP . 92.6 m-85 -134.63 122.82 22.82 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 120.802 0.334 . . . . 73.43 110.269 179.472 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 35.3 mt -122.41 117.44 52.09 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.593 0 CA-C-N 116.103 -0.499 . . . . 72.4 109.734 179.164 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' GLU . . . . . 0.417 ' HA ' ' HA ' ' A' ' 25' ' ' ASP . 22.8 pt-20 -79.41 148.31 32.01 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-O 121.257 0.551 . . . . 61.23 112.17 -170.976 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' ARG . . . . . 0.423 ' HG2' ' HG2' ' A' ' 21' ' ' GLU . 14.4 ttm180 -118.61 123.51 45.17 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 115.42 -0.809 . . . . 75.14 109.684 170.681 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . 0.423 ' HG2' ' HG2' ' A' ' 20' ' ' ARG . 43.1 mm-40 50.78 -90.02 0.02 OUTLIER 'General case' 0 N--CA 1.474 0.738 0 N-CA-C 113.407 0.891 . . . . 73.34 113.407 173.094 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 1.6 m-20 -58.31 -19.11 32.22 Favored 'General case' 0 N--CA 1.467 0.408 0 C-N-CA 123.847 0.859 . . . . 62.01 111.79 -175.215 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 104.35 19.92 10.9 Favored Glycine 0 N--CA 1.442 -0.951 0 N-CA-C 110.015 -1.234 . . . . 42.33 110.015 -170.604 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 5.3 t70 -71.69 90.01 1.04 Allowed 'General case' 0 N--CA 1.45 -0.434 0 N-CA-C 109.0 -0.741 . . . . 73.24 109.0 178.089 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.792 ' HB3' ' HB3' ' A' ' 17' ' ' PHE . 62.0 m-20 -63.37 104.32 0.6 Allowed 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 115.756 -0.656 . . . . 52.42 110.613 -179.553 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 59.3 t -74.48 132.36 33.49 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.598 0 CA-C-N 115.602 -0.726 . . . . 64.11 110.0 179.009 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' PHE . . . . . 0.493 ' O ' ' HA ' ' A' ' 59' ' ' GLN . 78.5 t80 -82.73 127.61 33.58 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 116.089 -0.505 . . . . 64.02 110.441 -177.261 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.545 ' HB ' ' HB3' ' A' ' 60' ' ' ALA . 14.2 p -131.35 147.64 32.8 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 CA-C-O 121.02 0.438 . . . . 63.32 111.647 -177.416 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 21.9 m170 -108.64 159.57 16.62 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.991 -0.549 . . . . 72.52 109.684 174.759 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' PHE . . . . . 0.676 ' CZ ' ' HA ' ' A' ' 11' ' ' ALA . 52.4 m-85 -71.95 -14.28 61.87 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-O 120.702 0.287 . . . . 62.15 111.309 -179.723 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 13.8 t -71.35 -22.13 61.94 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-O 121.337 0.589 . . . . 51.42 110.07 174.725 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -100.83 -22.53 14.81 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 115.846 -0.615 . . . . 73.32 110.487 179.387 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 70.6 mt -76.93 145.77 9.7 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 CA-C-N 115.883 -0.599 . . . . 75.31 109.452 174.521 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 34' ' ' GLN . . . . . 0.423 ' NE2' ' HG3' ' A' ' 65' ' ' LYS . 23.3 pt20 -68.92 100.4 1.19 Allowed 'General case' 0 C--N 1.327 -0.412 0 CA-C-O 121.455 0.645 . . . . 62.15 110.626 177.373 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -100.1 68.34 0.52 Allowed Glycine 0 N--CA 1.445 -0.708 0 C-N-CA 120.937 -0.649 . . . . 63.14 111.978 -178.914 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 6.2 m-20 -78.1 79.21 4.57 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-O 120.765 0.316 . . . . 54.21 110.41 177.316 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 71.82 -99.56 0.85 Allowed Glycine 0 N--CA 1.447 -0.606 0 C-N-CA 120.75 -0.738 . . . . 71.31 111.601 -178.004 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 93.8 m-85 -118.65 101.41 8.09 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-O 121.089 0.471 . . . . 71.23 110.567 178.954 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 75.2 mmtt -126.18 152.06 46.5 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 115.733 -0.667 . . . . 74.32 109.227 176.755 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 42.1 m -149.17 125.62 10.93 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-O 120.887 0.375 . . . . 44.25 110.986 -179.889 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 3.2 mm? -90.62 139.01 31.11 Favored 'General case' 0 C--N 1.324 -0.534 0 N-CA-C 109.228 -0.656 . . . . 73.43 109.228 175.021 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 30.9 t70 -90.23 146.76 24.0 Favored 'General case' 0 C--N 1.319 -0.729 0 C-N-CA 120.87 -0.332 . . . . 74.11 110.334 -178.792 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 37.4 mt-10 -70.97 102.01 2.31 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 116.319 -0.401 . . . . 63.13 109.932 178.293 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 123.03 1.19 9.59 Favored Glycine 0 N--CA 1.45 -0.433 0 CA-C-N 115.784 -0.644 . . . . 74.54 111.672 -173.272 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 52.1 tp60 -87.49 139.81 30.16 Favored 'General case' 0 N--CA 1.464 0.247 0 C-N-CA 122.247 0.219 . . . . 70.24 110.873 -179.734 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -90.54 131.68 36.13 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 121.084 0.469 . . . . 53.35 110.732 176.696 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 21.6 m -132.06 167.06 27.3 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 CA-C-N 116.062 -0.517 . . . . 72.13 110.782 -178.871 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 3.4 p -120.97 114.95 22.27 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-O 121.185 0.517 . . . . 62.24 110.211 179.312 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 49' ' ' PHE . . . . . 0.495 ' O ' ' HA ' ' A' ' 1' ' ' MET . 38.8 p90 -134.78 166.1 23.74 Favored 'General case' 0 C--N 1.319 -0.76 0 CA-C-N 115.949 -0.568 . . . . 73.45 110.348 -173.802 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . 0.597 ' HA ' ' HA ' ' A' ' 1' ' ' MET . 39.1 t0 -106.84 121.62 44.77 Favored 'General case' 0 C--N 1.324 -0.538 0 C-N-CA 120.4 -0.52 . . . . 71.32 110.447 175.253 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 86.5 t -77.83 117.16 22.54 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.55 0 CA-C-O 120.986 0.422 . . . . 74.55 111.294 -178.842 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . 0.66 ' HB3' ' HG3' ' A' ' 59' ' ' GLN . 8.9 tp10 -94.12 116.79 29.25 Favored 'General case' 0 C--N 1.321 -0.652 0 N-CA-C 108.904 -0.776 . . . . 74.35 108.904 174.022 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 47.5 mt-10 -92.78 95.73 9.72 Favored 'General case' 0 C--N 1.319 -0.721 0 CA-C-O 121.128 0.49 . . . . 71.34 110.107 179.837 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -103.61 -143.49 12.76 Favored Glycine 0 N--CA 1.445 -0.701 0 CA-C-N 115.597 -0.729 . . . . 52.42 112.68 -176.629 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -86.42 -40.41 15.4 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 121.008 0.432 . . . . 62.35 110.723 -175.381 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 77.2 mtm180 -108.23 81.94 1.56 Allowed 'General case' 0 C--N 1.322 -0.614 0 CA-C-N 116.273 -0.421 . . . . 62.34 111.305 -176.262 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 68.9 -171.29 38.92 Favored Glycine 0 N--CA 1.448 -0.507 0 CA-C-N 115.619 -0.719 . . . . 63.53 112.93 178.22 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 87.3 Cg_endo -86.94 123.62 2.05 Favored 'Trans proline' 0 N--CA 1.453 -0.857 0 C-N-CA 122.829 2.353 . . . . 75.44 111.764 175.752 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . 0.66 ' HG3' ' HB3' ' A' ' 52' ' ' GLU . 3.6 pt20 -109.3 126.91 53.86 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-N 116.212 -0.449 . . . . 51.44 109.852 178.181 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . 0.545 ' HB3' ' HB ' ' A' ' 28' ' ' VAL . . . -79.42 117.58 20.52 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-O 120.837 0.351 . . . . 64.41 110.802 -178.771 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -110.87 128.62 55.86 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 116.013 -0.54 . . . . 63.13 109.816 178.524 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 49.4 m-80 63.78 96.38 0.04 OUTLIER 'General case' 0 C--O 1.235 0.312 0 O-C-N 123.577 0.548 . . . . 71.43 110.674 -176.521 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.472 HG21 HG21 ' A' ' 28' ' ' VAL . 48.8 t -110.66 107.15 22.21 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.474 0 CA-C-N 115.661 -0.699 . . . . 65.11 110.746 179.718 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 64' ' ' GLN . . . . . 0.404 ' HG2' ' N ' ' A' ' 65' ' ' LYS . 34.4 tt0 -102.09 168.35 9.44 Favored 'General case' 0 C--N 1.324 -0.542 0 N-CA-C 108.816 -0.809 . . . . 75.12 108.816 177.556 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . 0.423 ' HG3' ' NE2' ' A' ' 34' ' ' GLN . 55.3 mtmt -103.78 155.29 18.72 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-O 120.801 0.334 . . . . 74.44 110.658 -179.125 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.251 1.135 0 CA-C-O 118.656 -0.688 . . . . 71.3 109.79 177.691 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 27.0 ptt? . . . . . 0 N--CA 1.483 1.177 0 CA-C-O 120.847 0.356 . . . . 70.24 110.842 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . 0.427 ' CD ' ' H ' ' A' ' 2' ' ' GLU . 1.8 pm0 -88.36 114.16 24.7 Favored 'General case' 0 C--O 1.239 0.514 0 CA-C-O 121.457 0.646 . . . . 51.4 110.822 -179.732 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -119.13 162.73 18.14 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 115.002 -0.999 . . . . 72.31 110.073 -179.297 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -160.65 165.24 34.99 Favored Glycine 0 N--CA 1.442 -0.95 0 C-N-CA 120.889 -0.672 . . . . 72.35 111.72 178.072 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . 0.465 ' O ' ' HG2' ' A' ' 19' ' ' GLU . 28.2 m -100.48 137.87 38.3 Favored 'General case' 0 C--N 1.319 -0.726 0 N-CA-C 110.06 -0.348 . . . . 74.4 110.06 178.451 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 48.1 t -68.62 108.36 1.55 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 N-CA-C 109.793 -0.447 . . . . 64.02 109.793 175.783 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . 0.614 ' HA ' ' HE3' ' A' ' 7' ' ' LYS . 0.0 OUTLIER -75.2 -56.15 5.01 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-O 120.93 0.395 . . . . 73.35 110.426 178.313 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' TRP . . . . . . . . . . . . . 4.1 p90 -156.98 136.98 12.6 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 115.749 -0.66 . . . . 75.03 110.205 179.162 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 17.5 p90 -124.35 108.55 12.32 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-O 121.807 0.813 . . . . 74.41 110.157 178.515 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 41.2 t-20 -85.93 86.83 7.35 Favored 'General case' 0 C--N 1.318 -0.761 0 CA-C-O 121.477 0.656 . . . . 74.2 109.401 -178.778 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -57.77 -32.46 67.52 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 114.914 -1.039 . . . . 73.21 111.623 179.182 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 74.2 mm-40 -64.08 -31.25 72.38 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 120.857 0.36 . . . . 70.45 111.132 178.848 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . 0.458 ' HB3' ' CE2' ' A' ' 15' ' ' PHE . 0.1 OUTLIER -92.28 -17.77 24.3 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.894 -0.594 . . . . 73.41 110.746 179.047 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 86.77 19.24 56.75 Favored Glycine 0 N--CA 1.447 -0.585 0 C-N-CA 120.82 -0.705 . . . . 75.32 112.898 177.635 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . 0.458 ' CE2' ' HB3' ' A' ' 13' ' ' LYS . 31.0 p90 -157.78 156.66 31.94 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 121.133 0.492 . . . . 54.45 111.443 179.587 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -134.87 -179.24 16.31 Favored Glycine 0 N--CA 1.442 -0.906 0 N-CA-C 111.291 -0.724 . . . . 73.52 111.291 178.671 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . 0.421 ' HA ' ' O ' ' A' ' 26' ' ' VAL . 97.2 m-85 -132.35 127.65 35.98 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-O 121.305 0.574 . . . . 75.24 111.266 -179.538 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 63.4 mt -101.32 138.86 24.11 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.569 0 CA-C-N 115.209 -0.905 . . . . 73.51 109.344 177.864 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' GLU . . . . . 0.495 ' HB3' ' HG3' ' A' ' 7' ' ' LYS . 11.7 pt-20 -82.86 134.84 35.08 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-O 121.196 0.522 . . . . 73.34 111.303 -177.022 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' ARG . . . . . 0.754 ' HD2' ' H ' ' A' ' 21' ' ' GLU . 0.1 OUTLIER -113.22 -177.96 3.26 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 115.904 -0.589 . . . . 72.14 109.775 178.506 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . 0.754 ' H ' ' HD2' ' A' ' 20' ' ' ARG . 10.0 pt-20 -59.51 -37.18 77.64 Favored 'General case' 0 C--N 1.327 -0.387 0 N-CA-C 112.93 0.715 . . . . 72.45 112.93 -173.205 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' ASN . . . . . 0.422 ' ND2' ' HG3' ' A' ' 21' ' ' GLU . 29.3 m-80 -94.21 5.67 51.03 Favored 'General case' 0 C--N 1.328 -0.346 0 O-C-N 122.096 -0.377 . . . . 72.41 110.805 -178.306 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 84.97 20.02 58.39 Favored Glycine 0 N--CA 1.447 -0.584 0 N-CA-C 110.236 -1.145 . . . . 31.11 110.236 -170.509 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . 0.457 ' HB2' ' CB ' ' A' ' 20' ' ' ARG . 3.8 m-20 -67.15 95.02 0.38 Allowed 'General case' 0 N--CA 1.45 -0.448 0 CA-C-N 114.879 -0.66 . . . . 73.4 109.463 179.59 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 11.1 p-10 -63.65 100.81 0.3 Allowed 'General case' 0 C--N 1.32 -0.676 0 CA-C-O 121.833 0.825 . . . . 60.43 110.309 175.97 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.421 ' O ' ' HA ' ' A' ' 17' ' ' PHE . 44.9 t -78.38 120.76 29.91 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 CA-C-N 115.15 -0.932 . . . . 72.12 110.756 -177.273 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' PHE . . . . . . . . . . . . . 68.9 t80 -73.34 113.16 10.11 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 115.65 -0.705 . . . . 54.13 110.433 -179.092 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.434 ' HB ' ' HB3' ' A' ' 60' ' ' ALA . 10.4 p -117.26 126.59 74.64 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.575 0 CA-C-O 121.083 0.468 . . . . 73.01 110.24 176.068 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' HIS . . . . . 0.433 ' O ' HG13 ' A' ' 33' ' ' ILE . 41.2 t60 -103.46 149.74 24.54 Favored 'General case' 0 C--N 1.324 -0.529 0 N-CA-C 109.452 -0.573 . . . . 73.41 109.452 -176.754 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' PHE . . . . . 0.438 ' HA ' HD12 ' A' ' 33' ' ' ILE . 42.2 p90 -58.44 -27.29 64.22 Favored 'General case' 0 N--CA 1.467 0.403 0 CA-C-O 120.819 0.342 . . . . 74.32 111.607 -175.657 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 6.7 m -72.98 -14.13 61.38 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 116.409 -0.36 . . . . 74.51 111.283 179.005 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -106.88 -17.65 14.14 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.921 0.391 . . . . 63.21 111.058 -178.466 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.438 HD12 ' HA ' ' A' ' 30' ' ' PHE . 66.5 mt -71.22 144.82 13.06 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 CA-C-N 116.032 -0.531 . . . . 73.45 110.49 177.989 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 34' ' ' GLN . . . . . 0.47 ' HG3' ' O ' ' A' ' 34' ' ' GLN . 21.6 pt20 -66.47 103.96 1.15 Allowed 'General case' 0 C--N 1.33 -0.263 0 N-CA-C 109.581 -0.526 . . . . 72.33 109.581 172.909 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.52 ' HA2' ' CG ' ' A' ' 39' ' ' LYS . . . -145.52 130.39 3.79 Favored Glycine 0 N--CA 1.442 -0.912 0 C-N-CA 119.633 -1.27 . . . . 74.03 114.054 -174.474 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 6.5 m-20 -83.03 80.56 9.01 Favored 'General case' 0 C--N 1.324 -0.543 0 N-CA-C 107.761 -1.2 . . . . 70.44 107.761 167.434 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 80.7 -73.32 2.56 Favored Glycine 0 N--CA 1.443 -0.895 0 N-CA-C 109.979 -1.248 . . . . 71.45 109.979 -167.137 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 68.2 m-85 -146.72 130.0 16.62 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-O 120.792 0.33 . . . . 73.43 110.27 173.403 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 39' ' ' LYS . . . . . 0.52 ' CG ' ' HA2' ' A' ' 35' ' ' GLY . 12.1 mmmm -125.69 128.16 47.37 Favored 'General case' 0 C--N 1.326 -0.456 0 N-CA-C 109.16 -0.681 . . . . 74.32 109.16 174.867 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 51.4 p -87.06 104.0 15.91 Favored 'General case' 0 C--N 1.32 -0.685 0 N-CA-C 112.206 0.446 . . . . 74.13 112.206 -173.725 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -88.77 103.64 16.16 Favored 'General case' 0 C--N 1.326 -0.439 0 N-CA-C 108.376 -0.972 . . . . 61.12 108.376 168.968 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 20.5 t70 -76.72 150.85 36.24 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 116.058 -0.519 . . . . 55.05 111.527 -169.718 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 83.6 mt-10 -61.59 112.82 2.38 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 115.629 -0.714 . . . . 72.24 110.552 -179.593 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 124.29 -12.87 7.96 Favored Glycine 0 N--CA 1.445 -0.758 0 C-N-CA 120.796 -0.716 . . . . 61.42 111.547 -177.203 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 6.5 tp-100 -80.06 143.15 34.25 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-O 120.857 0.36 . . . . 64.01 110.312 178.678 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -99.5 118.75 36.77 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 116.023 -0.535 . . . . 41.11 110.188 179.515 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 27.4 m -123.57 163.01 23.48 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.696 0 CA-C-N 116.227 -0.442 . . . . 70.11 111.11 -176.754 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 1.6 p -117.25 139.86 50.27 Favored 'General case' 0 C--N 1.321 -0.64 0 N-CA-C 108.91 -0.774 . . . . 74.31 108.91 176.548 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 33.5 p90 -141.24 159.18 42.76 Favored 'General case' 0 C--N 1.317 -0.823 0 C-N-CA 120.3 -0.56 . . . . 72.24 111.616 -175.26 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 4.9 t70 -88.14 103.16 15.49 Favored 'General case' 0 C--N 1.321 -0.657 0 N-CA-C 108.645 -0.872 . . . . 64.23 108.645 174.975 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 7.7 p -63.79 123.13 15.99 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 CA-C-O 121.295 0.569 . . . . 71.35 111.846 -173.09 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . 0.548 ' HB3' ' HG2' ' A' ' 59' ' ' GLN . 7.8 tp10 -117.52 139.86 50.38 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 115.648 -0.705 . . . . 63.41 110.067 178.997 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 10.8 tp10 -101.31 146.32 27.71 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-N 115.956 -0.565 . . . . 64.33 109.626 -179.701 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -144.83 -175.79 18.29 Favored Glycine 0 N--CA 1.45 -0.417 0 C-N-CA 120.709 -0.757 . . . . 40.03 112.527 -177.88 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 50.2 mt-30 -75.11 -34.15 61.67 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 120.755 0.312 . . . . 73.23 110.85 179.757 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 35.0 mtp-105 -77.1 -33.31 56.93 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-O 121.022 0.439 . . . . 74.21 110.436 174.39 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 146.87 -155.8 26.71 Favored Glycine 0 N--CA 1.448 -0.504 0 CA-C-N 115.904 -0.589 . . . . 31.05 111.798 -178.223 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 59.7 Cg_endo -74.26 137.13 23.07 Favored 'Trans proline' 0 C--O 1.234 0.298 0 C-N-CA 122.582 2.188 . . . . 73.55 112.775 -177.752 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . 0.548 ' HG2' ' HB3' ' A' ' 52' ' ' GLU . 0.0 OUTLIER -131.35 154.75 48.26 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 116.101 -0.499 . . . . 72.24 109.835 175.142 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . 0.434 ' HB3' ' HB ' ' A' ' 28' ' ' VAL . . . -101.77 106.53 17.54 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 116.294 -0.412 . . . . 55.04 110.993 -177.132 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -111.28 149.1 31.54 Favored 'General case' 0 C--N 1.321 -0.655 0 N-CA-C 109.263 -0.643 . . . . 33.32 109.263 175.082 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 86.5 m-20 57.06 82.79 0.11 Allowed 'General case' 0 N--CA 1.466 0.354 0 CA-C-O 121.304 0.573 . . . . 52.25 110.499 -178.459 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 46.4 t -103.54 134.48 44.61 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.588 0 CA-C-N 115.871 -0.604 . . . . 55.44 111.327 -174.985 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 28.0 mt-30 -130.71 178.2 6.82 Favored 'General case' 0 C--N 1.325 -0.484 0 N-CA-C 109.189 -0.671 . . . . 51.35 109.189 175.381 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . 0.437 ' HG3' HE22 ' A' ' 34' ' ' GLN . 50.7 mtmt -96.81 144.18 27.02 Favored 'General case' 0 C--N 1.323 -0.554 0 N-CA-C 110.028 -0.36 . . . . 74.45 110.028 178.074 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 0.98 0 CA-C-O 118.519 -0.753 . . . . 61.15 110.274 -179.922 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . 0.454 ' N ' ' HA ' ' A' ' 50' ' ' ASP . 21.1 ptp . . . . . 0 N--CA 1.478 0.935 0 CA-C-O 121.153 0.501 . . . . 64.44 109.926 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -91.37 157.7 16.95 Favored 'General case' 0 N--CA 1.452 -0.335 0 CA-C-N 115.653 -0.703 . . . . 62.24 109.994 -174.105 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' GLN . . . . . 0.455 ' HG2' HG22 ' A' ' 48' ' ' THR . 50.3 mt-30 -105.85 130.67 53.77 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-N 116.029 -0.532 . . . . 64.44 109.8 174.491 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -150.49 172.9 30.21 Favored Glycine 0 N--CA 1.443 -0.844 0 C-N-CA 120.794 -0.717 . . . . 61.22 111.683 178.571 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . 0.542 ' O ' ' HG2' ' A' ' 19' ' ' GLU . 24.3 m -122.65 135.76 54.69 Favored 'General case' 0 C--N 1.317 -0.829 0 N-CA-C 110.167 -0.309 . . . . 74.44 110.167 179.067 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 46.4 t -72.41 119.06 18.4 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.633 0 CA-C-N 116.741 -0.209 . . . . 72.13 110.524 -179.114 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . 0.572 ' CE ' ' HB3' ' A' ' 19' ' ' GLU . 97.7 mttt -66.01 -62.59 1.41 Allowed 'General case' 0 CA--C 1.52 -0.193 0 CA-C-O 121.7 0.762 . . . . 73.14 109.223 175.896 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' TRP . . . . . . . . . . . . . 55.1 p-90 -160.45 156.06 25.42 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-N 114.393 -1.276 . . . . 64.35 108.053 177.571 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . 0.412 ' CE2' ' HB2' ' A' ' 11' ' ' ALA . 2.1 p90 -136.03 138.52 42.28 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-O 121.603 0.716 . . . . 75.11 111.858 -174.113 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' ASN . . . . . 0.559 ' HB3' ' HG2' ' A' ' 13' ' ' LYS . 16.6 m120 -84.12 77.52 9.93 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 115.115 -0.948 . . . . 72.15 109.115 177.009 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . 0.412 ' HB2' ' CE2' ' A' ' 9' ' ' PHE . . . -54.12 -38.43 65.43 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.212 -0.904 . . . . 72.33 112.367 -175.07 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -90.75 -14.28 32.35 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 116.492 -0.322 . . . . 64.2 111.697 -175.288 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . 0.559 ' HG2' ' HB3' ' A' ' 10' ' ' ASN . 59.6 mmtt -90.55 -36.39 14.5 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 121.191 0.52 . . . . 72.31 109.649 177.017 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 99.59 32.88 5.54 Favored Glycine 0 N--CA 1.447 -0.619 0 CA-C-N 115.698 -0.683 . . . . 62.01 111.636 -177.676 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 74.0 m-85 -140.19 168.82 18.91 Favored 'General case' 0 C--N 1.329 -0.312 0 N-CA-C 110.152 -0.314 . . . . 72.11 110.152 -177.941 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -171.12 161.34 33.96 Favored Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.542 -0.837 . . . . 65.21 112.437 177.764 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 97.4 m-85 -123.93 120.21 31.86 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-O 121.033 0.444 . . . . 75.05 110.908 -179.847 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.4 HG21 ' CE2' ' A' ' 49' ' ' PHE . 54.0 mt -105.12 135.95 41.0 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.616 0 CA-C-N 115.869 -0.605 . . . . 74.25 109.74 178.981 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' GLU . . . . . 0.572 ' HB3' ' CE ' ' A' ' 7' ' ' LYS . 11.6 pt-20 -94.81 128.64 41.69 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 121.404 0.621 . . . . 73.44 111.654 -177.461 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 20' ' ' ARG . . . . . 0.48 ' HB3' ' HB3' ' A' ' 24' ' ' ASP . 18.6 ttt180 -89.67 177.13 6.61 Favored 'General case' 0 C--N 1.323 -0.548 0 N-CA-C 108.289 -1.004 . . . . 74.53 108.289 171.697 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 44.6 mt-10 -61.04 -12.05 10.41 Favored 'General case' 0 N--CA 1.467 0.409 0 N-CA-C 112.098 0.407 . . . . 73.33 112.098 -178.787 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 82.6 m-20 -98.05 -4.22 36.46 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.89 0.376 . . . . 73.43 111.239 177.826 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 82.42 3.17 90.64 Favored Glycine 0 N--CA 1.449 -0.461 0 N-CA-C 110.337 -1.105 . . . . 65.44 110.337 -168.657 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . 0.48 ' HB3' ' HB3' ' A' ' 20' ' ' ARG . 33.6 t70 -56.3 98.73 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 114.61 -0.795 . . . . 55.44 110.721 -179.062 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 12.4 m-20 -56.5 100.44 0.04 OUTLIER 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 114.964 -1.016 . . . . 73.2 111.698 174.999 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.506 HG12 ' HB2' ' A' ' 60' ' ' ALA . 21.4 t -83.1 116.6 27.55 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.743 0 N-CA-C 108.761 -0.829 . . . . 72.55 108.761 172.883 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 27' ' ' PHE . . . . . . . . . . . . . 81.1 t80 -83.22 116.15 22.26 Favored 'General case' 0 C--N 1.32 -0.682 0 CA-C-N 115.894 -0.594 . . . . 75.3 111.021 -173.414 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 9.0 p -105.73 148.91 9.61 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.581 0 N-CA-C 109.534 -0.543 . . . . 70.2 109.534 175.901 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 29' ' ' HIS . . . . . 0.447 ' O ' HG13 ' A' ' 33' ' ' ILE . 2.7 p80 -140.19 163.88 31.56 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 116.277 -0.419 . . . . 72.33 110.58 -174.173 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 31.3 p90 -53.18 -33.0 50.79 Favored 'General case' 0 N--CA 1.47 0.536 0 N-CA-C 112.871 0.693 . . . . 73.4 112.871 -174.001 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 27.5 m -84.92 34.23 0.54 Allowed 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 121.174 0.511 . . . . 72.44 110.906 176.866 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -160.57 -33.56 0.05 Allowed 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 115.826 -0.625 . . . . 63.54 110.729 -179.364 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.447 HG13 ' O ' ' A' ' 29' ' ' HIS . 71.7 mt -63.7 143.37 15.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.065 -0.516 . . . . 75.44 110.461 176.195 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 34' ' ' GLN . . . . . 0.504 ' O ' ' HA ' ' A' ' 39' ' ' LYS . 88.4 mt-30 -53.69 113.33 1.15 Allowed 'General case' 0 C--N 1.329 -0.293 0 N-CA-C 109.792 -0.448 . . . . 75.32 109.792 172.117 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -101.54 -31.32 5.55 Favored Glycine 0 N--CA 1.45 -0.431 0 C-N-CA 120.321 -0.943 . . . . 52.34 112.266 -178.839 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 9.7 m-20 -106.38 115.4 30.15 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-O 120.882 0.372 . . . . 62.11 110.099 -178.797 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 116.06 -123.3 5.83 Favored Glycine 0 N--CA 1.446 -0.667 0 N-CA-C 111.126 -0.79 . . . . 74.23 111.126 -175.407 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 72.9 m-85 -96.46 93.51 6.86 Favored 'General case' 0 C--N 1.325 -0.499 0 N-CA-C 109.628 -0.508 . . . . 65.44 109.628 175.899 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 39' ' ' LYS . . . . . 0.504 ' HA ' ' O ' ' A' ' 34' ' ' GLN . 0.0 OUTLIER -74.98 -29.34 60.87 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 116.098 -0.501 . . . . 75.21 111.901 -173.182 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 15.2 m -67.88 108.12 2.89 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-O 120.947 0.403 . . . . 72.14 111.619 -174.01 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 92.2 mt -82.16 74.35 9.15 Favored 'General case' 0 C--N 1.324 -0.51 0 N-CA-C 108.797 -0.816 . . . . 75.21 108.797 171.415 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 27.6 t70 -55.38 139.88 41.64 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 115.18 -0.918 . . . . 75.32 112.051 -172.467 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 7.8 pt-20 -64.66 129.72 40.87 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-N 115.428 -0.806 . . . . 71.24 110.582 179.121 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 97.15 -10.22 65.54 Favored Glycine 0 N--CA 1.45 -0.403 0 C-N-CA 120.871 -0.68 . . . . 34.42 112.036 -177.202 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 54.0 tp60 -81.78 135.35 35.47 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-O 120.767 0.318 . . . . 71.55 110.558 178.769 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -85.35 138.54 32.22 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 116.117 -0.492 . . . . 70.34 110.097 176.043 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 16.6 m -136.98 144.84 31.08 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.605 0 CA-C-N 116.348 -0.387 . . . . 73.14 111.25 -177.415 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 48' ' ' THR . . . . . 0.455 HG22 ' HG2' ' A' ' 3' ' ' GLN . 24.7 p -104.58 122.74 46.23 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-N 115.753 -0.658 . . . . 74.03 109.571 173.633 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 49' ' ' PHE . . . . . 0.48 ' HA ' ' O ' ' A' ' 62' ' ' ASN . 38.8 p90 -141.09 157.3 45.49 Favored 'General case' 0 C--N 1.32 -0.701 0 CA-C-O 120.701 0.286 . . . . 63.53 111.206 -172.403 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . 0.454 ' HA ' ' N ' ' A' ' 1' ' ' MET . 30.2 m-20 -90.48 149.49 22.19 Favored 'General case' 0 C--N 1.321 -0.674 0 N-CA-C 109.684 -0.488 . . . . 71.44 109.684 172.357 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 5.4 p -110.44 117.14 54.16 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.628 0 CA-C-O 121.428 0.633 . . . . 71.24 111.549 -175.28 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . 0.653 ' HB2' ' HB2' ' A' ' 59' ' ' GLN . 6.9 mm-40 -94.76 133.43 38.46 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 115.432 -0.804 . . . . 73.54 109.476 174.456 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 8.5 pt-20 -82.04 97.82 8.33 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-O 121.354 0.597 . . . . 72.5 110.86 -179.33 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -90.02 151.84 21.89 Favored Glycine 0 N--CA 1.446 -0.685 0 C-N-CA 120.736 -0.745 . . . . 74.41 111.671 179.041 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 49.8 mt-30 -58.38 -25.96 62.65 Favored 'General case' 0 C--N 1.327 -0.375 0 N-CA-C 112.377 0.51 . . . . 71.44 112.377 -177.182 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 81.4 mtt180 -130.49 26.86 5.06 Favored 'General case' 0 C--N 1.327 -0.41 0 N-CA-C 111.716 0.265 . . . . 61.21 111.716 -177.217 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 150.22 153.32 6.06 Favored Glycine 0 N--CA 1.449 -0.441 0 C-N-CA 120.128 -1.034 . . . . 45.02 113.074 177.319 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 7.2 Cg_exo -72.59 124.42 9.8 Favored 'Trans proline' 0 N--CA 1.46 -0.478 0 C-N-CA 122.834 2.356 . . . . 74.0 111.475 177.449 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . 0.653 ' HB2' ' HB2' ' A' ' 52' ' ' GLU . 26.0 mt-30 -94.53 123.44 37.96 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-N 116.243 -0.435 . . . . 70.42 110.664 -179.029 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . 0.506 ' HB2' HG12 ' A' ' 26' ' ' VAL . . . -78.99 106.59 11.14 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 116.308 -0.405 . . . . 72.41 109.946 176.244 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -116.86 139.48 50.57 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 116.311 -0.404 . . . . 62.45 110.033 -179.928 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 62' ' ' ASN . . . . . 0.48 ' O ' ' HA ' ' A' ' 49' ' ' PHE . 76.8 m-20 60.31 92.26 0.05 OUTLIER 'General case' 0 C--O 1.236 0.358 0 O-C-N 123.595 0.56 . . . . 74.31 110.008 -176.116 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 40.7 t -114.3 136.59 50.35 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.547 0 CA-C-N 115.469 -0.787 . . . . 72.15 110.55 -175.16 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 64' ' ' GLN . . . . . 0.429 ' HB3' ' OG1' ' A' ' 48' ' ' THR . 31.0 tt0 -121.5 149.14 43.51 Favored 'General case' 0 C--N 1.319 -0.737 0 N-CA-C 109.624 -0.51 . . . . 64.3 109.624 176.403 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 48.4 mttp -91.49 123.83 35.2 Favored 'General case' 0 C--N 1.324 -0.502 0 N-CA-C 110.112 -0.329 . . . . 73.43 110.112 178.491 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.246 0.886 0 CA-C-O 118.602 -0.713 . . . . 75.12 110.647 -179.942 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 27.2 ttt . . . . . 0 N--CA 1.483 1.178 0 CA-C-O 120.931 0.396 . . . . 73.12 110.852 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 60.7 mm-40 -81.48 69.7 8.18 Favored 'General case' 0 C--O 1.238 0.471 0 CA-C-O 121.388 0.613 . . . . 75.21 111.837 -178.979 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 35.3 tt0 -120.91 136.28 54.99 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-N 115.34 -0.845 . . . . 74.55 109.478 174.756 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -151.9 164.49 30.4 Favored Glycine 0 N--CA 1.444 -0.788 0 N-CA-C 111.368 -0.693 . . . . 64.31 111.368 179.027 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . 0.54 HG21 ' HE3' ' A' ' 7' ' ' LYS . 5.4 m -103.38 125.32 49.92 Favored 'General case' 0 C--N 1.318 -0.802 0 CA-C-N 116.984 0.392 . . . . 74.21 110.825 -178.623 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.488 HG22 HG12 ' A' ' 18' ' ' ILE . 46.1 t -81.52 90.47 1.94 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 N-CA-C 109.099 -0.704 . . . . 73.44 109.099 175.473 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . 0.54 ' HE3' HG21 ' A' ' 5' ' ' THR . 27.9 mmtp -78.02 -51.9 9.62 Favored 'General case' 0 C--N 1.323 -0.587 0 CA-C-N 115.818 -0.628 . . . . 61.0 111.584 -176.155 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' TRP . . . . . . . . . . . . . 8.8 p90 -133.12 122.25 23.81 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-O 121.41 0.624 . . . . 72.22 110.992 178.113 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 22.2 p90 -111.6 123.43 50.21 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-N 115.343 -0.844 . . . . 64.05 109.544 178.434 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 16.7 t-20 -88.39 76.18 8.34 Favored 'General case' 0 C--N 1.317 -0.806 0 CA-C-O 121.503 0.668 . . . . 61.44 109.893 -176.737 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -67.75 -7.93 31.39 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.241 -0.89 . . . . 73.53 110.442 178.438 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 27.3 mt-10 -70.45 -33.41 71.26 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 115.306 -0.861 . . . . 74.05 110.595 179.081 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . 0.423 ' HB2' ' CE1' ' A' ' 15' ' ' PHE . 74.3 mmtt -116.25 -29.66 6.18 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.235 -0.439 . . . . 52.34 111.296 -178.47 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . 0.618 ' HA2' ' CE2' ' A' ' 30' ' ' PHE . . . 117.52 24.83 3.33 Favored Glycine 0 N--CA 1.452 -0.265 0 C-N-CA 120.178 -1.011 . . . . 64.41 113.773 175.842 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . 0.423 ' CE1' ' HB2' ' A' ' 13' ' ' LYS . 54.9 p90 -142.1 -174.11 4.01 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 116.921 0.361 . . . . 75.52 110.124 179.334 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -169.65 170.39 42.68 Favored Glycine 0 N--CA 1.449 -0.454 0 C-N-CA 120.358 -0.925 . . . . 53.03 112.147 177.713 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 98.2 m-85 -120.17 126.59 51.04 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 121.054 0.454 . . . . 75.53 110.81 -179.728 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.488 HG12 HG22 ' A' ' 6' ' ' VAL . 62.9 mt -110.81 129.21 66.42 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.572 0 CA-C-N 115.777 -0.647 . . . . 64.14 110.179 179.724 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 7.0 pt-20 -79.71 113.26 17.73 Favored 'General case' 0 C--N 1.326 -0.436 0 N-CA-C 109.665 -0.494 . . . . 63.1 109.665 175.673 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 20' ' ' ARG . . . . . 0.409 ' HD3' ' OD2' ' A' ' 24' ' ' ASP . 73.0 ttt-85 -113.02 111.15 21.68 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 116.06 -0.518 . . . . 71.34 111.332 -175.604 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 10.7 mm-40 47.3 -89.6 0.01 OUTLIER 'General case' 0 N--CA 1.47 0.537 0 N-CA-C 114.158 1.17 . . . . 74.25 114.158 169.725 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 23.6 t-20 -70.51 -31.38 68.44 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 121.12 0.486 . . . . 53.41 111.27 -174.018 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 130.51 -1.67 5.66 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.728 -0.748 . . . . 62.44 111.255 -176.405 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . 0.409 ' OD2' ' HD3' ' A' ' 20' ' ' ARG . 2.6 p-10 -67.92 94.35 0.47 Allowed 'General case' 0 C--N 1.323 -0.565 0 CA-C-O 121.355 0.597 . . . . 61.34 110.185 175.937 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 5.7 p-10 -57.02 123.58 15.68 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 114.989 -1.005 . . . . 75.2 110.751 176.938 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 46.4 t -97.22 135.05 32.77 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.658 0 CA-C-N 115.614 -0.721 . . . . 72.22 110.326 -179.764 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 27' ' ' PHE . . . . . . . . . . . . . 32.5 t80 -80.77 105.58 12.12 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 116.142 -0.481 . . . . 72.35 110.161 -179.188 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.403 HG23 HG21 ' A' ' 63' ' ' VAL . 9.9 p -99.74 158.87 3.7 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.516 0 N-CA-C 110.011 -0.366 . . . . 65.44 110.011 179.522 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 1.1 p80 -147.89 159.49 43.8 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.534 -0.303 . . . . 71.52 110.29 -178.414 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 30' ' ' PHE . . . . . 0.618 ' CE2' ' HA2' ' A' ' 14' ' ' GLY . 23.0 m-85 -56.82 -37.14 70.8 Favored 'General case' 0 N--CA 1.468 0.443 0 N-CA-C 112.76 0.652 . . . . 72.4 112.76 -173.767 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 12.7 t -70.97 -3.31 18.75 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 120.893 0.377 . . . . 42.45 111.269 -178.157 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . 0.427 ' HB1' HG23 ' A' ' 63' ' ' VAL . . . -107.08 -34.13 7.25 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.75 0.31 . . . . 61.45 110.668 177.015 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.511 ' HA ' ' HB ' ' A' ' 63' ' ' VAL . 61.2 mt -65.17 140.27 20.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.109 -0.496 . . . . 72.22 110.708 179.041 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 11.3 pt20 -74.36 23.35 0.09 Allowed 'General case' 0 CA--C 1.537 0.443 0 N-CA-C 112.359 0.503 . . . . 55.12 112.359 -177.488 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -83.16 116.62 4.25 Favored Glycine 0 N--CA 1.449 -0.498 0 C-N-CA 120.617 -0.801 . . . . 74.54 112.003 -179.689 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 14.7 t70 -81.98 111.26 17.99 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.741 0.305 . . . . 34.41 110.512 178.825 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 75.41 -118.9 5.66 Favored Glycine 0 N--CA 1.446 -0.665 0 C-N-CA 120.969 -0.634 . . . . 62.12 112.076 179.915 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 97.5 m-85 -106.06 90.25 3.31 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-O 120.946 0.403 . . . . 74.43 110.515 -179.189 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 32.1 mmmt -130.57 146.58 52.11 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.785 -0.643 . . . . 61.33 109.66 177.367 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 18.6 m -109.05 113.69 26.78 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-O 120.682 0.277 . . . . 74.22 110.457 -179.691 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . 0.431 HD22 ' HA ' ' A' ' 41' ' ' LEU . 1.9 tm? -62.85 125.87 25.42 Favored 'General case' 0 C--N 1.326 -0.433 0 N-CA-C 109.078 -0.712 . . . . 63.22 109.078 178.374 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 18.1 m-20 -60.16 119.76 8.47 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 116.245 -0.434 . . . . 74.2 110.974 -176.627 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 8.2 pt-20 -67.18 119.5 12.2 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-O 121.34 0.59 . . . . 64.54 110.145 177.616 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 112.49 -4.61 26.43 Favored Glycine 0 N--CA 1.445 -0.713 0 N-CA-C 111.179 -0.768 . . . . 51.15 111.179 -174.532 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 5.8 tp-100 -72.67 132.91 44.31 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 120.874 0.369 . . . . 75.25 110.946 179.73 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -86.08 115.07 23.44 Favored 'General case' 0 C--N 1.325 -0.465 0 N-CA-C 108.89 -0.781 . . . . 44.13 108.89 173.073 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 0.51 ' HA ' ' HA ' ' A' ' 65' ' ' LYS . 29.3 m -110.27 155.29 11.6 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.811 0 CA-C-O 121.316 0.579 . . . . 51.43 111.51 -174.945 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 48' ' ' THR . . . . . 0.5 HG23 ' HB2' ' A' ' 66' ' ' ALA . 45.4 p -121.15 112.31 18.52 Favored 'General case' 0 C--N 1.318 -0.773 0 CA-C-N 115.322 -0.854 . . . . 73.15 108.832 175.376 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 49' ' ' PHE . . . . . 0.407 ' HA ' ' O ' ' A' ' 62' ' ' ASN . 35.4 p90 -127.07 171.98 10.9 Favored 'General case' 0 C--N 1.319 -0.748 0 CA-C-N 115.95 -0.568 . . . . 71.13 111.323 -170.969 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 62.9 m-20 -96.12 138.43 33.75 Favored 'General case' 0 C--N 1.322 -0.598 0 N-CA-C 109.065 -0.717 . . . . 73.45 109.065 169.935 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 12.5 p -102.31 134.67 42.39 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.721 0 CA-C-O 121.008 0.432 . . . . 63.2 111.27 -174.767 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 40.1 mt-10 -122.35 148.81 44.6 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 116.066 -0.515 . . . . 73.44 110.24 175.889 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 36.5 mt-10 -106.07 123.41 47.96 Favored 'General case' 0 C--N 1.319 -0.736 0 N-CA-C 109.61 -0.515 . . . . 71.33 109.61 177.401 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -118.46 -178.99 17.06 Favored Glycine 0 N--CA 1.445 -0.74 0 C-N-CA 120.669 -0.777 . . . . 74.54 112.287 -178.512 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -67.64 -29.45 68.76 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 120.772 0.32 . . . . 73.25 111.548 -179.755 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 22.0 ttt180 -85.03 -27.62 26.27 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.184 -0.462 . . . . 73.03 110.448 179.455 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 148.73 -164.87 29.16 Favored Glycine 0 N--CA 1.446 -0.645 0 C-N-CA 120.893 -0.67 . . . . 71.14 111.864 -179.282 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 56.4 Cg_endo -72.41 126.85 11.97 Favored 'Trans proline' 0 N--CA 1.463 -0.288 0 C-N-CA 122.702 2.268 . . . . 52.13 112.388 179.595 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 11.5 pt20 -123.72 154.33 39.61 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-N 115.851 -0.613 . . . . 72.51 110.152 -179.974 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -99.57 135.25 41.27 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 116.383 -0.371 . . . . 44.42 111.168 -177.958 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -131.97 149.63 52.38 Favored 'General case' 0 C--N 1.324 -0.529 0 N-CA-C 108.829 -0.804 . . . . 71.42 108.829 174.461 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 62' ' ' ASN . . . . . 0.407 ' O ' ' HA ' ' A' ' 49' ' ' PHE . 55.5 m-20 53.57 75.57 0.26 Allowed 'General case' 0 C--O 1.239 0.504 0 N-CA-C 110.028 -0.36 . . . . 73.12 110.028 -174.999 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.511 ' HB ' ' HA ' ' A' ' 33' ' ' ILE . 59.4 t -101.9 101.99 12.89 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.517 0 CA-C-O 121.171 0.51 . . . . 73.52 110.947 -176.191 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 50.8 mt-30 -107.48 170.27 8.07 Favored 'General case' 0 C--N 1.32 -0.707 0 N-CA-C 108.593 -0.892 . . . . 74.33 108.593 175.791 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . 0.51 ' HA ' ' HA ' ' A' ' 47' ' ' VAL . 21.9 pttp -93.58 169.1 10.59 Favored 'General case' 0 C--N 1.321 -0.66 0 C-N-CA 120.477 -0.489 . . . . 70.14 110.277 179.658 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 66' ' ' ALA . . . . . 0.5 ' HB2' HG23 ' A' ' 48' ' ' THR . . . . . . . . 0 C--O 1.246 0.907 0 CA-C-O 118.275 -0.869 . . . . 52.24 109.96 176.241 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . 0.435 ' HG2' ' OE2' ' A' ' 2' ' ' GLU . 22.3 ptp . . . . . 0 N--CA 1.486 1.326 0 CA-C-O 121.113 0.483 . . . . 73.31 110.075 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . 0.435 ' OE2' ' HG2' ' A' ' 1' ' ' MET . 6.9 mp0 -94.05 128.35 40.36 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 115.982 -0.554 . . . . 65.41 110.572 -169.887 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 27.0 tt0 -90.34 98.94 12.07 Favored 'General case' 0 C--N 1.322 -0.614 0 N-CA-C 109.085 -0.709 . . . . 73.5 109.085 174.567 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -120.91 163.42 14.41 Favored Glycine 0 N--CA 1.446 -0.667 0 C-N-CA 120.575 -0.821 . . . . 75.4 112.668 -174.591 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . 0.461 ' O ' ' HG2' ' A' ' 19' ' ' GLU . 0.2 OUTLIER -105.23 129.53 53.58 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-O 121.028 0.442 . . . . 74.1 110.969 179.826 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.552 ' HA ' ' HA ' ' A' ' 18' ' ' ILE . 17.0 t -71.06 121.66 21.44 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.582 0 CA-C-N 116.08 -0.509 . . . . 61.42 110.451 179.684 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 50.5 mttp -74.33 -49.48 22.7 Favored 'General case' 0 C--N 1.329 -0.302 0 C-N-CA 120.719 -0.392 . . . . 54.44 110.433 177.677 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' TRP . . . . . . . . . . . . . 14.9 p-90 -161.99 163.74 28.74 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.91 -0.586 . . . . 74.51 109.671 179.469 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 10.9 p90 -145.02 121.1 10.75 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-O 121.31 0.576 . . . . 71.43 111.098 -178.131 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 52.2 t-20 -82.73 86.43 6.88 Favored 'General case' 0 C--N 1.321 -0.631 0 N-CA-C 109.267 -0.642 . . . . 61.41 109.267 177.226 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -72.84 -5.33 37.47 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.303 -0.862 . . . . 64.35 111.748 -179.644 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 9.8 mm-40 -86.25 -19.4 30.01 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-O 120.977 0.418 . . . . 63.32 110.253 177.355 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 43.4 mmtm -108.76 -48.04 3.37 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 115.945 -0.571 . . . . 65.34 110.047 176.71 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 115.76 43.83 0.67 Allowed Glycine 0 N--CA 1.442 -0.929 0 C-N-CA 120.765 -0.731 . . . . 63.13 112.174 -179.134 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 43.8 p90 -152.03 161.29 42.87 Favored 'General case' 0 C--N 1.328 -0.349 0 N-CA-C 110.183 -0.302 . . . . 74.22 110.183 176.926 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -154.02 171.1 32.66 Favored Glycine 0 N--CA 1.448 -0.548 0 C-N-CA 120.877 -0.678 . . . . 74.11 112.166 179.88 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 80.9 m-85 -124.04 116.78 23.36 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-O 121.049 0.452 . . . . 75.11 110.75 179.591 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.552 ' HA ' ' HA ' ' A' ' 6' ' ' VAL . 11.3 mt -109.94 123.02 65.48 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.524 0 N-CA-C 108.715 -0.846 . . . . 75.52 108.715 178.63 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' GLU . . . . . 0.5 ' HA ' ' HA ' ' A' ' 25' ' ' ASP . 16.7 pt-20 -76.15 138.43 40.71 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-O 121.404 0.621 . . . . 73.33 112.092 -170.549 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 20' ' ' ARG . . . . . 0.602 ' HB3' ' HB3' ' A' ' 24' ' ' ASP . 78.1 ttt180 -91.73 161.33 14.93 Favored 'General case' 0 C--N 1.321 -0.659 0 N-CA-C 108.51 -0.922 . . . . 62.44 108.51 171.126 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . 0.506 ' OE1' ' HG2' ' A' ' 20' ' ' ARG . 0.0 OUTLIER -71.1 6.45 1.62 Allowed 'General case' 0 CA--C 1.537 0.455 0 N-CA-C 112.745 0.646 . . . . 71.03 112.745 -173.559 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 9.4 m-80 -108.63 5.29 24.82 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-O 120.792 0.33 . . . . 73.41 110.895 175.31 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 84.88 0.86 89.07 Favored Glycine 0 N--CA 1.453 -0.227 0 N-CA-C 110.572 -1.011 . . . . 54.4 110.572 -172.89 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . 0.602 ' HB3' ' HB3' ' A' ' 20' ' ' ARG . 31.5 t70 -76.07 87.49 2.97 Favored 'General case' 0 C--N 1.321 -0.669 0 CA-C-N 114.631 -0.784 . . . . 53.43 109.946 -178.859 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.5 ' HA ' ' HA ' ' A' ' 19' ' ' GLU . 55.9 m-20 -64.5 110.69 2.39 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 116.02 -0.537 . . . . 54.5 110.647 179.121 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.442 HG13 ' HB2' ' A' ' 58' ' ' PRO . 28.2 t -85.2 130.01 36.88 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.492 0 CA-C-N 115.639 -0.709 . . . . 54.23 110.977 -175.281 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 27' ' ' PHE . . . . . . . . . . . . . 85.3 t80 -84.87 122.84 29.75 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.745 -0.661 . . . . 74.2 110.816 -178.48 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.568 ' HB ' ' HB3' ' A' ' 60' ' ' ALA . 12.3 p -120.47 145.62 26.58 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.574 0 CA-C-N 116.591 -0.277 . . . . 61.43 110.276 178.249 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 29' ' ' HIS . . . . . 0.478 ' O ' HG13 ' A' ' 33' ' ' ILE . 2.0 t-160 -111.7 157.44 20.48 Favored 'General case' 0 C--N 1.327 -0.381 0 N-CA-C 109.432 -0.581 . . . . 63.12 109.432 -179.706 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 33.6 p90 -51.57 -40.18 59.28 Favored 'General case' 0 N--CA 1.471 0.582 0 N-CA-C 113.367 0.877 . . . . 73.32 113.367 -170.471 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 29.5 t -83.6 -6.95 59.58 Favored 'General case' 0 C--N 1.33 -0.282 0 C-N-CA 120.691 -0.404 . . . . 61.14 111.262 -176.056 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -93.67 -20.22 20.37 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-O 121.43 0.634 . . . . 50.34 109.457 174.791 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.478 HG13 ' O ' ' A' ' 29' ' ' HIS . 52.0 mt -75.53 154.28 6.2 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.408 0 CA-C-N 114.979 -1.01 . . . . 74.33 109.335 174.782 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 34' ' ' GLN . . . . . 0.405 ' HB3' ' O ' ' A' ' 63' ' ' VAL . 3.8 pt20 -69.43 128.0 35.01 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-O 121.052 0.453 . . . . 63.44 110.728 179.299 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -85.27 -9.53 79.52 Favored Glycine 0 N--CA 1.45 -0.429 0 C-N-CA 120.438 -0.887 . . . . 70.41 111.36 176.566 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 5.7 m-20 -124.61 146.57 49.0 Favored 'General case' 0 C--N 1.324 -0.537 0 N-CA-C 109.222 -0.658 . . . . 63.41 109.222 179.849 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 104.99 -88.68 0.6 Allowed Glycine 0 N--CA 1.448 -0.507 0 N-CA-C 111.164 -0.774 . . . . 74.45 111.164 -175.419 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 77.3 m-85 -112.96 109.57 19.08 Favored 'General case' 0 C--N 1.323 -0.565 0 N-CA-C 109.773 -0.455 . . . . 75.42 109.773 174.903 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -72.37 -15.43 61.86 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 121.262 0.553 . . . . 61.32 110.076 179.005 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 18.4 p -142.2 115.25 8.78 Favored 'General case' 0 N--CA 1.448 -0.561 0 CA-C-N 115.608 -0.724 . . . . 73.44 109.961 176.093 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 3.8 mm? -81.02 126.83 31.89 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 116.289 -0.414 . . . . 74.23 110.365 -179.503 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . 0.802 ' HB2' ' HB2' ' A' ' 45' ' ' GLN . 5.4 m-20 -65.11 143.93 57.57 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.801 -0.636 . . . . 74.31 110.18 178.98 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . 0.426 ' H ' ' HG3' ' A' ' 43' ' ' GLU . 0.1 OUTLIER -80.01 90.69 5.4 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-O 122.528 1.156 . . . . 70.13 109.332 174.737 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 130.65 0.5 5.29 Favored Glycine 0 N--CA 1.445 -0.713 0 CA-C-N 114.007 -1.451 . . . . 63.12 110.539 -169.148 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 45' ' ' GLN . . . . . 0.802 ' HB2' ' HB2' ' A' ' 42' ' ' ASP . 6.7 tp-100 -78.07 140.78 39.11 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.381 -0.41 . . . . 75.53 110.291 177.828 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -101.98 120.56 40.61 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 116.207 -0.451 . . . . 51.34 110.533 179.442 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 17.8 m -132.94 158.78 43.37 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.564 0 CA-C-N 116.181 -0.463 . . . . 74.24 110.72 -179.134 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 48' ' ' THR . . . . . 0.603 HG23 ' HB2' ' A' ' 66' ' ' ALA . 37.1 p -103.16 99.64 9.52 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 121.33 0.586 . . . . 64.41 110.876 -178.681 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 49' ' ' PHE . . . . . 0.428 ' HA ' ' O ' ' A' ' 62' ' ' ASN . 42.0 p90 -105.62 167.6 9.65 Favored 'General case' 0 C--N 1.315 -0.911 0 CA-C-N 115.635 -0.711 . . . . 74.22 109.732 -179.796 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 4.6 t70 -117.34 111.8 19.86 Favored 'General case' 0 C--N 1.319 -0.731 0 C-N-CA 120.197 -0.601 . . . . 72.33 110.351 172.703 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 9.1 p -69.15 125.67 27.58 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-O 121.707 0.765 . . . . 74.02 112.275 -176.407 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 6.4 mm-40 -102.69 134.14 46.56 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-N 115.314 -0.857 . . . . 62.33 108.995 172.467 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 15.4 pt-20 -87.77 127.03 35.32 Favored 'General case' 0 C--N 1.32 -0.709 0 C-N-CA 120.447 -0.501 . . . . 62.25 110.047 177.499 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -153.53 -158.39 8.56 Favored Glycine 0 N--CA 1.447 -0.625 0 C-N-CA 120.224 -0.989 . . . . 63.15 113.007 -178.42 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 39.8 mt-30 -66.28 -24.53 66.58 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.865 0.364 . . . . 63.44 111.276 -175.85 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -93.89 9.36 37.67 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 116.283 -0.417 . . . . 41.45 110.46 179.158 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 81.34 -115.92 4.11 Favored Glycine 0 N--CA 1.444 -0.791 0 N-CA-C 110.754 -0.939 . . . . 63.25 110.754 -174.504 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . 0.442 ' HB2' HG13 ' A' ' 26' ' ' VAL . 89.3 Cg_endo -81.53 109.01 2.0 Favored 'Trans proline' 0 N--CA 1.455 -0.749 0 C-N-CA 122.482 2.121 . . . . 74.34 112.005 175.217 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 51.1 tt0 -115.51 118.17 32.42 Favored 'General case' 0 C--N 1.322 -0.594 0 N-CA-C 109.455 -0.572 . . . . 75.02 109.455 176.947 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . 0.568 ' HB3' ' HB ' ' A' ' 28' ' ' VAL . . . -78.67 123.94 27.67 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-O 121.004 0.431 . . . . 64.42 111.818 -173.029 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -124.75 145.7 49.58 Favored 'General case' 0 C--N 1.321 -0.667 0 N-CA-C 109.14 -0.689 . . . . 63.33 109.14 173.325 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 62' ' ' ASN . . . . . 0.428 ' O ' ' HA ' ' A' ' 49' ' ' PHE . 47.3 m-80 60.61 87.83 0.09 Allowed 'General case' 0 C--O 1.236 0.394 0 CA-C-O 121.321 0.581 . . . . 73.51 110.704 -175.57 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.405 ' O ' ' HB3' ' A' ' 34' ' ' GLN . 58.0 t -100.29 106.72 19.7 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.547 0 CA-C-N 115.443 -0.799 . . . . 63.14 109.407 176.132 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 48.7 mt-30 -103.98 160.38 14.87 Favored 'General case' 0 C--N 1.319 -0.741 0 CA-C-N 116.086 -0.507 . . . . 75.13 110.665 -177.191 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 9.7 mtpm? -77.07 136.43 38.66 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 115.928 -0.578 . . . . 72.11 109.731 176.481 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 66' ' ' ALA . . . . . 0.603 ' HB2' HG23 ' A' ' 48' ' ' THR . . . . . . . . 0 C--O 1.248 1.006 0 CA-C-O 118.666 -0.683 . . . . 42.25 110.19 -179.505 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.479 1.003 0 N-CA-C 110.12 -0.326 . . . . 65.31 110.12 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 4.5 mm-40 53.21 61.47 3.14 Favored 'General case' 0 C--O 1.236 0.38 0 O-C-N 123.783 0.677 . . . . 74.13 111.299 175.729 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 24.1 tt0 -86.57 125.16 33.6 Favored 'General case' 0 N--CA 1.448 -0.528 0 CA-C-N 115.077 -0.965 . . . . 74.13 110.067 177.633 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -136.52 150.4 20.49 Favored Glycine 0 N--CA 1.442 -0.936 0 N-CA-C 111.311 -0.716 . . . . 74.12 111.311 176.435 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . 0.435 ' O ' ' HG2' ' A' ' 19' ' ' GLU . 0.7 OUTLIER -98.13 130.39 44.9 Favored 'General case' 0 C--N 1.319 -0.758 0 CA-C-O 120.672 0.272 . . . . 71.1 110.672 177.763 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 47.3 t -65.54 122.23 16.09 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.491 0 N-CA-C 109.857 -0.423 . . . . 51.23 109.857 176.547 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . 0.41 ' HG2' ' OE1' ' A' ' 19' ' ' GLU . 27.6 mtpp -78.33 -60.81 2.22 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 121.209 0.528 . . . . 73.12 109.604 179.788 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' TRP . . . . . . . . . . . . . 19.0 p90 -152.07 156.4 39.84 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 115.465 -0.789 . . . . 65.45 109.214 175.79 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 17.9 p90 -127.09 112.57 15.34 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-O 121.607 0.718 . . . . 65.22 111.055 -174.931 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 77.8 m-20 -86.67 73.5 10.02 Favored 'General case' 0 C--N 1.32 -0.696 0 CA-C-N 115.682 -0.69 . . . . 71.53 109.608 179.537 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -61.58 -25.52 67.38 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 115.553 -0.749 . . . . 72.32 111.118 -177.981 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 26.6 mt-10 -58.82 -36.87 75.23 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.531 -0.758 . . . . 74.42 110.864 179.287 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 28.2 mmtp -104.92 -18.33 14.23 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 116.024 -0.534 . . . . 71.33 111.007 -177.967 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 95.87 28.76 9.13 Favored Glycine 0 N--CA 1.449 -0.5 0 C-N-CA 120.748 -0.739 . . . . 73.12 113.491 174.399 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 50.2 p90 -150.69 156.4 41.25 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 117.155 0.478 . . . . 65.32 110.65 177.451 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -137.43 176.86 20.29 Favored Glycine 0 N--CA 1.447 -0.615 0 C-N-CA 121.075 -0.583 . . . . 54.11 111.736 178.64 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 75.8 m-85 -126.26 127.5 45.72 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 121.273 0.559 . . . . 73.34 110.948 179.54 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.412 ' HB ' ' HB ' ' A' ' 26' ' ' VAL . 64.3 mt -110.18 143.68 19.74 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.618 0 CA-C-N 115.408 -0.815 . . . . 73.53 109.845 179.191 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' GLU . . . . . 0.435 ' HG2' ' O ' ' A' ' 5' ' ' THR . 7.6 pt-20 -96.63 108.8 21.47 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 121.573 0.701 . . . . 75.44 110.649 177.213 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 20' ' ' ARG . . . . . 0.423 ' HG2' ' N ' ' A' ' 21' ' ' GLU . 61.3 ttt180 -97.0 162.87 13.2 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 114.954 -1.021 . . . . 65.45 110.123 -176.749 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . 0.423 ' N ' ' HG2' ' A' ' 20' ' ' ARG . 19.2 mm-40 -51.88 -41.65 62.07 Favored 'General case' 0 CA--C 1.531 0.241 0 CA-C-O 121.156 0.503 . . . . 74.13 111.002 176.618 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 15.3 m120 -111.09 26.34 10.8 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.983 -0.553 . . . . 62.55 111.761 -175.257 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 179.14 111.81 0.32 Allowed Glycine 0 C--O 1.225 -0.415 0 C-N-CA 119.86 -1.162 . . . . 44.45 113.084 -179.888 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 31.8 t70 -74.53 6.4 3.82 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-O 121.472 0.653 . . . . 61.34 111.05 -176.294 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 10.4 p-10 -152.04 93.21 1.8 Allowed 'General case' 0 C--N 1.324 -0.539 0 CA-C-O 121.882 0.849 . . . . 72.54 111.096 -178.768 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.412 ' HB ' ' HB ' ' A' ' 18' ' ' ILE . 89.0 t -102.59 121.18 53.38 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 CA-C-N 115.042 -0.981 . . . . 71.22 109.784 175.216 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 27' ' ' PHE . . . . . 0.485 ' O ' ' HA ' ' A' ' 59' ' ' GLN . 78.1 t80 -78.6 120.37 23.19 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 116.024 -0.534 . . . . 73.01 110.535 -178.558 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.485 ' HB ' ' HB3' ' A' ' 60' ' ' ALA . 8.7 p -128.7 136.05 60.82 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.728 0 CA-C-O 120.964 0.412 . . . . 74.41 111.277 179.516 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 29' ' ' HIS . . . . . 0.483 ' O ' HG13 ' A' ' 33' ' ' ILE . 3.2 m-70 -96.99 142.92 28.36 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 116.14 -0.482 . . . . 73.4 110.024 175.307 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 30' ' ' PHE . . . . . 0.436 ' HE2' ' HB3' ' A' ' 40' ' ' SER . 17.7 m-85 -62.28 -28.59 69.83 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-O 120.704 0.287 . . . . 73.41 111.216 -179.545 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 16.5 t -74.92 -12.44 60.35 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 121.0 0.429 . . . . 73.11 110.877 177.897 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . 0.476 ' HB1' ' HA ' ' A' ' 61' ' ' ALA . . . -97.67 -24.26 15.58 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 121.095 0.474 . . . . 52.43 110.464 178.858 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.501 HG23 ' HB ' ' A' ' 63' ' ' VAL . 31.8 mt -68.61 163.48 3.15 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.4 0 CA-C-N 115.86 -0.609 . . . . 75.55 109.936 176.233 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 34' ' ' GLN . . . . . 0.472 ' NE2' ' H ' ' A' ' 65' ' ' LYS . 24.9 pt20 -72.19 10.62 0.72 Allowed 'General case' 0 N--CA 1.466 0.358 0 CA-C-O 120.73 0.3 . . . . 64.22 111.703 179.426 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.41 ' H ' ' C ' ' A' ' 33' ' ' ILE . . . -65.21 114.96 7.19 Favored Glycine 0 N--CA 1.446 -0.634 0 C-N-CA 121.092 -0.575 . . . . 71.11 112.402 -175.599 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 22.6 t70 -62.05 112.28 2.28 Favored 'General case' 0 C--N 1.327 -0.403 0 N-CA-C 109.235 -0.654 . . . . 51.33 109.235 176.062 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 76.83 -99.45 1.38 Allowed Glycine 0 N--CA 1.447 -0.568 0 N-CA-C 110.49 -1.044 . . . . 23.24 110.49 -170.6 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 53.4 m-85 -146.58 100.66 3.37 Favored 'General case' 0 C--N 1.325 -0.477 0 N-CA-C 109.765 -0.458 . . . . 73.24 109.765 173.583 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 54.7 mtpt -125.22 135.01 52.14 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.163 -0.472 . . . . 72.55 110.205 -177.355 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . 0.436 ' HB3' ' HE2' ' A' ' 30' ' ' PHE . 13.8 p -91.95 149.56 21.48 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-O 121.036 0.446 . . . . 71.24 111.751 -175.862 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . 0.542 HD12 ' HG2' ' A' ' 45' ' ' GLN . 4.4 mm? -103.33 145.28 30.21 Favored 'General case' 0 C--N 1.325 -0.488 0 N-CA-C 109.397 -0.594 . . . . 73.35 109.397 174.858 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 6.5 m-20 -76.08 156.87 33.5 Favored 'General case' 0 C--N 1.32 -0.691 0 CA-C-N 116.112 -0.495 . . . . 62.01 111.29 -174.752 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 6.3 pt-20 -68.01 133.21 48.66 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-N 116.051 -0.522 . . . . 62.42 109.962 175.648 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 87.02 0.23 85.65 Favored Glycine 0 N--CA 1.446 -0.676 0 C-N-CA 120.558 -0.83 . . . . 73.31 112.146 -177.246 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 45' ' ' GLN . . . . . 0.542 ' HG2' HD12 ' A' ' 41' ' ' LEU . 24.3 tp60 -74.72 115.96 14.89 Favored 'General case' 0 C--N 1.328 -0.368 0 N-CA-C 109.637 -0.505 . . . . 73.44 109.637 176.9 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -74.84 116.07 15.14 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 116.049 -0.523 . . . . 64.43 110.125 177.14 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 0.505 HG12 ' HA ' ' A' ' 65' ' ' LYS . 27.5 m -122.13 150.15 25.58 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.737 0 CA-C-N 116.068 -0.515 . . . . 63.22 110.751 -179.44 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 59.0 p -106.9 119.01 38.19 Favored 'General case' 0 C--N 1.318 -0.777 0 N-CA-C 108.928 -0.767 . . . . 73.42 108.928 175.062 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 29.8 p90 -127.99 151.34 49.25 Favored 'General case' 0 C--N 1.319 -0.74 0 CA-C-O 120.932 0.396 . . . . 70.11 111.745 -172.135 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 17.8 t70 -82.66 120.4 25.52 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.809 -0.632 . . . . 62.54 109.306 174.397 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 49.6 t -83.33 115.94 26.56 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.63 0 CA-C-N 116.063 -0.517 . . . . 43.43 111.622 -174.044 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 34.6 tt0 -108.82 104.74 14.07 Favored 'General case' 0 C--N 1.323 -0.585 0 N-CA-C 109.471 -0.566 . . . . 75.44 109.471 174.417 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 5.9 pt-20 -90.98 108.19 19.69 Favored 'General case' 0 C--N 1.318 -0.785 0 CA-C-O 121.363 0.602 . . . . 72.44 110.639 -179.42 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -118.85 -171.4 15.03 Favored Glycine 0 N--CA 1.445 -0.72 0 CA-C-N 115.428 -0.805 . . . . 63.32 111.888 -178.856 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 10.7 mm100 -78.62 77.9 5.09 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 121.33 0.586 . . . . 62.01 110.621 -177.573 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 4.6 ptp85 170.75 -26.49 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 114.534 -1.212 . . . . 62.44 108.973 -178.954 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 139.32 -170.23 24.21 Favored Glycine 0 N--CA 1.443 -0.857 0 N-CA-C 110.812 -0.915 . . . . 71.23 110.812 -179.673 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 72.3 Cg_endo -78.56 111.44 3.0 Favored 'Trans proline' 0 N--CA 1.455 -0.742 0 C-N-CA 122.077 1.851 . . . . 70.5 111.77 177.264 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . 0.485 ' HA ' ' O ' ' A' ' 27' ' ' PHE . 15.0 pt20 -104.34 135.77 45.17 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-O 121.137 0.494 . . . . 71.15 109.881 176.009 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . 0.485 ' HB3' ' HB ' ' A' ' 28' ' ' VAL . . . -90.09 123.5 34.0 Favored 'General case' 0 C--N 1.321 -0.669 0 CA-C-N 115.879 -0.6 . . . . 53.4 111.457 -173.995 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . 0.476 ' HA ' ' HB1' ' A' ' 32' ' ' ALA . . . -124.09 150.5 44.95 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-N 115.463 -0.79 . . . . 63.32 108.878 175.373 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 30.8 m-80 56.45 74.06 0.41 Allowed 'General case' 0 C--N 1.329 -0.301 0 N-CA-C 109.313 -0.625 . . . . 72.31 109.313 -176.155 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.501 ' HB ' HG23 ' A' ' 33' ' ' ILE . 40.5 t -105.37 103.5 15.46 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.599 0 CA-C-N 115.786 -0.643 . . . . 71.43 110.858 -175.304 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 23.1 mt-30 -111.64 129.96 55.92 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 116.193 -0.458 . . . . 72.24 109.774 179.29 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . 0.505 ' HA ' HG12 ' A' ' 47' ' ' VAL . 18.2 pttp -62.75 153.51 32.5 Favored 'General case' 0 C--N 1.327 -0.386 0 N-CA-C 110.294 -0.261 . . . . 73.23 110.294 -178.495 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 0.992 0 CA-C-O 118.193 -0.908 . . . . 72.34 109.802 176.261 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 15.1 tpt . . . . . 0 N--CA 1.481 1.104 0 CA-C-O 120.773 0.321 . . . . 72.33 110.986 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . 0.541 ' HB2' ' O ' ' A' ' 49' ' ' PHE . 1.7 mp0 -81.01 101.98 9.89 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 121.325 0.583 . . . . 75.12 111.114 -178.854 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' GLN . . . . . 0.681 ' HG2' HG22 ' A' ' 48' ' ' THR . 47.8 mt-30 -106.82 120.1 41.12 Favored 'General case' 0 C--N 1.32 -0.711 0 CA-C-N 115.702 -0.681 . . . . 73.13 109.619 178.086 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -143.81 -164.26 10.29 Favored Glycine 0 N--CA 1.447 -0.57 0 C-N-CA 120.611 -0.804 . . . . 62.22 112.303 -176.706 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . 0.509 ' O ' ' HG2' ' A' ' 19' ' ' GLU . 42.7 m -139.76 134.64 32.13 Favored 'General case' 0 C--N 1.319 -0.746 0 CA-C-O 120.674 0.273 . . . . 65.23 110.589 -178.879 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.403 HG21 ' HB3' ' A' ' 41' ' ' LEU . 47.4 t -68.58 135.63 28.03 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.487 0 CA-C-O 120.773 0.32 . . . . 63.21 110.343 -179.774 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . 0.47 ' HE3' ' HA ' ' A' ' 7' ' ' LYS . 0.0 OUTLIER -108.13 -72.69 0.71 Allowed 'General case' 0 C--N 1.324 -0.518 0 CA-C-O 120.966 0.412 . . . . 71.03 110.723 177.632 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' TRP . . . . . . . . . . . . . 46.0 m95 -127.43 125.99 41.58 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 116.082 -0.508 . . . . 75.03 110.134 -176.499 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 4.6 p90 -112.92 93.95 4.67 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-O 121.67 0.748 . . . . 73.24 110.861 179.866 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' ASN . . . . . 0.415 ' HA ' HD22 ' A' ' 10' ' ' ASN . 2.0 t-20 -92.93 59.33 3.15 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-O 121.892 0.853 . . . . 72.14 109.11 -179.738 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -68.83 -15.12 63.41 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 114.751 -1.113 . . . . 62.02 112.115 -173.067 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 20.5 mt-10 -74.32 -26.79 60.37 Favored 'General case' 0 C--N 1.326 -0.44 0 C-N-CA 120.713 -0.395 . . . . 74.12 110.693 178.205 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 3.8 mmmp? -97.03 -26.48 14.99 Favored 'General case' 0 C--N 1.328 -0.352 0 N-CA-C 109.68 -0.489 . . . . 73.11 109.68 175.064 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 115.82 23.79 4.2 Favored Glycine 0 N--CA 1.449 -0.488 0 C-N-CA 120.306 -0.95 . . . . 61.5 114.265 169.937 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 55.9 p90 -151.08 162.63 40.48 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 117.576 0.688 . . . . 72.01 111.455 179.897 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -153.93 171.18 32.6 Favored Glycine 0 N--CA 1.444 -0.788 0 C-N-CA 120.998 -0.62 . . . . 64.41 111.771 178.299 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 94.9 m-85 -125.69 121.71 34.25 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-O 120.914 0.388 . . . . 72.52 110.965 -178.604 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 59.6 mt -114.7 127.63 72.13 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.574 0 N-CA-C 108.752 -0.832 . . . . 70.25 108.752 174.484 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' GLU . . . . . 0.509 ' HG2' ' O ' ' A' ' 5' ' ' THR . 17.1 pt-20 -86.66 137.19 32.67 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-O 121.517 0.675 . . . . 72.13 112.294 -171.074 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 20' ' ' ARG . . . . . 0.797 ' HB3' ' HB2' ' A' ' 24' ' ' ASP . 10.3 tpt180 -100.41 169.31 9.19 Favored 'General case' 0 C--N 1.325 -0.485 0 N-CA-C 108.215 -1.031 . . . . 71.44 108.215 169.769 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 44.2 mt-10 -58.44 -22.81 55.7 Favored 'General case' 0 CA--C 1.538 0.506 0 N-CA-C 114.029 1.122 . . . . 71.41 114.029 -171.54 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 7.3 m-80 -94.81 3.09 55.42 Favored 'General case' 0 N--CA 1.467 0.421 0 CA-C-O 120.964 0.411 . . . . 73.42 110.43 -179.333 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 92.97 8.61 61.61 Favored Glycine 0 N--CA 1.45 -0.414 0 N-CA-C 111.131 -0.788 . . . . 71.25 111.131 -174.242 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . 0.797 ' HB2' ' HB3' ' A' ' 20' ' ' ARG . 1.6 m-20 -61.06 97.45 0.06 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.193 -0.503 . . . . 74.45 110.168 -178.84 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 40.3 m-20 -67.55 98.53 0.68 Allowed 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 116.264 -0.425 . . . . 72.44 110.0 173.669 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 26.4 t -79.19 128.16 38.68 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.665 0 CA-C-N 116.069 -0.514 . . . . 74.33 109.69 178.595 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 27' ' ' PHE . . . . . . . . . . . . . 17.7 t80 -84.48 108.24 17.16 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 115.957 -0.565 . . . . 73.51 110.437 -173.062 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.504 ' HB ' ' HB3' ' A' ' 60' ' ' ALA . 12.2 p -101.62 151.34 5.64 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.487 0 CA-C-O 121.141 0.496 . . . . 72.23 110.828 -178.545 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 29' ' ' HIS . . . . . 0.472 ' O ' HG13 ' A' ' 33' ' ' ILE . 17.8 m170 -118.09 149.53 40.86 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.798 -0.637 . . . . 60.31 109.422 176.697 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 30' ' ' PHE . . . . . 0.504 ' HA ' HD12 ' A' ' 33' ' ' ILE . 49.3 p90 -68.58 -23.31 64.47 Favored 'General case' 0 N--CA 1.463 0.22 0 CA-C-O 120.955 0.407 . . . . 75.14 110.471 -177.363 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 23.0 t -71.86 -25.14 61.83 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 115.864 -0.607 . . . . 75.25 110.063 176.682 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . 0.48 ' HB1' ' HA ' ' A' ' 61' ' ' ALA . . . -92.13 -19.99 21.71 Favored 'General case' 0 C--O 1.235 0.302 0 CA-C-N 115.964 -0.562 . . . . 64.41 110.863 -179.656 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.633 HG22 ' H ' ' A' ' 35' ' ' GLY . 77.3 mt -65.42 116.4 4.61 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 CA-C-N 116.156 -0.474 . . . . 74.11 110.114 176.567 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 4.7 pp0? -87.95 14.32 9.16 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.184 -0.462 . . . . 72.53 111.246 -176.531 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.633 ' H ' HG22 ' A' ' 33' ' ' ILE . . . -53.95 121.81 20.38 Favored Glycine 0 N--CA 1.453 -0.187 0 CA-C-N 115.846 -0.615 . . . . 72.01 112.156 -178.952 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 11.4 p-10 -77.73 129.45 35.52 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-O 121.278 0.561 . . . . 74.11 111.065 -176.844 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 98.43 -53.48 1.15 Allowed Glycine 0 N--CA 1.448 -0.533 0 C-N-CA 120.841 -0.695 . . . . 53.01 112.379 179.57 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 39.7 p90 -146.61 150.54 35.68 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-O 120.69 0.281 . . . . 65.34 110.6 -177.917 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 73.5 mmtt -86.94 86.54 7.33 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.911 0.386 . . . . 73.22 110.615 -179.799 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 47.3 m -153.42 147.05 25.09 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 116.384 -0.371 . . . . 72.33 110.608 177.812 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . 0.403 ' HB3' HG21 ' A' ' 6' ' ' VAL . 94.7 mt -124.2 121.24 34.56 Favored 'General case' 0 C--N 1.325 -0.468 0 N-CA-C 108.908 -0.775 . . . . 64.11 108.908 175.825 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 12.1 m-20 -64.19 127.39 31.23 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-O 121.351 0.596 . . . . 62.15 111.495 -175.924 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 6.2 pt-20 -63.04 119.57 9.74 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 115.226 -0.897 . . . . 60.13 111.12 179.98 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 100.66 -5.49 56.87 Favored Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.705 -0.76 . . . . 54.14 112.667 179.167 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 59.2 tp60 -80.98 133.9 35.59 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 120.615 0.245 . . . . 74.52 110.489 -178.778 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -77.15 130.81 37.82 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.352 -0.386 . . . . 71.24 110.022 175.221 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 0.437 HG12 ' HA ' ' A' ' 65' ' ' LYS . 17.5 m -135.19 153.56 34.28 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.492 0 CA-C-O 121.025 0.441 . . . . 75.3 111.289 -176.05 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 48' ' ' THR . . . . . 0.681 HG22 ' HG2' ' A' ' 3' ' ' GLN . 46.3 p -114.18 107.75 16.04 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-N 115.582 -0.735 . . . . 62.03 109.223 175.719 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 49' ' ' PHE . . . . . 0.561 ' HA ' ' O ' ' A' ' 62' ' ' ASN . 37.0 p90 -119.53 167.38 12.03 Favored 'General case' 0 C--N 1.315 -0.899 0 CA-C-N 115.847 -0.615 . . . . 74.1 110.412 -173.515 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 38.7 t70 -107.04 129.21 54.84 Favored 'General case' 0 C--N 1.316 -0.85 0 C-N-CA 120.777 -0.369 . . . . 75.23 110.305 176.016 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . 0.461 ' HB ' ' HG2' ' A' ' 2' ' ' GLU . 7.3 p -77.26 120.8 28.4 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 CA-C-O 121.533 0.682 . . . . 63.55 111.388 -176.976 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -110.37 157.89 19.04 Favored 'General case' 0 C--N 1.323 -0.581 0 N-CA-C 108.721 -0.844 . . . . 70.03 108.721 179.541 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 1.3 mm-40 -95.78 110.32 22.49 Favored 'General case' 0 C--N 1.319 -0.725 0 CA-C-O 121.03 0.443 . . . . 61.14 110.835 -178.319 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -99.56 157.16 19.85 Favored Glycine 0 N--CA 1.443 -0.892 0 N-CA-C 111.139 -0.785 . . . . 63.54 111.139 177.033 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 78.5 mt-30 -77.7 7.07 6.19 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 117.014 0.407 . . . . 75.53 111.69 -178.276 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 99.1 mtt180 -127.79 10.28 6.52 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 120.922 0.392 . . . . 75.21 110.023 175.313 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 129.29 176.89 14.61 Favored Glycine 0 N--CA 1.446 -0.634 0 C-N-CA 120.854 -0.688 . . . . 62.24 111.713 -177.412 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 18.3 Cg_endo -60.1 124.45 15.27 Favored 'Trans proline' 0 C--O 1.235 0.349 0 C-N-CA 122.827 2.351 . . . . 74.21 112.067 179.471 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 6.8 tt0 -104.45 144.35 31.78 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 115.682 -0.69 . . . . 72.51 110.101 -177.003 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . 0.504 ' HB3' ' HB ' ' A' ' 28' ' ' VAL . . . -91.43 106.81 18.76 Favored 'General case' 0 C--N 1.32 -0.696 0 CA-C-O 120.89 0.376 . . . . 63.13 110.81 178.585 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . 0.48 ' HA ' ' HB1' ' A' ' 32' ' ' ALA . . . -117.18 164.38 14.86 Favored 'General case' 0 C--N 1.32 -0.687 0 N-CA-C 108.769 -0.826 . . . . 74.24 108.769 176.31 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 62' ' ' ASN . . . . . 0.561 ' O ' ' HA ' ' A' ' 49' ' ' PHE . 85.0 m-20 47.89 66.41 1.05 Allowed 'General case' 0 N--CA 1.465 0.289 0 CA-C-O 120.83 0.347 . . . . 75.45 110.304 -177.766 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 29.4 t -93.93 89.3 2.56 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 CA-C-N 116.09 -0.505 . . . . 73.15 110.636 -176.66 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 5.5 mt-30 -82.35 129.66 34.92 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 115.866 -0.606 . . . . 64.42 110.479 -179.47 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . 0.437 ' HA ' HG12 ' A' ' 47' ' ' VAL . 50.7 mtmt -81.83 137.84 35.2 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 116.532 -0.303 . . . . 74.0 110.262 178.989 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.251 1.133 0 CA-C-O 118.289 -0.862 . . . . 54.04 110.157 178.325 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 60.8 mtt . . . . . 0 N--CA 1.481 1.112 0 CA-C-O 120.765 0.317 . . . . 73.45 110.358 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 40.6 mt-10 -133.34 150.76 51.84 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 116.187 -0.461 . . . . 74.4 110.266 -179.366 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 35.1 tt0 -91.57 123.77 35.23 Favored 'General case' 0 C--N 1.322 -0.595 0 N-CA-C 109.48 -0.563 . . . . 72.03 109.48 177.759 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . 0.545 ' HA3' ' HE2' ' A' ' 49' ' ' PHE . . . -138.88 152.65 22.29 Favored Glycine 0 N--CA 1.444 -0.788 0 C-N-CA 120.818 -0.706 . . . . 74.54 111.829 -178.903 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . 0.425 ' HA ' ' HA ' ' A' ' 46' ' ' ALA . 9.6 m -85.57 131.05 34.43 Favored 'General case' 0 C--N 1.318 -0.761 0 CA-C-O 120.635 0.255 . . . . 65.41 110.908 -177.855 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 60.6 t -65.78 115.86 4.37 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 N-CA-C 109.507 -0.553 . . . . 64.21 109.507 174.761 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 9.3 mmmm -86.12 -62.08 1.6 Allowed 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 115.943 -0.571 . . . . 64.5 109.976 -178.493 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 8' ' ' TRP . . . . . . . . . . . . . 94.4 m95 -141.78 135.08 29.34 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 116.012 -0.54 . . . . 73.35 110.08 -179.638 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 62.7 t80 -118.93 98.4 6.17 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-O 121.217 0.532 . . . . 63.12 109.707 178.12 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 43.4 t30 -82.12 81.84 7.9 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-O 121.556 0.693 . . . . 72.41 110.262 -177.635 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -70.89 -10.4 59.56 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.103 -0.953 . . . . 72.44 111.143 179.732 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 31.2 mm-40 -69.77 -16.39 63.29 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.086 -0.507 . . . . 63.44 110.266 177.447 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . 0.585 ' HE3' ' HA ' ' A' ' 13' ' ' LYS . 0.0 OUTLIER -130.01 -35.17 1.63 Allowed 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.132 -0.486 . . . . 64.41 111.263 179.564 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 111.25 28.51 3.79 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.648 -0.787 . . . . 75.52 112.907 178.206 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 31.3 p90 -148.03 176.23 10.35 Favored 'General case' 0 C--N 1.323 -0.561 0 O-C-N 122.493 -0.416 . . . . 74.4 109.965 177.641 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -174.79 -168.43 35.46 Favored Glycine 0 N--CA 1.445 -0.733 0 C-N-CA 120.292 -0.956 . . . . 73.22 112.27 -179.974 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . 0.5 ' HB3' ' HB3' ' A' ' 25' ' ' ASP . 88.0 m-85 -127.47 124.42 38.32 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-O 120.949 0.404 . . . . 64.42 110.504 -178.166 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 40.2 mt -121.72 117.81 53.71 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.663 0 N-CA-C 108.38 -0.97 . . . . 73.45 108.38 175.063 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 19' ' ' GLU . . . . . 0.642 ' HA ' ' HA ' ' A' ' 25' ' ' ASP . 6.7 pt-20 -78.11 137.67 38.33 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-O 121.64 0.733 . . . . 60.21 112.449 -168.543 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 20' ' ' ARG . . . . . 0.593 ' HB3' ' HB3' ' A' ' 24' ' ' ASP . 62.7 ttt180 -80.3 164.02 23.5 Favored 'General case' 0 C--N 1.32 -0.688 0 N-CA-C 107.691 -1.226 . . . . 73.11 107.691 168.129 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 43.4 mt-10 -63.53 -12.51 32.92 Favored 'General case' 0 N--CA 1.468 0.466 0 N-CA-C 112.53 0.567 . . . . 72.23 112.53 -173.718 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 10.4 m120 -87.29 3.64 45.95 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-O 120.901 0.382 . . . . 72.04 110.774 178.637 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 85.46 2.39 87.35 Favored Glycine 0 N--CA 1.452 -0.271 0 N-CA-C 110.752 -0.939 . . . . 72.32 110.752 -173.164 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . 0.593 ' HB3' ' HB3' ' A' ' 20' ' ' ARG . 38.3 t70 -75.32 90.51 2.64 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 114.551 -0.825 . . . . 74.32 110.463 -176.909 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.642 ' HA ' ' HA ' ' A' ' 19' ' ' GLU . 42.8 m-20 -60.82 104.16 0.33 Allowed 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.107 -0.497 . . . . 75.35 110.248 176.28 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.461 HG13 ' HB2' ' A' ' 58' ' ' PRO . 22.1 t -81.01 132.52 31.39 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 CA-C-N 116.016 -0.538 . . . . 63.35 110.229 -177.851 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 27' ' ' PHE . . . . . . . . . . . . . 85.7 t80 -76.64 104.28 7.06 Favored 'General case' 0 C--O 1.238 0.452 0 CA-C-O 121.134 0.492 . . . . 72.05 110.881 -177.189 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.585 ' HA ' ' HB3' ' A' ' 60' ' ' ALA . 9.6 p -88.3 145.71 7.12 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.638 0 N-CA-C 109.392 -0.595 . . . . 53.3 109.392 177.464 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 29' ' ' HIS . . . . . 0.678 ' HE1' ' HB3' ' A' ' 59' ' ' GLN . 23.8 p-80 -142.05 143.73 33.25 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 116.563 -0.29 . . . . 73.42 110.997 -173.64 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 52.1 p90 -58.14 -23.37 54.89 Favored 'General case' 0 N--CA 1.469 0.488 0 N-CA-C 113.03 0.752 . . . . 74.1 113.03 -172.838 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . 0.412 ' OG ' ' HD2' ' A' ' 29' ' ' HIS . 2.7 p -77.57 -0.05 24.86 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-O 121.0 0.429 . . . . 55.03 111.576 -179.355 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -126.26 -24.9 3.6 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.149 -0.478 . . . . 75.34 110.689 175.337 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.499 HG13 ' O ' ' A' ' 29' ' ' HIS . 64.1 mt -68.95 118.47 13.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.293 -0.412 . . . . 72.32 110.872 179.686 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 2.5 pp0? -83.03 102.76 11.98 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-O 121.58 0.705 . . . . 75.44 109.508 172.798 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -82.82 56.54 5.05 Favored Glycine 0 N--CA 1.449 -0.45 0 CA-C-N 115.612 -0.722 . . . . 72.13 112.216 -175.76 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 27.4 t70 -78.74 102.96 8.37 Favored 'General case' 0 C--N 1.319 -0.737 0 CA-C-O 120.835 0.35 . . . . 63.33 110.479 -179.376 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 110.69 -91.33 0.61 Allowed Glycine 0 N--CA 1.448 -0.53 0 C-N-CA 121.101 -0.571 . . . . 72.33 111.722 -178.656 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 84.6 m-85 -122.37 135.8 54.77 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-O 120.859 0.361 . . . . 75.24 110.179 177.932 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 13.8 mptt -86.65 53.55 2.86 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-N 116.146 -0.479 . . . . 70.43 110.03 -178.902 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 39.6 m -149.86 110.68 4.31 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 116.154 -0.475 . . . . 75.01 111.122 -177.79 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 9.9 mp -94.02 131.76 39.19 Favored 'General case' 0 C--N 1.324 -0.532 0 N-CA-C 108.891 -0.781 . . . . 60.21 108.891 174.39 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 21.3 m-20 -96.82 128.1 43.44 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-O 120.775 0.321 . . . . 70.5 110.388 -173.858 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 2.0 pp20? -61.92 143.19 56.82 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 116.063 -0.517 . . . . 70.54 110.737 -179.047 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 99.11 -22.72 39.51 Favored Glycine 0 N--CA 1.447 -0.568 0 C-N-CA 120.74 -0.743 . . . . 53.32 111.847 -175.525 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 45' ' ' GLN . . . . . 0.456 ' HA ' ' OE1' ' A' ' 45' ' ' GLN . 6.1 tp60 -87.95 140.36 29.58 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.713 0.292 . . . . 74.4 110.315 178.334 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 0.425 ' HA ' ' HA ' ' A' ' 5' ' ' THR . . . -102.93 125.44 49.69 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-N 116.476 -0.329 . . . . 35.33 110.818 -179.869 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 30.7 m -118.2 171.51 6.43 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.561 0 CA-C-N 116.315 -0.402 . . . . 73.3 110.467 178.64 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 21.6 p -107.39 112.79 25.76 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-O 121.218 0.532 . . . . 74.11 110.954 -179.899 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 49' ' ' PHE . . . . . 0.545 ' HE2' ' HA3' ' A' ' 4' ' ' GLY . 41.5 p90 -121.89 161.16 23.29 Favored 'General case' 0 C--N 1.317 -0.833 0 CA-C-N 115.619 -0.719 . . . . 74.34 109.851 -178.219 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 19.7 t70 -109.06 128.29 54.85 Favored 'General case' 0 C--N 1.316 -0.875 0 CA-C-O 120.99 0.424 . . . . 54.2 110.311 174.128 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 98.9 t -77.22 104.8 5.46 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 CA-C-O 121.108 0.48 . . . . 71.34 110.878 -177.873 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -87.15 145.89 26.24 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 115.409 -0.814 . . . . 71.23 109.19 179.523 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 70.9 mm-40 -84.25 98.2 9.84 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-N 116.153 -0.476 . . . . 75.53 111.368 -175.641 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -81.39 164.77 45.88 Favored Glycine 0 N--CA 1.446 -0.69 0 C-N-CA 120.837 -0.697 . . . . 64.24 111.546 176.65 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 26.8 pt20 -69.32 -23.63 63.82 Favored 'General case' 0 C--N 1.324 -0.508 0 N-CA-C 112.207 0.447 . . . . 74.21 112.207 -175.664 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 9.5 ptm180 -132.1 16.57 4.61 Favored 'General case' 0 C--N 1.328 -0.346 0 C-N-CA 120.326 -0.55 . . . . 73.41 112.033 -179.26 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 157.69 -178.18 34.13 Favored Glycine 0 N--CA 1.449 -0.444 0 C-N-CA 120.018 -1.087 . . . . 63.24 112.702 179.282 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . 0.461 ' HB2' HG13 ' A' ' 26' ' ' VAL . 73.4 Cg_endo -75.56 128.59 11.17 Favored 'Trans proline' 0 C--O 1.235 0.341 0 C-N-CA 122.834 2.356 . . . . 33.13 112.89 -177.738 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . 0.678 ' HB3' ' HE1' ' A' ' 29' ' ' HIS . 90.5 mt-30 -112.61 135.32 53.47 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 115.965 -0.561 . . . . 70.52 109.92 176.665 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . 0.585 ' HB3' ' HA ' ' A' ' 28' ' ' VAL . . . -85.21 105.19 15.72 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-O 120.899 0.381 . . . . 75.44 111.037 -178.931 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -115.29 168.78 9.66 Favored 'General case' 0 C--N 1.319 -0.722 0 N-CA-C 108.615 -0.883 . . . . 71.43 108.615 174.931 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 62' ' ' ASN . . . . . 0.516 ' O ' ' HA ' ' A' ' 49' ' ' PHE . 87.1 m-20 51.03 75.5 0.19 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.981 0.42 . . . . 55.23 109.958 -175.714 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 22.0 t -98.83 93.25 3.06 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 CA-C-N 115.969 -0.559 . . . . 43.23 109.526 -177.285 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 40.4 mt-30 -98.12 148.78 23.2 Favored 'General case' 0 C--N 1.32 -0.705 0 CA-C-N 115.923 -0.581 . . . . 75.01 110.567 -175.96 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 94.9 mttt -76.86 129.12 35.78 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 115.871 -0.604 . . . . 73.2 110.439 -179.795 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.077 0 CA-C-O 118.366 -0.826 . . . . 75.41 109.457 175.856 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . 0.647 ' N ' ' HA ' ' A' ' 50' ' ' ASP . 26.0 ptm . . . . . 0 N--CA 1.482 1.16 0 CA-C-O 120.718 0.294 . . . . 71.04 111.268 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 4.4 mp0 -105.55 165.7 10.96 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 121.029 0.442 . . . . 73.51 111.151 -175.351 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 3' ' ' GLN . . . . . 0.564 ' HG2' HG22 ' A' ' 48' ' ' THR . 66.6 mt-30 -98.47 111.43 23.79 Favored 'General case' 0 C--N 1.326 -0.445 0 N-CA-C 109.037 -0.727 . . . . 73.11 109.037 173.422 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . 0.707 ' HA3' ' HE2' ' A' ' 49' ' ' PHE . . . -122.1 162.3 15.93 Favored Glycine 0 N--CA 1.447 -0.613 0 C-N-CA 120.101 -1.047 . . . . 71.11 112.984 -174.217 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 8.3 m -98.45 131.03 45.04 Favored 'General case' 0 C--N 1.321 -0.635 0 N-CA-C 110.033 -0.358 . . . . 64.12 110.033 177.948 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 59.7 t -70.17 118.48 14.71 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.436 0 CA-C-N 116.602 -0.272 . . . . 72.14 110.619 179.365 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . 1.032 ' HE2' ' HB3' ' A' ' 19' ' ' GLU . 70.7 mmtt -70.77 -72.58 0.2 Allowed 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 121.238 0.542 . . . . 73.22 109.803 176.62 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 8' ' ' TRP . . . . . 0.556 ' HA ' ' HG3' ' A' ' 43' ' ' GLU . 24.5 m-90 -143.85 127.23 16.81 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 114.939 -1.028 . . . . 74.44 109.005 178.558 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 54.3 t80 -105.82 103.08 12.51 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-O 121.243 0.544 . . . . 71.11 110.359 179.547 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 39.2 m-80 -83.9 78.46 9.72 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 115.785 -0.643 . . . . 75.45 110.104 -179.666 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -59.61 -30.86 68.99 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.025 -0.534 . . . . 75.41 110.59 178.029 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 24.7 mt-10 -64.61 -38.91 92.64 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.401 -0.818 . . . . 73.22 110.616 178.158 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 48.7 mmtm -90.6 -24.44 20.55 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.683 -0.69 . . . . 65.05 110.691 -174.201 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 96.15 18.62 30.87 Favored Glycine 0 N--CA 1.445 -0.738 0 C-N-CA 120.806 -0.711 . . . . 54.4 112.845 177.608 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 46.7 p90 -156.83 163.72 38.88 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 117.074 0.437 . . . . 74.32 110.803 179.855 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -148.95 177.12 27.4 Favored Glycine 0 N--CA 1.445 -0.703 0 C-N-CA 120.813 -0.708 . . . . 73.34 111.983 179.289 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 96.8 m-85 -123.98 131.15 53.52 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 120.76 0.314 . . . . 75.54 110.307 177.949 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.446 HD13 HG21 ' A' ' 47' ' ' VAL . 33.0 mt -122.88 146.61 27.9 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.695 0 N-CA-C 109.115 -0.698 . . . . 72.22 109.115 178.149 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 19' ' ' GLU . . . . . 1.032 ' HB3' ' HE2' ' A' ' 7' ' ' LYS . 12.9 pt-20 -99.79 129.23 45.88 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-O 121.351 0.596 . . . . 71.02 111.785 -178.52 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 20' ' ' ARG . . . . . 0.436 ' HG2' ' N ' ' A' ' 21' ' ' GLU . 27.9 ttm180 -98.3 153.81 18.26 Favored 'General case' 0 C--N 1.322 -0.609 0 N-CA-C 108.381 -0.97 . . . . 50.23 108.381 170.727 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . 0.436 ' N ' ' HG2' ' A' ' 20' ' ' ARG . 43.9 mt-10 -52.02 -34.44 42.96 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 121.047 0.451 . . . . 61.43 110.491 177.61 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 8.5 t-20 -123.9 58.58 1.16 Allowed 'General case' 0 N--CA 1.453 -0.311 0 CA-C-N 115.85 -0.613 . . . . 75.23 109.41 175.358 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 164.65 78.88 0.04 OUTLIER Glycine 0 N--CA 1.45 -0.369 0 N-CA-C 111.217 -0.753 . . . . 40.13 111.217 179.543 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 30.6 t70 -65.71 -2.84 3.97 Favored 'General case' 0 C--N 1.326 -0.445 0 N-CA-C 112.606 0.595 . . . . 64.14 112.606 -169.51 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 10.2 p-10 -144.73 93.67 2.44 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-O 121.813 0.816 . . . . 71.01 111.854 -178.575 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 38.9 t -104.12 128.74 57.26 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.492 0 CA-C-N 115.525 -0.761 . . . . 73.23 109.628 174.579 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 27' ' ' PHE . . . . . . . . . . . . . 42.7 t80 -83.61 106.52 15.4 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-O 120.716 0.293 . . . . 65.44 110.326 -177.28 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.586 HG23 HG21 ' A' ' 63' ' ' VAL . 12.5 p -99.38 143.9 12.81 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 CA-C-O 121.149 0.5 . . . . 71.11 111.354 -176.248 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 54.2 m80 -97.27 133.78 41.43 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.543 -0.753 . . . . 75.0 109.996 177.871 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 6.1 p90 -63.95 -26.46 68.6 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.803 0.335 . . . . 75.32 111.105 -176.837 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 28.2 t -89.57 -14.35 35.26 Favored 'General case' 0 CA--C 1.533 0.291 0 CA-C-N 116.355 -0.384 . . . . 73.13 110.436 179.689 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -83.22 -23.09 32.94 Favored 'General case' 0 C--O 1.233 0.224 0 CA-C-O 121.383 0.611 . . . . 63.12 109.9 178.117 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.541 ' HA ' ' HB ' ' A' ' 63' ' ' VAL . 53.1 mt -76.31 138.37 20.83 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.497 0 CA-C-N 115.542 -0.754 . . . . 72.35 109.51 172.113 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 34' ' ' GLN . . . . . 0.408 ' OE1' ' HG3' ' A' ' 65' ' ' LYS . 0.3 OUTLIER -75.93 59.84 1.31 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 121.397 0.618 . . . . 73.42 111.554 176.946 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -69.05 141.14 35.43 Favored Glycine 0 N--CA 1.446 -0.646 0 CA-C-N 115.841 -0.618 . . . . 41.3 112.376 -179.373 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -77.98 84.11 4.27 Favored 'General case' 0 C--N 1.324 -0.532 0 N-CA-C 109.95 -0.389 . . . . 71.05 109.95 177.332 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 75.16 -68.77 1.99 Allowed Glycine 0 N--CA 1.451 -0.346 0 N-CA-C 111.491 -0.644 . . . . 72.13 111.491 -176.125 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 44.1 t80 -152.26 93.81 1.85 Allowed 'General case' 0 C--N 1.321 -0.664 0 N-CA-C 108.505 -0.924 . . . . 74.44 108.505 174.965 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 41.1 tptt -114.15 115.87 28.19 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 116.241 -0.436 . . . . 72.12 110.569 -173.239 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 13.0 m -85.27 115.35 22.99 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-N 116.044 -0.525 . . . . 71.13 110.368 179.138 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . 0.529 HD21 HG21 ' A' ' 33' ' ' ILE . 3.7 mm? -74.96 107.69 7.2 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 116.298 -0.41 . . . . 73.2 110.215 178.606 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 32.5 t70 -58.98 135.08 57.5 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.76 -0.655 . . . . 73.15 111.267 -177.549 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . 0.556 ' HG3' ' HA ' ' A' ' 8' ' ' TRP . 17.9 mp0 -53.93 124.72 16.27 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 115.957 -0.565 . . . . 74.4 110.619 177.809 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 99.35 -0.68 57.11 Favored Glycine 0 N--CA 1.449 -0.481 0 C-N-CA 120.627 -0.796 . . . . 42.43 112.804 -179.908 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 58.7 tp60 -83.43 149.97 26.34 Favored 'General case' 0 C--N 1.325 -0.495 0 N-CA-C 109.918 -0.401 . . . . 70.35 109.918 178.423 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -90.8 140.49 29.74 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-N 116.554 -0.294 . . . . 75.31 110.246 177.21 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 0.446 HG21 HD13 ' A' ' 18' ' ' ILE . 16.0 m -139.0 153.59 25.01 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 CA-C-O 120.913 0.387 . . . . 72.24 110.396 177.579 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 48' ' ' THR . . . . . 0.659 HG23 ' HB2' ' A' ' 66' ' ' ALA . 34.4 p -106.47 101.88 11.31 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-O 121.323 0.582 . . . . 75.12 110.121 178.275 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 49' ' ' PHE . . . . . 0.707 ' HE2' ' HA3' ' A' ' 4' ' ' GLY . 42.1 p90 -111.55 147.47 35.33 Favored 'General case' 0 C--N 1.317 -0.821 0 CA-C-N 115.609 -0.723 . . . . 74.13 110.666 -174.455 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . 0.647 ' HA ' ' N ' ' A' ' 1' ' ' MET . 36.2 t0 -101.92 160.96 14.04 Favored 'General case' 0 C--N 1.316 -0.855 0 C-N-CA 120.357 -0.537 . . . . 73.5 109.706 172.279 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 67.4 t -109.66 119.37 58.77 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.701 0 CA-C-O 120.922 0.392 . . . . 62.54 111.459 -172.822 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 27.6 tt0 -111.11 111.31 22.3 Favored 'General case' 0 C--N 1.321 -0.642 0 N-CA-C 109.094 -0.706 . . . . 73.21 109.094 173.338 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 26.9 mt-10 -69.59 137.08 52.02 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-O 121.203 0.525 . . . . 72.13 112.091 -177.709 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -118.9 -158.04 10.6 Favored Glycine 0 N--CA 1.441 -1.026 0 N-CA-C 110.001 -1.239 . . . . 74.42 110.001 170.844 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 50.0 tt0 -99.43 -25.6 14.41 Favored 'General case' 0 C--N 1.319 -0.752 0 CA-C-N 117.162 0.481 . . . . 72.24 110.498 179.728 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 10.9 mmm180 -97.64 -5.23 35.86 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 116.292 -0.413 . . . . 65.13 111.191 178.561 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 151.39 -179.61 27.89 Favored Glycine 0 N--CA 1.444 -0.795 0 C-N-CA 120.62 -0.8 . . . . 63.34 112.311 178.527 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 8.9 Cg_endo -87.41 119.02 1.37 Allowed 'Trans proline' 0 N--CA 1.45 -1.057 0 C-N-CA 123.235 2.623 . . . . 74.1 112.18 178.931 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 15.8 pt20 -95.39 133.91 38.8 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-N 116.098 -0.501 . . . . 75.2 109.852 177.654 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . 0.572 ' HB3' ' HA ' ' A' ' 28' ' ' VAL . . . -76.27 112.13 12.43 Favored 'General case' 0 C--N 1.321 -0.645 0 CA-C-N 116.128 -0.487 . . . . 40.34 110.76 -178.885 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -112.91 153.3 28.18 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 115.493 -0.776 . . . . 54.12 109.011 176.583 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 95.1 m-20 52.48 77.3 0.16 Allowed 'General case' 0 C--O 1.235 0.341 0 CA-C-O 121.279 0.561 . . . . 64.33 110.337 -175.426 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.586 HG21 HG23 ' A' ' 28' ' ' VAL . 36.9 t -109.59 107.16 22.19 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 CA-C-N 115.686 -0.688 . . . . 72.1 110.174 -179.67 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 64' ' ' GLN . . . . . 0.516 ' HB2' ' OG1' ' A' ' 48' ' ' THR . 1.5 mt-30 -99.41 178.54 4.85 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 115.434 -0.803 . . . . 75.11 110.163 -177.154 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . 0.408 ' HG3' ' OE1' ' A' ' 34' ' ' GLN . 56.0 mttp -89.05 149.47 23.21 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-O 120.733 0.301 . . . . 52.3 110.588 -178.494 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 66' ' ' ALA . . . . . 0.659 ' HB2' HG23 ' A' ' 48' ' ' THR . . . . . . . . 0 C--O 1.251 1.165 0 CA-C-O 117.974 -1.012 . . . . 73.13 109.615 177.304 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 1.9 mpt? . . . . . 0 N--CA 1.482 1.174 0 CA-C-O 120.826 0.346 . . . . 75.22 110.156 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . 0.508 ' H ' ' CD ' ' A' ' 2' ' ' GLU . 1.4 mp0 -61.94 143.35 56.6 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 115.68 -0.691 . . . . 73.43 111.235 -176.113 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 3' ' ' GLN . . . . . 0.504 ' HB3' HG22 ' A' ' 48' ' ' THR . 0.9 OUTLIER -93.54 127.34 39.16 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 115.725 -0.671 . . . . 53.51 109.83 173.485 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -136.74 160.3 24.8 Favored Glycine 0 N--CA 1.445 -0.709 0 C-N-CA 120.887 -0.673 . . . . 55.32 111.566 -179.853 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -96.48 133.35 41.04 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-O 121.266 0.555 . . . . 72.24 111.421 -179.336 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 45.6 t -68.81 116.06 8.54 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.556 0 CA-C-N 115.824 -0.625 . . . . 71.11 110.034 177.759 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . 0.832 ' HE3' ' HA ' ' A' ' 7' ' ' LYS . 0.1 OUTLIER -83.04 -62.59 1.55 Allowed 'General case' 0 C--N 1.324 -0.507 0 CA-C-O 121.24 0.543 . . . . 73.03 109.705 -178.827 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 8' ' ' TRP . . . . . . . . . . . . . 99.5 m95 -126.72 146.94 50.03 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 115.365 -0.834 . . . . 70.14 109.727 -179.963 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . 0.52 ' CE2' ' HA ' ' A' ' 40' ' ' SER . 68.1 t80 -140.21 98.05 3.36 Favored 'General case' 0 C--N 1.318 -0.773 0 CA-C-O 121.093 0.473 . . . . 75.2 110.432 176.356 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 91.4 m-20 -82.2 82.57 7.69 Favored 'General case' 0 C--N 1.323 -0.57 0 N-CA-C 109.285 -0.635 . . . . 74.52 109.285 178.813 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -59.08 -33.74 71.16 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.574 -0.739 . . . . 71.14 111.297 -178.476 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 36.7 mt-10 -70.1 -26.22 63.87 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 116.066 -0.515 . . . . 72.2 110.892 -178.733 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 47.9 mmtm -91.44 -29.72 16.88 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.188 -0.46 . . . . 54.31 110.179 175.999 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 90.99 17.4 51.5 Favored Glycine 0 N--CA 1.447 -0.623 0 CA-C-N 115.853 -0.612 . . . . 64.44 111.655 -178.895 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 74.3 m-85 -138.15 144.46 40.77 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-O 120.864 0.364 . . . . 73.45 110.489 -176.568 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -131.16 168.64 21.98 Favored Glycine 0 N--CA 1.444 -0.787 0 C-N-CA 120.438 -0.887 . . . . 73.01 112.109 -178.621 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . 0.453 ' HA ' ' O ' ' A' ' 26' ' ' VAL . 76.6 m-85 -127.47 118.9 24.92 Favored 'General case' 0 C--N 1.322 -0.603 0 N-CA-C 109.757 -0.46 . . . . 74.04 109.757 -179.972 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.431 HG21 ' CE2' ' A' ' 49' ' ' PHE . 63.5 mt -109.05 141.82 23.28 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.659 0 CA-C-N 115.992 -0.549 . . . . 71.53 110.402 -177.526 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 19' ' ' GLU . . . . . 0.63 ' OE1' ' HG2' ' A' ' 7' ' ' LYS . 7.9 pt-20 -92.87 101.42 13.79 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 121.377 0.608 . . . . 72.34 110.476 178.372 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 20' ' ' ARG . . . . . 0.613 ' HG2' ' OE1' ' A' ' 21' ' ' GLU . 12.4 ttp180 -96.41 158.48 15.42 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 115.854 -0.612 . . . . 74.21 109.544 -179.503 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . 0.613 ' OE1' ' HG2' ' A' ' 20' ' ' ARG . 0.0 OUTLIER -57.29 -38.02 73.33 Favored 'General case' 0 N--CA 1.466 0.326 0 N-CA-C 112.155 0.428 . . . . 53.3 112.155 -177.931 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 41.3 m-80 -115.3 36.6 3.85 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-O 120.991 0.424 . . . . 72.34 110.181 174.949 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -170.38 82.19 0.09 OUTLIER Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.624 -0.798 . . . . 75.15 112.444 179.846 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 37.4 t70 -63.71 -2.98 1.97 Allowed 'General case' 0 N--CA 1.469 0.48 0 CA-C-O 121.09 0.471 . . . . 72.44 111.916 -177.039 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 17.5 t70 -152.97 88.55 1.33 Allowed 'General case' 0 C--N 1.325 -0.485 0 CA-C-O 121.105 0.479 . . . . 64.21 109.829 -179.328 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.453 ' O ' ' HA ' ' A' ' 17' ' ' PHE . 58.8 t -102.97 123.72 56.55 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 CA-C-N 116.005 -0.543 . . . . 74.4 110.43 179.374 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 27' ' ' PHE . . . . . 0.467 ' O ' ' HA ' ' A' ' 59' ' ' GLN . 62.7 t80 -85.45 102.46 13.48 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 115.612 -0.722 . . . . 72.22 110.277 -177.025 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.473 HG23 ' HB3' ' A' ' 60' ' ' ALA . 10.2 p -95.77 146.74 6.66 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.505 0 CA-C-O 120.94 0.4 . . . . 73.21 110.796 -177.453 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 17.3 m-70 -103.83 141.01 36.86 Favored 'General case' 0 C--O 1.234 0.24 0 CA-C-N 115.982 -0.554 . . . . 74.5 111.341 -175.841 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 41.2 p90 -55.91 -36.38 67.63 Favored 'General case' 0 N--CA 1.467 0.412 0 CA-C-N 115.838 -0.619 . . . . 73.12 112.177 -179.941 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 33.0 t -82.07 -10.52 59.18 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 116.707 -0.224 . . . . 63.14 111.17 -177.075 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . 0.54 ' HB1' ' HA ' ' A' ' 61' ' ' ALA . . . -92.81 -22.84 19.09 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 121.248 0.547 . . . . 70.34 109.99 178.829 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.546 ' HA ' ' HB ' ' A' ' 63' ' ' VAL . 67.3 mt -87.68 126.63 41.26 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.468 0 CA-C-N 115.503 -0.771 . . . . 74.23 110.318 177.012 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 34' ' ' GLN . . . . . 0.426 ' H ' ' HG3' ' A' ' 34' ' ' GLN . 2.3 pp0? -86.64 109.46 19.18 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-O 121.502 0.668 . . . . 74.51 109.457 172.639 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -81.89 62.2 4.56 Favored Glycine 0 N--CA 1.449 -0.459 0 CA-C-N 115.751 -0.659 . . . . 45.21 112.709 -175.485 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 31.0 t70 -74.98 109.69 8.65 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-O 120.772 0.32 . . . . 75.12 110.493 179.254 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 80.77 -53.95 4.61 Favored Glycine 0 N--CA 1.45 -0.407 0 CA-C-N 115.957 -0.565 . . . . 24.3 112.059 -178.957 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 84.1 m-85 -117.59 120.41 37.97 Favored 'General case' 0 C--N 1.324 -0.529 0 N-CA-C 109.901 -0.407 . . . . 74.43 109.901 179.111 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 4.4 mptp? -82.38 -30.93 29.97 Favored 'General case' 0 C--N 1.324 -0.528 0 N-CA-C 109.325 -0.62 . . . . 70.4 109.325 176.842 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . 0.52 ' HA ' ' CE2' ' A' ' 9' ' ' PHE . 23.5 p -93.46 116.23 28.76 Favored 'General case' 0 N--CA 1.448 -0.551 0 CA-C-N 115.467 -0.788 . . . . 65.32 109.981 173.803 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 52.0 mt -70.64 137.29 49.78 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-O 120.996 0.427 . . . . 70.5 110.648 179.196 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . 0.442 ' HB3' ' HB2' ' A' ' 45' ' ' GLN . 22.7 t70 -74.64 136.93 41.94 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 115.573 -0.74 . . . . 63.45 110.638 -176.322 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 8.4 pt-20 -65.81 115.25 5.74 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-O 121.25 0.548 . . . . 75.01 110.71 178.361 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 100.86 -1.54 55.35 Favored Glycine 0 N--CA 1.446 -0.635 0 C-N-CA 120.47 -0.871 . . . . 72.03 112.109 -178.218 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 45' ' ' GLN . . . . . 0.442 ' HB2' ' HB3' ' A' ' 42' ' ' ASP . 6.0 tp-100 -74.26 133.85 42.64 Favored 'General case' 0 C--N 1.327 -0.398 0 N-CA-C 109.974 -0.38 . . . . 73.23 109.974 175.802 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -90.23 123.66 34.21 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 116.186 -0.461 . . . . 33.2 110.454 179.784 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 0.495 HG23 ' HD2' ' A' ' 49' ' ' PHE . 21.1 m -127.62 153.56 37.02 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.596 0 CA-C-N 116.008 -0.542 . . . . 73.22 110.339 178.748 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 48' ' ' THR . . . . . 0.504 HG22 ' HB3' ' A' ' 3' ' ' GLN . 63.7 p -106.96 111.23 23.63 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-O 121.261 0.553 . . . . 62.04 109.733 179.609 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 49' ' ' PHE . . . . . 0.495 ' HD2' HG23 ' A' ' 47' ' ' VAL . 29.5 p90 -128.61 160.53 32.14 Favored 'General case' 0 C--N 1.318 -0.771 0 CA-C-N 116.138 -0.483 . . . . 73.54 111.171 -172.543 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 71.0 m-20 -105.02 115.09 29.69 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 116.157 -0.474 . . . . 70.14 110.435 175.536 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . 0.478 HG21 ' HD3' ' A' ' 20' ' ' ARG . 65.3 t -77.43 120.71 28.48 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.599 0 CA-C-O 121.052 0.454 . . . . 73.23 110.936 -177.459 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 9.2 tp10 -99.44 125.69 45.21 Favored 'General case' 0 N--CA 1.444 -0.769 0 N-CA-C 108.984 -0.747 . . . . 70.5 108.984 175.43 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 10.0 pt-20 -88.11 141.11 28.83 Favored 'General case' 0 C--N 1.317 -0.806 0 CA-C-N 116.16 -0.473 . . . . 72.23 110.806 -175.797 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -162.64 -171.46 28.87 Favored Glycine 0 N--CA 1.446 -0.669 0 C-N-CA 120.851 -0.69 . . . . 53.41 112.081 178.706 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 34.9 tt0 -58.35 -38.57 77.48 Favored 'General case' 0 C--N 1.326 -0.444 0 C-N-CA 122.488 0.315 . . . . 72.42 111.218 179.557 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 18.0 mmm180 -75.98 4.36 8.46 Favored 'General case' 0 C--N 1.328 -0.337 0 N-CA-C 111.708 0.262 . . . . 74.34 111.708 179.999 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 93.51 -136.82 13.28 Favored Glycine 0 N--CA 1.444 -0.818 0 C-N-CA 120.942 -0.647 . . . . 75.44 112.034 178.928 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 1.8 Cg_endo -83.05 108.94 1.63 Allowed 'Trans proline' 0 N--CA 1.454 -0.832 0 C-N-CA 123.132 2.554 . . . . 54.43 112.015 -179.69 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . 0.467 ' HA ' ' O ' ' A' ' 27' ' ' PHE . 47.6 mt-30 -110.17 117.27 33.25 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-O 120.906 0.384 . . . . 71.42 110.081 177.827 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . 0.473 ' HB3' HG23 ' A' ' 28' ' ' VAL . . . -77.72 119.05 20.7 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-O 121.078 0.466 . . . . 74.03 111.308 -175.852 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . 0.54 ' HA ' ' HB1' ' A' ' 32' ' ' ALA . . . -120.77 167.91 12.0 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 115.425 -0.807 . . . . 73.14 109.001 175.362 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 62' ' ' ASN . . . . . 0.49 ' O ' ' HA ' ' A' ' 49' ' ' PHE . 37.4 m-20 47.28 74.46 0.16 Allowed 'General case' 0 C--O 1.236 0.393 0 O-C-N 123.265 0.353 . . . . 73.55 110.314 -176.885 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.546 ' HB ' ' HA ' ' A' ' 33' ' ' ILE . 57.9 t -96.63 104.13 15.49 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.511 0 CA-C-N 116.337 -0.392 . . . . 65.15 110.817 -177.19 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 6.6 tp-100 -104.65 165.31 11.15 Favored 'General case' 0 C--N 1.321 -0.649 0 N-CA-C 109.127 -0.694 . . . . 75.54 109.127 178.093 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 86.0 mttt -80.78 176.57 9.69 Favored 'General case' 0 C--N 1.321 -0.635 0 N-CA-C 110.09 -0.337 . . . . 75.22 110.09 178.103 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 66' ' ' ALA . . . . . 0.459 ' HB2' HG23 ' A' ' 48' ' ' THR . . . . . . . . 0 C--O 1.249 1.052 0 CA-C-O 118.612 -0.709 . . . . 40.42 109.876 175.603 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 56.8 ttp . . . . . 0 N--CA 1.482 1.15 0 N-CA-C 110.289 -0.263 . . . . 70.34 110.289 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 34.3 mm-40 -100.35 145.17 28.48 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-O 120.811 0.339 . . . . 64.2 110.307 -179.32 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 3' ' ' GLN . . . . . 0.957 ' HG2' HG22 ' A' ' 48' ' ' THR . 88.3 mt-30 -124.72 111.78 15.97 Favored 'General case' 0 C--N 1.321 -0.648 0 N-CA-C 109.418 -0.586 . . . . 72.23 109.418 176.308 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -137.87 163.47 25.57 Favored Glycine 0 N--CA 1.446 -0.653 0 C-N-CA 120.363 -0.922 . . . . 44.41 112.143 -176.029 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . 0.553 ' HA ' ' HA ' ' A' ' 46' ' ' ALA . 22.0 m -106.67 130.44 54.4 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-O 120.516 0.198 . . . . 73.23 110.734 -178.431 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.531 HG22 HG12 ' A' ' 18' ' ' ILE . 42.7 t -70.65 120.67 18.95 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 N-CA-C 109.964 -0.384 . . . . 70.13 109.964 178.009 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . 0.714 ' HD2' ' HB3' ' A' ' 19' ' ' GLU . 27.2 mtpp -98.81 -34.05 10.65 Favored 'General case' 0 C--N 1.327 -0.393 0 C-N-CA 120.91 -0.316 . . . . 74.12 110.682 -179.305 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 8' ' ' TRP . . . . . . . . . . . . . 10.5 m-90 -140.0 110.82 6.83 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.067 -0.515 . . . . 72.44 110.361 179.791 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 65.2 t80 -101.88 91.99 4.61 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-O 121.194 0.521 . . . . 71.45 109.848 177.546 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 90.3 m-20 -79.15 84.97 5.07 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-O 121.238 0.542 . . . . 74.12 109.976 -178.037 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -60.41 -40.67 91.84 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.065 -0.97 . . . . 72.42 112.021 -175.761 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 42.7 mt-10 -81.81 0.45 39.25 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 121.134 0.492 . . . . 73.31 111.181 -176.786 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 70.5 mmtt -103.95 -28.07 11.78 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 115.782 -0.644 . . . . 63.13 109.38 170.695 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 82.08 19.26 65.38 Favored Glycine 0 N--CA 1.448 -0.554 0 N-CA-C 111.156 -0.778 . . . . 73.12 111.156 -175.854 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 48.8 m-85 -135.81 154.86 51.07 Favored 'General case' 0 C--N 1.325 -0.483 0 N-CA-C 110.2 -0.296 . . . . 73.15 110.2 -176.127 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -140.07 146.56 18.08 Favored Glycine 0 N--CA 1.447 -0.59 0 C-N-CA 120.524 -0.846 . . . . 73.14 112.14 -179.599 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 97.6 m-85 -104.47 111.88 24.71 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 121.051 0.453 . . . . 71.24 110.486 178.771 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.531 HG12 HG22 ' A' ' 6' ' ' VAL . 55.2 mt -104.48 135.36 42.67 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.589 0 CA-C-N 115.579 -0.737 . . . . 60.32 109.829 -179.493 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 19' ' ' GLU . . . . . 0.714 ' HB3' ' HD2' ' A' ' 7' ' ' LYS . 14.0 pt-20 -83.29 162.18 21.22 Favored 'General case' 0 C--N 1.327 -0.377 0 C-N-CA 120.265 -0.574 . . . . 72.41 110.686 -178.837 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 20' ' ' ARG . . . . . 0.425 ' HG2' ' H ' ' A' ' 21' ' ' GLU . 39.0 ttt180 -144.64 175.9 9.81 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 115.969 -0.56 . . . . 72.33 109.755 -173.255 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . 0.433 ' HG3' ' N ' ' A' ' 22' ' ' ASN . 7.8 pt-20 -45.71 -49.45 14.65 Favored 'General case' 0 N--CA 1.469 0.507 0 N-CA-C 113.046 0.758 . . . . 72.14 113.046 -177.488 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 22' ' ' ASN . . . . . 0.433 ' N ' ' HG3' ' A' ' 21' ' ' GLU . 14.9 t-20 -97.9 12.43 34.1 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-O 121.361 0.601 . . . . 61.2 110.761 -174.646 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 79.28 9.92 86.53 Favored Glycine 0 N--CA 1.452 -0.243 0 C-N-CA 120.528 -0.844 . . . . 72.13 111.124 -173.923 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 25.2 t70 -67.14 90.93 0.21 Allowed 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 114.8 -0.7 . . . . 53.41 110.062 179.871 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 4.8 p-10 -60.84 119.15 7.66 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 121.631 0.729 . . . . 74.23 111.451 -178.819 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.509 HG12 ' HB2' ' A' ' 60' ' ' ALA . 31.3 t -89.88 127.98 42.13 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.58 0 CA-C-N 115.049 -0.978 . . . . 53.12 110.179 -179.864 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 27' ' ' PHE . . . . . . . . . . . . . 43.4 t80 -92.67 100.18 12.73 Favored 'General case' 0 C--N 1.321 -0.674 0 CA-C-N 115.582 -0.735 . . . . 71.4 110.333 -175.854 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.546 ' HA ' ' HB3' ' A' ' 60' ' ' ALA . 11.8 p -89.06 142.52 12.76 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 CA-C-O 120.708 0.289 . . . . 73.34 110.345 178.812 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 29' ' ' HIS . . . . . 0.418 ' O ' HG13 ' A' ' 33' ' ' ILE . 7.9 p80 -118.87 142.12 48.03 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.389 -0.369 . . . . 72.52 110.832 -178.484 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 30' ' ' PHE . . . . . 0.519 ' HA ' HD12 ' A' ' 33' ' ' ILE . 43.9 p90 -52.43 -32.54 39.83 Favored 'General case' 0 N--CA 1.468 0.443 0 CA-C-N 115.501 -0.772 . . . . 64.02 112.934 -173.648 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 1.9 p -71.06 -9.19 57.61 Favored 'General case' 0 C--N 1.323 -0.585 0 N-CA-C 111.911 0.337 . . . . 74.3 111.911 -179.046 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . 0.417 ' HB1' ' HA ' ' A' ' 61' ' ' ALA . . . -122.07 -7.05 8.9 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-O 120.916 0.389 . . . . 61.54 110.941 177.905 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.519 HD12 ' HA ' ' A' ' 30' ' ' PHE . 68.3 mt -67.77 136.5 26.46 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.386 0 CA-C-N 116.21 -0.45 . . . . 73.4 110.115 175.78 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 24.0 pt20 -64.75 102.11 0.55 Allowed 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 121.434 0.635 . . . . 71.1 110.967 177.541 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -91.36 17.89 54.16 Favored Glycine 0 N--CA 1.45 -0.413 0 C-N-CA 120.847 -0.692 . . . . 71.34 111.967 179.143 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 22.4 t70 -90.5 105.81 18.07 Favored 'General case' 0 C--N 1.325 -0.491 0 N-CA-C 109.902 -0.407 . . . . 73.32 109.902 -179.711 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 93.66 -102.63 2.93 Favored Glycine 0 N--CA 1.446 -0.674 0 C-N-CA 120.757 -0.735 . . . . 71.24 112.001 -177.855 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 99.1 m-85 -90.57 117.46 29.26 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 120.814 0.34 . . . . 74.24 110.392 178.767 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 39' ' ' LYS . . . . . 0.427 ' H ' ' HD3' ' A' ' 39' ' ' LYS . 0.0 OUTLIER -83.09 -8.92 59.46 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-O 121.118 0.485 . . . . 64.03 110.357 179.494 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 3.7 p -103.37 92.66 4.59 Favored 'General case' 0 N--CA 1.447 -0.583 0 CA-C-N 115.974 -0.557 . . . . 62.52 111.844 -176.1 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 93.2 mt -85.62 81.47 8.64 Favored 'General case' 0 C--N 1.327 -0.394 0 N-CA-C 108.726 -0.842 . . . . 52.21 108.726 172.884 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 69.3 m-20 -73.97 172.21 12.04 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-O 122.038 0.923 . . . . 73.43 112.911 -169.677 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . 0.524 ' CD ' ' H ' ' A' ' 43' ' ' GLU . 22.2 mp0 -60.64 132.96 55.55 Favored 'General case' 0 N--CA 1.448 -0.554 0 CA-C-N 114.139 -1.391 . . . . 72.35 110.163 -178.44 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 98.99 -5.94 59.77 Favored Glycine 0 N--CA 1.446 -0.686 0 C-N-CA 120.711 -0.757 . . . . 53.1 112.713 178.102 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 3.4 tm0? -92.16 126.08 37.1 Favored 'General case' 0 C--N 1.328 -0.354 0 N-CA-C 109.566 -0.531 . . . . 75.23 109.566 176.751 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 0.553 ' HA ' ' HA ' ' A' ' 5' ' ' THR . . . -97.95 113.09 24.83 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-O 120.944 0.402 . . . . 75.13 110.675 178.795 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 23.2 m -106.26 160.95 5.74 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 CA-C-N 115.952 -0.567 . . . . 74.35 111.087 -178.44 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 48' ' ' THR . . . . . 0.957 HG22 ' HG2' ' A' ' 3' ' ' GLN . 53.8 p -106.79 126.13 51.89 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 115.748 -0.66 . . . . 73.45 109.411 175.743 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 49' ' ' PHE . . . . . 0.474 ' HA ' ' O ' ' A' ' 62' ' ' ASN . 33.4 p90 -142.0 167.49 22.01 Favored 'General case' 0 C--N 1.317 -0.813 0 CA-C-O 120.954 0.407 . . . . 62.21 111.33 -173.435 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 33.1 t70 -106.55 148.64 28.01 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.747 -0.66 . . . . 74.25 109.947 175.841 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 62.6 t -82.22 105.76 12.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-O 120.953 0.406 . . . . 71.0 111.137 -178.782 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . 0.428 ' HB2' ' HB3' ' A' ' 61' ' ' ALA . 40.6 tt0 -82.49 123.76 29.46 Favored 'General case' 0 C--N 1.319 -0.721 0 N-CA-C 108.881 -0.785 . . . . 54.44 108.881 174.459 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 43.5 mt-10 -87.94 109.55 19.88 Favored 'General case' 0 C--N 1.319 -0.731 0 CA-C-N 115.974 -0.557 . . . . 71.33 110.804 -174.901 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -138.16 166.8 25.12 Favored Glycine 0 N--CA 1.446 -0.663 0 CA-C-N 115.454 -0.793 . . . . 71.34 111.577 -179.579 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 72.6 mt-30 -79.97 82.95 5.95 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 121.343 0.592 . . . . 72.44 111.245 -175.843 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 56' ' ' ARG . . . . . 0.437 HH11 ' HD3' ' A' ' 56' ' ' ARG . 9.1 ptp180 -179.77 -32.01 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 114.764 -1.107 . . . . 74.05 109.326 177.893 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 144.95 -152.11 24.19 Favored Glycine 0 N--CA 1.448 -0.553 0 N-CA-C 110.737 -0.945 . . . . 32.32 110.737 -178.183 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 55.5 Cg_endo -70.98 105.2 1.64 Allowed 'Trans proline' 0 N--CA 1.46 -0.472 0 C-N-CA 122.158 1.906 . . . . 51.3 111.537 176.871 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 20.3 tt0 -97.8 139.04 34.26 Favored 'General case' 0 C--N 1.322 -0.596 0 N-CA-C 108.63 -0.878 . . . . 64.4 108.63 179.071 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . 0.546 ' HB3' ' HA ' ' A' ' 28' ' ' VAL . . . -96.11 120.42 36.37 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-O 121.255 0.55 . . . . 73.24 112.105 -174.835 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . 0.428 ' HB3' ' HB2' ' A' ' 52' ' ' GLU . . . -135.57 163.1 30.89 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 115.05 -0.977 . . . . 74.33 108.62 173.777 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 62' ' ' ASN . . . . . 0.474 ' O ' ' HA ' ' A' ' 49' ' ' PHE . 88.5 m-20 54.65 77.34 0.21 Allowed 'General case' 0 C--O 1.236 0.348 0 CA-C-O 121.067 0.46 . . . . 62.31 109.855 -174.494 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 45.9 t -112.67 121.38 64.87 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 CA-C-N 115.643 -0.708 . . . . 72.31 110.787 -175.998 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 5.1 tp60 -115.61 146.58 41.66 Favored 'General case' 0 C--N 1.323 -0.566 0 N-CA-C 109.29 -0.633 . . . . 62.23 109.29 177.642 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 19.4 ttpp -84.01 137.8 33.43 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 120.931 0.396 . . . . 64.45 111.481 -176.867 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 0.987 0 CA-C-O 118.202 -0.904 . . . . 51.42 108.882 171.109 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 1.4 mpt? . . . . . 0 N--CA 1.481 1.087 0 CA-C-O 121.177 0.513 . . . . 73.24 110.133 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . 0.469 ' O ' ' HA ' ' A' ' 48' ' ' THR . 5.0 mp0 -114.24 14.99 18.21 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-N 115.752 -0.658 . . . . 73.21 109.283 -179.453 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 17.9 mp0 -63.96 136.32 57.24 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.033 -0.985 . . . . 73.24 112.606 -173.968 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -153.09 163.38 30.52 Favored Glycine 0 N--CA 1.441 -1.003 0 N-CA-C 109.419 -1.473 . . . . 51.23 109.419 172.657 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . 0.41 ' O ' ' HG2' ' A' ' 19' ' ' GLU . 13.9 m -122.46 127.53 49.72 Favored 'General case' 0 C--N 1.316 -0.861 0 CA-C-N 118.04 0.92 . . . . 64.3 110.886 -178.174 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 61.5 t -64.93 120.7 12.44 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.462 0 CA-C-N 116.22 -0.445 . . . . 63.53 111.115 -178.026 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . 1.072 ' HE2' ' HB3' ' A' ' 19' ' ' GLU . 66.3 mmtt -74.93 -70.49 0.41 Allowed 'General case' 0 C--N 1.328 -0.344 0 N-CA-C 109.219 -0.66 . . . . 72.24 109.219 175.309 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 8' ' ' TRP . . . . . . . . . . . . . 15.6 m95 -140.36 128.35 22.08 Favored 'General case' 0 C--O 1.235 0.317 0 CA-C-N 115.059 -0.973 . . . . 71.43 108.786 -179.537 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 22.8 p90 -99.52 103.69 15.45 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-O 121.702 0.763 . . . . 74.13 109.706 177.377 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 10' ' ' ASN . . . . . 0.862 ' HB3' ' HG3' ' A' ' 13' ' ' LYS . 37.8 m-80 -91.45 63.79 4.91 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 115.775 -0.648 . . . . 63.21 110.557 -176.958 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -64.07 -26.29 68.48 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 115.609 -0.723 . . . . 65.21 110.435 178.732 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 4.1 mm-40 -71.64 -13.27 61.7 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 115.726 -0.67 . . . . 72.23 110.509 178.684 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . 0.862 ' HG3' ' HB3' ' A' ' 10' ' ' ASN . 1.7 mmpt? -112.97 -37.85 4.68 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.895 -0.593 . . . . 63.54 110.395 -176.99 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . 0.408 ' O ' ' HD1' ' A' ' 30' ' ' PHE . . . 116.85 15.61 6.7 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.956 -0.64 . . . . 73.42 112.835 178.474 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 45.3 p90 -151.49 -176.36 5.56 Favored 'General case' 0 C--N 1.324 -0.543 0 O-C-N 122.543 -0.386 . . . . 71.03 110.667 179.96 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -164.55 169.99 39.51 Favored Glycine 0 N--CA 1.445 -0.743 0 C-N-CA 120.915 -0.66 . . . . 73.14 111.795 177.581 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 96.6 m-85 -123.76 130.12 52.13 Favored 'General case' 0 C--N 1.323 -0.585 0 N-CA-C 109.979 -0.378 . . . . 73.15 109.979 178.695 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 61.0 mt -127.57 135.35 63.45 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.768 0 N-CA-C 109.701 -0.481 . . . . 62.43 109.701 178.308 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 19' ' ' GLU . . . . . 1.072 ' HB3' ' HE2' ' A' ' 7' ' ' LYS . 8.5 pt-20 -91.5 135.61 33.72 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-O 121.212 0.529 . . . . 65.14 110.811 179.451 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 20' ' ' ARG . . . . . 0.658 ' HB2' ' HZ ' ' A' ' 49' ' ' PHE . 45.5 ttt180 -133.93 161.75 33.94 Favored 'General case' 0 C--N 1.315 -0.928 0 N-CA-C 108.576 -0.898 . . . . 72.42 108.576 174.78 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . 0.408 ' HG2' ' H ' ' A' ' 21' ' ' GLU . 7.1 mm-40 -35.87 -57.47 0.67 Allowed 'General case' 0 N--CA 1.468 0.444 0 O-C-N 124.038 0.836 . . . . 73.41 110.806 178.025 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 34.9 t30 -110.06 76.92 1.02 Allowed 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 115.704 -0.68 . . . . 62.5 109.749 172.409 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . 0.583 ' O ' HG23 ' A' ' 26' ' ' VAL . . . 152.24 72.44 0.01 OUTLIER Glycine 0 N--CA 1.446 -0.674 0 C-N-CA 120.541 -0.838 . . . . 74.1 112.213 174.032 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 25.2 t70 -68.17 -1.79 6.76 Favored 'General case' 0 C--N 1.321 -0.663 0 CA-C-O 121.183 0.516 . . . . 50.41 111.062 -176.278 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 7.0 p-10 -142.65 31.49 1.47 Allowed 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 116.246 -0.434 . . . . 74.11 110.929 -174.988 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.583 HG23 ' O ' ' A' ' 23' ' ' GLY . 79.2 t -53.28 121.83 2.73 Favored 'Isoleucine or valine' 0 C--O 1.234 0.269 0 CA-C-O 121.109 0.48 . . . . 72.04 110.743 179.588 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 27' ' ' PHE . . . . . . . . . . . . . 42.6 t80 -84.21 116.74 23.1 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 115.583 -0.735 . . . . 74.12 110.603 -174.413 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.511 HG21 HG21 ' A' ' 63' ' ' VAL . 9.0 p -110.68 156.1 11.86 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.59 0 CA-C-N 116.339 -0.392 . . . . 75.32 110.281 179.853 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 92.7 m-70 -108.82 157.27 18.74 Favored 'General case' 0 C--O 1.239 0.513 0 N-CA-C 110.011 -0.366 . . . . 54.44 110.011 -179.674 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 30' ' ' PHE . . . . . 0.408 ' HD1' ' O ' ' A' ' 14' ' ' GLY . 50.8 p90 -61.65 -34.48 75.78 Favored 'General case' 0 N--CA 1.464 0.234 0 CA-C-N 116.54 -0.3 . . . . 74.25 111.605 -175.847 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 26.8 t -92.43 2.68 56.52 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 121.053 0.454 . . . . 74.21 110.589 -179.045 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -93.38 -29.9 15.37 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 121.168 0.509 . . . . 44.13 110.151 177.127 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.585 ' HA ' ' HB ' ' A' ' 63' ' ' VAL . 59.1 mt -72.66 137.89 22.56 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.386 0 CA-C-N 115.608 -0.724 . . . . 73.31 109.992 174.277 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 5.1 pp0? -71.66 146.51 48.23 Favored 'General case' 0 C--N 1.329 -0.318 0 N-CA-C 110.061 -0.348 . . . . 73.35 110.061 178.236 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 164.41 133.12 1.44 Allowed Glycine 0 N--CA 1.442 -0.955 0 C-N-CA 120.749 -0.739 . . . . 51.35 111.947 179.299 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 9.2 m-20 -65.26 106.42 1.34 Allowed 'General case' 0 C--N 1.326 -0.428 0 N-CA-C 109.735 -0.469 . . . . 72.45 109.735 178.307 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 78.4 -95.36 1.32 Allowed Glycine 0 N--CA 1.446 -0.636 0 N-CA-C 111.077 -0.809 . . . . 50.14 111.077 -173.737 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . 0.424 ' O ' ' HD2' ' A' ' 39' ' ' LYS . 74.1 m-85 -138.04 94.5 2.89 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 120.873 0.368 . . . . 64.4 110.406 176.379 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 39' ' ' LYS . . . . . 0.424 ' HD2' ' O ' ' A' ' 38' ' ' PHE . 13.1 mptt -125.95 88.41 2.85 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 116.159 -0.473 . . . . 72.11 110.497 177.509 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 20.0 m -76.21 121.82 23.46 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-N 115.902 -0.59 . . . . 71.34 110.034 177.594 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 98.4 mt -66.35 143.13 57.35 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 116.013 -0.539 . . . . 64.21 110.93 -177.882 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 35.4 t70 -68.07 149.38 49.73 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-N 115.462 -0.79 . . . . 71.32 112.176 -172.808 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 7.6 pt-20 -65.25 135.63 55.62 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 115.751 -0.658 . . . . 73.04 110.518 179.312 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 89.74 -1.23 80.89 Favored Glycine 0 N--CA 1.447 -0.583 0 C-N-CA 120.66 -0.781 . . . . 53.14 112.233 -177.18 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 6.5 tp-100 -82.92 141.49 32.14 Favored 'General case' 0 C--O 1.237 0.439 0 CA-C-O 120.732 0.301 . . . . 74.23 110.36 176.984 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -82.38 117.41 22.42 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 115.824 -0.626 . . . . 65.31 110.257 178.244 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 29.5 m -117.01 166.93 10.83 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.711 0 CA-C-N 115.727 -0.67 . . . . 62.52 110.884 -178.071 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 48' ' ' THR . . . . . 0.726 HG23 ' HB2' ' A' ' 66' ' ' ALA . 9.6 p -132.91 103.15 5.92 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-O 121.296 0.569 . . . . 63.41 110.106 178.461 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 49' ' ' PHE . . . . . 0.658 ' HZ ' ' HB2' ' A' ' 20' ' ' ARG . 36.5 p90 -117.16 166.82 11.79 Favored 'General case' 0 C--N 1.318 -0.792 0 CA-C-O 121.072 0.463 . . . . 74.03 111.751 -172.399 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 35.5 t70 -96.91 128.06 43.5 Favored 'General case' 0 C--N 1.32 -0.68 0 N-CA-C 109.016 -0.735 . . . . 73.14 109.016 174.169 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 7.4 p -80.62 118.0 27.56 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.564 0 CA-C-O 121.538 0.685 . . . . 73.42 111.254 -174.746 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 44.0 tt0 -89.14 113.16 24.3 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-N 115.419 -0.81 . . . . 74.03 109.109 176.942 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 13.9 mm-40 -73.62 86.13 1.62 Allowed 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 115.983 -0.553 . . . . 75.02 109.875 178.248 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -88.64 160.8 30.48 Favored Glycine 0 N--CA 1.443 -0.858 0 C-N-CA 120.88 -0.676 . . . . 61.11 112.331 -177.523 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 36.7 tt0 -84.77 0.34 50.99 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-O 121.392 0.615 . . . . 73.21 109.854 -179.295 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 90.8 mtm180 -119.84 15.64 12.6 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.597 -0.729 . . . . 71.52 110.855 179.184 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 121.68 169.17 13.56 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.884 -0.674 . . . . 60.31 112.182 -179.769 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 37.7 Cg_endo -68.03 118.41 5.6 Favored 'Trans proline' 0 C--N 1.344 0.291 0 C-N-CA 122.532 2.155 . . . . 51.42 111.768 177.249 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 49.9 mt-30 -119.45 164.31 15.96 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 116.325 -0.398 . . . . 62.33 110.429 -177.791 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -111.65 125.15 53.65 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-O 121.255 0.55 . . . . 75.3 111.943 -174.048 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -128.57 142.97 50.89 Favored 'General case' 0 C--N 1.321 -0.63 0 CA-C-N 115.3 -0.863 . . . . 65.51 109.005 174.426 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 39.4 m-80 56.53 78.57 0.21 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 121.216 0.532 . . . . 72.45 110.448 -175.899 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.585 ' HB ' ' HA ' ' A' ' 33' ' ' ILE . 51.8 t -101.42 109.59 26.14 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.519 0 CA-C-N 115.892 -0.594 . . . . 54.03 110.803 -177.965 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 86.7 mt-30 -94.06 -172.24 2.77 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 116.192 -0.458 . . . . 74.1 110.105 177.983 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 61.9 tttm -116.45 139.64 50.23 Favored 'General case' 0 C--N 1.321 -0.641 0 N-CA-C 109.303 -0.629 . . . . 71.34 109.303 178.508 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 66' ' ' ALA . . . . . 0.726 ' HB2' HG23 ' A' ' 48' ' ' THR . . . . . . . . 0 C--O 1.248 1.006 0 CA-C-O 118.795 -0.621 . . . . 75.01 110.557 -178.614 . . . . . . . . 1 1 . 1 stop_ save_